<SEC-DOCUMENT>0001628280-20-011806.txt : 20200805
<SEC-HEADER>0001628280-20-011806.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805162827
ACCESSION NUMBER:		0001628280-20-011806
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		201078016

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:025b09b8-2cad-4da1-9d9e-4c6905973d12,g:d4ee88be-e02e-4f39-96cc-71bae86b4889,d:a59e529445a14a10ab18f7d7fd95bd0f--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:sgmo="http://www.sangamo.com/20200630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV8yLTEtMS0xLTA_5d06f7f8-edb5-4b6d-954e-0c2de7d99ddc">false</ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV8zLTEtMS0xLTA_addf82d7-22db-4acd-80e7-6e040a32c484">2020</ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV80LTEtMS0xLTA_1efe7424-8428-4a9d-b12b-6b27712c6f5c">Q2</ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV81LTEtMS0xLTA_307773bc-a8cf-4dab-b7d9-2ee2c1c611b8">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV82LTEtMS0xLTA_5e752201-1d8a-497f-8539-9ed912b80a7f">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="ie7cdf45d785d456babc436bb1d8a2750_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0wLTEtMS0yMzU0L3RleHRyZWdpb246ZmQ5ZWViNjc3NjI0NDcyMDllNmE0ZjBiZWM4OTMwOTJfMzI5ODUzNDg4MzQwOQ_0c145ee5-f11e-4897-8b01-2b110be132b5">us-gaap:AccountingStandardsUpdate201801Member</ix:nonNumeric><ix:nonNumeric contextRef="ie7cdf45d785d456babc436bb1d8a2750_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xMjkzL2ZyYWc6NTAyMDQ3NzdmMDNiNGVlY2FhNGIwZGY1OWY1ZjU1YmYvdGFibGU6NzhkZGE2YjExZjI1NGVkNjkxYmQ1OWM3NTE2YjVmNjAvdGFibGVyYW5nZTo3OGRkYTZiMTFmMjU0ZWQ2OTFiZDU5Yzc1MTZiNWY2MF8xLTEtMS0xLTIzNTM_0c145ee5-f11e-4897-8b01-2b110be132b5">us-gaap:AccountingStandardsUpdate201801Member</ix:nonNumeric><ix:nonNumeric contextRef="i354359e0d25047c4ad89c7354597c2fe_D20200201-20200229" name="sgmo:CollaborativeArrangementStandstillRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk2MA_8a0774d0-1ee7-45ae-b865-08409446f2a7">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i354359e0d25047c4ad89c7354597c2fe_D20200201-20200229" name="sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNjE3OQ_91e689ec-675c-4164-b538-3b9389226c79">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="idadecadd2c3540d29b8bfd732262ee0a_D20200101-20200630" name="sgmo:ExtendedResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAyNzM_91569598-dc9b-4299-8c21-58e8ed1c15e0">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i4037038f39cc4dbd9f695b7bbd7e376a_I20200630" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNjY2_e5a325f2-0b18-490c-80b9-c74fd88bf207">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="iab09691164b34490b35b944f2f9fd50f_D20200727-20200727" name="sgmo:CollaborativeArrangementPeriodOfCollaboration" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk1NA_938ff3c2-f0c1-40b0-bd71-520363c2dffa">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="iab09691164b34490b35b944f2f9fd50f_D20200727-20200727" name="sgmo:CollaborativeArrangementExtendedPeriodOfCollaboration" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk2Ng_dc93b536-40db-442b-b669-b33786af281b">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ica30b2d4cf0e4ea79bfc15962f3df122_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i74a14aa270784e14b78266b6b869c0f0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i715b0ac6795a432590fdb6520e45e891_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc447274e11c46e99da86c204d9a409c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6090981ce294ff29297fc34c8c6e128_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a97ca934e54652924592147ff418b4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965e1b6625f34d2e8a6e6973f636c12c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210399ea6286402c8dcca9da42a400de_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ba413aed2bb4cb89498cb2272ebe365_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7d0c3d3b6440a1ab0e041e0722d6e3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f2c0ec83df46a188ead01f731d71b8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f58c14ac1f4042b5cec8f4b7109999_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ecc067020854944955a76da1ab1237b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7be5df5dcc8640e9a57dc51049938bb2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42b494f9fd740a38702396e27d699c3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfcdc625f9d448fa81dac8d80c9ab4f4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fee24599ecb470992405d7a99ed9663_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb11f265f924c26864eda12977fa01a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa736117878e411eb5f7b20e853a01b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia07e3195343d45368e897c17d04de6a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278c4f07da5c496fac619001ae98ef64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic12e6135fb424ea38f6945f7ac5f2eab_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife139e9caa184ca68f4d842bbb1a6e58_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14a3d5f5eac24d569f20aac4bfb416fc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9461724558f4674a9d41050e9ebaae9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2490d9038aa647379f0431522bd71baa_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id966f8a5fab94bbcbd2b71c5797f8185_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee7332332064c54a42898aae0aafedb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bdcd18b9c3d4780a78d371c7e732f38_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9cad5c531bc43ee9ebfdead3cc3a5da_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d659779f044072ae939f9bb6c17be9_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553271530d1747ccaa14899dff3e1650_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316b6d05c95040e2b1eff737183a7185_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539ed8df47a24071adb12e36bb3089ea_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6e0c73ca7c4fb19915320974638f19_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d04447fa724128824a433975c7334b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb20f98f6494310aba335324fea603a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009a92cb8ae04cd0bfbb29c780c42950_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d016582d2524cb58d1a7cb653294394_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb00e01938c41218801d630e5eed895_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id113f3f8a5e9489f8ba5ce4e97f34e4e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0726daec490b495ab4b81b5cc062f239_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if268975f048242d19e806873ecf0328f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i015db7a76e3c48e099a7af789a5fad56_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086101d733d94f44b607cc9a00cdd045_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7cdf45d785d456babc436bb1d8a2750_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3613e176873c4760beea58bab9dd7524_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293b616727bb4417b41b877fe73be3a6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0015c60565ea4383b437165b9285c82d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92671d3c141420f88e50a9fe64c3bf1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94be9ec349764546bf3b7c36db8f8ca3_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ba29b6972848c1bc27ede3e93b882d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerAndSanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ibf55388c1bfb4f1cb45c0812eebe6af4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c61a6784f940f8bd95841c65cc3de2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7d9b485d384d6f8ad54269d553b696_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e52d1ac0635451a9b507adfd21181b1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21370c70454d46adbd1945146055d853_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d8ff36c0ce4c9a8a25a0dd9e3431fa_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48bb61da0bcf4909ad5eeb72eb273bc7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c97ee7ce62e4dd8ab9222f36c803f8b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56021bdaf9354623bd7e8749bb327b83_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ec51d23f3a45679c02cba5fcfadea5_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5840d5f60f4d44dd9851bb922ea77df3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i946c25911d16465c94ce83c9e4b06fdb_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa847036ee74f318716774b63f7a97a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9afe62008bfd4661a107bdae92e16531_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i653ce1faadc3465a97bc8136db41ce20_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfe937211c1b4e088c934d0abe849d2a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a578789cb147eebdc1bb90088efe97_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d45598ab29c4e2db9f9dbb7cec8d9e7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08dc51273904752aaf728a6e1df8383_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab71f71232254a6f82150b71c8f007fb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3461528899214d58b2a932f24904ee6e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd13016ac46c48bc84616522d16a595d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c6ac9671754abdb804515a0bc88a5b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db5a3fc61af496597d6be764fbf968a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae3532bd280450d9b3d2aaf3fd3183f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45cab4a727634aa0ad89eeb42596a594_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97ba6efdd77a4d1fbdd0f8dac7ce03e2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic095f3bf93224fd7830f1bf15820b81b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8eb3ee87c64e9aacf30737f5a51adb_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd6b25106a84026b8dd26c57d4b4125_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bad4096995042179cc11bc904b183d9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452e2107611247cfb0d8f189bfc13b86_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c8bf564147c432e8c52d88f72ff45c0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62b06a1912424ff4a4459beb539c32da_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6936e5949976449dbccf475a22595e86_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a4a0a8362b4d67a4a3abae87fd40b9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa5e29888c3a4d52998814f37ae4dba1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911ca0f0d74e4372b382c1e5cbdefc37_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8298c84318b24ddfbc0a9b713fac9edf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia404f432f5f04e0c86cf5127ad1ee352_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie762e1bf5be24949acbc40644a441c6e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ceaaffd9f074529ba2189860ced6058_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2acfe069e546dca06761088abb331a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676d2b24c5dc42c3b6ff774ebc9c3059_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8cbc3d9d7b430fa2d784ba2a45bd2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fe4c003fa7745d7a49e88abcde0d99c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5eda06ebd043a18f2310ccfa139d5c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i762ba37e09d5444aa3f6af77efa79d0a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92733266bea4a4a995ec95b550ebc2d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e24edd72a4402e947ad3a231a68484_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i365bc9823489411ba4d7b9edcded0fbf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b0f5f2adab4805b0479111e623e2ee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3157fcf32f8c4a93b027d26e140b1f9e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d4d876ac904a2a86c3d4eb8f225dcf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfa387702344d33a007d4a3e6c45c05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74627613ca30495088c9bc6d70c91441_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaab7f3f0f42483f8054df0951921a69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6149f30571a74f36b05d423ef49c6d84_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef63d53d6da4bbfb421afc3382da2ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2aa92c23ee4bfeb3ee17ccff6a2fbf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10649c65a0334bc2a8640fb0be3a04f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ff8aa476e974c09bfed85e41fcd2fab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide0bd3414e1646898d32c7957fea55c8_I20180720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba32d30d24546eca925d1e03e695212_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0521a31195cf4bf6ba85a5da0f003cad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b51e6431f1d4e99b4e005735f3156ba_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80ae933af9fe439582f72421ca16b2d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ebf882acb394d3abcff4f7fbb84922d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a5014580264671a94f115ba17d478c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6f009aa07a4c399d8a95a107332098_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8dfb37df32ca419f81e76d4115394730_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550ea41dd94f4cde8ebccae40c9ea1ec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cd51b31128c404a88c55c12be0f8933_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c895422f38a4eb1a177bc4ea8d56a62_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88202f1ce8de4ff58b28e17316576426_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244af883f9fa4b53b32c33db2e3117c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i308ef5827e2d49879e8d190e7c992de4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b1c09f8aad47379da7b97362291428_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c70a615e27849df839c9cf2964b75f7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3065b36e03d44c578c215e8d30a54eea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9f1db38f654cd1aac9ab696795190d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8f47ed72c944d6aa88add3d596b953e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i255ad07213a74331b5ed4902d8ecc090_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e4e2653abb4a21bb55a0af1318ca23_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3210ae261f447489700bf8bcecaa49c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36f128cd73641d78e18a584b4115086_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27597a1795c6422786f8357584decb2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc450a3922854b8c925f767597c09e9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb25efc099444173a12e09cc80696876_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-08</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i426f14e574704e28836ba330c9dbd8f1_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a3af3ab08043c79aea248e4b3d6b16_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia146054470dd4f3f970c2b2d6eeea2c7_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33efcc2cf083437d856a10fb09d87586_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product_target"><xbrli:measure>sgmo:product_target</xbrli:measure></xbrli:unit><xbrli:context id="i8c8c2d2b28bb459ea77a5e1aca05aab8_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354359e0d25047c4ad89c7354597c2fe_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301f2d2ad4b84c369aa116bdd117c17a_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28405f7b815347269a780c9b058a7e44_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379eea47507e40cf90ab3746c20d3ff7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b3b95cd14d487b848403cb66fe002a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8d5183fb0e4f4ab6e439efc56e5af8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb17ceebd9543aba79ec3e8fbd2f4e8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2532bc5c847458ea5c245c9d0539d8a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea81ce0c28543c297d2984b8efc8ccd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d05a55da884263b1ec48182e49e978_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab06d3a3d932466caba07743e70c8ce3_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7495828dd6da4b6dab035cf784124b17_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f7cee7975f4b6f99d9a6ff2291d024_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if597a7e574f64566b96eae1440d9452d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic346d49a489e488999ebd8bf7e2e449b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa40a47c29de44d5a91538a3a9a70128_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7d1959f6e6453b984185527fca88b9_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd815dd54d643efa93f63fde2181db7_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610fb576d4dd469d840dbfd922ba836c_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>sgmo:option</xbrli:measure></xbrli:unit><xbrli:context id="idadecadd2c3540d29b8bfd732262ee0a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i534bf494758d4e65a8c5a9cd993bd211_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be7ebfec658496c9a397474592935f4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f3b66fa9254360addb420ddb70e7f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1ae59129e94570aabd4555fc76fe34_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed1d741701d4d8896d2e39462a3d431_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100c20eec6fc4407969c367a22a5aefa_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9f41236129499cad0f6ecbb3d8b103_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83e4ca4b8d794be49441483d40aedae6_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd22789c61a44f18dd2221f8e41eb4f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c126a939724395a8b70904f39a6201_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3874265bf7a4b8885aa894e0fca3eaf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c63d999a16941d1a68fc47f694643a4_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b9a9ad5cd14b529d554f21d154e6d7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia075c77e790a4ac991c3cd8ee89ad36b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f1c9d94c66418ba25576f42bb0c41c_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib291aca8325c43a6a2835d40a832c89d_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97cf3acb2d224d289dbcc3817e983d58_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if87eed0b34b64bfd8323247a51d95e6b_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9b91c91f3c407cbef414beccd16d53_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25d43c8653a40efb6068acc53cc63a5_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b47130e76b4541a0d85cafca758698_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5586bb63c84bd9bc5dba5e7ee29b1e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:context id="i68bf878067e24fd7b9f9e0feeab74893_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:context id="id835cc5e8ed34090b3843efa34d914a2_D20170601-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ad04bab0bd4c97b5268f8c70c60007_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a76ad6dd6db47e8bdb42c22f63955fb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42151476a064738ac709c94dbe11690_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbed171f600d4452b7074be69d363203_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e6673b29e749caa0cfd406195b12b2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib203359cf79c4a78b76345ab5cdd5ada_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1215983e16448081567393da2a173e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874cc070d9494a23bb75d5fe3a959fe7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c975adb10c4c80a444e6e169fef905_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e71b2952fdc443c82251bc33b95a5ca_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f1db50a2ee45a69dd2f7dd10845478_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a077c7a6e84585bf477e2bde29c32d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd717c13dbff4c08b4ac853e8fba45b5_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0621e82b115e42d3be6403068e7b2f9a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265e9d79e9a3440ba73a2f8dd054a88d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d56781fdc104f368a6db7f99c183153_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0042ba179bcf4a8d838c6c062581603d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5be0c8a3eaf44cfbdff12b3693acb7b_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c53a13e3ed4b41a51ff5afc0e24f34_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c86f3985aa4e6aaf7123281f53e1c9_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece818eb67d544e1b9ce5641695dda6a_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5106f4851d54887b1c366031ae40b6b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a27653fa2ae413986a3b7ac8ab2240d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74bd1c64097a48dab6c41893d097e234_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b663765efe486ba3be90af8e53ab8d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3679ea31262c4a9a8be73e04e54ce1da_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37ca88da7bc49fbaa868d8671da3f88_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sgmo:program</xbrli:measure></xbrli:unit><xbrli:context id="ie5657715ba8e402b814e812ea70780d8_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497ca7fec0544874896474aa8c59e3c8_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b492f3a18749d2a59bd07e6e047e96_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bd3d15a17e4dfeb83bce33be451571_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41bcbb1429a64230b1a3f20305b3b458_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17dbd8e9112456da64bc13b7c66591e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if322408f9ba44ac3a3050f9173bd5dbf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fdbfad3304d46fdbce872a95bb8f3d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb38c2c18aaf4cf6a67227cc3d5e88e2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e426bbd60b445f8f58775980820ade_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2993707ab04450c93d7c0cde818957f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ebcf7335d143a7b2165fc287c91a99_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e132461b3d342eab6814cba414941b1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7718ad78b270467e8ae7dd73f6379efe_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4652dd95590400a98b5f80879a90ffd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a527321d23c4aed94f50804dacc5d03_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f14044865d4879afb8479d9c63829d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da0f61970a045f19353779959c20d90_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56befc014b3d45ed9d4357b46df3211e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38f03f2a7b44058af0b32589f5cb20e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136a0633a1d642fe8d52aea0bb57ae3e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3250dbc4b25847b3b6cf42f0917717c0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed406253dd0408fa025ccc1e539acff_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if997601e608240a49794adff9baae92f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ba64af70834af7acab6ecdc62729b3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbab28971c8f4c168f2a753a668b5dd3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f81298b72494b5d8bfca23ef7846819_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936718d885f345a0962a1f03189aeecb_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7921fa4bd7c7486b81fa47d950ada799_D20180601-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b8e663d405457c8f481e73b7494220_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be268974b9a4fdc9861bb34708345c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i0ad8f21a630e48d2a8a38df95bced575_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c124d01f92f4f20abe3ffd4deee75f4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8278bf8bca164e85b22804fbba447080_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4037038f39cc4dbd9f695b7bbd7e376a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4787cbcb6bbc401c9aed2cc60462afc9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78f712514d644f0aeb72decbb03a5df_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe52cb8512a433bacfe3d8fc79e20c9_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3439f2f47737467aace116123f9168f1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780b21af471142fda76665c4670e1f9e_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a93dc1df704160a8e800276312cdd3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001922d1aa724eb9ba89ce4a309abafb_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c2dfc465984dfca02266cbfed874c2_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe38837c16248a78d0de8b944f254fb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa400bd785134038a5e827fe16db92fd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a3424384d1467db3554580d425e34a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ae7ba47695144fd9e5a674b88fd5103_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ee1f4e6dd5429489a79d5f03928607_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ae307928d74e0dbeabc531a4d6b23b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b6a65590a94cb39bd8e14b7ac7d841_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2ede07af0343f389b427458e393a41_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89248aaa3ba492aa4b8f488c3be6df5_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ccc4fdb8ea4e4c9cf7485785db1170_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77dd9fd15a104e948837f14e23f36760_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7739ea8df1214054a989dcff454b94a4_D20181001-20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dbedaa261e3453a99f6f409adcb45d5_D20181001-20181123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c49293724e4810919a1e33caec7e6a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i277faef5976144519b807ff6099f0c2a_D20180101-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i885f1a5affb04c469c5e9e4b478422c3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6874113b1491428eacb8504f0de4cfe8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8989c058d5ad4d3083e46b8de83336a3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b4b4f1e90f4a7183a57a1c0fce157c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic55a7e77392b4473b8950e77235bfa85_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40cf24533b514984a2ae3200f4197e14_I20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0dfb29e9e7045fb83ff2c12782a719e_I20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab09691164b34490b35b944f2f9fd50f_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib91cbc7a1cd2485baa09f334bf5ffbe1_D20200727-20200827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-08-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e110ed49cfa4b80989b60ab5d0101ae_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e7c06ca04f44e2b3804131674178f4_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_1"></div><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;margin-top:2pt;"><span><br/></span></div><div style="text-align:center;margin-top:2pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.527%;"><tr><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="15" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%;">UNITED STATES</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">Washington, D.C. 20549</span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">________________________________________________</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%;">FORM <ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjY5_99993108-a328-4cee-ac1d-10dd14553bb8">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">________________________________________________</span></div><div style="margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:1.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:94.667%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZjQ1ZWFmMWMxZGFjNGRlOTlmMmMwNzM4MGU3MWIyNTAvdGFibGVyYW5nZTpmNDVlYWYxYzFkYWM0ZGU5OWYyYzA3MzgwZTcxYjI1MF8wLTAtMS0xLTA_24c25f50-55de-44c3-8195-beadfead1b77">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">For the quarterly period ended <ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8zMjk4NTM0ODg1NjY2_9e58ca9c-ba3d-414b-b545-ce7cf242e9c7">June 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">OR</span></div><div style="margin-top:2pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:0.1%;"></td><td style="width:2.438%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.362%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NWQ5OGJhNDAwYjI4NDQzMTg1NjVjNDAwMzUwNjI1NzQvdGFibGVyYW5nZTo1ZDk4YmE0MDBiMjg0NDMxODU2NWM0MDAzNTA2MjU3NF8wLTAtMS0xLTA_e4dc1558-ae4e-4f12-a2b6-7990cfb22483">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number <ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjcy_76078133-5563-4d32-aae9-43f530217cb1">000-30171</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">________________________________________________</span></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjcw_304d03d2-2f43-402b-b0c0-e7b8589d4df3">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;">________________________________________________</span></div><div style="margin-top:2pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%;"><tr><td style="width:1.0%;"></td><td style="width:29.293%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.265%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.126%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.258%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.058%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8wLTAtMS0xLTA_0be6b811-8918-46e6-8935-f9f807e9b35c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8wLTQtMS0xLTA_62b39e20-d61a-4859-ae79-533d05f43fef">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV80_53a481ef-3656-4ec3-900d-91cee3c49b3f">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV84_a28b6cff-3d85-440b-ab86-c86ea821eefe">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV8xMg_a609a4c0-8b95-44aa-a1a1-63d879d248ad">California</ix:nonNumeric>, <ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV8xNg_cc3dd169-8a3d-4178-ba78-915c69fd9ad4">94005</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices) (Zip Code)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">(<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc0_385dbe26-6a18-48db-8deb-e202db19bcf2">510</ix:nonNumeric>) <ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc1_eba439a3-ca60-4943-9231-5f43530fcacf">970-6000</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">________________________________________________________________________________________________</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%;"><tr><td style="width:1.0%;"></td><td style="width:37.736%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.914%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:37.884%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NjNlMTc0YTU1ODRjNDg3ODgzY2IxZTQzNmQ3ODRmMWQvdGFibGVyYW5nZTo2M2UxNzRhNTU4NGM0ODc4ODNjYjFlNDM2ZDc4NGYxZF8xLTAtMS0xLTA_2a2880ee-0030-4dea-976d-d794695df2fa">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NjNlMTc0YTU1ODRjNDg3ODgzY2IxZTQzNmQ3ODRmMWQvdGFibGVyYW5nZTo2M2UxNzRhNTU4NGM0ODc4ODNjYjFlNDM2ZDc4NGYxZF8xLTItMS0xLTA_d01649b7-0897-4ffd-b3d3-017f33bc8702">SGMO</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NjNlMTc0YTU1ODRjNDg3ODgzY2IxZTQzNmQ3ODRmMWQvdGFibGVyYW5nZTo2M2UxNzRhNTU4NGM0ODc4ODNjYjFlNDM2ZDc4NGYxZF8xLTQtMS0xLTA_c5b03fff-dd14-4e3a-9164-e3a726f595db">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjcx_fd50d477-a340-4666-b1f3-7d03834eb5cb">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:27pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc2_0ee79546-e3b2-4c17-b493-142afcff33ae">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="text-indent:27pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:2pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%;"><tr><td style="width:1.0%;"></td><td style="width:20.873%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.422%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.011%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.539%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.155%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6OTFmZGNiNWRkNTRmNDhkNDliNWNiNzdjYmFiY2E0NGIvdGFibGVyYW5nZTo5MWZkY2I1ZGQ1NGY0OGQ0OWI1Y2I3N2NiYWJjYTQ0Yl8wLTAtMS0xLTA_bd5f5863-d806-441a-9e31-4dd6db666a66">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%;">&#9746;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#9744;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6OTFmZGNiNWRkNTRmNDhkNDliNWNiNzdjYmFiY2E0NGIvdGFibGVyYW5nZTo5MWZkY2I1ZGQ1NGY0OGQ0OWI1Y2I3N2NiYWJjYTQ0Yl8xLTQtMS0xLTA_98c174ca-aa6e-4cce-9ee3-e138ee0485cc">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:27pt;text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6OTFmZGNiNWRkNTRmNDhkNDliNWNiNzdjYmFiY2E0NGIvdGFibGVyYW5nZTo5MWZkY2I1ZGQ1NGY0OGQ0OWI1Y2I3N2NiYWJjYTQ0Yl8yLTQtMS0xLTA_51f41cac-2485-44b2-a377-4b4c6946fff1">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:27pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="text-indent:27pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc3_38c6721d-0d7f-445f-904b-fed8bc7d7cd1">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;&#160; &#9746;</span></div><div style="text-indent:27pt;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">As of August&#160;3, 2020, <ix:nonFraction unitRef="shares" contextRef="ica30b2d4cf0e4ea79bfc15962f3df122_I20200803" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMTgz_a254ad88-2135-4573-9599-6580176169ae">140,988,008</ix:nonFraction> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.527%;"><tr><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="15" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%;"><tr><td style="width:1.0%;"></td><td style="width:12.222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.498%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.280%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_19">Condensed Consolidated Balance Sheets at </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_19">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_19"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_19">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_19">, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22">Condensed Consolidated Statements of Operations for the Three</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22"> and Six</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22"> Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22">, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25">Condensed Consolidated Statements of Comprehensive Loss for the Three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25">and Six </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25">Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25">, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">a</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">nd S</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">ix </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_28">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31">Condensed Consolidated Statements of Cash Flows for the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31">Six</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31"> Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31">June</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31">, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_31">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_70">Item&#160;2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_70">30</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_88">Item&#160;3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_88">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_91">Item&#160;4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_91">38</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_94">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_97">Item&#160;1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_97">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_100">Item&#160;1A</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_100">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_100">39</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_103">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_103">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_103">67</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_106">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_106">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_106">67</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_109">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_109">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_109">67</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_112">Item&#160;5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_112">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_112">67</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_115">Item&#160;6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_115">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_115">68</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_118">SIGNATURES</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#ia59e529445a14a10ab18f7d7fd95bd0f_118">69</a></span></div></td></tr></table></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) and Sangamo Therapeutics UK Ltd.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some statements contained in this report are forward-looking with respect to our operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our strategy;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">anticipated product candidate development and potential commercialization of any resulting products;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the therapeutic and commercial potential of, technologies used by us in our product candidates, including our zinc finger protein, or ZFP, technology platform, zinc finger nucleases, or ZFNs, and ZFP transcription factors, or ZFP-TFs;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the expected benefits of the acquisition of Sangamo Therapeutics France S.A.S., or Sangamo France;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements; </span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our estimates regarding the impact of the evolving COVID-19 pandemic on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts; </span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our research and development and other expenses;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies required to develop and commercialize our product candidates;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our ability to manage the growth of our business;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our projected operating and financial performance;</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our operational and legal risks;&#160;and</span></div><div style="text-indent:-36pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In some cases, you can identify forward-looking statements by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should&#8221; and &#8220;will&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Quarterly Report. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I. FINANCIAL INFORMATION</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_16"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;1.&#160;FINANCIAL STATEMENTS</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_19"></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited; in thousands)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:74.293%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.495%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMy0xLTEtMS0w_9dbb5902-0a29-444c-972a-9e5cd80db207">467,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMy0zLTEtMS0w_48a49aba-3964-4558-b76c-4b127c333265">80,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNC0xLTEtMS0w_dd5cdb30-7749-416e-a53f-152aecae4d8f">197,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNC0zLTEtMS0w_4ff15843-6027-45b1-b387-51342fc05193">282,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNS0xLTEtMS0w_5963201f-faa9-44e9-8e8b-8fd16594df78">534</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNS0zLTEtMS0w_4abbb02f-3d71-43a9-8d05-7d19fc4a4976">682</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNi0xLTEtMS0w_d0ec3916-b0ed-4d8e-bf2b-21e03d5e9af8">5,618</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNi0zLTEtMS0w_034f938b-de7f-4721-baa5-446e90d5163d">36,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNy0xLTEtMS0w_774c3f43-4106-4ce6-ac75-b5dbb6b1d45f">8,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNy0zLTEtMS0w_3e54227f-4f12-45fd-97bb-c8a67f7b4f55">5,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOC0xLTEtMS0w_1dda80ad-bbac-40cb-b6e2-867e08b6a65d">679,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOC0zLTEtMS0w_4956c5a7-140b-4c9c-a54e-e8dc16046d5c">405,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOS0xLTEtMS0w_1a7bf4a8-b2c3-4cec-aec1-89a0460eff35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOS0zLTEtMS0w_379858dd-3d0f-41b5-80b6-396383de40ad">21,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTAtMS0xLTEtMA_012fbe81-fe04-418e-9b72-682f0a59c9a8">33,907</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTAtMy0xLTEtMA_116c5a89-04d5-4f5d-ae0a-968a13558497">29,926</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTEtMS0xLTEtMA_9dca6cd4-bd31-41ff-8b48-acef22cc4bc5">53,219</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTEtMy0xLTEtMA_2fdaff2d-0cf2-4d38-a090-4842411ef188">53,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTItMS0xLTEtMA_9c1fccfb-3b6f-4cce-ae33-2a07223e5cb9">39,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTItMy0xLTEtMA_9cabff06-aa0e-49b2-ad3c-6b5801012c9a">39,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTMtMS0xLTEtMA_a8ca7175-dbb5-4ac1-b4c8-98115fa88b6c">73,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTMtMy0xLTEtMA_ab0b4a36-53fa-4e71-8cca-20c986808f0b">77,289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTQtMS0xLTEtMA_cfcee5b0-efc9-4d3c-88b8-872ec19b756e">13,814</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTQtMy0xLTEtMA_f167c368-c4cf-496d-bd06-08ae71db5e78">9,067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTUtMS0xLTEtMA_899ba789-e7dc-4c75-9cc3-91631df619cb">1,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTUtMy0xLTEtMA_7b8755bf-b57f-4b8e-b63e-1e71abe19e51">1,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTYtMS0xLTEtMA_f44abfe9-0d01-4054-9bd3-1db9d6e344b6">894,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTYtMy0xLTEtMA_eb9d5b97-b058-4f19-96ea-2a3e249c0fc4">637,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTktMS0xLTEtMA_972e1b27-a03f-48d1-a1d8-071efe7618c2">19,221</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTktMy0xLTEtMA_b33d6abf-a16b-44d6-b8f7-4c2746a5e78f">17,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjAtMS0xLTEtMA_b30b0d16-d772-422f-b757-9dfdf7386097">13,332</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjAtMy0xLTEtMA_51f11a26-58cd-4018-9b43-9c94985534cd">13,605</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjEtMS0xLTEtMA_e5ac432a-6526-4ac4-ad6a-acd9f8e17fd1">61,389</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjEtMy0xLTEtMA_21cce942-a4f8-45a1-9b16-1fc0a5a7090c">38,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjItMS0xLTEtMA_5691d7ca-f630-45e9-95be-fcb8e0fbf2d5">93,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjItMy0xLTEtMA_2a4a1221-1946-4cf1-9336-7cb49a5c2a86">69,872</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenues, non-current</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjMtMS0xLTEtMA_a0519c5b-9f40-402f-83e5-e6e990aef5de">237,644</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjMtMy0xLTEtMA_7ffe1c2c-9274-4053-b889-73deaaeb1aa4">81,432</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term portion of lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjQtMS0xLTEtMA_d482ab9a-ecf9-49f6-b1b6-0397c6eb4550">39,234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjQtMy0xLTEtMA_97af7251-11d1-4cb1-9636-d9204d8d3f4b">41,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjUtMS0xLTEtMA_d90443e5-ef68-462b-9105-bb4ea531f149">6,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjUtMy0xLTEtMA_6593e49b-02c5-429b-a1bf-2192e6ee83ad">6,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjYtMS0xLTEtMA_6901fe40-6206-41cc-bee9-43214c2d561b">6,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjYtMy0xLTEtMA_1ec8e369-6d61-4010-b82f-4f427184deab">5,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjctMS0xLTEtMA_5e04bdca-f18a-41b1-93bb-affe93a43ff0">383,453</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjctMy0xLTEtMA_a2dfdb61-d652-434a-9025-bb7337c7ce11">204,777</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjgtMS0xLTEtMA_f4633b6f-9c8f-46c3-bc9e-ff99b8d27b55"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjgtMy0xLTEtMA_463f1ee2-c17a-4c27-8167-8e7d14125359"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzAtMS0xLTEtMA_f707fc91-877b-451f-956c-33f059fc0088">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzAtMy0xLTEtMA_c115078a-b3d0-4889-a5d2-3736c9249297">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzEtMS0xLTEtMA_8d6baf85-e074-44b5-81b5-1953419401a4">1,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzEtMy0xLTEtMA_8f8fc9fc-7891-45f9-a2a0-e9d97a263c09">1,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzItMS0xLTEtMA_192f592a-7e66-46da-a582-219fe174d761">1,247,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzItMy0xLTEtMA_ceae34df-3ac7-4e89-8f53-2b72de307de8">1,090,828</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzMtMS0xLTEtMA_a767ccc7-f612-4ba7-836a-67a33039bbf4">735,827</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzMtMy0xLTEtMA_00acb9fe-3943-4fcb-9248-343208d1983f">656,985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzQtMS0xLTEtMA_ee9b7804-3f88-480e-a0c3-80da3148a77c">1,653</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzQtMy0xLTEtMA_7ccce311-f5b2-4507-973c-ee8ee0d1b3a0">2,449</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Sangamo Therapeutics, Inc. stockholders' equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzUtMS0xLTEtMA_d7816de3-ee21-4a5e-982e-cb3e42b8b7e5">511,457</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzUtMy0xLTEtMA_be670f56-1bf8-4562-b7a7-eba9c01a3ccf">432,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzYtMS0xLTEtMA_fb232da5-c292-4a4e-84ad-87b0988eef81">251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzYtMy0xLTEtMA_c7c3f2ef-32bd-45bd-a6c8-f3d2aa275f58">185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzctMS0xLTEtMA_3c43485d-1304-4e33-b4fc-4906f4fd0ca9">511,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzctMy0xLTEtMA_e8333227-bdf7-455b-a114-ad516e7cb026">432,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzgtMS0xLTEtMA_f6e7af6b-871e-4810-807c-00f88e66667c">894,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzgtMy0xLTEtMA_0b0bf097-6fdf-421a-b1a0-a658fac5a428">637,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited; in thousands, except per share amounts)</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.425%;"><tr><td style="width:1.0%;"></td><td style="width:49.878%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.560%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.560%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.378%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.560%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.522%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.564%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0xLTEtMS0yODA_2371016b-d31e-4e53-bef2-02c3cf8cdf36">21,553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0zLTEtMS0yODA_e144a0cf-12fe-414f-818d-9238e17cba99">17,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0xLTEtMS0w_5b523547-1f0e-42ef-9f15-adcee1bb3f85">34,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0zLTEtMS0w_57afc49b-531b-4662-91bb-eb08a15d5a09">25,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0xLTEtMS0yODA_204719df-c357-4413-8529-b180dceedf07">41,523</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0zLTEtMS0yODA_dd4cf10f-3824-4718-b888-f02349eabe94">36,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0xLTEtMS0w_eab31bd3-7fdf-42ee-a246-6354abed36e0">83,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0zLTEtMS0w_f1a86c6d-2f42-4d2a-9811-e17065d1903d">71,305</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0xLTEtMS0yODA_f886a2fa-3639-416c-bd25-a09b21fe2a2b">17,927</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0zLTEtMS0yODA_1473e746-9639-4662-844e-ab891059d14e">14,597</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0xLTEtMS0w_29877009-9b7f-41cf-9a82-33cff630e6c9">34,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0zLTEtMS0w_a2a6f4be-7a2d-41ad-bd27-e40eda528c2a">31,715</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0xLTEtMS0yODA_b30abb9f-39c6-4a57-8720-52bc51100d09">59,450</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0zLTEtMS0yODA_20535205-aef9-40ad-bbc5-1f532d19b589">51,052</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0xLTEtMS0w_faa54b2e-5e38-435b-b746-077d11be6d2c">117,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0zLTEtMS0w_bf30ae9b-5ddf-4a05-bd7a-f2215358af36">103,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0xLTEtMS0yODA_730a3f21-fa0e-48e8-9025-7e83a243d56d">37,897</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0zLTEtMS0yODA_0f67bb1e-45cb-4407-acc0-ab34acb4e278">33,504</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0xLTEtMS0w_727e8e0f-18b4-411a-86b6-6a85acc263c3">82,419</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0zLTEtMS0w_5a3dedaf-f601-4e03-8ef3-cfd672e068f4">77,401</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest and other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0xLTEtMS0yODA_66617bc5-11b4-47eb-8810-ee7ef7de4148">1,932</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0zLTEtMS0yODA_196ade00-d3de-4b4c-8c8e-a0b78c40f855">3,148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0xLTEtMS0w_edac0a43-e7a3-4c35-bf19-eb3e21eb84fa">3,480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0zLTEtMS0w_09a14a2a-b71c-4fb8-93f9-904ce0960c25">4,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0xLTEtMS0yODA_c383af34-1c91-4c0d-aa79-b93461c980a9">35,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0zLTEtMS0yODA_c4f0e21b-fee8-4e2e-a1a2-33243783a015">30,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0xLTEtMS0w_a60f55c5-67aa-4903-96ff-06bb67546c26">78,939</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0zLTEtMS0w_6d095648-1d9d-43f3-8106-4cd28b75a884">72,559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMS0xLTEtMjgw_09dd6bda-33ea-433b-86c7-2b5f75660c1e">36</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMy0xLTEtMjgw_48580c84-bd2a-4986-aa0b-c4c1af3cc882">72</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMS0xLTEtMA_44cc1de5-1605-4bd0-86a7-b6d840091b94">97</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMy0xLTEtMA_ddf7dc9c-58ee-4abf-8a80-b37e1e8227e8">125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMS0xLTEtMjgw_e7fa1b0e-8fa6-4cd1-bf24-6b176b44ca22">35,929</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMy0xLTEtMjgw_eb28338f-472c-4630-9280-24e6c76f4a33">30,284</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMS0xLTEtMA_9b4c91c5-b0a0-47e9-95bf-41e24b389cf9">78,842</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMy0xLTEtMA_640cd587-432a-45d7-b2a6-02702f51d5ec">72,434</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share attributable to Sangamo<br/>&#160;&#160; Therapeutics, Inc. stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMS0xLTEtMjg1_9e450e16-ed1e-497d-97ec-5a9fc8eaab36">0.26</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMy0xLTEtMjgw_d08a4b62-cd80-40ae-b8ef-934fa7ef7f6f">0.26</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMS0xLTEtMA_72c96407-0fb2-4cb8-8739-ef6e29291d23">0.62</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMy0xLTEtMA_3302f247-7b6e-4ca2-8277-8f3873e94ba8">0.67</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in computing basic and diluted net loss per share     <br/>   attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMS0xLTEtMjg1_e7342e0a-b4fb-40ea-96b4-26d2e66d4d7d">138,977</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMy0xLTEtMjgw_e3d9f365-8b28-434e-9ec8-44eccf8eca96">114,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMS0xLTEtMA_6771bf7b-9c3f-4448-9f98-fe0ab70b5011">127,519</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMy0xLTEtMA_3d9b3da6-1952-4adc-8150-a6d98ac22317">108,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited; in thousands)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.718%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.949%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.805%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.949%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.497%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0xLTEtMS0yMDc_e7e8c3dc-f0f1-457a-9291-94904761f61c">35,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0zLTEtMS0yMDc_8090c041-40c2-4429-bc85-549574d03b56">30,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0xLTEtMS0w_a60f55c5-67aa-4903-96ff-06bb67546c26">78,939</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0zLTEtMS0w_623dbad7-a000-4720-a655-82873760695d">72,559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0xLTEtMS0yMDc_1761f49c-e9ce-4522-a3f9-3bfa2d26128b">1,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0zLTEtMS0yMDc_f20a264d-2ad9-4398-b576-831089e75eee">1,442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0xLTEtMS0w_5769ad03-e4c4-4d85-8913-ae7ef9a1a2c6">150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0zLTEtMS0w_715ef121-241f-4c3f-836f-b9ef14e3cd93">62</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in unrealized gain on available-for-sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0xLTEtMS0yMDc_fc738945-295f-4c02-8666-f49b4e066ac0">392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0zLTEtMS0yMDc_8f3f9c03-6022-4390-8173-5424fe3eb812">484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0xLTEtMS0w_eba966f3-9fd7-40d9-b773-098c3ad3df35">646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0zLTEtMS0w_96462689-5bb6-4592-9573-316d00e6d42b">737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0xLTEtMS0yMDc_08e108c3-6f9b-4ef7-afe7-c8bfa5afc94a">33,790</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0zLTEtMS0yMDc_bcb5cf53-bd67-4df6-a248-cbfa1c8c3ff7">28,430</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0xLTEtMS0w_08b5298a-e3ea-41ad-84f5-7987b16fd4ff">78,143</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0zLTEtMS0w_82c3dbf4-f313-4e60-b6c2-38ec61c3c962">71,884</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0xLTEtMS0yMDc_f7bfd6ff-c6c6-4e21-a139-31f276704677">36</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0zLTEtMS0yMDc_87db20f0-d5bc-4669-949e-fcc3af247fd1">72</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0xLTEtMS0w_6cfbc906-1e4f-42f5-9e01-a333347a8eb5">97</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0zLTEtMS0w_82b940b1-5a9f-47c4-8139-e202aed29b60">125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0xLTEtMS0yMDc_a6e00dd2-dacd-49c1-a996-11c0fe7e39f8">33,754</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0zLTEtMS0yMDc_8e05480e-52b0-44c4-be9c-a4f595ed6c9a">28,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0xLTEtMS0w_5a34705c-b66a-4b84-852c-f3a036b82140">78,046</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0zLTEtMS0w_a50053ed-6e91-41a2-926b-fe4ec847d55b">71,759</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:25.155%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.201%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.752%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.770%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.201%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.626%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.493%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i715b0ac6795a432590fdb6520e45e891_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0xLTEtMS0w_cba0cf0f-417b-4c51-bf24-c3f8635fa8b1">116,278,553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i715b0ac6795a432590fdb6520e45e891_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0zLTEtMS0w_c09caef1-fdd0-4a56-b870-9489fa074f6f">1,163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc447274e11c46e99da86c204d9a409c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy01LTEtMS0w_eba41734-05b8-473d-9a18-da89b72746d6">1,096,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib6090981ce294ff29297fc34c8c6e128_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy03LTEtMS0w_dc8f3473-1f7f-4161-95f6-79fd5c47b849">699,898</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if5a97ca934e54652924592147ff418b4_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy05LTEtMS0w_349f2137-e6f9-4dab-bd13-2e1c91b3bcc4">3,828</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i965e1b6625f34d2e8a6e6973f636c12c_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0xMS0xLTEtMA_270af5d2-74e1-4e87-ae52-27daf42ff70c">124</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i210399ea6286402c8dcca9da42a400de_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0xMy0xLTEtMA_036444b4-34a1-41ce-8b31-664ec9d2563d">394,415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC0xLTEtMS0w_d7cf6a96-23b2-4270-b873-97fcbe594e5d">103,262</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC0zLTEtMS0w_529db1d1-d2a0-4447-a5c2-c62c2cb3671e">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC01LTEtMS0w_877a9d82-920f-4eec-aa24-7988b4ae45d5">442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC0xMy0xLTEtMA_db107711-20f8-42c6-bde6-d0ec0c9e42d7">443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under <br/>  employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0xLTEtMS0xMDIw_76e22287-d416-41b0-9f6a-788bdfbcae6f">171,305</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0zLTEtMS0xMDIw_7377e689-6f5c-46c8-9ff8-d5c94095222a">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS01LTEtMS0xMDIw_34af9138-023e-4b75-bd0f-e7f350984f3e">1,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0xMy0xLTEtMTAyMA_86810d3c-4eec-410e-a4d6-096cd72c50dc">1,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in <br/>  connection with the Biogen <br/>  collaboration agreement, net of <br/>  issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xLTEtMS0xMDIw_dbd34f7b-9f1d-482b-8714-a7657e92723d">24,420,157</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0zLTEtMS0xMDIw_281619bd-26e9-4894-9a41-7cdab4568b2f">244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi01LTEtMS0xMDIw_7984e53d-d9a8-4c24-bf11-65f68076165b">142,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xMy0xLTEtMTAyMA_960975b8-b97c-43bd-81be-3e2cc98e6d47">142,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS01LTEtMS0w_364299a0-3a2a-40f4-8c6d-38e1612994a0">6,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0xMy0xLTEtMA_ea464391-ba37-4d8a-b01b-36d60e85f73d">6,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition of additional shares of <br/>  Sangamo France</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ba413aed2bb4cb89498cb2272ebe365_D20200401-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xMS0xLTEtMA_fb985bf5-5c41-4900-9824-ab7913ac4b4a">339</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xMy0xLTEtMA_52ff2bfa-e8e1-449e-8952-213158ecfd7b">339</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-4.5pt;padding-left:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e7d0c3d3b6440a1ab0e041e0722d6e3_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOC05LTEtMS0w_b1b37ef9-eb3b-48d6-acac-a5fc442b3158">1,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOC0xMy0xLTEtMA_f395ff01-c23c-4231-93e2-6d7ad4659b50">1,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net unrealized gain on marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e7d0c3d3b6440a1ab0e041e0722d6e3_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOS05LTEtMS0w_243d0404-4f92-4a2d-acea-cdfec9abc935">392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOS0xMy0xLTEtMA_8598f4cf-91c9-42cc-bacb-3c2e830748b1">392</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i11f2c0ec83df46a188ead01f731d71b8_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTAtNy0xLTEtMA_b5c0bc60-27d3-47df-bb3a-ce5f51d8c05e">35,929</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ba413aed2bb4cb89498cb2272ebe365_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTAtMTEtMS0xLTA_ff2c1d2b-17a8-4977-ab20-94f279840e35">36</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTAtMTMtMS0xLTA_9db28557-04bb-43de-946e-ef8882694dfe">35,965</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMS0xLTEtMA_907b1268-34f3-4a02-a6dc-7462d249b649">140,973,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMy0xLTEtMA_68b40b96-d480-4e99-93c9-8cbf51789bbc">1,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ecc067020854944955a76da1ab1237b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtNS0xLTEtMA_d2587f3e-9220-44c5-9404-410f7cf85962">1,247,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7be5df5dcc8640e9a57dc51049938bb2_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtNy0xLTEtMA_3e4cd5e7-c6b6-4c26-9680-aaa7c4827876">735,827</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib42b494f9fd740a38702396e27d699c3_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtOS0xLTEtMA_11941aec-df33-4627-b845-0e80afea20de">1,653</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idfcdc625f9d448fa81dac8d80c9ab4f4_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMTEtMS0xLTA_2f1563e2-080a-4c5d-bb5b-63dc78a84730">251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMTMtMS0xLTA_5a8b5b56-6e11-4e56-8e8b-3496e07c25c6">511,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:25.155%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.488%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.752%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.770%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.344%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.195%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.494%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3fee24599ecb470992405d7a99ed9663_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0xLTEtMS0w_e4edb9ba-2c64-4e2f-b0f4-e5f3125bfa4d">115,972,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3fee24599ecb470992405d7a99ed9663_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0zLTEtMS0w_e5cf20c1-8710-4739-855a-dd5e3c5845fd">1,160</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iebb11f265f924c26864eda12977fa01a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy01LTEtMS0w_77695df5-58ba-4ed5-b76b-e18e0119a2e8">1,090,828</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaa736117878e411eb5f7b20e853a01b0_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy03LTEtMS0w_20e9e6f4-ab40-47c3-bf52-0f7ec88b40a0">656,985</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia07e3195343d45368e897c17d04de6a7_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy05LTEtMS0w_60a2ce71-17d7-469b-aacc-7b0af1669015">2,449</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i278c4f07da5c496fac619001ae98ef64_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0xMS0xLTEtMA_802ff2b0-6f4f-4755-8548-1dce2b6e5381">185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0xMy0xLTEtMA_29b797d5-c6dc-40d1-9d1f-315cc575dc09">432,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS0xLTEtMS0w_e3027868-bac3-4acb-9f7c-5217836a53e0">409,107</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS0zLTEtMS0w_eb0fdfc1-94fd-4758-9102-f2c56b1b6c36">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS01LTEtMS0w_388706bf-1225-4ae0-8129-8460c9eb19cf">848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS0xMy0xLTEtMA_6d679fe4-d557-4a08-b2e2-e5bdfde2da21">852</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under <br/>  employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi0xLTEtMS0w_ea750d36-26ea-4d34-8df1-e4c8e4ce8fd3">171,305</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi0zLTEtMS0w_e5818675-7697-4615-9b86-55c934125451">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi01LTEtMS0w_a5e5ef67-d720-4b06-9c9b-48a5e5f17f17">1,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi0xMy0xLTEtMA_9f472637-4c40-42a1-8991-7105e51f0ddb">1,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock in <br/>  connection with the Biogen <br/>  collaboration agreement, net of <br/>  issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xLTEtMS02Ng_c22ed0b3-1e2a-4bae-9166-1ad521ee5ce6">24,420,157</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0zLTEtMS03Mg_02d8557d-8ae9-40aa-ab07-ebbad2bd1f73">244</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy01LTEtMS03Mg_bb472d0d-e6c8-4d92-8fcd-90bf81ab7f44">142,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xMy0xLTEtNzI_be9efc2f-7cdd-48de-8079-0c2b36eec734">142,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition of additional shares of <br/>  Sangamo France</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xMS0xLTEtMA_4a2a1304-33ee-4da4-9cfe-abf7dd53039e">339</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xMy0xLTEtMA_c0435f71-9754-4a69-8c1d-9bccc2026a15">339</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOC01LTEtMS0w_2f1f3420-204d-4ba6-be08-52b92b87dc20">12,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOC0xMy0xLTEtMA_2154b611-c4e0-4cc6-88d1-4a57364ad18f">12,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-4.5pt;padding-left:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic12e6135fb424ea38f6945f7ac5f2eab_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOS05LTEtMS0w_48211eff-53bc-4a2e-819c-1699ee0a48e4">150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOS0xMy0xLTEtMA_b6ee8c33-21c2-4db8-8be4-a84f843c467e">150</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net unrealized gain on marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic12e6135fb424ea38f6945f7ac5f2eab_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTAtOS0xLTEtMA_c8b36cec-a8aa-48ff-bb53-43926832bf96">646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTAtMTMtMS0xLTA_0f65c0db-6f48-4f5e-afa4-e4d38e01f292">646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ife139e9caa184ca68f4d842bbb1a6e58_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTEtNy0xLTEtMA_ff10b567-5ca0-439e-a2f4-0e098ee3ff13">78,842</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i14a3d5f5eac24d569f20aac4bfb416fc_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTEtMTEtMS0xLTA_6f005e0d-e8d3-411b-8b6f-00436977de16">97</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTEtMTMtMS0xLTA_5ed118b8-314a-4646-bf6c-f980b7604c4f">78,939</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMS0xLTEtMA_31a80e4e-1a79-4465-a0f1-8ec020d6cd5a">140,973,277</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMy0xLTEtMA_6d827725-0bf4-4f84-9008-296c249a2185">1,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ecc067020854944955a76da1ab1237b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItNS0xLTEtMA_84161c74-9484-4ec9-aa96-9f26be64b335">1,247,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7be5df5dcc8640e9a57dc51049938bb2_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItNy0xLTEtMA_4fef9e57-b932-4023-a7a5-5cdebc0b50f5">735,827</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib42b494f9fd740a38702396e27d699c3_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItOS0xLTEtMA_844fd9b1-3107-4e8c-8349-6d2c52c40e9c">1,653</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idfcdc625f9d448fa81dac8d80c9ab4f4_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMTEtMS0xLTA_6f284035-e070-4b65-83dd-11cc5b7d1caa">251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMTMtMS0xLTA_6d287422-4e37-4365-a826-148a40b5df4d">511,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center;margin-top:12pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:25.155%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.488%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.752%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.770%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.344%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.195%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.494%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9461724558f4674a9d41050e9ebaae9_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0xLTEtMS03Ng_d4892ea9-bc67-4697-a1a0-c9d9f3d1ffdc">102,328,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9461724558f4674a9d41050e9ebaae9_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0zLTEtMS03Ng_95776056-cd83-4967-a699-7f423ec7db81">1,023</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2490d9038aa647379f0431522bd71baa_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy01LTEtMS03Ng_8068246e-511c-4e8e-ad9c-4fd15e428bf0">934,112</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id966f8a5fab94bbcbd2b71c5797f8185_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy03LTEtMS03Ng_142ecc07-1d15-40d6-979f-7bae6dca0567">603,949</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ee7332332064c54a42898aae0aafedb_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy05LTEtMS03Ng_635e07a4-336d-4c82-a281-25e13440b2fe">2,691</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6bdcd18b9c3d4780a78d371c7e732f38_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0xMS0xLTEtNzY_475ae51d-b87b-43de-ab90-8c8eebc250a3">686</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9cad5c531bc43ee9ebfdead3cc3a5da_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0xMy0xLTEtNzY_9df2b074-841b-4840-8c5c-2beddfedaab1">329,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS0xLTEtMS03Ng_c6581f77-a2af-4f4b-8d28-c999baf84dc1">492,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS0zLTEtMS03Ng_f51b7bdf-b999-423f-8cd6-94ae6884e5bf">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS01LTEtMS03Ng_e65165e4-66e9-4204-9ae4-39efc022649f">2,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS0xMy0xLTEtNzY_782f9509-1a00-46bc-aa37-e2cec97b5fd0">2,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi0xLTEtMS03Ng_4fe45a3c-aa91-4c56-af7d-bbe0dc0260af">131,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi0zLTEtMS03Ng_b8f72204-732a-4e29-97d8-813e1cd63b04">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi01LTEtMS03Ng_686f1202-0aac-4a50-9600-749d90875532">1,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi0xMy0xLTEtNzY_f7161770-60a3-42da-8061-51bc8f20b2ce">1,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under public offering, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy0xLTEtMS03Ng_a314fcf9-39d8-4746-a469-6f03bc686f07">12,650,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy0zLTEtMS03Ng_6d2bfddb-6741-46de-9f36-6a9033119ff3">127</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy01LTEtMS03Ng_4f4f6405-a265-4fb5-8c6d-1799a1e96e66">136,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy0xMy0xLTEtNzY_2d5f075d-4fdb-435c-819e-e02c60dbd91d">136,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance costs related to public offering</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOC01LTEtMS03Ng_2887db48-558c-4c57-a2d7-e20e767d3f89">18</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOC0xMy0xLTEtNzY_a8ab887e-f0fd-4ec1-9281-f2a82cf20529">18</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOS01LTEtMS03Ng_a652f996-0dd3-4542-82c2-c285b8408f61">4,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOS0xMy0xLTEtNzY_f2fa508a-d2a7-496b-8c8c-c17c978e245e">4,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-4.5pt;padding-left:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38d659779f044072ae939f9bb6c17be9_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTAtOS0xLTEtNzY_7b91292d-4252-4eed-b376-3a277664e05a">1,442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTAtMTMtMS0xLTc2_ebb118a1-c6c5-43a5-935a-908ea120a086">1,442</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net unrealized gain on marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38d659779f044072ae939f9bb6c17be9_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTEtOS0xLTEtNzY_625f6fd9-1de2-4ffc-9b04-eb5764d7301b">484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTEtMTMtMS0xLTc2_87403bd1-c96a-4d9d-9b05-c185da87e524">484</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i553271530d1747ccaa14899dff3e1650_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTItNy0xLTEtNzY_bf30a9cb-883e-4e8d-9aea-8db2ac853abe">30,284</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i316b6d05c95040e2b1eff737183a7185_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTItMTEtMS0xLTc2_c03de015-87d2-4b49-b065-baf64a4bc618">72</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTItMTMtMS0xLTc2_f1bdfc68-58fa-4c1b-8cf2-ca564a2b9b10">30,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMS0xLTEtNzY_0d5f66d4-a06f-4ca8-bb01-145408d27a2e">115,603,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMy0xLTEtNzY_7ddc0e81-342f-4215-b075-be95798f023c">1,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice6e0c73ca7c4fb19915320974638f19_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtNS0xLTEtNzY_d8f04c9b-434a-42f7-a8a0-1cc15a1507ef">1,078,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6d04447fa724128824a433975c7334b_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtNy0xLTEtNzY_e22b6436-e723-457f-9c87-126d133c4a03">634,233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5bb20f98f6494310aba335324fea603a_I20190630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtOS0xLTEtNzY_2cd5ed39-8a3e-4915-8097-8cccadc90cbb">765</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i009a92cb8ae04cd0bfbb29c780c42950_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMTEtMS0xLTc2_8f89b7a2-27ab-454a-b3ec-6214bd852c40">614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMTMtMS0xLTc2_75a758ce-882a-4a72-b82a-9c70f818c94a">445,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:25.155%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.201%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.752%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.770%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.201%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.626%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.493%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="39" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5fb00e01938c41218801d630e5eed895_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0xLTEtMS0xMTQ_7db937bd-7103-489f-9605-aef09fe35496">102,187,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fb00e01938c41218801d630e5eed895_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0zLTEtMS0xMTQ_dac62ebf-26de-4327-8d53-ba1bb283ca34">1,022</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id113f3f8a5e9489f8ba5ce4e97f34e4e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy01LTEtMS0xMTQ_672e55df-8f96-4c61-bce2-557b7d3e9e75">929,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0726daec490b495ab4b81b5cc062f239_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy03LTEtMS0xMTQ_69266f1e-3361-45f9-94d2-33338842c717">562,696</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if268975f048242d19e806873ecf0328f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy05LTEtMS0xMTQ_c8daac30-d70c-4db8-8659-fe4840c66c92">1,440</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i015db7a76e3c48e099a7af789a5fad56_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0xMS0xLTEtMTE0_1035178f-5cf7-4f46-bebc-425d89edcfc5">739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0xMy0xLTEtMTE0_7a458e7a-8bc9-4e14-9a27-2cdc8b6b4c29">367,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Cumulative-effect adjustment of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0wLTEtMS0yMzU0L3RleHRyZWdpb246ZmQ5ZWViNjc3NjI0NDcyMDllNmE0ZjBiZWM4OTMwOTJfMzI5ODUzNDg4MzQwOQ_0c145ee5-f11e-4897-8b01-2b110be132b5">ASC Topic 842</span> on January 1, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3613e176873c4760beea58bab9dd7524_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC03LTEtMS0xMzg_7ca14b8c-7a38-4f96-8e37-2ad6d8bd52df">897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i293b616727bb4417b41b877fe73be3a6_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0xMy0xLTEtMTM4_1fd4e989-041d-47ed-990b-c5e2e0d26e6e">897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0xLTEtMS0xMTQ_ddb88777-a9e1-4cd7-9f6e-d630285f381d">633,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0zLTEtMS0xMTQ_374ec395-ca9e-421c-87e0-77cb989c4f6d">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC01LTEtMS0xMTQ_b318af45-360f-45a5-83c3-1004eaf138d3">2,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0xMy0xLTEtMTE0_47616388-1581-4bd9-829d-d818d83595a7">2,660</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS0xLTEtMS0xMTQ_b5514366-177c-4bda-956d-fa6c9ae6c3b9">131,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS0zLTEtMS0xMTQ_c84d50f6-c36a-4e84-b62e-8bf6ac25e73f">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS01LTEtMS0xMTQ_c898ae58-22d9-4beb-a480-7223c48f487a">1,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS0xMy0xLTEtMTE0_d2acb0ec-c184-41ae-beda-972f7c503fc9">1,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under public offering, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi0xLTEtMS0xMTQ_252a4632-8a5e-436d-85bc-9575b2f54975">12,650,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi0zLTEtMS0xMTQ_820398cf-a243-4c7c-9a67-dcef6e587517">127</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi01LTEtMS0xMTQ_0be9a5f7-b5e6-45e1-8652-f1133b6eaf3c">136,439</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi0xMy0xLTEtMTE0_387d9819-1e14-4852-8a20-bfc068487253">136,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance costs related to Sangamo France Acquisition</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNy01LTEtMS0xMTQ_0eb1cbe1-389e-4873-842a-1ffaa674bbdc">276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNy0xMy0xLTEtMTE0_b510416e-6bbf-448d-b10c-d08c9a4e1195">276</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOC01LTEtMS0xMTQ_bb637322-8368-4a3c-b37a-d274917af001">9,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOC0xMy0xLTEtMTE0_8e6a7b51-18d9-4dd3-8c9c-fdfdd448e3df">9,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-4.5pt;padding-left:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOS05LTEtMS0xMTQ_0dcb68fc-362d-4e92-a19b-51386cf63c72">62</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOS0xMy0xLTEtMTE0_a4d1575b-b90f-4a6e-8efd-9f0c6f6c1238">62</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net unrealized gain on marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie92671d3c141420f88e50a9fe64c3bf1_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTAtOS0xLTEtMTE0_8669e25c-e965-49ee-a4c3-e88b6952e996">737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTAtMTMtMS0xLTExNA_f4610209-cdf4-41ba-b5fc-5056ac6bc558">737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i94be9ec349764546bf3b7c36db8f8ca3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTEtNy0xLTEtMTE0_cb611608-d651-48f6-b686-d4ac3758e268">72,434</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i63ba29b6972848c1bc27ede3e93b882d_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTEtMTEtMS0xLTExNA_baa10d58-98d8-4b3a-9c73-4f13e7e51dd3">125</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTEtMTMtMS0xLTExNA_fe180899-5c02-48c1-af4f-8de4e13e16b9">72,559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balances at June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMS0xLTEtMTE0_d55740e0-6c2f-4daa-8acb-df84dbcaaf16">115,603,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMy0xLTEtMTE0_8062af12-bc38-40d3-bad6-0982b1c2e306">1,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice6e0c73ca7c4fb19915320974638f19_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItNS0xLTEtMTE0_2e9cab1f-cedc-45f9-9ba2-525b3e0b844b">1,078,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6d04447fa724128824a433975c7334b_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItNy0xLTEtMTE0_9dd67715-364e-424c-8710-5da067ab286d">634,233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5bb20f98f6494310aba335324fea603a_I20190630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItOS0xLTEtMTE0_f4b50bf4-10c2-4f6d-b1cf-1b1c91b9e552">765</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i009a92cb8ae04cd0bfbb29c780c42950_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMTEtMS0xLTExNA_b0428e8d-6092-4fbc-a880-ad8515f2e219">614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMTMtMS0xLTExNA_ea3eec42-20e6-4bd2-b363-a904849e9865">445,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited; in thousands)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:74.293%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.495%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMy0xLTEtMS0w_53d122a7-1b54-41b5-977c-7fa59dba473c">78,939</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMy0zLTEtMS0w_62f2dd48-9279-42b9-becd-33fef6fdd3e5">72,559</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNS0xLTEtMS0w_7db5448c-801b-4321-aeec-05374d5a68e1">2,639</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNS0zLTEtMS0w_f0985d6e-9b44-49ff-83cd-67b7b6af3346">1,583</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of discount on marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNi0xLTEtMS0w_8cfec018-c1e9-4851-b051-9456d0e0f258">1,146</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNi0zLTEtMS0w_8856fd94-6574-4612-ad8c-48a68e46e4d4">2,455</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization and other changes in right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNy0xLTEtMS0w_e5a9d9d2-8cee-4153-8d33-9da343594aed">3,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNy0zLTEtMS0w_0284cbf8-ef82-40a4-a9f6-9bc75088d793">1,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain on free shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="sgmo:GainLossOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOC0xLTEtMS0w_57214808-d7b0-4d82-a797-d60f938076de">48</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="sgmo:GainLossOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOC0zLTEtMS0w_e668d866-f042-4c65-98c4-bdcfc8835e6b">551</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOS0xLTEtMS0w_bebd9898-0a2c-4949-ab4c-bd663633dbbc">12,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOS0zLTEtMS0w_0da5cf29-2058-4991-8078-de8639aca8bb">9,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss on lease termination</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTEtMS0xLTEtMA_b3ff4fdf-7130-4d8e-a866-af392ccce077">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTEtMy0xLTEtMA_5a48b1c6-8c9c-40a8-8631-7c78e1f069e9">218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTItMS0xLTEtMA_4b56ffac-cf47-401d-9de0-3754944282e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTItMy0xLTEtMA_3e803602-33d4-4aec-a56d-23a8e5eeff77">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTQtMS0xLTEtMA_add9e20f-d45b-446e-82f1-bd49dcf6f47b">148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTQtMy0xLTEtMA_14a644d8-574f-461e-9052-1b4ed6239eea">391</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTUtMS0xLTEtMA_63b58b2d-fd10-4d73-ab67-add41d6effc6">31,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTUtMy0xLTEtMA_eec2bc89-2b5d-454d-b9c2-73fa9490dd7c">7,422</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTYtMS0xLTEtMA_0c680d9b-4871-4990-98a0-c9b493b25ea2">7,763</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTYtMy0xLTEtMA_b47b6dde-1510-4337-adda-5ca911401b75">5,449</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTgtMS0xLTEtMA_e891744f-e39d-4379-abbc-803d19a7f350">1,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTgtMy0xLTEtMA_5c866f4c-ded6-4cd2-a541-52724608e091">1,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation and employee benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTktMS0xLTEtMA_6df9f464-91e0-4dd2-b294-049d774d0432">248</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTktMy0xLTEtMA_bd227247-00af-4393-9f3b-c617283fe8ff">764</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjAtMS0xLTEtMA_ba832069-bc6b-407b-9366-b800c8026337">178,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjAtMy0xLTEtMA_736c5283-2600-4053-9a40-0a7dbb22fcad">10,821</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term portion of lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjEtMS0xLTEtMA_3cc6bcc0-a159-492f-bdba-77e26502e9d0">1,797</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjEtMy0xLTEtMA_8491bf05-bd33-458f-9a5a-a9442d60f3d6">563</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjItMS0xLTEtMA_1adb3da6-de01-4db1-bb74-336c539489d7">345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjItMy0xLTEtMA_a4e4b35d-c3ad-4052-b963-6d9cfd2e8e4b">1,327</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjMtMS0xLTEtMA_79328853-a2e7-4acf-b9d6-476ffd4a7221">141,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjMtMy0xLTEtMA_82ae0e7f-5973-4138-8be4-92866f0f03e0">84,712</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjUtMS0xLTEtMA_4ade0665-6406-4e85-8367-48c0b2c34154">43,580</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjUtMy0xLTEtMA_9bfbbb72-a4ba-47e3-b49a-1a6d47174221">244,306</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjYtMS0xLTEtMA_f4822c36-5e4b-4336-9fd8-9ba93d166aa8">151,839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjYtMy0xLTEtMA_6e9840c0-4982-40d8-a462-f40d374c1868">226,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjctMS0xLTEtMA_0ed3f2f1-c39a-4137-86b2-93bc0c15f39c">6,694</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjctMy0xLTEtMA_f1aa826f-968f-4a5b-859d-7fb595587816">9,760</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of additional shares of Sangamo France</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjgtMS0xLTEtMTEzMg_832ff1b0-9474-497a-a04e-78c6e700e9b6">237</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjgtMy0xLTEtMTEzNg_704e22ca-7b83-40d0-b338-9142612a521a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzAtMS0xLTEtMA_0d22b2af-99a8-41eb-b4ab-67bc43ea3265">101,328</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzAtMy0xLTEtMA_d67fb42e-18dc-4e37-9dad-bc1b1169307e">27,182</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzItMS0xLTEtNzg4_9a167646-3cbd-4362-a854-3f9947aedbcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzItMy0xLTEtNzg0_4ac901b9-643b-4408-bba8-76948321d21d">136,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMS0xLTEtMTA5Nw_cd300532-4c9e-4bbc-a869-f8272b493610">142,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMy0xLTEtMTA5Mw_ed99b979-adb1-4f89-8715-a2f48ab872e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMS0xLTEtMA_db693978-5473-463e-9616-84526a2a131b">455</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMy0xLTEtMA_37c866c4-1638-4c74-81d6-918e1cfeda8e">296</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of stock options and restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzQtMS0xLTEtMA_826d3d6c-3c6c-404a-9df9-dceea3ffd27f">1,307</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzQtMy0xLTEtMA_e40f2b61-f5b8-49e4-9bab-4404434e9b2f">4,094</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMS0xLTEtMTEyNQ_bd737755-1e8c-4756-920f-b9f89889129f">1,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMy0xLTEtMTEyMQ_d5918238-aaa8-47be-a33a-a67d699777df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzUtMS0xLTEtMA_27654f5d-b11f-48ec-bcd7-c23ad68f8a91">144,565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzUtMy0xLTEtMA_4750027b-f31c-4de4-99b8-d7b53de7067e">140,106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effects of changes in foreign exchange rates</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMS0xLTEtMA_8f12ce7f-e35e-49d8-a26d-fa4fabc9e575">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMy0xLTEtMA_0fa0c883-a888-4223-8804-2d02115ce3be">592</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzctMS0xLTEtMA_2fa1361c-4073-4ed7-b6ad-e5eb1b6e79ff">387,015</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzctMy0xLTEtMA_6e20cf07-2650-4656-920c-474720166061">28,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzgtMS0xLTEtMA_6237b600-ed63-44da-8ea7-c8290c8525c4">81,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzgtMy0xLTEtMA_f5c1918c-f890-4ce6-ab72-d41502973333">143,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzktMS0xLTEtMA_e638a7ff-fa06-4394-b195-c15248b940fb">468,943</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzktMy0xLTEtMA_d21bdfe9-fa1c-4717-9da2-e4d80aaf1f62">172,722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment included in unpaid liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDEtMS0xLTEtMA_8babb1be-127d-4de0-865e-fb35b1a9724f">1,977</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDEtMy0xLTEtMA_9467b78a-6cf5-4fb1-9610-c0f8757cc789">1,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDItMS0xLTEtMA_8c997fb4-c8fe-4967-8cd8-cafb65111327">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDItMy0xLTEtMA_cef9c0e3-ad33-4046-8f88-2ad5dbaab921">29,671</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">June&#160;30, 2020</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_37"></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 1&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODg_ef4beb94-c301-4fa7-918a-8d0d87ff9439" continuedAt="i217d238c68824b20a3f396684160660b" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i217d238c68824b20a3f396684160660b" continuedAt="i0a8fafa6d3844464bbe8cc55a636d29a"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Business Overview</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995. Sangamo is a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using the Company's platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation. </span></div><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODk_618d2e06-c93f-4bb7-a16e-11dc6eab075e" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. The Condensed Consolidated Balance Sheet data at December&#160;31, 2019 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 (the &#8220;2019 Annual Report&#8221;) as filed with the SEC on February&#160;28, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company's Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2019, included in the 2019 Annual Report.</span></div></ix:nonNumeric><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaboration funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2020, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12 months from the date the financial statements are issued. Sangamo may require additional financial resources to complete the development and commercialization of its products including zinc finger protein (&#8220;ZFP&#8221;) therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to advance its product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMzI5ODUzNDkxMDQ3OA_a38450fb-7a2c-450b-b18e-e1d04bb14f9c" continuedAt="i229756815c504c098ce8465df11cf3e1" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i229756815c504c098ce8465df11cf3e1">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</ix:continuation> </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i0a8fafa6d3844464bbe8cc55a636d29a" continuedAt="i113a59970f2e45be92514029c67779d4"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi Genzyme (&#8220;Sanofi&#8221;) as a result of a decision made by the joint steering committee of Sanofi and Sangamo to increase the project scope and related project cost, which resulted in a decrease in the measure of proportional cumulative performance. In March 2020, the Company also recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs after the successful investigational new drug (&#8220;IND&#8221;) transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">research collaboration and license agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pfizer-related adjustment in June 2020 increased revenue by $<ix:nonFraction unitRef="usd" contextRef="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTA5OTUxMTY1NDIzMA_e8f7c87d-a8c9-4e5d-aded-3a9a9879f5c8">3.0</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTA5OTUxMTY1NDI0NA_90f23e1a-0a71-4a6f-8a8e-bee4bad19675">3.0</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTA5OTUxMTY1NDI1MQ_65828224-44cf-4592-ae7d-f4c730ea1e5d">0.02</ix:nonFraction> for the three months ended June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pfizer and Sanofi-related adjustments in March and June 2020 increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfNTY4Nw_5fb816a0-e912-4e10-b1cd-fda396ca6dac">3.1</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfNTcxMw_5a797531-5c0c-4c28-b9e8-ba2186b2e5b0">3.1</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTY0OTI2NzQ2NzQyNw_ff69dba6-6848-414b-829a-b7fc54f52020">0.02</ix:nonFraction> for the six months ended June&#160;30, 2020.</span></div><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMzI5ODUzNDkxMDQ3OQ_c0d56397-72d5-4687-a223-308cbd7b855d" continuedAt="ic462753ed4e44d51966e2620a9eea043" escape="true"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i113a59970f2e45be92514029c67779d4" continuedAt="i1b81840b0a4047ed8af603a6bcbee457"><ix:continuation id="ic462753ed4e44d51966e2620a9eea043"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODM_557be307-523d-4863-81a1-e8612955b045" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.982%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.805%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.805%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.805%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.503%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibf55388c1bfb4f1cb45c0812eebe6af4_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0xLTEtMS0xOTc3_52ab2767-7e56-427c-a964-e84b772d17e1">38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic5c61a6784f940f8bd95841c65cc3de2_D20190401-20190630" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0zLTEtMS0xOTc3_7386a59f-59d3-40d2-87c3-470838ac1c69">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="idc7d9b485d384d6f8ad54269d553b696_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi01LTEtMS0xOTc3_99d88413-f1bb-4b71-b5a6-e4d4a8e18215">24</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i7e52d1ac0635451a9b507adfd21181b1_D20190101-20190630" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi03LTEtMS0xOTc3_0c8dc802-a1da-4ae6-af27-de763fbc5e94">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i21370c70454d46adbd1945146055d853_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0xLTEtMS01MDQ_b4876f69-ed27-447a-9fd3-d6346025e1b0">34</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia4d8ff36c0ce4c9a8a25a0dd9e3431fa_D20190401-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0zLTEtMS01MDQ_1007c23b-0324-4c44-8fe9-1a2427b0519b">52</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i48bb61da0bcf4909ad5eeb72eb273bc7_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0xLTEtMS0w_de187a30-5d45-4981-89e1-67294bbaa90f">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1c97ee7ce62e4dd8ab9222f36c803f8b_D20190101-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0zLTEtMS0w_c175db52-f608-4d79-8416-c3e388702ac2">61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i56021bdaf9354623bd7e8749bb327b83_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0xLTEtMS01MDQ_6dec59cf-a324-4b83-87f3-189d2ba25e9a">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib8ec51d23f3a45679c02cba5fcfadea5_D20190401-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0zLTEtMS01MDQ_9ec05935-09bb-4327-b557-2b50067c494c">26</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i5840d5f60f4d44dd9851bb922ea77df3_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0xLTEtMS0w_c5c25a0e-885d-4e0d-a4d5-5789a1e38b13">21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i946c25911d16465c94ce83c9e4b06fdb_D20190101-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0zLTEtMS0w_60dbddf3-8908-4896-bc40-9b10aadbc989">16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i0fa847036ee74f318716774b63f7a97a_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0xLTEtMS01MDQ_1158db97-3f37-4e52-8a11-9fec9b274f37">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i9afe62008bfd4661a107bdae92e16531_D20190401-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0zLTEtMS01MDQ_868ace2b-2861-43a2-9cf2-4e6948d5103a">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i653ce1faadc3465a97bc8136db41ce20_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0xLTEtMS0w_57751843-bb47-41ce-ace5-b8e6a060f9ee">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icfe937211c1b4e088c934d0abe849d2a_D20190101-20190630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0zLTEtMS0w_ccf85b21-a157-485b-888a-f2e1af599b21">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2020, the Company had not incurred any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2NzY_f0611061-99c9-4509-be6c-e942497902ad" escape="true"><div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div></ix:nonNumeric><div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODI_b82576a6-a6dc-4d4a-996a-b810fa66c532" continuedAt="i24a05dea9d114c3284af62cdf5294888" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i24a05dea9d114c3284af62cdf5294888">Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</ix:continuation> As of June&#160;30, 2020, no impairment of goodwill or indefinite-lived intangible assets has been identified.</span></div><div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2Nzg_779134e5-845b-4084-ac54-2d91b8326ffb" continuedAt="i2ead42c009b64d70a709fd870ba104d2" escape="true">Valuation of Long-Lived Assets</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2ead42c009b64d70a709fd870ba104d2">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</ix:continuation> As of June&#160;30, 2020, no impairment of any long-lived assets has been identified.</span></div><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2NzM_b0f1ea65-0366-4f99-8140-c86ded19ded5" continuedAt="if0c33e9c7d9f4e96bee203728199b97f" escape="true"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i1b81840b0a4047ed8af603a6bcbee457" continuedAt="i146f11b44aa64330a9a37353fde0821a"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if0c33e9c7d9f4e96bee203728199b97f">estimated fair values. The free shares asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.</ix:continuation></span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTA_840545c5-e5e0-4e7a-9a4a-6d314ee9862e" continuedAt="i4caee00eb71e45dfa3971e2e0b58bb82" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i4caee00eb71e45dfa3971e2e0b58bb82">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.</ix:continuation> Restricted cash consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTU1MTE_a24bfd25-3172-44e8-a089-79af488bbb24">1.5</ix:nonFraction>&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTc_4ee2308a-dad3-4ed2-90a6-bc3c205078f3" escape="true"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTc_a28d6e0b-a24d-44cb-9959-76fc60aa70b8" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%;"><tr><td style="width:1.0%;"></td><td style="width:52.505%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.191%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.465%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.046%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.615%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS0xLTEtMS0w_d9efcba9-1260-4427-be60-0d718da428da">467,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS0zLTEtMS0w_06434fab-8958-49ed-8107-82ce91af9c44">80,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS01LTEtMS0w_781f6ec2-0a96-4bb0-aa9f-fd37fa2f06e9">169,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS03LTEtMS0w_c03f3e54-ddfb-4f76-87a8-5e61be1a542e">140,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi0xLTEtMS0w_cef8d5cb-ae7d-45fa-8b31-1e1f9fb8eb35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi0zLTEtMS0w_106fc9b0-e239-46ad-ac51-28c71c42f5c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi01LTEtMS0w_f0a7871c-3a9b-429a-b536-0d1339076576">2,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi03LTEtMS0w_d25103ad-f53f-4e18-8a42-0fce653e2be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy0xLTEtMS0w_a4f6cbf4-1c24-4916-a6f1-d2128b04904a">1,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy0zLTEtMS0w_db96e2df-0d8d-41fc-9258-0138991a0c4a">1,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy01LTEtMS0w_40207275-f6aa-4c9b-8c9c-5f04544da77e">1,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy03LTEtMS0w_48c2ffbb-5aba-4337-9b2e-e24d6c263dda">3,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC0xLTEtMS0w_d68ada5b-f0eb-424c-9e8d-9b05c400edc3">468,943</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC0zLTEtMS0w_f9a3ed5b-9215-47a7-be95-9eab563c110c">81,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC01LTEtMS0w_1ced0599-3b80-40cf-b195-c0bd4ac9a0dd">172,722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC03LTEtMS0w_d6115296-d3f0-4d2e-84c1-df3a795c05fa">143,918</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODE_6493df70-e960-4e0a-919d-1c7ba3e68995" escape="true"><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in Accumulated Other Comprehensive Income (Loss) (&#8220;AOCI&#8221;) within stockholders' equity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in other income (expense) within the accompanying Condensed Consolidated Statements of Operations. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the estimated fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in interest and other income, net, which are determined using the specific identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODc_9d4617ce-eb9b-417b-bef4-075d287bbbe7" escape="true"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Risk</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an IND application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i146f11b44aa64330a9a37353fde0821a" continuedAt="i0924288a94624e0cb0625ea94c7f62f1"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTg_b03a2b8f-612a-4009-a03a-f663557a626a" escape="true"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2NzQ_45332edd-96e8-4182-84cf-7b1152c14a71" escape="true"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTE_274fb8ec-d6f5-40bc-9642-8929084e014f" continuedAt="i1630b54972184fb084e2577057e3120d" escape="true"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Goodwill Impairment Testing</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2017-04&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-04 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Credit Losses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i0924288a94624e0cb0625ea94c7f62f1"><ix:continuation id="i1630b54972184fb084e2577057e3120d"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes &#8211; Simplifying the Accounting for Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 740)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div id="ia59e529445a14a10ab18f7d7fd95bd0f_40"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 2&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk2Nw_6e0f2aa7-ce58-46ec-b0ed-b63158fb3338" continuedAt="i8162515cd41a43c29384578e47ab776a" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i8162515cd41a43c29384578e47ab776a" continuedAt="i6ac6f146dce741259861bc6e3a90cfbf"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk2OQ_37bb7eeb-15e0-4bca-812c-04b63dcb5271" continuedAt="ib3af9ec13cb24c77980299aca7e4c631" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.844%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4a578789cb147eebdc1bb90088efe97_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS0xLTEtMS0w_d72bd940-18e8-4b06-8ad0-507fcb5af713">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d45598ab29c4e2db9f9dbb7cec8d9e7_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS0zLTEtMS0w_9e35bcff-1ed8-4853-9da1-1a5576e1563f">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id08dc51273904752aaf728a6e1df8383_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS01LTEtMS0w_6e296aee-32eb-48b8-bb80-7915c0c00bde">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab71f71232254a6f82150b71c8f007fb_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS03LTEtMS0w_5e7c83e2-608c-47a5-b6ab-58d0a920c499">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3461528899214d58b2a932f24904ee6e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy0xLTEtMS0w_5877c237-9c13-4703-ab16-28ed77d0246e">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy0zLTEtMS0w_1bedf63a-c58c-47c7-aaec-fed692b8dea5">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd13016ac46c48bc84616522d16a595d_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy01LTEtMS0w_319a7f32-9ff2-465d-8abb-2c59833b4784">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65c6ac9671754abdb804515a0bc88a5b_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy03LTEtMS0w_652c2717-eab8-42fc-b320-67373fa35ae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4db5a3fc61af496597d6be764fbf968a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS0xLTEtMS0w_15aa4d45-43ea-4ff3-be6d-cc553e358cd5">90,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ae3532bd280450d9b3d2aaf3fd3183f_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS0zLTEtMS0w_62c3f126-020e-4ad4-8641-3c0367f3d090">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45cab4a727634aa0ad89eeb42596a594_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS01LTEtMS0w_31b3a1b2-26bc-40fd-a598-792596683a82">90,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97ba6efdd77a4d1fbdd0f8dac7ce03e2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS03LTEtMS0w_4a48ffed-12f3-41aa-befa-cbe76c655621">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic095f3bf93224fd7830f1bf15820b81b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtMS0xLTEtMA_29a4678a-ec0a-43c5-abcf-c7041448ff28">81,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c8eb3ee87c64e9aacf30737f5a51adb_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtMy0xLTEtMA_7504058c-9619-441f-81db-0c8f23fe501e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fd6b25106a84026b8dd26c57d4b4125_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtNS0xLTEtMA_da324e8a-1314-467a-8966-f46aef756008">81,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9bad4096995042179cc11bc904b183d9_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtNy0xLTEtMA_208ef13d-dff4-4a26-8ca3-7af7697e93ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i452e2107611247cfb0d8f189bfc13b86_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtMS0xLTEtMA_e23c6dac-5354-424e-a053-f4400eced9ad">25,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c8bf564147c432e8c52d88f72ff45c0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtMy0xLTEtMA_7f5ab89c-6478-48de-89e4-e186d532e4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i62b06a1912424ff4a4459beb539c32da_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtNS0xLTEtMA_c8f369ea-24cb-4da3-99f2-8989bf9e3370">25,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6936e5949976449dbccf475a22595e86_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtNy0xLTEtMA_37381a5f-2dac-4696-83ca-e5d9f8b1bf9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3461528899214d58b2a932f24904ee6e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItMS0xLTEtMA_65cef788-95ff-4165-9718-a6bfc7b8370f">197,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItMy0xLTEtMA_7cf3e884-74c6-485e-b773-0b092bf9ce07">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd13016ac46c48bc84616522d16a595d_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItNS0xLTEtMA_575bae1c-f93f-47f1-ab71-003e2e731503">197,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65c6ac9671754abdb804515a0bc88a5b_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItNy0xLTEtMA_a8c7a2e0-e5f1-4768-937a-a8fdef4a7e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:0.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3461528899214d58b2a932f24904ee6e_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtMS0xLTEtMA_6f11eee6-5896-4785-8fba-a55b71b27954">313,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtMy0xLTEtMA_ec3a1d39-cc6e-41c2-b31f-318f6167a324">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd13016ac46c48bc84616522d16a595d_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtNS0xLTEtMA_da6eea41-836b-405d-9707-8e188654457a">197,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65c6ac9671754abdb804515a0bc88a5b_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtNy0xLTEtMA_9bc3d46d-3bc4-4faf-a979-1c36dcaf9c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4a4a0a8362b4d67a4a3abae87fd40b9_I20200630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtMS0xLTEtMA_0caf299f-5844-4371-aee3-35bf3cd4aaa2">167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa5e29888c3a4d52998814f37ae4dba1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtMy0xLTEtMA_1ed46a06-402b-4258-918a-46a837b8016e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i911ca0f0d74e4372b382c1e5cbdefc37_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtNS0xLTEtMA_2c190811-e57f-4b05-ac06-c66cb0111a90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8298c84318b24ddfbc0a9b713fac9edf_I20200630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtNy0xLTEtMA_c07426eb-d7cc-433e-bd36-eee4ab65ae7f">167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i6ac6f146dce741259861bc6e3a90cfbf" continuedAt="i4ea36a7024734cf6a876dd09c15d3f3c"><div style="margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="ib3af9ec13cb24c77980299aca7e4c631"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.844%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia404f432f5f04e0c86cf5127ad1ee352_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS0xLTEtMS0w_6a06c86f-4bc2-4765-9abc-0fdd1c071d0b">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie762e1bf5be24949acbc40644a441c6e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS0zLTEtMS0w_41c8c74b-3bfc-4276-862e-c653b5a8a96f">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ceaaffd9f074529ba2189860ced6058_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS01LTEtMS0w_61f46880-5bee-40fd-85e8-69abe289e94d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d2acfe069e546dca06761088abb331a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS03LTEtMS0w_175fd836-b815-4e6b-9dcc-9e8f96d3877f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:23.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Commercial paper securities </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i676d2b24c5dc42c3b6ff774ebc9c3059_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi0xLTEtMS0w_ef7110c0-b1b6-45a0-83c4-c8ee2bce151d">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb8cbc3d9d7b430fa2d784ba2a45bd2c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi0zLTEtMS0w_5bf28c68-bb52-4f0d-80a6-52c42640ed24">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fe4c003fa7745d7a49e88abcde0d99c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi01LTEtMS0w_5adaa163-e239-4a1c-80ab-f4fce05bb75a">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e5eda06ebd043a18f2310ccfa139d5c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi03LTEtMS0w_db7be0c6-4270-44ac-9c9e-c050c24d2a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i762ba37e09d5444aa3f6af77efa79d0a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy0xLTEtMS0w_34b01cf3-fadb-4eb7-9cf3-3361f6f5f289">33,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia92733266bea4a4a995ec95b550ebc2d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy0zLTEtMS0w_26817a0d-d1ef-4747-bb32-f15fc2120c7c">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy01LTEtMS0w_981688fd-bc86-47c7-b74a-edbfc744d7d1">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7e24edd72a4402e947ad3a231a68484_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy03LTEtMS0w_d91b7f69-be94-4911-affe-683be11d2dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i676d2b24c5dc42c3b6ff774ebc9c3059_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS0xLTEtMS0w_29368c78-dec8-4179-9a22-c4ab21eb106d">155,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb8cbc3d9d7b430fa2d784ba2a45bd2c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS0zLTEtMS0w_73c70a99-88fe-4be2-93b5-f9e68e4fed45">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fe4c003fa7745d7a49e88abcde0d99c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS01LTEtMS0w_1172ca86-c1ea-4168-b698-1f87e698cd7b">155,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e5eda06ebd043a18f2310ccfa139d5c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS03LTEtMS0w_4c687f5a-f45f-41db-a045-01481e2f950f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i365bc9823489411ba4d7b9edcded0fbf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtMS0xLTEtMA_52c03b00-311d-46e4-9736-f1e927f7f729">95,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8b0f5f2adab4805b0479111e623e2ee_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtMy0xLTEtMA_fd211efe-b1d8-484e-acdf-73cd6753787e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3157fcf32f8c4a93b027d26e140b1f9e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtNS0xLTEtMA_7d2e2ed3-83a1-46f9-ae76-43f9d936069a">95,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5d4d876ac904a2a86c3d4eb8f225dcf_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtNy0xLTEtMA_2dd50d78-c082-411a-8f91-b2d95206923b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cfa387702344d33a007d4a3e6c45c05_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtMS0xLTEtMA_7397b7cc-2781-4f81-8099-ffd7108e5324">53,493</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74627613ca30495088c9bc6d70c91441_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtMy0xLTEtMA_a3353d9f-82e0-4a48-819c-1fe7a44616cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieaab7f3f0f42483f8054df0951921a69_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtNS0xLTEtMA_d91e7e6a-d869-4212-8bc2-4fb69f1445a3">53,493</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6149f30571a74f36b05d423ef49c6d84_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtNy0xLTEtMA_5a0e1a9f-1bab-4710-9bfc-24905f7476c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i762ba37e09d5444aa3f6af77efa79d0a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItMS0xLTEtMA_814c4f0c-df76-4007-8a51-70eece0ce40f">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia92733266bea4a4a995ec95b550ebc2d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItMy0xLTEtMA_fcaf3132-45d3-4ae6-8482-483a4e0b1b6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItNS0xLTEtMA_530beb31-3165-4827-acbf-45dc20686dad">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7e24edd72a4402e947ad3a231a68484_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItNy0xLTEtMA_2a66c48d-712e-41ba-9eba-82112a0e561b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i762ba37e09d5444aa3f6af77efa79d0a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtMS0xLTEtMA_96b08416-f5dd-4c28-8f81-83836e7c87ba">337,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia92733266bea4a4a995ec95b550ebc2d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtMy0xLTEtMA_94bb3a65-1099-4d40-b4c8-f690f2df91ee">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtNS0xLTEtMA_fd91b96d-6e3d-48e5-bff5-36409e56279d">306,877</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7e24edd72a4402e947ad3a231a68484_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtNy0xLTEtMA_2deacdc3-1679-4967-a651-e5b55aeab8dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icef63d53d6da4bbfb421afc3382da2ad_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtMS0xLTEtMA_202fb99b-772b-4dba-a4f7-18193b587d52">236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b2aa92c23ee4bfeb3ee17ccff6a2fbf_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtMy0xLTEtMA_4017a6c5-1d3f-45cb-a62e-096d3e269387">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10649c65a0334bc2a8640fb0be3a04f7_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtNS0xLTEtMA_1bf6ec75-a528-4e78-a1d7-d7276c572f31">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ff8aa476e974c09bfed85e41fcd2fab_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtNy0xLTEtMA_526f3715-2c84-4fa7-9cd7-8bfe7c742823">236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></ix:continuation></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company generally classifies its marketable securities and some cash equivalents as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Free Shares Asset</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 10 &#8212; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Acquisition of Sangamo Therapeutics France S.A.S.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), the Company entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMjYxNg_2dca1d96-23d7-4d9c-8528-755b12236cfe">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $<ix:nonFraction unitRef="usd" contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMjkxNg_034ca22b-4675-4b01-9686-136ecc44d815">0.2</ix:nonFraction>&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company purchased approximately <ix:nonFraction unitRef="shares" contextRef="i7ba32d30d24546eca925d1e03e695212_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjE1Ng_91a1504a-ae02-42b2-8cd9-1087e4f723b7">111,000</ix:nonFraction> shares during 2019 and <ix:nonFraction unitRef="shares" contextRef="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjE1OQ_f2dd38a6-aaf3-451d-a163-b8726cfbb6e3">117,000</ix:nonFraction> shares during the three months ended June&#160;30, 2020, of the <ix:nonFraction unitRef="shares" contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjExOA_944d9909-5303-40a4-92dd-b0a31ea0af1a">477,000</ix:nonFraction> total free shares for a cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i0521a31195cf4bf6ba85a5da0f003cad_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzU4OA_50271a76-2e19-435c-8b43-3a87405abb83">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1b51e6431f1d4e99b4e005735f3156ba_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjIyNA_5ac36520-2091-4a96-94ba-1eb5cddd3a3e">0.2</ix:nonFraction>&#160;million respectively, upon exercise of the put options. As of June&#160;30, 2020, approximately <ix:nonFraction unitRef="shares" contextRef="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjEyMQ_c92f1da9-9fef-46b2-a2c4-e7c73828414d">249,000</ix:nonFraction> free shares remain outstanding and subject to purchase by the Company. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the free shares asset was approximately $<ix:nonFraction unitRef="usd" contextRef="i80ae933af9fe439582f72421ca16b2d4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTA5OTUxMTYzMjQ4Mg_89389c5a-398a-4de4-86b6-5807f50f3d80">0.2</ix:nonFraction>&#160;million at December 31, 2019. The Company recognized an increase in the fair value of the free shares of approximately $<ix:nonFraction unitRef="usd" contextRef="i4ebf882acb394d3abcff4f7fbb84922d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjA1MQ_1c5000c1-d1b6-4ae5-9726-974acccc409d">0.1</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2020, offset by approximately $<ix:nonFraction unitRef="usd" contextRef="i1b51e6431f1d4e99b4e005735f3156ba_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionSharesAcquiredValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjA4NQ_6b1ad341-cfda-44ae-8751-3f463722fbfa">0.1</ix:nonFraction>&#160;million for the shares purchased during the six months ended June&#160;30, 2020, resulting in an asset balance of approximately $<ix:nonFraction unitRef="usd" contextRef="ib4a4a0a8362b4d67a4a3abae87fd40b9_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk1Mw_a9bf8440-d54a-48a9-8931-d46d28d7cc55">0.2</ix:nonFraction>&#160;million at June&#160;30, 2020.</span></div></ix:continuation><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk2NQ_5bbcebaa-ab94-48ee-bdfc-969f6ea235dc" continuedAt="i94fb163826734d28b6e34c330410f019" escape="true"></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="i4ea36a7024734cf6a876dd09c15d3f3c"><ix:continuation id="i94fb163826734d28b6e34c330410f019"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%;"><tr><td style="width:1.0%;"></td><td style="width:72.100%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.519%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.230%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.519%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.232%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free Shares valuation assumptions:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2a5014580264671a94f115ba17d478c_I20200630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMS0yLTEtMS0w_a06e15cd-a86c-4ec3-af49-329bda0de258">8.77</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i7a6f009aa07a4c399d8a95a107332098_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMS00LTEtMS0w_ffabfcc6-cb8a-4df5-ae3b-d17c256473a4">8.68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="eurPerShare" contextRef="i8dfb37df32ca419f81e76d4115394730_I20200630" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMi0yLTEtMS0w_fea35e27-e581-4c81-bd16-d376be94ebfb">2.16</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="eurPerShare" contextRef="i550ea41dd94f4cde8ebccae40c9ea1ec_I20191231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMi00LTEtMS0w_8bd9138d-d2e0-4359-85f9-32bbef396bf7">2.14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD / EUR Exchange Rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2cd51b31128c404a88c55c12be0f8933_I20200630" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMy0yLTEtMS0w_21e9964f-34ff-4161-9a9a-0041b1b9fe83">0.89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3c895422f38a4eb1a177bc4ea8d56a62_I20191231" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMy00LTEtMS0w_dcc0a02c-a737-490c-a946-2e156b9d0de5">0.91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Correlation Sangamo and Sangamo France Stock Prices</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i88202f1ce8de4ff58b28e17316576426_I20200630" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNC0yLTEtMS0w_ca874d96-ee44-43d4-8a5f-c2534cce747c">100.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i244af883f9fa4b53b32c33db2e3117c5_I20191231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNC00LTEtMS0w_244e4a97-0a3e-47dd-a36b-c624c53f5ecc">100.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD) Volatility Estimate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i308ef5827e2d49879e8d190e7c992de4_I20200630" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNS0yLTEtMS0w_14ba9573-b081-4ba5-917f-ecd4c21fd387">73.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i26b1c09f8aad47379da7b97362291428_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNS00LTEtMS0w_b4c0f966-7364-46b7-b562-7f41b4281753">72.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR) Volatility Estimate</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2c70a615e27849df839c9cf2964b75f7_I20200630" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNi0yLTEtMS0w_77b207fc-c056-46de-a52d-3deefb6c03d0">73.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i3065b36e03d44c578c215e8d30a54eea_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNi00LTEtMS0w_98b1162b-50d8-437d-9410-17e0bf03a562">72.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD / EUR Exchange Rate Volatility Estimate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ide9f1db38f654cd1aac9ab696795190d_I20200630" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNy0yLTEtMS0w_ca725931-b6b1-46f4-b03e-e430746ae461">6.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ie8f47ed72c944d6aa88add3d596b953e_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNy00LTEtMS0w_b7dc14ed-ca38-49c3-9df4-cb0f3ef43283">6.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 3&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzI5ODUzNDg4NTA5NA_54171648-733e-48b5-b9e8-962a96fa6248" continuedAt="i2876904a939a4c748da16c43939f987d" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i2876904a939a4c748da16c43939f987d"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMTY5NQ_4dee42ae-64fe-40b7-8cb3-cf7fbe91c611" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.710%;"><tr><td style="width:1.0%;"></td><td style="width:59.191%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.156%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.720%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.866%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.163%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC0yLTEtMS0w_022dd440-7408-4078-bb6e-be0c96499d89">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC00LTEtMS0w_74e070e8-61d8-4386-a049-fdcdcce0a921">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC02LTEtMS0w_e5efc00c-c9f1-4436-bfdc-dfd49274a272">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC04LTEtMS0w_b769ab0c-9c33-4477-a8ea-969747b76975">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi0yLTEtMS0w_88267bdc-3393-4c50-a703-e779c4190abc">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi00LTEtMS0w_9484b87c-191d-4570-864a-ef9c92784a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi02LTEtMS0w_c110234e-5c2e-4970-9703-861530de616a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi04LTEtMS0w_7e7eae58-bafa-4a20-98db-39c6c2c16a19">116,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC0yLTEtMS0w_0e5b9775-2370-471e-9d73-f8235e836d2c">89,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC00LTEtMS0w_d1026516-1398-451c-ba2e-a36b5d86f069">383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC02LTEtMS0w_bda6663f-bc28-44ab-91bb-8d3ea8973170">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC04LTEtMS0w_c8cee4a3-e4d0-4cd7-ace0-c11920e8513b">90,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS0yLTEtMS0w_2d5424f6-e958-4ae0-8211-d98e362a2f7a">81,424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS00LTEtMS0w_2fd17cfa-ae03-4086-bd09-3eb1f1b81c59">420</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS02LTEtMS0w_c6bbfe9e-a7c8-4dac-a7e4-f4bbc13e7671">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS04LTEtMS0w_1489dcac-cc85-4055-ae41-968f128412c2">81,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtMi0xLTEtMA_a170b7e3-8b9e-4a50-a3f2-7347d545474b">25,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtNC0xLTEtMA_d59e45d2-58fc-4433-ac6f-ebc3ace41db0">176</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtNi0xLTEtMA_b0d2104e-0228-48c9-8cc2-5157cecde25d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtOC0xLTEtMA_1e00e9ee-08a7-4f5d-9188-9b194680381e">25,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtMi0xLTEtMA_3b2d9222-180a-40b9-93b4-09b827e46210">196,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtNC0xLTEtMA_cf309f0c-f19f-431f-ae7f-0f680e1a0493">979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtNi0xLTEtMA_e5568c70-235d-422e-8521-e5e62315c7e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtOC0xLTEtMA_f3d0bf02-11d4-4c77-9f55-a03490433068">197,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItMi0xLTEtMA_f925084b-bc04-482d-b080-937c4ab525e6">312,824</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItNC0xLTEtMA_37fd33a0-7fe2-4318-a256-18c95ca13d97">979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItNi0xLTEtMA_28731c45-6a1a-40a8-905c-a4eb4a9861cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItOC0xLTEtMA_7cf0f395-9ec7-4cd6-b50f-8dacc89a5607">313,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36f128cd73641d78e18a584b4115086_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctMi0xLTEtMA_713ec372-f65b-4f99-8011-55a76c21fe73">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36f128cd73641d78e18a584b4115086_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctNC0xLTEtMA_5c341ea8-d781-467a-a9c6-31f59db05e1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36f128cd73641d78e18a584b4115086_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctNi0xLTEtMA_43eec33d-2d7c-4e78-b3b7-9c2df2b5a5ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if36f128cd73641d78e18a584b4115086_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctOC0xLTEtMA_bfb3c226-998e-4dad-9dff-09bd377cdf10">30,496</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtMi0xLTEtMA_f7dbf84e-1b8b-48d1-876d-41c96556067c">2,998</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtNC0xLTEtMA_561aac24-7203-4e17-adc4-7256dee80b04">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtNi0xLTEtMA_33edda64-7d62-4b47-aea5-11a4cd7c2342">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtOC0xLTEtMA_bb2c243a-c804-46c7-ab28-0b9220af6a43">2,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktMi0xLTEtMA_db28eea4-ae63-4c0e-a56c-fb5fc3b6f4d8">33,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231" decimals="-3" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktNC0xLTEtMA_4367c0aa-03e2-4e4e-bd9c-925db132712e">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktNi0xLTEtMA_33b6d2c1-0c80-47c5-9469-7aa5cda12504">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktOC0xLTEtMA_d2dac307-e0ff-42d6-9273-d4cff8765a70">33,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtMi0xLTEtMA_5cf42443-9f67-4347-a2a7-c2dab47f4934">155,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtNC0xLTEtMA_d7563643-32d3-4fe7-8f5a-b2a58ba89130">145</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtNi0xLTEtMA_b1b03990-0a54-4126-9ee0-208eb1434957">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27597a1795c6422786f8357584decb2c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtOC0xLTEtMA_22985304-346f-4960-b199-48c03785834d">155,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItMi0xLTEtMA_6692226d-4021-4557-a010-2ed29ff46d5b">94,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItNC0xLTEtMA_70c3868c-9aac-47be-9acd-b35327792a7a">115</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItNi0xLTEtMA_1763b100-341b-474b-85e0-cd32d5cc579d">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItOC0xLTEtMA_c667e05e-9631-4fae-a799-bb67920ac7b5">95,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtMi0xLTEtMA_936cab1e-d91c-41f1-b885-1a7ecdc9a8b9">53,411</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtNC0xLTEtMA_00b3f7c8-3e1f-4711-a337-85cb6c959edd">91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtNi0xLTEtMA_1e210207-39d4-469b-a669-e08262fb3d66">9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtOC0xLTEtMA_1c5f9a10-0c31-4bc5-accb-ab76bfbb4b6f">53,493</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtMi0xLTEtMA_abee4700-7281-48f7-9a74-7b683365c704">303,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtNC0xLTEtMA_1aa33fed-b3ca-4863-8f68-b45673d07b83">351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtNi0xLTEtMA_686e8402-3c90-4f24-aec6-86711a689eb5">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtOC0xLTEtMA_bd826152-57ba-4fe2-a6dc-a2ae293eb426">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtMi0xLTEtMA_97bf8790-e329-4d8b-ac48-67824d1015ea">337,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtNC0xLTEtMA_f99f07dc-0a92-44d4-8236-ff6182b426ef">352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtNi0xLTEtMA_faffc5fb-4dae-4dde-a128-6178075fa36a">19</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtOC0xLTEtMA_8adba5ed-f44d-4465-b3c4-31e49165ff7a">337,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMTY5Nw_9fae9ce2-ae10-4dcd-8ec6-97c8b05a4329" escape="true"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%;"><tr><td style="width:1.0%;"></td><td style="width:72.165%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.525%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.046%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.525%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.339%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMS0yLTEtMS0w_26f96a53-8efc-437b-9090-f9a8b1b51138">197,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMS00LTEtMS0w_17bb00a6-efa3-48ac-9f43-299ad2b277fb">282,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMi0yLTEtMS0w_fa199b12-39b4-458d-84d1-ff41037ed695">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMi00LTEtMS0w_9a5ea12b-e6ff-47ad-ada8-67d8918c99a4">21,832</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMy0yLTEtMS0w_0fd612d3-9aab-4fd5-8ae5-e4f4f3476fe3">197,410</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMy00LTEtMS0w_7ecf70a8-2259-4f75-af49-45fb231b776b">303,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company had <ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_05ec4f66-92a1-40de-a119-bfb261ca8fb8"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_1169cb41-d5f6-43f1-9ccd-60c33ac789f4"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_54d3c4ec-654e-413c-a7a1-c999e9c385d7"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_8c0376bb-98a1-49e0-abbf-95853f1ae16d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> realized losses of its available-for-sale securities for the three and six months ended June&#160;30, 2020 or 2019. The Company periodically reviews the available-for-sale investments for other-than-temporary impairment losses. <ix:nonFraction unitRef="usd" contextRef="icb25efc099444173a12e09cc80696876_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfNTQ5_429e142c-4a77-4b6c-8173-5613f3d0198f"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfNTQ5_aac934bf-7ceb-425e-9386-3d04758de03e">No</ix:nonFraction></ix:nonFraction> investments were other-than-temporarily impaired at either June&#160;30, 2020 or December&#160;31, 2019. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For available-for-sale securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company's review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company's ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these securities at June&#160;30, 2020. All available-for-sale securities with unrealized losses have been in a loss position for less than 12 months.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 4&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80Ni9mcmFnOjEzNzVhYjI5MjkwYzQ4MjFhMDM3MGZjMmMyN2FiMWQ1L3RleHRyZWdpb246MTM3NWFiMjkyOTBjNDgyMWEwMzcwZmMyYzI3YWIxZDVfMTA3Mw_e9a9bcc9-3c79-4271-9284-0616c9dd6989" continuedAt="i96a5d5362c304bc885487e5fe2be69ab" escape="true">BASIC AND DILUTED NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i96a5d5362c304bc885487e5fe2be69ab"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of June&#160;30, 2020 and 2019 totaled <ix:nonFraction unitRef="shares" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80Ni9mcmFnOjEzNzVhYjI5MjkwYzQ4MjFhMDM3MGZjMmMyN2FiMWQ1L3RleHRyZWdpb246MTM3NWFiMjkyOTBjNDgyMWEwMzcwZmMyYzI3YWIxZDVfMTA1MA_1492eb33-0646-4618-b745-7bb2f5b9d2d6">14,964,567</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icb25efc099444173a12e09cc80696876_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80Ni9mcmFnOjEzNzVhYjI5MjkwYzQ4MjFhMDM3MGZjMmMyN2FiMWQ1L3RleHRyZWdpb246MTM3NWFiMjkyOTBjNDgyMWEwMzcwZmMyYzI3YWIxZDVfMTA1Nw_0886fc53-6706-4d35-a136-57751f674e74">10,155,033</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="ia59e529445a14a10ab18f7d7fd95bd0f_49"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 5&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDkyODYwOQ_69286f0f-66a5-4586-8840-fc9d4e938675" continuedAt="i34d953d068ee49a1b35c6e860cc10165" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="i34d953d068ee49a1b35c6e860cc10165" continuedAt="ie13801ed00d742b0b1f8e581158613aa"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Biogen MA, Inc.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via adeno-associated virus (&#8220;AAV&#8221;) to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase <ix:nonFraction unitRef="shares" contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNzM2_e7298b63-5d34-4d4f-b522-430b054704a4">24,420,157</ix:nonFraction> shares of the Company's common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i426f14e574704e28836ba330c9dbd8f1_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODIz_6dba2835-091d-4237-8a8e-07f32e3ba4e3">9.2137</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODc2_f554df6b-0121-488c-baa3-e1ff9823e149">225.0</ix:nonFraction>&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $<ix:nonFraction unitRef="usd" contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTEzMA_bc1d1daf-c32b-4532-8b4b-8298061e0330">225.0</ix:nonFraction>&#160;million for the purchase of the Biogen Shares.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTI1Nw_bf0dd2a4-23d8-4f57-a522-db958ff27e01">125.0</ix:nonFraction>&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTQxOA_cfd79e83-ca97-4bef-b09c-1055614e9dbe">2.37</ix:nonFraction> billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $<ix:nonFraction unitRef="usd" contextRef="ia146054470dd4f3f970c2b2d6eeea2c7_I20200229" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTU4MQ_dd1ae014-ad0e-4e51-9b44-b1e9f78eb8e2">925.0</ix:nonFraction>&#160;million in pre-approval milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i33efcc2cf083437d856a10fb09d87586_I20200229" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTYyOQ_a3891216-7052-41d9-9b65-576061b2ee53">1.45</ix:nonFraction>&#160;billion in first commercial sale and other sales-based milestone payments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to <ix:nonFraction unitRef="product_target" contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjM0MA_314c79f3-2fe0-45da-b44f-b879728a3c5b">12</ix:nonFraction> neurological disease gene targets selected by Biogen. Biogen has already selected <ix:nonFraction unitRef="product_target" contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjQyNQ_b5e249da-0c8f-4df5-b232-c4ff8b425e78">three</ix:nonFraction> of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to <ix:nonFraction unitRef="product_target" contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAgreementNumberOfAdditionalProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjY1Mg_c04f1cec-873b-4a6f-ad96-2a3b91b272d9">nine</ix:nonFraction> additional targets over a target selection period of <ix:nonNumeric contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationAgreementTargetSelectionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjcwOA_f8594b93-c3e3-420a-97dc-4a00f63cbab9">five years</ix:nonNumeric>. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP transcription factors (&#8220;ZFP-TFs&#8221;) (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first <ix:nonFraction unitRef="product_target" contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM0Mg_7dff881b-0b77-40f1-aefa-7be86d07e2a7">three</ix:nonFraction> products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first <ix:nonFraction unitRef="product_target" contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzYwNQ_e6903220-821c-49f5-b462-e053a809036e">three</ix:nonFraction> products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed <ix:nonNumeric contextRef="i8c8c2d2b28bb459ea77a5e1aca05aab8_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationArrangementResearchPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDkzOTI0Ng_410d6ca1-8460-43c1-89e1-504b408df505">seven years</ix:nonNumeric> from the effective date of the agreement (i.e. through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to <ix:nonFraction unitRef="product_target" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDk0MjM4OA_c801d43a-b4ac-430d-af60-4ad6a5e47fd8">ten</ix:nonFraction> targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="ie13801ed00d742b0b1f8e581158613aa" continuedAt="idba01298cd60478993c0d9867b70b4aa"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk2MA_8a0774d0-1ee7-45ae-b865-08409446f2a7">three</span>-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="i301f2d2ad4b84c369aa116bdd117c17a_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNTA4NQ_1dabd71d-1848-42cc-b4ae-42e24ba4bbae">5</ix:nonFraction>% of the Company&#8217;s common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least <ix:nonFraction unitRef="number" contextRef="i301f2d2ad4b84c369aa116bdd117c17a_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNTQwNQ_3c5a662c-e7d0-414e-b97f-bb9d326791d9">50</ix:nonFraction>% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNjE3OQ_91e689ec-675c-4164-b538-3b9389226c79">two</span>-year anniversary of the effectiveness of the collaboration agreement, (ii) the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="i301f2d2ad4b84c369aa116bdd117c17a_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNjMwNg_2df46a43-e3da-4e75-b6a3-6dcdad668366">5</ix:nonFraction>% of the Company&#8217;s common stock and (iii) the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic 606 and concluded that Biogen is a customer. As of June&#160;30, 2020, the transaction price includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY2NjY0MQ_8d6dd2ea-e8fb-42f7-9b8e-de63171b8879">125.0</ix:nonFraction>&#160;million and the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="i28405f7b815347269a780c9b058a7e44_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY2NjgwOA_1215d77b-86db-4d63-9ac9-01016633b6cc">79.6</ix:nonFraction>&#160;million, which represents the difference between the $<ix:nonFraction unitRef="usd" contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY3MjcwMA_f9d4fabc-1319-44aa-8a30-4bfc19e2828e">225.0</ix:nonFraction>&#160;million received for the purchase of the Biogen Shares and the $<ix:nonFraction unitRef="usd" contextRef="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY3MjczNg_1c00814f-c538-4d91-8538-ce18d033517e">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of June&#160;30, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY2NjA2NA_aaa2e82d-6455-45bf-a79e-a3d75867823a">197.8</ix:nonFraction>&#160;million related to this agreement. </span></div><ix:nonNumeric contextRef="ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDkyODYwOA_20623e55-e92b-489e-a8e8-1ac727673822" continuedAt="iadc6f15db3f64d21aa5ced84ac260c3d" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"></td><td style="width:45.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i379eea47507e40cf90ab3746c20d3ff7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy0xLTEtMS00NjI_1562b56f-3c80-4620-9601-bb0ecac5e063">6,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76b3b95cd14d487b848403cb66fe002a_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy0zLTEtMS00NjI_58ba1bdd-ea67-4586-b764-76db25d11fae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae8d5183fb0e4f4ab6e439efc56e5af8_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy01LTEtMS00NjI_8c9e62de-25f5-4312-9894-9892d42b9530">6,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cb17ceebd9543aba79ec3e8fbd2f4e8_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy03LTEtMS00NjI_161b068d-374e-4a47-81f4-69699e1c3970">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2532bc5c847458ea5c245c9d0539d8a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC0xLTEtMS00NjI_cb5cc0e6-7ebf-4480-a99d-9c8315b0f849">1,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ea81ce0c28543c297d2984b8efc8ccd_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC0zLTEtMS00NjI_c14be5a0-2bc4-431f-803e-dd7297562667">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38d05a55da884263b1ec48182e49e978_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC01LTEtMS00NjI_d8b93eaa-57e4-48da-85fa-4801d6f84ed0">1,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab06d3a3d932466caba07743e70c8ce3_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC03LTEtMS00NjI_e3e1847b-9f18-4519-bed2-9fec636138d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7495828dd6da4b6dab035cf784124b17_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS0xLTEtMS00NjI_317b3dee-2c70-41bb-a245-ca00e6435538">8,178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6f7cee7975f4b6f99d9a6ff2291d024_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS0zLTEtMS00NjI_3a5755c4-bdb3-4aec-b7cd-4dd1befe70c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS01LTEtMS00NjI_95f0f172-6b7c-4c71-8170-46dd55c377e5">8,178</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if597a7e574f64566b96eae1440d9452d_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS03LTEtMS00NjI_413a64bf-4cfb-47f5-9ae0-11506a283515">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company paid $<ix:nonFraction unitRef="usd" contextRef="ic346d49a489e488999ebd8bf7e2e449b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTQ5NQ_c7f24363-955d-43cb-a6f0-b066e16adea1">7.0</ix:nonFraction>&#160;million for financial advisory fees during the quarter ended June&#160;30, 2020, equal to <ix:nonFraction unitRef="number" contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTU2NA_55fdf547-a4be-4e7e-94ca-34ce87fca52c">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTU3MA_f9d4fabc-1319-44aa-8a30-4bfc19e2828e">225.0</ix:nonFraction>&#160;million received for the sale of shares and <ix:nonFraction unitRef="number" contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTYwOQ_0f86c205-e6bf-493a-bd89-4d1b6effcee5">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTYxNQ_8d6dd2ea-e8fb-42f7-9b8e-de63171b8879">125.0</ix:nonFraction>&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ic346d49a489e488999ebd8bf7e2e449b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTkyNw_d537e667-d6b0-4379-9221-d2a971050a74">4.1</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTk0OA_4ed35f6b-9258-4894-86fd-80b5f646a6a0">2</ix:nonFraction>% of the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTk4MQ_8d6dd2ea-e8fb-42f7-9b8e-de63171b8879">125.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTk4OA_3e4b25c6-043d-4851-a702-31c41b9929cc">2</ix:nonFraction>% of the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="i28405f7b815347269a780c9b058a7e44_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjA0Ng_1215d77b-86db-4d63-9ac9-01016633b6cc">79.6</ix:nonFraction>&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Assets and </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="idba01298cd60478993c0d9867b70b4aa" continuedAt="ie714c2fb0b8c48bea6c51b5298404fe1"><div style="margin-top:12pt;"><ix:continuation id="iadc6f15db3f64d21aa5ced84ac260c3d"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred Costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ifa40a47c29de44d5a91538a3a9a70128_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjMxOA_eeebb2bb-5ab8-48aa-b5e2-cd19d3f73516">2.9</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjMzOQ_d4c4c5a1-a316-4f52-8136-ff585ca39bb7">2</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjM0OQ_1c00814f-c538-4d91-8538-ce18d033517e">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds.</span></ix:continuation></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Kite Pharma, Inc.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective in April 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the effective date, the Company received a $<ix:nonFraction unitRef="usd" contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODc0NQ_f9a98664-5538-42f5-a425-bbdf38171a3c">150.0</ix:nonFraction>&#160;million upfront payment from Kite. Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $<ix:nonFraction unitRef="usd" contextRef="ida7d1959f6e6453b984185527fca88b9_D20180405-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODk3NQ_a5086d73-e566-4c30-86b2-385217ebb74d">3.01</ix:nonFraction>&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $<ix:nonFraction unitRef="usd" contextRef="ibcd815dd54d643efa93f63fde2181db7_D20180405-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfOTA4NQ_eb659c43-4768-4e97-98b0-f52b14d00b0c">1.26</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $<ix:nonFraction unitRef="usd" contextRef="i610fb576d4dd469d840dbfd922ba836c_D20180405-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfOTIyNw_7b452eb3-a910-49ea-a651-19803cd32ab9">1.75</ix:nonFraction>&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial research term in the agreement is <ix:nonNumeric contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405" format="ixt-sec:durwordsen" name="sgmo:InitialResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAxODE_fafafa38-b50b-462f-8e82-efed97d7241b">six years</ix:nonNumeric>. Kite has an option to extend the research term of the agreement for up to <ix:nonFraction unitRef="option" contextRef="idadecadd2c3540d29b8bfd732262ee0a_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfOptionsToExtendInitialResearchTerm" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAyNTk_1891db50-dd00-447f-910c-bc73d0f2c8e4">two</ix:nonFraction> additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAyNzM_91569598-dc9b-4299-8c21-58e8ed1c15e0">one</span>-year periods for a separate upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SeparateUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAzMTk_6e248f9d-292e-4507-b550-116305557461">10.0</ix:nonFraction>&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i534bf494758d4e65a8c5a9cd993bd211_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA2MzI_38b97354-37ae-455b-acd5-008df8529f36">3.4</ix:nonFraction> million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA3Nzk_07fb44c5-786c-40ff-81bf-afd8bf520c8b">189.3</ix:nonFraction>&#160;million and includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA4MjI_97dcd97a-2651-4591-96af-c1f335acba80">150.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA4Mjk_ba2bf59e-15e7-48d6-b870-8c3effa0277a">39.3</ix:nonFraction>&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand-ready obligation to perform research services, and (2) the on-going research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="ie714c2fb0b8c48bea6c51b5298404fe1" continuedAt="ib9ff706077a34d4c922815dc053da728"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i3be7ebfec658496c9a397474592935f4_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTMzMjk_1fe6ab89-b606-4f43-a02a-9af09df78e27">94.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie4f3b66fa9254360addb420ddb70e7f0_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTMzMzY_238a13d5-d045-473d-af41-079216125f2f">106.5</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><ix:nonNumeric contextRef="i0c1ae59129e94570aabd4555fc76fe34_D20200101-20200630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NTQ_47948c61-b18a-4949-8fa1-f58eab11becb" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:45.844%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.502%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6ed1d741701d4d8896d2e39462a3d431_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0xLTEtMS0zNjI_8ff954b9-e4aa-4da8-8a0c-6cca6ddd27ac">6,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i100c20eec6fc4407969c367a22a5aefa_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0zLTEtMS0zNjI_36444052-fac1-4266-8305-3eb80fcb10a3">6,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f9f41236129499cad0f6ecbb3d8b103_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0xLTEtMS0w_8ee72da7-dabf-4c50-a444-5b3dd33cc87f">12,454</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83e4ca4b8d794be49441483d40aedae6_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0zLTEtMS0w_db1810d2-c594-4e78-954e-b01d4fa28fa5">12,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifdd22789c61a44f18dd2221f8e41eb4f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0xLTEtMS0zNjI_0c8921c5-7944-43ef-8b1d-17bc57554247">1,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30c126a939724395a8b70904f39a6201_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0zLTEtMS0zNjI_1256d323-6181-4f98-8751-c53fcb42478c">2,833</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3874265bf7a4b8885aa894e0fca3eaf_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0xLTEtMS0w_718f719e-59b5-4d60-83f7-407637a4ebcd">2,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c63d999a16941d1a68fc47f694643a4_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0zLTEtMS0w_ebb6db00-cb3e-4d57-af2f-0f232d21619d">4,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10b9a9ad5cd14b529d554f21d154e6d7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0xLTEtMS0zNjI_dbbac219-2b04-4d48-bb9b-4b5c5623a96f">7,422</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia075c77e790a4ac991c3cd8ee89ad36b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0zLTEtMS0zNjI_bd1f1e5b-b1f5-468d-9207-08765752b3e3">9,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0c1ae59129e94570aabd4555fc76fe34_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0xLTEtMS0w_aa5a0b70-f83f-4fd9-abec-79f2ce2edffc">14,641</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25f1c9d94c66418ba25576f42bb0c41c_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0zLTEtMS0w_339c7f1a-5bae-4ef8-8eef-ab5d28dc1427">17,372</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pfizer Inc.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">SB-525 Global Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;<ix:nonNumeric contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630" format="ixt-sec:durwordsen" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTUzMjY_5dc69705-3e2e-493b-b3ae-a5c12131ba6d">fifteen years</ix:nonNumeric> after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon execution of the agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ib291aca8325c43a6a2835d40a832c89d_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTYyMDU_ab8e8ba2-67c4-462d-a4ac-aaa9c2c9ccd7">70.0</ix:nonFraction>&#160;million and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i97cf3acb2d224d289dbcc3817e983d58_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTU_f624011e-4e84-43b1-9adb-ecde64cdfdd9">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="if87eed0b34b64bfd8323247a51d95e6b_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY2MjQ_1245ad43-91bc-423a-b3d5-40461fabd824">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="ide9b91c91f3c407cbef414beccd16d53_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY5MzI_078fb1f3-ed28-4bdf-9fc6-776baa06bddb">475.0</ix:nonFraction>&#160;million, which includes up to $<ix:nonFraction unitRef="usd" contextRef="ie25d43c8653a40efb6068acc53cc63a5_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY5NTc_493d2083-be8d-488e-a69d-cb38c820a45f">300.0</ix:nonFraction>&#160;million for SB-525 and up to $<ix:nonFraction unitRef="usd" contextRef="ic8b47130e76b4541a0d85cafca758698_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY5ODE_04008889-881d-489b-b0e5-b7f3891ca1ad">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="ib9ff706077a34d4c922815dc053da728" continuedAt="i701ef695d1974db0900aad5b0eaf276f"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, a $<ix:nonFraction unitRef="usd" contextRef="icf5586bb63c84bd9bc5dba5e7ee29b1e_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc1NjI_8b8a8dfd-2594-461d-a0de-bb36b04d1f0c">25.0</ix:nonFraction>&#160;million milestone has been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="i68bf878067e24fd7b9f9e0feeab74893_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc2MTE_a32593b1-c41b-41f4-8083-18b9fb59018b">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i68bf878067e24fd7b9f9e0feeab74893_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc2NTY_cf359d91-366d-4505-af0f-95651e195d08">no</ix:nonFraction> royalty fees have been earned under the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of June&#160;30, 2020, the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc5MDU_3de2cdb6-efc3-4693-b1b2-244de83becae">104.0</ix:nonFraction>&#160;million, which represents the upfront and research services fees of $<ix:nonFraction unitRef="usd" contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementResearchServiceFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc5Njg_d91f52a7-98e7-4120-92bb-af6b06dcb71a">79.0</ix:nonFraction>&#160;million and one unconstrained milestone in the amount of $<ix:nonFraction unitRef="usd" contextRef="id835cc5e8ed34090b3843efa34d914a2_D20170601-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTgwMjA_729a60f0-a350-4ba5-9cf2-3c83df168a2f">25.0</ix:nonFraction>&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the performance obligations within the agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going research services through 2020, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="if5ad04bab0bd4c97b5268f8c70c60007_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTk3MzA_9b79fccd-64e6-483d-99c0-8f8970520330">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9a76ad6dd6db47e8bdb42c22f63955fb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTk3Mzc_3af92766-c21f-40d9-abf6-d0cb7feac943">4.0</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company entered into an amendment to the agreement, pursuant to which the Company transferred the IND for SB-525 to Pfizer. Upon this transfer the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="ie42151476a064738ac709c94dbe11690_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTk5NzA_4203c2ac-5bcc-47b6-9a29-f30c62dd4418">25.0</ix:nonFraction>&#160;million milestone as the conditions for achieving the milestone were met. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibbed171f600d4452b7074be69d363203_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY3MjgwMw_ae3d45a8-9615-49ad-9edd-38ebf9c601cf">1.1</ix:nonFraction>&#160;million during the six months ended June&#160;30, 2020 and approximately $<ix:nonFraction unitRef="usd" contextRef="if5ad04bab0bd4c97b5268f8c70c60007_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjAwOTg_3f6ac41b-c2f9-45ff-a977-9246213f6ad4">24.8</ix:nonFraction>&#160;million on a cumulative basis attributed to this milestone as revenue. The balance of this milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ic3e6673b29e749caa0cfd406195b12b2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjAyNDY_a1c7eac1-7501-4686-999c-66bb5e441b79">0.2</ix:nonFraction>&#160;million will be recognized as revenue commensurate with the provision of research services over the remaining term of the agreement. </span></div><ix:nonNumeric contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NTg_a451203c-9183-4a22-81db-74e68d2ee744" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%;"><tr><td style="width:1.0%;"></td><td style="width:45.694%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.536%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.536%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.536%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.538%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Pfizer SB-525 agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee and research services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib203359cf79c4a78b76345ab5cdd5ada_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0xLTEtMS0zODc_c929023f-fddd-43c3-8df8-6ea87b7ec3e3">326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c1215983e16448081567393da2a173e_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0zLTEtMS0zODc_f8d6208a-f03d-4b21-bd28-f1ad165e30bc">4,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i874cc070d9494a23bb75d5fe3a959fe7_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0xLTEtMS0w_f3d30f21-1d39-4fd4-8e83-3aae91587383">2,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1c975adb10c4c80a444e6e169fef905_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0zLTEtMS0w_eb676c73-8f4e-45a2-9cdd-47ce2c73c1d5">1,595</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e71b2952fdc443c82251bc33b95a5ca_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0xLTEtMS0zODc_e08bfa82-457b-42a1-bfe2-ab4fceb2cf32">103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8f1db50a2ee45a69dd2f7dd10845478_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0zLTEtMS0zODc_f957fbe3-6edf-4d2d-b67f-a1f35550278b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6a077c7a6e84585bf477e2bde29c32d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0xLTEtMS0w_a8b7ddf6-57ed-452f-9449-0dc07d1608e2">1,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd717c13dbff4c08b4ac853e8fba45b5_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0zLTEtMS0w_1757f95c-b5ee-4c49-8f15-10f8fd66ea10">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0621e82b115e42d3be6403068e7b2f9a_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0xLTEtMS0zODc_53a7cbc0-0648-4088-805e-59f581869e38">429</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i265e9d79e9a3440ba73a2f8dd054a88d_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0zLTEtMS0zODc_7e04aa79-7d08-4023-9e47-24dbd2ce16a8">4,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0xLTEtMS0w_92e7475f-7022-4d57-84fd-c4f0d243dd6a">3,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9d56781fdc104f368a6db7f99c183153_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0zLTEtMS0w_91ff639d-5a19-4333-9701-0101668ea04d">1,595</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company received new data results, and expanded enrollment of patients in the ongoing trial. As a result, the estimated project cost increased and the proportional performance was updated based on the actual services delivered to Pfizer as a percentage of the updated project cost as of March 31, 2019. The increase in project cost resulted in a decrease in the measure of the proportional cumulative performance. During the six months ended June 30, 2019, the Company recorded a revenue reduction of approximately $<ix:nonFraction unitRef="usd" contextRef="i0042ba179bcf4a8d838c6c062581603d_D20190401-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjEwMjE_c093571a-45ba-4464-b420-654586a5af52">3.0</ix:nonFraction>&#160;million, or <ix:nonFraction unitRef="number" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="2" name="sgmo:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjEwMjc_96da5092-5046-42de-bd1c-7e35392b08f9">38</ix:nonFraction>% of total revenues, due to a decrease in the measure of the proportional cumulative performance.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjE2MDk_5fb0b870-9bb9-4e74-a72b-f52c1247e5ee">2.4</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjE2MzU_136c2c5f-a5ff-4bd1-90df-68cfa11a82b5">2.4</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331" decimals="INF" sign="-" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjE2OTU_abcb5d66-45a2-4fcb-9534-ebf163985b21">0.02</ix:nonFraction> for the six months ended June&#160;30, 2020.&#160;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">C9ORF72 Research Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i701ef695d1974db0900aad5b0eaf276f" continuedAt="ibeff517c6850442a9bb4a153a2f87324"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP-TFs&#160;that bind to and specifically reduce expression of the mutant form of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;<ix:nonNumeric contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630" format="ixt-sec:durwordsen" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjMxNzY_83a780a4-6d5b-47d7-8a3b-3030e125a0e2">fifteen years</ix:nonNumeric> after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene for a period of time.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company received a $<ix:nonFraction unitRef="usd" contextRef="ia5be0c8a3eaf44cfbdff12b3693acb7b_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjQ5OTM_531ebec3-a07f-496f-a013-ef5314645923">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib6c53a13e3ed4b41a51ff5afc0e24f34_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjUwNTc_264283ab-0090-401b-903f-bcd24e0e703e">60.0</ix:nonFraction>&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i61c86f3985aa4e6aaf7123281f53e1c9_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjUyNDM_b0d54dbe-44b2-47cf-a436-741709eb1ee3">90.0</ix:nonFraction>&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="ia5be0c8a3eaf44cfbdff12b3693acb7b_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjYwNDA_5d5c0ab2-00cc-4a91-b528-cdff36ab5b5d">12.0</ix:nonFraction> million, which represents the upfront fee. <ix:nonFraction unitRef="milestone" contextRef="iece818eb67d544e1b9ce5641695dda6a_D20171201-20171231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjYwNzg_8ecfbaf8-1811-4b51-8ed3-60961b57c5ae">None</ix:nonFraction> of the clinical or regulatory milestones have been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the performance obligations within this agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services, over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="if5106f4851d54887b1c366031ae40b6b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjc1NjM_a654ef6f-fc2c-40b7-92ad-b3c1c7ce98f3">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9a27653fa2ae413986a3b7ac8ab2240d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjc1NzA_b0a8ed40-7e7c-4e8c-bfb0-12c6a783bbf0">8.0</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="ibeff517c6850442a9bb4a153a2f87324" continuedAt="i0dd4e5c976a34b488e463ee5611a3c88"><ix:nonNumeric contextRef="ibbed171f600d4452b7074be69d363203_D20200101-20200630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NjE_bd617d20-b44c-401c-bb1a-e972b7b95bc7" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"></td><td style="width:45.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Recognition of upfront fee related to Pfizer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;agreement</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74bd1c64097a48dab6c41893d097e234_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0xLTEtMS00MTM_8e309dd6-53e9-4611-bab8-de3a868330d2">3,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2b663765efe486ba3be90af8e53ab8d_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0zLTEtMS00MTM_94f02189-e70f-4ecd-8b3e-1eab05a23c8a">455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3679ea31262c4a9a8be73e04e54ce1da_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0xLTEtMS0w_381d50fd-1d48-4ccc-993a-f0f30171e770">3,785</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic37ca88da7bc49fbaa868d8671da3f88_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0zLTEtMS0w_111394de-9315-4002-9175-726262de2b34">1,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTI2NzQ4MzE1MQ_79d34ed2-904a-4d68-a4b0-9c0c2778b02e">3.0</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTI2NzQ4MzE2NQ_e9b6811a-3a45-48ff-b8ad-257d359bde5c">3.0</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630" decimals="INF" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTI2NzQ4MzE3Mg_a6ea243c-bc99-45c3-b1e6-1efc65b4ab14">0.02</ix:nonFraction> for the six months ended June&#160;30, 2020.&#160;</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi Genzyme</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting <ix:nonFraction unitRef="program" contextRef="ie5657715ba8e402b814e812ea70780d8_D20140101-20140131" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfResearchProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjgxMzU_ae649733-8a5e-456e-8f54-daad6e9a26a8">two</ix:nonFraction> research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon <ix:nonNumeric contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630" format="ixt-sec:durday" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzAxNTk_42b41c73-60e0-419d-8f75-52efc11d6b38">180</ix:nonNumeric> days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the agreement, the Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ie5657715ba8e402b814e812ea70780d8_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzA0NzY_4ab7ed34-0573-4786-9ae7-db541ff36d19">20.0</ix:nonFraction>&#160;million and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i497ca7fec0544874896474aa8c59e3c8_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzA2OTU_9f62a244-7626-40b8-ae95-ae393a77e325">115.8</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $<ix:nonFraction unitRef="usd" contextRef="id6b492f3a18749d2a59bd07e6e047e96_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzA4MDk_4e173737-d2d8-44e9-bfc2-bd3d4ca62ea4">160.5</ix:nonFraction>&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="ie2bd3d15a17e4dfeb83bce33be451571_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzEwNDk_030be77d-44e1-4ff7-b6ce-81a6abd0a8ac">276.3</ix:nonFraction>&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $<ix:nonFraction unitRef="usd" contextRef="i41bcbb1429a64230b1a3f20305b3b458_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzEzNTg_9b36200b-9bb2-4429-8cd9-24ff2427cbeb">6.0</ix:nonFraction>&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $<ix:nonFraction unitRef="usd" contextRef="ib17dbd8e9112456da64bc13b7c66591e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE0NDA_bf50981d-19d6-4f54-8604-4ec495295f85">7.5</ix:nonFraction>&#160;million milestone has been achieved related to SCD, however <ix:nonFraction unitRef="product" contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE0OTU_8f038a64-1e93-4853-bc7a-2f1ae7b2f393">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="if322408f9ba44ac3a3050f9173bd5dbf_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE1NDA_d1f5609e-f58e-4d2f-be0a-200dac1fba36">no</ix:nonFraction> royalty fees have been earned under the Sanofi agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE3Mjc_273afd6c-0f02-40e6-8c59-57bf3b811640">93.3</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE3NjY_06acd00e-e0e9-4085-bb87-58c73f4df5f5">20.0</ix:nonFraction>&#160;million, two unconstrained milestones in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8fdbfad3304d46fdbce872a95bb8f3d2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE4MTY_ca3e4587-4108-4c18-bf90-63b5c5e0c8de">13.5</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE4NTE_022d1fa6-73be-4323-a513-861bdbab1644">59.8</ix:nonFraction>&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i0dd4e5c976a34b488e463ee5611a3c88"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ibb38c2c18aaf4cf6a67227cc3d5e88e2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM2NjM_10390095-7f4b-4e2c-a45e-a85af6b8e6fa">2.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia4e426bbd60b445f8f58775980820ade_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM2NzA_5df6447e-2048-4ca1-bbd6-73402af6bd03">1.7</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i41bcbb1429a64230b1a3f20305b3b458_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM3NTQ_9b36200b-9bb2-4429-8cd9-24ff2427cbeb">6.0</ix:nonFraction>&#160;million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The Company recognized on a cumulative basis approximately $<ix:nonFraction unitRef="usd" contextRef="ic2993707ab04450c93d7c0cde818957f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM5MjY_dc72e8fc-e27d-4354-895f-e3bec1a4f62d">5.6</ix:nonFraction>&#160;million as of June&#160;30, 2020 attributed to this milestone as revenue and a revenue reversal of $<ix:nonFraction unitRef="usd" contextRef="ic2993707ab04450c93d7c0cde818957f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQwMTY_32fcd565-1703-47ca-a70d-1d3799cb822c">0.1</ix:nonFraction>&#160;million related to a change in scope was recognized during the six months ended June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="ib17dbd8e9112456da64bc13b7c66591e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQxMjE_bf50981d-19d6-4f54-8604-4ec495295f85">7.5</ix:nonFraction>&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The Company recognized on a cumulative basis approximately $<ix:nonFraction unitRef="usd" contextRef="ibb38c2c18aaf4cf6a67227cc3d5e88e2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQyNzM_4a476040-120b-48b3-ba33-b9f14ce661f8">7.0</ix:nonFraction>&#160;million as of June&#160;30, 2020 attributed to this milestone as revenue and a revenue reversal of $<ix:nonFraction unitRef="usd" contextRef="ia6ebcf7335d143a7b2165fc287c91a99_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQzNjM_abafa7f4-1421-4617-8c93-3426997c4c4b">0.1</ix:nonFraction>&#160;million related to a change in scope was recognized during the six months ended June&#160;30, 2020.</span></div><ix:nonNumeric contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NjI_03f54f23-bfd5-47fa-be7a-fce623833529" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"></td><td style="width:45.391%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.608%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e132461b3d342eab6814cba414941b1_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0xLTEtMS00MzA_91f5454f-fc42-4de3-878d-b51dc0491103">380</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7718ad78b270467e8ae7dd73f6379efe_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0zLTEtMS00MzA_cd524ab3-7198-4e98-881a-7755afb069b2">901</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if4652dd95590400a98b5f80879a90ffd_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0xLTEtMS0w_6f2131ad-ba0c-40dc-b0be-fb857836ee05">349</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a527321d23c4aed94f50804dacc5d03_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0zLTEtMS0w_65431d6d-0985-48ce-bb2b-781bd6e78e9a">1,654</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2f14044865d4879afb8479d9c63829d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0xLTEtMS00MzA_d71e9637-c713-4915-9523-fd31677736ee">1,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4da0f61970a045f19353779959c20d90_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0zLTEtMS00MzA_fd2ffd12-0b57-4cf1-b4f7-2092fd07f2e3">2,158</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56befc014b3d45ed9d4357b46df3211e_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0xLTEtMS0w_5421a276-44de-44da-8219-299853db8287">2,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib38f03f2a7b44058af0b32589f5cb20e_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0zLTEtMS0w_6a6f77bb-a321-4a7d-af5d-456c05bca5dd">3,355</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i136a0633a1d642fe8d52aea0bb57ae3e_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0xLTEtMS00MzA_5a2f570d-6542-43fd-ad33-af0d95657593">257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3250dbc4b25847b3b6cf42f0917717c0_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0zLTEtMS00MzA_391f9ead-587d-49c5-a044-29035e45ca3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8ed406253dd0408fa025ccc1e539acff_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0xLTEtMS0w_a04936fd-35b4-4a8c-be88-43996135b1a2">235</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if997601e608240a49794adff9baae92f_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0zLTEtMS0w_11eda0cd-2674-452d-a77b-8394990cddb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5ba64af70834af7acab6ecdc62729b3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0xLTEtMS00MzA_270e71b7-95a0-405c-adaa-188769203718">1,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbab28971c8f4c168f2a753a668b5dd3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0zLTEtMS00MzA_b58cb3ac-05ed-42cf-8305-138fdf2054d3">3,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0xLTEtMS0w_612437d5-e757-4ace-b1a0-fa20cb6c989b">2,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f81298b72494b5d8bfca23ef7846819_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0zLTEtMS0w_398ac3f7-93ba-4c9d-854b-2a16ed630ff9">5,009</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. This adjustment decreased revenue by $<ix:nonFraction unitRef="usd" contextRef="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQ5NDI_81ac3027-5693-44b4-90d4-df8db6582126">2.2</ix:nonFraction>&#160;million, increased net loss by $<ix:nonFraction unitRef="usd" contextRef="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQ5Njg_2309cec9-114c-463e-81fc-eef7ea6b29b2">2.2</ix:nonFraction>&#160;million and increased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331" decimals="2" sign="-" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzUwMjg_fed1924d-1aa1-405e-81ca-3dc8e7735521">0.02</ix:nonFraction> for the six months ended June&#160;30, 2020.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">California Institute for Regenerative Medicine</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $<ix:nonFraction unitRef="usd" contextRef="i936718d885f345a0962a1f03189aeecb_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:GrantFundingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzUyMzY_1c41b37e-993c-47c2-81ae-c18d34af330f">8.0</ix:nonFraction>&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of June&#160;30, 2020, the Company had received $<ix:nonFraction unitRef="usd" contextRef="i7921fa4bd7c7486b81fa47d950ada799_D20180601-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzU2NDg_463633cb-10b6-4f4a-b0c5-807369ec5cb1">5.2</ix:nonFraction>&#160;million under the award.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of June&#160;30, 2020 and December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="ia8b8e663d405457c8f481e73b7494220_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzYyOTU_4c22d008-9166-4c00-8c4b-96c1b597084f">6.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3be268974b9a4fdc9861bb34708345c1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzYzMDI_40463839-b363-4bd4-b4e3-dc240d6d3513">5.7</ix:nonFraction>&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 6&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81Mi9mcmFnOmExZGMyNjIzYTFlNjQ1M2E4YTcyM2UwNTc3YWI0NmUzL3RleHRyZWdpb246YTFkYzI2MjNhMWU2NDUzYThhNzIzZTA1NzdhYjQ2ZTNfMTYwMg_9ef32d67-783b-44df-98fc-a62c026914e2" continuedAt="i501703bad321494daac0bc77cdc38a3f" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i501703bad321494daac0bc77cdc38a3f"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#8217;s history of losses. Accordingly, the Company&#8217;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 27, 2020, the President signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package that includes changes to the US tax code including but not limited to, (1) modifications to the calculation of interest deductibility in 2019 and 2020; (2) changes to rules related to the uses and limitations of net operating loss carryforwards created in 2018-2020 and (3) technical corrections for qualified improvement property. The CARES Act did not have a material impact on the Company's Condensed Consolidated Statements of Operations for the six months ended June&#160;30, 2020.</span></div></ix:continuation><div id="ia59e529445a14a10ab18f7d7fd95bd0f_55"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 7&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjQwOQ_7e676806-8b7c-41e1-ab78-7d9a2e292a1f" continuedAt="ie3a50ea0e6cb4f6fa5057c2db2489296" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ie3a50ea0e6cb4f6fa5057c2db2489296" continuedAt="i44d31c9975d24ada9079ff81f4512706"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo occupies approximately <ix:nonFraction unitRef="sqft" contextRef="i0ad8f21a630e48d2a8a38df95bced575_I20200630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfODA_07e2a433-e78a-4001-9d34-b18e2e7078c9">87,700</ix:nonFraction> square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately <ix:nonFraction unitRef="sqft" contextRef="i3c124d01f92f4f20abe3ffd4deee75f4_I20200630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjU3_5f8f10be-2875-485e-94af-26be8c5c36fe">45,600</ix:nonFraction> square feet of research and office space in Richmond, California pursuant to leases that expire in August 2026. In addition, the Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i8278bf8bca164e85b22804fbba447080_I20200630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNDE4_d2152f5a-106a-4a88-a99f-8ef30184d1f4">20,800</ix:nonFraction> square feet of research and office space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNjY2_e5a325f2-0b18-490c-80b9-c74fd88bf207">five</span> to <ix:nonNumeric contextRef="i4787cbcb6bbc401c9aed2cc60462afc9_I20200630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNjcy_8ff0cca7-712e-4a74-ad97-12a0bac4a2be">ten years</ix:nonNumeric>. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the three and six months ended June&#160;30, 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA3MA_430c74e6-a754-409a-899b-dd0dbcdb8be6">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMDI0OQ_7f3d351a-b42e-4db9-9889-b92c06e2ac61">5.1</ix:nonFraction>&#160;million of lease costs in relation to these operating leases. These lease costs were included in operating expenses in the Condensed Consolidated Statements of Operations. Variable lease expense was $<ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTI0MA_fae5426f-159f-408e-b82a-90e76d349d5a">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMDI3Nw_45e3fb78-e3ef-42f4-8ce0-b9e6e16246fe">1.0</ix:nonFraction>&#160;million for the three and six months ended June&#160;30, 2020 and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTcyNQ_be8bbd8b-4003-4235-b7e6-4b9485d59642">3.1</ix:nonFraction>&#160;million and was included in net cash used in operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flow.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="i44d31c9975d24ada9079ff81f4512706"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjQxMQ_bd738d01-67e2-4345-90bb-943706bb955f" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:86.505%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.495%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ending December 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMS0xLTEtMS0w_37e069b2-cf25-41b4-938d-1963395da6b8">2,717</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMi0xLTEtMS0w_ed1f925e-bf46-4d69-87a7-278af15b077b">6,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMy0xLTEtMS0w_a81a4c0b-f4f3-4052-a0fb-1c21f5899f3a">6,468</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNC0xLTEtMS0w_6370e1df-a260-4649-ab69-affdab78d468">6,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNS0xLTEtMS0w_cdafc47f-4512-4fb4-9746-8a4012ef6c46">6,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNi0xLTEtMS0w_03f74107-1463-48b9-ad77-97f23ae17e3c">26,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNy0xLTEtMS0w_5262491d-8b1f-409e-98e0-aaa4c966ef49">54,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfOS0xLTEtMS0w_e8b2c3f7-50b4-407e-a2bb-de7c11f9ad4a">12,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTEtMS0xLTEtMA_6f58298d-a91c-43f0-8def-80b7ee98e7ea">42,610</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reported as of June 30, 2020:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTQtMS0xLTEtMA_7c246695-a0c4-4e2a-b1e0-bd4d1e1bb7ab">3,376</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities - long-term</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTUtMS0xLTEtMA_587f66b6-424b-40cf-b4c4-11b8db7b1dbc">39,234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTYtMS0xLTEtMA_2d98ce12-2516-46d4-8811-5cff63b8cd18">42,610</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the weighted-average remaining lease term is <ix:nonNumeric contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjAxMA_e870a063-3f82-4a58-8797-2021c8e9361d">8.3</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjExNw_cac6d7fb-7201-4d97-909b-4664ac4a405d">6.2</ix:nonFraction>% for the Company&#8217;s operating leases.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not have any financing leases.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contractual Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, the Company has manufacturing obligations that include a fee of $<ix:nonFraction unitRef="usd" contextRef="ie78f712514d644f0aeb72decbb03a5df_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMzEwOA_0a2969f9-9450-4e4a-a748-1cc2d6936bd6">3.2</ix:nonFraction>&#160;million for dedicated capacity pursuant to the Development and Manufacturing Services Agreement with Brammer Bio MA, now a Thermo Fisher Scientific Inc. subsidiary ("Brammer"). The Company also has an Option Agreement ("Option") with Brammer, entered in April 2019, whereby Brammer granted the Company an option to secure dedicated capacity for manufacturing in Brammer&#8217;s facilities. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i2fe52cb8512a433bacfe3d8fc79e20c9_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:PaymentsForOtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDIzNA_3cf08685-7e61-4632-8526-bd0939d7ef4f">3.0</ix:nonFraction>&#160;million for the Option, which expires on December 31, 2021. In addition, the Company agreed to pay Brammer $<ix:nonFraction unitRef="usd" contextRef="i3439f2f47737467aace116123f9168f1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDI3Mg_55e12dce-99cb-4dfe-9377-5a50f69fbee7">2.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i780b21af471142fda76665c4670e1f9e_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:PaymentsForOtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDMxMA_839ccb92-7f35-4f50-944e-5a4beb201f60">1.0</ix:nonFraction>&#160;million of which has been paid, to assist it in establishing its manufacturing capabilities in Brisbane, California, which may increase Sangamo's contractual commitments in the future. Furthermore, the Company has non-cancelable contractual commitments under manufacturing-related supplier arrangements with Brammer, which requires minimum purchase commitments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i35a93dc1df704160a8e800276312cdd3_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDM0OA_5383547d-8380-428c-9739-57414aa3975e">2.5</ix:nonFraction>&#160;million through December 2021, $<ix:nonFraction unitRef="usd" contextRef="i001922d1aa724eb9ba89ce4a309abafb_I20190430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:ContractualObligationPaidUponExecution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDM4OA_44600414-5854-4e84-8305-6fc20458b637">0.5</ix:nonFraction>&#160;million of which was paid upon execution of the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, the Company entered into an amendment to an existing lease to acquire approximately <ix:nonFraction unitRef="sqft" contextRef="i85c2dfc465984dfca02266cbfed874c2_I20200531" decimals="-2" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMzI5ODUzNDg5MDkyMg_63a4eebf-1405-44f6-ac09-5274d7fc3def">8,500</ix:nonFraction> square feet of research and office space in Richmond, California that expire in August 2026. Total lease payment over the life of this lease under this amendment are approximately $<ix:nonFraction unitRef="usd" contextRef="i85c2dfc465984dfca02266cbfed874c2_I20200531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMTIzNg_4123e2b3-6cb9-4d64-84c3-3e3e6547b5a5">1.6</ix:nonFraction>&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The commencement date of this lease was determined to be in the third quarter of 2020, therefore the lease is not included in the Company&#8217;s operating lease right-of-use asset or operating lease liabilities as of June 30, 2020. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has $<ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LicenseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNTM1MQ_06c7a55a-9d4f-4922-91ff-735500a2fa68">1.2</ix:nonFraction>&#160;million of license obligations related to its intellectual property.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is not party to any material pending legal proceedings or contingencies. From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business.</span></div></ix:continuation><div id="ia59e529445a14a10ab18f7d7fd95bd0f_58"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 8&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RleHRyZWdpb246YWU0ZmFiM2MzODQzNDMwNzk2YjIyN2Q5NjNmNDc1NmJfMjE4_219b1857-68e3-4daf-a415-59ac5261a2f4" continuedAt="ie9765da554dc4b25b9095310a8ab3d40" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie9765da554dc4b25b9095310a8ab3d40" continuedAt="i5e5d6edd114246ac97c5d73c8011e691"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RleHRyZWdpb246YWU0ZmFiM2MzODQzNDMwNzk2YjIyN2Q5NjNmNDc1NmJfMjIw_fdb59735-abf7-4fc4-a8bc-cdf4dd6857a4" continuedAt="i37450410da0b43a2b1a1668eacaff364" escape="true">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-bottom:6pt;"><ix:continuation id="i5e5d6edd114246ac97c5d73c8011e691"><ix:continuation id="i37450410da0b43a2b1a1668eacaff364"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.534%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.362%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.805%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.362%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.805%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.362%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.805%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.365%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iafe38837c16248a78d0de8b944f254fb_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0xLTEtMS0zMjY_4f6434ed-0163-4528-bc94-d20611d0a180">3,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa400bd785134038a5e827fe16db92fd_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0zLTEtMS0zMjY_0c9230f9-bb3a-4767-bfb2-ae50e8b56705">2,763</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56a3424384d1467db3554580d425e34a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0xLTEtMS0w_b145dcc7-f94a-43ed-ae6d-237886cced65">6,417</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ae7ba47695144fd9e5a674b88fd5103_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0zLTEtMS0w_3b0a3af1-2709-4725-bd3c-ef934d98061f">5,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11ee1f4e6dd5429489a79d5f03928607_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0xLTEtMS0zMjY_8f856716-a4a4-4a38-91ca-1a9c7dd8b307">3,186</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0ae307928d74e0dbeabc531a4d6b23b_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0zLTEtMS0zMjY_2bcfe353-50d3-4c37-9106-7647312ea4ac">2,104</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60b6a65590a94cb39bd8e14b7ac7d841_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0xLTEtMS0w_e8777539-5c3d-47fd-8913-786e077217d0">5,967</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b2ede07af0343f389b427458e393a41_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0zLTEtMS0w_c802296a-5720-46eb-a15b-93612ed09f11">4,329</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0xLTEtMS0zMjY_b251e8a8-ee22-404b-903d-8116d682ef10">6,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0zLTEtMS0zMjY_12e8ca5d-2ee2-4541-9f04-a707b002dbf3">4,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0xLTEtMS0w_cfefbef7-adeb-40e4-a822-7b9f6471f8ae">12,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0zLTEtMS0w_c17b1d63-5043-4dc8-86ee-2fb9df173c32">9,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_61"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 9&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfNDI1_63574589-153c-49d9-a6eb-4e79a39e6d3c" continuedAt="i1cba2a8abd08417e8229508a372c793c" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i1cba2a8abd08417e8229508a372c793c"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the collaboration agreement with BIMA described in Note 5 of these Condensed Consolidated Financial Statements, the Company also entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase the Biogen Shares at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i426f14e574704e28836ba330c9dbd8f1_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMTY0OTI2NzQ0NTA3NQ_2adfd67c-9f87-469b-9dc1-3294270623f8">9.2137</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMTY0OTI2NzQ0NTAyMw_f9d4fabc-1319-44aa-8a30-4bfc19e2828e">225.0</ix:nonFraction>&#160;million. The Company closed the sale of the Biogen Shares on April 8, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="id89248aaa3ba492aa4b8f488c3be6df5_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMTY2_a0e51a1b-2bbf-47da-a590-e3ad7c0d01a4">12.7</ix:nonFraction>&#160;million shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i95ccc4fdb8ea4e4c9cf7485785db1170_I20190430" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMjI2_28d77f32-091c-4d20-a61e-7864ac42fb0d">11.50</ix:nonFraction> per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="i77dd9fd15a104e948837f14e23f36760_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfNDIz_1f370683-925a-42d5-ae04-290ae2f4cfc1">136.3</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ia59e529445a14a10ab18f7d7fd95bd0f_64"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 10&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzM1MA_31a69d0b-260f-4026-831b-1c6f6ed3770e" continuedAt="i6d4679a322a24656aee7d075898f9004" escape="true">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</ix:nonNumeric></span></div><ix:continuation id="i6d4679a322a24656aee7d075898f9004" continuedAt="ib917b1ba8486441fb5e8a476cffa2fa5"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On July 20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring <ix:nonFraction unitRef="number" contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720" decimals="INF" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTYy_c970d7b3-b12b-4885-9759-60799f3c15c7">100</ix:nonFraction>% of Sangamo France&#8217;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired <ix:nonFraction unitRef="shares" contextRef="i7739ea8df1214054a989dcff454b94a4_D20181001-20181001" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzIz_cbfa02a1-7e26-4984-b9e9-51a8243270ba">13,519,036</ix:nonFraction> ordinary shares of Sangamo France (&#8220;Ordinary Shares&#8221;) as part of a block transaction that closed on October 1, 2018 (the &#8220;Acquisition Date&#8221;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire <ix:nonFraction unitRef="shares" contextRef="i6dbedaa261e3453a99f6f409adcb45d5_D20181001-20181123" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfNTk1_5656699e-0968-467f-b13d-472cb65229ae">11,528,635</ix:nonFraction> Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November 23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned <ix:nonFraction unitRef="number" contextRef="i90c49293724e4810919a1e33caec7e6a_I20181231" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfODQw_007e2875-6b12-40ad-8526-02370deeed57">98.2</ix:nonFraction>% of the Ordinary Shares as of December 31, 2018 (or <ix:nonFraction unitRef="shares" contextRef="i277faef5976144519b807ff6099f0c2a_D20180101-20180630" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfODk0_221c7749-7936-43fd-816c-5d49ac7efcc8">25,047,671</ix:nonFraction> Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA2Mg_16328202-9289-4800-8320-df5b6e99fc94">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;). In June 2019, Sangamo France became a soci&#233;t&#233; par actions simplifi&#233;e (&#8220;S.A.S.&#8221;) and was renamed from &#8220;TxCell&#8221; to &#8220;Sangamo Therapeutics France.&#8221; During 2019, the Company acquired approximately <ix:nonFraction unitRef="shares" contextRef="i885f1a5affb04c469c5e9e4b478422c3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTU0OQ_b64fb94a-a2dd-4c51-8915-4b92d36e16a3">111,000</ix:nonFraction> vested free shares, increasing its ownership of the Ordinary Shares from <ix:nonFraction unitRef="number" contextRef="i90c49293724e4810919a1e33caec7e6a_I20181231" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTYyNQ_007e2875-6b12-40ad-8526-02370deeed57">98.2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6874113b1491428eacb8504f0de4cfe8_I20191231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTYzMQ_b5eb91c7-9efe-4ef6-8bd5-363aba8b0ab8">98.7</ix:nonFraction>%. During the three months ended June&#160;30, 2020, the Company acquired approximately <ix:nonFraction unitRef="shares" contextRef="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTY0OTI2NzQ0NTQ4OQ_6ab827ab-b7e3-482a-82cc-389c49589beb">117,000</ix:nonFraction> vested free shares, including <ix:nonFraction unitRef="shares" contextRef="i8989c058d5ad4d3083e46b8de83336a3_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA5OTUxMTYzMjExNg_d0beb2b4-06db-466d-9983-09d7d311f1ce">80,000</ix:nonFraction> from a former executive of Sangamo France who is now an executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $<ix:nonFraction unitRef="usd" contextRef="ic6b4b4f1e90f4a7183a57a1c0fce157c_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTY0OTI2NzQ0NTUwMw_3a5447fa-df3f-4b1a-aedb-cf0a3643a8dd">0.2</ix:nonFraction>&#160;million of cash, increasing its ownership of the Ordinary Shares to <ix:nonFraction unitRef="number" contextRef="ic55a7e77392b4473b8950e77235bfa85_I20200630" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA5OTUxMTYzMTg4Mw_56b03e1b-b304-4cbe-b1ef-bab5f8740de8">99.1</ix:nonFraction>% as June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $<ix:nonFraction unitRef="usd" contextRef="i40cf24533b514984a2ae3200f4197e14_I20181001" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTgyMg_e7a6781c-558c-4f4d-81b5-fe4b0fbe6721">0.2</ix:nonFraction> million. See &#8220;Note 2 &#8212; Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-Free Shares Asset</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $<ix:nonFraction unitRef="usd" contextRef="ic6b4b4f1e90f4a7183a57a1c0fce157c_I20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMjEzNg_8eb06063-8ac9-4d4c-861f-f5796e70af53">0.2</ix:nonFraction>&#160;million as of June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i7739ea8df1214054a989dcff454b94a4_D20181001-20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA5OTUxMTYzMjM4OQ_18511579-df9d-480b-b230-2d3b03a6c81e">45.9</ix:nonFraction>&#160;million at the Acquisition Date. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were <ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMjQ0OA_3acbf9dd-8ac7-4bd1-9922-a2233bd7027e"><ix:nonFraction unitRef="usd" contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMjQ0OA_82ddf848-711c-4a7b-86d2-e77a6c6220cf">no</ix:nonFraction></ix:nonFraction> goodwill impairments during the six months ended June&#160;30, 2020 or during 2019 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Non-Controlling Interest</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the remaining non-controlling was determined based on the number of outstanding shares comprising the non-controlling interest and the $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0dfb29e9e7045fb83ff2c12782a719e_I20181001" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzA4OA_5003d793-2234-4a54-997e-3df10b28a86c">2.99</ix:nonFraction> acquisition price per share as of the Acquisition Date. The non-controlling interest is presented as a component of stockholders' equity on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><ix:continuation id="ib917b1ba8486441fb5e8a476cffa2fa5"><ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzM1NA_49c49237-6e68-4bfe-a097-ef06d7bbc8b8" escape="true"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-controlling interest as of June&#160;30, 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:86.505%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.495%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfMS0xLTEtMS0w_e387ec78-4b79-49db-9d9a-c1c62a45c358">185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of additional shares acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfMi0xLTEtMS0zMzM_9a0e3d20-42c3-4192-8c99-4715a75f6be7">339</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfMy0xLTEtMS0w_a365ba41-371a-4cf6-8bd6-4de00882e293">97</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfNC0xLTEtMS0w_e395dcff-5679-41ff-884c-1ba889763af9">251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_67"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 11&#8212;<ix:nonNumeric contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfNDYw_c52d5c2f-c2e6-4b0c-b43a-dd2ccb8683d5" continuedAt="i84a9145f54b14773b6ad254f5599793a" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i84a9145f54b14773b6ad254f5599793a">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. The collaboration became immediately effective upon execution of the agreement. Under the agreement, the Company granted to Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its ZFP-TFs targeted to three undisclosed genes that are associated with neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. Over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk1NA_938ff3c2-f0c1-40b0-bd71-520363c2dffa">three</span>-year collaboration period, which may be extended by Novartis for up to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk2Ng_dc93b536-40db-442b-b669-b33786af281b">two</span> additional years, the Company will perform early research activities for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, investigational new drug-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company's proprietary AAVs for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. Under the agreement, Novartis will pay the Company a $<ix:nonFraction unitRef="usd" contextRef="ib91cbc7a1cd2485baa09f334bf5ffbe1_D20200727-20200827" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk3Mg_c1c897d4-30e3-4ff9-914d-d86aead348f8">75.0</ix:nonFraction>&#160;million upfront license fee payment no later than August 27, 2020. In addition, the Company is eligible to earn from Novartis up to $<ix:nonFraction unitRef="usd" contextRef="i5e110ed49cfa4b80989b60ab5d0101ae_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk4Nw_daff17be-efde-45ee-94c8-005d76471fc7">420.0</ix:nonFraction>&#160;million in development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i81e7c06ca04f44e2b3804131674178f4_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5MzAwMw_e7e0cc18-1f61-4360-867b-943d701eddad">300.0</ix:nonFraction>&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</ix:continuation></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 5, 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. Subject to the terms and conditions of the sales agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of the Company&#8217;s common stock from time to time based upon the Company&#8217;s instructions, including any price, time or size limits or other customary parameters or conditions the Company specifies, subject to certain limitations. Under the sales agreement, Jefferies may sell shares of the Company&#8217;s common stock by any method permitted by law deemed to be an &#8220;at-the-market offering.&#8221; The Company will pay Jefferies a commission of up to 3% of the gross proceeds from each sale of shares of the Company&#8217;s common stock sold through Jefferies under the sales agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, the Company agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, as well as certain ongoing disbursements of Jefferies&#8217; counsel, if required. The sales agreement will terminate upon the sale of all $150.0&#160;million of shares under the sales agreement, unless earlier terminated by either party as permitted therein.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_70"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160; 2.&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements containing the words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should&#8221; and &#8220;will&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to the &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. You should read the following discussion and analysis along with the financial statements and notes attached to those statements included elsewhere in this report and in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, or the 2019 Annual Report, as filed with the Securities and Exchange Commission, or SEC, on February&#160;28, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the section of this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; generally discusses 2020 and 2019 items and quarter-to-quarter comparisons between 2020 and 2019. Discussions of 2019 items and quarter-to-quarter comparisons between 2019 and 2018 are not included in this Quarterly Report on Form 10-Q and can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part I, Item 2 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the SEC on August 8, 2019. </span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_73"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategy is to maximize the value and therapeutic use of our technology platforms. For certain therapies, we intend to capture the value of our proprietary gene therapy, cell therapy, genome editing and genome regulation technologies by manufacturing and developing product candidates and commercializing approved products ourselves. For other therapies, we intend to partner with other biopharmaceutical companies to manufacture and develop product candidates and commercialize approved products as appropriate. Decisions to partner product candidates will be based on review of our internal resources, internal know-how, assessment of technical risk, anticipated length and complexity of clinical studies, competitive landscape and other commercial considerations. Our diverse pipeline includes genomic medicine product candidates across multiple therapeutic areas including inherited metabolic disorders, or IMDs, rare blood diseases, central nervous system diseases, neurodevelopmental disorders, oncology and immunology, which comprises inflammatory and autoimmune diseases.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of transcription factor proteins found in humans and other species. We have used our internal know-how and technical expertise to develop a proprietary synthetic ZFP platform with potential clinical utility in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">genome regulation. ZFPs may be engineered to make zinc finger nucleases, or ZFNs, that can be used to selectively modify DNA sequences by knocking in or knocking out genes of choice, or zinc finger protein transcription factors, or ZFP-TFs, that can be used to selectively increase or decrease gene expression. In the process of developing this platform, we have additionally accrued significant scientific, manufacturing and development capabilities, as well as related know-how, all of which are broadly applicable to the field of gene therapy. We have used this knowledge to advance a gene therapy platform.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a substantial intellectual property portfolio protecting our technology and product candidates. We continue to license and file new patent applications to strengthen and consolidate our existing patent portfolio. We believe that our intellectual property position is critical to our ability to research, develop, manufacture and commercialize gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation products and services.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Business Update</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 27, 2020, we entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., or Novartis, for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. The collaboration became immediately effective upon execution of the agreement. Under the agreement, we have granted to Novartis an exclusive, royalty bearing and worldwide license, under our relevant patents and know-how, to develop, manufacture and commercialize certain of our ZFP-TFs targeted to three undisclosed genes that are associated with neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. Over a three-year collaboration period, which may be extended by Novartis for up to two additional years, we will perform early research activities for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, investigational new drug-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, we are prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of our proprietary adeno-associated viruses for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. Under the agreement, Novartis will pay us a $75.0 million upfront license fee payment no </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">later than August 27, 2020. In addition, we are eligible to earn from Novartis up to $420.0 million in development milestones and up to $300.0 million in commercial milestones. We are also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, we entered into a collaboration and license agreement with Biogen MA, Inc., or BIMA, and Biogen International GmbH (together with BIMA, or Biogen), for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases, including ST-501 a preclinical ZFP-TF product candidate for tauopathies including Alzheimer&#8217;s disease, and ST-502, a preclinical ZFP-TF product candidate for alpha-synuclein related diseases including Parkinson&#8217;s disease, among other targets. Concurrently with the execution of the collaboration and license agreement, we entered into a stock purchase agreement with BIMA in which BIMA agreed to purchase $225.0 million of newly issued shares of our common stock, or the Biogen Shares. In April 2020, the collaboration agreement became effective and we received the stock sale proceeds, and Biogen paid us an upfront license fee of $125.0 million in May 2020. We are also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0 million in pre-approval milestone payments and up to $1.45 billion in first commercial sale and other sales-based milestone payments. In addition, we are also eligible to receive tiered royalties on potential net commercial sales of licensed products arising from the collaborations. For more information regarding the Biogen collaboration, see section entitled &#8220;&#8212;Collaborations&#8212;Biogen&#8221; in Item 1, Business of our 2019 Annual Report.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In collaboration with our partner, Pfizer Inc., or Pfizer, we are evaluating giroctocogene fitelparvovec (also known as SB-525)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">gene therapy for the treatment of hemophilia A. In 2019, we completed the manufacturing technology transfer to Pfizer. Pfizer presented updated follow-up data from the Phase 1/2 Alta Study assessing giroctocogene fitelparvovec in adult patients with severe hemophilia A at the World Federation of Hemophilia 2020 World Congress in June 2020. The data demonstrated that giroctocogene fitelparvovec was generally well tolerated, and all five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII, or FVIII, activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week nine post-infusion). No patients experienced bleeding events or required FVIII infusions.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FVIII activity levels presented reflected measurements up to 61 weeks, the extent of follow-up for the longest-treated patient in the cohort. Pfizer has announced that it is advancing giroctocogene fitelparvovec into a Phase 3 registrational clinical study, which may provide the basis for seeking regulatory approval as a therapeutic, and that it expects to dose the first patient in the study by the end of 2020.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also evaluating our wholly owned ST-920 gene therapy for Fabry disease, a rare inherited metabolic disease. In 2019, the IND was accepted by the U.S. Food and Drug Administration, or FDA, and a clinical trial authorization, or CTA, was granted in the United Kingdom. The FDA also granted Orphan Drug Designation to ST-920 for the treatment of Fabry disease. We are currently evaluating ST-920 in adult males with classic Fabry disease in the Phase 1/2 STAAR study, an open-label, dose-ascending clinical trial. We have successfully screened and enrolled patients into the STAAR study and, while we are carefully following the impact of the evolving COVID-19 pandemic on the operations of clinical sites, we currently anticipate infusing the first subject by the end of 2020. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In collaboration with our partner Sanofi Genzyme, or Sanofi, we are evaluating gene-edited cell therapies for two hemoglobinopathies, ST-400 for transfusion dependent beta thalassemia, and BIVV003 for sickle cell disease, or SCD. ST-400 and BIVV003 are both designed to induce the synthesis of fetal hemoglobin, achieved by gene-edited knock out of the erythroid specific enhancer of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BCL11a</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene, which encodes a strong repressor of the gamma globin gene. In December 2019, we achieved a $7.5 million milestone payment from Sanofi for the first subject dosed in Sanofi&#8217;s Phase 1/2 PRECIZN-1 trial evaluating BIVV003 for SCD. We have enrolled and dosed five patients into the Thales Study evaluating ST-400 for beta thalassemia. Sanofi continues to enroll sickle cell patients into the PRECIZN-1 study. We and Sanofi will look for an appropriate time to present data from these programs at a future date once both studies have accumulated a sufficient number of patients and follow up.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also evaluating chimeric antigen receptor regulatory T cell, or CAR-Treg, cell therapies for the treatment of inflammatory and autoimmune diseases. Our lead CAR-Treg program is TX200, which is being evaluated to treat HLA-A2 mismatched kidney transplantation. In late 2019, we received CTA authorization in the United Kingdom for the TX200 Phase 1/2 STEADFAST clinical trial, and in 2020 we received authorization for the study in the Netherlands. As we plan the initiation of </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the STEADFAST trial, we are monitoring the impact of the evolving COVID-19 pandemic on clinical operations for this study and expect to dose the first subject in 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, we entered into a global collaboration and license agreement with Kite Pharma, Inc., or Kite, a Gilead Company, which became effective in April 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, we are working together with Kite on a research program under which the companies are designing ZFNs and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells, or NK-cells including the insertion of genes that encode chimeric antigen receptors, or CARs, T-cell receptors, or TCRs, and NK-cell receptors, or NKRs directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products. In collaboration with Kite, we are evaluating KITE-037, an allogeneic anti-CD19 CAR-T cell product. Kite has informed us that the timeline for the initiation of the KITE-037 clinical trial planned for 2020 may be delayed due to the impact of the evolving COVID-19 pandemic. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently rely on contract manufacturing organizations, or CMOs, to produce our preclinical and clinical product candidates in accordance with FDA and the European Medicines Agency, or EMA, mandated regulations, also known as current good manufacturing practices, or cGMPs. We employ a technical operations staff in the areas of process development, analytical development, quality control, quality assurance, project management, and manufacturing to facilitate appropriate oversight of our CMOs, support of our regulatory filings and execution of clinical trials. We are building a cGMP manufacturing facility in our new headquarters building in Brisbane, CA. This facility is being designed to manufacture Phase 1/2 clinical trial supplies for our gene therapy and cell therapy pipeline and potentially collaboration programs. The gene therapy manufacturing facility is currently anticipated to become operational by the end of 2020. The cell therapy manufacturing facility in Brisbane, as well as another cell therapy manufacturing facility at our site in Valbonne, France, are anticipated to become operational in 2021.</span></div><div><span><br/></span></div><div style="text-indent:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Estimated Impacts of Evolving COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the World Health Organization characterized COVID-19 as a global pandemic. Also that month, governmental agencies imposed shelter-in-place orders in areas where we operate in California, France and the United Kingdom. The extent to which the COVID-19 pandemic will impact our business, operations and financial condition, either directly or indirectly, will depend on future developments that remain highly uncertain at the present time. As our understanding of events evolves and additional information becomes available, we may materially change our guidance relating to our revenues, expenses and timelines for manufacturing, clinical trials and research and development.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have implemented an operating plan to continue business operations during the ongoing COVID-19 pandemic in compliance with government orders and restrictions, including enhanced workplace safety protocols and modified working schedules. Office-based employees have been working from home since March 2020. Although certain government orders and restrictions have eased, and phased re-openings are underway, it is not certain when such restrictions and orders will be fully lifted, and recent resurgences in number and rates of infections, reactions to increased testing and further spread of the virus may result in the return of prior orders and restrictions or new orders and restrictions.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">   </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not anticipate any material negative impact on our financial condition in 2020 as a result of the COVID-19 pandemic. We believe we are well positioned financially to execute on our wholly owned and partnered research and clinical programs. We ended the second quarter of 2020 with $664.9&#160;million in cash, cash equivalents and marketable securities. Although we believe we are well capitalized currently, if the capital markets become impaired for a prolonged period of several years, our financial condition could deteriorate. We do not currently anticipate any material impairments to the valuation of the financial assets or goodwill on our balance sheet as a result of COVID-19. We do not believe that the remote workplace arrangements we have implemented for our office-based employees have affected our financial reporting or control systems. </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business relies on cooperation with clinical trial sites and with external biopharmaceutical research and manufacturing partners, and we have been working with these sites and partners to minimize any impact of COVID-19 on our clinical trials and our research and development operations. Although our laboratory operations in the United States and France have resumed, enhanced health and safety protocols and modified workplace schedules could result in reduced productivity. In addition to laboratory work supporting our proprietary research, we also conduct research to support collaborations with biopharmaceutical partners, which under certain circumstances provides us with expense reimbursements and other potential payments. While we have experienced periodic short-term disruptions to our laboratory operations due to COVID-19 health and safety protocols, at this time, we do not anticipate any material impact to our ability to conduct our research in a timely manner. We do anticipate that some clinical trial timelines may be impacted due to COVID-19 and the diversion of healthcare resources to fight the pandemic. We will continue to monitor the impact of COVID-19 on our research obligations and timelines of our clinical trials. We are not aware of supply shortages related to COVID-19 that will affect our clinical trials or research operations. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See also the section titled &#8220;Risk Factors&#8221; for additional information on risks and uncertainties related to the evolving COVID-19 pandemic. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Certain Components of Results of Operations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenues have consisted primarily of revenues derived from collaboration agreements with our strategic partners related to upfront license fees, reimbursable research services, milestone achievements and grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner funding will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since inception and expect to incur losses in the future as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities, payments from our strategic partners and research grants.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our gene therapy and our genome editing programs in the clinic and, if we are able, to progress our earlier stage product candidates into clinical trials.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying management's discussion and analysis of our financial condition and results of operations are based upon our Condensed Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes in our critical accounting policies and estimates disclosed in our 2019 Annual Report.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_76"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations for the Three and Six Months Ended June 30, 2020 and 2019</span></div><div style="padding-left:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%;"><tr><td style="width:1.0%;"></td><td style="width:24.080%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.772%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.782%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,548&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenues consisted of revenues from collaboration agreements and, to a significantly lesser extent, research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Novartis, Biogen, Kite, Pfizer and Sanofi as we continue to recognize upfront and milestone payments received under such agreements over time in revenues.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $4.0&#160;million in revenues for the three months ended June&#160;30, 2020, compared to the same period in 2019, was primarily due to an increase of $8.2&#160;million in revenue related to our agreement with Biogen, which took effect in April 2020. This increase was partially offset by a decrease of $4.2&#160;million in revenue related to our hemophilia A collaboration agreement with Pfizer after the successful IND transfer of the SB-525 product candidate to Pfizer in December 2019, which resulted in decrease in activities post IND transfer for the three months ended 2020 compared to the same period in 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $9.0&#160;million in revenues for the six months ended June&#160;30, 2020, compared to the same period in 2019, was primarily due to an increase of $8.2&#160;million in revenue related to our agreement with Biogen, which took effect in April 2020.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating expenses</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%;"><tr><td style="width:1.0%;"></td><td style="width:24.080%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.772%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.221%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.782%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41,523&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83,002&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71,305&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,927&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,597&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,715&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59,450&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51,052&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,028&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consisted primarily of compensation related expenses, including stock-based compensation, laboratory supplies and expenses related to preclinical and clinical studies, manufacturing clinical supply, allocated facilities, information technology expenses and contracted research.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $5.1&#160;million in research and development expenses for the three months ended June&#160;30, 2020, compared to the same period in 2019, was primarily driven by a $5.3&#160;million increase in headcount related compensation expense to support our programs and clinical trials, and a $3.8&#160;million increase in overhead costs as we ramp up our internal manufacturing operations. These increases were partially offset by a decrease of $4.0&#160;million in clinical and manufacturing supply expenses due to timing of our trials and programs. Stock-based compensation expense included in research and development expenses was $3.6&#160;million and $2.8&#160;million for the three months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $11.7&#160;million in research and development expenses for the six months ended June&#160;30, 2020, compared to the same period in 2019, was primarily driven by an $8.6&#160;million increase in overhead costs as we ramp up our internal manufacturing operations, an $8.1&#160;million increase in headcount related compensation expense to support our programs and clinical trials, partially offset by a decrease of $5.3&#160;million in clinical and manufacturing supply expenses due to timing of our trials and programs. Stock-based compensation expense included in research and development expenses was $6.4&#160;million and $5.1&#160;million for the six months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our earlier stage product candidates into clinical trials.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The length of time required to complete our development programs and our development costs for those programs may be impacted by the scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, and whether we pursue development of our product candidates with a partner or collaborator or independently. For example, our product candidates are being developed in multiple therapeutic areas, and we do not yet know how many of those therapeutic areas we will continue to pursue. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with our development programs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. The full extent of the impact of the evolving COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and Administrative Expenses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses consist primarily of compensation related expenses including stock-based compensation for executive, legal, finance and administrative personnel, professional fees, allocated facilities and information technology expenses, and other general corporate expenses.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $3.3&#160;million in general and administrative expenses for the three months ended June&#160;30, 2020, compared to the same period in 2019, was primarily due to an increase of $2.3&#160;million in professional fees, and an increase of $2.6&#160;million </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in headcount driven compensation costs. These increases were partially offset by a decrease of $1.7&#160;million in allocated facility and support costs. Stock-based compensation expense included in general and administrative expenses was $3.2&#160;million and $2.1&#160;million for the three months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-indent:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase of $2.3&#160;million in general and administrative expenses for the six months ended June&#160;30, 2020, compared to the same period in 2019, was primarily due to an increase of $5.1&#160;million in headcount driven compensation costs, and an increase of $1.4&#160;million in professional fees. These increases were partially offset by a decrease of $3.7&#160;million in allocated facility and support costs, and a decrease of $0.6&#160;million in travel and entertainment costs due to COVID-19 travel restrictions. Stock-based compensation expense included in general and administrative expenses was $6.0&#160;million and $4.3&#160;million for the six months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="text-indent:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As we continue to build out our product portfolio and advance our product candidates into the clinic, we expect higher general and administrative expenses to support the growth of the business.</span></div><div style="text-indent:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest and other income, net</span></div><div style="text-indent:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net, decreased by $1.2&#160;million for the three months ended June&#160;30, 2020, compared to the same period in 2019, primarily due to a decrease of $1.5&#160;million in interest income reflecting the decline in market interest rates.</span></div><div style="text-indent:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest and other income, net, decreased by $1.4&#160;million for the six months ended June&#160;30, 2020, compared to the same period in 2019, primarily due to a decrease of $2.1&#160;million in interest income reflecting the decline in market interest rates, partially offset by a decrease of $0.4&#160;million in foreign exchange losses.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_79"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Liquidity</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had cash, cash equivalents, and marketable securities totaling $664.9&#160;million compared to $384.3&#160;million as of December&#160;31, 2019, with the increase primarily attributable to our collaboration with Biogen, which became effective in April 2020. Our most significant use of capital is for employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including U.S. government-sponsored entity debt securities, corporate debt securities, commercial paper securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since the beginning of 2017, we have received significant amounts of capital as upfront payments under our collaboration agreements. Our collaboration agreements provide for the payment of development, regulatory, and commercial milestones. In February 2020, we entered into a collaboration and license agreement with Biogen for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases, which became effective in April 2020. Upon effectiveness of the agreement in April 2020, we received a payment of $225.0 million for the purchase of the Biogen Shares. In addition, Biogen paid us an upfront license fee of $125.0 million in May 2020. For more information see Note 5 &#8212; Major Customers, Partnerships and Strategic Alliances in the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q. In July 2020, we entered into a collaboration and license agreement with Novartis for the development and commercialization of gene regulation therapies for the treatment of neurodevelopment disorders. Under the agreement, Novartis is required to pay us a $75.0 million upfront license fee by August 27, 2020. In addition, in August 2020, we entered into an Open Market Sale Agreement with Jefferies LLC, or Jefferies, providing for the sale of up to $150.0 million of our common stock from time to time in &#8216;at-the-market&#8217; offerings under our existing shelf registration statement. We currently anticipate that our existing cash, cash equivalents and marketable securities, cash flows from operations and access to financing sources, including our at-the-market sale agreement with Jefferies, will continue to be sufficient to meet our cash needs for at least the next 12 months. During the period of uncertainty of volatility related to the evolving COVID-19 pandemic, we will continue to monitor our liquidity.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by operating activities was $141.1&#160;million for the six months ended June&#160;30, 2020, primarily reflecting an increase in deferred revenues of $178.9&#160;million driven by cash received in connection with the Biogen collaboration agreement, a decrease in accounts receivable of $31.3&#160;million and stock-based compensation of $12.4&#160;million and other activities, partially offset by our net loss of $78.9&#160;million.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by investing activities for the six months ended June&#160;30, 2020 was $101.3&#160;million related to a net increase in maturities of marketable securities, partially offset by purchases of property and equipment.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing activities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities for the six months ended June&#160;30, 2020 was $144.6&#160;million primarily, reflecting the $145.4&#160;million estimated fair value of the Biogen Shares issued, partially offset by $2.9&#160;million of issuance costs related to the issuance of these shares.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Capital and Capital Expenditure Requirements</span></div><div style="text-indent:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we believe that our available cash resources, as well as expected revenues from corporate collaborators, strategic partners and research grants, will be adequate to fund our currently planned operations through at least the next 12 months from the date the financial statements are issued. Future capital requirements beyond the next 12 months will be substantial and if our capital resources are insufficient to meet future capital requirements, we may need to raise additional capital to fund our operations through equity or debt financing. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities, including sales pursuant to our at-the-market financing facility, may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_82"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_85"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contractual Obligations and Commercial Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, we entered into an amendment to an existing lease to acquire approximately 8,500 square feet of research and office space in Richmond, California that expire in August 2026. Total lease payment over the life of this lease under this amendment are approximately $<ix:nonFraction unitRef="usd" contextRef="i85c2dfc465984dfca02266cbfed874c2_I20200531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl84NS9mcmFnOmQ0ZmRmMGJhNWJkYzQxMGRiZTAwZmUyNmY3MzYxM2VhL3RleHRyZWdpb246ZDRmZGYwYmE1YmRjNDEwZGJlMDBmZTI2ZjczNjEzZWFfMTA5OTUxMTYzMDIyMw_4123e2b3-6cb9-4d64-84c3-3e3e6547b5a5">1.6</ix:nonFraction>&#160;million. Variable lease payments include our allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The commencement date of this lease was determined to be in the third quarter of 2020, therefore the lease is not included in our operating lease right-of-use asset or operating lease liabilities as of June&#160;30, 2020. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no other material changes outside of the ordinary course of business in our contractual obligations as of June&#160;30, 2020 from those as of December&#160;31, 2019.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_88"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our exposure to market risk relates to our cash, cash equivalents and investments. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The securities in our investment portfolio are not leveraged and are classified as available-for-sale. The majority of these available-for-sale securities are short-term in nature and subject to minimal interest rate risk. Our investments currently consist of commercial paper, corporate debt securities and U.S. government-sponsored entity debt securities. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. We do not believe that a change in interest rates would have a material negative impact on the value of our investment portfolio. Our market risks at June&#160;30, 2020 have not changed materially from those discussed in Item 7A of the 2019 Annual Report.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Volatile market conditions arising from the evolving COVID-19 pandemic may result in significant changes to exchange rates relative to the U.S. dollar and may affect our operating results as expressed in U.S. dollars.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of June&#160;30, 2020. Based on that evaluation, as of June&#160;30, 2020, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Inherent Limitations on Controls and Procedures</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There has been no change in our internal control over financial reporting that occurred during the six months ended June&#160;30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not experienced any material impact to our internal controls over financial reporting even though most of our employees are working remotely due to the evolving COVID-19 pandemic. We continue to monitor and assess the COVID-19 pandemic in order to minimize the impact on the design and operating effectiveness of our internal controls.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II. OTHER INFORMATION</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_97"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160; 1.&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_100"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160; 1A.&#160;RISK FACTORS</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">An investment in our common stock involves significant risk. This Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our revenues, expenses, net loss and net loss per share. You should carefully consider the information described in the following risk factors in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2019, or the 2019 Form 10-K, together with the other information appearing elsewhere in this report, before making an investment decision regarding our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to Research, Development, Commercialization and Regulatory Approval of our Products and Technology</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our success depends substantially on the results of clinical trials of our therapeutic programs and ability to obtain regulatory approval of our product candidates, and we may be unable to demonstrate safety and efficacy of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a clinical-stage biotechnology company and have ongoing clinical trials evaluating product candidates that use</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> our platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">genome regulation.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We do not have any products that have obtained regulatory approval and are substantially dependent on the results of clinical trials of our therapeutic programs. However, there is no guarantee that we will be able to achieve positive final safety and efficacy results in our current or future clinical trials for our product candidates. If we fail to demonstrate safety or obtain positive clinical trial results, are unable to meet the expected timeline of these clinical trials or release of data for these programs, or if we are unable to obtain regulatory approval of our product candidates, our anticipated revenue from our product candidates and our prospects for profitability would be adversely affected, which would have an adverse effect on our business operations and financial conditions, which may cause a significant decline in our stock price.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are exposed to numerous risks associated with conducting required clinical trials for the development of our product candidates, and there is no guarantee that we will be successful in any of our clinical trials or obtain marketing approval for any of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates before we can obtain marketing approval for any such candidates. We have limited experience in conducting later stage clinical trials and may not possess the necessary resources and expertise to complete such trials. Clinical testing is expensive, time consuming and uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage. Events that may prevent successful or timely completion of clinical development include, among others:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in reaching a consensus with regulatory authorities on trial design;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in opening clinical trial sites or obtaining required institutional review board, or IRB, or independent ethics committee approval at each clinical trial site;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in recruiting and enrolling suitable patients to participate in our clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in clinical trial activities due to the evolving COVID-19 global pandemic and the diversion of healthcare resources to fight the pandemic;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to perform in accordance with the Good Clinical Practice regulations of the U.S. Food and Drug Administration, or FDA, or applicable laws and regulations in the European Union, or EU, and other countries;</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions, or as a result of manufacturing or formulation changes to our product candidates;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in having subjects complete participation in a trial or return for post-treatment follow-up;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">clinical trial sites or subjects dropping out of a trial;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">occurrence of serious adverse events or other safety concerns associated with the product candidate that are viewed to outweigh its potential benefits, result in approval delays or other regulatory restrictions, or harm our reputation;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">occurrence of serious adverse events or other safety concerns in trials of the same class of agents conducted by other sponsors; </span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to demonstrate that a product candidate is safe and effective for its proposed indication;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unexpected costs and expenses and lack of sufficient funding for these programs; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss of licenses to critical intellectual properties.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not yet reached agreement with regulatory authorities on the complete development pathway for certain product candidates, and such authorities can change decisions or guidance with respect to approvable endpoints, particularly as the technology continues to develop in these areas. Due to the novelty of certain programs, the endpoints needed to support regulatory approvals will likely be different from those originally anticipated. Any inability to successfully complete preclinical and clinical development of our product candidates, or complete such trials in the time frames anticipated, could result in additional costs to us or impair our ability to generate revenues from product sales, or achieve regulatory and commercialization milestones and royalties, or shorten any periods during which we may have exclusivity. Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn. If we are unable to obtain and maintain regulatory approval for our product candidates in one or more jurisdictions, or any approval contains significant limitations, we would not be able to generate anticipated revenues or become profitable, which would have an adverse effect on our business operations and financial conditions.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution since the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Results from preclinical studies or early clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. From time to time, we have and may in the future publish or report preliminary, initial or interim data. Preliminary, initial or interim data from our clinical trials and those of our partners may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data becomes available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time, or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is no guarantee that any of our pending clinical trials will be successful. Moreover, we have pending clinical trials involving our zinc finger nucleases, or ZFN, technology, where the clinical benefit has not been demonstrated in analyses conducted to date in the ongoing clinical trials. Although we are planning new clinical trials to evaluate updated ZFNs and other potential modifications to enhance the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> delivery of the ZFNs, there can be no assurance that we will be able to effectively deliver ZFNs to produce a clinical benefit to patients treated with our product candidates. In addition, our viral delivery systems and ZFN technologies continue to evolve and neither has been fully validated in human clinical trials for the therapeutic areas we are pursuing. If our viral delivery systems or ZFN technologies do not meet the safety criteria or cannot produce the desirable efficacy results we expect, we may be forced to suspend or terminate the affected program or seek alternative technologies to deliver ZFNs.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, there is a high failure rate for drugs, biologic products and cell therapies proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Any such setbacks could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates are subject to a lengthy and uncertain regulatory approval process in each jurisdiction where approval is sought.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A regulatory authority such as the FDA or the European Medicines Agency, or EMA, must approve any human therapeutic product before it can be marketed in such jurisdiction. The process for receiving regulatory approval is long and uncertain, and a potential product may not withstand the rigors of testing under the regulatory approval processes. Before commencing clinical trials in humans in the United States, we must submit an Investigational New Drug application, or IND, to the FDA. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial authorization, or CTA, must be submitted for each clinical protocol to each country&#8217;s national health authority and an independent ethics committee. Only after an IND becomes effective and/or the applicable CTA has been accepted may clinical trials begin. See the &#8220;Business&#8212;Government Regulation&#8221; section in our 2019 Form 10-K for details regarding the regulatory approval processes applicable to our product candidates. While there is some overlap, the regulatory requirements to conduct clinical trials and seek marketing approval vary by jurisdiction. There is no guarantee that the safety studies and other data generated will be sufficient to permit us to conduct clinical trials in all jurisdictions where planned, or once generated, that such clinical trial data will be sufficient to obtain marketing approval in all jurisdictions in which we intend to seek such approval. If we are not able to obtain the necessary regulatory approvals to conduct our clinical trials, or commercialize our products, or if such approvals are delayed or suspended, it would have an adverse effect on our business operations and trading price of our common stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to find suitable patients or may find it difficult to enroll patients for our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifying and qualifying patients to participate as subjects in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate, as well as completion of required follow-up periods. For example, hemophilia trials often take longer to enroll due to the availability of existing treatments. There are also a number of other product candidates in development by our competitors, who compete for the same limited patient populations. If we are not able to enroll the necessary number of subjects in a timely manner, we may not be able to complete our clinical trials. We may face similar challenges or delays in our other or potential future clinical trials. If patients are unwilling to participate in our gene therapy studies because of negative publicity from adverse events related to the biotechnology or gene therapy fields, competitive clinical trials for similar patient populations or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by factors including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">size of the patient population and process for identifying subjects;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">design of the trial protocol;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">eligibility and exclusion criteria;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">perceived risks and benefits of the product candidate under study;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">perceived risks and benefits of gene therapy-based approaches to treatment of diseases;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">availability of competing therapies and clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">potential delays related to the evolving COVID-19 global pandemic and the diversion of healthcare resources to fight the pandemic;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">severity of the disease under investigation;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">availability of genetic testing for potential patients;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">proximity and availability of clinical trial sites for prospective subjects;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">ability to obtain and maintain subject consent;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">risk that enrolled subjects will drop out before completion of the trial;</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patient referral practices of physicians; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">ability to monitor subjects adequately during and after treatment.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, or expand to additional jurisdictions, which could impose additional challenges on our company and expose us to risks. If we are not successful in conducting our clinical trials as planned, it would have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may encounter difficulties that may delay, suspend or scale back our efforts to advance additional research programs through preclinical development, IND and foreign equivalent submissions and into clinical development.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to advance early research programs through preclinical development and to submit new INDs, CTAs and equivalent filings in foreign regulatory jurisdictions necessary to commence and conduct human clinical trials evaluating the preclinical candidates in our pipeline. The preparation and submission of INDs and their foreign equivalents requires us to conduct rigorous and time-consuming preclinical testing, studies, and prepare documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and clinical protocol of our product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of our products and fail to demonstrate consistency in the formulation of the drug. Our preclinical tests may produce negative or inconclusive results, which may lead us to decide, or regulators may require us, to conduct additional preclinical testing. If we cannot obtain positive results in preclinical testing, we may decide to abandon the projects altogether. In addition, our ability to complete and submit certain IND applications and foreign equivalent filings depends on the support of our partners and the timely performance of their obligations under relevant collaboration agreements. If our partners are not able to perform such obligations or if they choose to slow down or delay the progress, we may not be able to prepare and submit the intended INDs or their foreign equivalents on a timely basis or at all. Furthermore, the submission of several INDs and their foreign equivalents involves significant cost and labor, and we may not have sufficient resources and personnel to complete the filing of all intended INDs and their foreign equivalents, which may force us to scale back the number of INDs and their foreign equivalents or forego potential INDs and foreign equivalents that we believe are promising. Any delay, suspension or reduction of our efforts to pursue our preclinical and IND strategy could have an adverse effect on our business and cause our stock price to decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Special regulatory designations, such as RMAT or orphan drug designations, may not be available for our product candidates or may not lead to a faster development or regulatory review or approval process.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received regenerative medicine advanced therapy, or RMAT, designation for our product candidate to treat severe hemophilia A. Additionally, some of our product candidates have also been granted Orphan Drug Designation by the FDA, and some have also been designated Orphan Medicinal Products by the EMA. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. For additional information regarding these special regulatory designations, see the &#8220;Business&#8212;Government Regulation&#8221; section in our 2019 Form 10-K.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we request such designations for our other current or future product candidates, there can be no assurances that the FDA or the EMA will grant any of our product candidates such designations. Additionally, such designations do not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, those product candidates, nor does it limit the ability of any regulatory agency to grant such designations to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval. Such designations can also be revoked. RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the approved indications or commercial potential, or result in significant negative consequences following any potential marketing approval.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the conduct of clinical trials, subjects report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine if the product candidate being studied caused these conditions, particularly as many of the diseases we are studying have complex comorbidities. If clinical experience indicates that our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results and financial condition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if our product development efforts are successful and even if the requisite regulatory approvals are obtained, our products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the applicable product may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the clinical indications and patient populations for which the product candidate is approved;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">acceptance by physicians, treatment centers and patients of the drug as a safe and effective treatment;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the adoption of novel gene therapies by physicians, hospitals and third-party payors;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential and perceived advantages of product candidates over alternative treatments;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the safety of product candidates seen in a broader patient group, including use outside approved indications;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any restrictions on use together with other medications;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prevalence and severity of any side effects;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of market introduction of our products as well as competitive products;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the development of manufacturing and distribution processes for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of treatment in relation to alternative treatments;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the availability of coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of coverage or inadequacy of reimbursement by third-party payors and government authorities;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">relative convenience and ease of administration; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effectiveness of our sales and marketing efforts and those of our collaborators.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors or treatment centers, we will not be able to generate significant revenues, which would compromise our ability to become profitable.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels, which can affect demand for, or the price of, any product candidate for which we obtain regulatory approval. Given the nature of the product candidates that we are developing, some patients may require treatment only one time (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">e.g</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">., single dose administration), and there is substantial uncertainty about the pricing structure for such products, and the level of coverage and reimbursement that will be available for a shift to single-dose treatment as compared to chronic therapy over a patient&#8217;s lifetime. If other companies establish a new pricing structure or business model, including payment based on demonstration of long-term efficacy, our ability to price or obtain reimbursement for our products may be adversely affected. If such pricing structure or business model do not adequately fund the costs of our research and development, manufacturing and commercialization efforts, our business may be adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to uncertainty about the potential pricing structure for certain of our product candidates, cost containment is a recurrent trend in the healthcare industry. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. We cannot be sure that coverage and adequate </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If reimbursement is not available or is available only at limited levels, we may be unable to successfully commercialize any product candidate for which we obtain regulatory approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. Also, there has been heightened governmental scrutiny recently over pharmaceutical and biological product pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical and biological products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, have been designed to encourage importation from other countries and bulk purchasing. For a discussion of health reform activity and the current pricing framework, see the &#8220;Business&#8212;Government Regulation&#8212;Healthcare Reform&#8221; and &#8220;&#8212;Pricing, Coverage and Reimbursement&#8221; section in our 2019 Form 10-K.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to set a price that we believe is fair for our products;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the level of taxes that we are required to pay; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the availability of capital.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates or impose ongoing requirements for potentially costly post-approval studies, post-market surveillance or patient or drug restrictions. For example, the FDA typically advises that patients treated with gene therapy undergo follow-up observations for potential adverse events for a 15-year period. Additionally, the holder of an approved biologics license application, or BLA, is required to comply with FDA rules and is subject to FDA review and periodic inspections, in addition to other potentially applicable federal and state laws, to ensure compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the BLA.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for any approved product will be subject to regulatory requirements and continuing regulatory review. Failure to comply with such requirements, when and if applicable, could subject us to a number of actions ranging from warning letters to product seizures or significant fines, among other actions. See the &#8220;Business&#8212;Government Regulation&#8212;U.S. Review and Approval Processes&#8221; section in our 2019 Form 10-K for more information.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our employees or contractors may engage in misconduct or other improper activities, including noncompliance with research, development, manufacturing or regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk of fraud or other misconduct by our employees and contractors, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Misconduct by our employees and contractors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, personal imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have limited resources and may forego or delay pursuit of certain programs or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities or pursue partnering arrangements rather than retain sole responsibility for development. Our current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may pursue opportunities that end up having a number of competitors that are more advance than our product candidates, or relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases where it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. We may also allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement or which does not prove to have viable commercial opportunities. Any failure to use our financial and human resources efficiently could harm our business and operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if our technology proves to be effective, it still may not lead to commercially viable products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we, our collaborators or strategic partners are successful in using our zinc finger protein, or ZFP, technology in drug discovery, protein production, therapeutic development or other areas in which we have licensed our technology, such as plant agriculture, we or they may not be able to commercialize the resulting products or may decide to use other methods competitive with this technology. To date, no company has received marketing approval or has developed or commercialized any therapeutic or agricultural products based on our ZFP technology. Should our technology fail to provide safe, effective, useful or commercially viable approaches to the discovery and development of these product candidates, this would significantly limit our business and future growth and would adversely affect our value.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to Manufacturing</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are building a manufacturing facility that could support future clinical production of our product candidates. We have no experience as a company manufacturing pharmaceutical or biological products, and there can be no assurance that we will be able to build a compliant manufacturing facility or, if built, we will be able to successfully manufacture any of our product candidates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to utilize both contract manufacturing organizations, or CMOs, and our own facility to meet our projected needs for clinical supply. We intend to expand our manufacturing capacity by designing and building a manufacturing facility in Brisbane, California that we plan to initially use to support our clinical supply needs. To meet these objectives, we will need to transition manufacturing processes and know-how of our product candidates to our own facility. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. Additional studies may also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies (and the related evaluations) intended to demonstrate the comparability of material previously produced with that generated by our CMOs. Although some of our employees have experience in the manufacturing of pharmaceutical and biological products from prior employment at other companies, we, as a company, have no prior experience in pharmaceutical and biological product manufacturing, and operating this facility will require us to comply with complex regulations and to continue to hire and retain experienced scientific, quality control, quality assurance and manufacturing personnel. Designing and building a manufacturing facility has been and will continue to be time-consuming and expensive, and we may experience delays or cost overruns. In addition, government approvals will be required for us to operate a manufacturing facility and can be time-consuming to obtain. As a manufacturer of pharmaceutical and biological products, we also will be required to demonstrate and maintain cGMP compliance. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Furthermore, establishing manufacturing operations will require a reallocation of other resources, particularly the time and attention of our senior management. Even if we are able to establish our own manufacturing capabilities, we could encounter challenges in operating the manufacturing facility in compliance with cGMP, regulatory or other applicable requirements, resulting in potential negative consequences, including regulatory actions, which could undermine our ability to utilize this facility for our own manufacturing needs. Any failure or delay in the development of our manufacturing capabilities could adversely impact the development of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Manufacturing our product candidates is costly and difficult and may not support regulatory approval or commercial viability.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are risks associated with manufacturing our product candidates including, among others, cGMP compliance, cost overruns, technical problems with process scale-up, process reproducibility, stability issues, lot consistency, yields and timely availability of raw materials. Even if efficacy and safety data from our clinical trials would otherwise support regulatory approval for a product candidate, there is no assurance that we or any third-party manufacturer will be able to manufacture our product candidates to specifications at levels necessary to support or maintain regulatory approval by the FDA or other regulatory authorities. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, some of our product candidates are biologics and their manufacture involves complex processes, including the development of cell lines or cell systems to produce the biologic, with the challenge of significant variability. Further, there are difficulties in growing large quantities of such cells, consistently and sufficiently isolating certain types of cells and harvesting and purifying the biologic produced by them. The cost to manufacture biologics is generally far higher than traditional small molecule chemical compounds, and the manufacturing process can be difficult to reproduce. Thus, there is no guarantee we will be successful in establishing a larger-scale commercial manufacturing process for our product candidates or obtaining the needed manufacturing capacity. Due to the high cost to manufacture, inherent uncertainty related to manufacturing costs, and uncertainty in our patient population, there is risk that some of our product candidates may not be commercially viable.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We operate laboratories and are building manufacturing facilities that use potentially harmful biological materials and hazardous materials. If we use these materials in a manner that causes injury or violates laws, we may be liable for damages, penalties or fines.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development activities involve and our planned manufacturing facilities will involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in the study of molecular and cellular biology. For example, we routinely use cells in culture and gene delivery vectors, and we employ small amounts of radioisotopes in trace experiments. We are subject to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we maintain up-to-date licensing and training programs, we cannot eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal of these materials or the risk of violating laws governing these materials. In the event of contamination or injury or violation of applicable laws, we could be held liable for damages, penalties or fines that result, and any liabilities could exceed our resources. We currently carry insurance covering certain liabilities arising from our use of these </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">materials. However, if we are unable to maintain adequate insurance coverage at a reasonable cost, we may not have insurance covering these liabilities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Supply interruptions may disrupt our inventory levels and the availability of our product candidates, and cause delays in obtaining regulatory approval, which could harm our business by reducing our potential revenues.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates are manufactured using technically complex processes requiring specialized facilities, highly specific raw materials and other production constraints. The complexity of these processes, as well as strict government standards for the manufacture and storage of our products candidates, subjects us to production risks. While product batches released for use in clinical trials undergo sample testing, some defects may only be identified following product release. In addition, process deviations or unanticipated effects of approved process changes may result in these intermediate products not complying with stability requirements or specifications. For example, our product candidates must be stored and transported at temperatures within a certain range. If these environmental conditions deviate, our product candidates&#8217; remaining shelf-lives could be impaired or their efficacy and safety could be adversely affected, making them no longer suitable for use.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The occurrence, or suspected occurrence, of production and distribution difficulties or delays, whether due to the impacts of the evolving COVID-19 pandemic or otherwise, can lead to lost inventories, with consequential reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause development delays and substantial expense. Any unforeseen failure in the storage of the product or loss in supply could delay our clinical trials and, with respect to our product candidates that may be approved, result in a loss of our market share and negatively affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We currently rely on third parties to conduct some or all aspects of manufacturing of our product candidates for preclinical and clinical development. If one of our third-party manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers or manufacturers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have limited experience in clinical-scale manufacturing of our product candidates and we rely upon third-party CMOs to manufacture and supply drug product for our preclinical studies and clinical trials. Although we are in the process of building out a cGMP compliant manufacturing facility in our Brisbane facility, it is not yet ready, and will only manufacture limited quantities of our product candidates for our early stage clinical trials. We intend to continue to rely on third parties for the manufacture of product candidates for later stage clinical trials, and commercial-scale manufacturing for any approved product. The manufacture of pharmaceutical and biological products in compliance with the FDA&#8217;s cGMP requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical and biological products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide study biologics in our clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial materials could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial programs and, depending upon the period of delay, require us to commence new studies at significant additional expense or terminate the studies completely.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our CMOs must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. We and our CMOs may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers&#8217; compliance with these regulations and standards. Failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall or withdrawal of product approval. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our product candidates, entail higher costs or impair our reputation.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current agreements with our CMOs do not provide for the entire supply of the drug product necessary for all anticipated clinical trials or for full scale commercialization. If we and our CMOs cannot agree to the terms and conditions for them to provide the drug product necessary for our clinical and commercial supply needs, we may not be able to manufacture the </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">product candidate until a qualified alternative manufacturer is identified, which could also delay the development of, and impair our ability to commercialize our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of third-party CMOs with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative CMOs, which could have an adverse effect on our business. New manufacturers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Industry</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates are based on novel technologies, which makes it difficult to predict the timing and costs of development and of subsequently obtaining regulatory approval.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have concentrated our research and development efforts on gene therapy, gene-edited cell therapy, genome editing and genome regulation. The regulatory approval process for novel product candidates such as ours is unclear and may be lengthier and more expensive than the process for other, better-known or more extensively studied product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These regulatory review committees and advisory groups, and any new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current or future product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. Even if our product candidates are approved, we expect that the FDA will require us to submit follow-up data regarding our clinical trial subjects for a number of years after any approval. If this follow-up data shows negative long-term safety or efficacy outcomes for these patients, the FDA may revoke its approval or change the label of our products in a manner that could have an adverse impact on our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, adverse developments in clinical trials of gene therapy or cell therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates. The FDA and EMA have only very recent and limited experience in the approval of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene therapy products. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or our competitors develop, acquire or market technologies or products that are more effective than ours, our financial condition and ability to successfully market or commercialize our product candidates or be profitable would be adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. We are aware of several companies focused on other methods for editing cells, editing genes and regulating gene expression and a limited number of commercial and academic groups pursuing the development of genome editing and genome regulation technology. The field of applied gene-edited cell therapy, genome editing and genome regulation is highly competitive and we expect competition to persist and intensify in the future from a number of different sources, including pharmaceutical and biotechnology companies, academic and research institutions, and government agencies that will seek to develop competing products as well as technologies that will compete with our ZFP technology platform. For example, in genome editing and gene therapy products, competing proprietary technologies with our product development focus include but are not limited to, recombinant proteins, other gene therapy/cDNAs, antisense, siRNA and microRNA approaches, exon skipping, small molecule drugs, monoclonal antibodies, Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR/Cas technology and Transcription Activator-Like Effector, or TALE, proteins, meganucleases, and MegaTALs. See the &#8220;Business&#8212;Competition&#8221; section in our 2019 Form 10-K for more information on the competition we may face.  </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any products that we or our collaborators or strategic partners develop by using our ZFP technology platform will enter highly competitive markets. Even if we are able to generate products that are safe and effective for their intended use, competing technologies may prove to be more effective or less expensive, which, to the extent these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and less expensive. Competing technologies may include other methods of regulating gene expression or modifying genes. ZFNs and our ZFP transcription factors, or ZFP-TFs, have broad application in the life sciences industry and compete with a broad array of new technologies and approaches being applied to genetic research by many companies.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to possessing competing technologies, our competitors include pharmaceutical and biotechnology companies with:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">substantially greater capital resources than ours; </span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">larger research and development staffs and facilities than ours; and </span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">greater experience in product development and in obtaining regulatory approvals and patent protection. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These organizations also compete with us to attract qualified personnel, attract parties for acquisitions, joint ventures or other collaborations and license the proprietary technologies of academic and research institutions that are competitive with our technology, which may preclude us from pursuing similar opportunities. Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us. Even if our product candidate is more effective, it may be disadvantaged if it is not first to market. In addition, any products that we develop may compete with existing products or services that are well established in the marketplace. Further, some of our product candidates in development are designed to use once. Any success in developing single-dose therapeutics could cause us to lose potential recurring revenues from therapeutics that are designed to be taken over a patient&#8217;s lifetime.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The evolving global COVID-19 pandemic could adversely affect our business and operations, including at our primary research facilities, which are currently subject to shelter-in-place orders, and at our clinical trial sites, as well as the business and operations of our collaborators, strategic partners, manufacturers, CROs and other third parties with whom we conduct business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 10, 2020, the World Health Organization declared the novel coronavirus, or COVID-19, outbreak a pandemic. Our business and operations could be adversely affected by the effects of the pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses, including in the three countries where we have most of our day-to-day operations, the United States, France and the United Kingdom. Our business has been directly impacted by pandemic restrictions aimed at reducing the spread of the disease, including multiple California executive orders, several semi-coordinated San Francisco Bay Area orders, several other state and additional local orders across the country and similar orders outside the United States, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. In response to these public health directives and orders, we have implemented work-from-home policies for most employees and modified working protocols and schedules in our laboratories. The effects of government orders and our work-from-home and laboratory protocols may negatively impact productivity, disrupt our business and delay our pre-clinical and clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. For example, we have experienced periodic short-term disruptions to our laboratory operations while administering our health and safety protocols, and adherence to these protocols in the future could result in longer operational disruptions in the event of a significant outbreak of COVID-19 among our laboratory workers. These disruptions, and possibly more severe disruptions in the future that could arise due to the extension of government orders or new government orders applicable in the places we operate or our industry generally or to us or our facilities specifically could impede our ability to conduct research in a timely manner, comply with our research obligations to our collaborators and advance the development of our therapeutic programs.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These disruptions could result in negative material impacts to our business, operating results and financial condition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although governments have begun phased re-openings, it is uncertain when restrictions will be fully lifted, and if so, when we will be able to resume pre-pandemic work routines.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain jurisdictions have rolled back such re-openings in light of continued and increased spread of COVID-19.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Imposition of government orders, including quarantine and shelter-in-place orders related to COVID-19 or other infectious diseases, is expected to continue to impact personnel at our laboratories and our third-party manufacturing facilities in the United States and other countries, for the foreseeable future, and could impact the availability or cost of materials, which would disrupt our supply chain. Many of our third-party manufacturers which we use for the supply of </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials are located in countries affected by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these tests and trials. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our clinical trials and clinical trials managed by our collaborators may be affected by the COVID-19 pandemic. Clinical site initiation, patient recruitment and enrollment and dosing of subjects may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some subjects may not be able or willing to comply with clinical trial protocols if quarantines impede subject movement or interrupt healthcare services. Similarly, the pandemic may limit the ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations. For example, we have not yet dosed subjects in our clinical trial for our ST-920 therapy to treat Fabry disease.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The global pandemic of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic impacts our business, our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, quarantines and social distancing requirements in the United States, France, United Kingdom and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States, France, United Kingdom and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, sales of our products, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these effects could have material adverse impacts on our business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, to the extent the evolving COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Negative public opinion and increased regulatory scrutiny of gene therapy and genomic medicines may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Genetically modified products are currently subject to public debate and heightened regulatory scrutiny, either of which could prevent or delay production of agricultural products. Gene therapy remains a novel technology, with only two </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene therapy products approved for a genetic disease to date in the United States and only a few </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene therapy products for genetic diseases approved to date in the EU. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. For example, reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked severe combined immunodeficiency, or X-linked SCID, in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in gene therapy, whether or not the specific company was involved with retroviral gene transfer, or whether the specific company&#8217;s clinical trials were placed on hold in connection with these events. Other adverse events could occur in the field of gene therapy and genomic medicine that could result in increased regulatory scrutiny, potential regulatory delays or negative impact on public perception of gene therapy and genomic medicines, which could cause our stock price to decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if the regulatory approval for genetically modified products developed using our technology is obtained, our success will also depend on public acceptance of the use of genetically modified products including drugs, plants, and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public attitudes. Our genetically modified products may not gain public acceptance. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia and death seen in other trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse, privacy, data security and other healthcare laws and regulations. If we fail to comply with such laws and regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a biotechnology company, even though we will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse, transparency, health privacy and security, and patients&#8217; rights are and will be applicable to our business. For details regarding the restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate see the &#8220;Business&#8212;Government Regulation&#8212;Additional Regulation&#8221; section in our 2019 Form 10-K.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Scrutiny has continued to increase, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations or if any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws or applicable regulations, we and they could be subjected to significant civil, criminal and administrative enforcement actions, see the &#8220;Business&#8212;Government Regulation&#8212;Additional Regulation&#8221; section in our 2019 Form 10-K.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, we are required to comply with privacy and data security laws, such as the EU General Data Protection Regulation, or GDPR, and the California Consumer Privacy Act of 2018, or CCPA, which apply to the collection, use, disclosure, transfer, or other processing of personal data. For more information regarding these regulations, see the &#8220;Business&#8212;Government Regulation&#8212;Privacy Regulation&#8221; section in our 2019 Form 10-K. To comply with the GDPR restrictions on transfer of personal data out of Europe, we have relied on Standard Contractual Clauses. However, a July 2020 decision of the EU&#8217;s highest court has called into question this practice, and UK authorities may similarly question the viability of the Standard Contractual Clauses as a mechanism for the lawful transfer of personal data outside of Europe. If we are unable to implement safeguards necessary to ensure that our transfers of personal data from and within Europe are lawful, we will face increased exposure to regulatory actions, substantial fines, and injunctions against processing personal data from Europe, and could be required to increase our data processing capabilities in Europe at significant expense. Restrictions on our ability to import personal data from Europe could impact our clinical trial activities in Europe and limit our ability to collaborate with CROs and other third parties subject to European data protection laws. Other countries may adopt similar restrictions to the GDPR, which could further impact our operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any failure or alleged failure (including as a result of deficiencies in our policies, procedures or measures relating to privacy, data security, marketing or communications) by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards or regulatory guidance relating to privacy or data security, may result in governmental investigations and enforcement actions, litigation, fines, penalties, injunctions prohibiting our data processing activities or adverse publicity. In addition, new regulation, legislative actions or changes in interpretation of existing laws or regulations regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards will have on our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased demand for any product candidates or products that we may develop;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">termination of clinical trial sites or entire trial programs;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">injury to our reputation and significant negative media attention;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">significant costs to defend the related litigation;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">substantial monetary awards to trial subjects or patients;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss of revenue;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">diversion of management and scientific resources from our business operations; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the inability to commercialize any products that we may develop.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Finances</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have generated operating losses since we began operations in 1995. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZFP technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. We expect to continue to incur additional operating losses for the next several years as we continue to advance our product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to raise additional capital on favorable terms, if at all, which would harm our ability to develop our technology and product candidates and could delay or terminate some or all of our programs. Future issuances of equity securities could also result in substantial dilution to our stockholders. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and product development activities. While we believe our available cash resources, as well as funds received from corporate collaborators, strategic partners and research grants will enable us to maintain our currently planned operations through at least the next 12 months from the date the financial statements are issued, we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. For example, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">worldwide resulting from the evolving COVID-19 pandemic. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our business and our ability to develop our technology and products candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may issue common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. New investors could gain rights superior to our existing stockholders.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although certain amount of our federal net operating loss carryforwards carry forward indefinitely (but are subject to a percentage limitation), a significant amount of our federal and all of our state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2024 and 2029, respectively. The net operating loss carryforwards subject to expiration could expire unused and be unavailable to offset future income tax liabilities. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change in its equity ownership value over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have experienced an ownership change in the past and we may also experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Reliance on Third Parties</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If conflicts arise between us and our contractors, collaborators or strategic partners, these parties may act in their self-interest, which may limit our ability to implement our strategies and otherwise harm our business and prospects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If conflicts arise between us and our contractors, corporate or academic collaborators or strategic partners, the other party may act in its self-interest, which may limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop or invest in competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of product candidates covered by the applicable agreement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, conflicts could arise between us and our collaborators resulting from disputes regarding our or our collaborators&#8217; or strategic partners&#8217; performance under the applicable agreement, including disputes arising from alleged breaches of our agreements with our collaborators and strategic partners. For example, we have certain confidentiality obligations to our collaborators and strategic partners under our agreements with them, and it is possible that, in connection with the data security incident we disclosed in April 2018, we could be subject to claims that we have breached our confidentiality obligations, which could result in damages payable by us and/or the affected collaborator or strategic partner seeking to terminate its agreement with us.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these developments could harm our product development efforts and otherwise adversely affect our business and prospects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our collaborators and strategic partners may control aspects of our research, development and manufacturing programs, including but not limited to, our clinical trials, which could result in delays and other obstacles in the commercialization of our proposed products.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We depend on third-party collaborators and strategic partners to design and conduct our clinical trials for some of our therapeutic programs. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these collaborators or strategic partners withdraws support for our programs or proposed products or otherwise impair their development; our business could be negatively affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our lack of control over the clinical development in our agreements with Novartis, Biogen, Kite, Sanofi and Pfizer could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from completing the intended IND filings in a timely fashion and receiving any milestone, royalty payments and other benefits under the agreement. In addition, under their respective agreements, our third-party collaborators have certain rights to terminate the agreements by providing us with advance notices, therefore, the actual milestone payments that we may receive under these agreements may be substantially lower than the full amounts provided for under these agreements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our license collaborators or strategic partners may decide to adopt alternative technologies or products or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of ZFP technology. Additionally, because many of our collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this would delay our ability to test our technology and would delay or terminate the development of potential products based on our ZFP technology. Further, our collaborators and strategic partners may elect not to develop products arising out of our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. If they terminate the collaborative relationship with us, we will be required to seek the support of other partners or collaborators. We may not have sufficient resources and expertise to develop these programs by ourselves, and we may not be able to identify a suitable partner or negotiate a favorable collaboration agreement to allow us to continue the development of these programs. If any of these events occur, we may not be able to develop our technologies or commercialize our products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commercialization of our technologies will depend, in part, on strategic collaborations with other companies. If we are not able to find such collaborators in the future or if our collaborators do not diligently advance the development, regulatory approval and commercialization of our product candidates, we may not be able to develop our technologies or product candidates, which could slow our growth and decrease the value of our stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have financial resources ourselves to fully develop, obtain regulatory approval for and commercialize our product candidates. We rely significantly on our strategic collaboration agreements with other companies to provide funding for our research and development efforts, including pre-clinical studies and clinical tests, and expect to rely significantly on such agreements to provide funding for the lengthy regulatory approval processes required to commercialize our product candidates. For example, we have collaboration agreements with Novartis to develop product candidates to treat certain neurodevelopment disorders, including autism and intellectual disability; with Biogen to develop product candidates to treat tauopathies including Alzheimer&#8217;s disease, alpha-synuclein related diseases including Parkinson&#8217;s disease and other neurological diseases; with Kite to develop product candidates to treat cancer; with Pfizer to develop product candidates to treat hemophilia A and amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene; and with Sanofi to develop product candidates to treat beta thalassemia and sickle cell disease.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to secure additional strategic collaborations or if our collaborators are unable or unwilling to diligently advance the development, regulatory approval and commercialization of our product candidates, our growth may slow and adversely affect our ability to generate funding for development of our technologies and product candidates. In addition, our collaborators may sublicense or abandon development programs with little advance notice or we may have disagreements or disputes with our collaborators, which would cause associated product development to slow or cease. In addition, the business or operations of our collaborators may change significantly through restructurings, acquisitions, other strategic transactions that may negatively impact their ability to advance our programs. The evolving COVID-19 pandemic may similarly impact our ability to realize the expected benefits of our collaborations due to the impacts of the pandemic on our collaborators and their business and operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under typical collaboration agreements, we expect to receive revenue for the research and development of our product candidates based on achievement of specific milestones, as well as royalties based on a percentage of sales of any commercialized </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">products. Achieving these milestones will depend, in part, on the efforts of our collaborators as well as our own efforts. If we or any collaboration partner fails to meet specific milestones, then the collaboration agreement may be terminated, which could reduce our revenues. In addition, if sales of commercialized products fail to meet expectations, we could receive lower royalties than expected.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Intellectual Property</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because it is difficult and costly to protect and maintain our proprietary rights, and third parties may have filed patent applications that are similar to ours, we may not be able to obtain or maintain proprietary protection of our technologies and products or we may only obtain protection in limited jurisdictions.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success may depend in part on obtaining and enforcing patent protection for our technology and successfully defending any of our patents that may be challenged. Obtaining and enforcing pharmaceutical and biotechnology patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and can involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims that may issue from any patent applications that we own or license, nor are we able to predict whether any third-party patents might issue with claims that are relevant to our product candidates or technologies. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Furthermore, if third parties have filed similar patent applications, an interference or derivation proceeding in the United States can be initiated by the United Stated Patent and Trademark Office, or U.S. PTO, a third party, or by us to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to various license agreements that grant us rights under specified patents and patent applications. We are also party to various license agreements by which we grant third parties rights under specified patents and patent applications. Our current licenses contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may be forced to delay or terminate aspects of our product development and research activities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to our present and any future sublicenses, because our rights derive from those granted to our sublicensor, we are subject to the risk that our sublicensor may fail to perform its obligations under the master license or fail to inform us of useful improvements in, or additions to, the underlying intellectual property owned by the original licensor.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are unable to exercise the same degree of control over intellectual property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent applications may not be prosecuted as we desire or in a timely manner.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the patents of others will not have an adverse effect on our ability to do business;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any of our pending patent applications will result in issued patents;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any patents issued or licensed to us, our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any patents issued or licensed to us will not be challenged and invalidated by third parties; or</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we will develop additional products, processes or technologies that are patentable.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Others have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE, CRISPR/Cas and other DNA-binding proteins, and that these groups and companies have filed patent applications. Several </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">patents with claims directed to this technology have issued, although we have no current plans to use the claimed inventions. If these or other patent applications issue as patents, it is possible that the holder of any patent or patents granted on these applications may bring an infringement action against us, our collaborators, or strategic partners claiming damages and seeking to enjoin commercial activities relating to the affected products and processes. The costs of litigating the claim could be substantial regardless of outcome. Moreover, we cannot predict whether we, our collaborators, or strategic partners would prevail in any actions. In addition, if the relevant patent claims were upheld as valid and enforceable and our products or processes were found to infringe a patent or patents, we or our collaborators may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, and we may be prevented from making, using, or selling the relevant product or process unless we or our collaborators could obtain a license or were able to design around the patent claims. We can give no assurance that such a license would be available to us or our collaborators on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent claims. There may be significant litigation in the genomics or cell therapy industry regarding patent and other intellectual property rights, which could subject us to litigation. If we become involved in litigation, it could consume a substantial portion of managerial and financial resources.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets, however, are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information or enforce these confidentiality agreements.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our collaborators, strategic partners, and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be able to receive patent protection or protect our proprietary information.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time, and may vary based on jurisdiction.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date or from the filing date of the corresponding international application. Various extensions may be available. However, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be adversely affected and our business would be harmed.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, collaborators, partners and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures have been and may in the future be breached, and we may not have adequate remedies for any breach. See also the risk factor titled, &#8220;Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.&#8221; In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, collaborators, partners and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have an adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in obtaining or maintaining necessary rights to gene or cell therapy product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Presently, we believe we have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our gene and cell therapy product candidates. Because our programs may involve additional product candidates, such as TX200 and potential future CAR-Treg therapies that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify on commercially reasonable terms, if at all. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In many cases, patent prosecution of our in-licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the priority of invention of patented technology.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have an adverse effect on our business, financial condition, results of operations, and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have an adverse effect on our business, financial conditions, results of operations, and prospects. As an example, Sangamo France has exclusively licensed the right to the chimeric antigen receptors, or CAR, for use in TX200 from the University of British Columbia, or UBC. Should UBC terminate this license agreement, we may have to develop or acquire the appropriate CAR which would extend our anticipated development timeline and add expense, and which could result in our failure to realize the anticipated benefits of the acquisition of Sangamo France.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be involved in patent or intellectual property lawsuits or similar disputes involving patents under our control or patents of third-parties claiming infringement, which lawsuits could be expensive, time-consuming and impair or prevent development and commercialization activities.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex parte</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reexaminations, post-grant review, and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review proceedings before the U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third parties may assert that we are employing their proprietary technology without authorization, and such parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of certain patents held by a third party related to certain vector manufacturing methods that are currently being used in certain of our product candidates. We have not yet finalized the commercial scale manufacturing process for any of our product candidates. If our commercial scale manufacturing process utilizes these vector manufacturing methods, and if these third-party patents are in force at the time of commercialization, we may need to use or develop a non-infringing manufacturing method or seek a license to these patents. In any event, if any third-party patents were held by a court of competent jurisdiction to cover the manufacturing methods of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license, or until such patents expires. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Competitors may also infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Moreover, if we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidate. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have an adverse impact on our business. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the U.S. PTO may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could expose us to significant monetary damages, result in the loss of valuable intellectual property, require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation, interference, derivation, or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have an adverse effect on our ability to raise additional funds or otherwise have an adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions in which we seek patent protection could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The United States enacted the Leahy-Smith America Invents Act, or the America Invents Act, which includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the U.S. PTO during patent prosecution and additional procedures to attack the validity of a patent by U.S. PTO administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review, and derivation proceedings. Because of a lower evidentiary standard in U.S. PTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a U.S. PTO proceeding sufficient for the U.S. PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition, the challenged patents are not accorded the presumption of validity as they are in Federal District Court. Accordingly, a third party may attempt to use the U.S. PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have an adverse effect on our business, financial condition, results of operations, and prospects. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the U.S. PTO, and similar legislative, judicial and regulatory bodies in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be unable to license gene transfer technologies that we may need to commercialize our zinc finger protein technology and potential products, if approved.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to regulate or modify a gene in a cell, the ZFP must be efficiently delivered to the cell. We have licensed certain gene transfer technologies for our ZFP in research, including adeno-associated virus, or AAV, and mRNA technology and we are evaluating these systems and other technologies that may need to be used in the delivery of ZFP into cells for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vitro </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> applications. We have not developed our own gene transfer technologies, and we rely on our ability to enter into license agreements to provide us with rights to the necessary gene transfer technology. Our approach has been to license appropriate technology as required. For example, we are aware of certain patents held by a third party related to certain vector manufacturing methods that are currently being used in certain of our product candidates. We have not yet finalized the commercial scale manufacturing process for any of our product candidates. If our commercial scale manufacturing process utilizes these vector manufacturing methods, and if these third-party patents are in force at the time of commercialization, we may need to use or develop a non-infringing manufacturing method or seek a license to these patents. However, we may not be able to license the gene transfer technologies on reasonable terms, if at all, required to develop and commercialize our product candidates. The inability to obtain a license to use gene transfer technologies with entities that own such technology on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of our therapeutic product candidates. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are conducting proprietary research to discover new product candidates. These programs increase our financial risk of product failure, may significantly increase our research expenditures, and may involve conflicts with future collaborators and strategic partners.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our proprietary research programs consist of research that is funded solely by us or by grant funding and in which we retain exclusive rights to therapeutic products generated by such research. This is in contrast to certain of our research programs that may be funded by corporate partners in which we may share rights to any resulting products. Conducting proprietary research programs may not generate corresponding revenue and may create conflicts with our collaborators or strategic partners over rights to our intellectual property with respect to our proprietary research activities. Any conflict with our collaborators or strategic partners could reduce our ability to enter into future collaborations or partnering agreements and negatively impact our relationship with existing collaborators and partners that could reduce our revenue and delay or terminate our product development. As we continue to focus our strategy on proprietary research and therapeutic development, we expect to experience </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">greater business risks, expend significantly greater funds and require substantial commitments of time from our management and staff.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Business Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are increasingly dependent on information technology systems and infrastructure to operate our business, which are large and complex. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. Many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the size, complexity, accessibility and distributed nature of our information technology systems, and the large amounts of sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology environment. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial and reputational harm to us. For example, in April 2018, we announced a data security incident involving the compromise of a then senior executive&#8217;s company email account. Upon learning of the incident on March 28, 2018, external network security experts were promptly engaged, and the incident response team worked diligently to investigate the incident. We also promptly notified federal law enforcement of the incident. The investigation concluded that the incident was limited to the compromise of the then senior executive&#8217;s company email account for approximately 11 weeks. The investigation did not reveal any evidence that our network or other information technology systems were otherwise compromised in connection with the incident or that the incident resulted in the disclosure of or access to personal information about patients or other individuals besides the holder of the company email account that was affected. However, proprietary, confidential and other sensitive information of ours and that of other entities was accessed and may have been compromised as a result of the incident. Unforeseen developments related to this incident could occur, which could have a further adverse impact on us. We do not maintain cyber liability insurance and will therefore have no coverage for any losses resulting from this data security incident. Any litigation or regulatory review arising from this incident could result in significant legal exposure to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our facility, development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we aware of the company email incident described above, there is no way of knowing with certainty whether we have experienced any other data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event, including the company email incident described above, that leads to unauthorized access, use or disclosure of personal information could, among other consequences, disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents. In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or further security incidents.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We continue to operate the acquired Sangamo France business in France and the Sangamo UK business in the United Kingdom, which may expose us to unanticipated costs or events.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo France&#8217;s historical operations have been based in France and we continue to operate the acquired Sangamo France business in France. Our operation of the acquired Sangamo France business in France involves significant risks, including:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">difficulty hiring and retaining appropriate personnel due to intense competition for such limited resources;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disruptions in relations with our employees, including legacy Sangamo France employees; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">compliance with regulatory requirements, including local French employment regulations and organized labor in France.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, we have operations and conduct business in the United Kingdom through Sangamo Therapeutics UK Ltd, or Sangamo UK. As a result of our operations outside of the United States, we have become more exposed to fluctuations in currency exchange rates between the Euro and the U.S. dollar and between the Pound Sterling and the U.S. dollar. Given the volatility of currency exchange rates, there is no assurance that we will be able to effectively manage currency transaction and/or conversion risks. To date, we have not entered into derivative instruments to offset the impact of foreign exchange fluctuations, which fluctuations could have an adverse effect on our financial condition and results of operations. In any event, difficulties resulting from these and other risks related to our operations outside of the United States could expose us to increased expenses, impair our development efforts, adversely affect our financial condition and results of operations and harm our competitive position.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may face difficulties as we expand our operations into countries in which we have no prior operating experience, and we may be exposed to risks associated with our operations and clinical trials in foreign jurisdictions, which could adversely affect our business.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to Sangamo France and Sangamo UK, we may expand our global footprint in order to enter new markets. Operating in foreign jurisdictions requires significant resources and management attention and subjects us to regulatory, economic and political risks that are different from those we face in the United States. We cannot be sure that any further international expansion will be successful. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain countries into which we expand may have less political, social or economic stability and less developed infrastructure and legal systems. It will be costly to establish, develop and maintain international operations and develop and promote our products, if and when approved, in international markets. We may also encounter regulatory, legal, personnel, technological and other difficulties that increase our expenses and/or delay our ability to become profitable in such countries, which could have an adverse effect on our business and operations. Consequently, we are, and will continue to be, subject to risks inherent with operating in foreign countries, in addition to those specific risks associated with Sangamo France and Sangamo UK, which include:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the increased complexity and costs inherent in managing international operations, including in geographically disparate locations;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">diverse regulatory, financial and legal requirements, and any future changes to such requirements, in one or more countries where we are located or do business;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adverse tax consequences, including changes in applicable tax laws and regulations;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">applicable trade laws, tariffs, export quotas, custom duties or other trade restrictions, and any changes to them;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">economic weakness, including inflation, or political or economic instability in particular foreign economies and markets;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business or operating in another country;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">liabilities for activities of, or related to, our international operations;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and other regulations;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of health epidemics, including the evolving COVID-19 pandemic, and the resulting global economic and social impacts;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">workforce uncertainty in countries where labor unrest is more common than in the United States; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">laws and regulations relating to data security and the unauthorized use of, or access to, commercial and personal information.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The withdrawal of the United Kingdom from the EU, commonly referred to as &#8220;Brexit,&#8221; may adversely impact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition of taxes and </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">duties for importing our product candidates into the EU and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the result of a referendum in 2016, the United Kingdom left the EU on January 31, 2020 pursuant to formal withdrawal agreements between the United Kingdom and the EU. Under these agreements, the United Kingdom will be subject to a transition period until December 31, 2020, during which EU rules will continue to apply. Negotiations between the United Kingdom and the EU are expected to continue in relation to the customs and trading relationship between the United Kingdom and the EU following the expiry of the transition period.   </span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, and as such, following the transition period, Brexit could negatively impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the EU. Any delay in obtaining, or an inability to obtain, any clinical trial authorizations or marketing approvals, as a result of Brexit or otherwise, would prevent us from developing or commercializing our product candidates in the United Kingdom or the EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our clinical trial materials and/or our product candidates into the EU or into the United Kingdom from the EU, or we may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and significantly harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We and third parties on which we rely may be adversely affected by natural disasters and catastrophic or other events outside of our control, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or event.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Natural disasters could severely disrupt our facilities and our operations and have a negative impact on our business, financial condition, results of operations and prospects. If a natural disaster, pandemic or epidemic, including the evolving COVID-19 pandemic, political crisis, power outage or any other event that is out of our control occurred that prevented us or third parties on which we rely from using all or a significant portion of our or their facilities, that damaged critical infrastructure or that otherwise disrupted our or their operations, it may be difficult or, in certain cases, impossible for us to continue our business and operations for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and may not prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have an adverse effect on our business, financial condition, results of operations and prospects. Such disasters or events occurring at facilities of third parties on which we rely could also negatively impact our business and operations.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth and attracting and retaining employees.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will need to grow the size of our organization in order to support our continued development and potential commercialization of our product candidates. In particular, we will need to add substantial numbers of additional personnel and other resources to support our development and potential commercialization of our product candidates. As our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. We may not be able to attract or retain employees with the appropriate levels of experience and skills to accomplish our objectives. As our development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will increase. Future growth will also impose significant added responsibilities on members of management. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and preclinical studies and clinical trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on certain key members of our executive team and certain of our scientific and manufacturing personnel, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. We do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of such key employees might impede the achievement of our research, development and commercialization objectives.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recruiting and retaining other qualified employees for our business, including scientific and technical personnel is, and will continue to be, critical to our success. There currently is a shortage of skilled individuals with substantial gene therapy experience, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives or key employees, may impede the progress of our research, development and commercialization objectives and have an adverse effect on our business, financial condition, results of operations and prospects. Moreover, our ability to recruit and retain qualified executives and employees may be adversely impacted by the evolving COVID-19 pandemic.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not successful in our efforts to identify, discover or acquire new potential product candidates</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> and may fail to capitalize on programs or product candidates that may be a greater commercial opportunity or for which there is a greater likelihood of success</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Part of our business strategy is to expand our product candidate pipeline by identifying and validating new product candidates, which we may develop ourselves, in-license or otherwise acquire from others. If our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to continue to expand our product pipeline through in-licensing or other acquisitions. We may be unable to identify relevant product candidates. If we do identify such product candidates, we may be unable to reach acceptable terms with any third party from which we desire to in-license or acquire them. Further, while we seek to mitigate risks and liabilities of potential acquisitions and in-licensing transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess, or that we are not able to effectively manage. Additionally, we may not realize the anticipated benefits of such transactions for a variety of reasons, including the possibility that acquired product candidates, such as TX200, prove not to be safe or effective in clinical trials, the integration of an acquired product candidate, technology or business gives rise to unforeseen difficulties and expenditures, or that the expected benefits will not otherwise be realized or will not be realized within the expected timeframe.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to our Common Stock and Corporate Organization</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors, and could be influenced by public perception of genomic medicines and the biotechnology sector.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock price has been volatile and may continue to be volatile, which could cause stockholders to incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response to various factors, some of which are beyond our control, including but not limited to the following:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or collaborators providing updates on the progress or development status of product candidates or data from clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">initiation or termination of clinical trials;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in market valuations of similar companies;</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">overall market and economic conditions, including the equity markets for emerging biotechnology companies;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">deviations in our results of operations from the guidance given by us;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcement of changes in business and operations by our collaborators and partners, or changes in our existing collaboration agreements;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in public opinion of gene therapy and genomic medicines;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory developments, including increased regulatory scrutiny of gene therapy and genomic medicines;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes, by one or more of our security analysts, in recommendations, ratings or coverage of our stock;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">additions or departures of key personnel; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock and decreases in our cash balances.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies, including very recently in connection with the evolving COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the evolving COVID-19 pandemic, and political, regulatory and other market conditions, may negatively affect the market price of shares of our common stock, regardless of our actual operating performance. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Actual or potential sales of significant amounts of shares of our common stock into the market could cause the market price of our common stock to fall or prevent it from increasing for numerous reasons.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. With the exception of shares recently issued to Biogen in connection with our collaboration agreement, our outstanding shares of common stock generally may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act of 1933, as amended, or the Securities Act, or to the extent such shares have already been registered under the Securities Act and are held by non-affiliates of ours. While Biogen agreed not to sell any shares until the first anniversary of the effectiveness, and to limit resales through the second anniversary, such restrictions are only temporary. Further, we also agreed, subject to certain limitations, to register for resale any the shares issued Biogen. We have also filed registration statements registering all shares of common stock that we may issue under our equity compensation plans. Such shares can be freely sold in the public market upon issuance, subject to volume limitations and black-out periods applicable to affiliates. Additionally, we recently entered into a sales agreement with Jefferies LLC which permits us from time to time at our discretion to sell up to $150.0 million of shares of our common stock in the public markets at prevailing market prices. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, in accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and our policies regarding stock transactions, c</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ertain of our employees, executive officers and directors </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">have adopted, and may continue to adopt, stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Our employees, executive officers, directors and affiliated stockholders also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information. Actual or potential sales of our common stock by such persons could be viewed negatively by other investors and could cause the price of our common stock to fall or prevent it from increasing. </span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our certificate of incorporation, Delaware law and our bylaws could make an acquisition of our company more difficult and could prevent attempts by our stockholders to remove or replace current management.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000 shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. Our certificate of incorporation further provides that stockholders may not take action by written consent.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our amended and restated bylaws:</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#8217; meetings; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">prohibit stockholders from calling a special meeting of stockholders.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also subject to Section 203 of the General Corporation Law of the State of Delaware, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#8220;interested stockholder&#8221; and may not engage in &#8220;business combinations&#8221; with us for a period of three years from the time the person acquired 15% or more or our voting stock. The application of Section 203 may, in some circumstances, deter or prevent a change in control of our company even when such change may be beneficial to our stockholders.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our amended and restated bylaws provide that a state or federal court located within the State of Delaware will be the exclusive forum for the adjudication of certain disputes, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amended and restated bylaws provide that a state or federal court located within the State of Delaware is the sole and exclusive forum for:</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any derivative action or proceeding brought on our behalf;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee or stockholder of Sangamo to us or our stockholders;</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our charter or our bylaws, as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware; and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any action asserting a claim governed by the internal affairs doctrine.</span></div><div style="padding-left:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This provision further provides that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provision.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While this provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act or the Securities Act, or any claim for which the federal courts have exclusive jurisdiction, this provision may nonetheless limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2.&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_106"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3.&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_109"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 4.&#160;MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_112"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 5.&#160;OTHER INFORMATION</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Open Market Sale Agreement&#8480;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 5, 2020, we entered into an Open Market Sale Agreement&#8480; with Jefferies LLC, or Jefferies, with respect to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.01 per share, having an aggregate offering price of up to $150.0 million through Jefferies as our sales agent or principal.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not obligated to sell any shares under the sales agreement. Subject to the terms and conditions of the sales agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sales agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The issuance and sale, if any, of shares of our common stock by us under the sales agreement will be made pursuant to our effective registration statement on Form S-3 (Registration Statement No. 333-224418), filed with the U.S. Securities and Exchange Commission on April 24, 2018. The offering will be described in our Prospectus dated April 24, 2018, as supplemented by a Prospectus Supplement dated August 5, 2020, to be filed with the SEC on August 5, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will pay Jefferies a commission of up to 3% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sales agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies&#8217; counsel, if required. The sales agreement will terminate upon the sale of all $150.0 million of shares under the sales agreement, unless earlier terminated by either party as permitted therein.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cooley LLP, our counsel, has issued a legal opinion relating to the validity of the shares of common stock being offered pursuant to the sales agreement. A copy of such legal opinion, including the consent included therein, is filed as Exhibit 5.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Agreement nor shall there be any offer, solicitation or sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM&#160;6.&#160;EXHIBITS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%;"><tr><td style="width:1.0%;"></td><td style="width:8.192%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.988%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:83.082%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration: underline;">number</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description of Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex11.htm">Open Market Sale Agreement, dated August 5, 2020, between Sangamo Therapeutics, Inc. and Jefferies LLC.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Composite copy of Seventh Amended and Restated Certificate of Incorporation of Sangamo Therapeutics, Inc., as amended (incorporated by reference to Exhibit 3.1 to the registrant's Quarterly Report on Form 10-Q, filed with the SEC on August 9, 2017). </a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">Fourth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation of Sangamo Therapeutics, Inc., as amended (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K, filed with the SEC on May 22</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">,</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm"> 2020).</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex31_6.htm">Third Amended and Restated Bylaws of Sangamo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K, filed with the SEC on June 15, 2018.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex51.htm">Opinion of Cooley LLP.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1#+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex101.htm">Employment Agreement between the Company and Mark McClung effective as of April 13, 2020.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2#+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex102.htm">Letter Agreement </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex102.htm">Regarding Andrew </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex102.htm"> Ramelmeier </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex102.htm">Special</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex102.htm"> Bonus</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3#</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 22, 2020).</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex104.htm">Seventh Amendment to the Triple Net Laboratory Lease Agreement, dated May 2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex104.htm">0</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex104.htm">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex104.htm">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex104.htm">, between the Registrant and Point Richmond R&amp;D Associates II, LLC.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex105.htm">Eighth Amendment to the Triple Net Laboratory Lease Agreement, dated May 29, 2020, between the Registrant and Point Richmond R&amp;D Associates II, LLC.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.1+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex51.htm">Consent of Cooley LLP (included in Exhibit 5.1 hereto).</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex311.htm">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex312.htm">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1+</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="sgmo-20200630xex321.htm">Certifications Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the six months ended June 30, 2020, is formatted in Inline XBRL and it is contained in Exhibit 101</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________________</span></div><div style="text-indent:-54pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* &#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:54pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">#&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">Indicates management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">+&#160;Filed herewith.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><div id="ia59e529445a14a10ab18f7d7fd95bd0f_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Table of Contents</span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dated: August&#160;5, 2020 </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:56.189%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.811%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ SUNG H. LEE</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sung H. Lee</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">Executive Vice President and Chief Financial Officer</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%;">(Duly Authorized Officer and Principal Financial Officer)</span></div></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>sgmo-20200630xex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6dd077af6b9a48babad5e431c8c8c7bb_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;"> </font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">OPEN MARKET SALE AGREEMENT</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;vertical-align:top;">1</sup></div><div style="text-align:right;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">August 5, 2020</font></div><div style="padding-right:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">JEFFERIES LLC </font></div><div style="padding-left:0.72pt;margin-bottom:0.06pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">520 Madison Avenue</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New York, New York 10022</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Ladies and Gentlemen&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and&#47;or principal (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Common Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), having an aggregate offering price of up to $150,000,000 on the terms set forth in this agreement (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  DEFINITIONS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Certain Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective meanings&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agency Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the introductory paragraph of this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the introductory paragraph of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Anti-Money Laundering Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Applicable Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(u)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Authorizations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(u)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Base Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="width:150pt;margin-top:10pt;margin-bottom:5pt;border-bottom:1pt solid black;"></div><div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">SM</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8220;Open Market Sale Agreement&#8221; is a service mark of Jefferies LLC</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMERICAS 102797349 v3</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(cc)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commission</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Common Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the introductory paragraph of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the introductory paragraph of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company Benefit Plans</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(cc)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company Stock Plans</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Default</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2(s)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EDGAR</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Electronic Data Gathering Analysis and Retrieval system.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Environmental Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(bb)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ERISA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(cc)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ERISA Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(cc)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exchange Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Existing Instrument</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;&#8206;Section 2(s)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FCPA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(hh)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(u)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FFDCA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FINRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Financial Industry Regulatory Authority, Inc.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Floor Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&#8217;s sole discretion.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Free Writing Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 4(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Hazardous Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(bb)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">HMT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(jj)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Intellectual Property Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(t)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Interim Prospectus Supplement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Investment Company Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(x)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Issuance Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Issuance Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that is executed by its Chief Executive Officer, President or Chief Financial Officer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Issuance Notice Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 3(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Issuance Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Sales Price less the Selling Commission.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IT Systems</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(ss)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Material Adverse Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Maximum Program Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Common Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of Common Shares registered, if any, under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, vesting, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form S-3, or (d) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">OFAC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(jj)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Original Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Other Offering Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an amendment or supplement to the Registration Statement or Prospectus relating solely to the issuance or offering of securities other than the Common Shares. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or other entity of any kind.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Personal Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(ss)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Principal Market</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Nasdaq Global Select Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Regulation M</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(nn)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Representation Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the introductory paragraph of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Rule 102</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 4(u)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sales Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sanctioned Country</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(jj)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sanctions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(jj)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Securities Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Selling Commission</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means three percent (3%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Settlement Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the second business day following each Trading Day during the period set forth in the Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean the Company&#8217;s Common Shares issued or issuable pursuant to this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Specified Courts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 8(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Stock Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Time of Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 3(b)(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Time of Sale Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Trading Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any day on which the Principal Market is open for trading.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Triggering Event Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">UNSC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(jj)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  REPRESENTATIONS AND WARRANTIES OF THE COMPANY </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company represents and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each Settlement Date, (4) each Triggering Event Date and (5) each Time of Sale (each of the times referenced above is referred to herein as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Representation Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date&#58;  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company has prepared and filed with the Commission an &#8220;automatic&#8221; shelf registration statement, as defined under Rule 405 under the Securities Act on Form&#160;S-3ASR&#160;(File No.&#160;333-224418), which contains a base prospectus (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Base Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act.  The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares.  Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3ASR under the Securities Act as from time to time amended or supplemented, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be part of such registration statement pursuant to Rule 430(B) of the Securities Act, is herein referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3ASR under the Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">,&#8221; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use.  The Registration Statement at the time it originally became effective is herein called the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Original Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;  As used in this Agreement, the terms &#8220;amendment&#8221; or &#8220;supplement&#8221; when applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in, or &#8220;part of&#8221; the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">date&#59; and all references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. All references in this Agreement to the Registration Statement, the Prospectus or any amendments or supplements thereto, or any Free Writing Prospectus (as defined herein), shall be deemed to include any copy filed with the Commission pursuant to EDGAR.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Compliance with Registration Requirements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Original Registration Statement became effective under the Securities Act prior to the issuance of any Issuance Notices by the Company. The Company and the transactions contemplated by this Agreement meet the requirements for and comply with the applicable conditions set forth in Form S-3ASR under the Securities Act.  The Company has complied to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental information, if any.  No stop order suspending the effectiveness of the Registration Statement or registration statement filed under Rule&#160;462(b) under the Securities Act (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Rule 462(b) Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. At the time the Registration Statement originally became effective and at the time the Company&#8217;s most recent annual report on Form 10-K was filed with the Commission, the Company met the then-applicable requirements for use of Form S-3ASR under the Securities Act, including, but not limited to, General Instruction I.D.  During the Agency Period, each time the Company files an annual report on Form 10-K, the Company will meet the then-applicable requirements for use of Form S-3ASR under the Securities Act, including, but not limited to, General Instruction I.B.1.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Prospectus when filed complied, and at each Representation Date will comply, in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation&#160;S&#30;T under the Securities Act) to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares.  Each of the Registration Statement, any Rule&#160;462(b) Registration Statement and any post-effective amendment or supplement thereto, at the time it became or becomes effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.  As of the date of this Agreement, the Prospectus and any Free Writing Prospectus considered together (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Time of Sale Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) did not, and at each Settlement Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The Prospectus, as of its date, did not, and at each Settlement Date, the Prospectus, as amended or supplemented, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule&#160;462(b) </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Registration Statement, or any post-effective amendment thereto, or the Prospectus or the Time of Sale Information, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the only such information consists of the information described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  below.  There are no contracts or other documents required to be described in the Time of Sale Information or the Prospectus or to be filed as exhibits to the Registration Statement that have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said Rule.</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Status under the Securities Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. At the time of filing the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not (as applicable) an &#8220;ineligible issuer,&#8221; and is a well-known seasoned issuer, in each case as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the first Issuance Notice. Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act.  Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or the Time of Sale Information, including any document incorporated by reference therein.  Except for any Free Writing Prospectus and electronic road shows, if any, furnished to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the prior written consent of the Agent, such consent not to be unreasonably withheld or delayed, prepare, use or refer to, any Free Writing Prospectus.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Incorporated Documents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The documents incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading&#59; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Securities Act or the Exchange Act and will not contain any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified&#59; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States applied on a consistent basis throughout the periods covered thereby, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein&#59; and the other financial information included or incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly the information shown thereby&#59; and the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">pro forma</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> financial information and the related notes thereto included or incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information, if any, have been prepared in accordance with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and the assumptions underlying such </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">pro forma</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> financial information are reasonable and are set forth in the Registration Statement, the Prospectus and the Time of Sale Information. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Prospectus and the Time of Sale Information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.03pt;">No Material Adverse Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Since the date of the most recent financial statements of the Company included or incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information, (i) there has not been any material change in the capital stock (other than the issuance of Common Shares upon exercise of stock options and warrants or vesting of restricted stock units described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Prospectus and the Time of Sale Information), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock&#59; (ii) there has not occurred any event, the occurrence of which would, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#8217; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Material Adverse Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), or any development involving a prospective Material Adverse Effect&#59; (iii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole&#59; and (iv) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">other calamity, including a health epidemic or pandemic outbreak of infectious disease (including without limitation, a further outbreak or escalation of COVID-19 or any related&#47;mutated form of COVID-19), whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement,  the Prospectus and the Time of Sale Information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Organization and Good Standing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a Material Adverse Effect. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Company&#8217;s most recent annual report on Form 10-K filed with the Commission.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Capitalization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Company has an authorized capitalization as set forth in the Registration Statement, the Prospectus and the Time of Sale Information&#59; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights&#59; except as described in or expressly contemplated by the Registration Statement, the Prospectus and the Time of Sale Information, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options&#59; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Prospectus and the Time of Sale Information&#59; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable except as otherwise described in the Registration Statement, the Prospectus and the Time of Sale Information, and are owned directly or indirectly by the Company, free and clear of any material lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">Stock Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. With respect to the stock options (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Stock Options</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company Stock Plans</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), (i) each Stock Option intended to qualify as an &#8220;incentive stock option&#8221; under Section 422 of the Code so qualifies, (ii) each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements, including the rules of the Principal Market and any other </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">exchange on which Company securities are traded, and (iii) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#8217;s filings with the Commission in accordance with the Exchange Act and all other applicable laws.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">Due Authorization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder&#59; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">The Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement has been duly authorized, executed and delivered by the Company.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(l)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">The Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Shares to be issued and sold by the Company hereunder have been duly authorized and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and non-assessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Prospectus and the Time of Sale Information&#59; and the issuance of the Shares is not subject to any preemptive or similar rights.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(m)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.69pt;">Stock Exchange Listing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Common Shares are registered pursuant to Section 12(b) of the Exchange Act and are listed on the Principal Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Principal Market, nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration or listing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(n)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">No Violation or Default</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws or similar organizational documents&#59; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject&#59; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">No Conflicts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement, the Registration Statement, the Prospectus and the Time of Sale Information will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(p)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">No Consents Required</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. No consent, approval, authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by FINRA and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Agent.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(q)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Legal Proceedings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is a party or to which any property of the Company or any of its subsidiaries is the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect&#59; no such investigations, actions, suits or proceedings are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others&#59; and there are no current or pending legal, governmental or regulatory actions, suits or proceedings that are required under the Securities Act to be described in the Registration Statement, the Prospectus and the Time of Sale Information that are not so described in the Registration Statement, the Prospectus and the Time of Sale Information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(r)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.03pt;">Independent Auditors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Ernst &#38; Young LLP, who have audited certain financial statements of the Company and its subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(s)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:23.36pt;">Title to Real and Personal Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company and its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii) would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(t)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  To the Company&#8217;s knowledge with respect to patents, patent applications, trade and service marks, trade and service mark registrations, and trade names only, the Company and its subsidiaries own, possess, or license, and otherwise have legally enforceable rights to all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, and know-how, except with regard to off-the-shelf software provided by third parties, (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Intellectual Property Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) necessary for the conduct of the Company&#8217;s business as now conducted or, to the knowledge of the Company, as proposed in the Registration Statement, the Prospectus and the Time of Sale Information to be conducted. Except as disclosed in the Registration Statement, the Prospectus and the Time of Sale Information, (i) to the knowledge of the Company, there are no rights of third parties to any such Intellectual Property Rights that conflict with the Company&#8217;s right to own, possess or license, as applicable, such Intellectual Property Rights&#59; (ii) the Company is not aware of any material infringement by third parties of any such Intellectual Property Rights&#59; (iii) there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or claim by others challenging the Company&#8217;s rights in or to own, possess and license such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim&#59; (iv) there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim, except for any such action, suit, proceeding or claim that would not have a Material Adverse Effect&#59; (v) there is no pending, or to the knowledge of the Company threatened, action, suit, proceeding or claim by others that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any such claim, except for any such action, suit, proceeding or claim that would not have a Material Adverse Effect&#59; (vi) to the knowledge of the Company, there is no U.S. patent or published U.S. patent application (other than U.S. patents or U.S. patent applications of the Company) which contains claims that dominate or may dominate any Intellectual Property Rights described in the Registration Statement, the Prospectus and the Time of Sale Information as being owned by or licensed to the Company or that interferes with the issued or pending claims of any such Intellectual Property Rights, except for such claims and interferences that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect&#59; (vii) there is no prior art of which the Company is aware that may render any U.S. patent held by the Company invalid or any U.S. patent application held by the Company unpatentable which has not been disclosed to the U.S. Patent and Trademark Office, and (viii) to the knowledge of the Company, all pertinent prior art references known to the Company or its counsel during the prosecution of the patents and patent applications comprising the Intellectual Property Rights were disclosed to the relevant patent authority and, to the knowledge of the Company, neither such counsel nor the Company nor any licensor made any misrepresentation to, or concealed any material fact from, the relevant patent authority during such prosecution and the Company, and to the knowledge of the Company, any licensor, has complied with all applicable duty of candor requirements of the relevant patent authority with respect to such patents and patent applications. To the knowledge of the Company, all licenses to which the Company and its subsidiaries is a party relating to the Intellectual Property Rights are valid, subsisting, enforceable, and in good standing and each of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Company and its subsidiaries has, in all material respects, complied with its respective contractual obligations pursuant to all such licenses relating to the Intellectual Property Rights and has not committed any material breach thereof (declared or undeclared). The Company is not a party to or bound by any options, licenses, or agreements with respect to the intellectual property rights of any other person or entity that are required to be disclosed in Registration Statement, the Prospectus and the Time of Sale Information and that are not disclosed therein. None of the Intellectual Property Rights used by the Company and its subsidiaries has been obtained by them or is being used by them in violation of any material contractual obligations binding on the Company, its subsidiaries or, to the knowledge of the Company, any of their officers, directors, or employees. Except as required to be set forth in the Registration Statement, the Prospectus and the Time of Sale Information, (i) the Company and its subsidiaries are not obligated to pay a material royalty, grant a license or provide other consideration to any third party in connection with the Intellectual Property Rights and (ii) no third party, including any academic or governmental organization, possess material rights to the Intellectual Property Rights owned by the Company.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(u)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Compliance with Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company has not been advised, and has no reason to believe, that it and each of its subsidiaries are not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure to be so in compliance would not result in a Material Adverse Effect. Except as described in the Registration Statement, the Prospectus and the Time of Sale Information, each of the Company and its subsidiaries&#58; (A) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Applicable Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; (B) has not, within the past five years, received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Authorizations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations&#59; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding&#59; (E) has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such action&#59; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission)&#59; and (G) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, &#8220;dear doctor&#8221; letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company&#8217;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Clinical Studies</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The studies, tests and preclinical and clinical trials conducted by or on behalf of the Company or any of its subsidiaries were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FFDCA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Prospectus and the Time of Sale Information are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials&#59; except as disclosed in the Registration Statement, the Prospectus and the Time of Sale Information, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study results, test results, or trial results described or referred to in the Registration Statement, the Prospectus and the Time of Sale Information when viewed in the context in which such results are described and the clinical state of development&#59; and, since December 31, 2016, the Company has not received any notices or correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(w)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:19.36pt;">No Undisclosed Relationships</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents and in the Time of Sale Information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(x)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Investment Company Act.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Prospectus and the Time of Sale Information, will not be required to register as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Investment Company Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(y)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company and its subsidiaries have paid all material federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof&#59; and except as otherwise disclosed in the Registration Statement, the Prospectus and the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Time of Sale Information, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(z)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Licenses or Permits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as otherwise described in each of the Registration Statement, the Prospectus and the Time of Sale Information, the Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect&#59; and except as described in each of the Registration Statement, the Prospectus and the Time of Sale Information, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course that, individually or in the aggregate, if revoked, modified or failed to renew, could result in a Material Adverse Effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(aa)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:17.38pt;">No Labor Disputes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#8217; principal suppliers, contractors or customers, except as would not have a Material Adverse Effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ab)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">Environmental Laws and Hazardous Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as described in the Registration Statement, the Prospectus and the Time of Sale Information or except as would not, singly or in the aggregate, result in a Material Adverse Effect, (i) the Company has not been advised, and has no reason to believe, that either the Company or any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law, rule, regulation, ordinance, code or rule of common law or any binding and enforceable judicial or administrative interpretation thereof, including any binding and enforceable judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Hazardous Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Environmental Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), (ii) the Company has not been advised, and has no reason to believe, that the Company and its subsidiaries do not have all permits, authorizations and approvals required under any applicable Environmental Laws to operate the business of the Company as currently conducted or are not each in compliance with their requirements, (iii) there are no pending or to the Company&#8217;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (iv) the Company has not </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">been advised, and has no reason to believe, that there are any events or circumstances that might reasonably be expected to form the basis of an order for clean- up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against the Company or any of its subsidiaries relating to Hazardous Materials pursuant to any applicable Environmental Laws.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ac)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:17.38pt;">Compliance with ERISA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company and its subsidiaries and any &#8220;employee benefit plan&#8221; (as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (collectively with the regulations and published interpretations thereunder, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ERISA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)) established or maintained by the Company, its subsidiaries or their &#8220;ERISA Affiliates&#8221; (as defined below) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company Benefit Plans</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) are in compliance in all material respects with ERISA. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ERISA Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to the Company or a subsidiary, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) of which the Company or such subsidiary is a member. No Company Benefit Plan is a multiemployer plan (as defined in Section 4001(a)(3) and Section 3(37) of ERISA) or a &#8220;multiple employer plan&#8221; (as defined in Section 4063 or 4064 of ERISA). Furthermore, no Company Benefit Plan is a &#8220;defined benefit plan&#8221; as defined in Section 3(35) of ERISA or plan subject to Part 3, Subtitle B of Title I of ERISA, Section 412 of the Code or Title IV of ERISA. None of the Company, its subsidiaries or any of their ERISA Affiliates has incurred or reasonably expects to incur any material liability under Sections 4975 or 4980B of the Code. Each Company Benefit Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification, except where such act or failure to act would not, individually or in the aggregate, result in a Material Adverse Effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ad)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">Disclosure Controls</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Company and its subsidiaries maintain an effective system of &#8220;disclosure controls and procedures&#8221; (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ae)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:17.38pt;">Accounting Controls</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company and its subsidiaries maintain systems of &#8220;internal control over financial reporting&#8221; (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in accordance with management&#8217;s general or specific authorizations&#59; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability&#59; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization&#59; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences&#59; and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Prospectus and the Time of Sale Information, there are no material weaknesses in the Company&#8217;s internal controls. Based on the most recent evaluation of its disclosure controls and procedures, the Company is not aware of&#58; (i) any significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have materially adversely affected or are reasonably likely to materially adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal controls over financial reporting.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(af)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.71pt;">eXtensible Business Reporting Language</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ag)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance, to the knowledge of the Company, is in amounts and insures against such losses and risks as are adequate to protect the Company and its subsidiaries and their respective businesses&#59; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business, except for such notices or non-renewal that would not result in a Material Adverse Effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ah)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">No Unlawful Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither the Company nor any of its subsidiaries nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity&#59; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">17</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">political party or party official or candidate for political office&#59; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FCPA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law&#59; or (iv) made, offered, agreed, authorized, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted and maintain and enforce, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ai)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:19.37pt;">Compliance with Anti-Money Laundering Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Anti-Money Laundering Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(aj)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:19.37pt;">No Conflicts with Sanctions Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither the Company nor any of its subsidiaries, directors, officers, nor, to the knowledge of the Company, any employees, agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">OFAC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or the U.S. Department of State and including, without limitation, the designation as a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221;), the United Nations Security Council (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">UNSC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the European Union, Her Majesty&#8217;s Treasury (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">HMT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or other relevant sanctions authority (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sanctions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), nor is the Company, any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria and Crimea (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Sanctioned Country</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">18</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ak)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">No Restrictions on Subsidiaries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#8217;s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary of the Company.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(al)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:19.37pt;">No Broker&#8217;s Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or the Agent for a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of the Shares.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(am)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:13.37pt;">No Registration Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(an)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">No Price Stabilization or Manipulation&#59; Compliance with Regulation M</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company has not taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in stabilization or manipulation of the price of the Common Shares or any other &#8220;reference security&#8221; (as defined in Rule 100 of Regulation M under the Exchange Act (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;Regulation M&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">)) whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action that would directly or indirectly violate Regulation M.  The Company acknowledges that the Agent may engage in passive market making transactions in the Shares on the Principal Market in accordance with Regulation M.  The Common Shares are &#8220;actively traded securities&#8221; (as defined in Regulation M).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ao)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">Forward-Looking Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Prospectus or the Time of Sale Information has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ap)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">Statistical and Market Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information is not based on or derived from sources that are reliable and accurate in all material respects.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(aq)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">No Outstanding Loans or Other Extensions of Credit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Since the adoption of Section 13(k) of the Exchange Act, neither the Company nor any of its subsidiaries has extended or maintained credit, arranged for the extension of credit, or renewed any extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">19</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Company and&#47;or such subsidiary except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ar)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.71pt;">No Ratings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There are no debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#8220;nationally recognized statistical rating organization,&#8221; as such term is defined in Section 3(a)(62) of the Exchange Act.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(as)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.04pt;">Cyber Security&#59; Data Protection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, data and databases (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IT Systems</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) are adequate for, and operate and perform as required in connection with the operation of the business of the Company and the subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants, except where such inadequacy in, or failure to operate or perform, would not, individually or in the aggregate, have a Material Adverse Effect. The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Personal Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)) used in connection with their businesses, and except as otherwise disclosed in the Registration Statement, the Prospectus and the Time of Sale Information, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person or as would not, individually or in the aggregate, have a Material Adverse Effect, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company and its subsidiaries or any of their properties or assets, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification, except where such non-compliance or failure to protect would not, individually or in the aggregate, result in a Material Adverse Effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(at)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:19.37pt;">FINRA Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  To enable the Agent to rely on FINRA Rule 5110(b)(7)(C)(i), the Company represents that the Company (i)&#160;has a non-affiliate, public common equity float of at least $150 million or a non-affiliate, public common equity float of at least $100 million and annual trading volume of at least three million shares and (ii)&#160;has been subject to the Exchange Act reporting requirements for a period of at least 36 months.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(au)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:16.7pt;">Sarbanes-Oxley</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent in connection with an issuance </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">20</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 4(p)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  ISSUANCE AND SALE OF COMMON SHARES</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Sale of Securities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Mechanics of Issuances</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Issuance Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that (A) in no event may the Company deliver an Issuance Notice to the extent that (I) the sum of (x) the aggregate Sales Price of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount&#59; and (B) prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e&#30;mail to the persons set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereto and confirmed by the Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agent Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement.  For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both agree in writing to any such modification.  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Method of Offer and Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Shares may be offered and sold (A) in privately negotiated transactions with the consent of the Company, (B) as block transactions with the consent of the Company or (C) by any other method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act, including sales made </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">21</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">directly on the Principal Market or sales made into any other existing trading market of the Common Shares.  Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clauses (A) and (B) above) the method of placement of any Shares by the Agent shall be at the Agent&#8217;s discretion.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(iv)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Confirmation to the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of Shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(v)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Settlement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent&#8217;s or its designee&#8217;s account at The Depository Trust Company through its Deposit&#47;Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date.  The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Time of Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(vi)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Suspension or Termination of Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period set forth in an Issuance Notice shall immediately terminate&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that (A) such suspension and termination shall not affect or impair either party&#8217;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice&#59; (B) if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 3(b)(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> with respect to such Shares&#59; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v) above, and may use the Shares to settle or close out such borrowings.  The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 3(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">22</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(vii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Guarantee of Placement, Etc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in placing Shares&#59; (B) the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares&#59; and (C)&#160;the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(viii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Material Non-Public Information.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is, or could be deemed to be, in possession of material non-public information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3(b)(vi))</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> by the Agent deducting the Selling Commission from the applicable Issuance Amount.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&#160;all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs), (ii)&#160;all fees and expenses of the registrar and transfer agent of the Shares, (iii)&#160;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares, (iv)&#160;all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors, (v)&#160;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement, (vi)&#160;all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws, and, if requested by the Agent, preparing and printing a &#8220;Blue Sky Survey&#8221; or memorandum, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions, (vii) the reasonable fees and disbursements of the Agent&#8217;s counsel, including&#160;the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#8217;s participation in the offering and distribution of the Shares, (viii) the filing fees incident to FINRA review, if any, and (ix) the fees and expenses associated with listing the Shares on the Principal Market.  The fees and disbursements of Agent&#8217;s counsel pursuant to subsections (vi) and (vii) above shall not exceed $50,000.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  ADDITIONAL COVENANTS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement&#58;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">23</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Exchange Act Compliance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  During the Agency Period, the Company shall (i) file, on a timely basis, with the Commission all reports and documents required to be filed under</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act and (ii) either (A) include in its quarterly reports on Form 10-Q and its annual reports on Form 10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to this Agreement and (2) the net proceeds received by the Company from such sales or (B) prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Interim Prospectus Supplement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">such summary information and, at least once a quarter and subject to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Securities Act Compliance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (ii) of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, or any Free Writing Prospectus, (iii) of the time and date that any post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.  If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment.  Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were filed in a timely manner with the Commission.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Amendments and Supplements to the Prospectus and Other Securities Act Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections&#160;4(d</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">4(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">24</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">with applicable law including the Securities Act.  Neither the Agent&#8217;s consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#8217;s obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 4(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Notwithstanding the foregoing, the Company shall not be required to file such amendment or supplement if there is no pending Issuance Notice and the Company believes that it is in its best interests not to file such amendment or supplement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Agent&#8217;s Review of Proposed Amendments and Supplements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Prior to amending or supplementing the Registration Statement (including any Rule 462(b) Registration Statement) or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act in connection with this Agreement and the Shares) relating to the Shares, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent&#8217;s prior written consent, such consent not to be unreasonably withheld or delayed, and the Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.7pt;">Use of Free Writing Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#8217;s prior written consent, any &#8220;written communication&#8221; that constitutes a &#8220;free writing prospectus&#8221; as such terms are defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Free Writing Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.03pt;">Free Writing Prospectuses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus relating to the Shares or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed free writing prospectus relating to the Shares or any amendment or supplement thereto without the Agent&#8217;s prior written consent, such consent not to be unreasonably withheld or delayed.  The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus relating to the Shares prepared by or on behalf of, or used by the Company, as the Agent may reasonably request.  If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule&#160;173(d)) to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">25</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Agent&#8217;s prior written consent, such consent not to be unreasonably withheld or delayed.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Filing of Agent Free Writing Prospectuses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall not take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Copies of Registration Statement and Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  After the date of this Agreement through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule&#160;173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule&#160;424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time&#59; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable)&#59; and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance&#59; provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">Blue Sky Compliance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions designated by the Agent, shall comply with such laws </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">26</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares.  The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.  The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">Earnings Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least 12 months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Listing&#59; Reservation of Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  (a)  The Company will maintain the listing of the Shares on the Principal Market, and (b) the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(l)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:24.69pt;">Transfer Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(m)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:18.69pt;">Due Diligence</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.   During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during normal business hours and at the Company&#8217;s principal offices, as the Agent may reasonably request from time to time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(n)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto), and (ii)&#160;an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">27</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Deliverables at Triggering Event Dates&#59; Certificates.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> The Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon&#58;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(A)&#160;the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(a)(ii)(B)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus&#59; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;the filing with the Commission of an annual report on Form 10-K or a quarterly report on Form 10-Q (including any Form 10-K&#47;A or Form 10-Q&#47;A containing amended financial information or a material amendment to the previously filed annual report on Form 10-K or quarterly report on Form 10-Q), in each case, of the Company&#59; or</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(C)&#160;the filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other than information &#8220;furnished&#8221; pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) if the Agent reasonably determines that such amended financial information is material to the offering of securities of the Company&#59; </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(any such event, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Triggering Event Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Company shall furnish the Agent (but in the case of clause (C) above only if the Agent reasonably determines that the information contained in such current report on Form 8-K of the Company is material to the offering of securities of the Company) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A) confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B) confirming that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof, and (C) containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> dated as of the date that the instructions for the sale of Shares are issued.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">28</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(p)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Legal Opinion and Negative Assurances Letter.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause to be furnished the written legal opinion and negative assurances letter of Cooley LLP, counsel to the Company, each dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event Date).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(q)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:22.02pt;">Comfort Letter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause Ernst &#38; Young LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel&#59; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus.  If requested by the Agent, the Company shall also cause a comfort letter to be furnished to the Agent within ten (10) Trading Days of the date of occurrence of any material transaction or event requiring the filing of a current report on Form 8-K containing material amended financial information of the Company, including the restatement of the Company&#8217;s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per calendar quarter. </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(r)    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Secretary&#8217;s Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. On or prior to the date of the first Issuance Notice, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i) certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii) certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii) containing any other certification that the Agent shall reasonably request. </font></div><div style="text-indent:29.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Agent&#8217;s Own Account&#59; Clients&#8217; Account</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#8217;s own account and for </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">29</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement.</font></div><div style="text-indent:26.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Investment Limitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.</font></div><div style="text-indent:23.01pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Market Activities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company will not take, and will use reasonable efforts to ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.  If the limitations of Rule 102 of Regulation M (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Rule 102</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d) of Rule 102.</font></div><div style="text-indent:23.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice of Other Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice&#59; and will not directly or indirectly enter into any other &#8220;at the market&#8221; or continuous equity transaction offer to sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that such restriction will not be required in connection with the Company&#8217;s (i) issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise or settlement of options, restricted stock unit awards or other equity awards pursuant to any employee, consultant or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award or inducement award plan under the rules of the Principal Market or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii) issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting or settlement of warrants, options, restricted stock unit awards or other equity awards outstanding at the date of this Agreement, and (iii) modification of any outstanding options, restricted stock unit awards, warrants or of any other rights to purchase or acquire Common Shares. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">30</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">v.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Use of Proceeds</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Company intends to apply the net proceeds from the sale of the Shares sold by it in the manner described under the caption &#8220;Use of Proceeds&#8221; in the Registration Statement and the Prospectus.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT</font></div><div style="text-indent:23.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">vi.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions&#58;</font></div><div style="text-indent:20.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">vii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Accuracy of the Company&#8217;s Representations and Warranties&#59; Performance by the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall have delivered the certificate required to be delivered pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> on or before the date on which delivery of such certificate is required pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Company shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 4(p)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(q)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(r)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Injunction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Material Adverse Effects</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Effect&#59; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating organization&#8221; as such term is defined under Section 3(a)(62) of the Exchange Act.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(e)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Suspension of Trading in or Delisting of Common Shares&#59; Other Events</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Nasdaq Stock Market, the New York Stock Exchange or any of their constituent markets.  There shall not have occurred (and be continuing in the case of occurrences under clauses&#160;(i) and (ii)&#160;below) any of the following&#58;  (i)&#160;trading or quotation in any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">31</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of the Company&#8217;s securities shall have been suspended or limited by the Commission or by the Principal Market, or trading in securities generally on either the Principal Market shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or FINRA&#59; (ii)&#160;a general banking moratorium shall have been declared by any of federal, New York or Delaware authorities&#59; or (iii)&#160;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities&#59;</font></div><div style="text-indent:29.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Documents Required to be Delivered on each Issuance Notice Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Agent&#8217;s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate as required to be delivered pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice).</font></div><div style="text-indent:26.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Misstatement or Material Omission</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Agent shall not have advised the Company that the Registration Statement, the Prospectus or the Time of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s reasonable opinion is material, or omits to state a fact that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</font></div><div style="text-indent:23.01pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  On each date on which the Company is required to deliver a certificate pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4(o)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company shall have furnished to the Agent such appropriate further information, certificates and documents as the Agent may have reasonably requested. All such opinions, certificates, letters and other documents shall have been in compliance with the provisions hereof. The Company will furnish the Agent with such conformed copies of such opinions, certificates, letters and other documents as the Agent shall have reasonably requested.</font></div><div style="text-indent:23.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Securities Act Filings Made</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All filings with the Commission required by Rule 424 under the Securities Act with respect to the Shares to have been filed prior to the issuance of any Issuance Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  INDEMNIFICATION AND CONTRIBUTION</font></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">v.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification of the Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">32</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&#160;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule&#160;430B under the Securities Act, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; or (ii)&#160;any untrue statement or alleged untrue statement of a material fact included or incorporated by reference in the Prospectus or any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading&#59; and to reimburse the Agent and each such officer, employee and controlling person for any and all expenses (including the reasonable and documented fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action&#59; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection (b) below.  The indemnity agreement set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  shall be in addition to any liabilities that the Company may otherwise have.</font></div><div style="text-indent:23.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">vi.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification of the Company and its Directors and Officers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer, or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&#160;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&#160;any untrue statement or alleged untrue statement of a material fact included or incorporated by reference in any Free Writing Prospectus or the Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">33</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, Free Writing Prospectus or the Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to the Agent furnished to the Company by the Agent in writing expressly for use therein&#59; and to reimburse the Company, or any such director, officer, or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer, or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Agent have furnished to the Company expressly for use in the Registration Statement, any Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement to the foregoing) is the information set forth in the first sentence of the ninth paragraph under the caption &#8220;Plan of Distribution&#8221; in the Prospectus. The indemnity agreement set forth in this&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section&#160;6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;shall be in addition to any liabilities that the Agent may otherwise have.</font></div><div style="text-indent:20.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">vii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notifications and Other Indemnification Procedures</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Promptly after receipt by an indemnified party under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or to the extent the indemnifying party is not prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement.  In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded based on the advice of counsel that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and&#47;or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties.  Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&#160;the indemnified party shall have employed separate counsel in accordance with the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">34</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Agent (in the case of counsel for the indemnified parties referred to in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">above), (ii)&#160;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</font></div><div style="text-indent:17.01pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">viii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Settlements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The indemnifying party under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment.  Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&#160;such settlement is entered into more than 30&#160;days after receipt by such indemnifying party of the aforesaid request and (ii)&#160;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.</font></div><div style="text-indent:23.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ix.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Contribution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If the indemnification provided for in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&#160;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement or (ii)&#160;if the allocation provided by clause&#160;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&#160;(i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.  The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">35</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of the Shares pursuant to this Agreement (before deducting expenses) received by the Company bear to the total Selling Commission received by the Agent.  The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.  The provisions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that no additional notice shall be required with respect to any action for which notice has been given under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> for purposes of indemnification.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Agent shall not be required to contribute any amount in excess of the Selling Commission received by the Agent in connection with the offering contemplated hereby.  No person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.  For purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  TERMINATION &#38; SURVIVAL</font></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">x.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the term of this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:23.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xi.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Termination&#59; Survival Following Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  (i) Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement, upon ten (10) Trading Days&#8217; notice to the other party&#59; provided that, (A) if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 3(b)(v)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> with respect to such Shares and (B) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall survive </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">36</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">termination of this Agreement.  If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii) In addition to the survival provision of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 7(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt;">  MISCELLANEOUS</font></div><div style="text-indent:20.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Press Releases and Disclosure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company may issue a press release describing the material terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a current report on Form&#160;8&#30;K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation,  any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.</font></div><div style="text-indent:17.01pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xiii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">No Advisory or Fiduciary Relationship</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company acknowledges and agrees that (i) the transactions contemplated by this Agreement, including the determination of any fees, are arm&#8217;s-length commercial transactions between the Company and the Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Agent and its respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (v) the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">37</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:17.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xiv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Research Analyst Independence</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company acknowledges that the Agent&#8217;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#8217;s research analysts may hold views and make statements or investment recommendations and&#47;or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions.  The Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.</font></div><div style="text-indent:21pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows&#58;</font></div><div style="text-indent:-36pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to the Agent&#58;</font></div><div style="text-indent:-36pt;padding-left:54pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Jefferies LLC</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">520 Madison Avenue</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New&#160;York, NY 10022</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Facsimile&#58;  (646) 619-4437</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58;  General Counsel</font></div><div style="text-indent:-36pt;padding-left:54pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">with a copy to (which shall not constitute a notice)&#58;</font></div><div style="text-indent:-36pt;padding-left:54pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">White &#38; Case LLP</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1221 Avenue of the Americas</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New&#160;York, NY 10020-1095</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Facsimile&#58;  (212) 354-8113</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to the Company&#58;</font></div><div><font><br></font></div><div style="text-indent:-36pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Sangamo Therapeutics, Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7000 Marina Boulevard</font></div><div style="text-indent:-36pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Brisbane, CA 94005</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Facsimile&#58; (510) 236-8951</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58; General Counsel</font></div><div style="text-indent:-36pt;padding-left:54pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:54pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">with a copy to (which shall not constitute a notice)&#58;</font></div><div style="text-indent:-36pt;padding-left:54pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Cooley LLP</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">101 California Street, 5</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Floor</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">San Francisco, CA 94111</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Facsimile&#58; (415) 693-2222</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58; Chadwick Mills</font></div><div style="padding-left:18pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">38</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 8(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:17.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xvi.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the affiliates, agents, employees, officers and directors and controlling persons referred to in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and in each case their respective successors and personal representatives, and no other person will have any right or obligation hereunder.  The term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">successors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase.</font></div><div style="text-indent:14.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xvii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Partial Unenforceability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof.  If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></div><div style="text-indent:11.01pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xviii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Governing Law Provisions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.  Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Specified Courts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.  Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.  The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.  </font></div><div style="text-indent:17.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xix.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Recognition of the U.S. Special Resolution Regimes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In the event that the Agent is a Covered Entity that becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from the Agent, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. In the event that the Agent is a Covered Entity that becomes, or a BHC Act Affiliate of the Agent becomes, subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">39</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BHC Act Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Covered Entity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any of the following&#58; (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b)&#59; (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b)&#59; or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Default Right</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">U.S. Special Resolution Regime</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></div><div style="text-indent:21pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">xx.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">General Provisions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.  This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file.  The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;sign,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper- based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.  The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;Signature Page Immediately Follows&#93;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">40</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i6dd077af6b9a48babad5e431c8c8c7bb_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="margin-bottom:12pt;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Very truly yours,</font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.</font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Sung H. Lee</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;  Sung H. Lee</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;    Chief Financial Officer</font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:252pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">JEFFERIES LLC </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Michael Brinkman</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;    Michael Brinkman</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;   Managing Director </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:6pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMERICAS 102797349 v3</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div></div></div><div id="i6dd077af6b9a48babad5e431c8c8c7bb_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT A</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ISSUANCE NOTICE</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;Date&#93;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Jefferies LLC</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">520 Madison Avenue</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New York, New York 10022</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attn&#58; &#91;__________&#93;</font></div><div><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Reference is made to the Open Market Sale Agreement between Sangamo Therapeutics, Inc. (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and Jefferies LLC (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) dated as of August&#160;5, 2020.  The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Date of Delivery of Issuance Notice (determined pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#8206;Section 3(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">)&#58; _______________________</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Issuance Amount (equal to the total Sales Price for such Shares)&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Number of days in selling period&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">First date of selling period&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Last date of selling period&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Settlement Date(s) if other than standard T+2 settlement&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&#8217;s sole discretion)&#58; $ ____ per share</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Comments&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">SANGAMO THERAPEUTICS, INC.</font></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;</font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;  </font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A-1</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div></div></div><div id="i6dd077af6b9a48babad5e431c8c8c7bb_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT B</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Notice Parties</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">The Company</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Alexander Macrae</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Sung H. Lee</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Gary H. Loeb</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Holly Cuneo</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">The Agent</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Michael Magarro</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Donald Lynaugh</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B-1</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:38.032%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.934%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.034%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>sgmo-20200630xex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7a1b961d7fa64117a4d66535bf552fda_1"></div><div style="min-height:72pt;width:100%;"><div style="padding-left:5.4pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Exhibit 5.1</font><img alt="image11.jpg" src="image11.jpg" style="height:44px;width:136px;"></div><div style="padding-left:5.4pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#616161;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Chadwick L. Mills</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#616161;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">+1 650 843 5654</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#616161;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">cmills&#64;cooley.com</font></div><div style="padding-left:5.4pt;padding-right:5.4pt;margin-bottom:36pt;"><font><br></font></div></div><div style="margin-top:18pt;margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;">August 5, 2020</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7000 Marina Blvd.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Brisbane, California 94005</font></div><div style="margin-top:12pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ladies and Gentlemen&#58;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have acted as counsel to Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), in connection with the sale of shares of its common stock, par value $0.01 per share (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), having an aggregate offering price of up to $150.0 million (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Shares</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) pursuant to the Registration Statement on Form S-3 (File No. 333-224418) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Registration Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) filed with the Securities and Exchange Commission (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Commission</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) under the Securities Act of 1933, as amended (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), the prospectus included in the Registration Statement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Base Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) and the prospectus supplement dated August 5, 2020 to be filed with the Commission pursuant to Rule 424(b) promulgated under the Act (together with the Base Prospectus, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Prospectus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). The Shares are to be sold by the Company in accordance with that certain Open Market Sale Agreement, dated August 5, 2020, by and between the Company and Jefferies LLC (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), as described in the Prospectus.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with this opinion, we have examined and relied upon the Registration Statement and the Prospectus, the Agreement, the Company&#8217;s Seventh Amended and Restated Certificate of Incorporation, as amended, the Company&#8217;s Third Amended and Restated Bylaws, each as currently in effect, and originals, or copies certified to our satisfaction, of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below.  In rendering this opinion, we have assumed the genuineness of all signatures&#59; the authenticity of all documents submitted to us as originals&#59; the conformity to originals of all documents submitted to us as copies&#59; the accuracy, completeness and authenticity of certificates of public officials&#59; and the due authorization, execution and delivery by all persons other than the Company of all documents where authorization, execution and delivery are prerequisites to the effectiveness thereof.  As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.  </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have assumed (i) that each sale of Shares will be duly authorized by the Board of Directors of the Company, a duly authorized committee thereof or a person or body pursuant to an authorization granted in accordance with Section 152 of the General Corporation Law of the State of Delaware (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">DGCL</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;), (ii) that no more than 30.0 million Shares will be sold under the Agreement pursuant to the Prospectus and (iii) that the price at which the Shares are sold will equal or exceed the par value of the Common Stock. We express no opinion to the extent that future issuances of securities of the Company and&#47;or anti-dilution adjustments to outstanding securities of the Company cause the number of shares of Common Stock outstanding or issuable upon conversion or exercise of outstanding securities of the Company to exceed the number of Shares then issuable under the Agreement.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our opinion herein is expressed solely with respect to the DGCL.  Our opinion is based on these laws as in effect on the date hereof.  We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image21.jpg" src="image21.jpg" style="height:12px;width:18px;"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%;">Cooley LLP   101 California Street   5th Floor   San Francisco, CA   94111-5800</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%;">t&#58; (415) 693-2000  f&#58; (415) 693-2222  cooley.com</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-indent:-4.5pt;margin-bottom:6pt;"><img alt="image1.jpg" src="image1.jpg" style="height:71px;width:151px;"></div><div style="text-indent:-4.5pt;margin-bottom:6pt;"><font><br></font></div><div style="padding-left:5.4pt;padding-right:5.4pt;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued against payment therefor in accordance with the Agreement, the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consent to the reference to our firm under the caption &#8220;Legal Matters&#8221; in the Prospectus and to the filing of this opinion as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Commission on the date hereof and incorporated by reference into the Registration Statement.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sincerely,</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cooley LLP</font></div><div style="margin-top:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#47;s&#47; Chadwick L. Mills&#160;&#160;</font></div><div style="text-indent:31.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Chadwick L. Mills</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image011.jpg" src="image011.jpg" style="height:24px;width:18px;"></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%;">Cooley LLP   101 California Street   5th Floor   San Francisco, CA   94111-5800</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:142%;">t&#58; (415) 693-2000  f&#58; (415) 693-2222  cooley.com</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>sgmo-20200630xex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6a69cfbe666c4a618bd1b57afb814f69_1"></div><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Employment Agreement (&#8220;Agreement&#8221;) made as of the 13</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> day of April, 2020 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Mark McClung (&#8220;Executive&#8221;) (collectively, the &#8220;Parties&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">R E C I T A L S</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WHEREAS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set forth in this Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOW, THEREFORE</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the mutual promises set forth herein, the Parties agree follows&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Company hereby agrees to employ Executive and Executive hereby agrees to accept such employment, on the terms and conditions set forth in this Agreement, with a start date of  1</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">st</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> day of May, 2020  (the &#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">At-Will Employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Executive shall be employed on an at-will basis.  Either Executive or the Company may terminate employment at any time, with or without cause, and with or without advance notice.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Position, Duties and Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Executive shall be appointed as the Executive Vice President and Chief Business Officer and shall serve in such position, and in such other positions as the Board and the Company may from time to time reasonably determine, subject at all times to the direction, supervision and authority of the Chief Executive Officer.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">During Executive&#8217;s employment, Executive shall perform Executive&#8217;s duties faithfully and to the best of Executive&#8217;s ability, and shall devote substantially all of Executive&#8217;s business time, attention, knowledge, skills and interests to the business of the Company (and its affiliates or subsidiaries).  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">During Executive&#8217;s employment, Executive shall not, whether directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation or otherwise, without the prior written consent of the Chief Executive Officer. </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The foregoing in this Section 3 shall not preclude Executive from serving on any corporate, civic or charitable boards or committees on which Executive is serving as of the Effective Date and discloses to the Chief Executive Officer prior to the Effective Date or on </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">which Executive commences service following such date with the Chief Executive Officer&#8217;s prior written approval, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Executive&#8217;s principal place of business will be located in Brisbane,  California.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">Executive represents that Executive may enter into this Agreement, and as of the Effective Date, 1) accept employment with the Company under the terms of this Agreement, and 2) perform the duties and responsibilities contemplated by this Agreement without violating any other agreement or agreements with other parties including but not limited to and any prior employers.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Compensation and Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Base Compensation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall pay to Executive an annual base salary of $415,000 Dollars, prorated for any partial employment period and payable in equal monthly installments in accordance with the Company&#8217;s payroll schedule.  The Compensation Committee of the Board shall annually review the then-current level of Executive&#8217;s base salary (for increase only) to determine the amount, if any, of change to such salary.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Annual Performance Bonus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive is eligible to earn an annual performance bonus commencing with the 2019 calendar year performance period.  The target amount of Executive&#8217;s annual cash bonus shall be 40% percent of Executive&#8217;s annual base salary.  The Board shall have sole discretion to determine whether any annual cash bonus will be paid based upon achievement of both corporate objectives and Executive&#8217;s personal objectives, and the reasonable discretion to determine that actual amount of any such bonus.  Executive must be an employee in good standing on the date that the Board makes such determination in order to earn any such bonus, which determination shall be made by the Board no later than March 31 of the calendar year first following the performance period calendar year.  The actual bonus may be more or less than the target amount based upon the Company&#8217;s achievement over the year.  Any bonus to which Executive becomes entitled for a particular calendar year shall be paid in accordance with the terms of the applicable bonus plan, but in no event later than the second payroll period following such Board determination.  The Compensation Committee of the Board shall annually review Executive&#8217;s then target amount for the annual cash bonus (for increase only) to determine the amount, if any, of change to such target amount.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Executive Severance Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive shall be deemed an Eligible Employee and an Executive Officer and entitled to receive certain severance benefits under the Sangamo Therapeutics, Inc. Executive Severance Plan dated February 6, 2019 (the &#8220;Severance Plan&#8221;) subject to the terms and conditions of the Severance Plan.  A copy of the Severance Plan has been provided to Executive concurrently with this Agreement.  Notwithstanding the foregoing, in the event that the Company withdraws this offer after it is signed by Executive or terminates this Agreement prior to the Effective Date for any reason other than Executive&#8217;s failure to successfully pass the requirements for a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">required under Section 8(a) herein, then Executive shall be entitled to severance under the Severance Plan as though his employment was terminated by the Company other than for Cause to the same extent as he would otherwise be entitled had such termination occurred after the Effective Date&#59; provided, however, that Executive shall not be entitled to such severance if he has not notified his current employer of his intent to resign his employment at the time the Company informs him of the withdrawal or termination of this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive will be entitled to the employee benefits generally provided to other executive officers of the Company pursuant to the terms of the applicable benefit plans.  Executive will not be subject to a formal paid time off program.  Executive is free to take paid time off from work for vacation, medical appointments, and other short-term absences due to illnesses or other personal reasons.  If Executive desires to take time off for a duration longer than two (2) weeks manager approval is required.  Unlimited paid time off is available from the first day of employment.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Equity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Effective as of May 25</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  2020 or the trading day immediately preceding in the event May 25</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> 2020  is not a trading day (the &#8220;Grant Date&#8221;), the Compensation Committee of the Board</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall grant you astock option to purchase up to 200,000 shares of the Company&#8217;s Common Stock subject to the terms and conditions of the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;Plan&#8221;),with an exercise price per share equal to the fair market value of the Company&#8217;s Common Stock on the Grant Date (the &#8220;Option&#8221;).  The Option will be evidenced by the standard stock option agreement under the Plan and will be subject to the terms and conditions of that agreement and the Plan, with one-quarter of the Option shares vesting twelve (12) months from the Grant Date and the remainder vesting in equal monthly installments for thirty-six (36) months thereafter, provided Executive remains a full-time employee through each such vesting date.  Vesting of the Option and any subsequent equity grants will cease upon termination of Executive&#8217;s service by either party for any reason.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;">Also, subject to approval by the Compensation Committee of the Board, we intend to grant you 100,000 restricted stock units (&#34;Restricted Stock Units&#34;) under the Plan. Each Restricted Stock Unit represents the right to receive one share of the Company's common stock upon the specified issuance date following vesting. Your Restricted Stock Units will vest in a series of three (3) successive equal annual installments upon your completion of each year of service to the Company measured from the Vesting Commencement Date. The issuance of the underlying shares of common stock in settlement of vested Restricted Stock Units will be subject to the Company's collection of all applicable withholding taxes. The Restricted Stock Units will be evidenced by the Plan's form of Restricted Stock Unit Issuance Agreement and will be subject to its terms and conditions and the Plan.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Retention Bonus Advance.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Executive shall be advanced a retention bonus (the &#8220;Retention Bonus&#8221;) in the amount of one hundred thousand dollars ($150,000), payable in the first regularly rescheduled payroll after the Effective Date.  Although the Retention Bonus is advanced at the beginning of Executive&#8217;s employment, it is expressly conditioned on Executive not terminating employment prior to the first (1st) anniversary of the Effective Date under any circumstances other than a termination that would entitle Executive to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">receive benefits under the Severance Plan, and such advanced Retention Bonus shall not be deemed earned by Executive until such service condition has been met.  If Executive&#8217;s employment terminates at any time prior to the first (1st) anniversary of the Effective Date and Executive is not entitled to receive benefits under the Severance Plan (such termination, a &#8220;Disqualifying Termination&#8221;), then, Executive shall at the time of such Disqualifying Termination promptly repay the full Retention Bonus to the Company.  In the event Executive does not earn and fails to promptly repay the Retention Bonus in connection with a Disqualifying Termination, then the Company shall be further entitled to recover from Executive its costs and expenses incurred in enforcing Executive&#8217;s repayment obligation, including reasonable attorney&#8217;s fees and costs.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Clawback</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding anything to the contrary in this Agreement, all compensation paid to Executive by the Company (whether payable pursuant to this Agreement or otherwise) will be subject to reduction, recovery and&#47;or recoupment to the extent required by any present or future law, government regulation or stock exchange listing requirement (or any policy adopted by the Company which ensures compliance with the requirements of any such law, government regulation or stock exchange listing requirement).</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Resignation from Positions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any other provision of this Agreement to the contrary, upon any termination of employment (whether voluntary or involuntary), Executive, upon written request from the Board, shall immediately resign from any positions Executive has with the Company (or any subsidiary), whether as an executive, officer, employee, consultant, director, trustee, fiduciary or otherwise.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive agrees to abide by the terms and conditions of the Employee Confidential Information and Invention Assignment Agreement between Executive and the Company, a copy of which is attached as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Executive further agrees that at all times both during Executive&#8217;s employment by the Company and after Executive&#8217;s employment ends, Executive will keep in confidence and trust, and will not use or disclose, except as directed by the Company, any confidential or proprietary information of the Company.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Tax Withholdings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any and all cash compensation and other benefits (including without limitation, base salary, annual bonus and sign-on bonus) paid to Executive under this Agreement shall be subject to all applicable tax withholding requirements, and the Company shall make such other deductions as may be required and&#47;or allowed by applicable law and&#47;or as authorized in writing by Executive.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any dispute, controversy, or claim, whether contractual or non-contractual, between Executive and the Company shall be resolved by binding arbitration before the Judicial Arbitration and Mediation Service (the &#8220;JAMS&#8221;), in accordance with the JAMS Employment Arbitration Rules and Procedures, available at www.jamsadr.com.  Executive and the Company each agree that before proceeding to arbitration, they will mediate disputes before the JAMS by a mediator approved by the JAMS.  If mediation fails to resolve the matter, any subsequent arbitration shall be conducted by an arbitrator approved by the JAMS and mutually acceptable to Executive and the Company.  All disputes, controversies, and claims shall be conducted by a single arbitrator, who shall&#58; (i) allow discovery authorized by California Code of Civil Procedure </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 1282, et seq., or any other discovery required by applicable law&#59; and (ii) issue a written award that sets forth the essential findings of fact and conclusions of law on which the award is based.  The arbitrator shall have the authority to award any relief authorized by law in connection with the asserted claims or disputes.   Judgment upon the arbitrator&#8217;s award may be entered in any court having jurisdiction thereof.  If Executive and the Company are unable to agree on the mediator or the arbitrator, then the JAMS shall select the mediator&#47;arbitrator.  The resolution of the dispute by the arbitrator shall be final, binding, non-appealable, and fully enforceable by a court of competent jurisdiction under the Federal Arbitration Act.  The arbitration award shall be in writing and shall include a statement of the reasons for the award.  The arbitration shall be held in San Francisco, California.  The Company shall pay all JAMS, mediation, and arbitrator&#8217;s fees and costs, irrespective of who raised the claim and the outcome of arbitration.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Conditions to Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement is contingent upon a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States.  Executive agrees to provide any documentation or information at the Company&#8217;s request to facilitate these processes.  </font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">17.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of California.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">18.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Attorneys&#8217; Fees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event of any controversy, claim or dispute between the parties, arising out of or relating to this Agreement or the breach hereof, or the interpretation hereof, each party shall bear its own legal fees and expenses.  Notwithstanding the foregoing, in the event of a finding by any court having jurisdiction over such matter that any party initiating an action under this Agreement failed to have a reasonable prospect of prevailing on its claim, the arbitrator shall have discretion to award the prevailing party attorneys&#8217; fees and costs incurred by it with respect to such claim or action.  The &#34;prevailing party&#34; means the party determined by the arbitrator to have most nearly prevailed, even if such party did not prevail in all matters, not necessarily the one in whose favor a judgment is rendered.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">19.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the Parties hereto.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">20.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any provision of this Agreement as applied to any party or to any circumstance should be adjudged by a court of competent jurisdiction (or determined by the arbitrator) to be void or unenforceable for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by law) the application of such provision under circumstances different from those adjudicated by the court or determined by the arbitrator, the application of any other provision of this Agreement, or the enforceability or invalidity of this Agreement as a whole.  Should any provision of this Agreement become or be deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">amended without materially altering the intention of the parties, then such provision will be stricken, and the remainder of this Agreement shall continue in full force and effect.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">21.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Successors and Assigns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company.  Executive shall not be entitled to assign any of Executive&#8217;s rights or obligations under this Agreement.</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">22.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement, along with any other agreements set forth herein, including without limitation, the Proprietary Information and Inventions Agreement, constitutes the entire agreement between the parties with respect to the employment of Executive.</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6</font><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div></div></div><div id="i6a69cfbe666c4a618bd1b57afb814f69_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.237%;"><tr><td style="width:1.0%;"></td><td style="width:11.953%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.973%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:75.740%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.134%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SANGAMO THERAPEUTICS, INC.</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="9" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Alexander Macrae</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font></div><div style="margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;  CEO</font></div><div style="margin-bottom:0.12pt;"><font><br></font></div><div style="margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Date&#58; Apr 22, 2020</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:30pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Mark McClung</font></div><div style="margin-bottom:12pt;"><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="height:30pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:30pt;text-align:justify;"><font><br></font></div><div style="padding-left:30pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; CBO</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:30pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i6a69cfbe666c4a618bd1b57afb814f69_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;padding-right:50.4pt;text-align:center;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">EXHIBIT A</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EMPLOYEE CONFIDENTIAL INFORMATION AND </font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INVENTION ASSIGNMENT AGREEMENT</font></div><div style="text-indent:36pt;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In consideration of my employment or continued employment by Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;), its direct and indirect subsidiaries, parents, affiliates, predecessors, successors and assigns (together with Sangamo, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), and the compensation and benefits provided to me now and during my employment with the Company, I hereby enter into this Employee Confidential Information and Invention Assignment Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), which will be deemed effective as of the first day of my employment with the Company&#58;</font></div><div style="margin-bottom:6pt;"><font><br></font></div><div id="i6a69cfbe666c4a618bd1b57afb814f69_10"></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">Confidential Information Protections.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">a.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Recognition of Company&#8217;s Rights&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Nondisclosure.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company&#8217;s Confidential Information (as defined below) and that Company has a protectable interest therein.  At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any of Company&#8217;s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure.  I will obtain Company&#8217;s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and&#47;or incorporates any Confidential Information.  I hereby assign to Sangamo any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Sangamo and its assigns.  I will take all reasonable precautions to prevent the inadvertent accidental disclosure of Confidential Information.  Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58;  (1) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">b.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Confidential Information.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  The term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Confidential Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> shall mean any and all confidential knowledge, data or information of Company.  By way of illustration but not limitation, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Confidential Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> includes (a)&#160;trade secrets, inventions, mask works, ideas, processes, formulas, </font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">software in source or object code versions, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">)&#59; (b)&#160;information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing&#59; (c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non-public information relating to customers and potential customers&#59; (d) information regarding any of Company&#8217;s business partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information relating to business partners&#59; (e) information regarding personnel, employee lists, compensation, and employee skills&#59; and (f) any other non-public information which a competitor of Company could use to the competitive disadvantage of Company.  Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry through no </font></div></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">breach of this Agreement or other act or omission by me.  Further, notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between the Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with any federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act. </font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">c.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Third Party Information.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I understand, in addition, that Company has received, and in the future will receive, from third parties their confidential and&#47;or proprietary knowledge, data or information (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Third Party Information&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes.  During my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">d.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">No Improper Use of Information of Prior Employers and Others.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">Assignments of Inventions.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">a.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Definitions.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">As used in this Agreement, the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Intellectual Property Rights&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country&#59; the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Copyright&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country&#59; and the term </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Moral Rights&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means all paternity, integrity, disclosure, withdrawal, </font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">special and any other similar rights recognized by the laws of any jurisdiction or country.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">b.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Excluded Inventions and Other Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> is a list describing all existing Inventions, if any, that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Excluded Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">).  If no such list is attached, I represent and agree that it is because I have no rights in any existing Inventions that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development.  For purposes of this Agreement, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Other Inventions&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> means Inventions in which I have or may have an interest, as of the commencement of my employment, other than Company Inventions (defined below) and Excluded Inventions.  I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement, I will immediately so notify Company in writing.  Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions.  To the extent that any third parties have rights in any such Excluded Inventions or Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">c.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Assignment of Company Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Inventions assigned to Sangamo, or to a third party as directed by Sangamo pursuant to Section 2.6, are referred to in this Agreement as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8220;Company Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Subject to Section 2.4 (Unassigned or Nonassignable Inventions) and except for Excluded </font></div></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:91%;">2</font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"></div></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Inventions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> and Other Inventions, I hereby assign to</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Sangamo all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the period of my employment by Company.  To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions.  Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights.  To the extent such Moral Rights cannot be assigned to Sangamo and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights.  I further acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">d.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Unassigned or Nonassignable Inventions.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I recognize that this Agreement will not be deemed to require assignment of any Invention that is covered under California Labor Code section 2870(a) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Specific Inventions Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), as detailed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Attachment 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">e.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Obligation to Keep Company Informed.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others.  In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment.  At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law&#59; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief.  Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law.  I will preserve the confidentiality of any Invention that does </font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">not fully qualify for protection under the Specific Inventions Law.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">f.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:32.99pt;">Government or Third Party. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">g.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Ownership of Work Product.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that Sangamo will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to Sangamo all right, title, and interest worldwide in and to such work product.  I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C., Section 101).  I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">h.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Enforcement of Intellectual Property Rights and Assistance.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries.  To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof.  In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Sangamo or its designee, including the United States or any third party designated by Sangamo.  My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company's request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for </font></div></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:91%;">3</font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"></div></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Agreement with the same legal force and effect as if executed by me.  I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Sangamo. </font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">i.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.6pt;">Incorporation of Software Code.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">except</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> in strict compliance with Company&#8217;s policies regarding the use of such software.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">Records.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">Duty of Loyalty During Employment.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree that during the period of my employment by Company I will not, without Company's express written consent, directly or indirectly (a) engage in any other employment or (b) engage in any other activities that are competitive with, or would otherwise conflict with, my employment by Company.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">No Solicitation of Employees, Consultants, or Contractors.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company, solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company, even if I did not initiate the discussion or seek out the contact. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">Reasonableness of Restrictions.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">I agree that I have read this entire Agreement and understand it.  I </font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">agree that this Agreement does not prevent me from earning a living or pursuing my career.  I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#8217;s legitimate business interests.  I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">No Conflicting Agreement or Obligation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I represent that my employment by Company does not and will not breach any agreement with any former employer or third party, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company.  I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">Return Of Company Property. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> Subject to the nondisclosure requirements of Section 1.1 above, upon termination of my employment or upon Company&#8217;s request at any other time, I will deliver to Company any and all of Company&#8217;s property and equipment and any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company.  I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company.  In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems&#59; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed.  I further agree that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time with or without notice.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;">Legal and Equitable Remedies.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">a.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.77pt;">I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms.  I agree that any </font></div></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:91%;">4</font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"></div></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">b.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.15pt;">In the event Company enforces this Agreement through a court or arbitration order, I agree that the restrictions of Sections 5 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">Notices.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other.  Notice will be effective upon receipt or refusal of delivery.  If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark.  If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.</font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">Notification Of New Employer.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or otherwise. </font></div><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;">General Provisions.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">a.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Governing Law.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement will be governed by and construed according to the laws of the State of California as such laws are applied to agreements entered into and to be performed entirely within California between California residents. </font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">b.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Severability.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement.  If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be </font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear. </font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">c.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Successors and Assigns.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, direct and indirect subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">d.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Survival.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement shall survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">e.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.77pt;">Employment At-Will.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree and understand that nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company's right to terminate my employment at any time, with or without cause or advance notice.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">f.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:32.99pt;">Waiver.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.  No waiver by Company of any right under this Agreement will be construed as a waiver of any other right.  Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">g.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Export.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></div><div style="text-indent:21.6pt;text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">h.&#1;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:31.15pt;">Entire Agreement.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">  This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between the parties&#59; provided, however, prior to the execution of this Agreement, if Company and I were parties to any agreement regarding the subject matter hereof, that agreement will be superseded by this Agreement prospectively only.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and an authorized officer of the Company.  Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.  If no other agreement governs nondisclosure and assignment of inventions during any period in which I was previously engaged or </font></div></div></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:91%;">5</font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"></div></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%;"><div><font><br></font></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div style="text-align:justify;margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">am in the future engaged by Company as an independent contractor, the obligations pursuant to sections of this Agreement titled &#8220;Confidential Information Protections&#8221; and &#8220;Assignment of Inventions&#8221; shall apply.</font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"><div style="margin-bottom:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font></div><div id="i6a69cfbe666c4a618bd1b57afb814f69_13"></div></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.000%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:5pt;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Mark McClung&#58;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">I have read, understand, and Accept this agreement.</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">(Signature)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">By&#58;__________________________________________&#160;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Title&#58;________________________________________&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Date&#58; ________________________________________</font></div><div style="margin-bottom:10pt;"><font><br></font></div></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:5pt;"><font><br></font></div><div style="margin-bottom:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">SANGAMO THERAPEUTICS, INC.&#58;</font></div><div style="margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Accepted and agreed&#58;</font></div><div style="margin-bottom:10pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">(Signature)</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">By&#58; __________________________________________&#160;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Title&#58; ________________________________________&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Date&#58; ________________________________________&#160;</font></div><div style="margin-bottom:10pt;"><font><br></font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.666%;"><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:91%;">6</font></div></div><div style="display:inline-block;vertical-align:top;width:6.666%;"></div><div style="display:inline-block;vertical-align:top;width:46.668%;"></div></div></div></div><div id="i6a69cfbe666c4a618bd1b57afb814f69_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Attachment 1</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Prior Inventions</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TO&#58;&#160;Sangamo Therapeutics, Inc. </font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FROM&#58;&#160;Mark McClung</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DATE&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:-57.6pt;padding-left:57.6pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SUBJECT&#58;&#160;Prior Inventions </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by Sangamo Therapeutics, Inc. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Company&#58;</font></div><div style="text-indent:28.8pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No inventions or improvements.</font></div><div style="text-indent:28.8pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;See below&#58;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:72pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:-28.8pt;padding-left:28.8pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section&#160;1 above with respect to inventions or improvements generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div><div style="text-indent:28.8pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Invention or Improvement&#160;Party(ies)&#160; Relationship</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font></div><div style="text-indent:-28.8pt;padding-left:28.8pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Attachment 2</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Limited Exclusion Notification</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This is to notify you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&#8217;s equipment, supplies, facilities or trade secret information, except for those Inventions that either&#58;</font></div><div><font><br></font></div><div style="text-indent:29.67pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.Relate at the time of conception or reduction to practice to Company&#8217;s business, or actual or demonstrably anticipated research or development&#59; or</font></div><div style="text-indent:26.34pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.Result from any work performed by you for Company.</font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A-2</font></div><div><img alt="image01.jpg" src="image01.jpg" style="height:26px;width:268px;"></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>sgmo-20200630xex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i1be45b4bf9c445959eff31b7dc52595f_1"></div><div style="min-height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:4.5pt;padding-right:27.35pt;margin-top:3.9pt;"><img alt="image012.jpg" src="image012.jpg" style="height:82px;width:332px;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%;"> </font></div><div style="padding-left:293.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:293.05pt;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Dear Andy&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">The Executive Leadership Team recognizes your recent contributions and the critical importance of your leadership and experience to Sangamo&#8217;s manufacturing strategy.  Therefore, on behalf of Sangamo, you have been awarded a one-time Spot Bonus as of December 19, 2019 to acknowledge your accomplishments, subject to the terms and conditions set out below. </font></div><div><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">The Spot Bonus will be in the gross aggregate amount of $100,000 (subject to applicable withholdings and taxes), with 25% of such amount payable on July 1,&#160;2020, December 1,&#160;2020, July 1,&#160;2021 and December 1,&#160;2021, subject to your continued full-time employment with Sangamo through and including each payment date. </font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I appreciate your continued effort and dedication to Sangamo and look forward to continuing working with you.  If you have any questions concerning this Spot Bonus, please contact me.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:136%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We appreciate your contributions and support as we collectively work towards transforming patients&#8217; lives.  </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Sincerely,</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#47;s&#47; Sandy Macrae</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Sandy Macrae</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Chief Executive Officer</font></div><div><font><br></font></div><div style="padding-left:293.05pt;"><font><br></font></div><div style="padding-left:293.05pt;"><font><br></font></div><div style="padding-left:293.05pt;"><font><br></font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>sgmo-20200630xex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia526229f517c48449327a48c2aecda2c_1"></div><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:18pt;"><font><br></font></div><div style="text-align:center;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">SEVENTH AMENDMENT TO LEASE</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">THIS SEVENTH AMENDMENT TO LEASE (this &#8220;Seventh Amendment&#8221;) is entered into as of May 20, 2020 (the &#8220;Effective Date&#8221;), by and between POINT RICHMOND R&#38;D ASSOCIATES II, LLC, a California limited liability company (&#8220;Landlord&#8221;), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (formerly known as Sangamo Biosciences, Inc., a Delaware corporation) (&#8220;Tenant&#8221;), with reference to the following facts&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A.&#160;Landlord and Tenant entered into that certain Triple Net Laboratory Lease dated as of May 23, 1997, together with an Addendum thereto dated May 28, 1997 (collectively, the &#8220;Original Lease&#8221;), as amended by those certain letter agreements dated June 15, 1999, April 21, 2000 (the &#8220;April 21, 2000 Letter Agreement&#8221;) and November&#160;3, 2000, that certain First Amendment to Lease dated March&#160;12, 2004 (the &#8220;First Amendment&#8221;), that certain Lease Addendum dated December 12, 2006 (&#8220;Lease Addendum II&#8221;), that certain Second Amendment to Lease dated March 15, 2007, that certain Lease Addendum III dated April 2, 2012 (&#8220;Lease Addendum III&#8221;), that certain Third Amendment to Lease dated August 1, 2013, that certain Lease Addendum dated December 1, 2013 (&#8220;Lease Addendum IV&#8221;, and collectively with Lease Addendum II and Lease Addendum III, the &#8220;Storage Space Lease Addenda&#8221;), that certain Fourth Amendment to Lease dated June 10, 2016, that certain Fifth Amendment to Lease dated July 10, 2017 (the &#8220;Fifth Amendment&#8221;), and that certain Sixth Amendment to Lease dated May 11, 2018 (the &#8220;Sixth Amendment&#8221;), pursuant to which Tenant leases certain premises consisting of approximately 26,629 rentable square feet known as Suites A, B and C-1 (&#8220;Suites A, B and C-1&#8221;), approximately 5,165 rentable square feet known as Suite C-2 (&#8220;Suite C-2&#8221;), and approximately 6,153 rentable square feet known as Suite F (&#8220;Suite F&#8221;, and collectively with Suites A, B and C-1, and Suite C-2, the &#8220;Existing Premises&#8221;), in the building located at 501 Canal Boulevard, Point Richmond, California (the &#8220;Building&#8221;).  The Original Lease, as so amended, is collectively referred to herein as the &#8220;Existing Lease&#8221;&#59; provided, however, the Storage Space Lease Addenda are no longer in effect pursuant to the terms of the Fifth Amendment.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B.&#160;Tenant has requested that additional space described as approximately 8,541 rentable square feet known as Suite Nos. G, H &#38; J, (of which Suite J alone contains approximately 700 rentable square feet&#59; hereinafter, the &#8220;Suite J Expansion Space&#8221;) as shown on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereto (collectively, the &#8220;Suite Nos. G, H &#38; J Expansion Space&#8221;), be added to the Premises and that the Existing Lease be appropriately amended, and Landlord is willing to do the same on the following terms and conditions.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant hereby agree as follows&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Incorporation of Recitals and Defined Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Recitals above are hereby incorporated herein.  As of the Effective Date, unless context clearly indicates otherwise, all references to &#8220;the Lease&#8221; or &#8220;this Lease&#8221; in the Existing Lease or in this Seventh Amendment </font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">shall be deemed to refer to the Existing Lease, as amended by this Seventh Amendment.  Capitalized terms which are not otherwise defined in this Seventh Amendment shall have the meanings set forth in the Existing Lease.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Expansion</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Effective as of the later of (i) October 1, 2020 and (ii) the date the Suite Nos. G, H &#38; J Expansion Space is delivered to Tenant with the work described in the last sentence of Section 7(a) below completed (the &#8220;Suite Nos. G, H &#38; J Expansion Effective Date&#8221;), the Premises, as defined in the Existing Lease, is increased from approximately 37,947 rentable square feet to approximately 46,488 rentable square feet by the addition of the Suite Nos. G, H &#38; J Expansion Space, and from and after the Suite Nos. G, H &#38; J Expansion Effective Date, the Existing Premises and the Suite Nos. G, H &#38; J Expansion Space, collectively, shall be deemed the Premises, as defined in the Existing Lease, for all purposes under the Existing Lease, including, without limitation, Section 8 of the First Amendment (as amended by Section 2 of the Third Amendment, Section 14 of the Fifth Amendment, and Section 6 of the Sixth Amendment).  The Term for the Suite Nos. G, H &#38; J Expansion Space shall commence on the Suite Nos. G, H &#38; J Expansion Effective Date and end on the Second Extended Expiration Date (as defined in the Sixth Amendment).  The Suite Nos. G, H &#38; J Expansion Space is subject to all the terms and conditions of the Existing Lease except as expressly modified herein and except that Tenant shall not be entitled to receive any allowances, abatements or other financial concessions granted with respect to the Existing Premises.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Base Monthly Rent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As of the Suite Nos. G, H &#38; J Expansion Date, in addition to the Base Monthly Rent payable for the Existing Premises, Tenant shall pay Base Monthly Rent payable with respect to Suite Nos. G, H &#38; J as follows&#58;</font></div><div style="text-align:justify;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.923%;"><tr><td style="width:1.0%;"></td><td style="width:46.958%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.042%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Base Monthly Rent</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10&#47;01&#47;20 &#8211; 08&#47;31&#47;21</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21,352.50</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">09&#47;01&#47;21 &#8211; 08&#47;31&#47;22</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$21,886.31</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">09&#47;01&#47;22 &#8211; 08&#47;31&#47;23</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$22,433.47</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">09&#47;01&#47;23 &#8211; 08&#47;31&#47;24</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$22,994.31</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">09&#47;01&#47;24 &#8211; 08&#47;31&#47;25</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$23,569.17</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">09&#47;01&#47;25 &#8211; 08&#47;31&#47;26</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$24,158.40</font></td></tr></table></div><div style="text-indent:0.72pt;text-align:justify;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">All such Monthly Base Rent shall be payable by Tenant in accordance with the terms of the Existing Lease.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Additional Security Deposit</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Upon Tenant&#8217;s execution hereof, Tenant shall pay Landlord the sum of $21,352.50 which is added to and becomes part of the Security Deposit, if any, held by Landlord as provided under Section 4.3.2 of the Original Lease, Section 9 of the Fourth Amendment and Section 10 of the Fifth Amendment, as security for payment of Rent and the performance of the other terms and conditions of the Lease by Tenant. Accordingly, simultaneous with the execution hereof, the Security Deposit is increased from $32,367.00 to $53,719.50.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Tenant&#8217;s Pro Rata Share</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. For the period commencing with the Suite Nos. G, H &#38; J Expansion Effective Date and continuing through the Second Extended Expiration Date, </font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Tenant&#8217;s Pro Rata Share for the Premises (including Suite Nos. G, H &#38; J Expansion Space) is 57.17%.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Operating Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For the period commencing with the Suite Nos. G, H &#38; J Expansion Effective Date, Tenant shall pay for Tenant&#8217;s Pro Rata Share of Operating Expenses applicable to the Suite Nos. G, H &#38; J Expansion Space in accordance with the terms of the Existing Lease.  As of the Suite Nos. G, H &#38; J Expansion Effective Date as to Suite Nos. G, H &#38; J Expansion Space and ending as of the Second Extended Expiration Date, Tenant&#8217;s Pro Rata Share of Operating Expenses (exclusive of Taxes) shall not increase by more than 5% per calendar year on a compounding and cumulative basis (e.g., Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) for calendar year 2021 shall not exceed 105% of Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) for 2020&#59; Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) for calendar year 2022 shall not exceed 105% of the maximum allowable amount of Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) permitted for 2021, etc.).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Improvements to Suite Nos. G, H &#38; J Expansion Space</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:22.7pt;">Condition of Suite Nos. G, H &#38; J Expansion Space</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Tenant has inspected the Suite Nos. G, H &#38; J Expansion Space and agrees to accept the same &#8220;as is&#8221; without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Amendment.  Landlord represents and warrants that the mechanical, electrical, plumbing and drainage systems within and serving the Suite Nos. G, H &#38; J Expansion Space are and will be, as of the Suite Nos. G, H &#38; J Expansion Effective Date, in good working order and free from defects.  Should Tenant determine that there is any noncompliance with the foregoing representation and provide Landlord with a written notice thereof, Landlord shall promptly after receipt of written notice from Tenant setting forth with specificity the nature and extent of such noncompliance, rectify the same&#59; such noncompliance shall not, however, entitle Tenant to an abatement of rent or to terminate the Lease, or otherwise release Tenant from any of Tenant&#8217;s obligations under the Lease.  Prior to the Suite Nos. G, H &#38; J Expansion Effective Date, Landlord shall replace air conditioning unit No. 7 (serving Suite H) with a new air conditioning unit of equal quality to the other air conditioning units serving the Suite Nos. G, H &#38; J Expansion Space.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:22.02pt;">Responsibility for Improvements to Suite Nos. G, H &#38; J Expansion Space</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Tenant may perform improvements to the Suite Nos. G, H &#38; J Expansion Space in accordance with Section 7.3 of the Existing Lease&#59; provided, however, that Landlord shall not unreasonably withhold its consent to any proposed Alterations.  Landlord shall respond to any request by Tenant for approval of proposed Alterations within seven (7) business days, and if Landlord disapproves of the proposed Alterations, it shall provide Tenant with written notice of the reason for such disapproval.  If within such seven (7) business day period, Landlord informs Tenant that Landlord has submitted the proposed Alterations to an outside third party for review, then Landlord shall make diligent, good faith efforts to have such outside third-party review completed, and to deliver to Tenant an approval or any written notice of additional required revisions to or comments regarding the proposed Alterations, within not less than twenty (20) </font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">business days.  In the event Landlord fails to respond to Tenant&#8217;s request for approval of the proposed Alterations within the original seven (7) business day period, Tenant shall send a reminder notice to Landlord, and if Landlord fails to respond to the reminder notice within three (3) business days after receipt thereof, the proposed Alterations shall be deemed approved.  Provided that Tenant is not in breach of any of its obligations under the Existing Lease beyond any notice or cure period(s), Tenant shall be entitled to an allowance (the &#8220;Suite Nos. G, H &#38; J Expansion Space Improvement Allowance&#8221;) in an amount not to exceed the sum of $256,230.00 (i.e., $30.00 per rentable square foot of the Suite Nos. G, H &#38; J Expansion Space) for the costs (the &#8220;Suite Nos. G, H &#38; J Expansion Space Improvement Costs&#8221;) relating to the design, permitting and construction of Tenant&#8217;s improvements which are permanently affixed to the Suite Nos. G, H &#38; J Expansion Space (the &#8220;Suite Nos. G, H &#38; J Expansion Space Work&#8221;).  As used herein the term &#8220;Suite Nos. G, H &#38; J Expansion Space Improvement Costs&#8221;&#160; shall mean payments to contractors, subcontractors, architects, engineers and material suppliers for services, labor and materials with respect to the Suite Nos. G, H &#38; J Expansion Space Work.  Landlord shall be entitled to deduct from the Suite Nos. G, H &#38; J Expansion Space Improvement Allowance a construction management fee for Landlord&#8217;s oversight of the improvements in an amount equal to 3% of the total hard costs of the improvements.  The Suite Nos. G, H &#38; J Expansion Space Improvement Allowance (or so much of same as qualifies for disbursement under this Section&#160;6(b)) shall be paid to Tenant in a single-lump sum following the date that Tenant has satisfied all of the following conditions&#58; (i) Tenant has delivered to Landlord reasonable evidence of the amounts so incurred and paid by Tenant in connection with the refurbishment of the Suite Nos. G, H &#38; J Expansion Space&#59; (ii) Tenant shall have provided Landlord the final unconditional lien waivers and releases from all parties providing labor or materials on behalf of Tenant at the Suite Nos. G, H &#38; J Expansion Space in a form reasonably satisfactory to Landlord&#59; (iii) Tenant shall have provided as-built drawings (.pdf and CAD formats) for the Suite Nos. G, H &#38; J Expansion Space Work&#59; and (iv) the Suite Nos. G, H &#38; J Expansion Space Work shall have been completed in compliance with the requirements imposed on Alterations pursuant to Section 7.3 of the Existing Lease.&#160; If Tenant does not submit a request for disbursement of the entire Suite Nos. G, H &#38; J Expansion Space Improvement Allowance in accordance with the provisions contained in this Section 6(b) by August 31, 2022, the Suite Nos. G, H &#38; J Expansion Space Improvement Expansion Space Improvement Allowance, or any unused portion thereof, shall be forfeited and shall accrue for the sole benefit of Landlord.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Early Access to Expansion Space</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Tenant may enter the portion of the Suite Nos. G, H &#38; J Expansion Space that constitutes Suite Nos. G &#38; H as of the Effective Date of this Seventh Amendment, but any early entry into the portion of the Suite Nos. G, H &#38; J Expansion Space that constitutes Suite No. J requires not less than forty-five (45) days prior written notice to Landlord.  During any period that Tenant shall be permitted to enter the Suite Nos. G, H &#38; J Expansion Space prior to the Suite Nos. G, H &#38; J Expansion Effective Date (e.g., to perform alterations or improvements, if any), Tenant shall comply with all terms and provisions of the Existing Lease, except those provisions requiring payment of Base Rent or Additional Rent as to the Suite Nos. G, H &#38; J Expansion Space.  If Tenant takes possession of and occupies the Suite J Expansion Space prior to the Suite Nos. G, H &#38; J Expansion Effective Date for any reason whatsoever (other than the performance of work in the Suite J Expansion Space with Landlord&#8217;s prior approval), such possession shall be subject to all the terms and conditions of the Existing Lease and this Seventh Amendment, and Tenant shall pay Base Monthly Rent and Additional </font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Rent as applicable to the Suite J Expansion Space occupied to Landlord on a per diem basis for each day of occupancy prior to the Suite Nos. G, H &#38; J Expansion Effective Date (such occupancy date is hereafter defined as the &#8220;Suite J Expansion Space Early Occupancy Date&#8221;) in accordance with Paragraphs 2 and 3 of the Suite J Expansion Space Early Occupancy Date Letter (whether or not the same is delivered to Tenant).  At Landlord&#8217;s option, promptly after the determination of the Suite J Expansion Space Early Occupancy Date, if any, Landlord and Tenant shall execute and deliver a commencement letter in the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;Suite J Expansion Space Early Occupancy Date Letter&#8221;).  Tenant&#8217;s failure to execute and return the Suite J Expansion Space Early Occupancy Date Letter, or to provide written objection to the statements contained in the Suite J Expansion Space Early Occupancy Date Letter, within thirty (30) days after the date such Suite J Expansion Space Early Occupancy Date Letter is delivered to Tenant, if at all, shall be deemed an approval by Tenant of the statements contained therein.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Parking</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For the period commencing with the Suite Nos. G &#38; H Expansion Effective Date and continuing through the Second Extended Expiration Date, in addition to the parking spaces available to Tenant for the Existing Premises in accordance with the Existing Lease, Tenant shall be entitled to up to twenty-five (25) unreserved off-street parking spaces (i.e., 3 spaces per 1,000 rentable square feet of the Suite Nos. G, H &#38; J Expansion Space) in the surface lot serving the Building at no additional cost to Tenant.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">April 21, 2000 Letter Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The parties acknowledge and agree that (a) neither party currently has a copy of or knows the terms of the April 21, 2000 Letter Agreement, (b) to the extent such a copy is located by either party, such party shall provide such copy to the other party, and (c) both parties agree to remain bound by the terms of the April 21, 2000 Letter Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Brokers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Tenant shall be solely responsible for any commission, fees or costs payable to any real estate broker, sales person or finder claiming to have represented Tenant in connection with this Seventh Amendment, any future amendment to the Lease and&#47;or Tenant&#8217;s exercise of any extension option or right of first refusal contained in the Existing Lease.  Tenant shall indemnify, defend and hold Landlord harmless from and against any and all claims by any real estate broker, salesperson or finder claiming to have represented Tenant for a commission, finder&#8217;s fee or other compensation in connection with this Seventh Amendment.  Landlord shall be solely responsible for any commission, fees or costs payable to any real estate broker, sales person or finder claiming to have represented Landlord in connection with this Seventh Amendment, any future amendment to the Lease and&#47;or Tenant&#8217;s exercise of any extension option or right of first refusal contained in the Existing Lease. Landlord shall indemnify, defend and hold Tenant harmless from and against any and all claims by any real estate broker, salesperson or finder claiming to have represented Landlord for a commission, finder&#8217;s fee or other compensation in connection with this Seventh Amendment.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Inspection by a CASp in Accordance with Civil Code Section 1938</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  To Landlord&#8217;s actual knowledge, the property being leased or rented pursuant to the Existing Lease (as amended by this Seventh Amendment) has not undergone inspection by a Certified Access Specialist (CASp).  A Certified Access Specialist (CASp) can inspect the subject premises and </font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.  The foregoing verification is included in this Seventh Amendment solely for the purpose of complying with California Civil Code Section 1938 and, except as otherwise expressly stated above, shall not in any manner affect Landlord&#8217;s and Tenant&#8217;s respective responsibilities for compliance with construction-related accessibility standards as provided under the Existing Lease.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">OFAC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Tenant represents and warrants to Landlord that Tenant is currently in compliance with and shall at all times during the Term of the Existing Lease remain in compliance with the regulations of the Office of Foreign Asset Control (&#8220;OFAC&#8221;) of the Department of the Treasury and any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action relating thereto.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Counterparts&#59; PDF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Seventh Amendment may be executed in multiple counterparts each of which is deemed an original but together constitute one and the same instrument.  This Seventh Amendment may be executed in so-called &#8220;pdf&#8221; format and each party has the right to rely upon a pdf counterpart of this Seventh Amendment signed by the other party to the same extent as if such party had received an original counterpart.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Seventh Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns.  Each party hereto and the persons signing below warrant that the person signing below on such party&#8217;s behalf is authorized to do so and to bind such party to the terms of this Seventh Amendment.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:21pt;">Status of Existing Lease</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as amended hereby, the Existing Lease is unchanged, and, as amended hereby, the Existing Lease remains in full force and effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, Landlord and Tenant have entered into this Seventh Amendment as of the date first set forth above.</font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:15.973%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.516%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:72.511%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Landlord&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">POINT RICHMOND R&#38;D ASSOCIATES II, LLC,<br>a California limited liability company</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Wareham-NZL, LLC, its Manager</font></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:0.36pt;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; &#160;&#47;s&#47; Richard K. Robbins</font></div><div style="text-indent:0.36pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Its Manager</font></div><div style="text-indent:0.36pt;margin-bottom:0.12pt;"><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tenant&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">SANGAMO THERAPEUTICS, INC.,</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a Delaware corporation</font></div><div style="margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; &#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; &#160;Sandy Macrae</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; &#160;CEO</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7</font></div></div></div><div id="ia526229f517c48449327a48c2aecda2c_4"></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">EXHIBIT A</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SUITE NOS. G, H &#38; J EXPANSION SPACE</font></div><div style="text-align:center;"><img alt="image01.jpg" src="image01.jpg" style="height:766px;width:497px;"></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;"><img alt="image111.jpg" src="image111.jpg" style="height:807px;width:624px;"></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A-2</font></div></div></div><div id="ia526229f517c48449327a48c2aecda2c_7"></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT B</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">SUITE J EXPANSION SPACE EARLY OCCUPANCY DATE LETTER</font></div><div style="text-align:justify;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:13.359%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:82.641%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">______________________</font></div><div style="text-align:justify;"><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tenant&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">__________________________</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Address&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_________________________</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_________________________</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_________________________</font></div><div style="text-align:justify;"><font><br></font></div></td></tr></table></div><div style="text-indent:-36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Re&#58;&#160;Suite J Expansion Space Early Occupancy Date Letter with respect to that certain Seventh Amendment to Lease dated as of May __, 2020 (the &#8220;Amendment&#8221;), by and Point Richmond R&#38;D Associates II, LLC, a California limited liability company, as Landlord, and Sangamo Therapeutics, Inc., a Delaware corporation (formerly known as Sangamo Biosciences, Inc., a Delaware corporation), as Tenant, for approximately 700 rentable square known as Suite J within building located at 501 Canal Boulevard, Point Richmond, California.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dear Tenant&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Capitalized terms used in this Suite J Expansion Space Early Occupancy Date Letter and not otherwise defined herein shall have the meanings given such terms in the Amendment.  In accordance with the terms and conditions of the Amendment, Tenant accepts possession of the Suite J Expansion Space and acknowledges that&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">The Suite J Expansion Space Early Occupancy Date under the Amendment is __________, 2020.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">As of the Suite J Expansion Space Early Occupancy Date, Tenant&#8217;s Base Monthly Rent under the Lease is increased by $1,750.00, calculated on a daily basis from the Suite J Expansion Space Early Occupancy Date through the day before the Suite Nos. G, H &#38; J Expansion Effective Date.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">As of the Suite J Expansion Space Early Occupancy Date, Tenant&#8217;s Pro Rata Share for the Premises is increased by 0.86%, calculated on a daily basis from the Suite J Expansion Space Early Occupancy Date through the day before the Suite Nos. G, H &#38; J Expansion Effective Date.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;">As of the Suite Nos. G, H &#38; J Expansion Effective Date, the provisions of Sections 3 and 5 of the Amendment shall apply in lieu of Paragraphs 2 and 3 above, because as of that date, the Suite J Expansion Space shall be reflected in the Base Monthly Rent and Tenant&#8217;s Pro Rata Share as shown in those Sections 3 and 5.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Please acknowledge the foregoing and your acceptance of possession of the Suite J Expansion Space by signing all three (3) counterparts of this Suite J Expansion Space Early Occupancy Date Letter in the space provided and returning two (2) fully executed counterparts to my attention.  Tenant&#8217;s failure to execute and return this Suite J Expansion Space Early Occupancy Date Letter, or to provide written objection to the statements contained in this Suite J Expansion Space Early Occupancy Date Letter, within thirty (30) days after the date this Suite J </font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Expansion Space Early Occupancy Date Letter is delivered shall be deemed an approval by Tenant of the statements contained herein.</font></div><div style="text-align:justify;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:48.980%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:47.020%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Sincerely,</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">___________________________________</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Authorized Signatory</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Acknowledged and Accepted&#58;</font></div><div style="margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Tenant&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc.,</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a Delaware corporation</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;______________________</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;______________________</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;______________________</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Date&#58;&#160;______________________</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">00038102.7 &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B-2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>sgmo-20200630xex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="idaf153cba1c34a188b9322de25886c08_1"></div><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;margin-bottom:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">EIGHTH AMENDMENT TO LEASE</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">THIS EIGHTH AMENDMENT TO LEASE (this &#8220;Eighth Amendment&#8221;) is entered into as of May 29, 2020 (the &#8220;Effective Date&#8221;), by and between POINT RICHMOND R&#38;D ASSOCIATES II, LLC, a California limited liability company (&#8220;Landlord&#8221;), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (formerly known as Sangamo Biosciences, Inc., a Delaware corporation) (&#8220;Tenant&#8221;), with reference to the following facts&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A.&#160;Landlord and Tenant entered into that certain Triple Net Laboratory Lease dated as of May 23, 1997, together with an Addendum thereto dated May 28, 1997 (collectively, the &#8220;Original Lease&#8221;), as amended by those certain letter agreements dated June 15, 1999, April 21, 2000 and November&#160;3, 2000, that certain First Amendment to Lease dated March&#160;12, 2004, that certain Lease Addendum dated December 12, 2006 , that certain Second Amendment to Lease dated March 15, 2007, that certain Lease Addendum III dated April 2, 2012 , that certain Third Amendment to Lease dated August 1, 2013, that certain Lease Addendum dated December 1, 2013 , that certain Fourth Amendment to Lease dated June 10, 2016, that certain Fifth Amendment to Lease dated July 10, 2017, that certain Sixth Amendment to Lease dated May 11, 2018 (the &#8220;Sixth Amendment&#8221;), and that certain Seventh Amendment to Lease dated May 20, 2020, pursuant to which Tenant leases certain premises consisting of approximately 46,488 rentable square feet known as Suites A, B, C-1, C-2, F, G, H and J, in the building located at 501 Canal Boulevard, Point Richmond, California.  The Original Lease, as so amended, is collectively referred to herein as the &#8220;Existing Lease&#8221;.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B.&#160;Tenant has requested that Landlord extend the date by which Tenant must apply to receive the Suites A, B and C-1 Allowances (as defined in the Sixth Amendment), and Landlord is willing to do the same on the following terms and conditions.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant hereby agree as follows&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Incorporation of Recitals and Defined Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Recitals above are hereby incorporated herein.  As of the Effective Date, unless context clearly indicates otherwise, all references to &#8220;the Lease&#8221; or &#8220;this Lease&#8221; in the Existing Lease or in this Eighth Amendment shall be deemed to refer to the Existing Lease, as amended by this Eighth Amendment.  Capitalized terms which are not otherwise defined in this Eighth Amendment shall have the meanings set forth in the Existing Lease.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Suites A, B and C-1 Allowances</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Section 1.2 of Exhibit A to the Sixth Amendment is hereby amended to change the date therein from &#8220;August 31, 2021&#8221; to &#8220;November 30, 2021&#8221;.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Counterparts&#59; PDF</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Eighth Amendment may be executed in multiple counterparts each of which is deemed an original but together constitute one and the same instrument.  This Eighth Amendment may be executed in so-called &#8220;pdf&#8221; format and each party </font></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#123;00042745.1 &#125;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">has the right to rely upon a pdf counterpart of this Eighth Amendment signed by the other party to the same extent as if such party had received an original counterpart.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:27pt;">Status of Existing Lease</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as amended hereby, the Existing Lease is unchanged, and, as amended hereby, the Existing Lease remains in full force and effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, Landlord and Tenant have entered into this Eighth Amendment as of the date first set forth above.</font></div><div style="text-align:justify;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:15.973%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.516%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:72.511%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Landlord&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">POINT RICHMOND R&#38;D ASSOCIATES II, LLC,<br>a California limited liability company</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Wareham-NZL, LLC, its Manager</font></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:0.36pt;margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Richard K. Robbins</font></div><div style="text-indent:0.36pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Its Manager</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tenant&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">SANGAMO THERAPEUTICS, INC.,</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a Delaware corporation</font></div><div style="margin-bottom:24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sung Lee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;Sung Lee</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; &#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">EVP &#38; CEO</font></div></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="position:relative;width:100%;height:64.8pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;">&#123;00042745.1 &#125;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>sgmo-20200630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i08ae8a0c3f2e4f5f9862f9aaf6e12ae9_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Alexander D. Macrae, M.B., Ch.B., Ph.D., certify that&#58;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alexander D. Macrae, M.B., Ch.B., Ph.D.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>sgmo-20200630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie46b5e662f5c4774a64da90f3a4944dd_1"></div><div style="min-height:42.75pt;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div><div style="text-align:right;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">CERTIFICATION</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Sung H. Lee, certify that&#58;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-54pt;padding-left:54pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="text-indent:-54pt;padding-left:108pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:73.219%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.781%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; SUNG H. LEE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sung H. Lee</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice&#160;President and Chief&#160;Financial&#160;Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:6pt;"><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>sgmo-20200630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iaf4955cf03544ac49938ae78a4c7c1c5_1"></div><div style="min-height:42.75pt;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div><div style="text-align:right;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="text-align:center;margin-top:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June&#160;30, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:78.234%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.766%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alexander D. Macrae, M.B., Ch.B., Ph.D.</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; SUNG H. LEE</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sung H. Lee</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice&#160;President and Chief&#160;Financial&#160;Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 5, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>sgmo-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:025b09b8-2cad-4da1-9d9e-4c6905973d12,g:d4ee88be-e02e-4f39-96cc-71bae86b4889-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
        <link:definition>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2105102 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2306302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail">
        <link:definition>2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSNarrativeDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail">
        <link:definition>2408403 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail">
        <link:definition>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>2110103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>2311303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail">
        <link:definition>2412405 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2413406 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails">
        <link:definition>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHARE" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE">
        <link:definition>2115104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail">
        <link:definition>2416408 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
        <link:definition>2117105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
        <link:definition>2318304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail">
        <link:definition>2419409 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
        <link:definition>2420410 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sangamo.com/role/INCOMETAXES">
        <link:definition>2121106 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2122107 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>2323305 - Disclosure - COMMITMENTS AND CONTINGENCIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail">
        <link:definition>2424411 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail">
        <link:definition>2425412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1">
        <link:definition>2425412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2126108 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2327306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
        <link:definition>2428413 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2129109 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetail" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail">
        <link:definition>2430414 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS">
        <link:definition>2131110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables">
        <link:definition>2332307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail">
        <link:definition>2433415 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail">
        <link:definition>2434416 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS">
        <link:definition>2135111 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail">
        <link:definition>2436417 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesMilestonesMember" abstract="true" name="AchievementOfSpecifiedSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" abstract="false" name="BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" abstract="false" name="IncreaseInFairValueOfFreeSharesAssetAndLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" abstract="true" name="SharePurchaseAgreementAndTenderOfferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNetIncomeLossPerShare" abstract="false" name="CollaborativeArrangementNetIncomeLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgmo_NonCancelableContractualCommitmentMember" abstract="true" name="NonCancelableContractualCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" abstract="false" name="CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveMember" abstract="true" name="SBFiveTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BrisbaneCaliforniaMember" abstract="true" name="BrisbaneCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ResearchAndOfficeSpaceMember" abstract="true" name="ResearchAndOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" abstract="false" name="CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" abstract="true" name="CaliforniaInstituteForRegenerativeMedicineAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementPercentOfInitialRecognition" abstract="false" name="CollaborativeAgreementPercentOfInitialRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" abstract="false" name="CollaborativeArrangementIncreaseDecreaseInRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ValbonneFranceMember" abstract="true" name="ValbonneFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfSharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" abstract="false" name="BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" abstract="false" name="BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionPeriod" abstract="false" name="CollaborativeArrangementStandstillRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborationAgreementTargetSelectionPeriod" abstract="false" name="CollaborationAgreementTargetSelectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" abstract="false" name="CollaborativeArrangementVotingProvisionsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_PfizerAndSanofiMember" abstract="true" name="PfizerAndSanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_LicenseObligations" abstract="false" name="LicenseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AmendedCollaborationAndLicenseAgreementMember" abstract="true" name="AmendedCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ContractualObligationPaidUponExecution" abstract="false" name="ContractualObligationPaidUponExecution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration" abstract="false" name="CollaborativeArrangementExtendedPeriodOfCollaboration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ChangeInCollaborationAgreementScopeMember" abstract="true" name="ChangeInCollaborationAgreementScopeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_GrantFundingAmount" abstract="false" name="GrantFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MeasurementInputStockPriceCorrelationMember" abstract="true" name="MeasurementInputStockPriceCorrelationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" abstract="false" name="CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_SangamoFranceMember" abstract="true" name="SangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" abstract="false" name="CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" abstract="true" name="ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_GainLossOnFreeShares" abstract="false" name="GainLossOnFreeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" abstract="false" name="CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" abstract="false" name="CollaborativeArrangementNumberOfProductTargetsSelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMilestoneRevenueReversal" abstract="false" name="CollaborativeArrangementMilestoneRevenueReversal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementPeriodOfCollaboration" abstract="false" name="CollaborativeArrangementPeriodOfCollaboration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionSharesAcquiredValue" abstract="false" name="BusinessAcquisitionSharesAcquiredValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesHeldByHolders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" abstract="false" name="CollaborativeArrangementCumulativeMilestoneAchieved" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockExcessConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_FreeSharesAssetMember" abstract="true" name="FreeSharesAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" abstract="false" name="CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_ManufacturingObligationsMember" abstract="true" name="ManufacturingObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="sgmo_PropertySubjectToOperatingLeaseOneMember" abstract="true" name="PropertySubjectToOperatingLeaseOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" abstract="false" name="ScheduleOfNoncontrollingInterestTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ManufacturingCapacityMember" abstract="true" name="ManufacturingCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementMaximumMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationArrangementResearchPeriod" abstract="false" name="CollaborationArrangementResearchPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_TxCellSAMember" abstract="true" name="TxCellSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PreApprovalMilestoneMember" abstract="true" name="PreApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargets" abstract="false" name="CollaborativeArrangementNumberOfProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborationAgreementEquityIssued" abstract="false" name="CollaborationAgreementEquityIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AmortizationAndOtherChangesInRightOfUseAssets" abstract="false" name="AmortizationAndOtherChangesInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" abstract="false" name="ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_MeasurementInputExchangeRateMember" abstract="true" name="MeasurementInputExchangeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PaymentsForOtherCommitment" abstract="false" name="PaymentsForOtherCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>sgmo-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:025b09b8-2cad-4da1-9d9e-4c6905973d12,g:d4ee88be-e02e-4f39-96cc-71bae86b4889-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20200630.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9e0ee377-3f68-44c0-b3b0-274c0b8acbc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4605b63a-ce27-42e3-9e4c-4c086e71f938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9e0ee377-3f68-44c0-b3b0-274c0b8acbc6" xlink:to="loc_us-gaap_Liabilities_4605b63a-ce27-42e3-9e4c-4c086e71f938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3561521c-0b76-4fb5-b0de-4ee19ff577a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9e0ee377-3f68-44c0-b3b0-274c0b8acbc6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3561521c-0b76-4fb5-b0de-4ee19ff577a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f385743-74c9-402f-b6fb-79c14fc9a2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9e0ee377-3f68-44c0-b3b0-274c0b8acbc6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f385743-74c9-402f-b6fb-79c14fc9a2f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a31d0fe7-41be-4cfc-82f6-9e9cb586e752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d99ba83b-02f5-4a7f-ad26-b3b0e429a6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a31d0fe7-41be-4cfc-82f6-9e9cb586e752" xlink:to="loc_us-gaap_PreferredStockValue_d99ba83b-02f5-4a7f-ad26-b3b0e429a6d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c6983fed-d49e-42e0-a7f2-b358ffbdb21e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a31d0fe7-41be-4cfc-82f6-9e9cb586e752" xlink:to="loc_us-gaap_CommonStockValue_c6983fed-d49e-42e0-a7f2-b358ffbdb21e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_43034d73-4f70-45b8-8639-5bf3fa2f5266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a31d0fe7-41be-4cfc-82f6-9e9cb586e752" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_43034d73-4f70-45b8-8639-5bf3fa2f5266" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4ee769f-9c2b-46e4-b97e-730894b9390c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a31d0fe7-41be-4cfc-82f6-9e9cb586e752" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4ee769f-9c2b-46e4-b97e-730894b9390c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_11a776ee-9d92-4256-936e-a252af7ed33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a31d0fe7-41be-4cfc-82f6-9e9cb586e752" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_11a776ee-9d92-4256-936e-a252af7ed33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3b0106fe-f4a0-466d-ad95-9b4a56950601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fd126132-88cf-4b6f-bba1-ac94ea551f52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b0106fe-f4a0-466d-ad95-9b4a56950601" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fd126132-88cf-4b6f-bba1-ac94ea551f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_4e3f22ee-797a-46f1-ab89-0c078fd6e2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b0106fe-f4a0-466d-ad95-9b4a56950601" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_4e3f22ee-797a-46f1-ab89-0c078fd6e2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1145ea7f-643a-4110-97b7-81704ac2a831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3b0106fe-f4a0-466d-ad95-9b4a56950601" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1145ea7f-643a-4110-97b7-81704ac2a831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b967885-1827-491e-918a-4c2b307864ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e1a8128d-bece-40c8-9610-6b5efe1b9f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b967885-1827-491e-918a-4c2b307864ca" xlink:to="loc_us-gaap_StockholdersEquity_e1a8128d-bece-40c8-9610-6b5efe1b9f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_22649190-3c33-4684-b1b4-a7b9aa6b6842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7b967885-1827-491e-918a-4c2b307864ca" xlink:to="loc_us-gaap_MinorityInterest_22649190-3c33-4684-b1b4-a7b9aa6b6842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_187cc49d-b2f1-4246-aa6d-a03236ab1cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51680093-054a-4bba-8945-b04862b58c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_187cc49d-b2f1-4246-aa6d-a03236ab1cf8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51680093-054a-4bba-8945-b04862b58c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_401f3e67-1e1a-4ad6-b5da-7f952d590fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_187cc49d-b2f1-4246-aa6d-a03236ab1cf8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_401f3e67-1e1a-4ad6-b5da-7f952d590fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_b0141e06-41f4-4171-a0cd-ddac8fcd1db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_187cc49d-b2f1-4246-aa6d-a03236ab1cf8" xlink:to="loc_us-gaap_InterestReceivableCurrent_b0141e06-41f4-4171-a0cd-ddac8fcd1db6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d5a90059-3742-447b-891d-6de6b00f39f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_187cc49d-b2f1-4246-aa6d-a03236ab1cf8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d5a90059-3742-447b-891d-6de6b00f39f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29499204-a862-4d64-9aaa-34be4b2733c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_187cc49d-b2f1-4246-aa6d-a03236ab1cf8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29499204-a862-4d64-9aaa-34be4b2733c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4d9e1ae6-9771-4e2c-baa6-69d430af454a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_AssetsCurrent_4d9e1ae6-9771-4e2c-baa6-69d430af454a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_875f5a4b-1788-46da-b0dc-8149e22e60d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_875f5a4b-1788-46da-b0dc-8149e22e60d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_55ec8753-87d6-40eb-b4b6-de1e54b23c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_55ec8753-87d6-40eb-b4b6-de1e54b23c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dc09efca-09da-495e-9293-76ca8e804166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dc09efca-09da-495e-9293-76ca8e804166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_27b502e5-6549-49be-a5a8-d1c9b7cd0b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_Goodwill_27b502e5-6549-49be-a5a8-d1c9b7cd0b7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_799b6924-344d-4128-81fd-9b7ee4c49749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_799b6924-344d-4128-81fd-9b7ee4c49749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7af60316-39c8-4eb0-94bf-c7456bdfdba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7af60316-39c8-4eb0-94bf-c7456bdfdba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_eb0896da-503f-4fd8-94cb-7c44385e92fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_36102be8-b03e-4ffd-a6ac-513f2a818f06" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_eb0896da-503f-4fd8-94cb-7c44385e92fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_df0a61c6-e950-4c98-aac3-12851da71c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_965faae1-b250-4d45-bb5b-7ed990a20da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df0a61c6-e950-4c98-aac3-12851da71c63" xlink:to="loc_us-gaap_LiabilitiesCurrent_965faae1-b250-4d45-bb5b-7ed990a20da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f8c7e49b-6275-4d6b-9807-c7471cac8ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df0a61c6-e950-4c98-aac3-12851da71c63" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f8c7e49b-6275-4d6b-9807-c7471cac8ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e0c12ff-2510-420a-b987-cacdd13ecd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df0a61c6-e950-4c98-aac3-12851da71c63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e0c12ff-2510-420a-b987-cacdd13ecd66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_767efc1d-9434-4806-a59b-6e10573075a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df0a61c6-e950-4c98-aac3-12851da71c63" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_767efc1d-9434-4806-a59b-6e10573075a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_48c50f02-8f76-415f-8a86-d928e369c813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_df0a61c6-e950-4c98-aac3-12851da71c63" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_48c50f02-8f76-415f-8a86-d928e369c813" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_08b0cac1-6e91-47f1-8f11-ce82ea648449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f9a9c921-7b2c-4a45-95e7-c6e1b5c39d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_08b0cac1-6e91-47f1-8f11-ce82ea648449" xlink:to="loc_us-gaap_OperatingIncomeLoss_f9a9c921-7b2c-4a45-95e7-c6e1b5c39d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_9c76cae7-a4c5-4bdf-9e8b-e47a0eda7b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_08b0cac1-6e91-47f1-8f11-ce82ea648449" xlink:to="loc_us-gaap_InterestAndOtherIncome_9c76cae7-a4c5-4bdf-9e8b-e47a0eda7b50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30f49b03-93e6-49f4-bc35-2aecb2f1661c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2a52a80e-a5a8-49c5-96a5-b8395ec6056f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_30f49b03-93e6-49f4-bc35-2aecb2f1661c" xlink:to="loc_us-gaap_ProfitLoss_2a52a80e-a5a8-49c5-96a5-b8395ec6056f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a2127cdd-8bdc-4226-bb26-1617217df195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_30f49b03-93e6-49f4-bc35-2aecb2f1661c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a2127cdd-8bdc-4226-bb26-1617217df195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e3e25c27-d89b-4c01-b56f-1b35eea213c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_025a3d21-502d-4078-9a98-349ddddda495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e3e25c27-d89b-4c01-b56f-1b35eea213c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_025a3d21-502d-4078-9a98-349ddddda495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d5361a7e-492c-4a6b-9a07-5dd71f020a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e3e25c27-d89b-4c01-b56f-1b35eea213c8" xlink:to="loc_us-gaap_OperatingExpenses_d5361a7e-492c-4a6b-9a07-5dd71f020a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3b4f28ae-400e-477d-ac16-db79ba682b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c1cb640-98f8-4669-8a59-09166ebafd3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3b4f28ae-400e-477d-ac16-db79ba682b85" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c1cb640-98f8-4669-8a59-09166ebafd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fa2d9243-b26a-427e-9c5e-ba19c73da9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3b4f28ae-400e-477d-ac16-db79ba682b85" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fa2d9243-b26a-427e-9c5e-ba19c73da9b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebde872d-76b8-4804-b445-41229b9135ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c3cd37a7-39fc-4fc6-a2da-9ed74f1c5416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebde872d-76b8-4804-b445-41229b9135ba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c3cd37a7-39fc-4fc6-a2da-9ed74f1c5416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b0041d1b-03d5-45da-9181-2177690c0bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebde872d-76b8-4804-b445-41229b9135ba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b0041d1b-03d5-45da-9181-2177690c0bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2ae8a7ff-78a2-4c46-a908-8d1be61e8d73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bc3be2cd-8240-479e-932f-40f19dd473d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2ae8a7ff-78a2-4c46-a908-8d1be61e8d73" xlink:to="loc_us-gaap_ProfitLoss_bc3be2cd-8240-479e-932f-40f19dd473d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2378104-a65a-40eb-89eb-8cec125818db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2ae8a7ff-78a2-4c46-a908-8d1be61e8d73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c2378104-a65a-40eb-89eb-8cec125818db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_db795adb-f293-4711-aca6-f325687ad053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2ae8a7ff-78a2-4c46-a908-8d1be61e8d73" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_db795adb-f293-4711-aca6-f325687ad053" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a52f77-3a40-4e00-8d81-f6f5e6a47904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a446c067-30f4-4260-b8ec-9d1d69c90a70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a52f77-3a40-4e00-8d81-f6f5e6a47904" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a446c067-30f4-4260-b8ec-9d1d69c90a70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ac2e4bb9-ed18-4ce9-9a36-e530af998e84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a52f77-3a40-4e00-8d81-f6f5e6a47904" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ac2e4bb9-ed18-4ce9-9a36-e530af998e84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8121bca0-deb7-445c-b247-ed5a3a181fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a52f77-3a40-4e00-8d81-f6f5e6a47904" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8121bca0-deb7-445c-b247-ed5a3a181fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_5957ff79-ae34-40ee-b78f-66894ab647f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a52f77-3a40-4e00-8d81-f6f5e6a47904" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_5957ff79-ae34-40ee-b78f-66894ab647f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6fa8e9ba-b1a0-461e-83af-088b31cbed87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_ProfitLoss_6fa8e9ba-b1a0-461e-83af-088b31cbed87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_864bfa2c-0dd7-41c9-b721-10d8c842a31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_864bfa2c-0dd7-41c9-b721-10d8c842a31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a3d93ca9-5495-420f-8de0-c97308bb29d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a3d93ca9-5495-420f-8de0-c97308bb29d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_0175b06f-0a1e-43a8-b27a-458a8ab4f1a3" xlink:href="sgmo-20200630.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_0175b06f-0a1e-43a8-b27a-458a8ab4f1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_d6c3e964-51da-4d68-b59f-ea9004104875" xlink:href="sgmo-20200630.xsd#sgmo_GainLossOnFreeShares"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_sgmo_GainLossOnFreeShares_d6c3e964-51da-4d68-b59f-ea9004104875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_18dc93c5-d640-4b03-8b6e-b414403f27ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_ShareBasedCompensation_18dc93c5-d640-4b03-8b6e-b414403f27ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_6d80ecef-8156-47bc-acfc-d6e4d30203bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_6d80ecef-8156-47bc-acfc-d6e4d30203bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_883a6d6a-888b-4ca5-ba29-879c02abc5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_883a6d6a-888b-4ca5-ba29-879c02abc5fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_5622a0a8-8273-47a6-ad9b-457595942c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_5622a0a8-8273-47a6-ad9b-457595942c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d6f3e7d1-3c02-4d0a-a01a-41f910e98072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d6f3e7d1-3c02-4d0a-a01a-41f910e98072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6df6b783-dc4f-4186-b820-6b331b68773e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6df6b783-dc4f-4186-b820-6b331b68773e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_30f7b7f6-ccf8-4c4d-8fa6-f9eb82ecc1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_30f7b7f6-ccf8-4c4d-8fa6-f9eb82ecc1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_6b1babd7-9578-44fe-8ff8-0d9cce04eab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_6b1babd7-9578-44fe-8ff8-0d9cce04eab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_64a643cf-2370-493f-b244-2262998a9151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_64a643cf-2370-493f-b244-2262998a9151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_e23b7474-28f8-4c80-b666-b680d21b3cfd" xlink:href="sgmo-20200630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_e23b7474-28f8-4c80-b666-b680d21b3cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_61656d9f-a4fb-422d-b350-ad0360d4e92c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d14eaba-9834-4d4f-a102-2aad161e8809" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_61656d9f-a4fb-422d-b350-ad0360d4e92c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be293b7f-ae42-4cf2-865f-95dc25039378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a948c5-efd8-46ff-8e4e-261d373a4796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be293b7f-ae42-4cf2-865f-95dc25039378" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5a948c5-efd8-46ff-8e4e-261d373a4796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21693f05-1246-4839-a4d7-c947b68e0ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be293b7f-ae42-4cf2-865f-95dc25039378" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21693f05-1246-4839-a4d7-c947b68e0ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18dfe2f5-4023-4079-ae18-c8f5fee68ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be293b7f-ae42-4cf2-865f-95dc25039378" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_18dfe2f5-4023-4079-ae18-c8f5fee68ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b9e88cd-edf7-4fdc-96f5-cc2ad9c51960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be293b7f-ae42-4cf2-865f-95dc25039378" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b9e88cd-edf7-4fdc-96f5-cc2ad9c51960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e4f2e02-4fa8-4262-93cd-322637460f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8192f675-df5c-4dc8-ab21-89339e55a9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e4f2e02-4fa8-4262-93cd-322637460f30" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8192f675-df5c-4dc8-ab21-89339e55a9c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_4640015e-64cf-4a03-b871-3321e3e71843" xlink:href="sgmo-20200630.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e4f2e02-4fa8-4262-93cd-322637460f30" xlink:to="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_4640015e-64cf-4a03-b871-3321e3e71843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d75fac08-c5fe-4b0c-8109-b7ccf3599fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e4f2e02-4fa8-4262-93cd-322637460f30" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d75fac08-c5fe-4b0c-8109-b7ccf3599fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8ee983d2-429c-4953-b91b-3425dbcc3def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e4f2e02-4fa8-4262-93cd-322637460f30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8ee983d2-429c-4953-b91b-3425dbcc3def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a40feedd-1da3-4378-b2ed-6abaf2cda218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1e4f2e02-4fa8-4262-93cd-322637460f30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a40feedd-1da3-4378-b2ed-6abaf2cda218" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36075844-6991-4ab3-becc-37523934432e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc173f93-a256-497b-83aa-e93be479f7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36075844-6991-4ab3-becc-37523934432e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc173f93-a256-497b-83aa-e93be479f7a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_fcac8c57-87b2-4de0-9522-69639d7ff6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36075844-6991-4ab3-becc-37523934432e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_fcac8c57-87b2-4de0-9522-69639d7ff6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_145e5dc5-a6bd-42ac-b877-fa632f677ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36075844-6991-4ab3-becc-37523934432e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_145e5dc5-a6bd-42ac-b877-fa632f677ada" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_86e9cb9f-08d0-426d-9c93-e8049d738f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df90115c-28ae-440d-a808-bcf561cde02a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_86e9cb9f-08d0-426d-9c93-e8049d738f08" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_df90115c-28ae-440d-a808-bcf561cde02a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6cc5af9-57ab-4b7a-a323-06e8f57affce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_86e9cb9f-08d0-426d-9c93-e8049d738f08" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6cc5af9-57ab-4b7a-a323-06e8f57affce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_846f3754-b840-4283-aa31-9e2a74d4b9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_3565fe98-ce22-4e80-89ed-e545c48ba6bb" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_846f3754-b840-4283-aa31-9e2a74d4b9df" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_3565fe98-ce22-4e80-89ed-e545c48ba6bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_f66c591a-5221-4796-bb29-84e00769a86e" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_846f3754-b840-4283-aa31-9e2a74d4b9df" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_f66c591a-5221-4796-bb29-84e00769a86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f96c4abd-d16a-4718-8118-eee4824eea3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_846f3754-b840-4283-aa31-9e2a74d4b9df" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f96c4abd-d16a-4718-8118-eee4824eea3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fe2798ee-4234-4e49-8ce1-736e49570443" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_65ee491b-7328-4b50-bf52-9de843acb4ba" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fe2798ee-4234-4e49-8ce1-736e49570443" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_65ee491b-7328-4b50-bf52-9de843acb4ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b376571b-9533-4044-a215-5a5f380084f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_fe2798ee-4234-4e49-8ce1-736e49570443" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b376571b-9533-4044-a215-5a5f380084f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_53520458-074d-4e77-858a-e55c6ad2672d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1cce28d-c158-4cff-814a-fb99cf0653ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_53520458-074d-4e77-858a-e55c6ad2672d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c1cce28d-c158-4cff-814a-fb99cf0653ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b9ef18e-bb5b-4e92-8f88-2ae6dc4f4c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_53520458-074d-4e77-858a-e55c6ad2672d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b9ef18e-bb5b-4e92-8f88-2ae6dc4f4c2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79f59e66-c29a-41e2-bc14-61cf88a0342c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_53520458-074d-4e77-858a-e55c6ad2672d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79f59e66-c29a-41e2-bc14-61cf88a0342c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_ec81b2a4-56e5-4cc1-94f9-b007914a53d9" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_a7e11bd4-8b56-42ca-92c1-29524b982465" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_ec81b2a4-56e5-4cc1-94f9-b007914a53d9" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_a7e11bd4-8b56-42ca-92c1-29524b982465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee6bed6c-4ba1-4eb0-afe8-d65a5503e133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_ec81b2a4-56e5-4cc1-94f9-b007914a53d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ee6bed6c-4ba1-4eb0-afe8-d65a5503e133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_82a1e2d3-8cc5-43b6-b722-4dc87c4fdc7f" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f1a43fb0-be07-4fca-9dc5-b102f9daaa34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_82a1e2d3-8cc5-43b6-b722-4dc87c4fdc7f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f1a43fb0-be07-4fca-9dc5-b102f9daaa34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4a5de681-7720-421c-b86d-3a8ffd593824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_82a1e2d3-8cc5-43b6-b722-4dc87c4fdc7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4a5de681-7720-421c-b86d-3a8ffd593824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_5da3df9b-3566-439e-af4d-70f222813310" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_100ab3ab-15e6-4c49-af51-ef64ccf46a47" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_5da3df9b-3566-439e-af4d-70f222813310" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_100ab3ab-15e6-4c49-af51-ef64ccf46a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_024a61c6-92e4-4dd5-a5ff-811366440379" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_5da3df9b-3566-439e-af4d-70f222813310" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_024a61c6-92e4-4dd5-a5ff-811366440379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_cb0b1422-ad56-460d-8f46-b0a46ba3b8a1" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_5da3df9b-3566-439e-af4d-70f222813310" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_cb0b1422-ad56-460d-8f46-b0a46ba3b8a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dadb5d68-37e3-4025-92df-58f9d0afbdc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e565bb11-ad73-40d6-8522-7a9fa7865e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dadb5d68-37e3-4025-92df-58f9d0afbdc4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e565bb11-ad73-40d6-8522-7a9fa7865e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_edb95db4-ce31-4d61-8a18-b00acd6ca4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dadb5d68-37e3-4025-92df-58f9d0afbdc4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_edb95db4-ce31-4d61-8a18-b00acd6ca4ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20200630.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60d87dfc-6f2b-45a9-9980-c2b9a14815c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43ee81c4-bdcc-440c-b2bb-f7ed898f1a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60d87dfc-6f2b-45a9-9980-c2b9a14815c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43ee81c4-bdcc-440c-b2bb-f7ed898f1a0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_98c89281-c059-4ecc-99a4-22fbab3331a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60d87dfc-6f2b-45a9-9980-c2b9a14815c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_98c89281-c059-4ecc-99a4-22fbab3331a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_613238cc-e6be-4419-9195-f37d2fe43bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60d87dfc-6f2b-45a9-9980-c2b9a14815c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_613238cc-e6be-4419-9195-f37d2fe43bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_82dcd400-205f-4bfa-82c5-c384b3018be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60d87dfc-6f2b-45a9-9980-c2b9a14815c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_82dcd400-205f-4bfa-82c5-c384b3018be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1a6a3e05-e05b-475e-91f9-df116dae8562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60d87dfc-6f2b-45a9-9980-c2b9a14815c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1a6a3e05-e05b-475e-91f9-df116dae8562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d81774f9-9819-405d-adca-0116691ca103" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60d87dfc-6f2b-45a9-9980-c2b9a14815c1" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d81774f9-9819-405d-adca-0116691ca103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a64662ab-d41f-488f-b1ef-f475a0a68ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5c689343-307b-4b6b-aa85-4396d95d9b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a64662ab-d41f-488f-b1ef-f475a0a68ea7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5c689343-307b-4b6b-aa85-4396d95d9b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a3ee06c-e467-46e5-ab86-27d667bd383b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a64662ab-d41f-488f-b1ef-f475a0a68ea7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a3ee06c-e467-46e5-ab86-27d667bd383b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_615a9ba6-20aa-4bb4-bc38-f82699c23928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3ec02424-c3ee-4b4c-a0fd-48a7e12f6069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_615a9ba6-20aa-4bb4-bc38-f82699c23928" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3ec02424-c3ee-4b4c-a0fd-48a7e12f6069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e12f773c-b640-4d05-9da6-a645035e1288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_615a9ba6-20aa-4bb4-bc38-f82699c23928" xlink:to="loc_us-gaap_OperatingLeaseLiability_e12f773c-b640-4d05-9da6-a645035e1288" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#SUBSEQUENTEVENTS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#SUBSEQUENTEVENTSAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>sgmo-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:025b09b8-2cad-4da1-9d9e-4c6905973d12,g:d4ee88be-e02e-4f39-96cc-71bae86b4889-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20200630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended" id="ib0afccd623eb4922a79456bbd3095681_Cover"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i0d934bc817654af0a96e800984801612_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i1e76f3a558074708898515331c24cbe3_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended" id="ia6498fdde545457899c608e89f85836c_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ie558315ade22451d8313a36212e7e444_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_89c04f26-a897-4268-808a-b1abc21dc1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_CommonStockSharesIssued_89c04f26-a897-4268-808a-b1abc21dc1d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ab11f16-6f8e-4c0d-821a-6f84f98d4e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ab11f16-6f8e-4c0d-821a-6f84f98d4e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f67eb74-836f-4eae-abc9-9b0586564da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f67eb74-836f-4eae-abc9-9b0586564da3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2d1f9eb7-3f57-46ab-9180-39cc0e8916f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2d1f9eb7-3f57-46ab-9180-39cc0e8916f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c1f323c4-5967-4016-a14c-40848cdfabfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c1f323c4-5967-4016-a14c-40848cdfabfe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542ace64-f4cf-4e7c-89cf-5071542df2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542ace64-f4cf-4e7c-89cf-5071542df2bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_408b2f21-cada-405b-8ec3-86b8a5b01071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_408b2f21-cada-405b-8ec3-86b8a5b01071" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b4880589-465b-4ea7-a53c-a436cf69a685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b4880589-465b-4ea7-a53c-a436cf69a685" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_cbfa1330-c376-434e-9d49-6097f315ab1d" xlink:href="sgmo-20200630.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_cbfa1330-c376-434e-9d49-6097f315ab1d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c258aaed-1862-4f05-8abd-51d99aec492f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c258aaed-1862-4f05-8abd-51d99aec492f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1cd30ee3-58cc-4d4f-916f-c18b231f971e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1cd30ee3-58cc-4d4f-916f-c18b231f971e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_446d125c-9502-4940-9aec-01fea5ccb485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_446d125c-9502-4940-9aec-01fea5ccb485" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c13f7b31-01a0-4220-b007-d92ebe3f4eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c13f7b31-01a0-4220-b007-d92ebe3f4eca" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1028f699-94e7-4b82-aa88-bd0828220ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_ProfitLoss_1028f699-94e7-4b82-aa88-bd0828220ab4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7cb61cf6-9d0b-4637-be9a-d50f912eb219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36205c15-7def-449d-9ca6-5f4420373e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6b61cecf-aa7c-4889-b3f5-316c76fcc182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6b61cecf-aa7c-4889-b3f5-316c76fcc182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:to="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6be1e449-cf5d-4a32-9297-a3e503bd58fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6be1e449-cf5d-4a32-9297-a3e503bd58fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6be1e449-cf5d-4a32-9297-a3e503bd58fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6be1e449-cf5d-4a32-9297-a3e503bd58fa" xlink:to="loc_us-gaap_EquityComponentDomain_6be1e449-cf5d-4a32-9297-a3e503bd58fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6be1e449-cf5d-4a32-9297-a3e503bd58fa" xlink:to="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3158efc9-ca8e-468f-900b-d6330f95531b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_CommonStockMember_3158efc9-ca8e-468f-900b-d6330f95531b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_87dc58c0-97f0-42d3-9444-8958e9cd526e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_87dc58c0-97f0-42d3-9444-8958e9cd526e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e8b242c4-a156-4b0e-9294-7a4be8f90bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_RetainedEarningsMember_e8b242c4-a156-4b0e-9294-7a4be8f90bb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79e1ca64-d1ba-48f3-93c0-4558628db0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79e1ca64-d1ba-48f3-93c0-4558628db0ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1ea1cd7a-091d-41f3-abf2-da27a81260b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1ea1cd7a-091d-41f3-abf2-da27a81260b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f0fb8a45-469a-4af2-802f-fa618043db3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:to="loc_srt_RestatementAxis_f0fb8a45-469a-4af2-802f-fa618043db3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f0fb8a45-469a-4af2-802f-fa618043db3e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_f0fb8a45-469a-4af2-802f-fa618043db3e" xlink:to="loc_srt_RestatementDomain_f0fb8a45-469a-4af2-802f-fa618043db3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_49be6bd3-284f-48be-b577-6d39722311e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_f0fb8a45-469a-4af2-802f-fa618043db3e" xlink:to="loc_srt_RestatementDomain_49be6bd3-284f-48be-b577-6d39722311e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_cc980873-dce8-4451-aba0-e458b0054678" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_49be6bd3-284f-48be-b577-6d39722311e1" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_cc980873-dce8-4451-aba0-e458b0054678" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i3a076ac7bcdf45058987e932fd653f4e_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i5264b92c9fd045bbb290b0c19bdf0aba_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="i3bd35cc82877496db5c933be036e174b_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended" id="i1a617e21da794b50882f555c145b44d1_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended" id="i2e57972e43324e2386d7e02756b88184_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:href="sgmo-20200630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7ed6a5a-a9f5-4267-b2d7-eeaf3d319dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7ed6a5a-a9f5-4267-b2d7-eeaf3d319dd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a9320178-4415-4b08-97ab-04ee96746c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_ProfitLoss_a9320178-4415-4b08-97ab-04ee96746c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_55d07dd1-78d8-465e-abdf-788750aa9c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_EarningsPerShareBasic_55d07dd1-78d8-465e-abdf-788750aa9c9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_16e5e806-a0b6-4131-a567-f93fc15a9f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_16e5e806-a0b6-4131-a567-f93fc15a9f6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_40411dce-fd12-4459-845b-2cbc3941f22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_40411dce-fd12-4459-845b-2cbc3941f22d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b021e10-d0c2-42fe-858f-c139585ae1af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b021e10-d0c2-42fe-858f-c139585ae1af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e1f52b5-c082-4a54-ba76-57866fddb0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e1f52b5-c082-4a54-ba76-57866fddb0e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c924c377-9ecc-44e6-9aef-5a7119870d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c924c377-9ecc-44e6-9aef-5a7119870d7e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa901d34-9dd3-4ab9-9b7e-ea2102fc2e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa901d34-9dd3-4ab9-9b7e-ea2102fc2e64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:href="sgmo-20200630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b892654a-6340-4b07-be67-bc308a12d283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b892654a-6340-4b07-be67-bc308a12d283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_b892654a-6340-4b07-be67-bc308a12d283_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b892654a-6340-4b07-be67-bc308a12d283" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_b892654a-6340-4b07-be67-bc308a12d283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c3b74df5-7af8-4099-92a9-9c14f8b98077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b892654a-6340-4b07-be67-bc308a12d283" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c3b74df5-7af8-4099-92a9-9c14f8b98077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5c29208a-c149-4567-94de-4da18007652d" xlink:href="sgmo-20200630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c3b74df5-7af8-4099-92a9-9c14f8b98077" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5c29208a-c149-4567-94de-4da18007652d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1794ae6-9346-4451-9399-b053da97d9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1794ae6-9346-4451-9399-b053da97d9b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1794ae6-9346-4451-9399-b053da97d9b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1794ae6-9346-4451-9399-b053da97d9b8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1794ae6-9346-4451-9399-b053da97d9b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2a5c99a-291e-4243-84db-309ca88af7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1794ae6-9346-4451-9399-b053da97d9b8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2a5c99a-291e-4243-84db-309ca88af7a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6c7d2341-80f8-40fd-928b-80ae63788f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2a5c99a-291e-4243-84db-309ca88af7a2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6c7d2341-80f8-40fd-928b-80ae63788f4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a72b52c3-befa-4ff3-904d-8011665e6c24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_srt_CounterpartyNameAxis_a72b52c3-befa-4ff3-904d-8011665e6c24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a72b52c3-befa-4ff3-904d-8011665e6c24_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a72b52c3-befa-4ff3-904d-8011665e6c24" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a72b52c3-befa-4ff3-904d-8011665e6c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a72b52c3-befa-4ff3-904d-8011665e6c24" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_4ea25c97-639c-4d1f-a289-a819f07b5b83" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_BiogenMAIncMember_4ea25c97-639c-4d1f-a289-a819f07b5b83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_10efcf68-b614-477a-84ba-4db3ad229576" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_KitePharmaIncMember_10efcf68-b614-477a-84ba-4db3ad229576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_4cb8c486-e168-4484-a8b8-42dbeb541bc6" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_PfizerMember_4cb8c486-e168-4484-a8b8-42dbeb541bc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_cc0b298d-df76-42f3-a6eb-f0521d58f42e" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_SanofiMember_cc0b298d-df76-42f3-a6eb-f0521d58f42e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerAndSanofiMember_16e97bef-9260-4abc-99f1-07f5f8789bd2" xlink:href="sgmo-20200630.xsd#sgmo_PfizerAndSanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_PfizerAndSanofiMember_16e97bef-9260-4abc-99f1-07f5f8789bd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_1363bfb7-bb7d-4c7d-bdad-85377b1a9f3c" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_757f4844-42f2-4291-ba59-be38f1b95837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_757f4844-42f2-4291-ba59-be38f1b95837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c2554351-3805-4b5b-8d02-a46c9a4ab0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_757f4844-42f2-4291-ba59-be38f1b95837" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c2554351-3805-4b5b-8d02-a46c9a4ab0f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_708807e8-8d44-47c9-8e10-3d34ea88cacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_708807e8-8d44-47c9-8e10-3d34ea88cacc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_708807e8-8d44-47c9-8e10-3d34ea88cacc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_708807e8-8d44-47c9-8e10-3d34ea88cacc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_708807e8-8d44-47c9-8e10-3d34ea88cacc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_708807e8-8d44-47c9-8e10-3d34ea88cacc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f293de85-fe19-4789-afa8-c71552f94c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f293de85-fe19-4789-afa8-c71552f94c5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_92936e5a-e630-49dd-9ab1-f3244e6cd55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:to="loc_us-gaap_SalesRevenueNetMember_92936e5a-e630-49dd-9ab1-f3244e6cd55f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended" id="i872d81108d0b45cc9a43965a74855ec0_FAIRVALUEMEASUREMENTS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended" id="i0565c8797eb34229a8aa054b5c905d4d_FAIRVALUEMEASUREMENTSTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended" id="i940ee2d8534c4eaa833308c4ce302591_FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97bed1b2-0185-4787-ae00-18a13db525c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97bed1b2-0185-4787-ae00-18a13db525c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91cf1105-1586-46af-ac4f-8ca540d34704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91cf1105-1586-46af-ac4f-8ca540d34704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_dc5a3bc3-bca1-49d6-988e-0af581f41479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_dc5a3bc3-bca1-49d6-988e-0af581f41479" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2630d72-d2ff-4d54-9613-ecf188fb4ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2630d72-d2ff-4d54-9613-ecf188fb4ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_02997f41-3348-4ac9-afc5-d85cfe44a36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2630d72-d2ff-4d54-9613-ecf188fb4ff5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_02997f41-3348-4ac9-afc5-d85cfe44a36e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68dfdd5-fb01-45d9-9a35-3b487d5527bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68dfdd5-fb01-45d9-9a35-3b487d5527bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b68dfdd5-fb01-45d9-9a35-3b487d5527bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68dfdd5-fb01-45d9-9a35-3b487d5527bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b68dfdd5-fb01-45d9-9a35-3b487d5527bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68dfdd5-fb01-45d9-9a35-3b487d5527bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b58a3b81-bb47-4d4f-a292-cfebf5083811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b58a3b81-bb47-4d4f-a292-cfebf5083811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f754517e-10a4-4ab9-8065-798a89fbe38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f754517e-10a4-4ab9-8065-798a89fbe38d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d5f43485-6735-4b4d-98f8-65f69575c340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d5f43485-6735-4b4d-98f8-65f69575c340" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:to="loc_us-gaap_FinancialInstrumentAxis_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_342cd856-d4e4-413a-92e3-9894b9c65130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_342cd856-d4e4-413a-92e3-9894b9c65130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_e4068fab-a0a1-48fe-a2f4-dc792993a2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_CommercialPaperMember_e4068fab-a0a1-48fe-a2f4-dc792993a2ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c7d2490d-8133-4639-bbd2-6a4494c34605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c7d2490d-8133-4639-bbd2-6a4494c34605" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be509143-c674-48b3-a910-29251afb1471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be509143-c674-48b3-a910-29251afb1471" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_428d541e-6260-4edc-b888-c0dee020b287" xlink:href="sgmo-20200630.xsd#sgmo_FreeSharesAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_sgmo_FreeSharesAssetMember_428d541e-6260-4edc-b888-c0dee020b287" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended" id="i2ecb398b23e9417899bfa3f1d1936f05_FAIRVALUEMEASUREMENTSNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_9b0a3bea-3271-471a-955a-4e9ea027b09e" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_9b0a3bea-3271-471a-955a-4e9ea027b09e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_a5f9e0d0-a2d9-49b2-a6a4-f7c051883fcf" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_a5f9e0d0-a2d9-49b2-a6a4-f7c051883fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_22d89850-1a3e-4422-8b3d-a56b11731d6e" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_22d89850-1a3e-4422-8b3d-a56b11731d6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_4ff9a66f-92d3-4597-ad4a-cff07f5a25ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_4ff9a66f-92d3-4597-ad4a-cff07f5a25ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ebef7b45-0ea4-471d-a038-4e6ec38964bb" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ebef7b45-0ea4-471d-a038-4e6ec38964bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_320f0e87-9fc6-4606-866a-d07efdb8659f" xlink:href="sgmo-20200630.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_320f0e87-9fc6-4606-866a-d07efdb8659f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionSharesAcquiredValue_adad6a13-32bc-412b-a59a-6cab6ed68040" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionSharesAcquiredValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionSharesAcquiredValue_adad6a13-32bc-412b-a59a-6cab6ed68040" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_593fde0c-e0e6-4910-b86f-c495a74d4d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_593fde0c-e0e6-4910-b86f-c495a74d4d1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2a3fbdb5-301a-4166-ae28-94b7e198a341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2a3fbdb5-301a-4166-ae28-94b7e198a341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a3fbdb5-301a-4166-ae28-94b7e198a341_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a3fbdb5-301a-4166-ae28-94b7e198a341" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a3fbdb5-301a-4166-ae28-94b7e198a341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a3fbdb5-301a-4166-ae28-94b7e198a341" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_eead54c2-94cc-434e-bbc4-cc378607bd44" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:to="loc_sgmo_SangamoFranceMember_eead54c2-94cc-434e-bbc4-cc378607bd44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TxCellSAMember_4d0091ca-fce9-47ab-9b7f-9802ac876125" xlink:href="sgmo-20200630.xsd#sgmo_TxCellSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:to="loc_sgmo_TxCellSAMember_4d0091ca-fce9-47ab-9b7f-9802ac876125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d0b5de07-d8a0-4892-9f2b-c485c55f6981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d0b5de07-d8a0-4892-9f2b-c485c55f6981" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0b5de07-d8a0-4892-9f2b-c485c55f6981_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0b5de07-d8a0-4892-9f2b-c485c55f6981" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0b5de07-d8a0-4892-9f2b-c485c55f6981_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c175a01-f0bb-4847-8b30-f1e59d56fb47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0b5de07-d8a0-4892-9f2b-c485c55f6981" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c175a01-f0bb-4847-8b30-f1e59d56fb47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_ed9ece3d-d943-4ec4-aeb0-b3da789a440e" xlink:href="sgmo-20200630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c175a01-f0bb-4847-8b30-f1e59d56fb47" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_ed9ece3d-d943-4ec4-aeb0-b3da789a440e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_56d31f71-3044-4dc5-86f9-c45ce1bd6de7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:to="loc_srt_StatementScenarioAxis_56d31f71-3044-4dc5-86f9-c45ce1bd6de7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_56d31f71-3044-4dc5-86f9-c45ce1bd6de7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_56d31f71-3044-4dc5-86f9-c45ce1bd6de7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_56d31f71-3044-4dc5-86f9-c45ce1bd6de7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_25d1a5d9-cb1b-497d-b81e-9b1e83ddf745" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_56d31f71-3044-4dc5-86f9-c45ce1bd6de7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_25d1a5d9-cb1b-497d-b81e-9b1e83ddf745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_112933c9-f04b-4200-994f-0763fe16d2c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_25d1a5d9-cb1b-497d-b81e-9b1e83ddf745" xlink:to="loc_srt_ScenarioForecastMember_112933c9-f04b-4200-994f-0763fe16d2c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended" id="i196540cd57ba4674a5bb62c56ca020bb_FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_98c2afac-d885-4bf8-9865-448ef3d166a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_SharePrice_98c2afac-d885-4bf8-9865-448ef3d166a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_59d15418-349b-4aaa-b890-b56a57fa1d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_59d15418-349b-4aaa-b890-b56a57fa1d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_67114644-71bf-4b6b-9804-44b133e3041f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_67114644-71bf-4b6b-9804-44b133e3041f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f387f3a9-f633-45cf-a7c9-61398c6c51a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f387f3a9-f633-45cf-a7c9-61398c6c51a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_42d8b9dc-4330-4a4d-a3b0-2c7c1669ec6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_42d8b9dc-4330-4a4d-a3b0-2c7c1669ec6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60314645-7266-4ccf-a65d-e5235a1d1022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60314645-7266-4ccf-a65d-e5235a1d1022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60314645-7266-4ccf-a65d-e5235a1d1022_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60314645-7266-4ccf-a65d-e5235a1d1022" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_60314645-7266-4ccf-a65d-e5235a1d1022_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fef54670-567d-4f33-b45d-633fc4852aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60314645-7266-4ccf-a65d-e5235a1d1022" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fef54670-567d-4f33-b45d-633fc4852aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_c055d4b7-ea1f-43bf-aea3-a23c0a4e9359" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fef54670-567d-4f33-b45d-633fc4852aad" xlink:to="loc_sgmo_SangamoFranceMember_c055d4b7-ea1f-43bf-aea3-a23c0a4e9359" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_4b742837-5cd9-4ba8-8e9b-dcd351b4c315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_4b742837-5cd9-4ba8-8e9b-dcd351b4c315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_1749878a-2f04-428e-b046-b0726620a297" xlink:href="sgmo-20200630.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_1749878a-2f04-428e-b046-b0726620a297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_c06a6cc1-1850-4174-abba-a955378f9531" xlink:href="sgmo-20200630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_c06a6cc1-1850-4174-abba-a955378f9531" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_df3e27d6-4db4-4464-bca9-33db81220128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_df3e27d6-4db4-4464-bca9-33db81220128" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_5433a595-4484-4ec7-8e84-265634517f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_5433a595-4484-4ec7-8e84-265634517f94" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended" id="if0f6dfc42b96489b96f7ad0e37d5a7a7_CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended" id="ib92f877c565b4904959c0615f93b3250_CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended" id="i888838926f804e4c845fd1006b78a5d5_CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="i10c83f870550405f8c5382341b928701_CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b40d34ca-1e1f-4f11-93fc-3dd979108b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b40d34ca-1e1f-4f11-93fc-3dd979108b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e5329952-497b-4c5b-8e33-d594d03cdd88" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e5329952-497b-4c5b-8e33-d594d03cdd88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_b6400261-c803-4d84-af92-0ea0fdabd8cc" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_b6400261-c803-4d84-af92-0ea0fdabd8cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c9941083-ff60-4d78-a858-ef6c0ac8f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c9941083-ff60-4d78-a858-ef6c0ac8f46b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2a1f7f6-bcf0-4a38-8a15-c1c2a92a62bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2a1f7f6-bcf0-4a38-8a15-c1c2a92a62bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_562382de-6fb8-4d30-8094-a3ad77a9baf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_562382de-6fb8-4d30-8094-a3ad77a9baf1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c3b1939-8741-4f10-aa74-a8a2dd5e3da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c3b1939-8741-4f10-aa74-a8a2dd5e3da7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6772db92-048a-482d-9cf0-a5d3338688bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6772db92-048a-482d-9cf0-a5d3338688bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_dea9d157-543a-4675-9963-b427ea409489" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_dea9d157-543a-4675-9963-b427ea409489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_c0d8fe66-a4c7-4645-bf90-d20eca0f41e7" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_c0d8fe66-a4c7-4645-bf90-d20eca0f41e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_8d6ca2a8-0020-4a30-875d-fe4d99896645" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_8d6ca2a8-0020-4a30-875d-fe4d99896645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_a3511bb5-42ad-4170-afe7-75cae0e6bbab" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_a3511bb5-42ad-4170-afe7-75cae0e6bbab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6c11af6a-406b-4f9c-936d-0ff1199fba37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6c11af6a-406b-4f9c-936d-0ff1199fba37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0280d2dc-6145-44be-9d7b-659f7d980fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6c11af6a-406b-4f9c-936d-0ff1199fba37" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0280d2dc-6145-44be-9d7b-659f7d980fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0280d2dc-6145-44be-9d7b-659f7d980fa8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0280d2dc-6145-44be-9d7b-659f7d980fa8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0280d2dc-6145-44be-9d7b-659f7d980fa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0280d2dc-6145-44be-9d7b-659f7d980fa8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0882dd13-3f25-4f2c-aac8-998d26eb0cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0882dd13-3f25-4f2c-aac8-998d26eb0cd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_da0cbd5d-f055-403f-8cdf-451fb3a103a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_CommercialPaperMember_da0cbd5d-f055-403f-8cdf-451fb3a103a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_c07d5e4d-f660-40ff-a0f9-8f4b00a1d031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_CashEquivalentsMember_c07d5e4d-f660-40ff-a0f9-8f4b00a1d031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_93abd82d-026d-4018-ac2a-cb565385e97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_93abd82d-026d-4018-ac2a-cb565385e97c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2364e23e-5991-43d9-92a0-177d0f3f77b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2364e23e-5991-43d9-92a0-177d0f3f77b5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended" id="i389b5c2226034458822fe72b57507b4b_CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20200630.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended" id="i8539a50568664486a1dfe6189e39bf8d_BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended" id="i94bed9558a9a46b3b6516bcbba48ebf8_BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended" id="id798b8df01824c46897fe5619d276cc9_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended" id="i90373c22bf0546868e8a98b1cd568274_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be1cb6aa-500e-43da-9a82-253ebcd57156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1ea64efc-4332-42c6-9637-8ef1a2be78e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be1cb6aa-500e-43da-9a82-253ebcd57156" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1ea64efc-4332-42c6-9637-8ef1a2be78e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01406a39-3b60-4049-8251-f0cb434b7e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be1cb6aa-500e-43da-9a82-253ebcd57156" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01406a39-3b60-4049-8251-f0cb434b7e99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01406a39-3b60-4049-8251-f0cb434b7e99" xlink:to="loc_srt_CounterpartyNameAxis_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_96ac5a09-b326-41af-9985-2ce90b0c5621" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_BiogenMAIncMember_96ac5a09-b326-41af-9985-2ce90b0c5621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1d37a712-e532-41c7-aef2-7cd9fadbb7c4" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_KitePharmaIncMember_1d37a712-e532-41c7-aef2-7cd9fadbb7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_e767bc55-2b2c-4d8c-bb6e-2a019d6ebc83" xlink:href="sgmo-20200630.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_PfizerSB525Member_e767bc55-2b2c-4d8c-bb6e-2a019d6ebc83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_14f3412f-b314-4c0a-af38-68423aeb0dad" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_PfizerMember_14f3412f-b314-4c0a-af38-68423aeb0dad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_52774316-6005-4a08-b90e-a2a7e8041673" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_SanofiMember_52774316-6005-4a08-b90e-a2a7e8041673" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended" id="i8526e98f525440dfbd0abf72447140f3_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7d081389-1b95-4bae-984c-24955423ecd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7d081389-1b95-4bae-984c-24955423ecd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0e2c81f4-f453-4a68-a529-514971c4e9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0e2c81f4-f453-4a68-a529-514971c4e9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_070ec2e0-2113-4bd2-81f8-07515e83fa89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_070ec2e0-2113-4bd2-81f8-07515e83fa89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_52dc2a81-5b5a-42c6-9969-5d21120c9096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ProceedsFromCollaborators_52dc2a81-5b5a-42c6-9969-5d21120c9096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_fbcfe46a-53eb-45cd-bc7b-8fd5b364a429" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_fbcfe46a-53eb-45cd-bc7b-8fd5b364a429" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_ba7dfc31-ae35-47c3-afae-1def135d7240" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_ba7dfc31-ae35-47c3-afae-1def135d7240" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_119cae4e-b0b1-49b2-a74e-36d80a7ee77d" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_119cae4e-b0b1-49b2-a74e-36d80a7ee77d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0122bed3-aae6-45aa-ad65-783655ca2b6e" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0122bed3-aae6-45aa-ad65-783655ca2b6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_5e3d0fc9-011f-479f-8dbd-49d04e2106d6" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_5e3d0fc9-011f-479f-8dbd-49d04e2106d6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_4a7655bf-16df-47e7-8574-9e9931a17f80" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_4a7655bf-16df-47e7-8574-9e9931a17f80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_4c1473fc-69df-4950-9f3f-cdb3471598bb" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_4c1473fc-69df-4950-9f3f-cdb3471598bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_47d7152d-540f-47bb-bb53-3f9743b1e12d" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_47d7152d-540f-47bb-bb53-3f9743b1e12d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_b8893afa-7aa2-40ff-8526-51cca8c38a99" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_b8893afa-7aa2-40ff-8526-51cca8c38a99" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_33c51e71-2520-4d88-95fc-40f6aa2c2b11" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_33c51e71-2520-4d88-95fc-40f6aa2c2b11" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5053f8a0-fac3-4910-a33a-fb05c68f2661" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5053f8a0-fac3-4910-a33a-fb05c68f2661" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d2e79828-9b97-45c7-a002-826002dc6a25" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d2e79828-9b97-45c7-a002-826002dc6a25" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_2e70cf7b-a782-45ad-851e-0b98bff262f2" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_2e70cf7b-a782-45ad-851e-0b98bff262f2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_1dde5589-882c-415b-a876-84eec6df3780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_1dde5589-882c-415b-a876-84eec6df3780" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_d4bd96e5-4493-4829-9ce8-0b98b5e1a928" xlink:href="sgmo-20200630.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_d4bd96e5-4493-4829-9ce8-0b98b5e1a928" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ae6fa389-47b7-49f4-ba25-9484df1cac21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ae6fa389-47b7-49f4-ba25-9484df1cac21" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_082fe6c0-46a2-4b11-ad5f-fb013d348d58" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_082fe6c0-46a2-4b11-ad5f-fb013d348d58" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_ac316c5e-b815-4dca-9c6a-e5d7abf11cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_DeferredRevenue_ac316c5e-b815-4dca-9c6a-e5d7abf11cc9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_1ca17382-9b3d-44d4-a4db-18803b661933" xlink:href="sgmo-20200630.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_MilestonePaymentsReceived_1ca17382-9b3d-44d4-a4db-18803b661933" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c5dd84a7-a708-430e-bebb-d8268ce2dafa" xlink:href="sgmo-20200630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c5dd84a7-a708-430e-bebb-d8268ce2dafa" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_14441822-f961-4f8d-b1da-04d5afee8837" xlink:href="sgmo-20200630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_14441822-f961-4f8d-b1da-04d5afee8837" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_3633a9aa-ed08-43e0-b80f-d16d13eea01b" xlink:href="sgmo-20200630.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_3633a9aa-ed08-43e0-b80f-d16d13eea01b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_7dc913ee-d6f7-48ed-899f-0677b917915c" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_7dc913ee-d6f7-48ed-899f-0677b917915c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_3fd5863f-a26b-4262-abe4-04dba9e97bd9" xlink:href="sgmo-20200630.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_3fd5863f-a26b-4262-abe4-04dba9e97bd9" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_b5501739-c11a-4709-9485-92bacb745e65" xlink:href="sgmo-20200630.xsd#sgmo_SeparateUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_SeparateUpfrontFee_b5501739-c11a-4709-9485-92bacb745e65" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_6dd3fa6b-626b-41fd-8fe1-f02c0978e279" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_6dd3fa6b-626b-41fd-8fe1-f02c0978e279" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_d3474f14-1b51-4774-acc0-67aa197e4921" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_d3474f14-1b51-4774-acc0-67aa197e4921" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_353255f2-6733-4c89-9371-0b5d64e4f192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_353255f2-6733-4c89-9371-0b5d64e4f192" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ebb85661-8d32-4418-bf53-bdfee9050db0" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ebb85661-8d32-4418-bf53-bdfee9050db0" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_58340f64-99d5-4a0a-8833-853612f4be58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ContractWithCustomerLiability_58340f64-99d5-4a0a-8833-853612f4be58" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_fad1de25-3617-4b4d-8fac-d89bd8f4ef92" xlink:href="sgmo-20200630.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_fad1de25-3617-4b4d-8fac-d89bd8f4ef92" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_8d8bc3f6-1d04-415a-b88b-ea5a97aeccf4" xlink:href="sgmo-20200630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_8d8bc3f6-1d04-415a-b88b-ea5a97aeccf4" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_1c55ee6d-cad4-4d51-a002-e76580100621" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_MilestoneRevenueReceivable_1c55ee6d-cad4-4d51-a002-e76580100621" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_770d9f3c-1a32-4b37-81c1-2ff0f18c70de" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_770d9f3c-1a32-4b37-81c1-2ff0f18c70de" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_7e1b640a-9dff-446c-ad1f-1745ffda8696" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_7e1b640a-9dff-446c-ad1f-1745ffda8696" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_19cccba0-e075-4854-87b4-4cb6b09ca6c2" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_19cccba0-e075-4854-87b4-4cb6b09ca6c2" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_8ac8ae53-867a-45e7-9fff-957b3ee7ab13" xlink:href="sgmo-20200630.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_AgreementTerminationTerm_8ac8ae53-867a-45e7-9fff-957b3ee7ab13" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d53e852e-f50e-4d63-8e87-16c27e883902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d53e852e-f50e-4d63-8e87-16c27e883902" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage_84210049-2115-4f87-ab9c-366226d7f161" xlink:href="sgmo-20200630.xsd#sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage_84210049-2115-4f87-ab9c-366226d7f161" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_b650283b-0740-495d-bd5e-cca1a15cf1b8" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_b650283b-0740-495d-bd5e-cca1a15cf1b8" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_7e7a0695-498f-44f7-8d92-77a028a242c2" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_7e7a0695-498f-44f7-8d92-77a028a242c2" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_11a83a48-631a-4187-a5c7-8f1398bc1a50" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_11a83a48-631a-4187-a5c7-8f1398bc1a50" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b513d193-8beb-4c24-be74-8ad0785c8fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b513d193-8beb-4c24-be74-8ad0785c8fd6" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_b52cf7b0-e16d-47b4-9935-8f0fd121a2a6" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_NumberOfResearchProgram_b52cf7b0-e16d-47b4-9935-8f0fd121a2a6" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_ba77b68e-606d-4c52-9de4-b18fb80f152b" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_ba77b68e-606d-4c52-9de4-b18fb80f152b" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_5f85bd64-576f-4e56-855e-8af8055a7b46" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMilestoneRevenueReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_5f85bd64-576f-4e56-855e-8af8055a7b46" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_bd04de15-59a3-44e5-a88e-655d2d4c7fb8" xlink:href="sgmo-20200630.xsd#sgmo_GrantFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_GrantFundingAmount_bd04de15-59a3-44e5-a88e-655d2d4c7fb8" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1dc45915-42ae-49eb-9ce6-4f8a9a65fc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1dc45915-42ae-49eb-9ce6-4f8a9a65fc06" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_8e28089f-9f1f-421c-8fcf-80d8b2cd0e99" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_8e28089f-9f1f-421c-8fcf-80d8b2cd0e99" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ad53539-8ac1-4d5e-be86-0f58a8663b8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_srt_CounterpartyNameAxis_8ad53539-8ac1-4d5e-be86-0f58a8663b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ad53539-8ac1-4d5e-be86-0f58a8663b8c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8ad53539-8ac1-4d5e-be86-0f58a8663b8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ad53539-8ac1-4d5e-be86-0f58a8663b8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8ad53539-8ac1-4d5e-be86-0f58a8663b8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_a0b0b4aa-4e4a-410c-adeb-88081a8474ae" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_BiogenMAIncMember_a0b0b4aa-4e4a-410c-adeb-88081a8474ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_5a272b84-0ef2-40f3-8157-e639298d9bbf" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_KitePharmaIncMember_5a272b84-0ef2-40f3-8157-e639298d9bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_c9d47268-3f92-4b9f-b7bd-4177903af920" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_PfizerMember_c9d47268-3f92-4b9f-b7bd-4177903af920" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_c06846a4-d2df-481a-a3bc-8b19dfbdc649" xlink:href="sgmo-20200630.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_PfizerSB525Member_c06846a4-d2df-481a-a3bc-8b19dfbdc649" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_0f788973-20b3-4d5a-97c1-ef909e78e1ec" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_SanofiMember_0f788973-20b3-4d5a-97c1-ef909e78e1ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_b9d6887a-8410-44f1-8217-2817b8841561" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_b9d6887a-8410-44f1-8217-2817b8841561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_57a60122-cdf1-4022-b4f9-ed60361d44a3" xlink:href="sgmo-20200630.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:to="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_57a60122-cdf1-4022-b4f9-ed60361d44a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_7fe43c9f-5284-4a3f-9d29-dda0068d1a36" xlink:href="sgmo-20200630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:to="loc_sgmo_StockPurchaseAgreementMember_7fe43c9f-5284-4a3f-9d29-dda0068d1a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_71236735-ecfc-40d8-a8fb-47c74f37548e" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_71236735-ecfc-40d8-a8fb-47c74f37548e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_f52b8597-bd9a-4339-a2f3-96a7d156a09e" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_f52b8597-bd9a-4339-a2f3-96a7d156a09e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_594482e4-4506-4cf4-9393-93d9e809478f" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_594482e4-4506-4cf4-9393-93d9e809478f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dcb8315f-d956-40fb-80f3-8d2b48706882" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dcb8315f-d956-40fb-80f3-8d2b48706882" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_dcbd79a4-09a8-4ada-92ba-92bbc7a2b935" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_dcbd79a4-09a8-4ada-92ba-92bbc7a2b935" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_91d82506-41b2-42b4-b98b-ab9f05b28508" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_91d82506-41b2-42b4-b98b-ab9f05b28508" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_598b19e3-01d8-41f6-be7e-ee211661b185" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_598b19e3-01d8-41f6-be7e-ee211661b185" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_a2831043-477b-46f0-b8d5-6ed901adb6cb" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_a2831043-477b-46f0-b8d5-6ed901adb6cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_fe718b61-9f43-4d54-8539-c2bccc7871be" xlink:href="sgmo-20200630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_fe718b61-9f43-4d54-8539-c2bccc7871be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d690cb8-868b-4d3d-8179-1750e28d4c0e" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d690cb8-868b-4d3d-8179-1750e28d4c0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_7d690cb8-868b-4d3d-8179-1750e28d4c0e_default" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d690cb8-868b-4d3d-8179-1750e28d4c0e" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_7d690cb8-868b-4d3d-8179-1750e28d4c0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d690cb8-868b-4d3d-8179-1750e28d4c0e" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_585c016b-7f61-46bb-b728-5a03dd123c29" xlink:href="sgmo-20200630.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_PreApprovalMilestoneMember_585c016b-7f61-46bb-b728-5a03dd123c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_7942e665-6067-44d4-98ba-fd11f9131a71" xlink:href="sgmo-20200630.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_SalesBasedMilestoneMember_7942e665-6067-44d4-98ba-fd11f9131a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_f0acca2b-c980-4ff6-aa38-fa8ca9c58f44" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_MilestoneTwoMember_f0acca2b-c980-4ff6-aa38-fa8ca9c58f44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_d99bd9fc-810c-44c2-ba02-6ff29627e465" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_MilestoneThreeMember_d99bd9fc-810c-44c2-ba02-6ff29627e465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_7c95b2f2-d71b-478f-81a7-c1b1b224547e" xlink:href="sgmo-20200630.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_7c95b2f2-d71b-478f-81a7-c1b1b224547e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_srt_RangeAxis_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0" xlink:to="loc_srt_RangeMember_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3069a357-99e4-4ce8-be91-e374a93fedec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0" xlink:to="loc_srt_RangeMember_3069a357-99e4-4ce8-be91-e374a93fedec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5bee439c-8c75-4640-b577-37f6d3431ece" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3069a357-99e4-4ce8-be91-e374a93fedec" xlink:to="loc_srt_MaximumMember_5bee439c-8c75-4640-b577-37f6d3431ece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_76976e41-2ebb-412c-8d85-8e6206a6ab67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_srt_ProductOrServiceAxis_76976e41-2ebb-412c-8d85-8e6206a6ab67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_76976e41-2ebb-412c-8d85-8e6206a6ab67_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_76976e41-2ebb-412c-8d85-8e6206a6ab67" xlink:to="loc_srt_ProductsAndServicesDomain_76976e41-2ebb-412c-8d85-8e6206a6ab67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_76976e41-2ebb-412c-8d85-8e6206a6ab67" xlink:to="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_f17fabe8-ebf0-4451-8285-bc0e0b456205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_us-gaap_LicenseAndServiceMember_f17fabe8-ebf0-4451-8285-bc0e0b456205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_60e9dc76-2bc7-426c-a614-95f033118530" xlink:href="sgmo-20200630.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_60e9dc76-2bc7-426c-a614-95f033118530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_b23ffeda-358b-40d4-9ca0-fc68bb942f61" xlink:href="sgmo-20200630.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_SBFiveTwoFiveMember_b23ffeda-358b-40d4-9ca0-fc68bb942f61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_34cbe639-9346-4a41-91f3-4be24767a174" xlink:href="sgmo-20200630.xsd#sgmo_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_OtherProductsMember_34cbe639-9346-4a41-91f3-4be24767a174" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_bf243557-9506-450a-af0d-cac57153ee94" xlink:href="sgmo-20200630.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_CNineORFSevenTwoMember_bf243557-9506-450a-af0d-cac57153ee94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_48a6ad3d-ed7a-47d7-87a0-ffbd1b75499f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_us-gaap_GrantMember_48a6ad3d-ed7a-47d7-87a0-ffbd1b75499f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_0569fcd5-b6dd-48e3-81c2-56fe2c220144" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_MilestoneAchievementMember_0569fcd5-b6dd-48e3-81c2-56fe2c220144" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended" id="ia16b228c314740b0b2e028639eba184f_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8da5a9aa-cb00-4909-872c-3fc0f42e3485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1f536aa-cf47-4b1e-8b41-61ef1068a55b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8da5a9aa-cb00-4909-872c-3fc0f42e3485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1f536aa-cf47-4b1e-8b41-61ef1068a55b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8da5a9aa-cb00-4909-872c-3fc0f42e3485" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c94e001c-3aa3-426b-ba60-b902d8419954" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:to="loc_srt_CounterpartyNameAxis_c94e001c-3aa3-426b-ba60-b902d8419954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c94e001c-3aa3-426b-ba60-b902d8419954_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c94e001c-3aa3-426b-ba60-b902d8419954" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c94e001c-3aa3-426b-ba60-b902d8419954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c94e001c-3aa3-426b-ba60-b902d8419954" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_ada22be4-2cc9-430a-a40a-702a7c57d0ee" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_BiogenMAIncMember_ada22be4-2cc9-430a-a40a-702a7c57d0ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_03d1fc78-e86c-46cb-a9dc-ae510590642d" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_KitePharmaIncMember_03d1fc78-e86c-46cb-a9dc-ae510590642d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_17200c6c-9efa-4aee-9c24-5648ea7093fb" xlink:href="sgmo-20200630.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_PfizerSB525Member_17200c6c-9efa-4aee-9c24-5648ea7093fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_37e8cb79-72be-4a56-b4b1-a9092064c618" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_PfizerMember_37e8cb79-72be-4a56-b4b1-a9092064c618" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_0c525bab-9447-4b96-86b7-2c0ed727f10e" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_SanofiMember_0c525bab-9447-4b96-86b7-2c0ed727f10e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5ff6ca60-a956-4a9c-9920-75da927705c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:to="loc_srt_ProductOrServiceAxis_5ff6ca60-a956-4a9c-9920-75da927705c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ff6ca60-a956-4a9c-9920-75da927705c2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5ff6ca60-a956-4a9c-9920-75da927705c2" xlink:to="loc_srt_ProductsAndServicesDomain_5ff6ca60-a956-4a9c-9920-75da927705c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5ff6ca60-a956-4a9c-9920-75da927705c2" xlink:to="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_01bd35c8-e1d9-40ea-bfdc-bf1b8b4b7ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:to="loc_us-gaap_LicenseAndServiceMember_01bd35c8-e1d9-40ea-bfdc-bf1b8b4b7ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_e1904f54-9ae0-4c61-98ef-a4e281737144" xlink:href="sgmo-20200630.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:to="loc_sgmo_ResearchServicesMember_e1904f54-9ae0-4c61-98ef-a4e281737144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_f8c09a93-c444-4ca2-b4e0-558340793e26" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:to="loc_sgmo_MilestoneAchievementMember_f8c09a93-c444-4ca2-b4e0-558340793e26" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended" id="i9aa782d34dcb45bba6616137c39314ee_INCOMETAXES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="i265dd3a883db46f2bb2c1cea554e624e_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended" id="ia8aaca0d934b49beb0f962161b4b0d2e_COMMITMENTSANDCONTINGENCIESTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="extended" id="i0b088ca5b73d48dea8ec92c60c8f3378_COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:href="sgmo-20200630.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_4a3ad0b1-dada-4bb0-8ff4-f793d0e672ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_4a3ad0b1-dada-4bb0-8ff4-f793d0e672ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_85c0aa81-347e-4a41-880c-e502ad3ad725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_85c0aa81-347e-4a41-880c-e502ad3ad725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2038d1f2-8fc0-4737-8a01-5b9e6485113d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseCost_2038d1f2-8fc0-4737-8a01-5b9e6485113d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0d3f7d16-9e17-43fe-82f0-17b01381d237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_VariableLeaseCost_0d3f7d16-9e17-43fe-82f0-17b01381d237" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4adb2c86-2ec7-4d84-8d90-7f555c944804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeasePayments_4adb2c86-2ec7-4d84-8d90-7f555c944804" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c4859607-0cc6-4bce-b8f6-73362dad525b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c4859607-0cc6-4bce-b8f6-73362dad525b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dc693645-9392-43f7-853f-937102465432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dc693645-9392-43f7-853f-937102465432" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_4f71dfe7-aaf3-4218-adb0-74d0d193c698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OtherCommitment_4f71dfe7-aaf3-4218-adb0-74d0d193c698" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PaymentsForOtherCommitment_0b4a4099-e609-44ec-9ac8-7086455b5c6b" xlink:href="sgmo-20200630.xsd#sgmo_PaymentsForOtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_PaymentsForOtherCommitment_0b4a4099-e609-44ec-9ac8-7086455b5c6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d6951731-7195-4f37-b192-a63cf89fa87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_ContractualObligation_d6951731-7195-4f37-b192-a63cf89fa87e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractualObligationPaidUponExecution_9d3e91d1-c5ea-4796-bcc1-066e808bb399" xlink:href="sgmo-20200630.xsd#sgmo_ContractualObligationPaidUponExecution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_ContractualObligationPaidUponExecution_9d3e91d1-c5ea-4796-bcc1-066e808bb399" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dd506605-b97d-4179-a5a0-490db1a0f2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseLiability_dd506605-b97d-4179-a5a0-490db1a0f2c3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a33dabd-8eea-48b6-bf39-a6e7fd198a48" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a33dabd-8eea-48b6-bf39-a6e7fd198a48" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_65e8e654-ec18-4613-aac1-ebc8960f53d0" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_65e8e654-ec18-4613-aac1-ebc8960f53d0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_ea1d9467-e737-4b6c-8167-6df9a320ced5" xlink:href="sgmo-20200630.xsd#sgmo_LicenseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_LicenseObligations_ea1d9467-e737-4b6c-8167-6df9a320ced5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:href="sgmo-20200630.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_55d10c72-a4a7-4183-9372-5d65f45ec6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_55d10c72-a4a7-4183-9372-5d65f45ec6d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_55d10c72-a4a7-4183-9372-5d65f45ec6d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_55d10c72-a4a7-4183-9372-5d65f45ec6d2" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_55d10c72-a4a7-4183-9372-5d65f45ec6d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_04db9491-2073-4ba6-8f3e-02dc2917b0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_55d10c72-a4a7-4183-9372-5d65f45ec6d2" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_04db9491-2073-4ba6-8f3e-02dc2917b0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_437f86f2-c3ec-46fe-901f-7783e11dfbba" xlink:href="sgmo-20200630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_04db9491-2073-4ba6-8f3e-02dc2917b0bb" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_437f86f2-c3ec-46fe-901f-7783e11dfbba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_031726e4-4662-4ab7-9af4-da8ab044224d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_031726e4-4662-4ab7-9af4-da8ab044224d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_031726e4-4662-4ab7-9af4-da8ab044224d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_031726e4-4662-4ab7-9af4-da8ab044224d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_031726e4-4662-4ab7-9af4-da8ab044224d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_031726e4-4662-4ab7-9af4-da8ab044224d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_510b666a-c0e8-48b1-bbc5-b13c1eda97e9" xlink:href="sgmo-20200630.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_510b666a-c0e8-48b1-bbc5-b13c1eda97e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_c71aa6a1-3acb-4d63-a46f-2a1504e785cf" xlink:href="sgmo-20200630.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_c71aa6a1-3acb-4d63-a46f-2a1504e785cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_15ecabff-5f9f-451f-80df-7cc21e5bb614" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_srt_StatementGeographicalAxis_15ecabff-5f9f-451f-80df-7cc21e5bb614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_15ecabff-5f9f-451f-80df-7cc21e5bb614_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_15ecabff-5f9f-451f-80df-7cc21e5bb614" xlink:to="loc_srt_SegmentGeographicalDomain_15ecabff-5f9f-451f-80df-7cc21e5bb614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_15ecabff-5f9f-451f-80df-7cc21e5bb614" xlink:to="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_db1776c5-3923-40fc-9ba4-9e0fc3856e0c" xlink:href="sgmo-20200630.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_db1776c5-3923-40fc-9ba4-9e0fc3856e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_60f41bc0-0e41-46b8-915e-19a5ed6fe073" xlink:href="sgmo-20200630.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:to="loc_sgmo_RichmondCaliforniaMember_60f41bc0-0e41-46b8-915e-19a5ed6fe073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_0eb2a80a-b439-4775-93e5-687ef898255b" xlink:href="sgmo-20200630.xsd#sgmo_ValbonneFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:to="loc_sgmo_ValbonneFranceMember_0eb2a80a-b439-4775-93e5-687ef898255b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_803740f2-1c68-4440-bb68-a7f06c29e93b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_srt_RangeAxis_803740f2-1c68-4440-bb68-a7f06c29e93b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_803740f2-1c68-4440-bb68-a7f06c29e93b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_803740f2-1c68-4440-bb68-a7f06c29e93b" xlink:to="loc_srt_RangeMember_803740f2-1c68-4440-bb68-a7f06c29e93b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_803740f2-1c68-4440-bb68-a7f06c29e93b" xlink:to="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_361a4e0c-7e00-4749-991a-5ebc7c4aa1ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:to="loc_srt_MinimumMember_361a4e0c-7e00-4749-991a-5ebc7c4aa1ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_67a7cc4e-6a4d-41b8-9c77-361989858d37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:to="loc_srt_MaximumMember_67a7cc4e-6a4d-41b8-9c77-361989858d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_us-gaap_OtherCommitmentsAxis_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4" xlink:to="loc_us-gaap_OtherCommitmentsDomain_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4" xlink:to="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingCapacityMember_947fda66-44d1-4898-8d0e-2d70b2430f35" xlink:href="sgmo-20200630.xsd#sgmo_ManufacturingCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:to="loc_sgmo_ManufacturingCapacityMember_947fda66-44d1-4898-8d0e-2d70b2430f35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingObligationsMember_5e6b56e2-27bb-414b-8ec2-e028d1a29dcd" xlink:href="sgmo-20200630.xsd#sgmo_ManufacturingObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:to="loc_sgmo_ManufacturingObligationsMember_5e6b56e2-27bb-414b-8ec2-e028d1a29dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NonCancelableContractualCommitmentMember_2092c6b9-d949-424d-8e21-073db8c7e07e" xlink:href="sgmo-20200630.xsd#sgmo_NonCancelableContractualCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:to="loc_sgmo_NonCancelableContractualCommitmentMember_2092c6b9-d949-424d-8e21-073db8c7e07e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended" id="i4e98028d10a644678f45ccea7fdec3a4_COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended" id="i3b69ed3119a64ad985352be02c3fd6ad_STOCKBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended" id="i751c202b96df4b22b14a6017a982cf90_STOCKBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended" id="ic8353aecb49f48f98154e6fdd07cabe0_STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a72ad6e3-f995-47a3-981b-830a70a496f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3780d088-e4cc-47fe-84f2-868622588ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a72ad6e3-f995-47a3-981b-830a70a496f6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3780d088-e4cc-47fe-84f2-868622588ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c100ab0-2c1f-4711-926a-5570473e1bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a72ad6e3-f995-47a3-981b-830a70a496f6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c100ab0-2c1f-4711-926a-5570473e1bf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dec2b419-1f14-4df5-a7bc-95b9d3920523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c100ab0-2c1f-4711-926a-5570473e1bf3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dec2b419-1f14-4df5-a7bc-95b9d3920523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dec2b419-1f14-4df5-a7bc-95b9d3920523_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dec2b419-1f14-4df5-a7bc-95b9d3920523" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dec2b419-1f14-4df5-a7bc-95b9d3920523_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dec2b419-1f14-4df5-a7bc-95b9d3920523" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5417bf8a-f074-444b-a5ba-a0ef8f28867c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5417bf8a-f074-444b-a5ba-a0ef8f28867c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7b7d41a2-cd60-42c4-94ef-e8f846142037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7b7d41a2-cd60-42c4-94ef-e8f846142037" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended" id="ifcb62d746b8740aba998c71183677312_STOCKHOLDERSEQUITY"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended" id="ia09e1ede9d8b47f080820b5d0318f8bd_STOCKHOLDERSEQUITYNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8e26a377-e068-4955-bd3d-10373872ed6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8e26a377-e068-4955-bd3d-10373872ed6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_10ee61a6-14ca-4797-bef3-e57c87a3776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_10ee61a6-14ca-4797-bef3-e57c87a3776c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_077e5b9e-8d2c-4190-a482-f50ea9295a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_077e5b9e-8d2c-4190-a482-f50ea9295a6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cb898311-3293-4b49-9678-0acb588aeef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cb898311-3293-4b49-9678-0acb588aeef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9fce542e-a164-42dd-9dbe-7c29f6450d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9fce542e-a164-42dd-9dbe-7c29f6450d90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a816864-0bfb-4516-8dab-373b86884ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a816864-0bfb-4516-8dab-373b86884ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a816864-0bfb-4516-8dab-373b86884ab1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a816864-0bfb-4516-8dab-373b86884ab1" xlink:to="loc_us-gaap_EquityComponentDomain_1a816864-0bfb-4516-8dab-373b86884ab1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b7f6ff54-c761-4309-9a7f-f79a87356099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a816864-0bfb-4516-8dab-373b86884ab1" xlink:to="loc_us-gaap_EquityComponentDomain_b7f6ff54-c761-4309-9a7f-f79a87356099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_594bd389-6883-4738-80a9-59c32438e727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7f6ff54-c761-4309-9a7f-f79a87356099" xlink:to="loc_us-gaap_CommonStockMember_594bd389-6883-4738-80a9-59c32438e727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0695bc6d-2acf-4aa4-a25e-1865dc692bc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:to="loc_srt_CounterpartyNameAxis_0695bc6d-2acf-4aa4-a25e-1865dc692bc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0695bc6d-2acf-4aa4-a25e-1865dc692bc8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0695bc6d-2acf-4aa4-a25e-1865dc692bc8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0695bc6d-2acf-4aa4-a25e-1865dc692bc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f1bf22f-fee6-4397-872a-61508f4b3264" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0695bc6d-2acf-4aa4-a25e-1865dc692bc8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f1bf22f-fee6-4397-872a-61508f4b3264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_df9521d1-bce2-4e5d-b484-ff52dbdc2934" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f1bf22f-fee6-4397-872a-61508f4b3264" xlink:to="loc_sgmo_BiogenMAIncMember_df9521d1-bce2-4e5d-b484-ff52dbdc2934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_41d6e817-cd0a-4f32-99ad-dc33077fcd57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:to="loc_us-gaap_TypeOfArrangementAxis_41d6e817-cd0a-4f32-99ad-dc33077fcd57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41d6e817-cd0a-4f32-99ad-dc33077fcd57_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_41d6e817-cd0a-4f32-99ad-dc33077fcd57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41d6e817-cd0a-4f32-99ad-dc33077fcd57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e0507db-953f-44f0-b5d3-6e7fb459d7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_41d6e817-cd0a-4f32-99ad-dc33077fcd57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e0507db-953f-44f0-b5d3-6e7fb459d7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_12ee05a0-2a6e-4537-841a-494f055a03e4" xlink:href="sgmo-20200630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e0507db-953f-44f0-b5d3-6e7fb459d7d1" xlink:to="loc_sgmo_StockPurchaseAgreementMember_12ee05a0-2a6e-4537-841a-494f055a03e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="extended" id="i0bfd1db437d84170bacf868572f38d57_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="extended" id="i7205e5a65a3747d9a53cabd4745e35ce_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended" id="i21a36ac6b3aa4a2c8d7529ce235fb9cd_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_99d2727f-8b1e-4b5b-b8ca-504458807987" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_99d2727f-8b1e-4b5b-b8ca-504458807987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d4d23d3f-1f2a-497a-8691-855043a7dfb0" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d4d23d3f-1f2a-497a-8691-855043a7dfb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7c280ca3-71af-4912-b4f0-b7fc58f44d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7c280ca3-71af-4912-b4f0-b7fc58f44d23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_001831c7-a73c-484d-9a30-33f2279ec29e" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_001831c7-a73c-484d-9a30-33f2279ec29e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2d55367f-1083-43dd-9579-274b4969122d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2d55367f-1083-43dd-9579-274b4969122d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_9cf07f3c-f0de-4f98-bab7-205bc982d50b" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_9cf07f3c-f0de-4f98-bab7-205bc982d50b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_2e28af25-89d3-4b78-a0d5-9777a872c492" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_2e28af25-89d3-4b78-a0d5-9777a872c492" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_182a57b1-081a-4383-be45-762363a83e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_182a57b1-081a-4383-be45-762363a83e99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3b5ba8e8-c7a3-4ad7-a206-4a949d8a4f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_3b5ba8e8-c7a3-4ad7-a206-4a949d8a4f1d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4fec4739-da41-43d6-8482-6c008186d59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4fec4739-da41-43d6-8482-6c008186d59d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2266a9d5-0b5f-4786-b316-e56e9301102e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2266a9d5-0b5f-4786-b316-e56e9301102e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2266a9d5-0b5f-4786-b316-e56e9301102e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2266a9d5-0b5f-4786-b316-e56e9301102e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2266a9d5-0b5f-4786-b316-e56e9301102e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_001a0a38-e1ec-499c-b4a3-f8ddd41a3ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2266a9d5-0b5f-4786-b316-e56e9301102e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_001a0a38-e1ec-499c-b4a3-f8ddd41a3ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_1807ff60-ce0d-487a-898a-97cce86774fb" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_001a0a38-e1ec-499c-b4a3-f8ddd41a3ef5" xlink:to="loc_sgmo_SangamoFranceMember_1807ff60-ce0d-487a-898a-97cce86774fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6fa57028-9f40-46d8-8c31-ff13066a5ba4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_srt_OwnershipAxis_6fa57028-9f40-46d8-8c31-ff13066a5ba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6fa57028-9f40-46d8-8c31-ff13066a5ba4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6fa57028-9f40-46d8-8c31-ff13066a5ba4" xlink:to="loc_srt_OwnershipDomain_6fa57028-9f40-46d8-8c31-ff13066a5ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2c1312b7-9103-44af-b323-9bef6715f1a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6fa57028-9f40-46d8-8c31-ff13066a5ba4" xlink:to="loc_srt_OwnershipDomain_2c1312b7-9103-44af-b323-9bef6715f1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_ca8baf18-5315-40ba-8dfa-306160fbe19d" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2c1312b7-9103-44af-b323-9bef6715f1a6" xlink:to="loc_sgmo_SangamoFranceMember_ca8baf18-5315-40ba-8dfa-306160fbe19d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ed820e65-d748-4914-affe-f369dbe14f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ed820e65-d748-4914-affe-f369dbe14f4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed820e65-d748-4914-affe-f369dbe14f4e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ed820e65-d748-4914-affe-f369dbe14f4e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed820e65-d748-4914-affe-f369dbe14f4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a6f2d9a-9c9d-4f5e-922e-1ba35a53b27a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ed820e65-d748-4914-affe-f369dbe14f4e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a6f2d9a-9c9d-4f5e-922e-1ba35a53b27a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_68f49731-b122-47a1-a0bb-49f6aff6e966" xlink:href="sgmo-20200630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a6f2d9a-9c9d-4f5e-922e-1ba35a53b27a" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_68f49731-b122-47a1-a0bb-49f6aff6e966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a78eb18c-9b2d-499e-b7a6-3ed2c455d486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a78eb18c-9b2d-499e-b7a6-3ed2c455d486" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a78eb18c-9b2d-499e-b7a6-3ed2c455d486_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a78eb18c-9b2d-499e-b7a6-3ed2c455d486" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a78eb18c-9b2d-499e-b7a6-3ed2c455d486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a2c1ce54-3783-48c1-909e-843d36006418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a78eb18c-9b2d-499e-b7a6-3ed2c455d486" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a2c1ce54-3783-48c1-909e-843d36006418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4c4faf17-bf86-492a-96b9-4d3eb70095f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_a2c1ce54-3783-48c1-909e-843d36006418" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4c4faf17-bf86-492a-96b9-4d3eb70095f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34514e71-5ec0-4e8b-b84e-8b35bc950f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34514e71-5ec0-4e8b-b84e-8b35bc950f83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_34514e71-5ec0-4e8b-b84e-8b35bc950f83_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34514e71-5ec0-4e8b-b84e-8b35bc950f83" xlink:to="loc_us-gaap_RelatedPartyDomain_34514e71-5ec0-4e8b-b84e-8b35bc950f83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_59b29674-0de0-4413-8ebf-3fb9bd6699b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34514e71-5ec0-4e8b-b84e-8b35bc950f83" xlink:to="loc_us-gaap_RelatedPartyDomain_59b29674-0de0-4413-8ebf-3fb9bd6699b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_ea6369fd-49bc-4148-8e62-81355a6746fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_59b29674-0de0-4413-8ebf-3fb9bd6699b9" xlink:to="loc_srt_ExecutiveOfficerMember_ea6369fd-49bc-4148-8e62-81355a6746fd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="extended" id="i636ba947b15f4de98243bb5e9c7f7915_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#SUBSEQUENTEVENTS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="extended" id="ie0e0172721d94abfa81bcd2f10d1c506_SUBSEQUENTEVENTS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#SUBSEQUENTEVENTSAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail" xlink:type="extended" id="ie871b6f500cf44038b7e28fb14cef2a9_SUBSEQUENTEVENTSAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementPeriodOfCollaboration_aa332cf8-98d1-49b7-8cbc-88eb3f0c4f72" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementPeriodOfCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_sgmo_CollaborativeArrangementPeriodOfCollaboration_aa332cf8-98d1-49b7-8cbc-88eb3f0c4f72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration_41dba052-c10f-4d94-94d5-f6d8aaee6601" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration_41dba052-c10f-4d94-94d5-f6d8aaee6601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_eafe881f-81c3-415e-be9a-8d9c00f4b9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_us-gaap_ProceedsFromCollaborators_eafe881f-81c3-415e-be9a-8d9c00f4b9fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_afb6a510-0b00-4d59-8e35-b9b8fc0ac261" xlink:href="sgmo-20200630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_afb6a510-0b00-4d59-8e35-b9b8fc0ac261" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_23b35201-66e7-4875-ad00-e05c0ce6f448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_23b35201-66e7-4875-ad00-e05c0ce6f448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_23b35201-66e7-4875-ad00-e05c0ce6f448_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_23b35201-66e7-4875-ad00-e05c0ce6f448" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_23b35201-66e7-4875-ad00-e05c0ce6f448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6446c9c7-2618-4016-ad3f-f357bdb28a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_23b35201-66e7-4875-ad00-e05c0ce6f448" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6446c9c7-2618-4016-ad3f-f357bdb28a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b006ec0-9842-4ef2-a1be-4602c1f3b21e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6446c9c7-2618-4016-ad3f-f357bdb28a64" xlink:to="loc_us-gaap_SubsequentEventMember_5b006ec0-9842-4ef2-a1be-4602c1f3b21e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_srt_CounterpartyNameAxis_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb297a27-2791-46b8-a35c-e4811a73b974" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb297a27-2791-46b8-a35c-e4811a73b974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d541b42d-7743-4215-87b9-9e0b31d0a6f6" xlink:href="sgmo-20200630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb297a27-2791-46b8-a35c-e4811a73b974" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d541b42d-7743-4215-87b9-9e0b31d0a6f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_edd0edda-f7f5-4378-bb66-57ebc44110c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_edd0edda-f7f5-4378-bb66-57ebc44110c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edd0edda-f7f5-4378-bb66-57ebc44110c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_edd0edda-f7f5-4378-bb66-57ebc44110c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_edd0edda-f7f5-4378-bb66-57ebc44110c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401fcbce-0bff-4aad-808d-6ed8dc94021b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_edd0edda-f7f5-4378-bb66-57ebc44110c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401fcbce-0bff-4aad-808d-6ed8dc94021b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_36d13090-8f24-48ca-b1b5-7b52ca8a59cb" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401fcbce-0bff-4aad-808d-6ed8dc94021b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_36d13090-8f24-48ca-b1b5-7b52ca8a59cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c386754-59e2-4c5e-b0dc-a1f91f8c5660" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_srt_RangeAxis_7c386754-59e2-4c5e-b0dc-a1f91f8c5660" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c386754-59e2-4c5e-b0dc-a1f91f8c5660_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7c386754-59e2-4c5e-b0dc-a1f91f8c5660" xlink:to="loc_srt_RangeMember_7c386754-59e2-4c5e-b0dc-a1f91f8c5660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ded397c-4869-4bf4-ae1d-52787e3ad982" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7c386754-59e2-4c5e-b0dc-a1f91f8c5660" xlink:to="loc_srt_RangeMember_7ded397c-4869-4bf4-ae1d-52787e3ad982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_77b25c5c-cf16-4d65-a41f-49e587eefca5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ded397c-4869-4bf4-ae1d-52787e3ad982" xlink:to="loc_srt_MaximumMember_77b25c5c-cf16-4d65-a41f-49e587eefca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38d2728c-5e2e-4a64-a3d8-35db708dd8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38d2728c-5e2e-4a64-a3d8-35db708dd8e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38d2728c-5e2e-4a64-a3d8-35db708dd8e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38d2728c-5e2e-4a64-a3d8-35db708dd8e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38d2728c-5e2e-4a64-a3d8-35db708dd8e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38d2728c-5e2e-4a64-a3d8-35db708dd8e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45aeac95-a78d-4d6c-a446-72f101a2db04" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45aeac95-a78d-4d6c-a446-72f101a2db04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_28d81a91-eb95-4309-ae37-9d433bf63d76" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_28d81a91-eb95-4309-ae37-9d433bf63d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a360ff52-2fa6-41a0-8ff2-591c0080e242" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_srt_StatementScenarioAxis_a360ff52-2fa6-41a0-8ff2-591c0080e242" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a360ff52-2fa6-41a0-8ff2-591c0080e242_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a360ff52-2fa6-41a0-8ff2-591c0080e242" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a360ff52-2fa6-41a0-8ff2-591c0080e242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_619ec21c-027f-4992-b00b-0b02904c42a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a360ff52-2fa6-41a0-8ff2-591c0080e242" xlink:to="loc_srt_ScenarioUnspecifiedDomain_619ec21c-027f-4992-b00b-0b02904c42a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0b6e3476-da0a-4c97-948e-9ceb88a9e244" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_619ec21c-027f-4992-b00b-0b02904c42a0" xlink:to="loc_srt_ScenarioForecastMember_0b6e3476-da0a-4c97-948e-9ceb88a9e244" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>sgmo-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:025b09b8-2cad-4da1-9d9e-4c6905973d12,g:d4ee88be-e02e-4f39-96cc-71bae86b4889-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_9ddf5f45-c362-4a76-adc9-d7275c9f5f43_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_3a254773-5ef5-45ea-be06-c3a7ba03a73e_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_5272df0b-3b95-4a68-abda-7f8de0a4369a_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9241cff6-405f-445f-8643-af39529e5d7f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_52847b4d-ce2c-4182-bf4d-94d063ce21cd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6e93d34d-c6b0-44c7-8088-36236637e69b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6706687e-51b1-4fa7-9b25-fd24751f9fd7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_58f4761f-d7f3-4e6f-af2c-960b74fd0145_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price Correlation</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:href="sgmo-20200630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:to="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4191bc13-ee82-4229-b572-22cb273fd781_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherProductsMember_dda7c2dd-8fc2-4b4a-9085-fb26553550d5_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_label_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember" xlink:href="sgmo-20200630.xsd#sgmo_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember" xlink:to="lab_sgmo_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_6a39303e-465b-4a10-b62d-1dc71a0d0a0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9ca24c1b-41da-4476-867c-5ed21c3ae615_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_c3402f6b-5aed-498e-b3ce-450aa74594ae_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c46e57fa-737b-4806-811d-e8ea3213d1e6_verboseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_41c35136-af95-43ac-afe0-461f1f9252f7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f5527af2-173e-4a43-9d0a-fbad6a6decd3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e261dbc5-9775-4f56-914a-e520f070208a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_07d7244e-d6ab-42ce-8804-1715f0c7b7b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0c565007-df97-4d09-b1f6-c1a4002441f1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_df941fbb-9189-4586-a186-9c3293ad3662_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_72a9b57b-b4fc-44f6-92c3-1725b47db013_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_3f486f47-4489-430f-90ae-11528b7ab927_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SanofiMember_68d53575-ded4-4304-955a-d88e4e0ca70b_verboseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sgmo_SanofiMember_label_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_documentation_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember" xlink:to="lab_sgmo_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d6ab58de-8d73-4dee-80a9-29a89d9881d0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9a2cd276-5c73-4414-84c0-c14ebf80673c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_42bd715a-2405-4bf0-b2bf-bf1c2bb6efea_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4f19f986-7776-4c2e-a130-5896c73e78b1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_7dea715f-aa4d-4105-9e2f-4a4937634e0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c8d02ce-6665-412b-861f-0d6b509b6ee1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_412672dc-2edf-4fef-9c0b-34851af438a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_474c69e4-b8f9-44de-ba64-42f2fd03550f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ef365eb7-f8f7-4a5f-828d-b2d3cdcf3469_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f51f13d8-49dd-44c0-a33d-9748249a7072_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3bee9335-d289-41a0-b13b-996ccafd3fb1_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments Due After Year Four</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_0f791fb9-5181-4cda-be00-9056f8d4dbc9_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value of the free shares</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_label_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Fair Value Of Free Shares Asset And Liability</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_documentation_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value of free shares asset and liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:href="sgmo-20200630.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:to="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c4b92d54-1cd0-4ec2-8db2-20a45e89347a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4592346a-54ff-4b68-8d84-ac11efee78e7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_394502f3-78fe-4f91-b8bf-c3b479dce1f0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e30085c2-0a96-447e-883f-c22e7ab1a631_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities included net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_98b90382-8720-4707-a9cc-a39699b806d5_terseLabel_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_label_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember" xlink:href="sgmo-20200630.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondCaliforniaMember" xlink:to="lab_sgmo_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7fd14691-bdf2-44fe-ab46-4c5f4c3c5fdd_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_260e2ff5-1305-4f10-a76e-962f56384b63_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:to="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f701411d-6cc2-4ec1-bdd0-d70ffa90c71e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5fb84a4f-2a54-4462-bb49-eeab826dbfd6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_ad2b42c0-2810-4ec5-9bb6-ed787a4f90fe_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_9bad0591-8bdb-4bc5-ad98-6b9aa0816fda_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_31aa9a75-3f33-4354-92e3-4c6c6839fc0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_b019c20a-f041-4bd0-bf43-edcc3af4d1a5_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20200630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d8699496-9539-4745-b1ac-9d038f6bd008_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b8617f83-3a7e-4540-ae18-2a0d3aaa10b8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_0a55123e-d718-4af9-b35b-75cb3be7b7fc_terseLabel_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of additional shares of Sangamo France</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_label_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:href="sgmo-20200630.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:to="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_2f8768b3-14bd-4089-b7b9-aa7a79de3769_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_3d541713-5062-43d5-9f72-aa5fe392a1df_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_7154121a-1e1d-4fa7-a1a5-4a9105812dea_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneThreeMember_dfb55d86-9918-49f7-9ff0-3b2f1b48b31b_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_label_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneThreeMember" xlink:to="lab_sgmo_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1106acc3-bdea-4880-8296-d15708735d81_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_90d33203-9238-4f1a-8a86-826c401c4a2f_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Rate</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember" xlink:href="sgmo-20200630.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputExchangeRateMember" xlink:to="lab_sgmo_MeasurementInputExchangeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_9e127b79-81fd-4ec3-88a6-0f7d04fc5bfc_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_14dfacd6-b9ff-4958-84ba-c212e1b8e04b_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-controlling Interest</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Noncontrolling Interest Table [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of noncontrolling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:href="sgmo-20200630.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:to="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_1889f61d-a1b6-4180-ac47-a59b4537a282_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_7f57b9ee-d9f8-48df-9127-4ca48125dcdb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_4a6858a2-ebed-4d7e-bafb-764298082f12_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_69d82a12-f590-49ab-8904-73f710363d89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8aed9363-967c-4d43-82f7-8646d161ed3b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b22ba5c7-36d9-4cd3-be9f-50f94ddf5546_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efa48e73-7c0d-422a-accf-1723e39c055a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of changes in foreign exchange rates</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_68ddb7c1-dcc5-498d-8e38-e2a5a0d17d64_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f83c74c-a4b7-4a25-aca8-d287d2324d01_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_345d9a79-24bd-408a-a2a8-83ca48410f8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_c344b900-75f7-4e93-8fd1-2bdece8dbb75_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Stock Price (USD) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_9996f243-70d1-4b93-8922-64cccb4a1668_negatedTotalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_8aa300de-a61b-40b0-8036-998a69851509_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_0b9736cb-fde7-4f54-bdc9-d95eb6164448_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income (Loss) Per Share</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income (Loss) Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:to="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4d3f984f-c739-41cf-8fae-331627322a8e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_61bbf278-39eb-4ebd-9ec7-27568b5dd938_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_4890afdc-672b-4945-8d77-b274ecda1ef4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f2e4b493-6ea1-44c7-a23c-3dc128f17c6b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_3b2426b1-22d4-4f1a-b4c5-05ae73086039_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, area of real estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Real Estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:to="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_4209d349-ca96-456f-96c0-69c6e385a920_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Pricing Method</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_80bdf17f-bd4c-4ee9-9e73-01dae3f03c78_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfResearchProgram_47bfa8c1-78df-45a2-b926-45b6c1d59c76_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram" xlink:to="lab_sgmo_NumberOfResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementPeriodOfCollaboration_b21c9fb1-15af-406e-be36-a27c8b7751c9_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementPeriodOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of collaboration</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementPeriodOfCollaboration_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementPeriodOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Of Collaboration</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementPeriodOfCollaboration_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementPeriodOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Period Of Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementPeriodOfCollaboration" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementPeriodOfCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementPeriodOfCollaboration" xlink:to="lab_sgmo_CollaborativeArrangementPeriodOfCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_93d78fa1-f6f0-4d02-9146-ae919da4f0d4_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_cc7630e4-1ded-4c73-b140-3a12f00e9ecf_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_279b3be8-5e16-48a1-893a-5c889c013cc4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5bd2451b-8aa7-4081-864a-e2763c3fd925_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d028d222-c867-4882-9a2d-a8865509fe59_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d3e52853-67c5-4508-a425-de6a7b1b7830_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8de559c1-061f-4c8e-8def-54a3ee04f9fa_verboseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_940db3e7-d8b1-450d-86fa-b57b9b282054_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a125167a-b7cf-4359-9eb7-3f39a1ecd8c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_702f6bc3-35df-4168-b151-b1fdc2ffb16e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2e1e8027-b8d3-4954-896c-60d7ec63220f_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8b51610e-721b-44a5-aa3b-08dc65e11f54_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_412a2c4e-1769-4835-b0ca-77ce650f7b9c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net loss</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:to="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_5c7b3f5b-bcad-446b-8059-5d599b0b8097_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional shares of Sangamo France</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_d05733cd-b543-48e2-827a-fce4b63c683d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional Sangamo France shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_b30f9653-3e60-47be-96ce-5d28e2c4dc07_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_916df668-390c-4315-ad8e-38fe67fd9c0d_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value liability of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Liabilities Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition estimated fair value liabilities of free shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_6b4c3cfd-2379-4117-b36a-93f367c1f6d3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_9d75592a-a1e6-4ea4-9d9c-95e83f6f38eb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_09918aaf-ea8c-452f-99f8-99b02ad49c3a_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20200630.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3381ac00-9cb1-491f-bda1-fa09ab2e9ca6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_bfa4bbe8-f6fa-4dee-8c78-d9bbb89cffc5_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares held by the holders (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Free Shares Held By Holders</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of free shares held by the holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e8eae217-abaf-4881-8574-45e373ec87e9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f5d66d1e-07b5-4306-936e-8f0afd1096b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_1dc8caf7-447b-4a56-b3ee-d9aa374a30e2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d30b562d-26ed-42b4-b5f7-f9b53aeb419e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_9ca98d60-53fe-461a-95ad-8ed4ca8a793e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9046a164-61d0-4d58-ac20-1c6021deec42_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_ca7ecac2-c1ad-421a-b656-410c3d517036_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USD / EUR Exchange Rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1e94cea2-1d88-4ae5-b421-5d3fe05c9f11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb0d7c2d-aa0d-47d4-b170-1872217cb563_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_1a7af0fb-330d-4eb4-939c-f68ec432a451_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_34e435e1-a52a-4af2-9a32-be7ee48fa745_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_09d8c783-45fb-411f-a7e3-7154d16c899c_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of equity interests agreed to acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Percentage Of Equity Interests Agreed To Acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of equity interests agreed to acquire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:to="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b17be2c1-7ecb-48fa-bfdc-e7f3939abd7a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f4219ea1-eb6d-4f28-b22f-bc4a85727bcd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10954ca9-8f37-472a-9ea6-1fc8ef465d9f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_c866c2fd-be05-4d72-aa43-8f668854ff2f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_29d29ec4-4e3d-4453-aa3e-9a6ff172cd4d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_15b3ba3b-20c1-4634-8272-11f3c25cbdee_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e13a30d4-1821-45c7-83f8-c64c5f0833d3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7e1b57cb-4026-4b7f-9275-7a13e459f81c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c9ed4364-6c4f-4ef1-b651-cb87e114b0c4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4d9e1ede-8f7d-4557-ad11-fd26ad1560e5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_71742ef0-f186-4bda-8764-247d043cd04b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_241c8f37-977a-4187-8abb-7acefabacc15_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement, extendable lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_816e3385-240b-42f2-aa97-a729826760e8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_838597d6-99fd-4bb6-9684-bcfb41b3395a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_b44f394a-a0eb-404e-b971-3852d73b61f4_terseLabel_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease One</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_label_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject To Operating Lease One [Member]</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_documentation_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property subject to operating lease one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:href="sgmo-20200630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:to="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f30b150-f560-4264-b255-83fbe55a2df4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionSharesAcquiredValue_5fd3abc7-2542-4f69-b814-98e23cc88db1_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionSharesAcquiredValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares repurchased</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionSharesAcquiredValue_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionSharesAcquiredValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Shares Acquired, Value</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionSharesAcquiredValue_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionSharesAcquiredValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Shares Acquired, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionSharesAcquiredValue" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionSharesAcquiredValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionSharesAcquiredValue" xlink:to="lab_sgmo_BusinessAcquisitionSharesAcquiredValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_690fc07a-a61d-4840-ad07-dd8f6cfbc954_terseLabel_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Collaboration And License Agreement</link:label>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:href="sgmo-20200630.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_22c28a6c-2944-4aee-ab45-988fe6887136_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_010bf03c-ef8c-469d-9682-40f84269a11e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a86fec87-d6d7-4fa8-8717-c23e7101c11f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_53713217-cf0e-402a-9fa3-dcadfc411c29_terseLabel_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone</link:label>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_label_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone [Member]</link:label>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:href="sgmo-20200630.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:to="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_86999d8f-ecbe-4c15-8b35-349be18ef932_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_628323b0-0085-4ee7-bbf8-aebf61e78b8c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a4517135-0cdb-49da-93cd-0f30da494ad9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_da699471-d40d-4c4f-82b7-a84e6be0f12b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_343979ba-60db-41fc-80cf-b167179907cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_656567e7-9fb2-482e-9fa5-0e324d325865_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_de997db8-f900-45b0-bf07-6c0ff0742a56_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1f4e452c-bd6d-4bef-80f4-2e62373b5e3b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e7c2619b-4723-433c-a40e-fd26deae275f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_0d0d9fab-df7c-4365-8117-95a5b5733e42_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_21c73aad-abaa-4058-a458-ed14ef19b4b7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_73429bd9-635f-45b1-92cf-e05a26aa420b_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc. [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20200630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c26b0798-7509-4831-9429-46e7edb54f9b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d3e5083a-def3-4825-85a3-aa73757be646_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1329d900-cdf1-4247-b0b4-f1bb8980ab40_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_c3ff2d51-6389-419c-8cf5-82ade3d02b07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue reduction due to decrease in measure of proportional cumulative performance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_69945e6f-30df-438c-ac92-a079638c0d7f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7e574bd9-3ded-4ca1-98e8-22b3b201bdef_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_2f9c06d7-c4e6-46eb-b4c1-b14d64566163_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_1dd93a1b-7006-43a4-add5-01da75786b51_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_6bd51e9d-1841-4476-9483-cbe71921e3bf_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional product targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:to="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a721e6c6-b80e-42c3-816a-c542a07cf2d8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c8edc19d-c8a8-4ba5-b67a-f384a2f84509_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a8347b27-8282-4145-b035-5cde30b6335e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_4e7c4c4a-c40f-4afc-a452-50666a7e7b1f_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="sgmo-20200630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_facb080d-8075-4c27-a229-031185cee4e9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ad3b1998-b3c6-4c5c-afde-41e75383ade3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d23d4d0c-f0e6-4c2d-8ec0-d0c2f6c8e604_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting provisions, ownership threshold percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_aeaa7e84-0c30-459e-9b33-f29ad856b643_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_f8f16938-6ebb-4e0f-938a-bc2db710d96f_negatedLabel_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other changes in right-of-use assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_label_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_documentation_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:href="sgmo-20200630.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:to="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_783ef0a5-3c29-4028-bfbf-46eae316799c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_efd57aa0-3548-4d72-836b-5215f610e8d3_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d34ad63-b0a9-443d-a322-8b4fe4211800_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0b5357d7-479c-4f06-abbb-de655b2bddf3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_4e10e45c-a758-44e4-9098-fc761461247a_terseLabel_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory [Member]</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and laboratory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember" xlink:href="sgmo-20200630.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeAndLaboratoryMember" xlink:to="lab_sgmo_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PaymentsForOtherCommitment_e72490ab-c7bf-46ce-8954-b75107eb375e_terseLabel_en-US" xlink:label="lab_sgmo_PaymentsForOtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for other commitment</link:label>
    <link:label id="lab_sgmo_PaymentsForOtherCommitment_label_en-US" xlink:label="lab_sgmo_PaymentsForOtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Other Commitment</link:label>
    <link:label id="lab_sgmo_PaymentsForOtherCommitment_documentation_en-US" xlink:label="lab_sgmo_PaymentsForOtherCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PaymentsForOtherCommitment" xlink:href="sgmo-20200630.xsd#sgmo_PaymentsForOtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PaymentsForOtherCommitment" xlink:to="lab_sgmo_PaymentsForOtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_7ae82dcd-8832-4598-80b1-739aa0d57e93_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_87044698-b4e6-489a-81a2-0a37b9bbd72c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:to="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_abd38cd8-7fb8-4fc6-9c84-0d8df7aa750c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fa4fbd16-a338-4649-a128-2efa396ad7ef_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e7934503-d353-4d56-93b1-0512f5a80ade_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2c46b759-f4c5-4269-aa53-8e4772c1dfbb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_b0e029e4-1adb-47cc-bb71-08b9d0df2db4_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target selection period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:to="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_ab9aaea5-3aa2-44a8-85e8-3f1b6623899b_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting provisions expiration period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_49688c31-3475-4d6f-9462-6d24419e989c_terseLabel_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_label_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone [Member]</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember" xlink:href="sgmo-20200630.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreApprovalMilestoneMember" xlink:to="lab_sgmo_PreApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_6632f08d-c364-4033-9676-ab2b90220398_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesMember_e375b9d5-5471-488c-93ca-5c580fe3f4b2_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember" xlink:href="sgmo-20200630.xsd#sgmo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember" xlink:to="lab_sgmo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_efedaf4a-5ab4-462c-8372-8ca6b52a47c7_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_04c8f2af-7a16-4f5e-8094-64a399ef376a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_bba2bbb9-a473-4bbc-9d8c-dcd687a7c119_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of additional shares acquired</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5c3e2f27-2db7-4254-8bfa-37b202f70c60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e95e5fe9-6f42-4737-bec7-c49f941e1f5e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_6f94dc3f-5a26-45e9-8ef3-97dcd28562a0_verboseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares acquired (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_089319f2-bd5e-4921-ba37-f31aeedea79f_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares acquired (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Shares Acquired</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of shares acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FreeSharesAssetMember_e5cc4346-e761-489c-b9fc-dac05a22bd74_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_label_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Asset [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_documentation_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember" xlink:href="sgmo-20200630.xsd#sgmo_FreeSharesAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesAssetMember" xlink:to="lab_sgmo_FreeSharesAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_40216af4-d2a1-4bd3-a6d7-5d08fedbb186_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_75bf91f5-4646-449a-9a5c-5c8ea70a349d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_12bb41dd-7c26-4683-be34-0689ab63fb34_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_16979844-cad7-486d-898c-9073e1a18e72_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a7624cee-b76a-4ebb-971d-f94df99f0e22_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_201b9881-2d31-47e0-b16b-e545a680c23b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage_fa334c81-130e-4625-95db-2da68b0731cd_terseLabel_en-US" xlink:label="lab_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue reduction due to decrease in measure of proportional cumulative performance, percentage</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage_label_en-US" xlink:label="lab_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress, Percentage</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage_documentation_en-US" xlink:label="lab_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" xlink:href="sgmo-20200630.xsd#sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" xlink:to="lab_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bba86f93-6ffd-4c5e-b7bf-79dac5aa1837_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6fe7cadf-9b87-4312-a618-a3430dd4638b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fc9deb7d-30ef-4c3c-b51a-c79a056fae27_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2961e492-9801-4bf7-8d84-9d02e3e84cf7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a83bfd72-9f98-44ed-8c79-6ab10fcb82fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91c991b4-9efd-476b-a8c3-0b763cdb6bc7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_82c4768b-f32f-4f0a-a199-0b3517df8fa9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_33a6c339-f5ed-42e0-a2ec-04cec32ea424_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b8a8e029-37c0-4503-b2a9-2b1405d256b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_73b670d2-dff6-4f9f-b566-8d34ea8df93a_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of space leased (in sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_eeadd255-b0e5-4cf4-bc52-06eafb51a090_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20200630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_551dc735-81a4-4efe-896f-a759074db4cc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fc4a5f69-b553-4f9c-9e35-5fc4a47e4241_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_d9fd93c7-59d0-4d19-b322-38414a4e0c11_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement and Tender Offer Agreement</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement And Tender Offer Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement and tender offer agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:href="sgmo-20200630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:to="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8b1413df-42b1-4db7-a0fe-53bfae7aee21_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_92bb005f-c962-47ca-bde2-119725ecae12_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_e88b6218-5b52-457d-a798-35737bba0913_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Clinical Development and Regulatory Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_50fa2d2a-c0ef-495f-86d6-2239a1dd8561_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_543f6004-6019-41ca-898f-037906fa8206_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess consideration received on transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:href="sgmo-20200630.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:to="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_14d52af4-7c5f-4cec-9d54-8ceb127d25dd_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction, percentage of shares held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:to="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_0848cbe5-c5bc-44da-b0da-78e2eb6626d6_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_28368dc5-32ea-4f35-aa85-a145187ebfd1_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02fc6da3-5e2a-402d-867f-f18cf7d0cb8e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9d84e480-8652-4759-aa49-2e8a8f65809b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_5aea2b27-a0ea-488b-80a4-42d748f76878_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc. [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SeparateUpfrontFee_6b275a19-5f3e-4dd1-8fc8-2d970ae24bef_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee" xlink:href="sgmo-20200630.xsd#sgmo_SeparateUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee" xlink:to="lab_sgmo_SeparateUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_71fd819a-17a5-469a-8880-29a376669e35_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0d8f1864-cd18-4471-86fb-87e4cb9458d9_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c7fe8dfb-7746-42f7-9b8b-d1e952433339_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8aedf894-77a2-4735-8474-3e4fe11db9fc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5f2387dd-c9fa-437e-a341-f53942b77e5e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_af3a02f3-8baa-489b-ad71-05fab22422ea_terseLabel_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</link:label>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</link:label>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="sgmo-20200630.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_db7bc4a4-5694-4a37-8a95-194a95209d81_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares outstanding subject to purchase (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_583ceafd-d143-442f-857b-08d13eb9bb3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GainLossOnFreeShares_cd650d67-2bbc-4e34-8a31-8e32c6dfe5ae_negatedLabel_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on free shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_label_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Free Shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_documentation_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on free shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares" xlink:href="sgmo-20200630.xsd#sgmo_GainLossOnFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GainLossOnFreeShares" xlink:to="lab_sgmo_GainLossOnFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_429b67fc-0a94-467a-aa7e-66f157fd6853_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ba13dde5-3ce4-4ab0-892d-6d77f6eeaf29_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_f2698815-15ed-4a48-80a1-e183f2cbf271_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend initial research term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_label_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_documentation_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:to="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_fb2cd0c6-6bbf-405d-8c82-7989496ebfb0_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_aeec03e7-6a00-49d9-afa2-143df85158fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_225dadb7-9235-4dcb-88c2-238868355fe9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8280dd39-ec2e-49de-8d4f-f90a7e30b12e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_93afd6d3-43a2-4614-b554-cecc0cd6e293_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_fd5e781f-4c9d-4703-8001-27b1e5e4711f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a10aff2e-54fd-4a10-a049-8c62948f2d99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9c14b417-93d0-44a9-853a-298a7b976f5e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_13c43d03-730d-4ba7-98a0-6f8a5c53f3fa_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d034ad7b-a356-4bb1-a82c-7985a9035a5d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_69476d7b-9b3e-4690-942f-8cdc5b821c6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_92e42b50-4a75-4e6a-9676-1a2e1d4d02b6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf3ca64d-2ba9-4031-b488-f05c51514090_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fc7b7fbe-78fe-4939-8655-69cc09b4b048_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration_4e19f7be-fa91-4c40-9aa1-ffe6e0dc74b3_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended period of collaboration</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Extended Period Of Collaboration</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Extended Period Of Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration" xlink:to="lab_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_92ef12ee-579d-4c51-85ca-32be2d0b4075_terseLabel_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember" xlink:href="sgmo-20200630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockPurchaseAgreementMember" xlink:to="lab_sgmo_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d43d8f2d-b124-4a57-826a-394213038a86_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheet)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_8a8a6212-c2fd-49b3-aa85-7f920dd332b6_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_1f174bca-f8a2-4151-be8d-dd24d6045b5c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in revenue</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Revenue</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:to="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_4f62f01f-d2fe-48ea-aebd-d2776d10a6ba_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_bff7a97e-34ae-4dcf-b36a-4502011a4558_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_54bef6e3-4e5f-4d6b-9330-418c32926a9f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_92715fa3-0dcc-48ef-87f6-5c03f17fdf8b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_016374f9-bcec-4e2e-a40a-d278b8b8c912_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_71df6260-e460-48a2-8e36-a3491b70862b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39b34dca-f6d9-4fc1-84cc-5654ff71324a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_565e3531-30f6-49f1-99ad-7a6f61d51119_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_731bbca9-8b4c-42b2-a028-b0fbb8dbd001_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_4c5357f4-7190-45fe-8955-4f41a6646502_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative milestone achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cumulative Milestone Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cumulative Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:to="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_95ef7e8d-f6b2-42c5-a99c-18056921ab4d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_1a46e3c7-48d0-4036-afd7-3425e5133aa2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_18f1b4d7-30e3-4a3e-a50c-82ae9f33de86_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction, ownership threshold percentage ownership percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_07ed68ad-3ca8-40ad-95b5-9e98f746e67f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f1a3ea2d-a8fa-424b-a285-2446aa265bb8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_ee74b1e4-cea5-4efa-b51d-2ba81200e05e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerAndSanofiMember_f306ec0e-afba-4d69-9328-106ad1445a46_terseLabel_en-US" xlink:label="lab_sgmo_PfizerAndSanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and Sanofi</link:label>
    <link:label id="lab_sgmo_PfizerAndSanofiMember_label_en-US" xlink:label="lab_sgmo_PfizerAndSanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_PfizerAndSanofiMember_documentation_en-US" xlink:label="lab_sgmo_PfizerAndSanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerAndSanofiMember" xlink:href="sgmo-20200630.xsd#sgmo_PfizerAndSanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerAndSanofiMember" xlink:to="lab_sgmo_PfizerAndSanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_5fbe4114-5c18-4236-81bc-ce0d7ad01201_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_a25f389d-74f6-4f41-8379-72aa28503b8d_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB-525 and Other Products</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:href="sgmo-20200630.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:to="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e0b52ffd-80e2-4d06-aed1-08c4cf40e23a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2be7ac2d-a463-400d-94b8-1d8f22b0672d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_5e8bfb51-6ad9-4516-8adc-0eeaaa5f2097_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8155fb51-e9fd-46f6-a8e5-874fc329d30f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_4cdc0003-9c25-4c41-b871-a42acfff6039_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e7207a3-dfd1-49ca-a555-89e7342edd64_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_844287dc-b10f-4886-876c-05be4ad6b45a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporarily impaired investments</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_e123af2a-4be5-4a82-a368-caa2394986ff_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_772eb2cd-2db0-4105-b1cb-16b0ac3ff125_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price of common stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_df160e1b-cb07-4fea-b888-e2b177688b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_9db8df9c-28b9-400d-8626-532c9c78d055_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_a08b2459-f0e9-479b-a55b-e117b0c493cb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e451f332-10a6-4138-bacb-98a5fdd90a7a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8b1633dd-cc9d-444e-a5ac-1c8ad25e2d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3663fa6a-fe9f-41ac-ae29-ef2b71c64070_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_d59d77ea-7ecf-4bf5-8771-b6605e187f05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c122d6f3-73c8-44d2-92d8-d4a52713c481_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5348dc81-1b95-4077-a4cf-ee78c66588ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_125bf484-62ad-439d-bb3d-b66872c1931a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ed031e9-7d23-4fc2-883f-c678f270eec9_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ce38044f-a19a-4de4-869b-ec11420f0a40_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f4f18152-9cd7-46aa-976d-c5b0e488be53_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b7a326f5-7d01-4b9b-a633-0365a0823cc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c06f9c49-9f79-418c-b1c8-d0ae7116abc3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c6418725-fc0e-470f-9448-c55deb3b78e2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_21089177-7166-4594-8f3f-706b70ea9d15_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities and free shares asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_942dcd34-f5b0-4fb2-8ab0-8279deaee2b0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_32b855ed-314f-426d-9e6e-786e9e26603c_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs related to public offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5938999d-4828-4875-914c-ef88e72c60d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized portion of equity issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ade6bced-fa89-48c4-a000-a854cb402d6a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_afa17654-2f3b-4bd9-9786-665cae23d4aa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_31550955-3235-4e84-b5d4-9fb55697a8af_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_b4f68a4f-6505-4e17-a2f5-c77963d4acce_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_f6a72114-dc69-4cde-9bfc-4eaa54919021_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_abf243dd-f9f6-4487-8a6f-7b00845eedfc_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Accounting Standards Update, Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3bf50556-94c2-466d-a9dd-407aa60e4627_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3e35d63d-37e0-4aba-bb74-9a9448c4f838_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e81392e7-c33e-42f1-8024-31792460bc12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_dadf3743-736d-4d31-9ae2-2f684758a2b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_d5346dd9-e348-479d-a5d7-26b246a24ba5_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_b769dbd8-eb42-4ffa-bc61-7e8bb2226eaf_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value asset of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Assets Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition estimated fair value assets of free shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_560af34d-b39d-46a1-b126-9cfdd88effc7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_17acac0b-d11d-4132-a050-52971f90cf6b_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Office Space</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_label_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Office Space [Member]</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_documentation_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and office space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:href="sgmo-20200630.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:to="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LicenseObligations_28df4766-2042-4ca9-ad8e-c2018fac27aa_terseLabel_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_label_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_documentation_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations" xlink:href="sgmo-20200630.xsd#sgmo_LicenseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LicenseObligations" xlink:to="lab_sgmo_LicenseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_00fe6a39-f1d7-49a8-a5bd-114d16fd1312_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement" xlink:href="sgmo-20200630.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement" xlink:to="lab_sgmo_InitialResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9d26330c-465a-45df-9ae8-c5c62d52112f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_30795ebd-c118-433b-98d6-39cb857d969a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_00d5adf4-8640-45d1-8cb9-75ae9c33beaf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_630cd534-8410-4f9d-8e0c-e45ded36e5be_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f8b37cfb-883f-4b7c-996e-68cfedb9fbca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_5e653b3a-3f06-4912-946b-e2dc71a5a1f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_e8186e84-1e47-44c7-b19e-49719dddc318_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_000eee7b-a5f4-4541-8a79-e44b5e92ba3e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_aa089d81-d633-4dd9-832d-274759b26a47_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs for new research plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_81ccd0b0-1a07-4334-8a6b-9b72eb0ba9c9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_c95067f0-294c-4d5e-b47e-894537a373aa_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_70425c10-f507-4bec-89ca-3e9ac8fea65b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5d65dc30-6ff5-437f-bfe1-d7a6104bdee4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4e28ae30-2e7b-47e0-b048-e7efdca5c31d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ValbonneFranceMember_eba3dccd-4c06-44fa-929c-b6a0426853de_terseLabel_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_label_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France [Member]</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_documentation_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember" xlink:href="sgmo-20200630.xsd#sgmo_ValbonneFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ValbonneFranceMember" xlink:to="lab_sgmo_ValbonneFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_cf14454f-a9c6-4f19-a4a0-6a0646d366ea_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_68e8b158-1643-43e6-a82a-4392c544e2c3_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_9edaadd4-6ddb-44ef-ac76-1c11545f81a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at June 30, 2020</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_06c2e19f-ba91-4e33-87ab-530bb8a64aec_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_5f7a75a1-ca26-4705-a789-dc89eae5f14a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France Stock Price (EUR) (in euros per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_1f180d6f-28c1-4044-9bbe-dea5937e4aa9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_fbed04ac-2d68-4bd1-a3a1-fdbd9f52a6e3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e1ef8e6-47d9-4849-aa88-d9061c12e996_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1b96158d-ce5e-492d-b71f-9cb0765c2a18_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_85acd97d-369e-4595-9b63-a3cbac23bd0a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4595f329-6f27-48ab-9b5a-bb7d80ce62a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_02c1db72-18ab-47c2-a111-75495435f5e7_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e376f9c2-5445-44fd-81eb-fa3e8aa138cc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payment</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d8e9278c-8c1e-4f6d-bbee-da9183c7a5aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_92865d9b-b70a-4017-83da-80821ac5c42b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_5ad90515-b9c0-46d0-9b46-606fe630e4f4_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_66f113b5-5a14-4fb9-a185-68b6a92f7144_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3f335b27-376d-4b31-a3b7-a4f7cfc8336f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_925ba96a-d04a-4d0e-9078-9c1c8aeded73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ea0489e9-acd8-417f-a241-87faf76febe4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sangamo Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ce143575-dd19-4f64-9409-c49f895a64ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_12c3d199-1d1c-4f06-a358-e101d626d6e8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SangamoFranceMember_45448a47-8c14-423e-b5c4-e235e64d2488_terseLabel_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_label_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France [Member]</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_documentation_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SangamoFranceMember" xlink:to="lab_sgmo_SangamoFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_09305e58-c54f-4afd-af8e-7f9f79fc7b24_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ced7072-1423-4f9c-a16f-147e5bf8cc9b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7373e34d-714e-4325-9abe-55574436f275_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_6012956b-1bb9-4fe4-95e1-448e9c6fa4ff_terseLabel_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute For Regenerative Medicine Agreement</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_label_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute For Regenerative Medicine Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California institute for regenerative medicine agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:href="sgmo-20200630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:to="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cdd510f9-b6fa-4c92-915a-5c93cfbc9e69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_b0588b7d-26bb-4854-a18e-ef29bee63205_terseLabel_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_label_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California [Member]</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember" xlink:href="sgmo-20200630.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrisbaneCaliforniaMember" xlink:to="lab_sgmo_BrisbaneCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_0b7bc3c8-caf2-4e5a-b104-602a77a4fdd1_verboseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20200630.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2140c55d-6d45-4208-b3b8-d8a8b52fcf53_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3cae3bb4-0823-42d0-9ead-ec9a6cc59efa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1db1b02b-d265-4b0e-bf25-4c6541028493_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_dcbfa766-74b2-4437-8abc-12099ebf2dd8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb5ea360-96b9-48a2-84f4-6c2c40ac20b4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_689d6d84-411f-489a-be07-2adcd1694f52_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration Agreement Scope</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_label_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_documentation_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:href="sgmo-20200630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:to="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_f70396ee-eb9f-400b-aa62-fb59444313be_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e66960ca-eee3-4b1e-8df1-6d7d8b61195c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4bf5b256-22c0-42f7-b4bc-f3047ab77a26_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_296924b9-8a35-4c15-90eb-908d744d9903_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f4d45a2f-80e1-4f4d-97ef-f04bdcff91bf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_3f197a49-a1eb-4f11-969f-3cfa9a760a50_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_af279a9d-879d-4485-bacc-49be79727c06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_87f3c483-f45a-4457-860c-dc66faa779e9_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ee32674b-0491-42db-8a2a-fb0cbdaa303b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_28527328-9306-4fd4-9eea-f150a436f555_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_243cbbe7-c625-4281-9e91-cdfb306d13d0_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:to="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bb2498da-40b0-40f8-bd46-54dff5cd9781_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_02e7a5d1-1ed8-4a76-85a2-18018b226027_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development - and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:href="sgmo-20200630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_3bbacea6-c8ea-4b9e-bb4c-225018d3f2c9_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8b5183fd-cc5b-4172-80e2-1b8a242be206_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_616bf762-5f9d-42ba-9980-653c93772ff2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fbb97dcd-e69b-41fc-a0a2-3b8a42307ba2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_96fff456-f796-480c-87bd-a838ceb43098_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six months ending December 31, 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GrantFundingAmount_3c26b7a6-031e-4f7c-9453-f6949c8e1d6c_terseLabel_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds due under the agreement</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_label_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Amount</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_documentation_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount" xlink:href="sgmo-20200630.xsd#sgmo_GrantFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GrantFundingAmount" xlink:to="lab_sgmo_GrantFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_67fe7a3e-9b3d-4dff-b6e4-42ccf9f1682c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_23015e48-6eef-47e4-9d49-3404e979aca6_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_44d0abb7-6939-4083-8caa-c526dfa8f944_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7e948560-c834-48c1-9b7d-5733525d989a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c085acea-5cb7-47bc-be20-58521b051d37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_23e8ad75-3606-42f7-93a4-c666c66f0390_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7f6d96e8-5a7e-4796-b078-4b4e252f44bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneTwoMember_a39689d9-bfab-44ce-aa8b-e5d22c609249_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_label_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneTwoMember" xlink:to="lab_sgmo_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b4c2632f-6e86-40a0-80b3-0b4e07cb3cf9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_5a197583-4567-491b-9805-1bf99dbe0e4e_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in long-term portion of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:href="sgmo-20200630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:to="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_27bd631a-88a9-4c61-addb-82250a34b56d_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_5b9088da-f0ce-4a3e-994f-e058c7a40a15_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_743cd1e2-8861-4001-90a8-97940b617b14_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NonCancelableContractualCommitmentMember_7b2c285d-09da-47a2-97a9-eb5162164b71_terseLabel_en-US" xlink:label="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable Contractual Commitment [Member]</link:label>
    <link:label id="lab_sgmo_NonCancelableContractualCommitmentMember_label_en-US" xlink:label="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable Contractual Commitment [Member]</link:label>
    <link:label id="lab_sgmo_NonCancelableContractualCommitmentMember_documentation_en-US" xlink:label="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable Contractual Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NonCancelableContractualCommitmentMember" xlink:href="sgmo-20200630.xsd#sgmo_NonCancelableContractualCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NonCancelableContractualCommitmentMember" xlink:to="lab_sgmo_NonCancelableContractualCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_eb18d9ae-584d-4428-9219-f11279905940_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable" xlink:href="sgmo-20200630.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable" xlink:to="lab_sgmo_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_835f221c-2af1-4fd4-b84b-d4c3b00d7ff0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_27430234-5bdf-4522-bedb-4772f592e865_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_138ef375-3c59-43f3-920a-7a499e0a502a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_80079827-8824-4178-a229-ec8f26b90cd1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c95700c0-bc01-4177-ace6-f3b7e68c1fa5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1dddf058-ec17-4210-b89a-928909513eaf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1b42ed1e-3727-4aeb-a053-e32dea2bf49a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized under Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_90586118-894d-4f1c-b440-7c3b34957852_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_3a2d7886-12d4-4759-9156-02bdf4313eef_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_99c4b839-93c9-4b40-8c63-2c7ad6a6366a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_5b6983c6-a8c9-4ee0-9109-f486a6f9da4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_83f5be7b-4488-4226-b707-27c2037f11d5_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20200630.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_83239837-0a63-478c-b7aa-f1e383fc3a5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_cb3b5729-84e4-4c16-804c-d6fd204e8c16_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5d85920b-637f-4dd1-82b9-49be4dc462a9_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_3c7194ee-cf8f-48ae-992e-c558e1cb9557_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_e6f68be9-29d5-44ad-a832-d173470cb746_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_83733fe5-ef96-493d-87a9-3777641e67d4_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:href="sgmo-20200630.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:to="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_9cc4cb6e-805b-4c95-ad2c-ddf13d76a984_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_73ccc476-4201-481e-a995-ca00b631f0c0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_af8fb622-05be-40b6-9f0a-ebc1399c2467_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7f73b056-8e76-4f98-83af-2738c9f0fad1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_689733d3-6c90-4f88-95c3-040069525f0e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_1e0fc8c1-d23c-495a-bf1f-33691a2b345b_verboseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_ba28ff00-0ba9-4f94-b64c-c8d6719af0f1_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_603bf9ee-d0d3-4544-936b-3050b65bc239_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bb966d66-f470-4cf6-9892-b8280a24dc1a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_03458040-59d2-4dc6-a12a-bdcc4c2ca69f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_02d4de67-87f0-42be-8ca1-c9ca6345fb56_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32baacd7-402a-45e1-bedb-0f4a2f9d1490_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_51a2cdc2-1b50-483d-9da8-dc289fa1442c_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_d5491063-c226-401e-9377-e03d2b4e0674_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of product targets replaced</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:to="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_f0dc2dcc-53c3-419c-9492-109e95a7d71d_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_d6ab7fa2-0ade-486f-bf47-ca732dd85ab2_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:to="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c0f159c-a717-41fe-9893-c8245ccb1d4b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f45fe917-0cfb-4eb7-9196-9eb8f92c413f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e391f34d-a477-40e7-926c-ab2f68ed87a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_658b90b7-6d0f-4afb-8679-2308742ed909_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_982dbbc3-fe2c-4753-9489-5b0a06b99d16_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_76315541-f478-44ae-94d4-99bf411b535f_terseLabel_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone [Member]</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember" xlink:href="sgmo-20200630.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SalesBasedMilestoneMember" xlink:to="lab_sgmo_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4110a161-beac-4506-8f98-d75157dea5e1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_e0266428-b4f2-4c4b-9ff1-ebca1f875687_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20200630.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af59eb83-17b7-4736-a8fb-1442e0a88de0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7985a788-e817-4862-a1f2-f96153f2b7b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d814a538-267b-4fb9-b03f-eee1c8c397e2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_9696f04a-bfa0-4824-abd2-7570a1e4330b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_1e1e26a5-c1d2-458f-9411-4c30f62c505b_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ManufacturingObligationsMember_1f40710c-e3e0-41ad-8744-fd58bbb4b364_terseLabel_en-US" xlink:label="lab_sgmo_ManufacturingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Obligations [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingObligationsMember_label_en-US" xlink:label="lab_sgmo_ManufacturingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Obligations [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingObligationsMember_documentation_en-US" xlink:label="lab_sgmo_ManufacturingObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingObligationsMember" xlink:href="sgmo-20200630.xsd#sgmo_ManufacturingObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ManufacturingObligationsMember" xlink:to="lab_sgmo_ManufacturingObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_8d3b0f40-89bb-4906-8e36-ebbef0d3c048_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, equity issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementEquityIssued" xlink:to="lab_sgmo_CollaborationAgreementEquityIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_6edecb70-0857-4332-9649-078d41340037_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_d5163bff-082e-401b-95bc-36d253bfa583_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d67047e5-ced6-4e62-8fdc-add5c42eb624_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Correlation Sangamo and Sangamo France Stock Prices</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_10e5808d-3838-484c-bd01-5a7bf1bc750d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_e03c4b24-2b85-4082-9a9c-8a417f8cb151_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others, cumulative compensation earned</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_label_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_documentation_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:href="sgmo-20200630.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:to="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_bc9c5b1f-ccad-4fa0-94fe-2eafb50d1e02_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_91c38b7b-8fcf-4243-a028-2a06937de9d5_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_3f4b8248-46c6-4508-91eb-e65fc0fd1c07_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB-525</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB five two five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember" xlink:href="sgmo-20200630.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveMember" xlink:to="lab_sgmo_SBFiveTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7e984345-46e7-4dc5-8d04-d005890c695b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f4f45811-3e97-44ed-90f8-1c55e3f86c1c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_854830f6-f31e-4700-a899-dab7373101fb_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_de7046ce-2369-45e3-9646-116c2752e916_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="sgmo-20200630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_27177695-1d6d-41e8-9edb-0958a2df5330_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8ca1d520-8eee-4aeb-8cc2-0d49357842e2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_051bb3b5-aa21-4b45-841e-3075a7b615d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5241dc30-0be6-4d76-9b15-3e3b5403310b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b8f90c89-d46d-4476-b11c-181714278c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_TxCellSAMember_26cd91ac-9875-4a45-92b8-e2ecc949d646_terseLabel_en-US" xlink:label="lab_sgmo_TxCellSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tx Cell S A [Member]</link:label>
    <link:label id="lab_sgmo_TxCellSAMember_label_en-US" xlink:label="lab_sgmo_TxCellSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tx Cell S A [Member]</link:label>
    <link:label id="lab_sgmo_TxCellSAMember_documentation_en-US" xlink:label="lab_sgmo_TxCellSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TxCell S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TxCellSAMember" xlink:href="sgmo-20200630.xsd#sgmo_TxCellSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_TxCellSAMember" xlink:to="lab_sgmo_TxCellSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractualObligationPaidUponExecution_1b11811a-b0c8-41e2-ae54-a206c756ac45_terseLabel_en-US" xlink:label="lab_sgmo_ContractualObligationPaidUponExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation paid upon execution</link:label>
    <link:label id="lab_sgmo_ContractualObligationPaidUponExecution_label_en-US" xlink:label="lab_sgmo_ContractualObligationPaidUponExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation Paid Upon Execution</link:label>
    <link:label id="lab_sgmo_ContractualObligationPaidUponExecution_documentation_en-US" xlink:label="lab_sgmo_ContractualObligationPaidUponExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation Paid Upon Execution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractualObligationPaidUponExecution" xlink:href="sgmo-20200630.xsd#sgmo_ContractualObligationPaidUponExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractualObligationPaidUponExecution" xlink:to="lab_sgmo_ContractualObligationPaidUponExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_92e7aaa7-ae97-4b84-a592-66644b5f015d_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20200630.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fe85496d-bbf5-45d6-8f0f-dd3b02802758_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6dfa192a-f735-4b7d-a3a9-01aed0eec95f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_ca2dac8c-0d83-4da9-912b-f2086772ed9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneAchievementMember_3d62d41e-23ff-4c3b-986c-7c9fa9e80ef4_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_label_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneAchievementMember" xlink:to="lab_sgmo_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d8fe23be-79cc-4687-b543-8f2795af2561_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal_c1227c02-5886-4b17-ae1d-be49eb9db299_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue reversal</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Revenue Reversal</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Revenue Reversal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMilestoneRevenueReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:to="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_198204ba-f3e8-4c50-b640-50b012b511d3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of contract asset recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9649de14-d630-4292-8cc8-532437b48337_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIC AND DILUTED NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba9f1c63-b9d5-43d4-8c0f-f102e7186a7b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_f214b110-c4e5-4cca-80be-46d3d1dd587c_terseLabel_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended research term of agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:href="sgmo-20200630.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:to="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_02e34020-20e5-4ba4-b0c4-beb8d4f94356_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1adc7b5c-5502-4853-a65a-86be0abb4b1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7060b1c2-edf5-48ec-a7ca-abe97b4edc55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e31a3732-de49-4bbd-a680-88baf4682ec9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_25ce9e8e-dde0-42af-b230-7b3d80614441_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of initial recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:to="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7106b7a2-2705-4ba8-9fba-e592c8e94ad8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ManufacturingCapacityMember_ad1574c0-d91d-4baa-a165-0fbf8de43272_terseLabel_en-US" xlink:label="lab_sgmo_ManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Capacity [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingCapacityMember_label_en-US" xlink:label="lab_sgmo_ManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Capacity [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingCapacityMember_documentation_en-US" xlink:label="lab_sgmo_ManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingCapacityMember" xlink:href="sgmo-20200630.xsd#sgmo_ManufacturingCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ManufacturingCapacityMember" xlink:to="lab_sgmo_ManufacturingCapacityMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>sgmo-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:025b09b8-2cad-4da1-9d9e-4c6905973d12,g:d4ee88be-e02e-4f39-96cc-71bae86b4889-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20200630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6c22114f-acbf-4f83-a062-3bd38a22f113" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_DocumentType_6c22114f-acbf-4f83-a062-3bd38a22f113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0312e331-8cc3-48fe-ad47-be4049707cd9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_DocumentQuarterlyReport_0312e331-8cc3-48fe-ad47-be4049707cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_90c96bbe-b6f9-497a-a8d9-968b4a9e59ec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_DocumentPeriodEndDate_90c96bbe-b6f9-497a-a8d9-968b4a9e59ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_cb5c6cff-6cf7-4817-80ca-521585d8ff1c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_DocumentTransitionReport_cb5c6cff-6cf7-4817-80ca-521585d8ff1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ae791aaf-db54-4ad6-aff9-b9d2c0c2d2fd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityFileNumber_ae791aaf-db54-4ad6-aff9-b9d2c0c2d2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_22acd7a4-1571-4d5d-8cb0-cccdfe9df48f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityRegistrantName_22acd7a4-1571-4d5d-8cb0-cccdfe9df48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ba51e618-e7ff-419a-9f68-04a10a20c3d8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ba51e618-e7ff-419a-9f68-04a10a20c3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b662340c-a9dd-4fdd-a4b9-5e9cf9868637" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityTaxIdentificationNumber_b662340c-a9dd-4fdd-a4b9-5e9cf9868637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_77a49636-d5c0-4821-ba9c-e29957f8b58a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityAddressAddressLine1_77a49636-d5c0-4821-ba9c-e29957f8b58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c3551a3d-b033-4e21-a857-c40a0605bf5a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityAddressCityOrTown_c3551a3d-b033-4e21-a857-c40a0605bf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_243b9a41-926b-435a-8bcd-95ad94b911b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityAddressStateOrProvince_243b9a41-926b-435a-8bcd-95ad94b911b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3742dfe2-6024-4a43-b99f-70a182a9f5ce" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityAddressPostalZipCode_3742dfe2-6024-4a43-b99f-70a182a9f5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7c3cc150-458c-45f7-845a-5bcac6493a80" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_CityAreaCode_7c3cc150-458c-45f7-845a-5bcac6493a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_68c3c53a-6c98-42ab-a8fc-46602443db34" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_LocalPhoneNumber_68c3c53a-6c98-42ab-a8fc-46602443db34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bc7ebdd4-17e8-4c70-a309-dac444809883" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_Security12bTitle_bc7ebdd4-17e8-4c70-a309-dac444809883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2b4788ae-05c9-4bdf-b36d-9c4baf421281" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_TradingSymbol_2b4788ae-05c9-4bdf-b36d-9c4baf421281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b1578757-3456-4f50-91c5-4bd036b114e9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_SecurityExchangeName_b1578757-3456-4f50-91c5-4bd036b114e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ec094e23-7374-4a79-9ac0-661d774cc8d4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityCurrentReportingStatus_ec094e23-7374-4a79-9ac0-661d774cc8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7dc8e940-b5e4-40fb-99c7-2d260fbd4ff0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityInteractiveDataCurrent_7dc8e940-b5e4-40fb-99c7-2d260fbd4ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_657b5f16-784d-4ca0-8ef4-ac55d08125dd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityFilerCategory_657b5f16-784d-4ca0-8ef4-ac55d08125dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7916818c-090f-4345-998e-221fa47c6f5e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntitySmallBusiness_7916818c-090f-4345-998e-221fa47c6f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_decf32e0-d69b-487e-9d90-319b07733ded" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityEmergingGrowthCompany_decf32e0-d69b-487e-9d90-319b07733ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_eca0547a-f521-4794-9211-75bc27ce1cfa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityShellCompany_eca0547a-f521-4794-9211-75bc27ce1cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cedbeb8c-d5de-4666-98c4-3b07fe2ce28a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cedbeb8c-d5de-4666-98c4-3b07fe2ce28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b4f11dc9-a96d-489f-b972-4574be6fab32" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_AmendmentFlag_b4f11dc9-a96d-489f-b972-4574be6fab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_48d170b5-3d88-46e1-9c58-c6a126133ecc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_DocumentFiscalYearFocus_48d170b5-3d88-46e1-9c58-c6a126133ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7e9dcecf-514e-40ad-a50a-624022e3f9c7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7e9dcecf-514e-40ad-a50a-624022e3f9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_207538bb-c2b1-42ee-a1fa-87fe107163c6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_EntityCentralIndexKey_207538bb-c2b1-42ee-a1fa-87fe107163c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6049c470-5360-4579-9300-d86b7386bfe3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42cf83c6-8cb5-46e7-a338-c15064b7352d" xlink:to="loc_dei_CurrentFiscalYearEndDate_6049c470-5360-4579-9300-d86b7386bfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d3591470-d22c-45db-aff7-6dbbb55368f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d3591470-d22c-45db-aff7-6dbbb55368f6" xlink:to="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f5282e6-d81c-4253-b7c8-f6444e3938e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f5282e6-d81c-4253-b7c8-f6444e3938e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_063d2420-7206-4279-b61a-cacbe841610b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_063d2420-7206-4279-b61a-cacbe841610b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_2d90773a-b675-4735-8762-12b67bbd355e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:to="loc_us-gaap_InterestReceivableCurrent_2d90773a-b675-4735-8762-12b67bbd355e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c7378fad-7847-403d-9b02-a0114887e308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c7378fad-7847-403d-9b02-a0114887e308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2678f117-d18c-4c62-ac73-ae402aa08b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2678f117-d18c-4c62-ac73-ae402aa08b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3330d1a0-2329-4ce5-8dee-cb4fb523b894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0180e591-2e56-4e50-ab6a-b62772d122a0" xlink:to="loc_us-gaap_AssetsCurrent_3330d1a0-2329-4ce5-8dee-cb4fb523b894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_27944a88-e141-4fa4-840b-de94f146705a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_27944a88-e141-4fa4-840b-de94f146705a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4a343ea0-30d0-4408-ac0d-c81c50988e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4a343ea0-30d0-4408-ac0d-c81c50988e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f53d7a2e-b4c9-4244-b6fb-3936e37a2d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f53d7a2e-b4c9-4244-b6fb-3936e37a2d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a1c23f28-fc87-42d9-942e-5336e55b3561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_Goodwill_a1c23f28-fc87-42d9-942e-5336e55b3561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1058056-8779-4982-b11a-fcaefc5f11b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1058056-8779-4982-b11a-fcaefc5f11b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c3cd5921-9105-430f-80a3-111ca9f0b3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c3cd5921-9105-430f-80a3-111ca9f0b3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_afdcbf5c-e1ff-43c3-a337-cc5c8f1521b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_afdcbf5c-e1ff-43c3-a337-cc5c8f1521b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b5a16762-f610-4171-b161-3a5716b1bf59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d43ee843-7f18-43ed-9077-f734a2997580" xlink:to="loc_us-gaap_Assets_b5a16762-f610-4171-b161-3a5716b1bf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d3591470-d22c-45db-aff7-6dbbb55368f6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14940823-4816-4ac7-b295-5d84def0d184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14940823-4816-4ac7-b295-5d84def0d184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5865777c-f32b-4e34-af6f-4806cce9488a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14940823-4816-4ac7-b295-5d84def0d184" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5865777c-f32b-4e34-af6f-4806cce9488a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e84de151-ce8c-45c6-89c3-45ac24334ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14940823-4816-4ac7-b295-5d84def0d184" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e84de151-ce8c-45c6-89c3-45ac24334ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_19cbda4c-2ce1-444d-a15c-658e668fea79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14940823-4816-4ac7-b295-5d84def0d184" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_19cbda4c-2ce1-444d-a15c-658e668fea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0f52ffc6-5f42-42bb-b3e9-c3509a46461f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14940823-4816-4ac7-b295-5d84def0d184" xlink:to="loc_us-gaap_LiabilitiesCurrent_0f52ffc6-5f42-42bb-b3e9-c3509a46461f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cff27d3e-77b9-474d-9da5-6448cbc9c0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cff27d3e-77b9-474d-9da5-6448cbc9c0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_360d6c8a-b82d-413b-9e35-b6683b93a9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_360d6c8a-b82d-413b-9e35-b6683b93a9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c923d6b2-8916-4628-a16a-2171cb416af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c923d6b2-8916-4628-a16a-2171cb416af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_aaf9f6f3-1e43-4e1c-ac6b-11ecda3a620f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_aaf9f6f3-1e43-4e1c-ac6b-11ecda3a620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c359f757-6db0-4499-86b7-efa82056c9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_Liabilities_c359f757-6db0-4499-86b7-efa82056c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5fa7ccd4-4c35-4de6-89fd-beb94d143937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5fa7ccd4-4c35-4de6-89fd-beb94d143937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_580a2af4-b772-4361-8655-6a068f7279b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_PreferredStockValue_580a2af4-b772-4361-8655-6a068f7279b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6bb3b5f6-e5c5-40ae-ba73-b06042e74907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_CommonStockValue_6bb3b5f6-e5c5-40ae-ba73-b06042e74907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0b834afe-96db-4677-9a1c-eedb84a42d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0b834afe-96db-4677-9a1c-eedb84a42d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b140a20d-2498-426c-8578-e1ad9eb216bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b140a20d-2498-426c-8578-e1ad9eb216bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1a1d0a14-6a35-47e2-a7ee-7e947aaa9375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1a1d0a14-6a35-47e2-a7ee-7e947aaa9375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2d9a8f5-f6c7-426f-b95f-90cf1776db29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_StockholdersEquity_d2d9a8f5-f6c7-426f-b95f-90cf1776db29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a376e97f-bab4-43a0-9194-1159937bfee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_MinorityInterest_a376e97f-bab4-43a0-9194-1159937bfee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10b7790f-2bb1-4218-a72a-a322a77ac1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0ac99050-a38a-4f05-bb20-c41bb7c79b39" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10b7790f-2bb1-4218-a72a-a322a77ac1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_01827aa7-660f-46ab-8739-3974f441602d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ef226bf-9aac-4334-b150-48850b1a07f0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_01827aa7-660f-46ab-8739-3974f441602d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6fc47cc-e1d1-477e-86f9-0ded8689a648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6fc47cc-e1d1-477e-86f9-0ded8689a648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9fb55c90-419e-4e99-8c16-c08d48f4d8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9fb55c90-419e-4e99-8c16-c08d48f4d8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_77c6e512-720a-459a-9bb6-0d0990bb6c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9fb55c90-419e-4e99-8c16-c08d48f4d8d6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_77c6e512-720a-459a-9bb6-0d0990bb6c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_13ac608a-1428-430e-9510-29192dbe28e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9fb55c90-419e-4e99-8c16-c08d48f4d8d6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_13ac608a-1428-430e-9510-29192dbe28e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3921a12d-fd0b-48e7-9e2d-e48ac9580645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9fb55c90-419e-4e99-8c16-c08d48f4d8d6" xlink:to="loc_us-gaap_OperatingExpenses_3921a12d-fd0b-48e7-9e2d-e48ac9580645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a147fc6c-512d-4532-a98f-3076c896c08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_OperatingIncomeLoss_a147fc6c-512d-4532-a98f-3076c896c08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_39777c80-c51c-44dd-81da-aaea78ecf307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_InterestAndOtherIncome_39777c80-c51c-44dd-81da-aaea78ecf307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_96fc0e79-2500-4e00-93f5-1bc598c79ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_ProfitLoss_96fc0e79-2500-4e00-93f5-1bc598c79ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7f02a128-57f0-40a9-89f4-71312efad1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7f02a128-57f0-40a9-89f4-71312efad1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85a5976b-11ea-4650-baaf-f2295e108102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_NetIncomeLoss_85a5976b-11ea-4650-baaf-f2295e108102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_683c8b5a-c0ea-4f30-96d3-b3162264c74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_683c8b5a-c0ea-4f30-96d3-b3162264c74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_978196de-0813-47bc-bc04-647e0f4c5d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11766031-7256-49a7-ab1f-0d09fcd09aa9" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_978196de-0813-47bc-bc04-647e0f4c5d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_698a88fc-3006-401f-99fb-38c78b362724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b30a008-af16-4ab0-a1c5-264aadfe5b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_698a88fc-3006-401f-99fb-38c78b362724" xlink:to="loc_us-gaap_ProfitLoss_4b30a008-af16-4ab0-a1c5-264aadfe5b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e85a0bdc-986d-41a2-80e9-e16fc0d2aa17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_698a88fc-3006-401f-99fb-38c78b362724" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e85a0bdc-986d-41a2-80e9-e16fc0d2aa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16b65eaf-c348-45de-ad41-8af695e5a899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_698a88fc-3006-401f-99fb-38c78b362724" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_16b65eaf-c348-45de-ad41-8af695e5a899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_db8bab4a-9599-4b0a-936e-7aad487d2e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_698a88fc-3006-401f-99fb-38c78b362724" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_db8bab4a-9599-4b0a-936e-7aad487d2e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_73c30a92-dcf1-4dc7-a84c-b4bf800959ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_698a88fc-3006-401f-99fb-38c78b362724" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_73c30a92-dcf1-4dc7-a84c-b4bf800959ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c891cfb1-660f-4404-8061-80033e91c542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_698a88fc-3006-401f-99fb-38c78b362724" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c891cfb1-660f-4404-8061-80033e91c542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7c06c874-17dc-4a64-a49c-b6b4a1672cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7c06c874-17dc-4a64-a49c-b6b4a1672cf9" xlink:to="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6be1e449-cf5d-4a32-9297-a3e503bd58fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6be1e449-cf5d-4a32-9297-a3e503bd58fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6be1e449-cf5d-4a32-9297-a3e503bd58fa" xlink:to="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3158efc9-ca8e-468f-900b-d6330f95531b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_CommonStockMember_3158efc9-ca8e-468f-900b-d6330f95531b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_87dc58c0-97f0-42d3-9444-8958e9cd526e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_87dc58c0-97f0-42d3-9444-8958e9cd526e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e8b242c4-a156-4b0e-9294-7a4be8f90bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_RetainedEarningsMember_e8b242c4-a156-4b0e-9294-7a4be8f90bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79e1ca64-d1ba-48f3-93c0-4558628db0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_79e1ca64-d1ba-48f3-93c0-4558628db0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1ea1cd7a-091d-41f3-abf2-da27a81260b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_687597bd-1f50-4116-8259-1ffa962b740c" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1ea1cd7a-091d-41f3-abf2-da27a81260b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f0fb8a45-469a-4af2-802f-fa618043db3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:to="loc_srt_RestatementAxis_f0fb8a45-469a-4af2-802f-fa618043db3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_49be6bd3-284f-48be-b577-6d39722311e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_f0fb8a45-469a-4af2-802f-fa618043db3e" xlink:to="loc_srt_RestatementDomain_49be6bd3-284f-48be-b577-6d39722311e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_cc980873-dce8-4451-aba0-e458b0054678" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_49be6bd3-284f-48be-b577-6d39722311e1" xlink:to="loc_srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_cc980873-dce8-4451-aba0-e458b0054678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6d8fd366-7728-42b1-8ccc-80da1a32a900" xlink:to="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_89c04f26-a897-4268-808a-b1abc21dc1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_CommonStockSharesIssued_89c04f26-a897-4268-808a-b1abc21dc1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ab11f16-6f8e-4c0d-821a-6f84f98d4e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ab11f16-6f8e-4c0d-821a-6f84f98d4e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f67eb74-836f-4eae-abc9-9b0586564da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f67eb74-836f-4eae-abc9-9b0586564da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2d1f9eb7-3f57-46ab-9180-39cc0e8916f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2d1f9eb7-3f57-46ab-9180-39cc0e8916f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c1f323c4-5967-4016-a14c-40848cdfabfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c1f323c4-5967-4016-a14c-40848cdfabfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542ace64-f4cf-4e7c-89cf-5071542df2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542ace64-f4cf-4e7c-89cf-5071542df2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_408b2f21-cada-405b-8ec3-86b8a5b01071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_408b2f21-cada-405b-8ec3-86b8a5b01071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b4880589-465b-4ea7-a53c-a436cf69a685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b4880589-465b-4ea7-a53c-a436cf69a685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_cbfa1330-c376-434e-9d49-6097f315ab1d" xlink:href="sgmo-20200630.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_cbfa1330-c376-434e-9d49-6097f315ab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c258aaed-1862-4f05-8abd-51d99aec492f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c258aaed-1862-4f05-8abd-51d99aec492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1cd30ee3-58cc-4d4f-916f-c18b231f971e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1cd30ee3-58cc-4d4f-916f-c18b231f971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_446d125c-9502-4940-9aec-01fea5ccb485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_446d125c-9502-4940-9aec-01fea5ccb485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c13f7b31-01a0-4220-b007-d92ebe3f4eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c13f7b31-01a0-4220-b007-d92ebe3f4eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1028f699-94e7-4b82-aa88-bd0828220ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_ProfitLoss_1028f699-94e7-4b82-aa88-bd0828220ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7cb61cf6-9d0b-4637-be9a-d50f912eb219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_CommonStockSharesIssued_7cb61cf6-9d0b-4637-be9a-d50f912eb219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36205c15-7def-449d-9ca6-5f4420373e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_486c6859-1ff2-44ad-a2e3-2cd14d627f6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_36205c15-7def-449d-9ca6-5f4420373e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6b61cecf-aa7c-4889-b3f5-316c76fcc182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4d87d114-232b-4215-a5ef-827a6bb1d0dd" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_6b61cecf-aa7c-4889-b3f5-316c76fcc182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12a217f4-ae05-48bf-9c48-8d50d0d4e6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12a217f4-ae05-48bf-9c48-8d50d0d4e6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ac30a9fa-4ee4-48bb-a2d7-63fbd193d07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12a217f4-ae05-48bf-9c48-8d50d0d4e6ba" xlink:to="loc_us-gaap_ProfitLoss_ac30a9fa-4ee4-48bb-a2d7-63fbd193d07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12a217f4-ae05-48bf-9c48-8d50d0d4e6ba" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fa26af19-5109-4399-b50c-7e83f7eaf3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fa26af19-5109-4399-b50c-7e83f7eaf3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_beb5dbe0-70f1-48da-974f-25d4542517be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_beb5dbe0-70f1-48da-974f-25d4542517be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_a487fc66-743e-4b63-845c-587e57bdf25b" xlink:href="sgmo-20200630.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_a487fc66-743e-4b63-845c-587e57bdf25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_582f10e0-b72b-4cfb-8987-61fe40392e3e" xlink:href="sgmo-20200630.xsd#sgmo_GainLossOnFreeShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:to="loc_sgmo_GainLossOnFreeShares_582f10e0-b72b-4cfb-8987-61fe40392e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2162b645-0907-43d2-ba7a-8f0e46ca1f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:to="loc_us-gaap_ShareBasedCompensation_2162b645-0907-43d2-ba7a-8f0e46ca1f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_588f1089-35be-4742-a369-3ecbe24da397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_588f1089-35be-4742-a369-3ecbe24da397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_53e78ed9-b5e6-4b34-ab83-0a83450b58f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fd74aa3d-f818-42dd-a6db-2bbb02b14f3e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_53e78ed9-b5e6-4b34-ab83-0a83450b58f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12a217f4-ae05-48bf-9c48-8d50d0d4e6ba" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_c7cf6c7a-a2f1-477d-9004-626777d769fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_c7cf6c7a-a2f1-477d-9004-626777d769fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0f2971c-378f-49ba-ba72-c26f76609269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0f2971c-378f-49ba-ba72-c26f76609269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b40ae6d0-6cde-4d2f-9283-15709e5f81e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b40ae6d0-6cde-4d2f-9283-15709e5f81e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_08f768e3-8b75-41c9-a97c-49f13ef6ddd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_08f768e3-8b75-41c9-a97c-49f13ef6ddd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fa337961-ef9b-4f49-922c-a7d114f5453b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fa337961-ef9b-4f49-922c-a7d114f5453b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19c0403c-25e0-4998-84e6-7e4190e6773d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19c0403c-25e0-4998-84e6-7e4190e6773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_c267eb81-cc7b-43ad-ad1c-53da259a1bb5" xlink:href="sgmo-20200630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_c267eb81-cc7b-43ad-ad1c-53da259a1bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0cce19cf-8a17-4b58-83d8-ae41ffa53b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7208017b-2339-4ab1-95fc-cb50cf533702" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0cce19cf-8a17-4b58-83d8-ae41ffa53b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_227f0880-d9b8-48c6-b48e-007b55aad5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_12a217f4-ae05-48bf-9c48-8d50d0d4e6ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_227f0880-d9b8-48c6-b48e-007b55aad5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec006bac-9998-4511-bdae-e58a7e94e4b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec006bac-9998-4511-bdae-e58a7e94e4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1e8be5b8-cd5d-477a-a628-463f7f53954d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec006bac-9998-4511-bdae-e58a7e94e4b6" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1e8be5b8-cd5d-477a-a628-463f7f53954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6de16375-552b-496d-8640-c94c77e333c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec006bac-9998-4511-bdae-e58a7e94e4b6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6de16375-552b-496d-8640-c94c77e333c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b4b346d7-cf37-40be-a2c3-e9a5a9495930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec006bac-9998-4511-bdae-e58a7e94e4b6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b4b346d7-cf37-40be-a2c3-e9a5a9495930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_632227a2-6e23-4f05-a0df-90de262f61ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec006bac-9998-4511-bdae-e58a7e94e4b6" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_632227a2-6e23-4f05-a0df-90de262f61ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edf72471-8732-4a37-bf5b-d1c11a16759a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ec006bac-9998-4511-bdae-e58a7e94e4b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edf72471-8732-4a37-bf5b-d1c11a16759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2d0eb8e7-db21-408a-bf84-c32b99ec4fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2d0eb8e7-db21-408a-bf84-c32b99ec4fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_47a4e7f7-a6ae-48d1-91da-6ad282be4eda" xlink:href="sgmo-20200630.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:to="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_47a4e7f7-a6ae-48d1-91da-6ad282be4eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b6a9fc6e-693b-4618-a00f-21a965424748" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b6a9fc6e-693b-4618-a00f-21a965424748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fad4369a-7ca6-4c5a-8cc8-5deaab2e33b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fad4369a-7ca6-4c5a-8cc8-5deaab2e33b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ba563712-a6e4-4c96-a108-2ffce9d19044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ba563712-a6e4-4c96-a108-2ffce9d19044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_888401a7-9b00-43e0-935b-b8a470f34d75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4882cc70-a043-448e-baee-c1add1414f43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_888401a7-9b00-43e0-935b-b8a470f34d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95278e03-2e9c-4b9d-9dcf-c6cd3eb924a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95278e03-2e9c-4b9d-9dcf-c6cd3eb924a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fae921f-3c27-4840-bf49-875e836ac152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3fae921f-3c27-4840-bf49-875e836ac152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b940be0-a635-47a6-8f54-f3d1140de29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b940be0-a635-47a6-8f54-f3d1140de29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14cb5eb7-9c2f-4861-a998-089280a32983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14cb5eb7-9c2f-4861-a998-089280a32983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4955617c-8791-4481-88d9-688a8a1191f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a6d57009-8d19-41ad-9bbe-c48d83d4e470" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4955617c-8791-4481-88d9-688a8a1191f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_80721a77-180b-430b-8f9d-45b64a16ba18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4955617c-8791-4481-88d9-688a8a1191f8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_80721a77-180b-430b-8f9d-45b64a16ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd9d33ae-1dc3-4346-9bc5-e1009158dbf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4955617c-8791-4481-88d9-688a8a1191f8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd9d33ae-1dc3-4346-9bc5-e1009158dbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0f8d8013-5057-4128-9e78-f5737b334847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_19ce2cb1-3a54-40ec-acb3-efa5f47bf609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f8d8013-5057-4128-9e78-f5737b334847" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_19ce2cb1-3a54-40ec-acb3-efa5f47bf609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1c71d5a-06a2-4de3-8301-1eae8c015dad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1c71d5a-06a2-4de3-8301-1eae8c015dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_37df93f9-ce28-4b70-8462-e0aff30eb511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_UseOfEstimates_37df93f9-ce28-4b70-8462-e0aff30eb511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6c909dfc-dc86-40c0-87b3-a26323554195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6c909dfc-dc86-40c0-87b3-a26323554195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_4356697e-ee5c-4311-9a8b-96d59ac21c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_4356697e-ee5c-4311-9a8b-96d59ac21c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cf88c0b2-96b6-4de9-b2a8-feca2a25af34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cf88c0b2-96b6-4de9-b2a8-feca2a25af34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8eac1dcf-20df-4346-9940-6ecfc4551cc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8eac1dcf-20df-4346-9940-6ecfc4551cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a0effcb7-ae82-4a79-aa77-5d37de00cbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a0effcb7-ae82-4a79-aa77-5d37de00cbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_980d4590-0452-4f53-b3c2-f6b8320ffcca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_980d4590-0452-4f53-b3c2-f6b8320ffcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_3e930b52-55ed-4fed-bf11-dba89fc97a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_3e930b52-55ed-4fed-bf11-dba89fc97a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1a544e1b-297b-4776-b6f7-9dbf83cb645e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1a544e1b-297b-4776-b6f7-9dbf83cb645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f46efbbe-1319-4687-88e0-334a93bb0a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f46efbbe-1319-4687-88e0-334a93bb0a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ca13b048-3da9-4739-9e0c-809799482c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ca13b048-3da9-4739-9e0c-809799482c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b52cfcf7-ecd1-48ee-a7b9-1365424ce14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_67390380-0e55-4e8b-8a99-8c6ba717aaa3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b52cfcf7-ecd1-48ee-a7b9-1365424ce14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_34c11955-8c70-4098-bd73-5b5e0aded2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_80677ef5-270d-4eb5-ad03-51935f4ada32" xlink:href="sgmo-20200630.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c11955-8c70-4098-bd73-5b5e0aded2db" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_80677ef5-270d-4eb5-ad03-51935f4ada32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1404f520-2cd5-4774-9a49-55fe8928e3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c11955-8c70-4098-bd73-5b5e0aded2db" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1404f520-2cd5-4774-9a49-55fe8928e3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_93ee8c9a-3219-4f08-b3a0-57c00fe010ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c11955-8c70-4098-bd73-5b5e0aded2db" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_93ee8c9a-3219-4f08-b3a0-57c00fe010ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d25b8707-2bf4-42d6-8689-085133c9efb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:href="sgmo-20200630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d25b8707-2bf4-42d6-8689-085133c9efb0" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b892654a-6340-4b07-be67-bc308a12d283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b892654a-6340-4b07-be67-bc308a12d283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c3b74df5-7af8-4099-92a9-9c14f8b98077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_b892654a-6340-4b07-be67-bc308a12d283" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c3b74df5-7af8-4099-92a9-9c14f8b98077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5c29208a-c149-4567-94de-4da18007652d" xlink:href="sgmo-20200630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_c3b74df5-7af8-4099-92a9-9c14f8b98077" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5c29208a-c149-4567-94de-4da18007652d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1794ae6-9346-4451-9399-b053da97d9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1794ae6-9346-4451-9399-b053da97d9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2a5c99a-291e-4243-84db-309ca88af7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1794ae6-9346-4451-9399-b053da97d9b8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2a5c99a-291e-4243-84db-309ca88af7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_6c7d2341-80f8-40fd-928b-80ae63788f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e2a5c99a-291e-4243-84db-309ca88af7a2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_6c7d2341-80f8-40fd-928b-80ae63788f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a72b52c3-befa-4ff3-904d-8011665e6c24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_srt_CounterpartyNameAxis_a72b52c3-befa-4ff3-904d-8011665e6c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a72b52c3-befa-4ff3-904d-8011665e6c24" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_4ea25c97-639c-4d1f-a289-a819f07b5b83" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_BiogenMAIncMember_4ea25c97-639c-4d1f-a289-a819f07b5b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_10efcf68-b614-477a-84ba-4db3ad229576" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_KitePharmaIncMember_10efcf68-b614-477a-84ba-4db3ad229576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_4cb8c486-e168-4484-a8b8-42dbeb541bc6" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_PfizerMember_4cb8c486-e168-4484-a8b8-42dbeb541bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_cc0b298d-df76-42f3-a6eb-f0521d58f42e" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_SanofiMember_cc0b298d-df76-42f3-a6eb-f0521d58f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerAndSanofiMember_16e97bef-9260-4abc-99f1-07f5f8789bd2" xlink:href="sgmo-20200630.xsd#sgmo_PfizerAndSanofiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e297d5d-ce1f-4642-9b80-89b2e2b1d602" xlink:to="loc_sgmo_PfizerAndSanofiMember_16e97bef-9260-4abc-99f1-07f5f8789bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_1363bfb7-bb7d-4c7d-bdad-85377b1a9f3c" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_757f4844-42f2-4291-ba59-be38f1b95837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_97eb1cd6-ca9c-4051-b5a0-9abc6377f89b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_757f4844-42f2-4291-ba59-be38f1b95837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c2554351-3805-4b5b-8d02-a46c9a4ab0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_757f4844-42f2-4291-ba59-be38f1b95837" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c2554351-3805-4b5b-8d02-a46c9a4ab0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_708807e8-8d44-47c9-8e10-3d34ea88cacc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_708807e8-8d44-47c9-8e10-3d34ea88cacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_708807e8-8d44-47c9-8e10-3d34ea88cacc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f293de85-fe19-4789-afa8-c71552f94c5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f293de85-fe19-4789-afa8-c71552f94c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_92936e5a-e630-49dd-9ab1-f3244e6cd55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_574d5a20-8599-4f03-92fe-778bc087cee0" xlink:to="loc_us-gaap_SalesRevenueNetMember_92936e5a-e630-49dd-9ab1-f3244e6cd55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:href="sgmo-20200630.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_b3a848bf-6619-471e-bc10-a05a513160f5" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7ed6a5a-a9f5-4267-b2d7-eeaf3d319dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7ed6a5a-a9f5-4267-b2d7-eeaf3d319dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a9320178-4415-4b08-97ab-04ee96746c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_ProfitLoss_a9320178-4415-4b08-97ab-04ee96746c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_55d07dd1-78d8-465e-abdf-788750aa9c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_EarningsPerShareBasic_55d07dd1-78d8-465e-abdf-788750aa9c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_16e5e806-a0b6-4131-a567-f93fc15a9f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_16e5e806-a0b6-4131-a567-f93fc15a9f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_40411dce-fd12-4459-845b-2cbc3941f22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_40411dce-fd12-4459-845b-2cbc3941f22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b021e10-d0c2-42fe-858f-c139585ae1af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b021e10-d0c2-42fe-858f-c139585ae1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e1f52b5-c082-4a54-ba76-57866fddb0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e1f52b5-c082-4a54-ba76-57866fddb0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c924c377-9ecc-44e6-9aef-5a7119870d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c924c377-9ecc-44e6-9aef-5a7119870d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa901d34-9dd3-4ab9-9b7e-ea2102fc2e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_1234647a-dc21-4a63-bf1c-c0fd2920fcc0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa901d34-9dd3-4ab9-9b7e-ea2102fc2e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b07cffc5-bac7-408d-b275-7ab00c35d3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6a7b01c4-dbe1-40e5-84e8-da82f22eb4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b07cffc5-bac7-408d-b275-7ab00c35d3d3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6a7b01c4-dbe1-40e5-84e8-da82f22eb4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d9d16dfb-28e9-4326-a66e-d235dbfaf3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ef9009a2-eefb-4732-a9a5-0eab7432700e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d9d16dfb-28e9-4326-a66e-d235dbfaf3c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ef9009a2-eefb-4732-a9a5-0eab7432700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_633f29a5-c1af-4aa3-a12b-3e0f263eb8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d9d16dfb-28e9-4326-a66e-d235dbfaf3c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_633f29a5-c1af-4aa3-a12b-3e0f263eb8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eeb785a3-22e7-431d-9b9d-23beb3cfb986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eeb785a3-22e7-431d-9b9d-23beb3cfb986" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2630d72-d2ff-4d54-9613-ecf188fb4ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bdcf1891-9ca9-40fc-a4b1-c3bf5c3d9a25" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2630d72-d2ff-4d54-9613-ecf188fb4ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_02997f41-3348-4ac9-afc5-d85cfe44a36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2630d72-d2ff-4d54-9613-ecf188fb4ff5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_02997f41-3348-4ac9-afc5-d85cfe44a36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68dfdd5-fb01-45d9-9a35-3b487d5527bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68dfdd5-fb01-45d9-9a35-3b487d5527bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68dfdd5-fb01-45d9-9a35-3b487d5527bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b58a3b81-bb47-4d4f-a292-cfebf5083811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b58a3b81-bb47-4d4f-a292-cfebf5083811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f754517e-10a4-4ab9-8065-798a89fbe38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f754517e-10a4-4ab9-8065-798a89fbe38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d5f43485-6735-4b4d-98f8-65f69575c340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb2cb931-94e6-43ea-8c6d-e317c1f3ae54" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d5f43485-6735-4b4d-98f8-65f69575c340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:to="loc_us-gaap_FinancialInstrumentAxis_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27e1e4c2-3fbd-467f-b9fb-f054b7e880a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_342cd856-d4e4-413a-92e3-9894b9c65130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_342cd856-d4e4-413a-92e3-9894b9c65130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_e4068fab-a0a1-48fe-a2f4-dc792993a2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_CommercialPaperMember_e4068fab-a0a1-48fe-a2f4-dc792993a2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c7d2490d-8133-4639-bbd2-6a4494c34605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c7d2490d-8133-4639-bbd2-6a4494c34605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be509143-c674-48b3-a910-29251afb1471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be509143-c674-48b3-a910-29251afb1471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_428d541e-6260-4edc-b888-c0dee020b287" xlink:href="sgmo-20200630.xsd#sgmo_FreeSharesAssetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4cfa7dab-e5bf-4569-85fe-0755cc7cec9a" xlink:to="loc_sgmo_FreeSharesAssetMember_428d541e-6260-4edc-b888-c0dee020b287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_438a2c54-23d5-4a2c-85f1-2dcfa1402681" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97bed1b2-0185-4787-ae00-18a13db525c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97bed1b2-0185-4787-ae00-18a13db525c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91cf1105-1586-46af-ac4f-8ca540d34704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_91cf1105-1586-46af-ac4f-8ca540d34704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_dc5a3bc3-bca1-49d6-988e-0af581f41479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bb3bdeec-299d-43b3-99f7-e6f5b869557c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_dc5a3bc3-bca1-49d6-988e-0af581f41479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4ee7d048-d7bb-4e05-a4e8-8d52037014d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4ee7d048-d7bb-4e05-a4e8-8d52037014d8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2a3fbdb5-301a-4166-ae28-94b7e198a341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2a3fbdb5-301a-4166-ae28-94b7e198a341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a3fbdb5-301a-4166-ae28-94b7e198a341" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_eead54c2-94cc-434e-bbc4-cc378607bd44" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:to="loc_sgmo_SangamoFranceMember_eead54c2-94cc-434e-bbc4-cc378607bd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TxCellSAMember_4d0091ca-fce9-47ab-9b7f-9802ac876125" xlink:href="sgmo-20200630.xsd#sgmo_TxCellSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b63861d-18d7-40fe-b6ac-afb844eab088" xlink:to="loc_sgmo_TxCellSAMember_4d0091ca-fce9-47ab-9b7f-9802ac876125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d0b5de07-d8a0-4892-9f2b-c485c55f6981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d0b5de07-d8a0-4892-9f2b-c485c55f6981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c175a01-f0bb-4847-8b30-f1e59d56fb47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d0b5de07-d8a0-4892-9f2b-c485c55f6981" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c175a01-f0bb-4847-8b30-f1e59d56fb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_ed9ece3d-d943-4ec4-aeb0-b3da789a440e" xlink:href="sgmo-20200630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c175a01-f0bb-4847-8b30-f1e59d56fb47" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_ed9ece3d-d943-4ec4-aeb0-b3da789a440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_56d31f71-3044-4dc5-86f9-c45ce1bd6de7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:to="loc_srt_StatementScenarioAxis_56d31f71-3044-4dc5-86f9-c45ce1bd6de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_25d1a5d9-cb1b-497d-b81e-9b1e83ddf745" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_56d31f71-3044-4dc5-86f9-c45ce1bd6de7" xlink:to="loc_srt_ScenarioUnspecifiedDomain_25d1a5d9-cb1b-497d-b81e-9b1e83ddf745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_112933c9-f04b-4200-994f-0763fe16d2c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_25d1a5d9-cb1b-497d-b81e-9b1e83ddf745" xlink:to="loc_srt_ScenarioForecastMember_112933c9-f04b-4200-994f-0763fe16d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_24ac2f75-b27c-48fb-a6c3-753592f5f4b0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_9b0a3bea-3271-471a-955a-4e9ea027b09e" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_9b0a3bea-3271-471a-955a-4e9ea027b09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_a5f9e0d0-a2d9-49b2-a6a4-f7c051883fcf" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_a5f9e0d0-a2d9-49b2-a6a4-f7c051883fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_22d89850-1a3e-4422-8b3d-a56b11731d6e" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_22d89850-1a3e-4422-8b3d-a56b11731d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_4ff9a66f-92d3-4597-ad4a-cff07f5a25ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_4ff9a66f-92d3-4597-ad4a-cff07f5a25ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ebef7b45-0ea4-471d-a038-4e6ec38964bb" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ebef7b45-0ea4-471d-a038-4e6ec38964bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_320f0e87-9fc6-4606-866a-d07efdb8659f" xlink:href="sgmo-20200630.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_320f0e87-9fc6-4606-866a-d07efdb8659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionSharesAcquiredValue_adad6a13-32bc-412b-a59a-6cab6ed68040" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionSharesAcquiredValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_sgmo_BusinessAcquisitionSharesAcquiredValue_adad6a13-32bc-412b-a59a-6cab6ed68040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_593fde0c-e0e6-4910-b86f-c495a74d4d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9a9e6e94-b019-481e-9343-214b660ed116" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_593fde0c-e0e6-4910-b86f-c495a74d4d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ada3b2fb-7207-462a-818a-5b3e2c8a8ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ada3b2fb-7207-462a-818a-5b3e2c8a8ace" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_60314645-7266-4ccf-a65d-e5235a1d1022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_60314645-7266-4ccf-a65d-e5235a1d1022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fef54670-567d-4f33-b45d-633fc4852aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_60314645-7266-4ccf-a65d-e5235a1d1022" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fef54670-567d-4f33-b45d-633fc4852aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_c055d4b7-ea1f-43bf-aea3-a23c0a4e9359" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fef54670-567d-4f33-b45d-633fc4852aad" xlink:to="loc_sgmo_SangamoFranceMember_c055d4b7-ea1f-43bf-aea3-a23c0a4e9359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c3c6901-e3ff-4bb1-b11a-5757ea92a6f2" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_4b742837-5cd9-4ba8-8e9b-dcd351b4c315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_4b742837-5cd9-4ba8-8e9b-dcd351b4c315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_1749878a-2f04-428e-b046-b0726620a297" xlink:href="sgmo-20200630.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_1749878a-2f04-428e-b046-b0726620a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_c06a6cc1-1850-4174-abba-a955378f9531" xlink:href="sgmo-20200630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_c06a6cc1-1850-4174-abba-a955378f9531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_df3e27d6-4db4-4464-bca9-33db81220128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_df3e27d6-4db4-4464-bca9-33db81220128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_5433a595-4484-4ec7-8e84-265634517f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02a09e0e-ff9b-4789-9ee0-1bda466ef2e5" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_5433a595-4484-4ec7-8e84-265634517f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_32b8cc34-b718-400c-b71f-6de1c4726729" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_98c2afac-d885-4bf8-9865-448ef3d166a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_SharePrice_98c2afac-d885-4bf8-9865-448ef3d166a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_59d15418-349b-4aaa-b890-b56a57fa1d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_59d15418-349b-4aaa-b890-b56a57fa1d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_67114644-71bf-4b6b-9804-44b133e3041f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_67114644-71bf-4b6b-9804-44b133e3041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f387f3a9-f633-45cf-a7c9-61398c6c51a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f387f3a9-f633-45cf-a7c9-61398c6c51a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_42d8b9dc-4330-4a4d-a3b0-2c7c1669ec6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_53766dd7-d1b9-4359-81be-cf97a6b2456c" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_42d8b9dc-4330-4a4d-a3b0-2c7c1669ec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2d6cc7c-4f39-4fa3-aeb6-d98bba6cb491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_296cc6cf-c0fc-4081-b906-dec67fe807fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a2d6cc7c-4f39-4fa3-aeb6-d98bba6cb491" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_296cc6cf-c0fc-4081-b906-dec67fe807fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be1b5489-40ec-4d78-90dc-e11de97acf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_8fc128bc-49f2-4ff0-9519-d6505494dc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be1b5489-40ec-4d78-90dc-e11de97acf8b" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_8fc128bc-49f2-4ff0-9519-d6505494dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_aaa2ffac-e02f-4d2a-b987-08c505928a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be1b5489-40ec-4d78-90dc-e11de97acf8b" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_aaa2ffac-e02f-4d2a-b987-08c505928a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_39616f58-381f-413a-bac0-80cfb1b7d343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4e939bdf-b47f-4647-81c8-6eddd6e666f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_39616f58-381f-413a-bac0-80cfb1b7d343" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4e939bdf-b47f-4647-81c8-6eddd6e666f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_32a5ce0c-abff-468b-a27c-f8f6b45b9c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_39616f58-381f-413a-bac0-80cfb1b7d343" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_32a5ce0c-abff-468b-a27c-f8f6b45b9c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0ecb26e7-8e01-411b-878f-333022140d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6c11af6a-406b-4f9c-936d-0ff1199fba37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0ecb26e7-8e01-411b-878f-333022140d01" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6c11af6a-406b-4f9c-936d-0ff1199fba37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0280d2dc-6145-44be-9d7b-659f7d980fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6c11af6a-406b-4f9c-936d-0ff1199fba37" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0280d2dc-6145-44be-9d7b-659f7d980fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0280d2dc-6145-44be-9d7b-659f7d980fa8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0882dd13-3f25-4f2c-aac8-998d26eb0cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0882dd13-3f25-4f2c-aac8-998d26eb0cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_da0cbd5d-f055-403f-8cdf-451fb3a103a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_CommercialPaperMember_da0cbd5d-f055-403f-8cdf-451fb3a103a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_c07d5e4d-f660-40ff-a0f9-8f4b00a1d031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_CashEquivalentsMember_c07d5e4d-f660-40ff-a0f9-8f4b00a1d031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_93abd82d-026d-4018-ac2a-cb565385e97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_93abd82d-026d-4018-ac2a-cb565385e97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2364e23e-5991-43d9-92a0-177d0f3f77b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4894478-2260-433c-a740-a981155b3f80" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2364e23e-5991-43d9-92a0-177d0f3f77b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6c11af6a-406b-4f9c-936d-0ff1199fba37" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b40d34ca-1e1f-4f11-93fc-3dd979108b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b40d34ca-1e1f-4f11-93fc-3dd979108b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e5329952-497b-4c5b-8e33-d594d03cdd88" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e5329952-497b-4c5b-8e33-d594d03cdd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_b6400261-c803-4d84-af92-0ea0fdabd8cc" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_b6400261-c803-4d84-af92-0ea0fdabd8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c9941083-ff60-4d78-a858-ef6c0ac8f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c9941083-ff60-4d78-a858-ef6c0ac8f46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2a1f7f6-bcf0-4a38-8a15-c1c2a92a62bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2a1f7f6-bcf0-4a38-8a15-c1c2a92a62bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_562382de-6fb8-4d30-8094-a3ad77a9baf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_562382de-6fb8-4d30-8094-a3ad77a9baf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c3b1939-8741-4f10-aa74-a8a2dd5e3da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9c3b1939-8741-4f10-aa74-a8a2dd5e3da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6772db92-048a-482d-9cf0-a5d3338688bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c259b81-08ee-40ae-96df-1db053d582d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6772db92-048a-482d-9cf0-a5d3338688bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_dea9d157-543a-4675-9963-b427ea409489" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_dea9d157-543a-4675-9963-b427ea409489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_c0d8fe66-a4c7-4645-bf90-d20eca0f41e7" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_c0d8fe66-a4c7-4645-bf90-d20eca0f41e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_8d6ca2a8-0020-4a30-875d-fe4d99896645" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_8d6ca2a8-0020-4a30-875d-fe4d99896645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_a3511bb5-42ad-4170-afe7-75cae0e6bbab" xlink:href="sgmo-20200630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_64cf6bb8-2efa-4b69-8e7f-1fd5d7bfff0d" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_a3511bb5-42ad-4170-afe7-75cae0e6bbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20200630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f5eaecb-27f0-4156-807f-886295dbc074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3f6d36fd-7348-49b0-8677-d0b40905c44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f5eaecb-27f0-4156-807f-886295dbc074" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3f6d36fd-7348-49b0-8677-d0b40905c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_533776ab-2b4b-4d76-a6dc-a2a9217d0667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f5eaecb-27f0-4156-807f-886295dbc074" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_533776ab-2b4b-4d76-a6dc-a2a9217d0667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f991cd9-a9c2-42c4-b732-7efeb9af0bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f5eaecb-27f0-4156-807f-886295dbc074" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9f991cd9-a9c2-42c4-b732-7efeb9af0bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20200630.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_63647733-5ad2-40fe-967d-d2d8ebe8a68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0df0133d-a935-45c4-8af3-5e5bfef22eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_63647733-5ad2-40fe-967d-d2d8ebe8a68b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0df0133d-a935-45c4-8af3-5e5bfef22eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e297aaaa-c5b2-497f-ac3c-7ae3dc540327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_056c86df-b15d-483d-bce5-68747027f298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e297aaaa-c5b2-497f-ac3c-7ae3dc540327" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_056c86df-b15d-483d-bce5-68747027f298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbcb61ef-97a8-44c1-ae00-16589fa739fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_83c8b367-c6da-414b-a182-0173f65731bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fbcb61ef-97a8-44c1-ae00-16589fa739fa" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_83c8b367-c6da-414b-a182-0173f65731bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72f3f5b1-03a4-4cb0-95b7-26a6bba73ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01406a39-3b60-4049-8251-f0cb434b7e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72f3f5b1-03a4-4cb0-95b7-26a6bba73ee1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01406a39-3b60-4049-8251-f0cb434b7e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01406a39-3b60-4049-8251-f0cb434b7e99" xlink:to="loc_srt_CounterpartyNameAxis_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_73e9cc3a-0ed4-40d8-82b2-f8cee25bd026" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_96ac5a09-b326-41af-9985-2ce90b0c5621" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_BiogenMAIncMember_96ac5a09-b326-41af-9985-2ce90b0c5621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1d37a712-e532-41c7-aef2-7cd9fadbb7c4" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_KitePharmaIncMember_1d37a712-e532-41c7-aef2-7cd9fadbb7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_e767bc55-2b2c-4d8c-bb6e-2a019d6ebc83" xlink:href="sgmo-20200630.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_PfizerSB525Member_e767bc55-2b2c-4d8c-bb6e-2a019d6ebc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_14f3412f-b314-4c0a-af38-68423aeb0dad" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_PfizerMember_14f3412f-b314-4c0a-af38-68423aeb0dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_52774316-6005-4a08-b90e-a2a7e8041673" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eaa2545-d2c3-428f-9990-ba46dbec6b37" xlink:to="loc_sgmo_SanofiMember_52774316-6005-4a08-b90e-a2a7e8041673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be1cb6aa-500e-43da-9a82-253ebcd57156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01406a39-3b60-4049-8251-f0cb434b7e99" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be1cb6aa-500e-43da-9a82-253ebcd57156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1ea64efc-4332-42c6-9637-8ef1a2be78e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_be1cb6aa-500e-43da-9a82-253ebcd57156" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1ea64efc-4332-42c6-9637-8ef1a2be78e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6df7c65-b8a0-4c3d-ac4d-3b5586d0c771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a6df7c65-b8a0-4c3d-ac4d-3b5586d0c771" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ad53539-8ac1-4d5e-be86-0f58a8663b8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_srt_CounterpartyNameAxis_8ad53539-8ac1-4d5e-be86-0f58a8663b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8ad53539-8ac1-4d5e-be86-0f58a8663b8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_a0b0b4aa-4e4a-410c-adeb-88081a8474ae" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_BiogenMAIncMember_a0b0b4aa-4e4a-410c-adeb-88081a8474ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_5a272b84-0ef2-40f3-8157-e639298d9bbf" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_KitePharmaIncMember_5a272b84-0ef2-40f3-8157-e639298d9bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_c9d47268-3f92-4b9f-b7bd-4177903af920" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_PfizerMember_c9d47268-3f92-4b9f-b7bd-4177903af920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_c06846a4-d2df-481a-a3bc-8b19dfbdc649" xlink:href="sgmo-20200630.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_PfizerSB525Member_c06846a4-d2df-481a-a3bc-8b19dfbdc649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_0f788973-20b3-4d5a-97c1-ef909e78e1ec" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_648e4361-c991-413f-89a0-9cf1f2f12996" xlink:to="loc_sgmo_SanofiMember_0f788973-20b3-4d5a-97c1-ef909e78e1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bfa14bc5-30c7-4aa5-a78d-13c9d0aad075" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_b9d6887a-8410-44f1-8217-2817b8841561" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_b9d6887a-8410-44f1-8217-2817b8841561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_57a60122-cdf1-4022-b4f9-ed60361d44a3" xlink:href="sgmo-20200630.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:to="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_57a60122-cdf1-4022-b4f9-ed60361d44a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_7fe43c9f-5284-4a3f-9d29-dda0068d1a36" xlink:href="sgmo-20200630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb2c9306-a889-4799-9f82-bc7f23c955ef" xlink:to="loc_sgmo_StockPurchaseAgreementMember_7fe43c9f-5284-4a3f-9d29-dda0068d1a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bebc1041-b5be-4a43-a6e1-2ecd31ab1db1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_71236735-ecfc-40d8-a8fb-47c74f37548e" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_71236735-ecfc-40d8-a8fb-47c74f37548e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_f52b8597-bd9a-4339-a2f3-96a7d156a09e" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_f52b8597-bd9a-4339-a2f3-96a7d156a09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_594482e4-4506-4cf4-9393-93d9e809478f" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_594482e4-4506-4cf4-9393-93d9e809478f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dcb8315f-d956-40fb-80f3-8d2b48706882" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_dcb8315f-d956-40fb-80f3-8d2b48706882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_dcbd79a4-09a8-4ada-92ba-92bbc7a2b935" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_dcbd79a4-09a8-4ada-92ba-92bbc7a2b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_91d82506-41b2-42b4-b98b-ab9f05b28508" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_91d82506-41b2-42b4-b98b-ab9f05b28508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_598b19e3-01d8-41f6-be7e-ee211661b185" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_598b19e3-01d8-41f6-be7e-ee211661b185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_a2831043-477b-46f0-b8d5-6ed901adb6cb" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_a2831043-477b-46f0-b8d5-6ed901adb6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_fe718b61-9f43-4d54-8539-c2bccc7871be" xlink:href="sgmo-20200630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28d693dc-ac28-45f3-a3fe-f532406b938a" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_fe718b61-9f43-4d54-8539-c2bccc7871be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d690cb8-868b-4d3d-8179-1750e28d4c0e" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d690cb8-868b-4d3d-8179-1750e28d4c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_7d690cb8-868b-4d3d-8179-1750e28d4c0e" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_585c016b-7f61-46bb-b728-5a03dd123c29" xlink:href="sgmo-20200630.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_PreApprovalMilestoneMember_585c016b-7f61-46bb-b728-5a03dd123c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_7942e665-6067-44d4-98ba-fd11f9131a71" xlink:href="sgmo-20200630.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_SalesBasedMilestoneMember_7942e665-6067-44d4-98ba-fd11f9131a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_f0acca2b-c980-4ff6-aa38-fa8ca9c58f44" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_MilestoneTwoMember_f0acca2b-c980-4ff6-aa38-fa8ca9c58f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_d99bd9fc-810c-44c2-ba02-6ff29627e465" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_MilestoneThreeMember_d99bd9fc-810c-44c2-ba02-6ff29627e465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_7c95b2f2-d71b-478f-81a7-c1b1b224547e" xlink:href="sgmo-20200630.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_25f7116d-aaad-4d55-a30b-c170140be6c0" xlink:to="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_7c95b2f2-d71b-478f-81a7-c1b1b224547e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_srt_RangeAxis_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3069a357-99e4-4ce8-be91-e374a93fedec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fecb6ec7-3fac-48d1-be23-d5c2f7b908a0" xlink:to="loc_srt_RangeMember_3069a357-99e4-4ce8-be91-e374a93fedec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5bee439c-8c75-4640-b577-37f6d3431ece" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3069a357-99e4-4ce8-be91-e374a93fedec" xlink:to="loc_srt_MaximumMember_5bee439c-8c75-4640-b577-37f6d3431ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_76976e41-2ebb-412c-8d85-8e6206a6ab67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_srt_ProductOrServiceAxis_76976e41-2ebb-412c-8d85-8e6206a6ab67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_76976e41-2ebb-412c-8d85-8e6206a6ab67" xlink:to="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_f17fabe8-ebf0-4451-8285-bc0e0b456205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_us-gaap_LicenseAndServiceMember_f17fabe8-ebf0-4451-8285-bc0e0b456205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_60e9dc76-2bc7-426c-a614-95f033118530" xlink:href="sgmo-20200630.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_60e9dc76-2bc7-426c-a614-95f033118530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_b23ffeda-358b-40d4-9ca0-fc68bb942f61" xlink:href="sgmo-20200630.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_SBFiveTwoFiveMember_b23ffeda-358b-40d4-9ca0-fc68bb942f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_34cbe639-9346-4a41-91f3-4be24767a174" xlink:href="sgmo-20200630.xsd#sgmo_OtherProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_OtherProductsMember_34cbe639-9346-4a41-91f3-4be24767a174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_bf243557-9506-450a-af0d-cac57153ee94" xlink:href="sgmo-20200630.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_CNineORFSevenTwoMember_bf243557-9506-450a-af0d-cac57153ee94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_48a6ad3d-ed7a-47d7-87a0-ffbd1b75499f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_us-gaap_GrantMember_48a6ad3d-ed7a-47d7-87a0-ffbd1b75499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_0569fcd5-b6dd-48e3-81c2-56fe2c220144" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cf614741-795d-45dc-a279-7999093159d8" xlink:to="loc_sgmo_MilestoneAchievementMember_0569fcd5-b6dd-48e3-81c2-56fe2c220144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d70beebf-dbac-428a-be23-cdefc6897eaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7d081389-1b95-4bae-984c-24955423ecd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7d081389-1b95-4bae-984c-24955423ecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0e2c81f4-f453-4a68-a529-514971c4e9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0e2c81f4-f453-4a68-a529-514971c4e9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_070ec2e0-2113-4bd2-81f8-07515e83fa89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_070ec2e0-2113-4bd2-81f8-07515e83fa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_52dc2a81-5b5a-42c6-9969-5d21120c9096" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ProceedsFromCollaborators_52dc2a81-5b5a-42c6-9969-5d21120c9096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_fbcfe46a-53eb-45cd-bc7b-8fd5b364a429" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_fbcfe46a-53eb-45cd-bc7b-8fd5b364a429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_ba7dfc31-ae35-47c3-afae-1def135d7240" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_ba7dfc31-ae35-47c3-afae-1def135d7240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_119cae4e-b0b1-49b2-a74e-36d80a7ee77d" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_119cae4e-b0b1-49b2-a74e-36d80a7ee77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0122bed3-aae6-45aa-ad65-783655ca2b6e" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_0122bed3-aae6-45aa-ad65-783655ca2b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_5e3d0fc9-011f-479f-8dbd-49d04e2106d6" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_5e3d0fc9-011f-479f-8dbd-49d04e2106d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_4a7655bf-16df-47e7-8574-9e9931a17f80" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_4a7655bf-16df-47e7-8574-9e9931a17f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_4c1473fc-69df-4950-9f3f-cdb3471598bb" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_4c1473fc-69df-4950-9f3f-cdb3471598bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_47d7152d-540f-47bb-bb53-3f9743b1e12d" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_47d7152d-540f-47bb-bb53-3f9743b1e12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_b8893afa-7aa2-40ff-8526-51cca8c38a99" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_b8893afa-7aa2-40ff-8526-51cca8c38a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_33c51e71-2520-4d88-95fc-40f6aa2c2b11" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_33c51e71-2520-4d88-95fc-40f6aa2c2b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5053f8a0-fac3-4910-a33a-fb05c68f2661" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_5053f8a0-fac3-4910-a33a-fb05c68f2661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d2e79828-9b97-45c7-a002-826002dc6a25" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d2e79828-9b97-45c7-a002-826002dc6a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_2e70cf7b-a782-45ad-851e-0b98bff262f2" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_2e70cf7b-a782-45ad-851e-0b98bff262f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_1dde5589-882c-415b-a876-84eec6df3780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_1dde5589-882c-415b-a876-84eec6df3780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_d4bd96e5-4493-4829-9ce8-0b98b5e1a928" xlink:href="sgmo-20200630.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_d4bd96e5-4493-4829-9ce8-0b98b5e1a928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ae6fa389-47b7-49f4-ba25-9484df1cac21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ae6fa389-47b7-49f4-ba25-9484df1cac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_082fe6c0-46a2-4b11-ad5f-fb013d348d58" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_082fe6c0-46a2-4b11-ad5f-fb013d348d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_ac316c5e-b815-4dca-9c6a-e5d7abf11cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_DeferredRevenue_ac316c5e-b815-4dca-9c6a-e5d7abf11cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_1ca17382-9b3d-44d4-a4db-18803b661933" xlink:href="sgmo-20200630.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_MilestonePaymentsReceived_1ca17382-9b3d-44d4-a4db-18803b661933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c5dd84a7-a708-430e-bebb-d8268ce2dafa" xlink:href="sgmo-20200630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c5dd84a7-a708-430e-bebb-d8268ce2dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_14441822-f961-4f8d-b1da-04d5afee8837" xlink:href="sgmo-20200630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_14441822-f961-4f8d-b1da-04d5afee8837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_3633a9aa-ed08-43e0-b80f-d16d13eea01b" xlink:href="sgmo-20200630.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_3633a9aa-ed08-43e0-b80f-d16d13eea01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_7dc913ee-d6f7-48ed-899f-0677b917915c" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_7dc913ee-d6f7-48ed-899f-0677b917915c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_3fd5863f-a26b-4262-abe4-04dba9e97bd9" xlink:href="sgmo-20200630.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_3fd5863f-a26b-4262-abe4-04dba9e97bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_b5501739-c11a-4709-9485-92bacb745e65" xlink:href="sgmo-20200630.xsd#sgmo_SeparateUpfrontFee"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_SeparateUpfrontFee_b5501739-c11a-4709-9485-92bacb745e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_6dd3fa6b-626b-41fd-8fe1-f02c0978e279" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_6dd3fa6b-626b-41fd-8fe1-f02c0978e279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_d3474f14-1b51-4774-acc0-67aa197e4921" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_d3474f14-1b51-4774-acc0-67aa197e4921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_353255f2-6733-4c89-9371-0b5d64e4f192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_353255f2-6733-4c89-9371-0b5d64e4f192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ebb85661-8d32-4418-bf53-bdfee9050db0" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ebb85661-8d32-4418-bf53-bdfee9050db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_58340f64-99d5-4a0a-8833-853612f4be58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ContractWithCustomerLiability_58340f64-99d5-4a0a-8833-853612f4be58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_fad1de25-3617-4b4d-8fac-d89bd8f4ef92" xlink:href="sgmo-20200630.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_fad1de25-3617-4b4d-8fac-d89bd8f4ef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_8d8bc3f6-1d04-415a-b88b-ea5a97aeccf4" xlink:href="sgmo-20200630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_8d8bc3f6-1d04-415a-b88b-ea5a97aeccf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_1c55ee6d-cad4-4d51-a002-e76580100621" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_MilestoneRevenueReceivable_1c55ee6d-cad4-4d51-a002-e76580100621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_770d9f3c-1a32-4b37-81c1-2ff0f18c70de" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_770d9f3c-1a32-4b37-81c1-2ff0f18c70de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_7e1b640a-9dff-446c-ad1f-1745ffda8696" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_7e1b640a-9dff-446c-ad1f-1745ffda8696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_19cccba0-e075-4854-87b4-4cb6b09ca6c2" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_19cccba0-e075-4854-87b4-4cb6b09ca6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_8ac8ae53-867a-45e7-9fff-957b3ee7ab13" xlink:href="sgmo-20200630.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_AgreementTerminationTerm_8ac8ae53-867a-45e7-9fff-957b3ee7ab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d53e852e-f50e-4d63-8e87-16c27e883902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d53e852e-f50e-4d63-8e87-16c27e883902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage_84210049-2115-4f87-ab9c-366226d7f161" xlink:href="sgmo-20200630.xsd#sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage_84210049-2115-4f87-ab9c-366226d7f161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_b650283b-0740-495d-bd5e-cca1a15cf1b8" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_b650283b-0740-495d-bd5e-cca1a15cf1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_7e7a0695-498f-44f7-8d92-77a028a242c2" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_7e7a0695-498f-44f7-8d92-77a028a242c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_11a83a48-631a-4187-a5c7-8f1398bc1a50" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_11a83a48-631a-4187-a5c7-8f1398bc1a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b513d193-8beb-4c24-be74-8ad0785c8fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b513d193-8beb-4c24-be74-8ad0785c8fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_b52cf7b0-e16d-47b4-9935-8f0fd121a2a6" xlink:href="sgmo-20200630.xsd#sgmo_NumberOfResearchProgram"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_NumberOfResearchProgram_b52cf7b0-e16d-47b4-9935-8f0fd121a2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_ba77b68e-606d-4c52-9de4-b18fb80f152b" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_ba77b68e-606d-4c52-9de4-b18fb80f152b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_5f85bd64-576f-4e56-855e-8af8055a7b46" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementMilestoneRevenueReversal"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_5f85bd64-576f-4e56-855e-8af8055a7b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_bd04de15-59a3-44e5-a88e-655d2d4c7fb8" xlink:href="sgmo-20200630.xsd#sgmo_GrantFundingAmount"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_GrantFundingAmount_bd04de15-59a3-44e5-a88e-655d2d4c7fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1dc45915-42ae-49eb-9ce6-4f8a9a65fc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1dc45915-42ae-49eb-9ce6-4f8a9a65fc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_8e28089f-9f1f-421c-8fcf-80d8b2cd0e99" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_948a3b96-e668-4507-bab8-c3f620730eda" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_8e28089f-9f1f-421c-8fcf-80d8b2cd0e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21e86533-904b-4887-9184-4d84290ff655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21e86533-904b-4887-9184-4d84290ff655" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c94e001c-3aa3-426b-ba60-b902d8419954" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:to="loc_srt_CounterpartyNameAxis_c94e001c-3aa3-426b-ba60-b902d8419954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c94e001c-3aa3-426b-ba60-b902d8419954" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_ada22be4-2cc9-430a-a40a-702a7c57d0ee" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_BiogenMAIncMember_ada22be4-2cc9-430a-a40a-702a7c57d0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_03d1fc78-e86c-46cb-a9dc-ae510590642d" xlink:href="sgmo-20200630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_KitePharmaIncMember_03d1fc78-e86c-46cb-a9dc-ae510590642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_17200c6c-9efa-4aee-9c24-5648ea7093fb" xlink:href="sgmo-20200630.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_PfizerSB525Member_17200c6c-9efa-4aee-9c24-5648ea7093fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_37e8cb79-72be-4a56-b4b1-a9092064c618" xlink:href="sgmo-20200630.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_PfizerMember_37e8cb79-72be-4a56-b4b1-a9092064c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_0c525bab-9447-4b96-86b7-2c0ed727f10e" xlink:href="sgmo-20200630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b6b142-2c84-41da-aeed-68e6a1d03001" xlink:to="loc_sgmo_SanofiMember_0c525bab-9447-4b96-86b7-2c0ed727f10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5ff6ca60-a956-4a9c-9920-75da927705c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:to="loc_srt_ProductOrServiceAxis_5ff6ca60-a956-4a9c-9920-75da927705c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5ff6ca60-a956-4a9c-9920-75da927705c2" xlink:to="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_01bd35c8-e1d9-40ea-bfdc-bf1b8b4b7ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:to="loc_us-gaap_LicenseAndServiceMember_01bd35c8-e1d9-40ea-bfdc-bf1b8b4b7ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_e1904f54-9ae0-4c61-98ef-a4e281737144" xlink:href="sgmo-20200630.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:to="loc_sgmo_ResearchServicesMember_e1904f54-9ae0-4c61-98ef-a4e281737144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_f8c09a93-c444-4ca2-b4e0-558340793e26" xlink:href="sgmo-20200630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85fb9081-e230-48a9-a78c-1404930ef05a" xlink:to="loc_sgmo_MilestoneAchievementMember_f8c09a93-c444-4ca2-b4e0-558340793e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8da5a9aa-cb00-4909-872c-3fc0f42e3485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_afe94605-c147-4a98-b714-9e48f3ea0cd3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8da5a9aa-cb00-4909-872c-3fc0f42e3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1f536aa-cf47-4b1e-8b41-61ef1068a55b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_8da5a9aa-cb00-4909-872c-3fc0f42e3485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d1f536aa-cf47-4b1e-8b41-61ef1068a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1a82c75d-cdd2-479d-a765-e4d75fa984f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_eae4d016-b7bb-48ed-9780-41ef9f9bd312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a82c75d-cdd2-479d-a765-e4d75fa984f8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_eae4d016-b7bb-48ed-9780-41ef9f9bd312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8bc19fe-18a9-4800-a4ec-7e66d3c2990d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_131a1f87-fe7b-4d3a-9774-b0e00a638a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a8bc19fe-18a9-4800-a4ec-7e66d3c2990d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_131a1f87-fe7b-4d3a-9774-b0e00a638a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1a9817f-7cf7-4240-a7e5-acfb9a1b8f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7e2d9bb8-620b-492d-bc29-cb6f9a94a6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1a9817f-7cf7-4240-a7e5-acfb9a1b8f49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7e2d9bb8-620b-492d-bc29-cb6f9a94a6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7e2c0f8-bd88-4ed7-b651-4888d7b78ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:href="sgmo-20200630.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7e2c0f8-bd88-4ed7-b651-4888d7b78ceb" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_55d10c72-a4a7-4183-9372-5d65f45ec6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_55d10c72-a4a7-4183-9372-5d65f45ec6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_04db9491-2073-4ba6-8f3e-02dc2917b0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_55d10c72-a4a7-4183-9372-5d65f45ec6d2" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_04db9491-2073-4ba6-8f3e-02dc2917b0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_437f86f2-c3ec-46fe-901f-7783e11dfbba" xlink:href="sgmo-20200630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_04db9491-2073-4ba6-8f3e-02dc2917b0bb" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_437f86f2-c3ec-46fe-901f-7783e11dfbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_031726e4-4662-4ab7-9af4-da8ab044224d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_031726e4-4662-4ab7-9af4-da8ab044224d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_031726e4-4662-4ab7-9af4-da8ab044224d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_510b666a-c0e8-48b1-bbc5-b13c1eda97e9" xlink:href="sgmo-20200630.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_510b666a-c0e8-48b1-bbc5-b13c1eda97e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_c71aa6a1-3acb-4d63-a46f-2a1504e785cf" xlink:href="sgmo-20200630.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0258060-b9ce-4ac2-952f-1b3399029262" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_c71aa6a1-3acb-4d63-a46f-2a1504e785cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_15ecabff-5f9f-451f-80df-7cc21e5bb614" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_srt_StatementGeographicalAxis_15ecabff-5f9f-451f-80df-7cc21e5bb614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_15ecabff-5f9f-451f-80df-7cc21e5bb614" xlink:to="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_db1776c5-3923-40fc-9ba4-9e0fc3856e0c" xlink:href="sgmo-20200630.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_db1776c5-3923-40fc-9ba4-9e0fc3856e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_60f41bc0-0e41-46b8-915e-19a5ed6fe073" xlink:href="sgmo-20200630.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:to="loc_sgmo_RichmondCaliforniaMember_60f41bc0-0e41-46b8-915e-19a5ed6fe073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_0eb2a80a-b439-4775-93e5-687ef898255b" xlink:href="sgmo-20200630.xsd#sgmo_ValbonneFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7a4959f4-2f54-4b9b-8b15-eecc18fc2c23" xlink:to="loc_sgmo_ValbonneFranceMember_0eb2a80a-b439-4775-93e5-687ef898255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_803740f2-1c68-4440-bb68-a7f06c29e93b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_srt_RangeAxis_803740f2-1c68-4440-bb68-a7f06c29e93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_803740f2-1c68-4440-bb68-a7f06c29e93b" xlink:to="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_361a4e0c-7e00-4749-991a-5ebc7c4aa1ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:to="loc_srt_MinimumMember_361a4e0c-7e00-4749-991a-5ebc7c4aa1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_67a7cc4e-6a4d-41b8-9c77-361989858d37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_744a161c-8cf8-4e89-88a9-14e191a21273" xlink:to="loc_srt_MaximumMember_67a7cc4e-6a4d-41b8-9c77-361989858d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_us-gaap_OtherCommitmentsAxis_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6f14618e-5c3b-4ac6-a9aa-89a2f82c28f4" xlink:to="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingCapacityMember_947fda66-44d1-4898-8d0e-2d70b2430f35" xlink:href="sgmo-20200630.xsd#sgmo_ManufacturingCapacityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:to="loc_sgmo_ManufacturingCapacityMember_947fda66-44d1-4898-8d0e-2d70b2430f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingObligationsMember_5e6b56e2-27bb-414b-8ec2-e028d1a29dcd" xlink:href="sgmo-20200630.xsd#sgmo_ManufacturingObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:to="loc_sgmo_ManufacturingObligationsMember_5e6b56e2-27bb-414b-8ec2-e028d1a29dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NonCancelableContractualCommitmentMember_2092c6b9-d949-424d-8e21-073db8c7e07e" xlink:href="sgmo-20200630.xsd#sgmo_NonCancelableContractualCommitmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_dd877856-6dc4-43f9-b2de-f82f4b892c38" xlink:to="loc_sgmo_NonCancelableContractualCommitmentMember_2092c6b9-d949-424d-8e21-073db8c7e07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:href="sgmo-20200630.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_83a71cb6-9619-4480-a2d3-4e40e4129b2d" xlink:to="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_4a3ad0b1-dada-4bb0-8ff4-f793d0e672ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_4a3ad0b1-dada-4bb0-8ff4-f793d0e672ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_85c0aa81-347e-4a41-880c-e502ad3ad725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_85c0aa81-347e-4a41-880c-e502ad3ad725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2038d1f2-8fc0-4737-8a01-5b9e6485113d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseCost_2038d1f2-8fc0-4737-8a01-5b9e6485113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0d3f7d16-9e17-43fe-82f0-17b01381d237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_VariableLeaseCost_0d3f7d16-9e17-43fe-82f0-17b01381d237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4adb2c86-2ec7-4d84-8d90-7f555c944804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeasePayments_4adb2c86-2ec7-4d84-8d90-7f555c944804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c4859607-0cc6-4bce-b8f6-73362dad525b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c4859607-0cc6-4bce-b8f6-73362dad525b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dc693645-9392-43f7-853f-937102465432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dc693645-9392-43f7-853f-937102465432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_4f71dfe7-aaf3-4218-adb0-74d0d193c698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OtherCommitment_4f71dfe7-aaf3-4218-adb0-74d0d193c698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PaymentsForOtherCommitment_0b4a4099-e609-44ec-9ac8-7086455b5c6b" xlink:href="sgmo-20200630.xsd#sgmo_PaymentsForOtherCommitment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_PaymentsForOtherCommitment_0b4a4099-e609-44ec-9ac8-7086455b5c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d6951731-7195-4f37-b192-a63cf89fa87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_ContractualObligation_d6951731-7195-4f37-b192-a63cf89fa87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractualObligationPaidUponExecution_9d3e91d1-c5ea-4796-bcc1-066e808bb399" xlink:href="sgmo-20200630.xsd#sgmo_ContractualObligationPaidUponExecution"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_ContractualObligationPaidUponExecution_9d3e91d1-c5ea-4796-bcc1-066e808bb399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dd506605-b97d-4179-a5a0-490db1a0f2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_us-gaap_OperatingLeaseLiability_dd506605-b97d-4179-a5a0-490db1a0f2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a33dabd-8eea-48b6-bf39-a6e7fd198a48" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a33dabd-8eea-48b6-bf39-a6e7fd198a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_65e8e654-ec18-4613-aac1-ebc8960f53d0" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_65e8e654-ec18-4613-aac1-ebc8960f53d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_ea1d9467-e737-4b6c-8167-6df9a320ced5" xlink:href="sgmo-20200630.xsd#sgmo_LicenseObligations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_7fb30b1f-2410-49b8-9928-2770f236b712" xlink:to="loc_sgmo_LicenseObligations_ea1d9467-e737-4b6c-8167-6df9a320ced5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cdf79624-ad35-4ec4-b6d6-58647b706818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cdf79624-ad35-4ec4-b6d6-58647b706818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6769b631-a15b-4437-a32b-0b23f189e299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6769b631-a15b-4437-a32b-0b23f189e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_33eff22c-67f6-4933-b5ad-51a60593e9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_33eff22c-67f6-4933-b5ad-51a60593e9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f17e796-7fa5-4896-ab3a-daab0f522f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f17e796-7fa5-4896-ab3a-daab0f522f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5d540801-67ba-4562-8591-e4e133d3d3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5d540801-67ba-4562-8591-e4e133d3d3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_77de4007-2a88-407a-a000-b83663034d9c" xlink:href="sgmo-20200630.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_77de4007-2a88-407a-a000-b83663034d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b1135b5-dbfa-45ec-9f96-826bd1748786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4b1135b5-dbfa-45ec-9f96-826bd1748786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ab94e2d3-19d8-4517-a98a-579062bf1c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ab94e2d3-19d8-4517-a98a-579062bf1c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_292c096a-d7b3-4c61-b9b7-a0e25745db58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_292c096a-d7b3-4c61-b9b7-a0e25745db58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ddf3a659-3c32-48f5-9f3f-be95740e4afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ddf3a659-3c32-48f5-9f3f-be95740e4afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f75bdbd4-c455-40d7-a4a9-869640d58d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f75bdbd4-c455-40d7-a4a9-869640d58d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8807b94e-cf67-431a-a177-845168d4bcdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_607a3e31-8f03-4e21-a2a6-26e7ea4595d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_8807b94e-cf67-431a-a177-845168d4bcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="sgmo-20200630.xsd#COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e02fffda-1cff-44cc-97db-d066a967c4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_45b1b940-277b-4e13-befd-7738fada6da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e02fffda-1cff-44cc-97db-d066a967c4b4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_45b1b940-277b-4e13-befd-7738fada6da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f62e8dc-2c1b-4e60-b9ae-32fb6d5095cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_943ba956-852a-477b-9621-9ba3a258fd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f62e8dc-2c1b-4e60-b9ae-32fb6d5095cb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_943ba956-852a-477b-9621-9ba3a258fd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46000821-8348-4017-9d45-79239662c84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c100ab0-2c1f-4711-926a-5570473e1bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46000821-8348-4017-9d45-79239662c84a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c100ab0-2c1f-4711-926a-5570473e1bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dec2b419-1f14-4df5-a7bc-95b9d3920523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c100ab0-2c1f-4711-926a-5570473e1bf3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dec2b419-1f14-4df5-a7bc-95b9d3920523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dec2b419-1f14-4df5-a7bc-95b9d3920523" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5417bf8a-f074-444b-a5ba-a0ef8f28867c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5417bf8a-f074-444b-a5ba-a0ef8f28867c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7b7d41a2-cd60-42c4-94ef-e8f846142037" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e60f6b1d-2a45-4d8d-82c0-5225caf9a0eb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7b7d41a2-cd60-42c4-94ef-e8f846142037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a72ad6e3-f995-47a3-981b-830a70a496f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c100ab0-2c1f-4711-926a-5570473e1bf3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a72ad6e3-f995-47a3-981b-830a70a496f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3780d088-e4cc-47fe-84f2-868622588ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a72ad6e3-f995-47a3-981b-830a70a496f6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3780d088-e4cc-47fe-84f2-868622588ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bb901bc5-8895-4d75-b386-e6cd381f1a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3a7a5b59-76cd-4bf9-8bce-b93276b36394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb901bc5-8895-4d75-b386-e6cd381f1a10" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3a7a5b59-76cd-4bf9-8bce-b93276b36394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0e5d3e0b-a76f-4df2-a72f-9c954c5f24cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0e5d3e0b-a76f-4df2-a72f-9c954c5f24cd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a816864-0bfb-4516-8dab-373b86884ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a816864-0bfb-4516-8dab-373b86884ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b7f6ff54-c761-4309-9a7f-f79a87356099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a816864-0bfb-4516-8dab-373b86884ab1" xlink:to="loc_us-gaap_EquityComponentDomain_b7f6ff54-c761-4309-9a7f-f79a87356099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_594bd389-6883-4738-80a9-59c32438e727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7f6ff54-c761-4309-9a7f-f79a87356099" xlink:to="loc_us-gaap_CommonStockMember_594bd389-6883-4738-80a9-59c32438e727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0695bc6d-2acf-4aa4-a25e-1865dc692bc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:to="loc_srt_CounterpartyNameAxis_0695bc6d-2acf-4aa4-a25e-1865dc692bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f1bf22f-fee6-4397-872a-61508f4b3264" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0695bc6d-2acf-4aa4-a25e-1865dc692bc8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f1bf22f-fee6-4397-872a-61508f4b3264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_df9521d1-bce2-4e5d-b484-ff52dbdc2934" xlink:href="sgmo-20200630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f1bf22f-fee6-4397-872a-61508f4b3264" xlink:to="loc_sgmo_BiogenMAIncMember_df9521d1-bce2-4e5d-b484-ff52dbdc2934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_41d6e817-cd0a-4f32-99ad-dc33077fcd57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:to="loc_us-gaap_TypeOfArrangementAxis_41d6e817-cd0a-4f32-99ad-dc33077fcd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e0507db-953f-44f0-b5d3-6e7fb459d7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_41d6e817-cd0a-4f32-99ad-dc33077fcd57" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e0507db-953f-44f0-b5d3-6e7fb459d7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_12ee05a0-2a6e-4537-841a-494f055a03e4" xlink:href="sgmo-20200630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e0507db-953f-44f0-b5d3-6e7fb459d7d1" xlink:to="loc_sgmo_StockPurchaseAgreementMember_12ee05a0-2a6e-4537-841a-494f055a03e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e1b19fd-626f-4a4a-865b-34d4aab43519" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8e26a377-e068-4955-bd3d-10373872ed6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8e26a377-e068-4955-bd3d-10373872ed6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_10ee61a6-14ca-4797-bef3-e57c87a3776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_10ee61a6-14ca-4797-bef3-e57c87a3776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_077e5b9e-8d2c-4190-a482-f50ea9295a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_077e5b9e-8d2c-4190-a482-f50ea9295a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cb898311-3293-4b49-9678-0acb588aeef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cb898311-3293-4b49-9678-0acb588aeef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9fce542e-a164-42dd-9dbe-7c29f6450d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d510bd62-e64b-46e5-b841-e631014f1ed4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9fce542e-a164-42dd-9dbe-7c29f6450d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1bb10a62-7214-46e8-ac34-9df1ca9e0259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47865c40-7676-4a59-b39e-fec494efca62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1bb10a62-7214-46e8-ac34-9df1ca9e0259" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_47865c40-7676-4a59-b39e-fec494efca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f495e8f6-996f-4927-a333-d29c26cf9a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_e09cb02e-1813-4043-ab26-8d1daceb70e0" xlink:href="sgmo-20200630.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f495e8f6-996f-4927-a333-d29c26cf9a68" xlink:to="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_e09cb02e-1813-4043-ab26-8d1daceb70e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1c8e326e-46e4-4e8b-b504-c26d7cae5da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1c8e326e-46e4-4e8b-b504-c26d7cae5da7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2266a9d5-0b5f-4786-b316-e56e9301102e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2266a9d5-0b5f-4786-b316-e56e9301102e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_001a0a38-e1ec-499c-b4a3-f8ddd41a3ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2266a9d5-0b5f-4786-b316-e56e9301102e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_001a0a38-e1ec-499c-b4a3-f8ddd41a3ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_1807ff60-ce0d-487a-898a-97cce86774fb" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_001a0a38-e1ec-499c-b4a3-f8ddd41a3ef5" xlink:to="loc_sgmo_SangamoFranceMember_1807ff60-ce0d-487a-898a-97cce86774fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6fa57028-9f40-46d8-8c31-ff13066a5ba4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_srt_OwnershipAxis_6fa57028-9f40-46d8-8c31-ff13066a5ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2c1312b7-9103-44af-b323-9bef6715f1a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6fa57028-9f40-46d8-8c31-ff13066a5ba4" xlink:to="loc_srt_OwnershipDomain_2c1312b7-9103-44af-b323-9bef6715f1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_ca8baf18-5315-40ba-8dfa-306160fbe19d" xlink:href="sgmo-20200630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2c1312b7-9103-44af-b323-9bef6715f1a6" xlink:to="loc_sgmo_SangamoFranceMember_ca8baf18-5315-40ba-8dfa-306160fbe19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ed820e65-d748-4914-affe-f369dbe14f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ed820e65-d748-4914-affe-f369dbe14f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a6f2d9a-9c9d-4f5e-922e-1ba35a53b27a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ed820e65-d748-4914-affe-f369dbe14f4e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a6f2d9a-9c9d-4f5e-922e-1ba35a53b27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_68f49731-b122-47a1-a0bb-49f6aff6e966" xlink:href="sgmo-20200630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9a6f2d9a-9c9d-4f5e-922e-1ba35a53b27a" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_68f49731-b122-47a1-a0bb-49f6aff6e966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a78eb18c-9b2d-499e-b7a6-3ed2c455d486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a78eb18c-9b2d-499e-b7a6-3ed2c455d486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a2c1ce54-3783-48c1-909e-843d36006418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a78eb18c-9b2d-499e-b7a6-3ed2c455d486" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a2c1ce54-3783-48c1-909e-843d36006418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4c4faf17-bf86-492a-96b9-4d3eb70095f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_a2c1ce54-3783-48c1-909e-843d36006418" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4c4faf17-bf86-492a-96b9-4d3eb70095f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34514e71-5ec0-4e8b-b84e-8b35bc950f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34514e71-5ec0-4e8b-b84e-8b35bc950f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_59b29674-0de0-4413-8ebf-3fb9bd6699b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34514e71-5ec0-4e8b-b84e-8b35bc950f83" xlink:to="loc_us-gaap_RelatedPartyDomain_59b29674-0de0-4413-8ebf-3fb9bd6699b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_ea6369fd-49bc-4148-8e62-81355a6746fd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_59b29674-0de0-4413-8ebf-3fb9bd6699b9" xlink:to="loc_srt_ExecutiveOfficerMember_ea6369fd-49bc-4148-8e62-81355a6746fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5c09fb3-2d2b-43c5-87db-dcf95ba3c5c5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_99d2727f-8b1e-4b5b-b8ca-504458807987" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_99d2727f-8b1e-4b5b-b8ca-504458807987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d4d23d3f-1f2a-497a-8691-855043a7dfb0" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_d4d23d3f-1f2a-497a-8691-855043a7dfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7c280ca3-71af-4912-b4f0-b7fc58f44d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7c280ca3-71af-4912-b4f0-b7fc58f44d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_001831c7-a73c-484d-9a30-33f2279ec29e" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_001831c7-a73c-484d-9a30-33f2279ec29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2d55367f-1083-43dd-9579-274b4969122d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2d55367f-1083-43dd-9579-274b4969122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_9cf07f3c-f0de-4f98-bab7-205bc982d50b" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_9cf07f3c-f0de-4f98-bab7-205bc982d50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_2e28af25-89d3-4b78-a0d5-9777a872c492" xlink:href="sgmo-20200630.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_2e28af25-89d3-4b78-a0d5-9777a872c492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_182a57b1-081a-4383-be45-762363a83e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_182a57b1-081a-4383-be45-762363a83e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_3b5ba8e8-c7a3-4ad7-a206-4a949d8a4f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_3b5ba8e8-c7a3-4ad7-a206-4a949d8a4f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4fec4739-da41-43d6-8482-6c008186d59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1892c469-bc42-4712-86ab-43971bea8848" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_4fec4739-da41-43d6-8482-6c008186d59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_86eb306d-4d42-46ac-a1fd-92c28ff750f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_bc774504-a299-4109-9317-aa9b5f4cc79f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_86eb306d-4d42-46ac-a1fd-92c28ff750f4" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_bc774504-a299-4109-9317-aa9b5f4cc79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_355f77b0-a628-43c5-9d3e-51c7569f22b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_bc774504-a299-4109-9317-aa9b5f4cc79f" xlink:to="loc_us-gaap_MinorityInterest_355f77b0-a628-43c5-9d3e-51c7569f22b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7af3382d-63c0-43eb-816d-14d11036c231" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_bc774504-a299-4109-9317-aa9b5f4cc79f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_7af3382d-63c0-43eb-816d-14d11036c231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8c9a8564-ed72-4f7a-8c7f-f050363a15c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_bc774504-a299-4109-9317-aa9b5f4cc79f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8c9a8564-ed72-4f7a-8c7f-f050363a15c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_4cbbfb1c-c8d7-42ca-b95c-41897ad55b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_bc774504-a299-4109-9317-aa9b5f4cc79f" xlink:to="loc_us-gaap_MinorityInterest_4cbbfb1c-c8d7-42ca-b95c-41897ad55b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sgmo-20200630.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_166dddbc-5c81-4108-a436-b9e7c065b665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_fa7e06e0-3224-4f5b-a209-3a2a5e1d2568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_166dddbc-5c81-4108-a436-b9e7c065b665" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_fa7e06e0-3224-4f5b-a209-3a2a5e1d2568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20200630.xsd#SUBSEQUENTEVENTSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_23b7534a-6c85-4191-9c0c-4cf1c3ac1961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_23b7534a-6c85-4191-9c0c-4cf1c3ac1961" xlink:to="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_23b35201-66e7-4875-ad00-e05c0ce6f448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_23b35201-66e7-4875-ad00-e05c0ce6f448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6446c9c7-2618-4016-ad3f-f357bdb28a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_23b35201-66e7-4875-ad00-e05c0ce6f448" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6446c9c7-2618-4016-ad3f-f357bdb28a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b006ec0-9842-4ef2-a1be-4602c1f3b21e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6446c9c7-2618-4016-ad3f-f357bdb28a64" xlink:to="loc_us-gaap_SubsequentEventMember_5b006ec0-9842-4ef2-a1be-4602c1f3b21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_srt_CounterpartyNameAxis_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb297a27-2791-46b8-a35c-e4811a73b974" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d435ca38-e67b-4ccf-bbdf-c0576fa4cd22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb297a27-2791-46b8-a35c-e4811a73b974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d541b42d-7743-4215-87b9-9e0b31d0a6f6" xlink:href="sgmo-20200630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eb297a27-2791-46b8-a35c-e4811a73b974" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d541b42d-7743-4215-87b9-9e0b31d0a6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_edd0edda-f7f5-4378-bb66-57ebc44110c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_edd0edda-f7f5-4378-bb66-57ebc44110c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401fcbce-0bff-4aad-808d-6ed8dc94021b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_edd0edda-f7f5-4378-bb66-57ebc44110c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401fcbce-0bff-4aad-808d-6ed8dc94021b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_36d13090-8f24-48ca-b1b5-7b52ca8a59cb" xlink:href="sgmo-20200630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_401fcbce-0bff-4aad-808d-6ed8dc94021b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_36d13090-8f24-48ca-b1b5-7b52ca8a59cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c386754-59e2-4c5e-b0dc-a1f91f8c5660" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_srt_RangeAxis_7c386754-59e2-4c5e-b0dc-a1f91f8c5660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ded397c-4869-4bf4-ae1d-52787e3ad982" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7c386754-59e2-4c5e-b0dc-a1f91f8c5660" xlink:to="loc_srt_RangeMember_7ded397c-4869-4bf4-ae1d-52787e3ad982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_77b25c5c-cf16-4d65-a41f-49e587eefca5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ded397c-4869-4bf4-ae1d-52787e3ad982" xlink:to="loc_srt_MaximumMember_77b25c5c-cf16-4d65-a41f-49e587eefca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38d2728c-5e2e-4a64-a3d8-35db708dd8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38d2728c-5e2e-4a64-a3d8-35db708dd8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_38d2728c-5e2e-4a64-a3d8-35db708dd8e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45aeac95-a78d-4d6c-a446-72f101a2db04" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45aeac95-a78d-4d6c-a446-72f101a2db04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_28d81a91-eb95-4309-ae37-9d433bf63d76" xlink:href="sgmo-20200630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b623097d-3a5f-4f60-9ff7-6912fac80af6" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_28d81a91-eb95-4309-ae37-9d433bf63d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a360ff52-2fa6-41a0-8ff2-591c0080e242" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_srt_StatementScenarioAxis_a360ff52-2fa6-41a0-8ff2-591c0080e242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_619ec21c-027f-4992-b00b-0b02904c42a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a360ff52-2fa6-41a0-8ff2-591c0080e242" xlink:to="loc_srt_ScenarioUnspecifiedDomain_619ec21c-027f-4992-b00b-0b02904c42a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0b6e3476-da0a-4c97-948e-9ceb88a9e244" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_619ec21c-027f-4992-b00b-0b02904c42a0" xlink:to="loc_srt_ScenarioForecastMember_0b6e3476-da0a-4c97-948e-9ceb88a9e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f4853a4c-bad6-4f6a-8e14-5c3bce2dd1b6" xlink:to="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementPeriodOfCollaboration_aa332cf8-98d1-49b7-8cbc-88eb3f0c4f72" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementPeriodOfCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_sgmo_CollaborativeArrangementPeriodOfCollaboration_aa332cf8-98d1-49b7-8cbc-88eb3f0c4f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration_41dba052-c10f-4d94-94d5-f6d8aaee6601" xlink:href="sgmo-20200630.xsd#sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration_41dba052-c10f-4d94-94d5-f6d8aaee6601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_eafe881f-81c3-415e-be9a-8d9c00f4b9fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_us-gaap_ProceedsFromCollaborators_eafe881f-81c3-415e-be9a-8d9c00f4b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_afb6a510-0b00-4d59-8e35-b9b8fc0ac261" xlink:href="sgmo-20200630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3f01d056-914a-4f1d-bba3-b10162105933" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_afb6a510-0b00-4d59-8e35-b9b8fc0ac261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ^7"AX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***;)((UW$4 .HJ'[8!UB;ZTINXQ&7QR.J]Z ):*C-S$JAG; ([
MT?:4.-O(/4CM0!)13!,K.549XZBG!@1D\4 +12!\]!2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !395#(0:=2')7IS0!\
M(_\ !?']H+XL? ']E/PS<?"'QC>:%J/B7XAZ7H4FJ6,FV6WCNITB9UR""0&R
M![5\%_L^?LN?\%%/BQ^U9\=O@/X3_P""EGQ+U.]^$QMCHT-Q);J-4:4*2LIV
M?*!GM7V!_P '*Q _9;^&2X^7_A=WAS\_ML54O^"5.3_P5Y_:Z4GD3Z;@_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#\W?\ @Y8_Y-8^&/\ V7#PY_Z6Q52_X)3_ /*7K]KS_KXTW_T%
M*N_\'+'_ ":Q\,?^RX>'/_2V*J7_  2G_P"4O7[7G_7QIO\ Z"E 'Z7KT'TH
MH7H/I10 R15(^M,DB5[=H9VW*00<]Q4KYVX I@CVCYW_ -Z@#X8_X**?\$7/
M@E^UKI,?CGX3:E-\//'NG77VNS\3^&[51=7,B\K&[.2 N><X[U\Z_LF_\%6_
MCU^P]\5H_P!C?_@H3HUXUKI=P+'2_'+I+<RZBBX_>SN%5$8LV.O:OUR$: ;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPCXDM]4AOK&);B:V;*I.(U,B'W#$@UZ"  20* %HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@!:*3<?[AHW'^X: %HI-Q_N&C<?[AH 6BDW'^X:-Q_N&@!:*3<?[AHW'^X:
M%HI-Q_N&C<?[AH 6BDW'^X:-Q_N&@!:*3<?[AHW'^X: %HI-Q_N&C<?[AH 6
MBDW'^X:-Q_N&@!:*3<?[AHW'^X: %HI-Q_N&C<3P5H 6@YQQ2;%]*"J@=* /
MS>_X.6-I_98^&)4]/C?X<S_X&Q53_P""5 0?\%>?VNSG@SZ;S_P%*N_\'*87
M_AEKX9[1M'_"[O#N2?\ K]BJA_P2IV-_P5V_:Y"CY3/IV[V^5* /TO7I2T
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M "T4FX_W#1N/]PT +12;C_<-&X_W#0 M%)N/]PT;C_<- "T4FX_W#1N/]PT
M+12;C_<-&X_W#0 M%)N/]PT;C_<- "T4FX_W#1N/]PT +3=YSMP,TNX_W#3=
MP#%0.,=: %23<Q7'2G#/>H_F"AD!XZK3T&!0 M%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 &1@GTI%=6 8=_6F32/$N]4)YY JLM\9
M;E8G3:I/RD_Q4 7&8*,F@,#TK@/CW^TK\%_V8O!8^('QU^(VG^&M'-P(?M^H
ML53<?X> :_/KQ+_P<9+\1?C'XF^%O[$G[)VO?&*PT"[$(\1^%M0A\F<$ A@)
M&4@'/I0!^HN1C.:,C&:_,"/_ (*9?\%2OCDP^'/AW_@FY\0/AS<ZFWDV_BS5
MI+:6"R+\"5E60DA>O%4/B-\(/^"]7[,7A*Y^-<G[6T/Q;322K'P%H/AXPW6I
M GHCN0HQ[F@#]3$F1U+#/!QR*4,I&0:_*X?\%K_^"C/A/3;.;QG_ ,$@/B;%
MPL<MS)>6@61P!D_ZWN>:^B/@;_P6J_8L^(6A6NG_ !6^*^D^ _&J[(];\%ZQ
M<EKO3[DG_4OL!7=R.A[T ?9!E5<9SR<=*5F"C)K/T_6;+5;&#6+"\66VNK=)
M;9TZ.C*"K#V((-7+:0RH684 2@@C(HI/3;2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG36_Z<(?_0!0!^=7_"W?^#E[_HU?X+?^%<?_ (W2?\+>_P"#EWI_PRQ\%O\
MPKS_ /&Z_278#T-*44]J /S:_P"%N_\ !R]_T:O\%O\ PKC_ /&Z/^%N_P#!
MR]_T:O\ !;_PKC_\;K])=B^E&Q?2@#\VO^%N_P#!R]_T:O\ !;_PKC_\;H_X
M6[_P<O?]&K_!;_PKC_\ &Z_278OI1L7TH _-K_A;O_!R]_T:O\%O_"N/_P ;
MH_X6[_P<O?\ 1J_P6_\ "N/_ ,;K])=B^E&Q?2@#\VO^%N_\'+W_ $:O\%O_
M  KC_P#&Z/\ A;O_  <O?]&K_!;_ ,*X_P#QNOTEV+Z4;%]* /S:_P"%N_\
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MB^E&Q?2@#\VO^%N_\'+W_1J_P6_\*X__ !NC_A;O_!R]_P!&K_!;_P *X_\
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M_P '+W_1J_P6_P#"N/\ \;H_X6[_ ,'+W_1J_P %O_"N/_QNOTEV+Z4;%]*
M/S:_X6[_ ,'+W_1J_P %O_"N/_QNC_A;O_!R]_T:O\%O_"N/_P ;K])=B^E&
MQ?2@#\VO^%N_\'+W_1J_P6_\*X__ !NC_A;O_!R]_P!&K_!;_P *X_\ QNOT
MEV+Z4;%]* /S:_X6[_P<O?\ 1J_P6_\ "N/_ ,;H_P"%N_\ !R]_T:O\%O\
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M5_@M_P"%<?\ XW1_PMW_ (.7O^C5_@M_X5Q_^-U^DNQ?2C8OI0!^;7_"W?\
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MNOTEV+Z4;%]* /S:_P"%N_\ !R]_T:O\%O\ PKC_ /&Z/^%N_P#!R]_T:O\
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M;_PKC_\ &Z_278OI1L7TH _-K_A;O_!R]_T:O\%O_"N/_P ;H_X6[_P<O?\
M1J_P6_\ "N/_ ,;K])=B^E&Q?2@#\VO^%N_\'+W_ $:O\%O_  KC_P#&Z/\
MA;O_  <O?]&K_!;_ ,*X_P#QNOTEV+Z4;%]* /S:_P"%N_\ !R]_T:O\%O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4@')/K2T4 ?EQ_P '":YO_A\<_P#,[:)_Z6Q5^F_A;!\+Z<#_ ,^$/_H
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M/0?^@[8_^!2?XTG_  D>@GIKUC_X%)_C7X:/K7B/83%_P7O\%@CK_P 2F?\
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M1:18:7*LD@<X)!*@<5Z)\#O!/[7OQ=^#=O\ $J]_X*V:'IMU.A+V,NDRE@
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M7_X+U>"S'C@?V3/Q_P".THU?Q(#N?_@O9X+/&!_Q*)^G_?- '[CMXG\/ _\
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M?@O/\'_$IGY_\=IW]K^)'C\Z/_@O9X+VG@G^R)__ (F@#]R/^$CT'_H/6/\
MX%)_C2_\)'H/_0=L?_ I/\:_#4:UX@6,?\;ZO!>>Q_LF?G_QRD?6_$<;<_\
M!>[P5M/;^R)__B: /W*_X2/0?^@]8_\ @4G^-!\1Z".NO6/_ (%)_C7X<+JO
MB565#_P7I\%C<,I_Q*9^1_WS3!KGB%R8W_X+T^"\CI_Q*9^/_': /W*_X2/0
M?^@]8_\ @4G^-'_"1Z#U_MZQ_P# I/\ &OPX&J>)MOF-_P %Z/!90<%O[)GX
M]ON4C:UXCC<@_P#!>KP6!_=.D3\?^.T ?N3_ ,)'H/3^W;+_ ,"E_P :!XCT
M _\ ,>LOPND_QK\-/[:\2RL?L_\ P7M\% CO_9$_3_OBC^W?$'_+/_@O;X+
M_B_XE$__ ,30!^Y+^)O#Z===LO\ P*3_ !I&\3^'"G.N6?\ X$I_C7X=)JOB
M/SU67_@O-X,8$9 _LF?I_P!\UB_L1>&_V^_VZ_VJ?BA\#/A!_P %,-.O-"\
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M=XE\*^-/V?/B)J?B73]8TUC/'KMXLJEGDV H 3D8[U/\>?A__P %2/B5\?\
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M $$T >U1_P#!'#]CJ2-6D\$V_/7_ $)*D_X<V?L;C_F2[?\ \ DKZP3[HI:
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MW7[&GP_N'=F8^%;');O^Y6O?UW8YKP+_ ()DG=^Q3\/L_P#0JV/_ *)6O?J
M"DV_[1_.EHH 3;_M'\Z-O^T?SI:* $V_[1_.C;_M'\Z6B@!-O^T?SHV_[1_.
MEHH 3;_M'\Z-O^T?SI:* $V_[1_.C;_M'\Z6B@!-O^T?SHV_[1_.EHH 3;_M
M'\Z-O^T?SI:* $V_[1_.C;_M'\Z6B@!-O^T?SII7+;>U/HH 8S<E&!YZ$4Y
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M>"VT#(S7NGQA^#/@CXZ>$)="\0VD4OFI_H]W$H+QD9(VMVYJC\:O@/X)^/\
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M'>PQG/E/CYT/T.1^%>3?%OX!^*?@1XUN?CS\ M/DG\R8SZUH-H,?;CT&2>F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !0<8YHH(R,4 5KBT><;E8@@
M\8-?G)_P<+?"GXEZ=\*O"W[8_@P6<EA\'WGU76+><Y>1"I4!%_B.6K](R#C"
MUY7^V=^SMIW[6/[-OBG]GO5[X6EMXHTXVL]P4W! 2#G'?I0 ?LB?$?1OBO\
MLY^#/'NE:E!.;_P]:RSI;2 ^6[1@E2!T(]*]2)4MCIMZFOS9_P""&O[0_@CP
MP?%/[#OC'5(](\<>'M>NO[*T>5OWEWIL!91<#T! ''O7Z2@QR QD9!_6@!X
M XI::'0*.PZ"EWKG;GF@#\@/^#S/_E'7X5_['B/^2U^#W_!'W_D_WP/_ -?9
M_I7[P_\ !YG_ ,HZ_"O_ &/$?\EK\'O^"/O_ "?[X'_Z^S_2@#^TCP%_R)&B
M_P#8*MO_ $4M;-8W@+_D2-%/_4*MO_12ULY&,T %,D(0[VZ4OG1\_-TK.\3Z
MY:>']!O-=O9E$-I:23N6. %52Q_E0!^;O_!?'Q/'XW^)W[.'P/TWQ+<0PZQ\
M5#;^)-.MKDJ+FT> ?)(H/S*2.AXK]$/AIX \._#'P7IG@/PI:+;Z?I=JL%K
MB@*B#H !TK\K?V(O&7PQ_P""F_\ P5A\<_&3Q%Y?B3PSX.TRU;PC8R F/3-2
M@FEBEG0_WB,#\*_7"&%T.2O)ZT 3]**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAZK!B2(_=E6OF:3Q1\0_^"?/CE-(\1SS:MX!U*Z"VUVYV16;R-A8P.^T']*
M*OA"_P#B%_P3^^(D7@SQ";G4O FI3;=.NSNF>TB7^^W(3)KZ<\:^$/AY^T-\
M-VLK^"VO[+4;7"2 *YB++U![,*?J%E\/?VA_ATEE<6$.L^']:@RSG[I7L:^8
MK+QE\3OV _'R^%?&-S/J?@34KS%CJ4GRQVTDC<1@?[(('X4 <5:ZG\8?^"8G
MQ&_LO4);G5_ASJ4^8'RT\MI$O !ZA.<U]HZ!XB^'O[0/PYCN["6VOM-U& !P
M2KE"R@D>Q&:->\-?#3]H?X<?9M7L(-8T75H-V6Y5QS@_G7Q/'/\ %3_@F/\
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M,C_DRGX??]BK8_\ HE:]^H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$/_  1]_P"3_? __7V?Z5^[_P#P>8J?^'=OA5@W'_"<1\?@M?A!_P $??\
MD_WP/_U]G^E ']I'@/\ Y$?1?^P5;?\ HI:UBJ[2"_ZUD>!#CP-HQ_ZA-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+XP^(7_!/?X@1^'_ !#+-J7@#4[H"VO9#MCM9)&SL ']T$#\* (/!-Y\2?V
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MR A7 ^6/(Y[UA_\ !9KQ=X9^)G_!,75_$/A76$O+'4[VR:WG3^)6=AFO!OV
MH_B[^Q[^SA8Z[+>W.J^"-5+K/$WRQZ=D*SS#'4\@?A0!XK_P1X^,_C;]E_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&092/G@#(KQW]C_]LCQK\/?%<'[/7[37F:?K.GN+87%RY8W##DDGIWH Z?\
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M;^QIXP^"GBA_VGOV7)I;;5[:;=J.EV2A1/"6#2DMC/W01^- '<_M,_LT^(_
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MSFM+5M$T[QKX?DT;Q%I:3VM]:!+VRDY4AA\RG^5?/'@WP5^TA\)IO%UGX/\
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M[_E%]X<_[&/5?_1]?8G[0'_)!_&W_8HZE_Z2R5\=_P#!M]_RB^\.?]C'JO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$,EG15Y8DX'/K0!7OS\1/V$OB ^H6/VG4? FJ76^>&0M-+;RR-@89B=B*#G
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MWKAH]472OC5JGQ!\7?#.RTTV.CMYOB:&4O.\*9_=E<],5A_LQ:IXS^)WQ/\
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M;[_E%]X<_P"QCU7_ -'U]B?M ?\ )!_&W_8HZE_Z2R5\=_\ !M]_RB^\.?\
M8QZK_P"CZ /O*BBB@ KXK_X.'?\ E#M\;O\ L57_ /0A7VI7Q7_P<._\H=OC
M=_V*K_\ H0H ]6_X)D?\F4_#[_L5;'_T2M>_5X#_ ,$R/^3*?A]_V*MC_P"B
M5KWZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** # SF
MD[G'6EI!]XT ?$W[</A<_MC?M'V_[#FI>(-4TNPCTJ/6;FZTC4)+65D'WE$D
M9#=*[N+_ ()@? RU_9YA_9JM_%WC7^QH+001WC^*;@WF <@F;=N)SWK)_:*^
M OQD^&_[8>G?MO\ P4LF\47ESIT.@:MX5NY!%;VMF2!)>*RC<SJ,G;G'%;%S
M_P %3_V3KC]HAOV4K#Q3JC>-I+AK86)T>01>:!G'F=/QH P_V$?%/B/X%_$K
M4OV&/B;JDVL:[IMM)JVG:LDK/&-/8GR8W9B2T@4 $YY->D?\%"?!&L_$7]EK
M7?"VALJW-P\)3>N1@-DY'TKB?V._V6/B7HWQNUW]J+XS>(+E]<OA-865C+M9
M19!V\I@P /W2.*]V^.7PWO?BW\,]0\"Z=XKN=$GOH\)J5FH,D7N V10!\W?M
M,_"K]G+QE^Q!XH\ :#X;\&Q^([OP&;.&XBTFW$@N?(52<A-V[<#SG->&?"/]
MFSX::1_P2-^'?P2O=)\*/XTTK2+.*_NO[,A^TM*LS,27V[R<$=37"_M;_P#!
M'7XW_"?X ^._C7H?_!0/QU)<Z+I%UJ%IIZ6-OB1URP3A,^U>'_"'_@G_ /M*
M:O\ \$Y? G[:%S^W+XY_MW7;.SO;G06LX=JEIBK*3Y>[HOZT ?N'\.;#^SO
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M]MFVR(1DC#CD#/H:XS]M3]D+0?VA_"Y\3>&F%GXHT]?.T_4+= 9)G4?(A)X
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M6\RE]HW)E8^5)'RGW%8__!:7Q)X8^*7_  3-UG6?#ES%=V.HZA8O%*&YP78
MD=C7@G[$?Q?^*7[''[/FF#QZD^K^!M7+0VM_<,3]GD(5G(50,8!4<T >/?\
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M0KG. 3C-?'?QS^"OQ6_8,^,"_'#X'V\UWX-OI6DUC3T.R.W=V    R<*">M
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M^4.WQN_[%5__ $(4 >K?\$R/^3*?A]_V*MC_ .B5KWZO ?\ @F1_R93\/O\
ML5;'_P!$K7OU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>9(R#*IDYP,UQ?[#_P"V3XFBU=OV;/VER;/Q5I["VM+J=RQOF RS.QP!U[4
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MV+" .Q.X!0!P,4 ?+W_!2:_^+7[(?[.FO_ ;Q#%=WGAG4=;M'M)V#-Y:(^
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M/@;T(SG .1^%?+?QY^&OQ1_8-^()^/?P2MI=0\'7LYFU_0 =L-NQ(50JJ"S
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MS\(ZI-I^F)\6-'>\\.VT(\B67[3&S3GN7- $W_!P_P#L4'P3^QOXX^-_PSU
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MB?M ?\D'\;?]BCJ7_I+)7QW_ ,&WW_*+[PY_V,>J_P#H^@#[RHHHH *^*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLY?M-2^./,^&GQ-LX]+\8Z61#J=CN/E"7&2$=L;Q@]10!YG^Q=^VU?ZEJ0^
MO[16=,\3:<QBMKRZQ%'<QJ=D:JO)+$#KGG->J?M3_LHZ!\;]).NZ6JV7B*S4
MMINH0$Q[><G=MP6)^M<Q^V!^Q-X:^.&GMXR\%M_97BS3D$]C>6: /*ZCY5+'
MH,UR/[$_[:'B"+71^S7^TBAL/%.E,+6WNI6+"](&6=G; SSCB@#>_9@_:FU+
M2_$#? G]H2,Z?XCL_DM-1N5$45U%G;&BKR2V!G.><UV'[4/[*7A_XR:0VO:
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MX R3Q0!B_M:_L?ZIXQNX_B_\%;V/2?%6EX=90IV30J=[H47&68+@$^M?'?\
MP19\4>/?&'_!5;]J7Q#\2='FLM:DL=/6Z@FBV,"'4 XK[9_90_:TM/B<[_"K
MQ_C3/%.FDQW,#Y"R%!\Q#-C/X5\S?\$Z3G_@MS^URF<K]CTW:?\ @8H \5^#
M^L?%+2?^"T5Y'\.54F32KH70>#>?++_/WXXS7ZR^-M%UC6/!UY9:))9)?W$(
M"F]MA)'N_P!I3U%?FU^QD2?^"U6NL5&!X8U'G\Z_234;;7O[6@ET\F6"Y8^<
M';'ECVH / NC^+;+1$@\97MK<3IPGV6#8@'; [5MR1AL[L*/XLBO-O _P.\7
M>&/BC/\ $"?XR:WJ=I-"T?\ 85T%$$1)^\,<Y%;_ ,<=<\?>'_AOJ6H?#'08
M-3UR%!]AL[J4HDK>[#I0!F>*="\9ZI=7VB^(/%EG%I=]:-#;Q(A20.PP#N!K
M:^$W@:X^'7@K3/!]S>FY&GP>6DS,6+#U)/)KS6;P5\2?'W@&R\9_%[5)O#EY
MI-RMY<6NE2"97C3!*G(S@UT@_:?^&S:5IVJ1S7YBU)-UGBQ;D9QSZ4 >G37-
MO:PM<7%PJ(@R[,> *QO$'B[3M*T&3Q)YHFMA@I)$W!'UJ/Q)HI\;>$+C2+74
M);4ZC9;5G08:,.N0PSWYJAX<^'D'A3X66GP\O[Z34S9V1C$]RHW3L,D%L>YH
M Y_5_P!IGP/H>CVNOZHK6]C<W1@,\LH"H1U).*P/V?O 'B!_'?B3XFW?C^UU
MK2M6U+S]"CLF;$$!4#:V3@G(-9GPB_9OUS7KB^\1_'#1(!%//)#!X5#^9:11
M!CMG!X.]EQD5[;X5\)>&O!.EKHWA?2(+"TC4".& 855% #/%6C3:EI,B6MO;
M/<QJ6LY+F 2")_[W/3\*\T^ ^E>,M5\2ZUK'Q0\8:-KUYIU]Y&G-I=KY;V41
M7)C<G.3GFO2_%VGGQ9X2O=)T;Q"UJ;J%HEOK-PS0G^\O;(KGOA/\+M+^$OAR
M>PL+I[V[NB)+N^G4"2YD QN;'>@#N"X &3QZ>E>$_M/>#O!OQ-\76?@6XOKR
M#5WTZ2[MI8;UHX_+CY8%1USQ65\2/A/^T'\;/B!=6FJ^/]1\%>'[-%DT^]T*
M=7DNW.0R.K#@ 8->F/X$\/>"_ PUS6)7U;4M(T.:(:U=1_Z0R;"6Z>N* /@#
M_@DI:K9_\%6?VA;0$LL?A33DSGGB?&<U4_X)D)O_ ."E?Q$'\/\ ;6H\?A5+
M_@C#XXTGXC?\%1?VAO$OA_S?LDWARRC4SQ%&RMR0>#5[_@F.P;_@I9\12AY7
M6M1&/7B@#]3**** /S$_X+A?\GW_ +)O_8WW/_HIZ_2;P1_R*6F_]>,?\J_-
MG_@N%_R??^R;_P!C?<_^BGK])O!'_(I:;_UXQ_RH U:*** "OS@\.?\ *S)X
MG_[(?8_^@FOT?K\W_#W_ "LQ^*/^R'V7_H)H _1]/NBEIJ$X7Z4Z@ I&[?6E
MI",X^M 'Y6?\$8O^4BO[67_96?\ VUCK]5*_*O\ X(Q?\I%?VLO^RL_^VL=?
MJI0 4444 <C^T!_R0?QM_P!BCJ7_ *2R5\=_\&WW_*+[PY_V,>J_^CZ^Q/V@
M/^2#^-O^Q1U+_P!)9*^.O^#;\9_X)?>'.?\ F8M5_P#1] 'WG1110 5\5_\
M!P[_ ,H=OC=_V*K_ /H0K[4KXK_X.'>/^".WQN_[%5__ $(4 >K?\$R/^3*?
MA]_V*MC_ .B5KWZO ?\ @F1_R93\/O\ L5;'_P!$K7OU !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 &><4F"<TM% 'E?Q7\,?M$:GX
MC6?X6^/=,TVP,05K>[LC(V_N<@CBN(U7X)_M<:SK5EK=W\8- :ZTXG[._P#9
MC83/J-W-?1'D+G.>?6FFT0G<&(_O>] '!?!SP_\ '71[F1OBQXXTW58RI$8L
MK,Q8/;J37H5-CB6+[M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV'B&T7?8ZE&2H4@[B&VX))..]<G^V9^P[H'QNTC_ (3GP$YTKQ38'S[*^LE
M>5U'RJ6/05Q_[$7[9'B3^W'_ &;OVE$&F^)-'D%K973.6%\% +.[M@9RV.*
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M?M*>&(_&?@J=+7Q'IZF?3+RU*YN9", ,_8 $UY9^R/\ MD>(? /B9O@-^T1
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MV;X2-P!P3M;'!]Q7-_$CX8?"7]KKX41WC^1<B]MQ-87B*&DBX)5>OR\U\G^
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M!I'B O+*==C1D]MI.>E?,_[7_P"QIXK^"_C%?VI_V79Y;>_M2LFM:% 1%!+
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M\#R2_%W4H;K5&U*<QR00>6%@W?NU(R>0.]=?XAMI;G2KFW@?:\ENZ(W]TE2
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M+O -M?6KPRIX8LE:.5"K#]RO4&O?0<C- "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !14<MS%$I9R>/04J7$;IO4\4 /HI@N(B"03Q
MUXHBN(I3A&Y]#0 ^BC(SBC/.* "B@D#DT@8$X!H 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+C_@X/\ ^/WX??\
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M3M2-%&3G:N>:Z[]IW]E30OCAI US1=NG^(+("6QOH\KD*=VTA>3D@5#^UO\
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MQ@^'/[3OPU@\0Z#Y-Y9WT9COK2=0'!&-P9,YQGUKY6^.?PU^,G["WQ,'QO\
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M(/*N[<X<Q.RX*'(X89-4OAM\3/AQ^TO\-[;7M)$5_I6HQ;;JRN% 8CC(=,Y
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MKG"H/<DXK]#_ !UH_P "/C5XGA\,>(_$$-YJ&DO_ ,@Z*X(*%NSKC!K\J/\
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M+DEM8WD7T)4$BL_QU>ZUI?AVXU'PO;V\M]$,+%=R[(W^K4 ?/7Q*\1:]XO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'Y<?\'!__'[\/O\ L=M$_P#2V*OTX\*_\BQIO_7A#_Z
M*_,?_@X/_P"/WX??]CMHG_I;%7Z<>%?^18TW_KPA_P#0!0!;G[5^)WB?P9\7
M=2_X+;?&#Q_\'=4,>J>']6MYHK1(RS7#$< #('YU^V,_:ORR_9JN[6'_ (+J
M_&N":YC5Y-6M!'&[@%^!T'>@!W_!LWXXTW4?@K\5_ _BK58?^$CG^+.K7%[I
MK_ZS!FDW,1TQFOHO]LS]AS5I=6E^/?[.TPT[Q):L9[JUA0DWC]MJC %? O\
MP2N^ 'Q3U3X9?&3]H;X(:Q,GB#1OC3K'G67G^7'+;QW$C,N1DDD#&*_3C]B_
M]LK3?VG/"HTSQ):?V5XITU%77=.EC,060]H]^"_Y4 87[%'[9=E\6D;X<^/S
M_9WB/3T,,]K=.-[[/E+8&>I%=)^UA^RTWQ&L(?'GP\E&G>*-,0M97B@XW$Y.
MY5^]^-><?MR_L<:\EVO[07[.L8L=?T]EDO;2W;RDFB3YF/&2S'GBND_8B_;@
MTOXX:#%X*\9;M/\ $UBBQ:E:7B&+,AYPN_!;KZ4 :G[*/[5][XPN&^$WQ1LI
M-+\2:?E'@O" \\:G:L@ SPV,CZU<_:O_ &8+OXB(OQ'^'-R--\3:4";.Y53A
MLG+95?O$^]7?VA/V7-*\?,OCSP/<-IWB>S(EM+BTPGVDKRL;M_<)JM^SE^TY
M<>*KBZ^%/Q0A33_%NC2"VOX7RL$LF,DQNV/,&".10!G?LI?M5R>/)W^%GQ5L
MI-*\2Z:"K6]XP#S*IVJX SPV,BI_VL?V7Y_'LD7Q0^%]RNF^+=)0FTN5!(9<
M[F!5<;B< <U<_:'_ &7K7QY>Q^/? 4@T[Q!8E9[6>U(0W3J/ECD;^Y4'[.?[
M3,GB_5;CX6_$N%=.\2Z1)]FO8G!6.9\9)1FQO'(Y% %7]E+]JIOB,\GPV^)&
MG2Z5XGTP;;F"[8!I4!VJP S@-@D5G_MJ?L86'QHTK_A8'@5EL/$VEC=97<0(
M+ '<00O4G KI/VC?V6;/Q\1\1/AE<G3/$^G 3VSVQ$:WK*/ECE;^YUJ#]F[]
MJ2T\97#?#/XCQ_V?XHTH_9K^W=2L4L@&6*,V-XY'(H \]_8K_;EO;^_/[/GQ
M_B;1O%6G'9!-?D+]M!.U$11DYPI/->H?M._LN>'_ ([Z.-7TR2.Q\260$NGW
M\8*X"G=M(7DDD"N9_;(_8:T#XX:6_CKX?SMI?BW3U,^GWMIA#+(!A0S^G)KD
M/V'/VR]2?Q,_[,WQ\0V/BO3=T-K=W (CN4C'S,97P"22.G6@#I_V7OVLM9A\
M1']G_P"/\ATWQ%8$):7]YA%U')PL<:C)R%&>:Z_]J7]E?P]\:]+7Q'H2"SU^
MP ELKZ,D<H=P!"\G) K._; _9/TKX\^'DUOPY,VF>*++=+H^H6&%:27&!N?L
M,$\UQO[(7[4_BFTU@_LY?'R+[!XFT_,=A=N3Y-U#&,%VE; WDD8'>@#8_9@_
M:UOEU>3X _M!R?V?XHLL16MW=D(-18G"I&HR<@#/-=!^UM^Q[X6_:#\-MJFG
M0QVFN6D?FV=X@QDI\P7"C))(%5/VO?V2=+^-^D0>)/!DS6'B?32TUAJ%OA'D
MD(P,O]":YS]D7]JS77U-_@'\?8CIOB+3V*6-R0?+N88QC<TC8!8G''>@#A/V
M1/VM?&7P=\9K^SC^T.\EM<02B"RO[O"*QSUQDD\"O8/VL_V1O!_[2'A$^(M!
M$=MK=N@GL+^/($FT;E "C))(%0_MC?L;Z/\ M%>'WU[POBS\1VR%["[B(5I'
M/ W,>G6O(OV2?VR?$OPL\7']G_\ :.MY;2[MW,-E=E&974':I+L .3B@"?\
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M%_X(E_"O]CCPS\=]2^$_[0WP+TG7=/U#1+,:/J&H:1YRI<.=S&1ONHN!U)H
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M$G:"<&@#:\;?#WQ]^P5XYG^)_P +;*XOO!%W)OU71X.6@B7L68@#)]*^>?\
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M^%-^!WQT\!?M&>"OM6GRA;LQA;^QN%V.C$?=VDYZ5Y-\<?@CXK_9Z\0'X]?
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M]<U0Z!X>TRY2[@O=(NOWUS(I_P!5(I_@..:]4FO;73V8WETJ GYWF8*J_B:
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M_P""8?'_  4K^(V.AUO4<Y]<4 ?J71110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1L!B21TZT =%^S1^U7JR:TOP&^/LATWQ1:,(K*XO,+_:#$X"(HSR%!/-=?\
MM-_LMZ%\:](7Q!I"K:^(]/*RV-]&"#E/F"X'7) J#]K;]D;2?C_X<.O>&+@Z
M9XITU3-I6H6C!'>4C R_;@FN-_8T_:H\0#6)/V>OCW!_9_B/3]T=E>S K%<P
MQC&XRO@%SQP.M &E^S%^U3J::\_P)_: F.F^*[0B*RO+PA1J3GH$49P0!WK;
M_:\_9 \)_M%>&6UK38HX->LU$EK>(""Q09"X ZD@5)^US^R#IOQRT9?$WA"\
M;3_%&FAI=,O;9PC-(>!N;MQ7+?L?_M2:Y/K3_ /XUVXT[Q!IX9;>XG!2*XB3
M@-YCX!8^@ZT >??L>_M3>,O@]XT7]F_]H662TE@E%O8W-X0H?U(')KV3]K7]
MDCPA^T?X4/B/05BAUJ",2V-_&#\VT94  =<XJ/\ ;)_8XT3]H703K'A9C8^)
M;-&:PO(B$,CGNSU\]_";_@H3?_LE:+K/@+]J5WM%T.RGFM[R12?.$:G:JLV
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MVCSY\9.7PHPH^5<?C7?_ +,W[5O@_P#:$T V5Q;+INNVB[=0T.Y<-+'@A=Q
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MI7(?08[:<&XB@*8Q,G6)\Y^4\]* .E\!:'\7(?&NH^(/%OC"*YT:> 1V&E+
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MJ71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M48D" KT48W8K]D_ OB*T\<>$-'\9:<SBWU73+>[A##!VR1JXR/HU &]1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^7'_  <'
M_P#'[\/O^QVT3_TMBK]./"O_ "+&F_\ 7A#_ .@"OS'_ .#@_P#X_?A]_P!C
MMHG_ *6Q5^G'A7_D6--_Z\(?_0!0!;G[5^)WBKX<_%;Q)_P6Q^,7CKX/:N\6
ML^']5MY;6SB0LUPQ&,#M^=?MC/VK\L/V;+_3[;_@NQ\:K6ZO8HY)=7M!%&\@
M#.<#H#UH /\ @V8\>:5)\'OBMX"\4:O$/$K_ !6U:YO-.D'[PGSI-Q(Z=:^J
M_P!IW]E/5[;Q.?VBO@% VF>*+1S/<6\"Y:^?V X&/>OSP_X)7_LX>/\ 7_A9
M\9?C_P#!;6KB+Q+HGQHUAY;4S[(YK>.XD9EXY8D#&.]?I=^Q/^V7I7[3GA3^
MRO%]H=)\6V"*NJ:9<PF#]X>T:O@M^ H U_V7_P!J/1/CCIC^&-:06GB2P5H[
M[2)F!D;9PTA XP2#7%?M._LG:WIGB)?VB?V>5-AXFM6,]Y;VZ9:[8^@X XJM
M^V3^RMXHMM0'[0/[/,AL/$.E!9KVRAD\J*YAC^9@0.69L'CO77?L9_MEZ-^T
MUX/;2_$EL=*\4:>BIK.FW,1@S*><1J^"PP>PH U_V6_VH_"GQZT=_#NILEIX
MBL$:+4=)F8-(=GRM(1TP2":\I_;+_8@N9-3?X^?L\0-8^)8"9KFWME):Z;/)
M & . *L?MB_LK^*M&NO^&BOV?F-AKVF8FO=/MG\N.YBCY((7EBW.1CFN[_8R
M_:ZTO]HWP0L'B6-=.\46T:IK&EW*>41*1DB-6P2,$=J .9_8F_;2TWXH:?\
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M[MCA8P#Q7[L_L_?LS^#?VC/^"=.EZ?J21Q7ULDTNF7^#F&4I& _')XK\1O\
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M (.8?^A$^"7_ (,E_P * /TFHK\V?^$D_P"#F'_H1/@E_P"#)?\ "C_A)/\
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M (,E_P * /TFHK\V?^$D_P"#F'_H1/@E_P"#)?\ "C_A)/\ @YA_Z$3X)?\
M@R7_  H _2:BOS9_X23_ (.8?^A$^"7_ (,E_P */^$D_P"#F'_H1/@E_P"#
M)?\ "@#])J*_-G_A)/\ @YA_Z$3X)?\ @R7_  H_X23_ (.8?^A$^"7_ (,E
M_P * /TFHK\V?^$D_P"#F'_H1/@E_P"#)?\ "C_A)/\ @YA_Z$3X)?\ @R7_
M  H _2:BOS9_X23_ (.8?^A$^"7_ (,E_P */^$D_P"#F'_H1/@E_P"#)?\
M"@#])J*_-G_A)/\ @YA_Z$3X)?\ @R7_  H_X23_ (.8?^A$^"7_ (,E_P *
M /TFHK\V?^$D_P"#F'_H1/@E_P"#)?\ "C_A)/\ @YA_Z$3X)?\ @R7_  H
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M_P"#F'_H1/@E_P"#)?\ "C_A)/\ @YA_Z$3X)?\ @R7_  H _2:BOS:'B/\
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M[V_'S]G+QK\"_&TW[0WP#MY9,S&35]&M5YN2Q&Z3)X 517MW[/GQ]\$?M">
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MNEQ"X9'4%6]0>E?DK_P4"^"?PG^$'_!83]GJS^&/PUT/P]#=>&-0>5-&TZ.
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M8EI00?C-XG(P?^G^2@#]& 21DMCU&*!D]'_2HXIRS!2O^]D4>8^[;&!QU)H
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MY>YYW,_MPH%>$^'?^#9/]FW2;J;6-!_:K^,=E<396:>#Q7,CN,]R'R:UY/\
M@W&^#4EN\!_;-^-K9^4Y\9W'([_\M* /?OV*OVW++XN6Q^&?CZY6R\2Z<-DL
M<TF7?!VCC\#6]^UC^RW'\3XH_B!X&N!I_BW2US9ZE$N6,8.YH\?[6 *^1],_
MX-?/V7="U)M;TW]J+XO6UU(?FN(/%,RNQZ\D/FMEO^#<3X--E6_;4^-N#TSX
MUN/_ (Y0!])?LF_M:W?BK4'^#7Q5MCI_BO3@%N+6XDS(RDX4X]P,U<_:X_97
MC^)9C^(?@*<6/BK3 'MK^)<L8U.YH\?[6 *_/?\ ;D_X("?!C]FS]E?X@?M)
M>!?VH_BP?$_AO0'O+.YG\4S'S'5E #G?DCYC7YL>(X]2^#_QT^&WA;XE_M!_
M&_7/#OBWP#)JVJVOA?6[NYO1=?*%V*C$[.3F@#^BK]DS]JV3QS<S?";XI0_8
M/%>G*$N;:X?,DF3A>/?&:7]K;]E)OB#+%\3_ (:W0TWQ7IBAH;J%,M)$AW-%
MC_:QC\:_ R!/V);36'URS;]KF*^GP)[M;2_$AQT^;&:T(_%7[*3;D?Q7^V-R
M?XEU'&* /WD_94_:E/Q!<_#7XHP?V?XLTD!;BUN'S)N/ Z5PO_!4/]DC3OB5
M\(/$'QG\%7RZ3XI\.Z%<7EMJ4:9;;#$TF/S45^(<-K^Q+IVL-KUG<?M<I>S'
M,]TEK?AVQZMUKSSXYZ[X;\2ZIJ7A?X1_%[]H'3K(>'IYYH?&^H7D(E(C.5(D
M(RIZ8H _5?\ X-V/VG?@]XT^%2^*/B+8P67Q/\:HJZWXCGE_>:[*C8!V]L ?
MI7W]^TY^S'H/QJT=/$.EJEOK]CMET_4$7YMR<H ![@5^2'_!&K_@@)^SU^T_
M^P9X#_:5\3?'7XB:+KNM6;320Z%KTD,<#!L?(%8;:^MW_P"#<[X,D*G_  VA
M\<0,X 'C2X_^.4 ?1'[-/[6&L6_B$?L[?'^X-EXJL6%O;7MVWSZF_4L%[8KK
MOVF_V7M!^-&E+XIT!5LO$=AB:POT7+,Z#*@?C7QS)_P;$?LSW.O#Q)-^U;\8
M7U")MR7C>+)C(#Z[M^:TO^(<3X/*N9?VT_C=G.%"^-;C_P".4 ?0G[,?[6]_
M)XD7]G?X]S&R\7:>WV>&2[?Y]58#+. .F,UO_MA?LA>&?VA?"1U33[-+?7;7
M,EK=*N68@?*!7R-)_P &QW[-4WB&/Q'/^U5\7VU%22+X^*YO-4_[V_-;2?\
M!N-\((R!_P -H_&XD'(_XK2XQ_Z,H [']D/]KKQ3\%/&?_#-?[0DKP/9RBVT
MV\NWQ\J@9P/J:Q_^"]7P,\"?$#]D/4O'\>EQ'4;>REGMKH#E\1J5Q^=<7?\
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M?@";1-7MXI;:]@Q$Y]#7PEXA_P"#9+]G'Q7+')XC_:M^,%^L;!HVN?%DSLC
MY!&7XQ6G!_P;>_!:TC2&W_;/^-J*O"*OC2X '_D2@#?^,GQ?^)?[./P<\>_
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M _'%S+?> =3N/+T[49#LBMF8EF]S@;17TUX]\ _"_P#:/^&(T76+>#4=)U2
M2VDQZ'@[6'XFOA+7/^#9W]GCQ';BV\1?M:_&34(U.8UN_%T\@0^HR_%2V?\
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M ")5/P__ ,&TO[.GAI'M?#G[6/QCL8SRQM?%DZ;B?H] 'GW[6W_!N/\ L.>
MK^V^*'PI_9PM+C2++:-2\/0$_.FX%I2W^RH-=]^SS_P1(_X(E_M!^#HO$?AG
M]EW16E5,7MND[$QD<'/XU=O/^#<'X+7L36U[^V;\;9H7!5XV\9W!# \<CS*J
MZ'_P;-?LY^#8'M?"W[67QCL4E_UBVOBV9!Z]GH \[_:R_P"#<S]A?P1JUM\3
M_A5^S;9WVCV.T:AX?MR?FC!!>4L>P4&O!/\ @E=_P3+_ ."='[6/_!0/X^^
M=4_9_LYO!_AFTLCX=T=+E@EBS, ^".N>:^RKW_@V_P#@O<636\W[9GQKE23Y
M'1_&=P593P01YE>V?\$VO^"/?[/W_!,GQ-XK\4_!SQCXCU>^\7P11:K<^(;X
MS,0C!@023SD4 ?GQ^Q-^QKX<^"O_  5GNOAS^S)JB>#]%L],N9YK.-#()%1N
M5Y]1D?C7[-ZOX[\+:!K.F>%M:U>.&_U5O+TZW<\S,!SBOS<_8W2$_P#!:77$
ME /_ !36H8S^-??>F?$_0/$WQ6N_ [^"[LWVB3!8-1NK ^4">Z.1_*@#O9M
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M1T_Q2N/V=O&7B&32++2I6EN(;6Z:&UU,0GFXBZ"5F ^5AG.:^M/^"$NO._\
MP5J^&OA"RUW7YM.TWQ'&+.RUV5RT&5.<*WW<T ?U:@'NV:6D !;<"?3%+0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7=:C++<Q0K86$1DF(=L;]HYVCN>U 'Q$?^"9'_!8<#=_P^>\08'WC_8Z\?\
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MQ^UY\;RMM \K!?'UWDJJDG_EI[4 !_X)K?\ !7E>O_!:S6O_  5I_P#$T?\
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M[ W_  6]\/R6LD'_  55\22V;01RWUP-+4"V) +@_+SM.1^%=9X=_P""<O\
MP5R\3:1'K.E?\%H->DBD4,KKHZX(_P"^:_0CXF:!K_B/P)JWA[PO/$E]>6,D
M4#S'Y0Y'&:Y/X6:/XA^ WP'TVT\;*U[J>GV:IJ LP7#OD_=]10!\8C_@F#_P
M6$=2/^'S>OD'[P_L=?\ XFN3\6?L%?\ !8VR\.ZE/\._^"O?B#Q#J&EW"Q2Z
M7%I2J03SUV]A7W\/VC? T/PVE^*.MVM[I\,<LD45C=IY<T[I_"BGEB>U.^#M
MMX-L?#=Y\8=*EO;*#Q9(M]<P:LY4P-C:%PWW>G2@#\^/#_[#W_!8BT\.6.I?
M%#_@L-X@\.WM_=-!!8S:2K$L,8YVUH:E^Q'_ ,%1])\=:;\-[W_@MSKD>M:O
M:O<:?9'1ANFC4X9A\O;-??NBQ^,_%?Q&O=;OY-%U'P9':)_9+0A9)UN@3YA)
M],8KL9/#WAZ]U.VUU]&MVOK>(I;W,D(+Q*>H#8R!0!^;WB?_ ()^?\%8/"-Q
M9V_B'_@M=KT#WTWE6:MHR_O'QG ^6N.\7?LC?\%6_!&HR:=XT_X++Z[92-$\
MED)-(7]\JCC'R]SQ7ZB_$G1M>U+PE=-X1LK";6(HBVEM?QAD27L3FN%^!OBJ
M?XQ:5>V_Q*\#11:UX?NA97DMS8!8YGP26BW#E/<4 ?F_H/\ P38_X*Q?M@_"
M75_!WQ2_X*I:[_PC&O6[VES:3Z4I2[CW#*GY?8&N(UC_ (-TOVO_ ((>)]#^
M.'A/_@H]?'7O#FG?V1I=ZFD#=:V3D;T'R]./TK]I+#3--TR(:?8V<5O$G,:0
MH%4'Z"O/OB3\-/&!\+3V'P[U!9;R[UF&XN!JDA9%B#?.%STXH _/WP]_P2-_
MX*6>*M'AUC2?^"OFK21RCY7&B+R>X^Y4FN?\$<O^"G^FZ-=:@_\ P5OU>3[/
M;O-L_L1.2JDX^[[5^GVFV$.G:3%:001(J1C*PJ  V.:X?P3\8H?B+XSO/!L'
MAR_MTM&DCDEN[<JDFWK@D<@T ?F-\/O^"77_  5=\>:!I/B"R_X*B:TEMJ$K
M+=.-'7%NH[GY:@^+O_!N%^V3\=KPWOQ5_P""F]_JD[VIM]\VBJ,Q$8V\+7ZP
M_$'Q-I7PC^'&H>+(=#DE@TV R&RL(,LW/15 Y-<CX)_:.T/Q_P#$>Q\$>'-+
MNYEN=)^V2WRQ9A@;&3$[#A7]J /S:_9:_P"".7_!6C]GK3KC]GCX6_\ !2W7
M?"O@?PN!'X=E@TI3'<(>3M&WC%=]XZ_8-_X*J?#FSMK_ ,9?\%L=<LX[R[6U
MMY'T9?GE8X5?N^IK]/0RKA5.2:\6_:-T#XE_$'7[7X>^ M0\/-%(4DO;742I
MN(XL_-)&#R& S@T ?G9!^R5_P6VU#X['X4Z#_P %3/$=SIEO<F+4]<335VP#
M'!(VUZXO_!,?_@L*A+-_P69\0$X^7_B3K_\ $U]Y?#/X;Z#\-/#EOX6TGS9Y
M;5-CWMVV^6;W=CRQ^M:FJ^+/"VA2Q6.KZ_:VL\L@6*.XG"EV/0 'K0!^>4W_
M  3&_P""Q$43./\ @LAX@+L?F']CKS_X[4@_X)F_\%A8H%>?_@LYX@3<< '1
ME_\ B:_1#5K?5)[-TM&03DC86/%>9_M1?&'Q+\'O">D7_A^Q6:]U+4%M!))%
MNBA8@?._HOO0!\9Z[_P32_X+'V6ER367_!8CQ!=SY'EH-)4$C_OFFZ-_P3(_
MX+&SV/F7?_!8CQ! [9W1G2%_^)K[;T_X8S_%9/#7Q \8^+)QJFFV9$PT2\*V
M=PS,22 IPPK9^)?Q>TCX/IHEOJ^C7]X-8U 6,3V<)?R3C[\A'1?>@#\S_@[_
M ,$#/^"A'P'\=^*OB7\*_P#@JGJVDZSXUU3^T?$EY!HXW7MSL">8WR]=H KT
ME_\ @F'_ ,%B=HDC_P""S/B!R3S_ ,2=>/\ QVOT8L+B*Y4RQS*Z#[K*>"*-
M0E=;*1;0CS-IV_6@#\>OVL?^"1W_  4@^-L=C^S[\:O^"I.L>(]$U.>/4Y+6
MXTE0HN('!B;[O4$YKUSP=_P3!_X*_6.A0:='_P %@=?LXK:V2&W@_LA?W<:@
M*H^[Z 5[?X4^)/Q4\=^+O&/AVQ_L^Q\6Z9XB6'P]_;2;(YK/&9&7=][G&"*^
MI/ T/BP>'H(O&[6YOU0><UJ/D/ Z4 ?GZ?\ @F+_ ,%ACR?^"S?B#;C@_P!C
MKS_X[7+?$3_@G]_P6D\.:3<S>$/^"M_B'6]2MX]R:>FE*K$]A]VOT2UCXPZ1
MH_QCTWX.SZ!J,ESJ6G2W4>HQP$VT80@;6?& QSP*S_&WP&TGQMXVTKQ]/XAU
M.UO-(N_M%O!;7;)%.V"-LB@X9>>AH ^%O"W_  38_P""S6K^&[35=8_X+$>(
M;&\GA5[FR;2%)A8]5^[VK0/_  3&_P""Q#?,G_!9OQ!CN?['7_XFOJ3Q+XU^
M*WPAAN_B5\6=.DU&4ZW'9:1::!$75;61MN^51W'4GL*]BT+Q?H'B)532-3AN
M)?+5I$AD#;,C^(#I0!^?'_#L7_@L+;GC_@LSX@PW_4'7K_WS2M_P3'_X+!Q+
MMD_X+-Z^?^X.O'_CM?<7QT^+Z_!_PC%XF7PY?ZFTE]%;_9]/MC*XWL!NP >!
MGK6[X-\1?\)OX8MM;:PGMC<KEHIT*NOU!Z4 ?G3#_P $W?\ @JYX[T:]TR'_
M (+1:Y>6TA>UNXO[(7D$$,I^6OE+3?\ @V/_ &P?AU^U38_%?P+^VA?)K5U?
M&6[\5II8W0L!P^"O-?KUI?[)?AOPIXRN_&7AWQ5KGV^=GE2VEOW^S[R<\KG'
M6NCE^%^M^*]?T#QGXTUJ>+4]"=G\C3K@K!,3_?4'##ZT ?G[_P .8_\ @J!_
MK)?^"N.KKQ@$Z(O_ ,14G_#F/_@I^Z*C_P#!7C5^1P/[$7_XBOTXMGN)H]C@
M#:V>:YOP@GQ:7QGK\WC2?3/[#\\'P_\ 9L>8L6.?,]^M 'YN3?\ !(S_ (*0
MVVH2:5-_P6&U19HH?,=#HB9"^OW*YG5/^" _[<OQ!^*/AOX\ZE_P52U&Z\0^
M%[:6+0-7_L90]M'+G>!\O?-?97[0G[-_Q-_:+^.EA\0?AE\1[:/PW9/#%?K8
M:D59GC.)$.T\\@\5[/?^"/B!HOBOPO9^$;N'_A'+"W=-6$[9F<Y^7'K0!^;7
MP6_X(3?M_P#[*EEJ4_PE_P""K&JZ%!>W<][J3P:./G>5R\CGY>[$FNP\)?\
M!.O_ (+%^*3=:C'_ ,%@_$$-@L@_L^Y_LA<3H1]X?+ZYK]+W@BCA^RW">:).
M&5N>#ZUY/^T1XS\=Z7K>B?";X5Z&ZWNJ1F1+PVY^S0*C\JS#A21TH ^09/\
M@FC_ ,%?HHFDD_X+/:_B,;F_XDZ\#_OFDM_^":7_  5[O8UN(/\ @M%KQ0C@
MC1U_^)K[X\1:S%H&@:;H^O6L\\FI!+:62S4G8^T;B2.@S5?1/A!IFAV-YI-I
MK5^\5].LK-)<DM&1V!SP* /SFT7_ ()]_P#!<&Z^+.I^"-3_ ."K/B.U\/VM
ME'+8^(&TQ-MW*Q.Z,#;QC _.K.K_ +$?_!43P]\1+'X5ZE_P6XUNWUS5+9[F
MQL3HPW2QH0&8?+VR*^^Y?@?X=L_'T7C*]\9ZDDYV+#;/?L(G*]MN<&NRU?PC
MX?UJZ_M*\TFW:^2W>"*^,(\V-&'(5^H_^M0!^>__  [,_P""P1#,O_!9W7@%
M&?\ D#K_ /$UGC_@GG_P5E;6X_#G_#['7/MDL9=8!HZY('7^&ON_P)\&_#G@
MG3;_ ,,Z;XKU*[-TK&5KN^9WC#-G@D\5C_"_]E/PC\+_ !U<^/\ 3/$VLWMU
M<.Y*:A>M(B[NH4$\"@#XOM_^";W_  5RGU.XT>#_ (+4Z\9[90TT8T=<J#T_
MAJS_ ,.QO^"PVW</^"S6OCG_ * Z\_\ CM??&@_#G2]%\=:OX^@N[IKC5H$C
MN(I928T"G(*CL:Y_QC\1-&?XHVGP6DTG5_M5W8/?1:C;QM]G39_ SC@$^E '
MPUJW_!.S_@K1H%[:Z?J7_!:?78[B]?9:0G1UR[=<#Y:Q[G]B+_@J)8_$&'X5
MW'_!;K6UUZXM#=1Z=_8PW&(=6^[7V?KO@KQ]XJ^,?AW4->\4Z9'8Z!?>=;VD
M=R!.^000XSSUKV0^&_#\NL+XDDT>T:^2(HEV85,@3T#8SB@#\O?$/[(?_!2S
MP]XK'@77O^"X6M)JCOL%DVBC)/I]VKOA#]@?_@KSXBU.30-1_P""Q^O6MV 9
M+>W.D*2\0Z/]WI7Z6WOA+PGJ=^=6G\-V4EYG*W,MLI;/KDC-<Q#X+^'^B_&%
M?%8\2_\ $Z;3O)&FFZ'^J/\ $$S^M 'PQJ?_  3:_P""O&C6;ZAJG_!:77XH
M4&7<Z,O3_OFO,O$W[.G_  4UT;PK;^*_#W_!:K6K^RN=9_LTR+I  $^[:5^[
MUS7Z7Z5\;/#6L>./$7@?Q%9OI\.A2K']KU./RX;D'NC-PPYJUXU^!OPW\?Z/
MI^FRZ=%#9VNH)J$"V**BO*""&..H- 'YW^&OV&_^"L'BR+4++PS_ ,%H==N-
M0TL[;ZQ31US$V,X/RTGP;_86_P""P'Q7T6YU6/\ X+%>(+1K:^EMFB_LA3DH
MQ7/W?:OT[M/#>C:2T]UI6FV\,ER<W$D<0!<^Y'6I-)TO1M(9H=+M(8%<EG$*
M!06/4\=Z /SM;_@F+_P6&"%G_P""RGB C/0Z.OS?^.UY[XN_8R_X+&^%?&VI
M>#H/^"N_B&;[#IBW:3?V4OSEL_+]VOU+\2^.?!WA!XX/$WB:QT]Y1^X6\N%3
M?],GFN(TK5/%&J?&N_CU>]\.3>'9-*B-G''L-Z9#G);OL(QB@#X6\#_\$Y?^
M"QGB_P +6'B&]_X+%^(+:2\@$AA.D*=G)X^[6/\ $W]@[_@L%\/;W1+%/^"P
MFOWO]KZC]F/_ !*5'E<9W?=K]-[S4M)T%%L(KB&.4P,]M:A@&95'.U:\L^%O
M@[PQ\4O%ES\>=0CUJ"ZFF:RCTS4&98HC"Q'F)&> 3GJ!S0!\8^%?^">O_!7;
MQ/?:C967_!9C7@VG7/DRXTA>#C./NUS/[1'[$'_!;+X.^#U\8>'_ /@K!XCU
MJVA+-J!32E7[/&!]\_+ZU^B&BR_"7X/:IK]TGCF$7VJ7#7ES9W5\"Y=5^ZBD
MY_#UK1^#?Q;T/]H;P%)XAB\+W=K:27$MNUIJUKM+[&P25(Y4]10!^97[,W[*
M/_!83X_^"]1\4:I_P5N\0:3%:3@1EM*5O,3:3N^[[5V"?L#_ /!6_7?"MWKW
M@+_@LQKVK2VZ-Y-I'HZ@RN#C;G;7Z3-#X&\ ::9+B+3]*LV(1SM6*,L> .PR
M:Y[QA8_$"*#3Y?@I;:3!"\Y.HBZC !CQP5QWS0!\#^#?^";?_!9_6-/CO/$/
M_!7CQ%IURZ@FV;25)7U_AK8/_!,7_@L$Y;'_  64U\JPP!_8Z_\ Q-?H7ILM
M_!I GUMXDDCA+74BG"@@9)!]*\^\!_M2?#?X@_$S4_A9X0FFO;G1@K7-U 0\
M6&./O#WH _-#QO\ L9_\' 6@^/K?PUX8_P""A?BG4](>55EU5+!0L>6 SC'8
M9/X5Z_!_P3'_ ."Q,T"-<_\ !9?Q DC*"8SHZ\''3[M?;_P;NO$-AJ&M:+X[
M\2Z9<WL^HO+IUM:3AG6WY^\,YR*L:#\;?#VL^/M?\!2:3?69\-HC7.HWL12W
ME#?W'/!H ^(_V+?^"3_[0G[)7[1NM?M*?'']KB[\:W,GAJ]@DU2YL!&;=G1O
MWG 'W3S^%?9/[,NMGQ)\.;+5#\4?^$M\Q3C5S%M\[GKBNXL=6T7Q/:2Q:9>V
M]]"ZE9#&X>,@CE3V_"O&-3_:N\$_#;XK#X&:/\*-:C:&?RC<Z?I1%MZY4JN,
M4 7?VM+[XZ6)T:?X+ZA=*T>JP'5Q;XXM P\PGVVYKU?3;ZP\3:!%?:?="6T>
M/*2 <.*Y?XCVOQAUNTTV[^%<>F1QS3Q-J":HGS>02-X&>^,U8^(GQ)L?A8^F
MZ/'X7OKEKP$0C3[4M''C^]@<4 /\!>)HO'WAF\G\.?Z$+>]EMRZ<_,I()_2L
M?Q!X6U?XC:;)\,_'7A9KW2I6 FU"1OEFQR&Q7>>';6PCTU)+&Q2W6X7S62.,
M+\S#)R!WK@_V@/CQ%\#;&WEG\+:GJ7VOHNF6IE*\XYP#B@#<^)7@Z75?A/J7
M@'PW#M>;2#:6X7^'Y-H_E63^S'\/+SX3_!S1O!>KL3>VEDL=TS#!W FNRT:>
M3Q#X>M[V1&B-Y:)(5(VLBLH.#Z$9KR+]G3QAXXU[XC?$GPSJMC<10Z%K M]&
MFO(V"SJ8U.X$_>&3UH ]L6(J?,C;(/3 [UYSXA^"<>B3:SXT\*:K_9>I7A>=
M[U%R5(7G^5=-\(U^*J^&9!\8FT\ZI]NE\HZ8H$?D;OW>?]K;UK;\175Q!H5Y
M<6T:RR1VLC)&RYW,%. 10!Y)^SIX^\9ZI^SQ>^)FUN7Q=J]M?W:0.1M:<HX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<NHM7^!'P?N->^%EKK.H:IJ:R-91:JSSF&5L-\X;.%YQ77_LTCXLW'@H:O\
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M9?#;0?BO+J,<,*ZM%I,-OLVX*Q(,+S]*]&TS2+72-.CTZV=RD2X4LV37EWQ
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M,7@_]H/5/$7PNL-+U!;>*Q FU1!B"4%L8C<?Q#'-5OA=)\.-/U.;X:V/PZO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_)7]N/_ )2Y^!O^QD7_ -%O7ZT-
M(%.#Z5^)W_!77]HNV_9S_P""F7@_Q]/\/-<\1BWU[>-/T*W\R>3$;<*,')H
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MPS\%V7@?P]$L<%E&4MRBXQ5/XB_!GP[\3[NUO]8U34[9K*X2:);&^>(,R$$
MA3R..175R3K#:EKAP"%_$4 <C\+_  MXM^'.C7EEX_\ B)/X@GN]3DFM;F\
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M;&20?*LG8M[5PO[,?C+Q!X]\.WFA_$#PS)#J?ARX6RN[JYM@$N'P27C)'W:
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MM6U*';YT84MN4]Q5B;Q?\5_B!!H&M?">]TZ&P35Y$\1"^A#.]NO&(SV;=WH
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M[F-S@'H:\\UKP;\-]/\ C+_PL77_ !1+%J,^F?85TZXOB+>1#P#Y1.TL?7%
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MR)E0MWZ^M9'[*_C"W^(WPD&KMXE?6F?4+B)KN9<$A7QM^@KFOBWXN^''CCQ
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MYOX MKL&EZI9>*/%NG:I=MJT[1&QDW>7%N.%/N!7>73LD)BM77)4[2W.#VH
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M7CEUXM^,M_XZT?P)^S3\3O"TFB:3;1P:E9:H1/>N$(#MN)SG //K0!T'Q,^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% #)-I4C ZU\$?\% O^",WC#]L?XXZ
M;\<?A[^U?KGP[UC2;PW%G<:19QR-OVD=74XQFOO<*2Q+=>WI2*KC;OP2#U%
M'XF?M\?\$7OVK?"O@+POK7Q0_P""E?C3QU;VWC;39+32=5L8%C6<3H4<%4!R
M" :^[]$_9V_;$\*>$K.\N/VD]<U">6!1=6LYB5;< <<[:Z'_ (*M7']G?!CP
M[?I&[F+QKIS"-/O-B=3@52OM>\:>+_ ?Q'U#XJ>%]=?PQ/81?V;IND%H;\KQ
MD(XYS]* .2!_;]^ WQ ?QR+:Y\::$NF'?9ZA>K'&KXSN&T#)%'PI_;SU?PQX
MTOO$W[0MS<Z99^(Y0UCICJSQZ8!U5#Z?6O8_A?9>#?VL_@YIMKJ7ACQ1X=L]
M!U",6MMJ-V\5Q*T.-I<C&]3CD'K7H7CSX(_#WXB^''\'^*?"UDT5RFUIK>U1
M7C^C8R* .0^(GQ0^'?Q'\-Z+K&C7L.H6ZZC%(FX\KT.[&:U]2^&WC#Q5\0M,
M^(VE_%W4(M#A+-/X>6-?)NP>@;(SQ7R]\9OV?+'X;_%>X\(?LY2:NOB?2=)&
MJ,VIWCSV<L*C/EK&3C?Q5WX4?MR_$K5OB'X'T/XVZ0?"JM$ZZY)J5J+>*=\\
M&,=A0!]#>,_@==?$7XKVNMZY?/+H&G)%-9:8Z@QQW*]9!WS6U\<-7^*>G^&S
M>_"73/[3U&)U L1-M# GG)[8%,?XO7I^(\?A"Q\+WMQ9S6L<\6J019@97&0-
MWTKH_#'@#2/"6NZOKUI>732:O<B:Y$]P65&  P@/W1QT% &EHTE^^CVC:A9B
M"=[=&N8@<[9"HW#\\U@_%_X<:!\4O ]UX,\521I:7#JRF3&$8?=//H:L^//%
M]YX2?2TMM&N;W[?>B!C;)GRE_O-Z"N'_ &A_A?\ $3XG^*=%T(>(H[;P8(BV
MN6]J[17DDROF,I(I!"^H[T -\*_LX'3?!\'AOX@^/IO$4=O.SVKWZJNU3C:@
MQC@  5Z1I>A:?I?A^/0+5%\@6YB1%Z*I!&!^=>5?M<:1=P?"*TT7P[8:O/J2
M)Y>DS6,S 1R! %:7'WA@5K_LX>(?$.N> =$TN^\16=W>:78"#Q"D9R\=SR<'
MN..U '6_#[X8>%?AKIITSPUIL<2M,\D[(,9W')_6N,^.<&B> _%6F_'&V\-1
M7VJ6(%A [9!2*5P&((^E>E:O!>MI]Q%HUPD=U)'B)Y>5S]*\K\=Z[\3_  )\
M+]3O?B-HD?B)KC4([2TM=&M 72&3*ER#GD9SGM0!G:QX<O?&?Q!\16OA?X=6
M=FWB'2X8+SQ7;39E9>N",X^4UZ1\+OACX>^$^A1Z!X=MXQ*ZAKR51@SR8Y<^
M]9OP#^$WA[X6^"8-,\/2ZB4E+2D:I=-+*I?YB"6YX].U./AGX@6'Q43QE>^(
M+1- MK&47%N<[]V,ALYQ@ &@"G\9],\3ZCXD\.:;I?PQMM=L[J]9-7OYY2K:
M='M.)% ^\<X'XUT/@3X<>&?A]IT^EZ):11)<W'GR(HQEO6K>F>//"NNZ(?%&
MEZ[;SZ<N=M]%(#'P<')JIK^A'6';Q!H]\[226#I;,DA\O)4X; ]Z &:I\4/
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M_B[P+;W<L\D#I!+D^7E_SXQ6EXJOM;\2Z_X;T'P#KT]F^FRQ3:O9PKA7MR@
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MTKSC]KGQAX@^'W[//BCQ5X7N4AN]/TUI(991E5.1R?SKRS]AW]FKQ3H4%O\
M'KXH>-KK4=<U>W\RTB@OY/LJ02C.#&6*[O>@#T^'X V%U\9[KXO>+M<DUIK:
M59?#MA=1C;I;]S&1ZCUK'_;&\>ZU\/\ X?Z9>^&O$UQIMW=:W;Q*UHNXREG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9QWK-&6/&%C/% '=_%2QN;OP5?QZ=X9@UFXEMG6/3KABJ3DCA"1T!KR7X)_
MO4_A\=)\9>&_ =KX5O+^+S=?\/:>Y,*2] NXY)P *]:^&7C"\\9^&_[8U3P[
M=V$GG,OV>Z7#  ]?I53Q_IWQ2O\ 4+>7X>ZO96D,8/VE;R#>7/;'- '4+,EQ
M;(MYMW'LQ[UR.L:+\(/A&M_\1[[0H;.6>Y4WEY!"6=Y&X!///2N6^*D7Q&M]
M#\-KK'Q TC3;PZX!-+,A1;A.,1J,_>KU1+."]TP6FJ6\-P .1)&&5CZX- '!
M_%+X+V'QDU+P]XEN]7D6#2;U+^TAV ACM&,^G%1^*/A+'KOQ[\._%#^S4W:3
MI\T G[Q[R#@?E1=>(O&G@'XMRWWC?QMH]MX1U*VCMM!TQHMEPUV,[ANSR",8
M&*] BD$T)F'KPO<4 22W2PR@RSX#<*">M<+\9OVD/A/\!A WQ0UF:WBN<&(K
M;EQR<#I[UB?M(:GXS\,Z3;?$/2]3AATKPU*;[5+9E/F7$0&"JG/7/K6#XKTS
M5_VM_!&C>(-(L[.UT.[$5TUOJ-JK3L0V1M;L.#Q0!ZSX)\=^&?B/X=M?%_A?
M49#8SD^4SQ[<X]CTZU-XV\7Z#X.T%];\1W!6V5QED7<<?05F^,?#6M?\*XE\
M(^"A;V=Y+9B&TE6$".)P!\Q QQQ5'0/ WC6.^T9?$FI6=U;6FF&'48FBW":;
MLPSVH Y^ZOM9^(VN^'/'OPS\0SVV@QWQ:^4 (+A I&U@W.,D5ZA+>1PP//#M
ME.PD$'/:O//C?X,UN[BT;4=&\06.B:)I-RTVN*Z^6'A*D87;@ Y(K;^%&O?#
MO6=#EF^'OB>+5((YMEQ,ESYH5_3)Z4 >7?#KPUJ?Q0_:2\2:U\4O#B7>F:$8
MY?"DMR2?LDA.&9!Q@X)]:]+B\!ZP?BW'X\T[XCW$>E0Z<UO)X:B*&!Y#_P M
M3WW#ZUUL6GV0N&FBMHXB?ON$ W?E7G.H^!?"7P6GE\3Z78:WJ,FK7PCEB6]:
M0(96P6 /  SF@#TJ.2&6/?#,K,O7!Z56'B+28=:_L0WN;LQ;Q%WQ4'AKP?I7
MAOSIM/-P3< %A/,6Q^?2LQO#7@Q?BLOB9K]AKGV#RA 9SL\KUV=,^] '&W?[
M4>DW_P =8?@=X=LFFNX[@PZK,Z,OV8XX*GHU;_AY'^$.CFT\;?$&[U:34=7?
M[/<7:*"@=OEB&,<#.*K^+OAUXBU'XLZ-XUT!=-M[*RF9M3'V1?/N >F''.?K
M71>.O 'A?QS9VD?B)9EBL;I;J(QR[/G7D9QU''2@#>GAW.&5]GE] *X2_P##
MVH^&?BE<_$O5_B9>G29=/6!/#I53%'(.LHXW9/UJIJ/Q^TZ7XNZ5\-/#&F3Z
MFMRS+J-Y9X:.Q(Z"7T)K(^+WQ"^'7A'XHZ;;/I6HZSKM]-%;RZ;87&?LT1Z3
M/&>-OO0!VNK>+_%]_/IS^$_#D=UI=W&7N+YY"K1<\?+5'2?BW)?_ !,OO 1T
M^,6=EIJ7!U&)RQ+G.4].,5V#V5ND<ENS!82A3$? 4$8_"N;^%?P=\%_";0Y]
M \.K<S1W%[+=/<7LYFD+2-N*[VYV@G@=!0!3^&/Q'\'>.O$.N6GA?6;B_ETJ
M]$-\MQ 4$+E0=JGN,&MGXC^%]<\9^'9M(T+Q7<Z--*A6*\M0"Z,>XSZ5ROQ#
M^.?@OX*^,[#PY?>#)(K75U+W6M6T2)! X.T"5@.6/:NE\>?$3_A"O"H\30>'
M[K5HVB\Q(+  N5(!&/SH \_\4?%;6?A'\(9#X2LG\6Z[HUW#97S7P,;3NQ.7
M)7OC'2I_!_[2&J7?CU? GQ(\.0Z+--;Q/9>7(6\V1QG9S[5Z!X,O].\5^$K;
MQ$WA?[)_:*+.]I=0KYB'_;XY-<SXN^!6A>/_ (C6'B_Q3+^YT>9+C3%M'\MA
M* 0=Y'WEQVH V-;^(UQI/Q)T[P&=+#VU[9O-)><Y1E( 7TYS781QQ"/D8&.!
MCI5-[6QENEGFMHS*@Q%*R#('IFL#XJ_%K2/A;X6N==U&V>YN(HB;/3X"/-NW
M'\"#N: /%_B+\+-2^$FN7GQ0U;Q7-XNUB^U(1:5;:AM5K""4XVQ[<$JO!Y]*
M]2^$7A_Q_I<EQ>^,M:N+E+F)?(68C]R>O&!7#_ ^32?VBO%__"^_$7@;7M$U
M/2$:QM=/U64B)XVY+^5]TD8X/45VWQY^(<?@;P5+:V/CO2=!US4(S'H%QJW^
MJ$PYY7^(8SQ0!M?$?7?'?A[05O\ P%X9CU>]^T(AM)I2BE">7R/05F?#GP#;
MZ?KVI?$;4_#T.F:]KZJ-12$YR5Z9)ZUTG@.YUB]\&Z;=>(-3MKR\DM$-S=V:
MXBE?'+*.P-<5\1?CK)\//%,>E:KX>NH]-#XN=7=0((5_O,W84 6OC'\5?$G@
MBV&D^ /#L.KZZRADTV:4HK)_>R*X?X)W7[4_Q&\:3>)OC%X?/@ZPL9 UMI]C
M=>;'> ]0VX9&*]!L? >A^,=>MOB3?W9N)G@"VKVTA"&(\@X[_6NY%G#&I49V
ML/FYH X7X4^-OB/XCN;ZR^('@RTT>6&[D6T$-UO>:$$[9"#TR,5Q>J:I%^SQ
MXJ\:_&[XN_$"2T\-23K-##.R[8T &<#@]JR_B1\>OV/_ (3>-=3^/GB[XRV=
MKJ>F:9):RV4NL%8F" Y41]-_&,U\.HOQA_X+P_&J;3Y&U#P_\ =&N=MZP=[>
M?7;9^5:VGC(S@GDD&@"Q^TK_ ,%5?VF/VW_B-)\!_P#@EOX4DUC0( #K'CR.
MX>VFLV!VS*JD%6V$''K5?]E__@@S\$?B%\;K+XZ?M1^*'^*'B%9_.\66_B*T
M3]Y<'&"S)MR>!7T_^S+^RGIW['/Q?F_99_9U\'?8/ PT@7UQJVHVXFGEF<?.
MGVC 8GVKZ9^'GP@\*_#/4[_4_#8N!)J<HDNC/.7&0,<9Z4 ;7A7P5X7\!:%;
M>&O!^B0Z?86D"Q6UM "%C15"JHSV  %<W\:/AMXE^*'A:3PMX;\>WOA]IBOF
MWUDJEP >5^8$8(XJ7XG?%JX^&DFE1MX1O]5_M345M0+!0?L^?^6C_P"S75M<
M'E9%W#N%[4 ?D=_P<>_"#P)\'O@U^S_H?@O0H+4_\+5#7$L2D&>4Q)OD;GJQ
MR3]:Z+_@DGX5^(?C/P'\9] ^''B^ZT;5)O&UJR75F5WJHB&X#(/:L7_@Z[N_
M%5E\'?@OJ.@21LT'Q)WV493+&41)Q[U8_P"#=G2/C-K^L?$'QUXEU6V2S7Q!
M&-3L!"5D,C0C&.<#% 'ZE> -"UKPWX7MM'\1>))]2NDC'F7<X&]FP,]*R?!_
MBGQ'XEF\0Z?XOT.&TM+*X:"V>*7>;B(IR[#L?:NAUF4Z)IMQJ<-I+<>7$66*
M,Y9CZ"N.^%TO@?PUJMY:IK@75O$4IO#I5U<%I5 &" IZ 4 <G^SY\+(_"7C[
M7?%WAK69E\.7T(2RM?+"I%,')=@.O>O8M0DL;C3Y;2YF$D3V[B;OE<'/Z5D>
M.](\17?@35-+^'4MO8ZQ-;,-/FFBS%'*2,$J,9[UY'X!UCX[?L[_  ^O-<^/
M<:>,-1N]6AAM8_#EML\J*3Y26#$\#J: -7P)^S)^S9JK:I>67@JQO8M40QWB
M30%=PW9YY]:];T+1M-\+Z1;^'_#^GI;6EK"(K:"/A40= *BT72[")_[6M;,Q
M"]A4F(#&S(SR!6/>V/Q67XMV=S9ZQ9#PD-.<7=DT&;AKCC:P?/"CGB@#&^*V
MF_!K4/&'AJP^*6@0ZAJ<MZP\/&>%F\B;:<D$'CC/6MWP]X"\&^#=&U'1?!-C
M;:2+_P QI'M3TF8$;^3]X$YK>NM(L+R:&YN+2&66!MT,DD88QGU!/2OGN'P#
M\6)EO_ ]O\6]'EUVX\4)J-O;H6W)8+)N9",]<<>E '5>"OV2_#=I<7NK_$C6
M'\57%YR\FIQ $<_[.*[+5_A9X L)IO&]MH5M;:M::0]K::F!^\AB"\*,G&!7
M61*OE1EOO*HW 'J<5E>-/"=EXKT*71[^654F! ,,I4@D8ZB@#D?@#?ZE<^&9
M3XC\52ZIE1MENB!_*N]M[[2+1S9QW<*/MWF/S!D#U^E>(6M]\-_".KVG[-VF
MV.IZM<:@Q@U:ZTV[/_$NQR#(>JYJ]'^S'J>I?'F?XC:KXDNCHLGAO^RUL8KM
MU8';MW]<9]\9H ]"\4_#3X7^/=9LO%WBCPW8ZE>Z4K'3[USN:('KC![UYEX5
MU7X,^,HSX%^ /B>[\-"QU>2>_BL+(J)I0Q\P'?GJ0>17IWPP^%WA7X2:3_8'
MAV>^FM]H7??W;3$ >[5N:=X?T*UF>ZL=#M+=V)+-#;(A;W) YH =HMS"EO\
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M1;2:TNR.T@$JWN0/W3^BGUKT_P '^%=+\"^#['PCHD2V]E90B.WCC& B@DX
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M^R=\<-5^)=SJ?P[^(MG;W7BGPD535-3@MU6&9V[QCJO7UKVQHP93M; *\YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M./6H+Y8[0!;V Y2;D_,OM6YXE\;>$_!$5L?%7B"VL1>3^5:FX?;YKG^$>IH
M\"_;9?P98:[HJ?$+Q3<V>A21;;RSAAWK/*7PCL.N0:]?^$?A:?P;X!L]&O\
MQ1=:NDB>;;7MTH#^4X!1,#L!@5P?QJ^'W@_]IJ":/P/XELWUS0;M(F>5_,BA
MYW,KIZD=*]5%SI_A+PQ%/KE]%''862"YF8X1 J@%O84 :,5S"8]ELP)3Y2H/
M\ZY?Q5\.-;\0>)K#6]/\<WMA%97 EFL( NRX&/N-D9Q7GG[*WQ*\6^./%?C=
MM8TJX73/[=']B7S+^[G@V?>0]QFO0_C%\5++X.^";KQ]JND7%[:6$32SK;$
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M\\_\' EQ>>-_A'\!_B)XK\/ZCI6L_P#"UOL$]O>OA76*-%$BIT ;D@U]"_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@OPO'XJ^(=[\8-/^)>IW>FWL20PZ'+&HM[=D)RR]\G/-=')XM^'_ (JU:7P
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M+6>:/<D3=B1W% '(7NKZ!/\ '#3]-&@6UQ<OILK?VDN2\(XRF1P,^AKI=)\
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MO7_"5E-#>7\KRW1:<F-F?[QVT <9\"E\9R?'3QWJ&OZA<RZ?-+'_ &?#+]R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J.>01H6;H!FI*CN!E2&&0>@H A2?>5P3AAD581QCKQ7RO^WG\
M$_\ @I9\3?$.CW?[#O[3OA;P)IT%HR:M;:_H3W;3S%LJRE6& !QBOG\_L=?\
M'$@.X?\ !23X9YQ_T)4__P <H _2G>OK1O7UK\UO^&/?^#B;_I)'\,__  B9
MO_CE _8]_P"#B?/'_!23X9_^$3-_\<H _2G>OK06 YS7YKM^QY_P<3 _\I)/
MAG_X1,W_ ,<I/^&/?^#B?_I))\,__"*F_P#CE 'Z3/Y<@Y/?I7Y]_P#!1/\
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M_@H+\.[_ $[1]?M=9L8H/"4\92[MY!)$Q.\Y 91Q7I4/['/_  <0V4200?\
M!1[X:[(T"@#P5-G &!_RTH \G\=_\$^OVZM$\-R0>+[:W>PO+[S986U0,LD[
M')<C;US74_#_ /8\_P""HGASPE9Z?X"\7SV6EQ1XLK.WUI5CC7T V\5N>,/V
M#O\ @X)\;:<FDZ__ ,%&OAO)"L@D4)X-G7!'_ ZNZ%^Q-_P<)Z!I2:/I?_!1
MSX;"&)<1[O!DQX_[^4 92?LS?\%8XKQK63XCRO<%,B(^(4W@>N-N:S/%7[%/
M_!4/QE9'1/&?B5M0ADZVMUK:D''MMYJ])_P3J_X+[-\0C\3%_P""COP]_M0V
M@MRW_")7'E[!_L>9C/O6K?\ [#O_  <*ZCK%KKD__!1_X;^?:Y\G;X-G &?4
M>9S0!1M/V2/^"L]G:Q:=9^,[@00HJPQC7%P@ P /D["I+K]E[_@KG8)YQ\>W
M) [R:\H _P#'*UX_V//^#B",YC_X*1_#16[@^"I__CE5M;_8C_X.&/$%@VF:
MK_P4A^&YAD(+"/P9.IX]_,H Y3QY^S=_P5'LM"?3_&?CFXEL+Y3')"VMJRR@
MCE3\O2OT._9+\-ZIX%_9M\(>$O$\$<%Y8:.L=RD;[D5@S'K7P9XE_P""?O\
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M6-,-P:F_9G^/G_!0']IOX8^(_B'X=^..A:;!X=MY&FM[G1RS2%8FD&"&]L4
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M_B^_P* /TC;Q[X+\.>(-'\"PW3^?J,;&S%M'OCP#SEAP*NCX?>!3XMD\>_\
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M%;R7DFW1[JWN_-9H&0CS#P,$'M7:_"'X77WPP\+G0M2\=:AKCF9Y/M5_C?\
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M01@[N0:]OL]0L;XRVD%W!/+&=MQ&DH8H?1@.GXU^;FC?L.?\'!V@V:Z?IO\
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MF%+A)F\GPA.AWJ<CD2?I6M#^QM_P<,VMK%##_P %'_AJIC  SX+GY &/^>E
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MZ9:7$YW,]NCEAT)*@F@#17H/I2TU PR6;)]J=0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5'/C:0QP#QD5)4=RI9,8H
M ^3/^"A'[:?[17[+WB/1='^"/PFL_$MO?V3RW<MVTH,;AL #8I[5\X_\/?OV
M_P -M'[+&D$XZ[[G_P"-U^F-SH>EZB0VH:9!.5&%,T(;'YBD7PIX:"\^'K'_
M ,!$_P * /S0_P"'OW_!0#_HU?2/^^KG_P"-T?\ #W[_ (* ?]&KZ1_WW<__
M !NOTP_X13PU_P!"_8_^ B?X4?\ "*>&O^A?L?\ P$3_  H _,__ (>__P#!
M0$]?V5](_P"^[G_XW1_P]^_X* ?]&KZ1_P!]7/\ \;K],/\ A%/#7_0OV/\
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MS/[8-M/HUJT<=W8>7&UNI5?N]!CB@#%'_!7W]O[!'_#+6D<=3ON>O_?N@?\
M!7[_ (* E5V?LL:0,=1ON?\ XW7Z8CPKX9YQX>L>O_/HG^%'_"*>&O\ H7['
M_P !$_PH _,\_P#!7[_@H 7V#]EC2,8Z[[G_ .-T@_X*^_\ !0'!D'[+.D83
MK\]Q_P#&Z_3'_A%/#7_0OV/_ (")_A1_PBGAK_H7['_P$3_"@#\S?^'OO_!0
M+.1^RMHYSW+W/_QNG'_@K]_P4$&0?V5]']OGN?\ XW7Z8?\ "*>&O^A?L?\
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MOV/_ (!I_A1_PBGAK_H7['_P$3_"@#\S1_P5\_;]/SC]EG2-Q[;KG_XW3O\
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M^TWX/^*?@_P-\8O@)I>D6_BK5OL4-Q&9R00A8XW(!T%?J'_PBOAK'_(OV/\
MX")_A7YM?\%[]&TG3OB5^SP]CIEO"S>.I\F&!5)_T9_04 7O^#B7Q%_PE?\
MP3M\!>)&&S[9\7/"LN%]3?QU^B'@<._@W1F*@?\ $LM^?^V:U^:__!?#*_\
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ME?['FY)YZ"OD/_@D%;D?LN?%MV8MB&? ;_KS>OL3]M+_ )-K\6?]@>;^0KY
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M[B%I#&28V#A<XYH _.;X7_\ !?7XQ7GA&UO? GPD^']II97_ $6V;7/*V?\
M 2.*VM5_X.#/VB=&@62[^&W@';(X3]WXAW')X]*]T@_X-F?^"344"PI\(]>C
M7^%%\2R@#\A7DOQ+_P"#<7_@G_\ ".QF\4W7PH\0^)+5]111I]CX@D5[:W9O
MFE8L,;4&2?I0!A:Y_P ' ?[1.@Z/+K-_\/? ?V>!-[-'X@W.1],<UG>$/^#B
M7X^?$+0[B\\/_#OP,D:.T1:XUWRVW8]"*]S\'?\ !N?_ ,$?OB/X8M=?\+^
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M6H:=KO\ PEL*+<PPVFWRP"#C##C\*]WT3P3X1T73(=(L_#5E'#;QB.-&M4)
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MUS?AG_@WX_X)>>(_B3J/@,_LX>+;?3++3XKJR\0R>*'^SW9?/R+QG(&#SZT
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MKG)_E7X@_M)0(O[=?[5=NBA!BVR%_"OW#G[5^'_[3'_)^7[5G^[;?TH M_\
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M]^ZV?V&K&RU#_@N]^U>M]IT%QM\-:5M$T(?'[[MFOT4M_#7A^9<R>';$$?\
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M#7_0OV/_ (")_A1_PBGAK_H7['_P#3_"@#\SS_P5^_X*!E\C]E;1\?[]Q_\
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M]C_X!I_A3)_"OAIHS&OARR)/?[(G^% 'X5_LW?\ !2?]KW_@F)\#]1O/B3\
MM,73[_6[:)+B1YB1))E$7[@ZDU[?\1/^#@O]ICX5^%[GQ;XS^#GA"SM[2R6Z
MG@FU1UN/+(!&(V4$GD5[3_P<=>%_#UO_ ,$[K6ZATRTA=/B=X=7<ENJG'VKI
MP*^;O^"_7_!.#]D/6_V/3^USJWBZW\-^-H_"4$EO#<7LBKJSQP1A88XU&T,
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M@)X/[+&D%NXWW.#_ .0Z1/\ @K]_P4!(VG]EC1\Y_OW/_P ;K],O^$4\-?\
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M_P#&Z7_A[_\ M_D 1?LKZ.5[DO<?_&Z_3'_A%/#7_0OV/_@&G^%'_"*>&O\
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M8857/^C2]<"@#1_X.5A_QB-\-U$AR/C=X9!/_;_%7Z'^&H&70; %L 6D>/\
MO@5^>'_!RPA3]D/X< _]%P\,_P#I?#7Z)^&?^1>L/^O2/_T 4 74Y.0>*=11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTE &3_P7R.W_ ()>_#+"_P#-5/"?_I='7Z4>!/\ D2=&_P"P9;_^BUK\V/\
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MD1(X)P*\@_9+N_B[XUUG4_B'K'[06E>,O"\\DD.G0Z;9NGDNKG@LV,X&!^%
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M;^WLQ^[A&#-( ,XSZG- ''?#;P$WPN\(77@BT^(4_B6^EMW6(:M<J9&^4C!
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M>@]*_5CP><^%--.\-_H$/(_W!0!=G[5^'_[3'_)^7[5G^[;?TK]P)^U?A_\
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M ,(_ 4C?SIWD(W+]U>,\T ?J]_P2XRO_  3S^#Q ^7_A![//K]TU[XL8#G@
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MZ_+#_P!EH _1VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]'"OT?3K^% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JKKG_ "!;S_KUD_\ 035JJNN?\@6\_P"O63_T$T ?E_\ \&\G
M^M^)7_91M>_]+9:Z3_@CU_RDV_;:_P"RE6__ *315S?_  ;R?ZWXE?\ 91M>
M_P#2V6ND_P""/7_*3;]MK_LI5O\ ^DT5 'Z2)U_"G4U.OX4Z@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-C_@L/\
M\I+OV)?^RE7'_I--7Z3U^;'_  6'_P"4EW[$O_92KC_TFFH L?\ !RY_R:)\
M-_\ LN'AG_TOAK]$?#'_ "+EC_UYQ?\ H K\[O\ @Y<_Y-$^&_\ V7#PS_Z7
MPU^B/AC_ )%RQ_Z\XO\ T 4 7J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>P35--,B6\C E/FZ9H ^M(]K [>!GGZU(J[5"YSCN:;Y08 #IUI_2@ HHHH
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M/AC2O"VDKH^C6HA@0DA0?6N+^+;ZGK,\/A6;X67.K:?.!YUW$X 3G'KGH2:
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M=)1S@C\17EOP"TOQ'K?Q2U?XD_$'X37VDZY-&UH=6N905GMT<B-0H/''/XT
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M_P!K#_L6=)_]'"OT?3K^%?G!^P/_ ,IX_P!K#_L6=)_]'"OT?3K^% #J***
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K\L?VF_^4U'PV_[&M/\ T6]?J=7Y8_M-_P#*:CX;?]C6G_HMZ /U
M,_\ B:_.3_@FA_RF=_;%_P"ORP_]EK]&_P#XFOSD_P"":'_*9W]L7_K\L/\
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M65F)VRNHH^")ACH >*T/C[XT'A76_!,-G\3H_#\6I:UY1M73/]IC9GR1Z>M
M%[X^?&F3X3V$(TW3II9YF60OY)*!,\C/][T%9GPO^,?A+QIKL_BJ"'7;5M0B
M6)H=1M7BBB*]2-P&,^M=E\4_AXOQ,\)QZ +M;?\ TJ*X$Q3.-C9Q^-<A^T'8
M_$&ZTWP_X$^'GAB:\74[C[+JNJVX &G1!.)6'<9&/QH ]<M?*>W66%@ZLN0X
M.01]:X;XF_#.^\9>,/#>OVFMW-K;Z1?&:YMX9MJ3J5(VL/XASTJ33_B-X*^&
MD^D?"7Q+XOA?6FL08HWR&F4<%@/Q%7?BK\2O#/PR\&7?B7Q-J$=M;V\!D\V0
MX&* ,/7/'WC6R^)LGAOP[86D^CQZ'/,9E&YA<JI*(<>_:KOPA\?:CXB\&6-W
MX[O+*SUJZ9E:Q68*Q(/ "GGI[5H_#2'PS>>&(?$7AF)/(U2,7)F4Y#EAUJ.]
M^#GP^UCQ79^/;_0U?5+&7S;6ZW$;&Z9Q0!MZ9KWA[5/,71-5M;DQ2;9EMIE?
M:PZ@X/!I9]>T&"^739-7M4NY#B.W,ZAV/H%SDUA^!_A!X"^%MS>S^#- %L^H
MW+W-VX<G?(W+']:Y+Q[X5AT_XV^%M>TOX13ZK)<W3&\UZ.7"Z9@'#,,\YH W
MM4\,>&](^+DOQ2F\;W1O8M&,)T 78,90#_6"/.=WOBLWX,_$#XD>/_%7B&Y\
M5Z+!:Z%YR_\ ".L8RLS1X&?,!'!JC\.M"O?'_CN]^(/C[X0W&AZM:2R6EK<7
M$N?/MU)"N #T(YIOQU^.]MX)GC\&>!(!J'B:[;;9Z1 V))6'4"@"CXR\>VGP
M\_:1ANM8\,0BQO[&*U@U2&VS,93_  %L?=KV81L9'?.>>!GBO)/%MKXQ\7>+
M=&T/7_AU/-IT-O;WCW;,-L-S@%E^H->L!I A,4)8@?,!WH \^^-GQ2U;P1<:
M;!X-GL[RYDO%&JV32!I(K<]7"#D=^:LV.I_%K7_&.FZCHEAIA\*W$;-<32OB
MX7^[@5Q2:-&G[3=_KX^$TQDOM(CM;C53+\K1\_+CVKT?4OB-\./AQX@TWX<Z
MCKT%A>WUL\FEV#GYIHT^\1]* -GQ=Y2^&+KSY)D01-YAMQ\^/]D>M><_LVG0
M9E\0IX?U#Q#/G4%\W^WHW7:=O2/=_#]*[?X9_$OP3\7M D\3>#M5BO[..[EM
MGGB.1YD;;67\#70$16[@) $7^\!B@#EM>^+/AS1-1U72V:3SM'L5NKT;>D9X
M&/>O*?%.M^//VGKNQM/AG<7>F>'XG1]1NY2T$[R*P*A,XW*1G-3?%/2_B&/C
M@\.B?".[O]'UN**UUK5HW&P0<DYYZ U[3X<T73?"^D6^B:+:K%:VL02W51T4
M4 7M-MV@T^"$LS-'"J,7ZD@ 9KP#3/"OQ!C^,-]X!\<_#[0O^$7U6[:_6>T@
M#.\B$>6S\?>R>]?0"W8DSM8!A]Y:RVAOFUY+Y[X?95C(>';U;MS0!J6%K%96
MD=F <*H"^P[5Q'[0^L^._#W@-G^'EC'+>7=S';-N!^2.0[688Z$ YK#_ &N_
MB7XZ^''P2U?Q%X,@EMYA9N3JB$8T\ C]X1W]/QIO[)-C\4I/A!:Z]\3/B<?%
M5UJRQW5K<F';Y49'W?>@#3^ WA#XD^!-';PUXMOTO+.)-]I<R3[YG9CDAC[5
MN?%3XAVWP[\(S:O/$3/(?)L5V94SL,1@^V[&:6;XK_#ZS\6?\(/<^)8$U7<%
M6Q)^;<:TO%/A+PYXWL(M-\3V2SPQS)-'&Q_C4Y!_.@#E_@=JWQDUGP?%>_&:
MSTV&^F4D+IC[EZ\?I5^#Q8WQ#\)ZQ9^$XKB">)9K6-KE#&?-P0",]L]ZW[Y]
M*\,Z5)=7,JVUK F2S=%%?._[+OQ-^)NI?%/6M%N=5D\2>&6NYWCU^-0L5M)N
M.+?'<CIF@#7_ &=OV7/%OA,:KJGQLUR36+K4=I2WN+GSHH2#R$STKW--(MET
M_P#L/[.CVK1;#&XXVXQC'I4JRI*3NZ?P#TK L_B[X!O/B(_PNMO%,#Z]'9_:
M7TX'YQ%_>^E ' _"_3]2^'WQ?\0Z#9Z&(-+O+L?81;PD)&H Z8&!7K2ZC9//
M]B:Z E4;C&&^?'TZUS?@WPIX\T3QKXA\0^(/&G]H:=J4WF:-IGE8^QJ!]T'O
MFO'_ (,?$?7-<_:,U6U^(^H-I6NI \<'AFX_UAM0Q$=QGT88- 'J'C?X5:GX
ME^)^A>/[7Q+>V]KIL$J364=P5CE+="R]\4? KX$:3\*[*\O+O%[JEW?32OJ=
MP0\WE.Y98]W7:,\"N[FD38[2)]W^&O,_$G[6?P?\(_$J#X0ZIXNM8M;GV&.S
M9_G(?[O% '7_ !5\(:=XY\*OX6OO$=SI:S2(_P!JM)_+D&TYP#GO6A FF:3I
MEM;7.HL4$:PQM,_S2D #OU)KRSXB'XK?$7QS#X1M/#5SI>G0R$?VL3E7 (.<
M?I6Y\=O!_C36/">F7_@N^>;4O#4@N_[.B7YM0VJ (QZ9Q0!R&L^ ?AM^U?\
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MP!_?_L \_P#CM0:A_P $OO\ @LIJUA/IFH?\%@9W@N87BF0Z ?G5@01]WT-
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M^<'[ _\ RGC_ &L/^Q9TG_T<*_1].OX4 .HHHH **** "BBB@ HHHH ****
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M\* /U6_X);C9_P $]/A#N;EO!%F?8?*:]Z53O.?SKP/_ ()=9_X=X?!['/\
MQ0]GQ_P$U[ZGS '=G% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-C
M_@L/_P I+OV)?^RE7'_I--7Z3U^;'_!8?_E)=^Q+_P!E*N/_ $FFH L?\'+G
M_)HGPW_[+AX9_P#2^&OT1\,?\BY8_P#7G%_Z *_.[_@Y<_Y-$^&__9</#/\
MZ7PU^B/AC_D7+'_KSB_] % %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_+']IO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ IKDYP<8[4ZFR]!A<G/% 'YT_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?FQ_P6'_Y27?L2_\
M92KC_P!)IJ_2>OS8_P""P_\ RDN_8E_[*5<?^DTU %C_ (.7/^31/AO_ -EP
M\,_^E\-?HCX8_P"1<L?^O.+_ - %?G=_P<N?\FB?#?\ [+AX9_\ 2^&OT1\,
M?\BY8_\ 7G%_Z * +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^6/[3?_ "FH^&W_
M &-:?^BWK]3J_+']IO\ Y34?#;_L:T_]%O0!^IG_ ,37YR?\$T/^4SO[8O\
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M@'XN_&?Q29;W6/#EE)>W\ZY:6>2,$DX[DFND_P"$\\:Z_P"*]-U#P=X9:_\
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M+=:^/O@OP^=0U*QU*TM;6U2389#,Q7K]<4 ?&'Q]_P"#CS]F;XA6,GPWT_\
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MX0 9P/ ]GG_ODU[W&H*C!/![UX)_P2ZD"?\ !/#X0!VQCP39C/\ P$U[[G!
M7I_*@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-C_@L/\ \I+OV)?^
MRE7'_I--7Z3U^;'_  6'_P"4EW[$O_92KC_TFFH L?\ !RY_R:)\-_\ LN'A
MG_TOAK]$?#'_ "+EC_UYQ?\ H K\[O\ @Y<_Y-$^&_\ V7#PS_Z7PU^B/AC_
M )%RQ_Z\XO\ T 4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!E+4?VD_V.M-'CHK:2MX?TX9A_M&X0J#%D\KUZT >T9&,U^:O_  7^8?\
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M7_A^P%_NE\17+0Z8-A^9@"?Z5V$GA;0)_$J^+KC2X_[0B@,*7!'S;?2@# \
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MKWY8EDYZ$]:W_P#@WC\$^&_%_@'XH6^MZ%'J7V3XJ>(+BVMY1QY@O)<5C?\
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M>/Q3I_C'2_AAXETB02V6H>*]#GMWQU4WD1!K]2?"+*_A732AR/L$//\ P 4
M79^U?EW^RW_RG3^-W_86M/Y"OU$N"< 9[U^7?[+>?^'Z7QNR/^8M:?R% 'ZD
M4444 %%%% !1110 4444 %%%% !1110 5^</_!OS_P C5^U)_P!EOG_] >OT
M>K\X?^#?G_D:OVI/^RWS_P#H#T ,_8'_ .4\?[6'_8LZ3_Z.%?H^G7\*_.#]
M@?\ Y3Q_M8?]BSI/_HX5^CZ=?PH =1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP_X\/PKTC05M[BXMS>.T4"JA]>@ZU+\)=5\?:GHJGQUH'V&X3.]O,W%N:O\
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M;)5"MC<5]#VKKW.7 A8J".<5R^@?#5M&^)&K_$(Z[),NHVJ1+:,HVQ[3G(-
M&G9^.?!NHQSW&G^);.7['.+>[:.<$12G^!O1O:N+_:"\!^!?B1/H/A_QCXH%
MLLMVPMK/[7L%X2I^0KGY^.<&N+U'X7ZOK'BN]^'/AKX?6OAC3M4U5=4OM7M)
MLO=2QL""RG^]TKUSQ#\)?!7BS4]%U[Q%X=@O;W0I1+IMQ*#NMY-NW>OO@G\Z
M /S7_P""]&@VOA[2OAMH%FBI#:^+]#CB5>,*+R*OT_\ ![)#X3TU$!Q]@AZ_
M[@K\L/\ @Y4\,Z_XP\,>#O#_ (8\53Z'?77BK2(K?4K907@=KJ-0XSW!(/X5
MQG[;W[%W_!3C]B_]B7QA^U)8_P#!7SXAZH?"?AQ=0M](EL[=$EX4;-PCR!@_
MI0!^R$LP(!]Z_+[]EIPW_!=+XW$=/[6M,?D*R_V=/^"9G_!3;X[_  ,\)_&&
MY_X+,?$:P/B70K?46LTL;=EB,B!MH)CYQFO</^"?W_!('Q[^R)\?_$?[0WQ6
M_:QUOXE>(/$<L4EY>:Q9QH^Y,<Y11F@#[MR/6BH]K.NTG:0<_6G@@8'KWH 6
MBBB@ HHHH **** "BBB@ HHHH *_.'_@WZ('BK]J3)_YK?/_ .@/7Z/5^<'_
M  ;]J#XI_:D[?\7OG_\ 0'H ;^P/_P IX_VL/^Q9TG_T<*_1].OX5^;_ .P/
M_P IX_VL/^Q:TG_T<*_2!.OX4 .HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "JNN?\ (%O/^O63_P!!-6JJZY_R!;S_ *]9
M/_030!^7_P#P;R?ZWXE?]E&U[_TMEKI/^"/7_*3;]MK_ +*5;_\ I-%7-_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "ORQ_:;_ .4U'PV_[&M/_1;U^IU?EC^TW_RFH^&W_8UI_P"BWH _
M4S_XFOSD_P"":'_*9W]L7_K\L/\ V6OT;_\ B:_.3_@FA_RF=_;%_P"ORP_]
MEH _1VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHH/3B@ ICJS-R> . *<#\N339 2K;&P2.* "1P(SM8;@O&?6ORS_ &A?^"4_
MQ<_;(_X*XK\=_C1K\UQX"\-Z?87>CZ0;B06S7,9<-NC)*-D8R,<U;_X*&_M:
M?M8_%S]M?PC^S/\ L0>)[^)-+DDM_&T^GSA/(G60,%;((.4(K]+O!5KJUMX1
MTNU\02-+>QZ; MY+(<EI1&H<G_@6: )M"T32_#FDP:)H.G6]I:V\>R&VMH5C
MCC7T55 "CV%7=HW!1VYIP1 ,!<4;1G.* %HHHH **** "BBB@ HHHH ****
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MNS!;-;VJ^;$P0M\Y(S[5Z?X6UI?$VBVNNPVSPQ7, D\J4?,":Y3XO?"'PO\
M&FPTN\U"]\AM/?[39W1090LO7GIP:ZSP?'86FC0:3:ZBEV+2,1M,K Y(]<4
M/OM*TF\1[G6[&WG ' N(E<)^8XJI#XG\':-I[7']M6L5NLFPLT@"*W91V'TK
M2UW2AK6E7&G+.8//3;YJC)%?-'_!0_4+/X*_L_6NI^'M*,F_7;1+H1(22&<!
MI"!W R: /HN+7=/O+"74M-N4N5VY*P'.:S/ ?Q-\,?$:QN;KP[=K,EI=-;S!
M7#%)%."#7%?LBSZ5K/P@T[Q=I&L3W$-_#D--%M*X]J[CP3\._ W@2*ZMO!/A
MNWTW[9=-<W2VZD>;(QRSG/<T ?GA_P ').B>&/"/[ /C_4)=&\17U]KNG?\
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M3;]MK_LI5O\ ^DT5 'Z2)U_"G4U.OX4Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *CF8#"[<Y/;M4E1RL W!(/<T ?GG_ ,'.
MFN0^&O\ @EY<>(KBVDFCT[XB:!<O#']]Q'<,Q4>YQBOB[]O3]OS]O']K3_@G
M;XF\7? GP,/#WPEE\&I::S:^(M%#7C0QK&LA63C&6VD'TK['_P"#I'61H/\
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MIO"TF[0[*19"5:TCQ[?** ->BD0L1R*6@ HHHH **** "BBB@ HHHH ****
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M\^_:@\?>)?AE^SWXO^(?@R$2:KHFASW=C'Y>_=(BY V]_I7H%P0$Y.*\0_;
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MGYXQ_P""%OPYT3Q'!X5TGQ_\3KV.]TR2:'6(O'%ZUM&<<;COZ<Y^@JY\&?\
M@W1^'%[X39-:^/WBFZU=MWGW&D^-+N.,C/ (#]J_57PIX8@\-^$;;PK/<M<P
MVML(#)*.77&#D5C>%M0^&'AW5]0\/>&;**REL4#WA$915!/7)..M 'YTZ=_P
M;P_!?4$>WM_CWX[N&B?;*T/CV].UAV/SU\;?\%'/^"(GP=^'_P"V3^SI\!M3
M\9>(]5TOXC^*)K#5&U?Q%/<NB+&[95I"2AXZBOW>^&/PXL_ <6I3P:N]^-4O
MFNU=P,(#_",=17YW?\%O/"6I^/?^"@?['WA+2O$]SH4][XWN8XM7LE!EMSY,
MGS*#QF@#[)L_AS\#XOA!HW[*ME\0D@31--B@A@MM39)Q%$NW[PYZ"O3/@W\/
MO#OPQ^'^G>"?#M]=75G91[89[FZ:5V'NS<FO(/$/[/6J1^,M*L?"?P^LYC#8
MQK?>-F<K=RL,;E*_=P>2>*]W\+Z)#X:T2/2$O&E6%,&1A@B@"77AH4UM'!XC
MCMVC\T>4+E P+=N#WK\I_P#@M+X5L_BU_P %/?V8OAG-9WFG6Q?4$\ZUD,.\
M88Y0KC%?JEXHTR'4]*9KRP2=H@7M@_\ ?'0U^6__  4]T_Q#K?\ P5*_9/6_
M\12PWDS:CYB1N";8X?@?_7H YC_@V^\2Z9\*/A3\08;NUN+D1?$[7+90&RQ"
MW<@!)/6NQ_X./_#&@6O_  35\=^.]#ENUDUV".>YAN;@NJ'<1A0>%Z=JQO\
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ME'JD>OSF*P;QUHHOI N=D)E?><=\+FOF6X_97_X)4VG_  0K^(WQ:_9M\/\
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MUXSO(;TB6.X7@;0?]9P!S78?#_XP>'_B5JUWHFFQ2AK;<)/,A*@X)!P3UZ4
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MD=:]M?$T9,@Y':O-?''C7XQZ5X\TW1_"W@S2[O2I;G;>W<]_LE1,'D)W.<4
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M?%G[57[2O[6_B_1IM!\%I>1_#FUDAFTYHU6-5&\J&^96R?I0!^K/_!+C:/\
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M+?\ !1OX<_L#?\%E_P!J:?Q_HNJW?]OWMFMN-,TF6ZQMQG=Y?W>G>@#R$_\
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M\%:O^#C&<!(_V5_$F,]?^$23_P".5^I/_!.S]H/]L/XR?L>^(_B+^U!X O\
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M"BO_  6R^,?[8GA+X>_M4_L^:YI'@S4[LKK.HW7AQ8(X$QU+ASBOJK_@LO\
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M ?V.?ACH?Q-\8Z3J5S;ZV 84L=,DN'7,8?E4Y'![T ?B>O\ P4$_X+M,.?\
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M0^'/#5K8>8@$AMUP6K@OVB?V=V^/ES9V#_%G4]"%I/%.+6PV'S#&P;)!Y[4
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M%SI.E0P27<F^Z:,8+MTR:R673+/Q9)-+XNBW2(H%A)<(-I]0,YR: /FSX9?
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M_P#@#XB^ _BEI;:SX#\4VNK62R8,]G)N4-Z9KPGXR?\ !(G]@_XH:+J?]F?
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MGPW_ .RX>&?_ $OAK]$?#'_(N6/_ %YQ?^@"@"]1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?EC^TW_P IJ/AM_P!C6G_HMZ_4ZORQ_:;_ .4U'PV_[&M/_1;T ?J7
MD9Q_LU^:7_!.WPEX6\4?\%G_ -L(>)/#.GZCY5Y8>5]NLTFV?=Z;@<5^EO\
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MU_V4JW_])HJ /TD3K^%.IJ=?PIU !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?FQ_P %A_\ E)=^Q+_V4JX_])IJ_2>OS8_X+#_\I+OV
M)?\ LI5Q_P"DTU %C_@Y<_Y-$^&__9</#/\ Z7PU^B/AC_D7+'_KSB_] %?G
M=_P<N?\ )HGPW_[+AX9_]+X:_1'PQ_R+EC_UYQ?^@"@"]1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?EC^TW_RFH^&W_8UI_Z+>OU.K\L?VF_^4U'PV_[&M/\ T6]
M'ZF8&<_[-?G'_P $T /^'SW[8I_Z>[#_ -EK]'/_ (FOSD_X)H?\IG?VQ?\
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M 2,N>20,D"N@^!7PHA^#MC=:)-\5M1\37*(HN!J,ZO)$?<*21^- 'Q'\(?\
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MF]FC:*:09P=R,!BO1/!\?A2QTQD\)2P/%OQ*T# Y?N3@]: -"^U&PT?3WO\
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MKXENX;_6M'ANI8U_<R2QY*#.:R;+X2:38_$*[^(-OJ<WG7<,<36Q \M O3%
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M ,&_/_(U?M2?]EOG_P#0'H 9^P/_ ,IX_P!K#_L6=)_]'"OT>3K7YP_L#_\
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MW[$O_92KC_TFFK])Z_-C_@L/_P I+OV)?^RE7'_I--0!8_X.7/\ DT3X;_\
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M#CEO<4 <%X\^(/C70?%UKX$\/>#KQK2\TN:YE\2+M-O9N@X1AG.3G/ [5)\
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M?#6D\_\ ;:OT@3&[@YK\W_V!6"_\%WOVL#$/E_X1G2<Y_P"NU?I @.-R]#0
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M\@6\_P"O63_T$T ?E_\ \&\63/\ $I?^JBZ]_P"ELM=+_P $>A_QLU_;:/\
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M@FO!?^"7;A/^">'P?)R2? ]GV_V37O49+<MUH ?1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !GG%?FQ_P6(./^"EO[$O\ V4JX_P#2:6OTF_B_"OS9_P""
MP_\ RDN_8E_[*5<?^DTU %C_ (.7.?V1?AN/^JX>&?\ TOAK]$/#+ >'K)?2
MSB_]!%?G=_P<MG_C$?X;#_JN'AG_ -+X:_1#PVA_L"RY_P"7.+_T$4 : Y&:
M*09'&.U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'BO_ ()=>+?V:C\(?'OASQ!XC\%C3-,^U^![JULWG CY\QT"X.TG- 'ZL?\
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M:EYMM\]]$-^W<?F':OW(\,0LFB6>YA@6D7?_ &10!ICIS12+CL<TM !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYS\07.?3]T:^Y_\ @VZ$B_\ !-L8Q@?$KQ$?_)JOACQ(8A\5?V@W<G<?B$^
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M8;95!VY/%>L_M#>/O!<6D7WP@\6>'+J\EUCPU?7$,ALC);)Y<3???&%.>F:
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M_L1K#_T4*]EKQK_@GG_R8]\*?^Q&L/\ T4*]EH **** "BBB@ HHHH ****
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MOT)_X45\'/\ HFFC?^ *_P"%'_"BO@Y_T331O_ %?\* /SV_X??ZM_T85?\
M_?RW_P :/^'W^K?]&%7_ /W\M_\ &OT)_P"%%?!S_HFFC?\ @"O^%'_"BO@Y
M_P!$TT;_ , 5_P * /SV_P"'W^K?]&%7_P#W\M_\:/\ A]_JW_1A5_\ ]_+?
M_&OT)_X45\'/^B::-_X K_A1_P **^#G_1--&_\  %?\* /ST'_!;W52V)/V
M"+\D<_ZRW_QIK_\ !<+5(U:=OV#+_ &1^\M^GYU^AO\ PHKX.?\ 1--&_P#
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M^05^>/\ P<N?\FB?#?\ [+?X9_\ 2^&OT1\,\^';$G_GTC_] % %M&4OM0<
M=:?0 !T%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$%E\6KZTO[>*_M1-:Z3) 5O7!)&!$?F/(YXJ_\  ?XL_P#"Z/ 2^.?[#O+
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M#_\ *>/]K#_L6=)_]'"OT?3K^% #J*** "BBB@ HHHH **** "BBB@ HHHH
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MEL_\B19XQ_NFO?(B<_O.M $E%%% !1110 4444 %%%% !1110 4444 %%%%
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MAN(2KWA..(P>7/TJ7Q9X%\,_''P-)XP\4:,YEAL3+%'<Q8VD+D'![T ?E_\
M\&_?B[QUI.DZ#^S1\7_ 4\_B#X9J+:"UN'^;1V;D@COG/ZU^NGP?^*&I?$70
M[K4M7\,MIDMKJ$ELL+-G>J,0'_'%?G)_P2"-Q:_MK?M/7VEV,$EQ;:O:FU:9
M 2/E7I7Z!_![XG3>+=1N=&N?#KV/E,Y9FM?+5F!.3G'.: -CPO\ "7P/X.\8
M:_XY\,Z>D.HZ_<B;5)E)S(X  )_(5F?$WXC^*/ ^KB0> 9+O2((EEOM8W +#
M'CYB1[5N^+?B5X%\$W$,'B+Q-8V<T^?+CGN50R?0$\UCS^,WO/$Q?7M:T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K\U?\ @O\ ?\E$_9W_ .Q[N/\ TFDK]*J_-3_@O]_R47]G?_L>Y_\
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M RJ-O.02/QKM=0_X))_\%+]6^(T7Q)NOC!HTE];6K6\7F:HY 4^V[K2^,/\
M@F;_ ,%,8[VQ\9>)OCYHEJNC.91/+K3K&G&,L2^,<T =VG_!*_\ X*M6AWI_
MP6=\1 GM_9:?_$U@_%?_ ()X?\%>O /@._\ $>A_\%@_$FIW%K%NCLETY!O/
MIG;4=A_P3Y_X*DZE&DUA\=M!N(YEWQR1ZP[!@>XPW2J/C']@7_@IKX<LOM/B
MWX[^'8+,#]]+<:PX11[DMB@!^O\ [$7_  4^\!^"M.\8?$__ (+7>(-'@O\
MRTC633$.)7 PGW?>M>W_ ."8?_!4/QOHUOXKL/\ @LOK]^IB)LV.E)R".<?+
M7E7[2?\ P3G_ ."EFH> -.U;5/BOI-_IT%[%<1?9]2=U4#!#GYL;?>J/B+]G
MG_@I7X:^%-IXD\)_'#P[=3W%J9+&PL=59FDQU"H&YH ^R?\ @BI^PK\0OV)/
M@+KWAKXQ:I)JGB;4?&&H7D^K3QA7N8Y96;>0/[V<_C6C_P %9_V"V_X*"^"]
M+^!<7A@6+W<1$7CW&XZ(58L,+WR:\B_X-\_VHOC?\>/@[X@C^/&KQ3ZCH_B.
M_LYY-QPHAE9.2?I7?_\ !<+]K7Q=\!/V)?$7BKX&>);-]4B,2>>LN[RF9\=0
M>* /F+XY_L4?\%5/V4="T2SM?^"LNOS:1&L.GVK+IR*+>)$"J!\O90!^%>B^
M ?\ @G9_P59\=>$['QMI/_!9WQ$T-_ )8\:8G0G_ '?:O++3_@E-_P %&OV@
M] T3XLZO\:M/G36-"M+I+236)#&@DB5P=A; /S5U>A?\$^?^"D?A."V\$6/Q
M^\.P/;Q%;>T.M.&*CDX7?0!UVH?\$S/^"OT>L)#:?\%B/$DT1QYDXTU/E'_?
M-:D?_!+K_@K.I+)_P6@\1J#_ !?V6G/_ ([7 R?L7_\ !29=(363^T3X;:U:
MX:%9H]<?:77JI._J/2I)_P!BS_@I9'JMCHTW[0?AY9K^U>>UC_MI\R1KU8#=
MR!0!C^(O^"#'[?FL?&./X[7G_!5#6;KQ1+Y<4^L-IB"1$CSL/W>V35[X?_L=
M_P#!5?Q-\0=5^&VL_P#!8[Q%IEY:W;1V*G3D/VN-0,N/EXZXJ?3OV O^"F'Q
M6\+W \-_M Z--:7#/;375GK<AVE3A@K!N"#6??\ _!+W_@J=X-T:WC\,?%70
M);RV*QQ74^H.TK)GDEMV2: /4$_X)7?\%9,?+_P6A\18_P"P6G/_ ([7/?%C
M_@F-_P %5-$^%GB;5=5_X+'>(;RTMM"O)+JR;3$ GC6!RR'Y?X@"/QJ.W_X)
MW_\ !5J6.&2Y^,^D*Q4;P-5D&./]ZJ/B_P#X)P?\%2I?"VJ6^H_&+29K::PF
M26-=4D)>,HP8#YN21D"@#X6_X)DWOQUT_P#9?L]%T/\ X*_:A\-+*+6;Y&\,
M1:>KK PEPSYV_P 1YKT_5/C#^U%8?'"P^%]C_P %U]6N=+NM,DN)M8_LY0(9
M%QB/&WOFO&/A=_P;J_'/XAVVJ:S#XVU+PU:6LLDUX^IZI+;Q#+\E<L!U-=KX
M6_X-.OVI=5MF\1W7QOM+A97S87%IK\AS"?</0![K%<?'V*(1R?\ !P/J>'_Z
MA2_)_P".U4E;X[:#I5Y>Z#_P< :F\HB>18%TI?WT@!('W>YX_&O#/#__  ;!
M?M,>)?B!K'@.'XHZC!)I$:-+=W&MS"&8,>B-NY(J_P"+/^#6KX^^#+2&\\1?
MM!):Q37"0QF;Q+(H:1CA1R_<T ><?LI?#[]N/]J7_@H)<:/I?_!0/5K?Q%_:
M487Q:MJK.S'.'QBON[XQ?\$?_P#@JSX=\7:?\7O!W_!3WQ!XA\2O)'83W:V"
M*]O:,P#M]WH!S^%?)OPL_P""2W[<'[ _QZD\/^ =<BOI=<G2.;4IIWF8;1D&
M-\D@\=17VH?V#?\ @J8VF6VHW'QATM1<*I6$ZI)O /J-U %3XH_\$I_^"@WB
M._TCP;\3/^"RFN7,^H$KIEK-I:_.>X'RUJ>,O^"+7_!1WXAZ%8>'_%G_  5Y
MUVZL],ECELH9-+3$3)C:1\O; KEO'7_!/3_@K;%XKT5](^)GA^X,DC>7/->.
M_D>^=WRUU-O_ ,$YO^"L!1'G^->B!R!O U63_P"*H FL?^"<7_!2_2KX>"]*
M_P""UNOQW*'9]F72TY/_ 'S7,_'?_@GA_P %=M'T/_A'W_X*M>(]<L-2_P!'
MN =/10ZL,%?NUE?&[_@G=_P5*\"^';CXEZ;\3--N]1L,&W@M;^1WDR><@-S7
M4Z5_P3L_X*H:_HEEJ&H?%W0S)-:QS>3)J3Y1BH/(+<$9H O?"'_@DQ_P5*\.
M?#?2O#>B?\%<O$&D6-K;!(=*334*PKD_+]VOE/\ X*4_\$Q?VI/V;?B+\+_C
MY\<_VZ]1^)%QJ7CBWL3:7=DL>U5P0<@#UQ7U:W_!.C_@JQ%!Q\:-%Y' 359/
M_BJY;7/^".__  4/^,^O^%KCX_\ Q3T:]M/#OB!-16*WU)R"JGC +=< 4 ?>
M_P"R?\'?$GAW2=+\;V_CF3[!>V_F3Z7Y?RD]!S[8KWHE5B*QD,>3QVKY^^+_
M (J\4_"OX=Z'\%/!FB7T^MW&G%[:_@A9K>'RV.5D8=">U5/V'[_]HOQQ/??$
MSXVK#:I-OLK>Q6,QD>4Q ?:?4=^] 'J'PTT+XCZ-K_B2X\:>(YM2MKW4A)H\
M,J@"UAV@%![9YKSWQ5\;_%OBC]I1?@AX/G>U_L-8;S5Y(V_X^(),C81V&17T
M \:DX(^A%>,:/^S]J.D_M3Z]\=EN$\K5=*M[58]_>,L>GXT >N21*6CD/R@+
MQ[4Z1FE($D@6(\$$]:9?WBV&ESZC<PNX@@:1HXQEFV@G 'KQ7A/A&V\9_M3:
MXWB[Q&-1T'PG83M_8=F"UM>-.I*N91QN0CD9H 9\!/@/XZ\#_&WQ!X['B*72
MO#]W?3/+X?" I?2,/EGS[?UKY_\ ^"_/[ 5K^V5^SC8_%&W^(!T'4OAFT^JZ
M=,MOO+R,OEX'''#&OM&W^$>F#QSIWCX:QJ!FTS3WLXK4W+>3(K8^9ESAFXZU
ME_M._!RY^._P!\4?!ZWN5BDU[3&MEE#[0A+ YSVZ4 ?S?^'_ (#_ +0/@OPG
MX4\:>.?VDKSQ#H"?$#1X3H$T 5#(UU'M?..U?MO_ ,%QMO\ PYC^+NU<#_A
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M7XB:!-'#G&\K<,P7\2,5\[?MI_\ !:7]E/QY_P $KO'G[/?Q:U^T\)?$S4_
M"V-IX4E!>61L1>7ANGS!2?PKZ0_X.79;.S_X)K)<ZBZ+!%\3/#IF>0_*J"Y)
M8G/;&:^5_P#@MI^T?_P3!D_8,D\-VMIX:UGQOJ/A.*#1M0\-QVTDD5SY,?,S
MH-P P1UZT ?IC_P2WVG_ ()X?!\!L'_A![/_ -!->]K(';IQV->"?\$N0J_\
M$\/@^YZ_\(/9C_QTU[X@P,$#/M0 ZBBB@ HHHH **** "BBB@ HHHH ****
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MCE??9R6I^5H^Q]ZY_P"(GQ%USPGXS\/:+IF@W%U#JUT8[J6*#<L( )RQ[=*
M,C4O#UWI?PVTA?#-W_PB]U:)"/LL&#G:!^XY['I^-,\:_!NY^/\ 9Z.?B.GV
M73"3_;/AV1=T=XO]UC6=H/AG3_V@YKCQ#XP@U?3GTG5_+MX(YFA638V0VT8R
M.*[;XL^+]7\ ^!KSQ/I&ES7DMG%NCM8(M[O[ =Z +VM^&M$M/ -UX2TS2(Y[
M9--:V@T_HK($VB/Z8XKSCX:?LW_#G0/!>B^))?A;:Z-JVCV,ALK="2;0D'(!
MKN]%^)OAK4KVU\/7]]';ZI+IB7TMK*P5T0KDY':K4_BGP_XLTF]BT#6[>ZDA
MMW\U;>4';E3UQTH _-3_ (-[K*UET/XIV&IVZ.)_B3KZR!VQE3>2\4G_  7S
MT#X0:%^P]XUTCX=1P07,%[:KJT<*_=?S!C/KQBO/_P#@BS\(_&?Q6\)^.]#T
MOQ ]FUO\8-;FN9(+AHV:$7LF5RI':O3O^#A_X8^'/A+_ ,$Z?%-UI$TS,_D2
M7$US(69V63J2>O2@#[^_9@MK>+]G/P(]MB//@W3!M7N?LD5;MU\&OAQJ/BB'
MQOJ/A6W?5H8W2*[8?,H;AOSKX*_X)N_\%@?@CXA_9H\-1?&7XL^'+&XT[38+
M*.W^V1Q.JQ1(BDCZ"OJOX2_\%%/V5_C;X[M_AO\ #OXKZ-J>KW>XVUI::@CR
M.!UP!R: ,K]L;PK\.OV=_P!C#QSXQ\/>"+:2/PUI=YK-M9J<#SS\S-[$FOS1
M_9Q_9F_X*&_M[> O"W[6G@#]LKQ#H2W^BLVD:5;0HXTFWER&@0E>1P3^-??_
M /P5/T/Q\/V0?C)XMT[4(?[)N/ %Q";:4DL"%^8@=J\\_P""'_@ZYO\ ]B;X
M*>)O!>M1?V=9^"T37K4S98SEWV\=N* /"_AA_P $P_\ @K3\'_"P\)?#[_@H
M3XLL+%KR6X:WAMHP/,D;+-]WJ36_-^PC_P %F+<M=S?\%(_&9$:%B?LT? ')
M_AK]&?BQX-\8>(M0T&X\*:BEO%::EYFHAF(WQ8Z#%=+=QK%ILYN& @6%A(QZ
MA<')S]* /ROT#]DS_@KWXTLS?^'_ /@I9XPN85=D=OLT8 (.#_#5=_V4O^"N
MM]KZ^#(/^"F7B^2_="Z6JV\9^5>ISM[5^D7@_P +_#?QC\+;WPOX.U29]-O6
MECDN[.Y_>!BWS;77D$&N7\/_  T\#?L:^"+W7]!TW7_$+7^JQ"033-=7,9<[
M?E+9*H.I% 'P/\0?^">W_!6WQ)X#O](\??\ !1;Q=/HLUN5OX9K6/:\>1D'Y
M?I4W@3]@3_@K]H_A.TTKP9_P42\71Z;#"J64<-O'M2,#C'RU^EOQ$M$^(?PA
MU6R@L[F WVGX$7*R#.#@8[UG_L__  FTKX0^ QIFFW^I7/VMUFG%_=-*R/CH
MNXG ]J /S7\=?LO?\%=/AE:PWOC#_@IEXRACN&(1S:1G./HM<_XZ_8/_ ."F
M7Q=N=,\(^,_^"B?BK4V=HM1L+::T3JC!DD'R]0<&OUJ\2:EX$COK31_%USI_
MG7LFRQMKP*6E;'(0-U-<QXX^%FK)KMMXV^&[6\6J0A82MX,QB D;@%[''2@#
M\[M4_P""<'_!8/5;ZSU>[_X*&^+Y;G3SNLW:VCS$<8X^6N7^*7[,_P#P5H\
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M3;]MK_LI5O\ ^DT5 'Z2)U_"G4U.OX4Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *:X+Y0'''!IU,E&<'TH _/+_@YYM=(NO^
M"7-Q9>(E5["7XAZ"E\''!A,[!\^VW-?/'[5?_!+K_@D;;_\ !(KQU^T7\!O@
M/X6_MVP\!BYT_7;<;9H[H"+<P!/4$G\Z^CO^#F/3[?5O^":7]D7 /E7?Q)\/
MQ2$'^%KDJ?T-?&7_  6 _P""//P1^$?[$5]^T%\/OVAO%.C7B>$HKF?PU?\
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MZ_+#_P!EH _1VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[4/_  28^(VF^.?'VEVOBQ_#=_HWV&2X1'N)(0(PZ)W#$$@]Q7L7_!N1\2?
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M)<@_\.\?A '/)\$69X_W37OJG."J]>M #J*** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*J@<* !G\J )K/A0I49'5O6IE4*,*,4B1A*=0 @7DD\TN!C&***  <#%%%%
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M/]M/P'J^F?"ZQ_:.TVXO[>S18K9KR=Y_*&!O.7SCWKM?#7_!O+H7Q\OM0O\
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MZAJ\,C![N:-G5689QD\"OH;_ (*Q>*-+T7_@GA\53?SK']K\'W<408XW-M'
MKP+_ (('R>.?$/[$OPOU+XK62#^R_#$</A*:.#RPMH2Q8-_>.[/- 'UO/9_&
MOXD>!(9-1\WPEJL5_,K06,@?S(0<(26!ZCFN[T"VUG1/",5G=3-=ZC#:',DA
MP9G )&<>IQ6BDR#)*DQCICKFL'XH?$%_AMX4;Q3'X:O=787$<2V>GINDPYQN
M^@[T </X,\(:MXZNM0\7>/OAK8Z)XCD!2&[BGWRX5OD;D^E>F0&[TOP]':7-
MUYMS';'#R''F. <9^IKS'3[W1I?C%_PD3^$?$:7FH0PK)(T[?9D&"1\G0$=Z
MC\0:E\2/BUX.\2Z7IVGSZ9<:-K"FU:>,J;F&,%B$QC.<8% &K\&KKXL7OCO6
MM3^(J206C0J+&S,FY(R&Z@^XKF?V=/@_XM^"WQ'\2Z/'IWV_0?$NJRZG/J<K
M8-O,?NQA1U'/6O0/@5XPO/'/PVL]=U#PS>Z9.9'BDMK],2_+QD^QZBI+_P 8
MZY9_%FS\'0:).;*?3WFDO!'^[5AC"D^M $?Q=\)>-/%5E!;^$O&5WI$D)):2
MU )?ZY%5?"OPL\:Z;XXL_%VK_%"_OK2'3#!-H\J+Y<DI'^M) SN%7/"'C?Q'
MK7Q.U_P;J>ASP6&FQ(UI>2Q828L>=I[UQ6K?%GXN6?[2X\(Z;H$G_"'1>'I[
MFYG:URSW*+E55_?H!0!-=6G[07BW]H* W2S:+X3T*Z#PW%O,&&KH0<JX(^4#
MVJ?]MGX;^#OB;^S=XML/'?A^#4(;/0KNYMHYP2$E2%BK#'<$"JG@#]J./QAX
MYM?"[Z-/8?:9_+^QWB 2Q_[U=?\ M+1_\8\>-V8@@^%;\C_OP] 'PQ_P0#UG
M3_#G[-NH:EJLHA@CMD+MZ#(K[$T_XC_LY?M53_\ "'VKIJS:7=F407-N5$<J
M'[P^A%? _P#P1C^'WQ$\=?LT26G@76K6T86ZB?[6I(;YOK7U[=^$_BMHOQCL
M])^$6AVFE7D.FQG5-4NK ?9IE ^=5QCYSSS0!ZE\9_"/C[7?"<7P_P#AGJ,V
MDB==KZK:,-]M@]@00<U7^+WPI\5^/O!.A>$+/QC=6JVTT(UEHU!^WQ!0'1\C
MHV#G'K5_XA7_ ,17\"_\(]X,\5:58^+;Q!]B:^CW(S \_+GGBNKT.+6+71;6
MWU.6.2\6!/M<B+\K2;1N(]!G- '"?!+1;SPAJNO^#K;X46?AK0M-NEBT2XLY
M2?ML6 =Q!/&#D5Z&^L6,4JV<\T?G$ F/>,A?7%<8=-^. \=37<VN:6="=V,%
MN+;]ZHQQDY]:\O\ 'W@/XE?#NYNOBI/-=:MXMU\MIB?8&8VEM;@_NV,6<!@#
MRPY- 'M6F?#GP9X6EUG5/"6CP:;>:XYEOKRV'S3R[=H<^XP/RK*^"'A+Q;X'
M\(R:#XR\87&NW;ZC/,MS=E0ZQLV53 QP!P*TOA+:^)M+^'&D67C.9)M26S N
MW5< OD^M<OX=M#9?M#ZK+<>-K21)-,A":.)SYL1R?G*YZ'^E &W\-?AYXL\%
M:_XBU7Q#\0[W6[;5M1$]E972J$TZ/;CRDP.1WYKKUNH(QP $/W1ZFIG! .T@
M'MFO,_B?\2XK3Q[HG@SPM=+>7RWRG5;*W.Y[>%AP[CL"1UH Z31/'/AKXD6^
MLZ7X9U;?-ITS6ERRCF"4J<$>XZUROP;^ >A?![4;WQ9JVM#6->U8F.^UR]PD
MTL8;<J'& 0O:J'[/?P)\8?!_QIXSUR_UJ"XL_$VMF_BB4DF,;< <GBNK^)/P
M@\/?%9M,F\17NH0G3+HS6XL+UH06(Q\^T_,/8T 5=8\?:K-\5+;X<V?ABWOM
M*O=*FDN=1$V3&P&/*(!QSDUM^ M L/!OAMM!TWPW;:+:1LS1PPO\JDGD\^M9
M/PF^!GA#X-P:G%X<N;ZX;5;S[3-+J%XT[(^,84MRJ^PK'UWPIX[\0:GXKTCX
MJ>)[:+P9<V")8_8B8;B [AN)D!S0!\%?\' -S#+??#U(;I&/_"9:+T89/^FQ
M5[Q_P7(S_P .9/B[D8_XH$<?]^Z^+O\ @MC\.-37XD_#3QM;>-XM2TK2_$NC
MV%G%;7#-\AO(MIDYPS>YYK[1_P""XZJO_!&/XNA3D?\ " CO_P!<Z /</^">
M?_)CWPI_[$:P_P#10KV6O&O^">?_ "8]\*?^Q&L/_10KV6@ HHHH **** "B
MBB@ HHHH **** "BBB@ K\X?^#?G_D:OVI/^RWS_ /H#U^CU?G#_ ,&_/_(U
M?M2?]EOG_P#0'H 9^P/_ ,IX_P!K#_L6=)_]'"OT?3K^%?G!^P/_ ,IX_P!K
M#_L6=)_]'"OT?3K^% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JKKG_(%O/^O63_ -!-6JJZY_R!;S_KUD_]!- 'Y?\
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M+_T 4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K\L?VF_P#E-1\-O^QK3_T6]?J=
M7Y8_M-_\IJ/AM_V-:?\ HMZ /U,_^)K\Y/\ @FA_RF=_;%_Z_+#_ -EK]&__
M (FOSD_X)H?\IG?VQ?\ K\L/_9: /T=HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *,C.**0Y!S[4 )(Q5<BN*^/?B^7P?\(/$6MV
M=YY-W;Z7*]N^[#;@.,>]=G.W[DL:^8_^"C=[?#2/ >E64TB#4/%T5O-L8A64
MXX;'4>U &_\ L!^"X;#X2P_%J]A)U3QE$E]J,\BX>63[N6]\**]]MB6BR7)Y
M/)K'\'>&8_"_AJRT* 1*+2'9$L2X4#V K8MED2/;*06SV% $E%%% !1110 $
M@<FD) (![T \[6(-)ANQX[9H =1110 4444 %%%% !1110 4444 %%%% !7/
M?%O_ ))3XG_[%Z]_]$/70USWQ;_Y)3XG_P"Q>O?_ $0] 'Q!_P &VX(_X)N
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M;2+M;RV.Q'<V<>4#>M>S^";KP_XZ^'%C=P6+'3[RTRL%SAW53D<D]Z /"O\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y8_M-_\IJ/AM_V-:?\
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M?V>O^ADNO_ )O\:^:?\ AW5^VC_T67PE_P""9_\ XJC_ (=U?MH_]%E\)?\
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MD5W97]ND]K<0ME7C894@^X-:;/AL#G/?TH =12 @\TM !1110 4444 %%%%
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M_AE'_@X[_P"DBGPK_P#"&F_^.TA_90_X..C_ ,Y%/A7_ .$--_\ ': .:?\
MX(N?M\#Y8?\ @J5\5V(ZYEMO_B:?_P .7OV^RW_*4?XK#CKYMM_\371?\,H?
M\''6<_\ #Q3X5_\ A#3?_':7_AE'_@X[_P"DBGPK_P#"&F_^.T <[_PY=_;[
M_P"DI/Q7_P"_MM_\31_PY=_;[_Z2D_%?_O[;?_$UT7_#*/\ P<=_])%/A7_X
M0TW_ ,=H_P"&4?\ @X[_ .DBGPK_ /"&F_\ CM '._\ #EW]OO\ Z2D_%?\
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M7Z3.2!QUK\V/^"PK9_X*8?L3#80!\2KC)_[=I: +/_!RY_R:)\-_^RX>&?\
MTOAK]$?#'_(N6/\ UYQ?^@"OSN_X.7<?\,B_#?!R/^%X>&?_ $OAK]$/#!_X
MIZP'_3I'_P"@"@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?EC^TW_RFH^&W_8UI
M_P"BWK]3J_+']IO_ )34?#;_ +&M/_1;T ?J-=0"4+M&&&#NK\Z/^";6T?\
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MQ_P2\_8V\&>%G^*O[9?CWPE\1OB!KUNDFJZAXGU>UFDA;@@JXD&3CCI7S_\
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MPQXBU2?4I)UDN+9L3$ 1#S>WM7S]_P &KGPPM_!'AOQ7X$U;2YM2FT?Q%J4
M\21M^XN3',Z_+GGG&?QKWK_@YG\3^#8/V%=0\#Z]K<4-YJODK;V3.1),OFX.
MV@#Z6D^,_@F?]C+P=X4\._$/PM+)J/@K3K2^2;7X%:%#9Q D#=U'H:_*_P =
M_L@_M"?\$W/VH[#]N/\ 8X\?>$O'.F7LDE[XJTG7_%]O;K:L<+MC6,LS_(N>
MW->_> ?^"$O["ESI?AC5/$'P^\=+HUSX)TS4-0U;_A,)UMUDDMD>3'H 2>.U
M?"_[<G[//[%=Q^T7;_L\_L)?L_?$CQV+.22RUQ]%\9/.BS$C:Q#D8 # X]*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JNN?\@6\_Z]9/\
MT$U:JKKG_(%O/^O63_T$T ?E_P#\&\G^M^)7_91M>_\ 2V6ND_X(]?\ *3;]
MMK_LI5O_ .DT5<W_ ,&\G^M^)7_91M>_]+9:Z3_@CU_RDV_;:_[*5;_^DT5
M'Z2)U_"G4U.OX4Z@ HHHH **** "BBB@ HHHH **** "BBB@!DA Y(Z=34*W
M)6?R73*XR&J9@"3YAXKG?B7XTL_AI\/-;\?WMF]S;Z1ITUW+!&P#.$4L0"?I
M0!\ _P#!:7]LM_&=E%_P3Q^!^K7<7COQO)Y,-Q;1E3 8V^8!QD#(]17V;^Q[
M\ / /[.'P)T#P+X(\&V>C.VFP3:M%91[1/>M$IFE;U9GW$GU-?FY_P $L_!O
MB;]O_P#X*&_$']NCQCH[V&A:'KR3^";&_C#/'#(B[AN&0W.?2OUUB@\M0G&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "ORQ_:;_ .4U'PV_[&M/_1;U^IU?
MEC^TW_RFH^&W_8UI_P"BWH _4S_XFOSD_P"":'_*9W]L7_K\L/\ V6OT;_\
MB:_.3_@FA_RF=_;%_P"ORP_]EH _1VBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS5_X+_?\
M)1/V=_\ L>[C_P!)I*_2JOS5_P""_P!_R43]G?\ ['NX_P#2:2@#*_X+Y_\
M*+KX9?\ 95/"?_I='7Z4^ ?^1'T?_L%V_P#Z+6OS6_X+Y_\ *+KX9?\ 95/"
M?_I='7Z4^ ?^1'T?_L%V_P#Z+6@#6HHHH **** "BBB@ HHHH **** "N>^+
M?_)*?$__ &+U[_Z(>NAKGOBW_P DI\3Y_P"A>O?_ $0] 'Q#_P &W.3_ ,$W
M %.1_P +*\1<_P#;U7SG^PAXS^)'A_\ X*@_%ZR\$>&+2]MW\77AE>XD((D\
MM=HX%?1G_!MP"?\ @F[NC/ ^)/B'Y?\ MZKRS_@EW%"W_!2OXS,44L?&MUR1
MG'[I: /TC^',GCG5?#D.J^/M L['5I)&%Q':2[EV#[O.!FL_XY:S\2O#'@&;
M4_@UH&G7^KI<(9(=3N?)B\G/SMNP>0.@K8\;?$SP9\/[_2])\5^)+:QN-;NC
M;:5',2#-*!G:O')Q7/?%S7M5CL1X:7P%J&L6M^NR:>R<*(]WRY.3Z'- &I\%
MO&&K^-_ -IXAUZ&WBO)RRRQ6DN^-6'H:WM<EU2#2;J31X$DO$MW-LDC8#R!3
MM4GT)QFN0\,Z1X,_9O\ @\6=C;Z=IR/<2M-*3L#$$Y)H^$7BWQ7X\M)O$VHJ
M4T^:7-B&7_61G[K ^E 'A%[\.OVJ-?UB:+Q7JLFFR>-W-MK4.GWN]-&C4Y62
MV..6.!G..M?1OP]\*#P=X0B\-IXFFU-H8!$UW-(&<L!C)QWKHFMXA*#(5)!^
M3(Y4URGPOU7X;7=GJ9\!:O'=!-3=+XI,6V3Y.0<].>U %?X??"_6?"/BG5_$
MFI^--0OHM1*F"SN6!2WQ_=KJ=>T@:]I5QHTEPT GA95EB^\I(QD>]<]X,UCQ
MK??$/Q#I6OZ=*FF6A3^SIF4!90>N*\\^%OB7]H[7_C;JFK>*[">T\)6MM-%;
MZ;-  \LH)VR!@>A]* &^"/V/-9\ _$.U^)"?'GQ+J0L9#(NC7;K]GD_V3@YQ
M7H7P@\3>/O$.C7EQ\2-"M]/NDU*6*V2TD+AX0Q"L20.2,5/X$\:ZUXQUB_TW
M4?!=YI<&GL!;W5RRE;D'NN#_ #IJ>/?$!^+TGPT3X=WR:='IPNE\1Y7[.TA_
MY98SG=^% ')_M'^"/B!)>:=\1? /B"Y6;10<Z6)=L5UN/\??BNU^'.MZSK_A
MB#4]<B@CNB DD=O+N4$#GGUJ77_'W@GP]K=KX6\4^([6WOM5#?8;.8G=-CK@
M8KR;XLZ=\5?AMH'AVQ^!7F7D=[XLWZVT*;]EJ[9?.2,#DT ='^T-^SUKOQMU
M32;BP^*FL>'+>Q4^?'I,@ G.[(W9Z^E=%XT\+6GB'PDG@Z[\=2Z>]K9JCWD$
MZB7 4+O;)XSC.?>NGD+S02Q1(Q5 ?* _BXKQKQ/X&U/7_#>N>*[OP?J,FKZG
M;RV%S DV"]NI^7:,X&?6@#U;P3H=OHG@?3O#]KXBDU&."T\M=1=PS3#GYLC@
M]:R_$=IK/P\^'&I7?ABY^W7MM')/;)>OM5W)R%8]A7P]^U__ ,%;!_P34U/X
M7_LQ^'?V3_%7CO7_ !/X?EN+#2])OHA- L4I4HWF,-Q[_C7E'Q]_X*I_\%.O
MV@/"$?@GX0?\$O?B=X+FNLBXU+4C:RHT; 8X67/O^- 'Z5Z3I_A[QM\*;'7_
M (L:1I,3WMLLFHPSS+]G1SG@,Q (KY7_ &U?^"EW['G_  3K^'U]HWPET"#4
MO&5[$\>A:3X8L#=Q37/W@LQA+%%//..M?/O@[X"?\%;_ -M[X5IX'^(7Q#?X
M:^&]$L3;:CH>MZ6WGZK* 626)XF.T#)7![FO2O\ @GG_ ,$<?"7P<^%C_$77
MG\WXIW-[/'<ZWJ[/<0F-7S$1$^<=6_.@#YU_8$_X)$_M'?MS_'T?M^_\%)[Z
M6:SU&=KSPCX4ENA<V]M:R;652CA6C*N@PI'>OU6\9_#+2/A]X034?A3\.="-
M[ID .F_;G$,<3*  =W\/'>IO@/X'^,7@2RN=-^+?Q'T[796F!L$T^R,*P1 <
MKCZUV'CCPOH'CGPI?^$?$X9M-OH#'>)'(48(>O(Z=* ,&'6/'OB?P+! J:>U
M_>V?EW[65X)$MV<$,48=2,Y'TK"^&?[,/@#X:)87=WIL>NZY:SM,WB#4H@;D
MDY(^8>F<"L3X,? 'QY\)?$TD?@[XGVO_  B99B-*EC>27/\ #\Y]!FO:Y9X(
M;<SRL"JCD^E &!\1?#7PZ\9^%I]&^).E64^G29\Z&^QLDX^[R1G/3%?G'^T%
M_P $!/"?Q2\;ZU\7/V8?VD_&'@'3/$I'G^$O#JQP6,2KV4%LX)YK[C\<:5X<
M_:W\%3>'?#/B*.(:-XAA:YDC=NL3ABAQZXKU#1=#L]!TR+3;5<1Q( .: /S"
MTCXT?\%_/@AX?;X:>!?V;/A+K^C^&;0PV>I:EXY(O;FVA7 EDC$9PQ49(]:\
MG\"?\$B?VR/^"J'C/4_VE?VU?C3J_@&T\02":QT#P;J:7-K:]F5 X4@5^D=Y
M^QQKUMXBU'QUH?C58-:U&62&2YE+M']CDR&BV>I!QFNQO?#^O_ ?X!MX<^&]
MF]Y>Z7;'[';0+EI6ST&<4 ?./[#7_!!W]B+]B7P/<>%]0\(6GCZ^EU)[_P#X
M2;Q38)]KC=CG;E6(P#7T/XP\-//;V7@/PQX*T&]\();2)J8%P"ULFTXVH.OY
MUW&A7<OB'PM;V.O1M%<WEBOVN!CAE++\P]C63X<^%W@KX76.I1>&EEB-_ YE
M$TY?<0IZ9Z4 ?E__ ,$)=<\8>#/"'Q%/P\L]*8CXGZY$(M4O1!&J"[E&%)ZG
MVKL_^#BB+0O%W[ 4WBKQ-8:1-KNFFW$\MM<+*;1C-R P/'XUPW_!$7X8?#3X
ME>!_B9!\4A*-,TKXI:]>F6.Y:(1E;R4[B1VXJ7_@MK\$OA[X?_8'\<^,_ 'B
M0:GH7C"YM9K1H[AW!CW[?E+?C0!]\>%?B;\)_%'[%V@^#M.^+OA1+Z\^'6GV
M\<<WB*V3$ALXAM.7XYK\KO\ @G[\<W_87_X*1ZQ^S_\ %GP?X3N4^(6J2W&E
M^)?#VH+?7,2QQHF<Q\*2?4]J^MO@Q_P;V?\ !-+Q/\'_  AXBUGP-XFDN=1\
M+:?=77E^*YU'F26T;L0.PR3Q7H?P;_X(2_\ !.#]G?XM:=\:OA_\.]2CUS2]
MWV*[O]:>?;NQG[P]J /HCX=Z2?@SX/N_$_C#QY>ZC:2^9=1RWS@N$<[@JC/.
M 0,5NZG\:_!NC^ [3XC:A)=#3;L(8&BMRSD,<#*]N:F\6_#;P?\ $31[;0/$
M%A(UI:$-;*DI7G '..HP*Y?Q1>6ECXIT+X(6'PQOM2T2>U9[C6('7R+%T;Y4
M?/.3G(P* .YU'PYX3\<P6.K:WH,%V+9A<V#SQY,3$###T.*T9[J&PMWO[E0L
M<$3,P3GY0,FN2^,/_"4:7X*&J^'/&]IX<M=.0O?7E["7180 .<=,5<\':M9^
M(?AG#J$GB.WOXKK3VD_M6$$13+M.9!WQ_A0!R.@?M=_"SQ9JLFC^'X-4D>&0
MJS-ICA<@X//UKG?VE?B'X-\=?"*YOK;Q?K>CVUCJ]O'?2Z=:GS7^;)CV]U89
M!KJ?V=?#?A2/0)-<\*>)]-UJTDN95^TVD/&X-RN2.H-2_%NU^$?P^\)7&K^.
MXHHM-N]5A:7S7PIG+83MZT -^$7B'X;^-_AP-)^&%K?:99QP?(K6+0D-QE@#
MW)YK:^#/PXO/AY8:E'?^(+F^-]>&93=$94$'@5T_A-M(N=%AN]'AA6"2,>68
MD !&..E7;FW$W&-I'1J /)_$WC3PM9_&*PT'XE^'K6..&Z'_  C.H%-Q64@[
MBQ. G&>:L>"/VH/A?\2?BA<?##PS)J9U&V21I)&T]EMR$ZXDZ$U>\3Z!\%_C
M7K]UX%US48;[6-" DO+2WE*RVX;@%N.,UO>!_A?X/^'UD;/PGI26RE\M(X#.
M?^!8S0!0\=>)_'NC>.O"^B>&="M[C3-1NV36;B5R'@0 X*@#FHOC#\)+[XM6
MMEIJ>--0T..PU"*Z\S32,S;&!\ML_P )Q@_6N[58Y6#/",IR"1TKRW]J7Q?X
MG\)^&]*NO#?CVS\.F36[=+B\O8BRS1EQNB&.A8<9H ZWXAR^-['P/<2_#G3K
M>ZUE(A]D@N9=D;M[MSBG2>*)]"T"PN?%EJ8KZX6..6.U0NHE(&1GTSWKBOB+
M^U3\)O 4]OH%QXULA>7(VHAD.5/Y5M?!GQAK/COPC+K'B_2WA(NV-JTP'S19
M^5Q[8H YKXV2:NOQ<\&3Z+X@U""]Q+Y>DP#_ $6[//\ K6[5M:'XU^+6G_#K
M4=7^)VD:1IFN12S#2[2*^!CN%!/E@D@<D8R!6G\0O&?@?P>]GX@\2W4(:/)M
M+AC@#/IQ3_'/PQ\!_&S2])N_%4,MS'8W4=]9&"<H-X *DXZCVH L_"[Q!XF\
M4_#ZPU[QEIL=GJ<]N'O+2%B4C?T!/:N7^('BSP)\+M4M/'7C#PB#K6L7(T^R
MN[&S:9V(^XKD?=7GK6MJ7QV^&FF_VK;6'B"UN'T*=8-7BB?'V-ST5^.O-&D_
M$[P!XM\9'X?V-]:WU];V:7Q@X9D1QD-@CB@"O=_#C5/%OQ!T#XK77BN_L&TF
MU>.71K8CR+DN<[GSSD=J;;?"CQ-;_&6\^(C^-M0>QNK*.%=(:0>1&5)RP'J<
MUTMC\1O MUXA_P"$/@\0VW]I D?80WSDCKVKHF5"G7@=J .:L?&.A:S>W>G6
M]^$^PSB*?>0N&]!GK6#\<_AYXI\<6NBZOX,\47=E<Z)?&ZBMH) L=Z=N/+D/
M]VN'_:8B\*_"W29_%-I>_99KNY266)I#F=\X 'IG&*]%^!WCC6/B+\.K3Q%K
M7@^\T&5R8_L%\P,FQ0,29!(PPY% %KP9/X[US0Y[;XDZ+:6L[_)Y5K+O5D((
M8$XKQ7XE_!GX:?"SQ2^@:5XU\0Z+'\0F_LW3[+1+'=#I\P^=I00?D)QR3Q7N
M7C_XB>'OAEX?'B;Q1=)!;"YCMU>1L LYP/UK-\>>++O1]4\-C3_ -QK*:G>
M->0!2MDI3(D.[G';CUH V?A[X8E\%^%K#PM/K$U\VG6RP?;+HCS)\?QM[UM2
MK'<1M$V-KC!!KRJP\3^*O&OQ2NO%?@CQW:7WAWP_:3VVKZ!!$3-)> ;D&[H.
MA&/>F_ 7X_>.?C!XBU?1_&'P,UKPE%IB VUWJCH4O/FQA-I/;GF@#\H_^"P7
MB+XZQ_%[P[X9\<Z);KHI^(>EO8WGGEGV"]CVC!&,5]R_\%R6W?\ !&7XNL?^
MA!'_ +3KPG_@X0@@%Y\/95B5&/C71/FVX/\ Q^Q5[M_P7+_Y0S?%W_L05_\
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M/!<=_=^%+UIII;K<D9=%;[HRQ!Y]* /1?^"B7'_!OY^S\C_>_P"$H\&X_P#
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M#_T7#PS_ .E\-?HCX8_Y%VP_Z\X__0!0!?HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"ORQ_:;_ .4U'PV_[&M/_1;U^IU?EC^TW_RFH^&W_8UI_P"BWH _4S_XFOSD
M_P"":'_*9W]L7_K\L/\ V6OT;_\ B:_.3_@FA_RF=_;%_P"ORP_]EH _1VBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OS5_X+_?\ )1/V=_\ L>[C_P!)I*_2JOS5_P""_P!_
MR43]G?\ ['NX_P#2:2@#*_X+Y_\ *+KX9?\ 95/"?_I='7Z4^ ?^1'T?_L%V
M_P#Z+6OS6_X+Y_\ *+KX9?\ 95/"?_I='7Z4^ ?^1'T?_L%V_P#Z+6@#6HHH
MH **** "BBB@ HHHH **** "N>^+?/PI\3C_ *EZ]_\ 1#UT-<]\7/\ DE/B
M?_L7KW_T0] 'Q#_P;<*%_P"";I4M@GXD>(<X_P"OJO*?^"8EP\?_  4I^,B*
M@_Y'6ZY_[9K7JW_!ML,?\$W/F& ?B3XAR?7_ $JOG;_@GOXC\;Z'_P %8?BM
M!H'A^XO]+?Q=>?:U@Q\K[$P22>PS0!^L_B3P3X7\37NGW_B/0;6_ET^?SK&6
MX3<;>3&-R^AQ3?''B*W\(>&;C5Y$E>-4*[8HRQ!(/( K#\7^%_BGKGB+1];\
M(^-X=+TVVN1)JNGRP%FN8MO^K!'0YJWX\U+5]5\.O%X4(:=;M(YDV[OD)^;]
M* /'_P!FK1O&OC_Q[XQUGQS++J/A35;-(]-LM08E=P?Y@4/3BO6K>/XFZ-\3
M]/\ #NA>&M,B\$1:4PFN%FQ-%./N(J8^[[U>TE[/PTUGX=T70G96?_23&1^Z
MR,Y/XUL:K-=PZ7=2:=$SS+"YBC7J7P<?K0!8\N27>S  XXK@/A;X]^%VK:OJ
M/ACP+X6N+&6.[D:^:33FB224$[FR>&^M3V?Q$O\ P3\(9/'WQ/8VDUG&TEX)
M_E.T'BN,^$GQ?N?CE\2'\1_"_P 06LWA6.PDANA;Q9"W>.,MZYH [CP-XC^(
M^H_$GQ%HOB;1K:'1+5D&C7<3DR3@]=XQQ6A\3/B#H/P]T:"Z\1O<1QW]VEI"
M;6(N=[G ) Z=>M4O 7A?XE^&_%.JZAXU\=6^IZ?>%?[*M(K<HUKCKDGK5'Q1
M\,/&'BSXH0>(/$/B6&X\+6]L#%H/DD.+H<B;=TQGM0 OPM^'D_@_QIK^LR>.
M+S4EOY5:*QN9@RVV.P /%>BF(LH.<=^*\Q\/?"CQYHOQ?U#X@6OC*-=,U&X$
MDVF-$2S*!T!Z"M/Q;\5?%>@>+K?P]H7PZOM5M9642ZE;LHCBR><Y.>* /+_&
MWB+X[W?[3MEH6O?##PQ-X>$\B:1K$USF[2+'4+C@]:]B^'/@>'X=>'IM*EU^
M>]6:YDN'GO&&8]YW%0?[HS@55\<?#.X\9>,]&\71:HENNE!MT;*29,UFZ]KG
MB_Q'XUU3X/#P->VVFOH8>+Q4S#[.TC#F, '=D?2@#MS?:9:VOVT7T7D?\]1(
M-OX'H:66^62W:>S=&PF4(;[QKCD^#MX?A!8_#AM;$D]M J/? '#X).?6LGXP
M^,+OX-^"]-MM#TF6\O+N<6T"1-R7VCGF@#\.O^#@G]J#QY\-O^"E?PN\=>-;
M#[#;:!I]U'8SZ%NFN&A,X+%E49!Z\5]F_!W_ (.<_P#@G-X9^'6EZ+?O\2M0
MNK>VC6ZN3X*N'^<(H8!AUP0:\ _X*)_L^6_B_P#X+ _ G3?C-9B[@\5>&]1N
M;W3I5P82)@NT]1G_ !K])? __!*[]A;P3X2M]/T;X16R6IC$S,[*=KL 6.=O
MK0!\\:K_ ,'07_!-;5;.:P-C\38A+"R&1? ESE<@C/3J*YOX1?\ !R?_ ,$Q
M_AEX0'A&VUKXJ:RRW4LS7=YX(N&E&]L[>.PZ"OI7X;?L*_LO>/=7UW2M<_9>
MDTFTT^]\BRO+DQE=1CVY\V/ X';FK/B#_@E;^QKX+\)ZUK_@CX(1/J?V,FWM
ME*LSOGH,C% 'S/\ %+_@Z3_8!L_"4]QX"T'X@2:FQ$<9OO!-S&H5L@G<1U]*
MH_!/_@YS_8%TGP'#I?CNQ^)%S>&1VFE7P3<R!@3D#=CD"OJ*Z_X)4?LL_$[X
M3Z=9ZO\ "JVTS5)XXY;KSD7*,"<@X6ND\'?\$J/V//#7A^+19OAE9S>6#^\"
M+S^:T ?-%K_P="?\$RK12D6A?$H GH/ 5SC^5<S\7?\ @Y%_X)O_ !.\+R>'
M-/U'XK:49$*M<6?@:Y5AGTKZ?\/_ +#G[(<\NH'Q?^SRFAVUI?\ V:WNKPH5
MN<]&7 /!KI[C_@F?^QI+"T\/PAM70+E"H7YO_': /CCP1_P<E_\ !,SX:^"W
MT+PGX<^(J7$5LS-.W@.X4W4X4X:0XZD]37+_  !_X.:/V#=/\5ZWXY^)>L_$
M5]2UH*#H<'A.>2"TVGCRQUY^E?1_[+__  3?^&/BR#Q>?C5\&4L(X];F@T.&
MYA12]J00KC .1TKH?A[_ ,$4?V&?#GC.Y\3W_P -K6\NRX:-5;'E'W!7F@#R
M$_\ !T?_ ,$TV4J^F_$WKD#_ (0.Y_PJ&X_X.?\ _@FKJ*FU_LWXF+N^[)_P
M@=SD?I7U>W_!,;]C&,;C\)+3/0<+_P#$U#_P[%_8U+;3\);4-V.%Y_\ ': /
MBBQ_X.._^"97_"U6^*%OXE^+,VRQ^R-I:>![AK<$?Q\?Q5%\1?\ @XW_ ."=
M?CCQKH_C'3]3^*MK'HT<H:QB\$7 BNMP.-X[XS7TU%_P1W_9R\/^.FU;PEX:
ML+30IOFN-+D@#,\I.6;=MXSZ57^/?[%?[$'@KPAJ'A_PA\/;";Q4]NXL-+CV
M^;*P!R "N/UH ^0?^#9WXAW'QB/Q&EMM!23PEK7BS6;N![R,K*XEN9&V.AZ<
M$9%>S_\ !QYI_AKX;_\ !.#5K/2-)CL]/TY(##;6D?$:"4G"BO//^#;6P_X1
MSX8?$&ST_32DUOXXUH10J!E6%S( GX=*UO\ @OOXN\6>+?V$O%>A>.](FMS]
MHMD@68 94R<]* //O#O_  =-?LI?#[0/!'@'PWX4\4W&GZ=X<TVTU>XN?"TX
ME4QV\:2%!CYAE3@]Z[_XP?\ !R;_ ,$W?BGX#N/#6F7GQ2TS?AX;^R\#W <%
M>0 ?0G@UZ1HO_!'3]EWQ]\._ 7C_ $CX<0)<7OA/2A>G .2;6,LW3N2:]OT[
M_@F'^Q7X9\))IVL_"^S:.RMRDLA"C<.23]V@#X;\&?\ !T_^S8?AM9+=^#/%
M\NM0:A);R+%X3N7B:U3"QR%@/OD#)'8UT?P:_P"#CC_@G=\.+O6?$'B#4_BO
M?7OB*\%W=6<_@>Y:*R8+M\N(_P!WC-?4/P*_8 _X)R>)?#D\7PW^&=C-;17\
MWF!) V) V&Y*^M=)XV_8'_8'^&VAMXJ\<> ].TZQ614:XN-H4,QP!POK0!\I
M_%K_ (.@O^"=.H?#?6;+1/"OCZ_O);%EMK+4O URMO*W97)'"UR,W_!QK_P3
MM^)?[/NE?#[6XOB5X9OC#"UT/#O@FX,<6TG=%&W0H0<5]J>)_P#@E]^Q=\0_
M U[I>@?#FQ6/4[/;!>* 0-P!!^[3O"'_  2I_8X\#^!;#0]3^&=G<-IUGMEN
M@H (7))Y6@#Y8^'G_!R1_P $N/A7X8B\(>'-"^)$5O$"3L\!7(W,>K''<D9J
M36?^#EW_ ()>^+[-M.\<>#_B%?6HF62*WF\ W+H2IRK$8Z@U]0>$/V$/^"?W
MCZ W7A/P-IM_ KE#)!@@,#@CE>QK5U[_ ()H?L<P:-=M;_"NS@*VLC+<,JD1
MD*?F/R]NOX4 ?,%K_P '0'_!,^QMTM]+T;XDI&1M2-? =R OZ5PND_\ !R'_
M ,$XU^,*_$>/Q9\6;BW@M9+>324\%W#0;F[D#N*]W^"/['7[$WB[POK/@ZWB
MT;6M9T6-I;K5[:,!%5GPHVE<C'2K'[-'_!*G]DFTU/5]:T^UTK7;*:]=[N*W
MB_U4I'W267M0!Y/!_P ',7_!+71]6OO%.A>#OB''JU\@%U=+X N0\^.@8XYK
M$U'_ (.0/^"=%_\ %"U^*1UOXMQ"WTUK9M$3P-<_9G8_QD>M?6_BW]@[]AGP
M=>Z?#K?PGLX_MTQ19F*@+@=?NT[PE^P/^P=X[CGO?"O@'3M0AMYC%,\ 7"./
MX3\O6@#YDT3_ (.E_P!@6>_N1JWA[XB1Q\?9-G@>Y.[USQQ63\0?^"^__!+3
M]LR_T?X*3^+/&^DZC'JT%W;QW7AAX#(ZN,+\Y&<GBOIOXH_L,_LJ>!;>.?PU
M^S*WB"8YW6UD8PT?UR!7X+?\%>OA7X(^$O\ P6%^$^B>"?"AT6UO=1TF2;3P
MP!C9KF+(./3- '])_P /?AI\$_B=X3TWQM'X&M[Q98M]M/J5ELF/U!Y!KOM6
MT"PG\-S^'K/_ $2.:V,,;VXP8LC Q]*P_%.NZE\-OADVN>%_"LVLS6-JAATN
MRPKR\#@9P*WM$U"76]'M;^ZLVM9+BW222WD.6B8@$J<=QTH \V<_#WX?3^%O
M@9XSL;[7;V_B:.PO+JR,J':>3(XX3\:ZCQ3\3_ WP^>PT75)VB:ZN$M[>"!,
MD$\#([#WI/BT;R/PM<)H_B.UT?4%C)M-0N8=^SUQWKPS]GC0;K]H?5I_C/XT
MU9;M=*O9+)(AD;G@8KY@[<XS0!]"Q?"_P!'-J,J>$K'?JTHEU%O)&;EQT9_4
MUQWQ;^ _AWQ+=V7B+PU-)H5[I\JO<7NF*%DGA4<1,>Z^U>CP70N;9);<_?'R
M>U>?:UXT\7>&_'^M6WB;2Y1X8LM&%S_:+ ",OSN7/7(H V_#_AOP9I5E#XPN
M-.M4NL#;J,P"R'/J3WK6\4>)=+\.Z#=>(]1FD%I96_G2F%=Q*CT ZUX]\5_B
M!<>/_#7ASPGX2\,W+>'/$=L+J7Q3%(/L]CL<A4?N2W; KT76_"NI^(= T_PY
M8:_$MLD:+J$;(3Y\.T#'MG% &'\0OB)\)[CX76?Q/\9>%[C4]&N'A^SI_9[2
MS NV%.P<CD<^E9?BWQ=H/Q)^)&D_#WPQJ>N:9?>'5AU*98K1H[>YAD7"1,YX
M.,<KVKU#3O#^F:7HD/A_3[!/LEN@6%&4,H KFOB1X2\=>(;G36\ >++71I+>
MZW7[R6V]KB+& @(Z<T =1JGAG0O%VE#2_%6CP7L/F+(8)TW*'7D'\*LWDMIH
M]GY\\D4,$*\M(X58U'N>!5.:^O?#?AN;4=2D\][*S>2=U&/-*J6X],XKR*U^
M-GAW]I/]E7Q'XRN[1]&LY8+BWG,\N?+$;A2V5H Z_P" _CKX5^-KGQ"_PUT>
M2U-KJQCU20VAC6XFP?G4_P 8_P!H5V7BC6[#PGH=UXEOH)'AM(M\JPQEW(SV
M ZFN*_9G\)VGA+X7:?!I>IPW5O<6Z207,2X#+CN>IKT%O)O%*;ED4CYE(R*
M/RL_X+M^*]*\;0_#W6-%DWQ'QEHF4D&"I^V1<$=C7T+_ ,%PV9O^",/Q=+=?
M^$!'_M.OF'_@MS\-KGX:W/A5)]36Z74_B/HUS&$!'E WL?R\U]0_\%R5"?\
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M@/\ \&4O_P ;H_X>%_\ !;?_ *-4\!_^#*7_ .-UZE_P_P _V!?^AWT3_O\
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M\_V!?^AWT3_O^/\ XFC_ (?Y_L"_]#OHG_?\?_$T >6_\/"_^"V__1JG@/\
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MXNW]D?X;_-G/QO\ #/\ Z7Q5^B?AG_D7K#_KSC_] %?G9_P<MIL_9(^&_O\
M'#PS_P"E\5?HGX9_Y%ZP_P"O./\ ] % %^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_+']IO_ )34?#;_ +&M/_1;U^IU?EC^TW_RFH^&W_8UI_Z+>@#]3/\ XFOS
MD_X)H?\ *9W]L7_K\L/_ &6OT;_^)K\Y/^":'_*9W]L7_K\L/_9: /T=HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K\U?^"_W_)1/V=_^Q[N/_2:2OTJK\U?^"_W_ "43]G?_
M +'NX_\ 2:2@#*_X+Y_\HNOAE_V53PG_ .ET=?I3X!_Y$?1_^P7;_P#HM:_-
M;_@OG_RBZ^&7_95/"?\ Z71U^E/@'_D1]'_[!=O_ .BUH UJ*** "BBB@ HH
MHH **** "BBB@ KGOBY_R2GQ/_V+U[_Z(>NAKGOBW_R2GQ/_ -B]>_\ HAZ
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MU<-KWBK_ (2;X:'1?V=_#:6-M?Z[+8:PTD!@:$;MLDJ<<MG)!KUSP-X'\/\
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M_DQ[X4_]B-8?^BA7LM !1110 4444 %%%% !1110 4444 %%%% !1110 48
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M \>_X=^?L3_]&Q>#_P#P4)1_P[\_8G_Z-B\'_P#@H2O8:* /'O\ AWY^Q/\
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MG_\ @G[^T1_P1Q_X*375Q8?LX_LUZ5));;S+_:OA06XP@)/7Z5J-_P &SO\
MP1Y3 C_9CC&[O]O;_"OG7_@WL^!'A?P!^T1\5-1^$'P_FT;PEX9\8:CHR*7W
MKN7<J\_04 ?I)%_P3_\ V)7C#+^S%X0Q[Z0E._X=^?L3_P#1L7@__P %"5Z]
M Z21!DZ&GT >/?\ #OS]B?\ Z-B\'_\ @H2C_AWY^Q/_ -&Q>#__  4)7L-%
M 'CW_#OS]B?_ *-B\'_^"A*/^'?G[$__ $;%X/\ _!0E>PT4 >/?\._/V)_^
MC8O!_P#X*$H_X=^?L3_]&Q>#_P#P4)7L-% 'CW_#OS]B?_HV+P?_ ."A*/\
MAWY^Q/\ ]&Q>#_\ P4)7L-% 'CW_  [\_8G_ .C8O!__ (*$H_X=^?L3_P#1
ML7@__P %"5[#10!X]_P[\_8G_P"C8O!__@H2C_AWY^Q/_P!&Q>#_ /P4)7L-
M% 'CW_#OS]B?_HV+P?\ ^"A*/^'?G[$__1L7@_\ \%"5[#10!XZ__!/S]BC'
M_)L7@_K_ - A*^!?^"FG[.WP.^!O_!3?]C&X^$'PMT;PX][\2)UNFTJS$1E
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M@ K\U?\ @O\ ?\E$_9W_ .Q[N/\ TFDK]*J_-7_@O]_R43]G?_L>[C_TFDH
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MU34;1I[+4]=YN(]RG$>X\A2<9%6?%EOXH^&7[,FMS_$_Q6-=O;2TEDGU(Q[
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M4^(-?\5?%3XL#Q->:SL+'R"GED&NJ_X3#P&WQU'@U8HW\0?V29E?=\PA],4
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M7LM>-?\ !//_ ),>^%/_ &(UA_Z*%>RT %%%% !1110 4444 %%%% !1110
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M?NC>QP<8SZU\(?\ !8;_ (*_^ OV"/A[=>$_".N0WGCN_B>/3-*AFVS+,.0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7Y8_M-_P#*:CX;?]C6G_HMZ_4ZORQ_:;_Y34?#;_L:T_\ 1;T
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M!K4444 %%%% !1110 4444 %%%% !7/?%OCX4^)S_P!2]>_^B'KH:Y[XM_\
M)*?$_P#V+U[_ .B'H ^(?^#;C!_X)N!CC/\ PLGQ%@?]O5>1?\$V3-_P\/\
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MP-_90\+7W['W[4/[,^I>-_AYX)8Q^!->TOPB^I EG_>%Y51E''?-><2? ?\
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MO!@ \9KX2_X+"_\ !8/P'^P9\/;KP5X/U"*\\?:E$\.DZ=%-ME28#(Q[D T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:\*UK_@XC_87^#&HW7A3Q7$RZ[;DK>S:3;H89#GL1UY!K\B/B9_P1Z_X*N?
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M+^*OV9])^&VG_#G5?BOX?U>RL(%C4ZKJT,K2E22&;<QR>>M?SSZ'_P $*?\
M@L/H&8-*;Q#$7<LZK&.23DUG>$/^"1W_  63\8ZSK.E6=_XB!T>\%O*!&/O$
M T ?TA7_ ,7_ ("W>AR:$GQ<\.6\4L7EC[/J\*E5]L-Q7)^'/''[/WP;\.:W
MJ8^.FFZC:M')=SQW6NQR.%1"2B MW /%?@8/^"(7_!:4GG5O$8'8^4M4?%'_
M  17_P""RVE>&M2U;5M7\1&UM;&66Y#1#!C5"6_0&@#](?$G_!QI_P $RM?\
M':U\.K9->TJ*X>:TGFL+41,"KX9E(QU(ZU>\(?\ !RW_ ,$X/!OA33O!UM?^
M(;F/3[98EENH@S.!W)/4U_-)I?P@^'MT;R/QS\5O[-U.*^FBNK*2V)975R"3
MQW(-3+\#_@@_,GQY08Z#[&W^% ']1WPD_P""R?[ '[<.H:S\*_ _B*Y\/WVL
M6JV\VL3NEM( 6X/F9!XQZU[]\-/VAO#>@>-=,^']M\9/"MYX7T_2VCGO)M9B
M>X>51\N6W<Y[U_)G^R#^R%\7OCG\9F^'/[*?BN\U6]9HU^T6<)!.XG'4>U?=
M&E_\$+/^"R.@0O#I-SXBC\Q]SE8AUH _HNUSXY? W6M)GTV+XQ:!#YR;=Z:Q
M$K+]#NKP/P_^RW_P3DTW2?$&FZZ? 6H7?B&6>2;5[M[62ZBDD4C>CDY!!.0<
M\$"OPP^(W_!)?_@L3\.+:*ZUC5/$6)20A:,=JV]/_P"",'_!:#5=#BURTU+Q
M'(LL DC'E#G(R!0!^C6N_P#!$']AV1Y[[P[_ ,% ?'%E*[%H8[?X@E$B)/10
M)>*_*SQ[X9^''_!*+_@KGX0\-_!;5=/\<Z;X@NK6.]NO$LR7ZI+-.BM,&)8!
MQN)#=0:[30O^"+W_  6VU6-CJ)\26LJ_\LBBFOCSXV?LP?M"_ /_ (* ?#SX
M7_M(W%W_ &Y>^(M. EO%^94:Y0?UH _L&O\ XB:,?"#7>@Z]I]S>) I6.&X5
ML''H#5O1=.\(ZM>IX[^QV#WPM1'/>HBEE '*EO3VKQ_X!_L7Q_!^XU?6-9\;
MG4X[^.,V2/%M^QX SCUS7I_PN^'FE^&O"U]H*WZZC#=7,CR-C ^8G*T ;,FG
M>$_$>J6_B:"UL+RXLLFUN=JNT6?[I[5@?%_X7Z1\2-*M)M7\3WVDQ:;=BZDF
MM+HQ A>SD$?+6OX,\!Z5X'>:VTJ%8[><CR[<=(P.U<U^TMXATO2_ $OA'6M0
M6U3Q1G2X)V_@>08!]^M '2>&/'WP\,%IH.C^-["]E9,6R1WJ.\P]0 <FKOB;
MP-X:\7S6]WK.FPSFWD$D1DC!(8?6O*_@)^Q)\)_@OHOAN0Z9#?\ B'P[:F%-
M:*D/(222V.U>S"-DR2N !P/>@#R+]H?X@2Z?>Z;\$O!NFV%QXAUW$VFV^IQ!
MK?RXWP^<]#Z5ZKHD4]OI=I9:BD7GQVZ"58ONJ^T X]L]*YOQ9\-?!^N>*['X
MI2^%8[W7]$@>/3K@GYX@W)4?4U8\%>+-0U+1SJGB[1/[(O7N'B%N[Y)4'Y6_
M&@!?BS\7?"?P?\+MXK\4NY@6YCAV1<L6<X&!6;\0=#T*3P5JWCC0-!TDZG=Z
M2KQW6IPKL92 5$C'^$9[US?C;X=7OQ^%]H7C?P\=.LK&_C-C)(=PO%4[@X].
M>*] UWPKH&K^#)?!WB*V2;3I;(6]U _1HP ,'\J ,KPAKL^B_"73=8\116ID
M2Q#S+I !AR >(\<8X[5>^&7Q&TGXF^'5\0:%87$,1E9 MU$5;*G!ZU-X:\->
M&+#PI;^%/#MHB:99PB&"W3E40=JT-$TO0O"VDFWTR-(+9"6P. "3S0!S/QI\
M(^'O$_@.:W\1ZW=:?;VUW'=O-;S^6[-&=P0'/(.,8[T[X7^//#/Q;\&Q:AI>
MEW L9 86AOX<;PO'(/6MGQ%I'A/X@:4=%UN*.^MF<.82>,CH:E\.>'M$\,6<
M6EZ/;K!!$?W<"]%H _,C_@OQI6E:+<_#^TT[3XK:(^-=$.R&,*,_;8O2O??^
M"Y#;O^",GQ=./^9!7K_VSKPO_@X1>WDN_A\@F"M_PFVB=#_T^Q5[K_P7*!'_
M  1E^+H)S_Q0*\_]^Z /;_\ @GG_ ,F/?"G_ +$:P_\ 10KV6O&O^">?_)CW
MPI_[$:P_]%"O9: "BBB@ HHHH **** "BBB@ HHHH **** "OBGXJ_\ !<O]
ME3X7?$#5?A_-X9\3ZO=Z+>/:7\FCZ<T\<<JG!4E0<&OM:ORJ_P""*7[/7PG^
M+_CG]IW5_B)X/M]1N;?XUSI!-/R53:QP* /EW]L'_@Z;_:[\/?M*:_X _9/^
M"ZW_ (=T](VMHM4\/N]W'G.3( I([5YR_P#P=0?\%6A@?\,VVI..?^*6E_\
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M_P""KO0_LUVO_A+2_P#Q%?:7_#TS_@E5_P!$YT7\VH_X>F?\$JO^B<Z+^;4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[1_BG]HOQ5;W>EZ%9^!]&U1X;IUM@EU-\BE7S_%CG)KZ"T?3(-'T6#2X3Q!
MJ  =< #/Z5\Y?&S5/B7\*_CCIEO\-'GUK^WX9'O?"R?(ERI(5F+?[*T >T>+
M=>\7>)] CU3X+:UI=V?/9)I7D#Q_+P0".X/6MS1K6_N=!MXO& BDN7M2M\D8
M_=L3PPQZ8K&\!^ =&^$WP\_LKX=^#H]/4[KM]*@/'GR89QGU+9K4\-:IK.NZ
M:XU_0/L,[<&$MG([T >+Z!_P3Y_8OB^+NM_%:T^#?A6]OM8MTBGLY-'MY(8B
MK$[PFW ))Y/>K7QH^#7[#GP)\%'QUXY_9Q\$I9BZC@>1/#5K@,YP.J=*["P\
M9?#_ ,'_ !+F\"Z7I44%]*%\YD!RP8DU\G?\'('B/Q=X:_X)L7=SX'O)H+VX
M\:Z1;H\ RVUY2I7Z'- ';77Q]_8<\ '4[?\ 9_T#P!HGBK[*K:=<QV=K"HD/
M(W%0#ZUTW[''[=OA_P"*7A76KGXR?$+P[9:EI>J_9%5+R.)95P<NH)Y'O7Q1
M^R5_P0RT7XT?!C1/B[\0_$@TK7-0B#S1?9PY7Y00<X]Z[B+_ ((!^&$\;I,O
M[0KR)Y#?\2W["N&_VNG:@#[4\>?M??LO>'_$VA^'->\?:#?MKUT8('%[%(D!
M )RV3\HXZUU%[^T!^SQ<Z5-I:_&'P[%#);M#B'58E*@@C(P>.M?#T_\ P;X_
M#W4)8[NY^*6^2-LQ$V(^0^O2FZW_ ,$$/"EAH]S>V7Q-\ZXAMW-O;&T \YPI
M*KG'<X'XT ?3LOQY_9F_9H^'.I^+1\98M;@LH3(;9-96>XDYZ*-Q)-?S_?\
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M&3XN@'_F01_[3KYF_P""WDOC)M.\!_\ "<1R+=-XYT0JDAR0/MD=?2O_  7
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M))@C<<]\$UZL+:$;<1CY>E #2BN=KJ"!ZT]"#@ $4X@$8(HH **** "BBB@
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MF[_B]WADD?\ ;_%7Z'^&9Y'T2RCCC^3[)'\W_ 10!J44<^M% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!&V_.TXSVK\(_^"B_QZ^/'Q&_X+:Z3\#OV/9--L_'?ASQ!&8[O
MQ!!OM#(\;;<^HK]WI-NW+5^!/_!0O6=._8/_ ."[FF?M9:O*^I6?B7Q%$;N!
MD(%FL<;'(V\G- 'MNL?\%&_^"K'["G[7_AGX>?\ !0C3O#6I>$_$0@M8-8\)
M:1MA2ZGD6.-&DY .6'%>T?\ !,:<W7_!9']K^XC Q)/IS$'W"FOF^;XJ?M=_
M\%^/BKI7@ZY^$-QX(^%W@WQ;;:K%KD$QD6\N+.=94!1\XW[.OO7T=_P3 MGL
M_P#@L5^U[;NV62;3DW'O@** /TBC14R <^]/I%VC@=>]+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7YJ_\ !?[_ )*)^SO_ -CW<?\ I-)7Z55^:O\ P7^_Y*)^SO\ ]CW<?^DT
ME &5_P %\_\ E%U\,O\ LJGA/_TNCK]*? /_ "(^C_\ 8+M__1:U^:W_  7S
M_P"477PR_P"RJ>$__2Z.OTI\ _\ (CZ/_P!@NW_]%K0!K4444 %%%% !1110
M 4444 %%%% !7/?%O_DE/B?_ +%Z]_\ 1#UT-<]\6_\ DE/B?_L7KW_T0] '
MQ#_P;;)G_@FYN'3_ (63XA_]*J^9?V0? /Q6^)/_  4?^+OAGPEJ]M9:6_C6
MX:\DW%)LA%^ZP((XS7TW_P &W+'_ (=NJ4&!_P +*\0Y'_;U7A?[!WB/QCX:
M_P""@'QGU'P5X9_MB^_X6!*@LR^T>644,V?8<T ?<WQN_9-^']_\)HSXIU_Q
M7.OA]6NO+TG5)1-<,0 5&#EOI7K_ ,((M/M?AEH=MH]O>Q6R:<@BCU$DSJOH
M^>=U6/&&L>*-,\"W&N>&_#"ZAJT-IYEIIQDQYDO'R9_$_E7 >+_CAKND>"K2
M'Q+I3:-XDO?+*Z?&2V,G!Y^I% 'K;2AX@B*=K'#>HKRW4OA'=?#;P3XCL/AI
MJMU-?>(+B625]0N&E\HR*RG9D_+C/&.E/\;?\+DNOV;=7C\*M.GB^>P;^S=C
M@.)"5*X/TS6U\(++QI8?#"Q/CW4)9]9%BOVXS$;EEV\C/UH \Y^'UGXX^!7[
M.-K\/-/\9V<OC-ED&G?VO<F4SRDY &XY;C/%>N> M%CL= M+[5=(LX=5F@5M
M0FM;=4#2D?-T'K7,:7\%?#/BKQ/9_$WQI''J-_83>;H\DHR;*3H64CO@FO0O
MD1/FZ9_,^M #=0O[+2X6O]0O8H8HQF221L*/K7"7'P3^'WB/XM'XXO=S7>IM
MI9L8T6;= L9'W@O0-[UPLND>*_B#XV^)GA&Y\;75_:RQQII^E2(-EETSM..<
MUTO[./PJ^('@2UF?Q5XRNKR,,RPV4RC:J]L<4 :_PP^!6@_#/Q;X@\96>M:C
M<S:Y(LDZ7=XTB1D?W 3\OX5C>.O"WP]_:3T"RD\36%_&- UX3V\*':YEB;AL
M=UXKJ?%O@#QGXB\8Z'XCT?Q]=:7I]@S&_P!'B4&.\!Z!B1VK0U/3&\):/>:K
MX8T9;J^2%WCMP<>:^,A<^YH T9?$.F66GKJ^JSBUM\9WS':$^IJ#4=0\,S#[
M!J>H6T@ND'[B5P5E1N@P>N17(:KI&L?&KX/6VC>/K-?#VI:K"KW.GA]WDL#T
M&>M4]4_9_N-1^(EAXND\9S?9;&PMX(]-\L;"T:@;\XZG% %+]H#X9RV5GI7Q
M/^'.H1Z5JWAA/)TJUD?R[+RW;+!XQA3[<5Z7X=OFU32[2_N)U>=[9#.\1^0R
M;1NQ[9J/QGIGAW7O#=QI_B:T2>R S+&XX!'(KQ[X>76H>/O&2Q>"OB5=6.F:
M=/\ /I<,7R.%)!'([XH ]U^R6R2F\D?# $G)XKB_'_QS^&7@CPO>^)-8\463
MK;1L9(H;A=[;>H7WKM)3;R1.MR!M(*X/H>U>'?M _LH_#W7-!CO_  Q\-[2\
MFM;AKF33\$"[)ZH3[F@#2M/A;X/_ &@;SPY\;KV^OVL5L"UEIYN3Y;JS9!D3
MHS CJ17I>EZ_X6N]8?PG:ZQ;MJ-A"KS6,4HWQ1]%++V'%4/A3IITSX?:/IR^
M&DT4Q607^R8FRMMR?D!/I6'XS\'P_#[6=2^+OPY^&EOJ/BO4K58+N<.5>XC0
MY1"?3)- %CX_:7XLU/P-L\!:?I]W?C48-]OJMN)H3%N^<[3QN Z'M7EO_!1O
M]HJV_9(_81\=?%C1=3TNQUW3/#+3:-8W(4)/<J4RJQ_Q=3Q7J'BC5OB!>_#6
MUUG3]+_L[6YA&UU:++_JB2=PR:_,[_@LOJTG[7_Q(^%'["=BRRZEK?B=[3Q-
MJ$#>8VFP20,5E(&0>5QSZT >B?\ !#;X6_%[]EC]CKQ'\>_CU8V^MW7QG\66
M^OVUGX?AW^3%<JR$.O. -W(]*^S/C9XC\<_"BW\/:[\-])LH/#MI<&;Q!I\5
MJ!(T)7.(@.C9(KI?V=_@[8_L^_ [PO\ !:UU,WB>&](BL8[IDVF4(,;L#I3?
MC?\ %?X0_"3PG-XF^,>O6]GI<:%I9+@C!4=>,\T =5X<UB'Q)X>M==AMGB6\
M@66.-UPP!&>?>O%_VJ_V\_V4/V2_"NL^,/BYX\T=]4\.0><VBK=Q_;7/]V-#
MSNKR+_@HO_P58^&_[*'[)T'Q3^$-W9ZW?:Y>V^DZ';)<[#&UT?*CE&#P59@?
MPKYD_8Q_X)U?LT?'&SOOVD_^"G]QI?COQOXI19?[*\0,K'3&!R"K*1G*G'-
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M7*PW(.<*2AP<'M7M'PFG^)4]A=WOCS4-.NXY9@VG3::O!BQW(Z\U\&?MB_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEL[#[BAON#_9%<IX_P#$/PZ^(WQAT^U\7ZQJ&AR^ KH7ZSO?-;V]WN!3:0"
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MOS#GO0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5$G^-'_#PS_@NA_TB3T/_P *B3_&@#](<CU%&1ZBOS>_X>&?\%T/^D2>A_\
MA42?XT?\/#/^"Z'_ $B3T/\ \*B3_&@#](<CU%&1ZBOS>_X>&?\ !=#_ *1)
MZ'_X5$G^-'_#PS_@NA_TB3T/_P *B3_&@#](<CU%&1ZBOS>_X>&?\%T/^D2>
MA_\ A42?XT?\/#/^"Z'_ $B3T/\ \*B3_&@#](<CU%&1ZBOS>_X>&?\ !=#_
M *1)Z'_X5$G^-'_#PS_@NA_TB3T/_P *B3_&@#](<CU%&1ZBOS>_X>&?\%T/
M^D2>A_\ A42?XT?\/#/^"Z'_ $B3T/\ \*B3_&@#](<CU%&1ZBOS>_X>&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K\L?VF_^4U'PV_[&M/\ T6]?J=7Y
M8_M-_P#*:CX;?]C6G_HMZ /U,_\ B:_.3_@FA_RF=_;%_P"ORP_]EK]&_P#X
MFOSD_P"":'_*9W]L7_K\L/\ V6@#]':*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *;(X3&5)R>U.J&>5U&57(/WO84
M /(+@[?7BD=\+G@9XS5/4=8L]'L6U"]NTBACZM(X Q^-?,_[0'[>NK:9XO/P
MB^!WA"/7]9N J;BSJL6[."&''4&@#Z-U_P 6>&O"L)NO$NOVUG&!D/-)M&*\
MI^(O[;?PC\$"*[\/ZB/$\MQ(8VL]$G$DD&/XF'85Y9X"_9$^/?QKOG\6_M$_
M$G4M/B7*)X<!26!E8>NW/'U[U[+\(?V+_@%\(X'.C> K"34)!^_OS$0\@SD
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MJ#P%9_#VZS-I$]_-K=M;*($$8R49@/O$=*S8?VQ/V=D0)#\0]-15&%Q<I_\
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MWH _.'_B(.NO^D9OQP_\% _^(H_XB#KK_I&;\</_  4#_P"(K]'O+]Z/+]Z
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M%% !1110 4444 %%%% !1110 4444 %%%% !7YL?\%A_^4EW[$O_ &4JX_\
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M_P#B:_.3_@FA_P IG?VQ?^ORP_\ 9: /T=HHHH **** "BBB@ HHHH ****
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M10 4444 %?!__!QW_P HM?%G_8<TS_T?7WA7P?\ \''?_*+7Q9_V'-,_]'T
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MP%!)&TD4 ?T"!@W0YI:\\_99^.6B?M'? _0OC%X>_P"/36;02Q'!&?P->AT
M%%%% !1110 4444 %%%% !1110 4444 %?EC^TW_ ,IJ/AM_V-:?^BWK]3J_
M+']IO_E-1\-O^QK3_P!%O0!^IG_Q-?G)_P $T/\ E,[^V+_U^6'_ ++7Z-__
M !-?G)_P30_Y3._MB_\ 7Y8?^RT ?H[1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %,?'4'FEESMR*PO&7B^U\'>&[[Q)= %
M+&V::7=V4"@#YQ_;M^/7B_3=>TKX'?")Q-K&O*3+&B;RBJ^&!'!Z&O:?V>O@
MMX/^#G@*UTCPQI/D27$8N+V23!=IG :3G&<;L\5X+^Q5X+O_ (K_ !I\9?M$
M>,H#,DVKB7PE-(,^5;M&NX)Z#(/K7UU!&$7&P >@H 6(;> .*?1@#H** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[XM_\ )*?$_P#V+U[_
M .B'KH:Y_P"+7_)*O$W_ &+U[_Z(>@#X?_X-N"4_X)N@@$G_ (63XBX_[>A7
MEG_!,B%;S_@I)\98[J)'3_A-KDA64'_EFM>J?\&W*A/^";X9W/S?$GQ"!@?]
M/5?+G[)_BGXA_P##R?XK^!OA79E]7NO'<TV[>4 A55WY;!'0]* /UX^*LGB6
MV^'^J2^#]<L],U!+0_8KZ^BWPV[Y'S..,BO/?BMXKT\?LN^(;+Q[XKTS4-2?
MP1?FYE@3$<\OV63YT4YP,UZ/KOAV;Q;X%?PSJ_'VRS$5TPY(.!GZ\BO-?CA\
M&/""_LW>+='CC#267A*_$=PT?S*%MI#@4 ?._P#P;D1^9_P2Z\+,S@J->U3R
MR.W[^ON32_%/A[6+M[#3]7AFFA)62-'R01UKX<_X-R@(?^"7'A6"W&Y1KNI@
MYXQ^_KZ)UNX\.^$?B#/\*O!TMR_BG6()-0BD^SE46,?>'F= >>E $O[67PQL
M=;\(O\1]*\5-I&M^'$:XTF_N+EA;0R=-TJ C>N">*V_@IXM\*0:=8>#F\=66
MH:]=V*WES##*293C+.H/1:T_#7@Z[UWX=+X+^)VF17[3H4U"&X.Y9%)Z'UK(
M^#T?P)\8:O<^,/AIX.BM]0T.5]*DO'LVB= O!1<GE>.M '9:7XV\-ZWKNH>&
MM+U^VN+_ $O N[2-LO;D]-PK)^+'C[PYX#\.#7/$%@+F,R!%@(!WL>@ (K3T
MWP!X5T/Q+J/BK1_#]O;:CJQ!OKR)?GN2.FXU7^(OAJUU_P +7,3Z!;:A=0Q-
M)8VMT<(TP&5Y[<XH =\-_$=CXM\&VOB6PT1]-@N(MWV210IC'I@<"OQN_P""
MG7C+P9\0/^"BOA']F/X:^'M8\5V?A[5[+Q1>QZ9=^9Y$JR!G)ST (/'M7Z0+
M\2E_9 ^ _B;]I']JWQA<:591VGG:AHMN1-#I?;;%T+ ^]?'O_!!WX6WGQR\<
M^-_VW/&W@2-9=5U[4M/TK4+N-EEEL3,YB.& X*$&@#]-/!_B"Q^(GA*R\13:
M(T4%[%O6TO%#&/V88P:M>*-=A\*>'KO6AI\DRV%LTHMH.&DVC[JUX7\6=1U[
MXQ>,Y?A1\%O%NIZ';^'9##XBNK6+RS WWAY>X$/Q7HO[/GBSPKX^^'LG]D>(
MM0UA+.ZDLKJZU2V,<CR1G8XQW&0>: .B\!^-X/B'X+T_QD^AW5@E_;^<UK<D
M;X>3PV/I7RG^U'\*M0^,OQL?Q[8_$6/4/#6GV\8?0]'N'CN1)'D/E@<<].E?
M2VN_"C5;_P ?Z'XOTOQM>V&G:5!)'-H,&W[/=AN[YYXIM_X;^&/@;PWJOC3P
MQX6T\K##))</:#=YC Y8'!/.: .?_9:^)MIXQ\+3>%M.^'.N:#::,RV]M+K<
MH=KI<9WJW4CG%>GW5J\EJR,25D!5B.PKC(_BA96'P9L?B7;Z(4BN(4:*U6-L
MJ&)&,=1TKH?"'C"T\6Z3'>+<11N1N:VW@.![J><4 <%\9OC6/A3K^D>$?^%0
M:KKUI?(&DO;.-&B@;< -^X=><UT_Q/\ $NGZ'X;L_%5QH%S="T07$=K;$!E^
M4<5@_%+X?_$3QM\1=)?2M>N+#0(8&-]Y$@YD# J-I'/&:[2[U?PPC0^']4N(
MG9E$:I(PS(<>F: %TCQBNL^$K+Q+#HUPHO(T?[,Q&],]C6L\C2Q"6),%ARG>
MB&"WMH$AMH5BAC7&!QM KB/CEKV@0_#76+Q_'%QI45M:,TU]I>V2>(9'*KW-
M $WQT?6H?!*2:+J&FVD@NHLR:K;"6,<^A[^AJC>_#:Q^,GPO/ASXAZH;N.\A
M,<T^F2F$,./ND=*ET3PYHWQ3^#^D:1-KUW>6\D$,T=[=Q;99P.0S#L34?Q/\
M76'[/_PNGU%(99K:Q@+@Q1%F'3H!0!S?[2_@CPCH?P6T;PE<:#K6H6UAJ-FF
MGQ:7>E)DD5QY;NW5E!P6'<5V?PBTOXL644UU\1M>LKF"6)1:106Y1HA_M')S
MQ7"^"KV[^%WPF;Q[XF\3:EXG7Q!J4=Y:1ZE#\UFDAXC4+R ,]Z]:\*^(4\4>
M&HM<CBV"5<A&&/YT <S\?_BC=_"GP(^H6.D7%W<WLHMK:6 #;;N_"ROZJI()
M]A7D/PE\=?&7P!X?UOQ/\5]=TKXBW%LBOIUIX6L=D]N<\@EB>?I7K.B>-_AU
M^TMX1UO2/"]XT\-I/-IUU(\6#!. 5++ZX//X4GP/^"OAG]GOP9!H<6K"YEA7
M%YK%Z51Y^>"YZ4 =7X3MK"?1+75;71(].DNXEGDMQ"J.A89(; Y;UKGOB=X6
M\9ZOXRTC7]#N].32K*&8ZI'<V@>9P5./+?\ @J@OQ>\1S?M"_P#"I;?08I-*
M;1?M@U97))<_PCMBNYUA96T:X.XX6V?/O\IH _+K_@WPUK2- L_B??:MJ4<$
M3?$S7E0ROU;[9+4'_!P+^TIX-\;_ +)OC'X<SV<NGW6G7]M#9RW4@VZD/,!+
MP@=AG%>7_P#!'KQFF@:+\0+'5--26SE^+&MA'C!>7>;R7@J.@]Z]?_X. OAY
M\/M0_P"">3>,Y/"MM_:,0MS:7CQD21YFYQZ4 ?H1^S?I.FC]G_P%>/9Q,P\&
MZ7MD,8+C_1(N_7%<A^UY\)?AYXLM;'X@^+_!OB36;K2R([:UT#43"S!GY) Z
MXJ7P-XP\9^"_V9?AS>>!]$M=2N)_"FEQ/%?3^6JC[)%R#77^*?$_Q@M_AK'K
MOA#P=8WWB!MGF:9)=D0KD_-AP.<#F@#HO!6A:3I/A>RATK2_LD1M8V6%U&]<
MJ.&(ZGU]ZJZQ\1?!<'B>V^&]]K4"ZEJ5M(8;$R8ED4<$@>V:BUCQS=V&@M8V
MEO!)XA6Q61=.>7"^:5'RYZXSD9]J\O\ @O\ #;XG^._B=+\8/CS\/=.T35M&
MD:#038W)F,L#@%B20-O/:@#5U?X*>(O !T-/@Y<Q11?VT\VM)JZ&Y9X6Y(C)
M^XV>]>NS7[6FG/<"$NT4#.8A]YB 3@>YI+^_MM*M?M.I7*1@=6=@/RS7&?!^
MW\;IJ/B#5/%DYEL[C4=^D-YN[,&W].: .5^&>@>&_BCXRN/BU>^"-?T/4U?8
M(]0NR$;8Q .T<8.<UV7QO^-F@? GP2GB_P 3VDEQ#)>PVH2%@I+R-M!YK6\6
M^/=!\#:6VK^);E8K=02!U9\=E7N?85X9\=="^,GQ'NM.\2> O %CXIT24+*F
ME:Q<&*,'<"LF ,[EZB@#W:UM- \=:%:W]_H$4JE1+"EY"LA3(ZC(XZU=M-/L
M=.A\JQL8K5 ,%8XPH/X"L[X3?\)</!%H?'&CPV&H*N);:WDWJ@&, &J?QE^&
MNK?$_P /0:+HOCK4/#[PW\-RUUIX4M(J,&,9SV;&#]: .7^)GP8T&]O9_&'A
M:SDD\13C-G<73^;;P2#HS1GM786>IZCH'A)9O$<*S75GI[37 MDV!RBDD*.V
M<5G_ !'\4>+O!FDV]]X5T&*_BA7&H/*Y5@H&,@#J2:S_ !YX2O\ X]^ K2RT
MOQ??^'9A<13W%Q8H-[JI!:$[OX6'!^M %GX0_%JV^,N@?V_'X.O=/MI!\B7N
M#NYQV%036'Q1T3XNB]TS5=.M_!HTXM<6BV>)//\ [Y<'&/PK4^'E[X=TC[1\
M/M%>;S-(4"56A*KSZ'O6KXKUK0M-TAK37+L0PWO^CJQQ]Y^ .?K0!<@U;3-0
MTY=6TZ_BEMW7*S(<JP]JI^#_ !%X.\3VTUWX.U"SFMXIVCG-F  )0<,#@=<U
MQ/B'P/XF\%^!'\-^#KUKB(1X#RN$\H>U'P5\<?!^VOF^''@BQ%M?K&;B_2WM
MR(WE_C8MG&XG- %O1/V@/AWKOQ5U+X1W=\MEJUA<^3##/,-UT<9)08J/]H7P
M?\1?%WARQT+X?:K!:)=WPAUHR1$F2T/#*I!&UL9YKG/'/P5O_#?Q+F^+/@'X
M>Z;KNMW<_FBXU"0QO:'H=A'7->T:4]W/IT#W]NL4QA4SQJ<A7Q\P'XT ?D'\
M3/AUJ?\ P3E_X+)_"P2^/;+3_A[X[>[N;Q[DMNB"D(@FD)^9CCKBOTVL[3XB
M7WQCE\5Z1>Z6?"EQH\+VOEV(^T2L1DGS>I4@@@5\Y_\ !;C]BR/]JO\ 9AU'
M6O"&D1OXRT!%ET.^ Q+"JL78*W;./2O!_P#@EO\ MU?&']M^;2]5AUXZ7>^%
MI5\/ZMX5M;O,*Q6/^CFY.[YMSE"3VH ^Z/%?[25EI7QATWP)JML^EZ?*'%S=
MW9 1F!XP?QKV&&>"YB6X@&]#&&1E_B&."*Y_Q7\+_AYXOF2\\4>$[2\:,Y66
M9"2#G/K6[;^586L<$$86)$"1A>P P!0!Y]::?\6[3XCR>(-5\6Z='X<61A]C
M:W(EYQM&[/\ 2O28Y%G48.< '([USWB7Q#X6L;^#0]:C>1[L;XT$)93@]2>U
M<O\ &CX_:#\&[C0M*N );C6KW[-'#$I=H_ER"0.5'N: -']H&;XH6WP_FU#X
M2WUO!J=O/&[?:+?S T(),B@9') P#7RS_P %./C3;?$;_@DA\8]3_P"$?N[.
MZD\%W$-S:W!&]&5XP7..Q/2OM;1;HZKI,5U)%\L\62&'.#7QU_P7!\/:KX=_
MX)I?%>3P!X7M##/X5G&JR^85*1[D.1Z\T ;G_!/OXN0?#3_@G7\%PWA*_P!1
M$_@RQ0FU(^4MD9.:]Z\&?%M_&OC?5/!D?A>\LVTRWCF:YN<;)=_8>XKP3_@E
M!\+98?V$OA)KVI^+[S4(G\%VKK83J/+CX.,8YXKZ)\8C5] \/:AXB\$Z+:W&
MK&#]R+B7RUF8$85F["@#\J?^"\G@[XIVOQ7\!^(=6U;29-%_X3#2 MM!8[9]
MQO8MIWYZ>M?5_P#P7%);_@C%\72PQ_Q0(Z_]LZ^:O^"\']K:WJ7PP\3:CJWD
M7 \3Z(E[IMK*'B64WD6>>^*^EO\ @N/G_AS)\7=Q_P"9!'_M.@#W#_@GG_R8
M]\*?^Q&L/_10KV6O&O\ @GG_ ,F/?"G_ +$:P_\ 10KV6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?O^"J__ "CF^,?_
M &(]W_(5P_\ P2O_ .4.'PP_[)8__H$U=Q_P57_Y1S?&/_L1[O\ D*X?_@E?
M_P H</AA_P!DL?\ ] FH \#_ .#>G_D4/%G_ &']2_\ 2IJ_3.+[E?F9_P &
M]/\ R*'BS_L/ZE_Z5-7Z9Q?<H =1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7P?\ \''?_*+7
MQ9_V'-,_]'U]X5\'_P#!QW_RBU\6?]AS3/\ T?0!Z?\ M0_\HDM;_P"R.VW_
M *1Q5PO_  01_P"3"/"7_8'@_P#9J[K]J'_E$EK?_9';;_TCBKA?^""/_)A'
MA+_L#P?^S4 ?;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?FQ_P6'_Y27?L2_P#92KC_ -)IJ_2>OS8_X+#_ /*2
M[]B7_LI5Q_Z334 6/^#ES_DT3X;_ /9</#/_ *7PU^B/AC_D7+'_ *\XO_0!
M7YW?\'+G_)HGPW_[+AX9_P#2^&OT1\,?\BY8_P#7G%_Z * +U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !0>G%%!&1C- 'Y&_P#!QY^Q'X_U
M_P 4^#/V\O@I\.]4\3>*?".L:;;W&FZ4F^1[%+F.2;"G ^ZAY[53NO\ @[._
M9G\#6]OX3^(/[,OB[0]6LH5CO=,OM1@66)@H'("\=*_6W7+>RO;5M/U&*)XI
M!M=)3PP/!%>&^,?^":'_  3U^(_B2X\6>/?V6/!>I:G=-FXO;FTW/(?<[J /
MP\_X* _MV?MF_P#!>[Q?I'P9_8N^&?B71?A.]W!'JMSL\PI>!P&=YHF4^6!D
ME<=*_7+_ ((Z?\$D?AK_ ,$N?@?'HUK(FI>--7M4'BG6;>0^3<NN""B,,IT]
M37T7\%/V:?V<?V:M'D\/_ ?X9:'X6LY93++;:3&(U9CU)Y/-=O)=64C++#?Q
MJG]T2#F@#Y9_X*C_ +=?C[]C7X'ZGJ7P]^ ?B/QEJ^IVSVFE3Z&$*VMQ(N$=
MPW4*2"1[5\L?\&[/[(_[2EG=>-?VX_VQ94_X2KXGSP:@+,69@DM7  (=<D=N
MU?I[XDT3P;XIM!I/B&QM;V(-O$<Q!4'UZU<T73M'T+2XM,T:U@BMH5PL4)X4
M4 :$:(LF<]NE.E&4;*G\*CM764G'X5(59^-^ .] 'YR?\')_[ WQ2_;K_8EM
M=!^%.IPQ7OA'4Y-9EMI(&D>Y147]VF",,<=Z\M_X(6_\%?\ ]G;P[^S3X6_8
MK^.NIQ^"?%/@'3(]+O8->NE0RR#+DA0,C&X=:_6/5-*L]5M9+?4$#PR)MEC(
MR'7N#7YL?MP_\&Z'[&_[2/Q+O?CM=?%JZ^'%[=SM+=7^EV\$8+-CDO*X';%
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M)5E)!X ]10!^KH8$9I-X)Q^M?E9XB_X.1?#GA3Q1IW@_7?A=>0W^J!C86O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H.<<&BB@#\Q/^#@C]M?\ :=_99TWP
MKI7[.?C2UT:^\0^(=-TM+BZM/-6-KFX2+<1D<#=FL_3OV _^"_.H64&HQ_\
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MFZ,\#(SWQ33@$!9,GO0 EI%)$NR0Y(4 GU-34R.0R$X''8T^@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\L?VF_P#E-1\-O^QK3_T6]?J=7Y8_M-_\IJ/A
MM_V-:?\ HMZ /U,R!_WS7YQ?\$TR4_X+/_MC;NUW8?\ LM?HU,^P#'TYK\??
M!O[<WPA_X)P?\%=OVFO&7[1_AKQD--\:7EH-!NO#WA6XOEFV8W9*# Z4 ?L*
MK$GFG5^?!_X.4/\ @G8#E=%^*O\ X;:[I?\ B)3_ ."=_P#T!/BK_P"&WNZ
M/T&HK\^?^(E/_@G?_P! 3XJ_^&WNZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&H
MK\^?^(E/_@G?_P! 3XJ_^&WNZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&HK\^?
M^(E/_@G?_P! 3XJ_^&WNZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&HK\^?^(E/
M_@G?_P! 3XJ_^&WNZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&HK\^?^(E/_@G?
M_P! 3XJ_^&WNZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&HK\^?^(E/_@G?_P!
M3XJ_^&WNZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&HK\^?^(E/_@G?_P! 3XJ_
M^&WNZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&HK\^?^(E/_@G?_P! 3XJ_^&WN
MZ/\ B)3_ ."=_P#T!/BK_P"&WNZ /T&HK\^?^(E/_@G?_P! 3XJ_^&WNZ/\
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MX-_LB_!CQT?^%AZI\/?$OA^_L=:DDAM=0U=B797)$F!QM/4"NA\ ZSJWPO\
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M7&FG1->F1#<W8PT<X,:%=N5Z$9YK]?H_^"3O_!.4C+_L:^!__!7_ /7IDO\
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M)^!2W^MZ?;W-AI.OJELT,TJHR1S@,N2I(#8]*_8\?\$GO^"<I8J?V._!./\
ML%__ %Z<W_!)W_@G+&-R?L=^"<C_ *A?_P!>@#\O/^""W[27['WPW^'GBO\
M:9_;'_;"^&0\5_%:.*[OM N+/RIM+D4!2CJ4*@\?PUXOX9_X*B?LX?\ !,;_
M (*3>*+Z#Q+X:^+7P]UW19+NSE\+VT:I!=3NS["TJ]5W8(QVK]JC_P $I?\
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MC':OZ!/A8I3X=:"C!@5T6U#!Q@@^4O% '04444 %%%% !1110 4444 %%%%
M!1110!\_?\%5_P#E'-\8_P#L1[O^0KA_^"5__*'#X8?]DL?_ - FKN/^"J__
M "CF^,?_ &(]W_(5P_\ P2O_ .4.'PP_[)8__H$U '@?_!O3_P BAXL_[#^I
M?^E35^F<7W*_,S_@WI_Y%#Q9_P!A_4O_ $J:OTSB^Y0 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O@__@X[_P"46OBS_L.:9_Z/K[PKX/\ ^#CO_E%KXL_[#FF?^CZ /3_V
MH?\ E$EK?_9';;_TCBKA?^""/_)A'A+_ + \'_LU=U^U#_RB2UO_ +([;?\
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M_ 1?_C5'_#U3_@B]_P!'/_"O_P !%_\ C5>B_P##K3_@G=_T9]X'_P#!0/\
M&C_AUI_P3N_Z,^\#_P#@H'^- 'G7_#U3_@B]_P!'/_"O_P !%_\ C5'_  ]4
M_P""+W_1S_PK_P# 1?\ XU7HO_#K3_@G=_T9]X'_ /!0/\:/^'6G_!.[_HS[
MP/\ ^"@?XT >=?\ #U3_ ((O?]'/_"O_ ,!%_P#C5'_#U3_@B]_T<_\ "O\
M\!%_^-5Z+_PZT_X)W?\ 1GW@?_P4#_&C_AUI_P $[O\ HS[P/_X*!_C0!YU_
MP]4_X(O?]'/_  K_ / 1?_C5'_#U3_@B]_T<_P#"O_P$7_XU7HO_  ZT_P""
M=W_1GW@?_P % _QH_P"'6G_!.[_HS[P/_P""@?XT >=?\/5/^"+W_1S_ ,*_
M_ 1?_C5'_#U3_@B]_P!'/_"O_P !%_\ C5>B_P##K3_@G=_T9]X'_P#!0/\
M&C_AUI_P3N_Z,^\#_P#@H'^- 'G7_#U3_@B]_P!'/_"O_P !%_\ C5'_  ]4
M_P""+W_1S_PK_P# 1?\ XU7HO_#K3_@G=_T9]X'_ /!0/\:/^'6G_!.[_HS[
MP/\ ^"@?XT >=?\ #U3_ ((O?]'/_"O_ ,!%_P#C5'_#U3_@B]_T<_\ "O\
M\!%_^-5Z+_PZT_X)W?\ 1GW@?_P4#_&C_AUI_P $[O\ HS[P/_X*!_C0!YU_
MP]4_X(O?]'/_  K_ / 1?_C5'_#U3_@B]_T<_P#"O_P$7_XU7HO_  ZT_P""
M=W_1GW@?_P % _QH_P"'6G_!.[_HS[P/_P""@?XT >=?\/5/^"+W_1S_ ,*_
M_ 1?_C5'_#U3_@B]_P!'/_"O_P !%_\ C5>B_P##K3_@G=_T9]X'_P#!0/\
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MQ-X5TGQ1X8G\)7>Y8+FW\EP%_AX_PJA8Z9I'PN\'M96\D<5M9VY*EV"[MH)
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M*** "BBB@ HHHH **** "BBB@#Y^_P""J_\ RCF^,?\ V(]W_(5P_P#P2O\
M^4.'PP_[)8__ *!-7<?\%5L?\.YOC'G_ *$>[_D*X?\ X)6 -_P1R^&)/0?"
MU_\ T":@#P/_ (-Z?^10\6?]A_4O_2IJ_3.+[E?F9_P;TC'@[Q9M.0?$&I<_
M]O35^F!4_P"KR1GG- $M%,##!8L:5G54W$G'2@!U%,#Y.Q>2.N:5,J<$G)H
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M -@NW_\ 1:T :U%%% !1110 4444 %%%% !1110 5SWQ<_Y)3XG_ .Q>O?\
MT0]=#7/?%O\ Y)3XG_[%Z]_]$/0!\0?\&W!Q_P $W -X'_%RO$77O_I5>3?\
M$UKM[+_@HO\ &Z\M+=I6@\77LGE+UD9800H]STKUG_@VY0O_ ,$VPP _Y*5X
MA!]O]*KR7_@FIIXOO^"B?QOLGG:(3>+[R/S$/*[H0-WU% 'Z1?!KXD:_\4?
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M@ H)P,FB@].: (GC6<;2,J>M?!'_  <#_LZ>._C+^REHGC'X7>)8='U+X?\
MB6/Q$;V2 O\ +;@/CCG^&OOK:"0RG %<Y\6/A[H_Q2^'6K^ -?MTDM=5L9;:
M96&<JZX- 'D/_!,'XY>*_P!I#]A+X<?&CQSKR:GJ_B#0EN;Z]C3:)G+$9 [=
M*]_3=L/\/IFOR#_X)@?'RV_X)_?\%%?B%_P3Y^+>MZW'I'B/Q (?A7!=0-]C
M@M8HUWJK'"QC=GH:_7>WO$NT$L9!0C*G/44 3QYVC<<GU]:=2!@5W#I2@Y&1
M0 44<T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YK^V+\%]1
M_:*_9=\<_ [2=42RN?%'A^:PANY4++$S@?,0.37YI_"G_@FI_P %Q?@I\&M+
M^ 7P]_X*%>'[3PQH^E'3K&R/A>5BEN005S_P(U^NU($ .: /QH_9T_X)#_\
M!97]EBRN]/\ @I^WQH&F0WUS+/<!O#4K[GD<NY_$FO5].N/^"WG[$UXOQG^,
M'Q#E^/VC6H\F7P'X4T46MU<,_"R!Y6"@)C)Y[U^G_EKQ@8 [5$Z2%B" 1Z4
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MV]<XH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX@P_CU_T?_:_^ MU7[]'6M%'76+?_P "%_QI#KFB X_MBW_\"%_QH _ 9O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!?K80W,<Z!3 [ &7&>@'-;OPAF\3>!-&MM$^)>OVQEE<OIX>\!FG+<[2"<G
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M/Z.-8\<P>([HQ$/K5O&52<YZ@'FOY9[']O+_ (*!:3IE]IV@_$/P[:1ZAO\
MM30>(U4N7!#,>>2<TO@G_@H-_P %'/A]X8M?"VD_&/2!;6BD1 >*%_H: /ZF
MO$OQ1U?1OB/%X%A\#W-W:RVRO)J2L/+&>JD&OYW/^#L^TM$_:G\.0QVP6%;F
MXVQH,#J>F*\8/_!2?_@I').+Q_B[HYDQC>?$XZ?G7SC^TW^T;XK^/.N:CJ_[
M1WC";4/%-A(?[ %K=>?;NQ^]O?H* /V?_P"#7CQOJ_PW_9)BE\.^$+C6#?\
MBJYMYXK9@#;HSG,ASV&:]I_X.2O#7B7P_P#L"?$/5M9\3I<VNH+&^FVPC(-L
M@)RI/>O'O^#5;XM?";PG^RQ=VOQ!^(_AK1[@ZU=LL.J:U! V"QP0)'!KK?\
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M?VY/BC^RW^P]\'_A]J.E?#;[,+B\\4W"6\L@E48.2.3DT ?L!_P]A_X)Y?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX5_M&?#C2OBO\%/&-KX@\/ZQ )M,U:R8F.9/[PSVKB_VJ_V,_@G^TK\']?\
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MA]KMC\4DNM1N#YL>G_V?;*SQGS&"[RH]/7M0!Z9']W+K@'MZ5R/Q1^-OPO\
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M"4>EZ1;Z=/\ L\JTD-NHFFAU&1!*X'+8'J>:R/C#_P &T?\ P3+\<> KK0O
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M0-_\.])_X*-_%S^PK&QAGDO)?%[ MN+!@K>9@D8'%;U_^S'^Q/9_%33O _\
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MP!@/R2>U>AV4_GP),LBNK@%60Y!!Z$&@">BBB@ HHHH **** "BBB@ HHHH
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MHCX8_P"1<L?^O.+_ - % %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]^E97_!M3^WG\+_VDOV%_#OP(\/&>TUOX6Z9!I&K6]]'Y9EE.9,Q@\L,,.:
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M_@FA_P IG?VQ?^ORP_\ 9:_1O_XFOSD_X)H?\IG?VQ?^ORP_]EH _1VBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OS5_X+_?\E$_9W_['NX_])I*_2JOS5_X+_?\ )1/V=_\
ML>[C_P!)I* ,K_@OG_RBZ^&7_95/"?\ Z71U^E/@'_D1]'_[!=O_ .BUK\UO
M^"^?_*+KX9?]E4\)_P#I='7Z4^ ?^1'T?_L%V_\ Z+6@#6HHHH **** "BBB
M@ HHHH **** "N>^+?\ R2GQ/_V+U[_Z(>NAKGOBW_R2GQ/_ -B]>_\ HAZ
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M6&&!X/2OT6_X)C_\$T+?]E3Q$WB3]IWQ)+XP^)=U&SR7>HWGVT01-SB-G)(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HZ44$X&: /SI_X+A_\%?+O]@?3M/^#/PILC=_$#Q3Y,&B
M6\$VV56G<1(X]<,ZFOF#X3_\$)_VU_\ @H?8>#OCG_P4_P#VD-2OIK.=KN;P
M+J]ES$K#[FY1W!]:X'_@Y/TR3P?_ ,%5O@]\9?%FFR-X8MHM-M9[IX\Q13->
M0X9B>!CKGVK]QOA+XZ\%_$'P?8:YX'\56&KZ>]G$8;G3[E95/RCNIQ0!\@:5
M_P &YW_!).VTJWL]0_9-T>:=(566Y9WS(V.3U[TZ+_@W/_X))),P?]DW1\8^
M3]X_%?<S%!R#GVI=V'RPZ]* /PU^(G_! ;]I_P#X)T:3XT_:3_8Q_;$OM$AT
M^*\U&'1["P_U-LNZ3RLD= .,U]'?\&[?_!8CQG_P4.^"=W\._C'%+<>,?!T,
M,&H:O<S9DU61\$N1_#C-?H#\>?B5X!^$OPF\1>,_B689-(T[2KBYO;:8 ^?&
MJ%F0*?O9 QCO7Y"_\&_7Q1^'?[3G_!0+X]?M$? 'P5)H?@K6/$%O<:38_81;
MK%$448"* %_"@#]L;:)$'F.N&(Y]O:GS@;0-OX^E16<P8E4!VCKNIUP=L3,0
M3GH!0!B^-? WASXB^%]1\#^,=.2\TO5+5K>^MI/NS1L,%3^%?DEJ'_!'3]I_
M]A']OJT^+?[!&JWJ> _$M])>:UHFEVX6+3\%46-B>ORKG\:_3C]J[5OBAX<^
M!>O>+O@_#'-X@TK3Y;K3;>9"PEE5?E4J.HSVK\C_ -GO_@XO_;G^#OCZ_A_X
M*+?LU:M:^&[>]6$ZIX>\*2I&@( R7*8'.: /VV\-OJ'_  CMA_;#G[5]CB^T
MENOF;!NS^.:L3(9Y1B3*C[RU\[? +_@IQ^Q_^T!):P>#/BUI,%W>P1R165[J
M<2RY<9";<YW<XQ7T/:74-S$DUO(KQN,K(IR#^- 'PG_P70^!G[=/[2?PF\'?
M C]C?6-2LM.\4Z_+8?$*ZTY PM],:-?G<'JNX5Z%_P $OO\ @EG\$O\ @G)\
M([/POX+T&V?Q!-"C:YK*1E7O)P"#(0>A(-?6 +X# J.>?<4_Y,]J $"@KD]3
M0JXY-+DAL <4.H9<$XH ^??^"H7PJ\>_&[]@CXJ_"WX7:%-J6OZ[X6DMM)L(
M/OW$ID0A1[X!K\H/^#6G]J+P!^RMI?CS]B[XZW<.A^+I/&,DDMK>-B1'12I3
M\R!7[L'R5F?>_P S#A2:_-S_ (**_P#!O;\&/VJO&,GQP^$OB76/"WCAYLM-
MI.H&SAD5F!=FV$9?@<T ?>/QB^._PJ^ 7PPU?XP?%;QI:Z3X;TBS^TZC?S.-
MEO%Q\QQ]17X"?M!?M#_M1?\ !PK^V)8?"+X.Z'?K\%?#^N1&_M;=_,M]36WG
M5C.>XW(K?G7T9HO_  ;*_&'QEJ5MX9^./[4WC34?"=P^S6;'_A,IY#-#_=VF
M3![<5^G?['7[#/P&_8D\ 6OPZ^#OAF&*&")0;V6!/M#X&/F<#)SWH Z?]G3]
MF_X4_LQ_"G1OA'\'O"5OHNA:1;A+6P@7Y83@9Y^M?CG_ ,'-7[>WPG^/VC>%
M_P!B;X12V^K>(/\ A-M/E9[5OG$HF1?+Q]>*_<?RV,S2L^%[\U\5?#C_ ((4
M?L<_#G]JJ^_:VN&UG6M?O9I9A:ZS<?:+:&1WW[D1LA2#T(Z4 >Q_\$O_ (8^
M//@W^Q)X'^&_Q*T*;3=8TW3 EY:3_>1O0U] 5!I[*;=0BX ' Q4] !1110 4
M444 %%%% !1110 4444 %%%% !7Y8_M-_P#*:CX;?]C6G_HMZ_4ZORQ_:;_Y
M34?#;_L:T_\ 1;T ?J9_\37YR?\ !-#_ )3._MB_]?EA_P"RU^C?_P 37YR?
M\$T/^4SO[8O_ %^6'_LM 'Z.T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^:O_!?[_DHG[.__
M &/=Q_Z325^E5?FK_P %_O\ DHG[._\ V/=Q_P"DTE &5_P7S_Y1=?#+_LJG
MA/\ ]+HZ_2GP#_R(^C_]@NW_ /1:U^:W_!?/_E%U\,O^RJ>$_P#TNCK]*? /
M_(CZ/_V"[?\ ]%K0!K4444 %%%% !1110 4444 %%%% !7/?%S_DE/B?_L7K
MW_T0]=#7/?%S_DE/B?\ [%Z]_P#1#T ?$'_!MOM?_@FX!G[OQ*\0G_R:KX9\
M1E1\6_V@Y%/3X@N#_P!^C7W-_P &W#'_ (=N!>.?B3XA_P#2JOA/Q;<1K\5/
MVA"B-F/Q_(6XX.(C0 ?\&Y&E>(->_;P_:*T?POX@;3K^;P19+:WR+DPO]I/S
M 5^TGP#^!.C?!+0[V"Q<7.H:O<BZUB]Q@W$^,%R/4YK\4O\ @V0AL/&?_!1G
MXW:ZOVVV^Q^&+)HX<E"Y%PPPP[BOV&\3_M.SQ_%ZU^&'A7P[>W+21LUS>QVI
M:")@0"K,!@'GI0!ZQ?G4(+BVM[4GRS)^]QZ5AZSX$^'=GXY'QGU?0XTU?3-,
MEA&JL>8K?&7'TP/TJAX2\:>*?$'Q-USPAK>EO%8:?:Q26ER(BH=F/(W=Z[&\
MMEN;&6T:-7#Q,H609#9!&#ZB@#'\ _$CP;\2?"L?BWP-KT=_8S;@MY'TX.#3
M?$GPT\'>,-5M_$&N:)'<W4 7RI6/(P<@UX3\4_C!\9/@QXMT7X3>"O#^BP77
MB.[:VT98[0"!'P6R^!@#BO;AK'C70O"-C<:]!#+J4CQQW8MDR@8G#8]J .?^
M/NJ_&)=/M/!GPFT&=7U$&.?782#_ &<.SD=Z_(S_ (*2?$_X]_MT?M\_#O\
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M<K%N/ P1G\*_1/XI^"/A9\!O@U/J?_":KH]AIETE[>7]S?"(S&+YRA8D;F8
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M??!EM;?$CP"TT2Z3<Z>$D2U@80P3!&&[+!"=W>@#ZDM_V@[3QK\9O^%2>%-
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M-\= 5''C%>1_UR2@#]2(1@D5)4</4\U)0 4444 %%%% !1110 4444 %%%%
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M.FK>+C_P%:_1W_AZ/^UO_P!&K2_^$BW_ ,10?^"HW[77\/[*LO\ X2#?_$4
M?G%]N_X.-?\ H*^+O^^5I1>_\'&N>=6\7#_@*U^CG_#T7]KO_HU67_PD&_\
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M\:I_X3,G_P 30!^HV]?6C>OK7Y<_\/=OVYO^C>-4_P#"9D_^)H_X>[?MS?\
M1O&J?^$S)_\ $T ?J-O7UHWKZU^7/_#W;]N;_HWC5/\ PF9/_B:/^'NW[<W_
M $;QJG_A,R?_ !- 'ZC;U]:-Z^M?ES_P]V_;F_Z-XU3_ ,)F3_XFC_A[M^W-
M_P!&\:I_X3,G_P 30!^HV]?6C>OK7Y<_\/=OVYO^C>-4_P#"9D_^)H_X>[?M
MS?\ 1O&J?^$S)_\ $T ?J-O7UHWKZU^7/_#W;]N;_HWC5/\ PF9/_B:/^'NW
M[<W_ $;QJG_A,R?_ !- 'ZC;U]:-Z^M?ES_P]V_;F_Z-XU3_ ,)F3_XFC_A[
MM^W-_P!&\:I_X3,G_P 30!^HVY>QKX0_X..U_P"-6OBQBW_,<TSY?^V]>3G_
M (*[_MS@9'[/.IY]_#,G_P 37@__  48_:^_;D_;>_9?U7]GYO@1J4/]I7MM
M.TG_  C\B8,3[NNWB@#]'?VGW#_\$D=<R<$?!ZWX_P"W.*N%_P"""DJ_\,#^
M$F4]-(@R/^^J^0?B9^WY^W/X_P#V1[[]G!_@#J2F]\(QZ)YG_".R# 6%8\YV
M_P"SUK#_ &!_VR?VY?V/?@7I/P<?X"ZE,NFV:0;QX>D;.W/?;[T ?MJTBKC/
M<TI('4U^7"?\%=OVXV!S^SWJ?'3_ (IJ3_XFE_X>Z_MS#G_AGK4SG_J6I/\
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MZ<X__0!7YV?\'+:LO[)'PXW8Y^.'AGI_U_Q5^B?A@?\ %/6!_P"G./\ ] %
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MA()<XV;<YSGC% 'JC01E#$4RIZBAH4.%V9&,50TSQ)I>L*\FFZK;W*  _N)
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M) D<4MIG;<XQDX[<C-?%W_!-K_@H!_P3A_9E^"C_  X^#JWVEVPN%>\_M:5
M\LH4@MDCGZU]&I_P6*_8^*%I?%"@)]W_ $E,F@#W3]HCQIXQ^'_@07G@+P2V
MM7=U=K T"2;?+1S@R?AG-?$_[4__  3:\<_MEWNB?$KPCJLO@7Q_X+=Y]&\4
M6T0DGDE?/S#.0",UT'[17_!:W]GO0/!4 \!ZQ#<W5WJ$<#B5TDV(Y +>V,]:
MD^"G_!4K]F+PBEW<^)/B%!/-(%,J1WZG:?IGB@#'_97_ ."P?A7X<>)[7]E3
M]O&Z7P9X\MKI;#2X]0D+/J\0/EQW/H/,.#CWK@/^"R/A[Q1XR_X*B?LHZ/\
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MLW^-[DLOH?LDF17ZO:1\$= L/B"WQ"_M?4I;DHZBVGNF:#YNN$)QVXK\G/\
M@[/E-KJ'[.4L4T<7D^-[L[Y3A1_HLE 'S[X]P?V</"S(W_-3]"RW_;VE?J?_
M ,%R1M_X(S?%['?P"O\ [3K\J_%#FZ_9E\)2-*C;OB7H3;E/!_TM.E?JI_P7
M*.?^",OQ=/\ U(*_^TZ /;O^">B _L._"D=O^$'L/_10KV4 CJ<UXW_P3S_Y
M,>^%/_8C6'_HH5[+0 4$ C!HHH : <[2?>ORU_8T+C_@M-\=E5L*WC)=P]?W
M:5^I?\?X5^6O[&G_ "FG^.O_ &.2_P#HI* /U'@[U)4<'>I* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1N%)SVK\>_\
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M \/V8!&.+9?\*0>$O"P&/[!L_P#P'7_"@#\U/^'R'_!27_I%I=_^#<__ !5
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M ;+_ ,!U_P * /S5/_!97_@I3_TBUNO_  ;G_P"*H_X?*_\ !2G_ *1;7?\
MX-C_ /%5^E7_  B?A;_H V7_ (#K_A1_PB?A;_H V7_@.O\ A0!^:O\ P^5_
MX*4_](MKO_P;'_XJC_A\K_P4I_Z1;7?_ (-C_P#%5^E7_")^%O\ H V7_@.O
M^%'_  B?A;_H V7_ (#K_A0!^:O_  ^5_P""E/\ TBVN_P#P;'_XJC_A\K_P
M4I_Z1;7?_@V/_P 57Z5?\(GX6_Z -E_X#K_A1_PB?A;_ * -E_X#K_A0!^:O
M_#Y7_@I3_P!(MKO_ ,&Q_P#BJ/\ A\K_ ,%*?^D6UW_X-C_\57Z5?\(GX6_Z
M -E_X#K_ (4?\(GX6_Z -E_X#K_A0!^:O_#Y7_@I3_TBVN__  ;'_P"*H_X?
M*_\ !2G_ *1;7?\ X-C_ /%5^E7_  B?A;_H V7_ (#K_A1_PB?A;_H V7_@
M.O\ A0!^:O\ P^5_X*4_](MKO_P;'_XJC_A\K_P4I_Z1;7?_ (-C_P#%5^E7
M_")^%O\ H V7_@.O^%'_  B?A;_H V7_ (#K_A0!^:O_  ^5_P""E/\ TBVN
M_P#P;'_XJC_A\K_P4I_Z1;7?_@V/_P 57Z5?\(GX6_Z -E_X#K_A1_PB?A;_
M * -E_X#K_A0!^:O_#Y7_@I3_P!(MKO_ ,&Q_P#BJ/\ A\K_ ,%*?^D6UW_X
M-C_\57Z5?\(GX6_Z -E_X#K_ (4?\(GX6_Z -E_X#K_A0!^:O_#Y7_@I3_TB
MVN__  ;'_P"*H_X?*_\ !2G_ *1;7?\ X-C_ /%5^E7_  B?A;_H V7_ (#K
M_A1_PB?A;_H V7_@.O\ A0!^:O\ P^5_X*4_](MKO_P;'_XJC_A\K_P4I_Z1
M;7?_ (-C_P#%5^E7_")^%O\ H V7_@.O^%'_  B?A;_H V7_ (#K_A0!^:O_
M  ^5_P""E/\ TBVN_P#P;'_XJC_A\K_P4I_Z1;7?_@V/_P 57Z5?\(GX6_Z
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M $BVN_\ P;'_ .*H_P"'RO\ P4I_Z1;7?_@V/_Q5?I5_PB?A;_H V7_@.O\
MA1_PB?A;_H V7_@.O^% 'YJ_\/E?^"E/_2+:[_\ !L?_ (JC_A\K_P %*?\
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MBY8_]><7_H K\[?^#EL,/V1?AP&Q_P EP\,XQ_U_PU^B7AC_ )%RQ_Z\XO\
MT 4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D90PVL,@T
MM!Z4 ?$G_!8'_@K7J_\ P2_\"VWBW2O@\OBHSS0Q^2977;O8+GY?3-?G8?\
M@\V\9Q@Q-^Q4A(_B^US?XU^YOCCX;^ /'T*P>.? >CZW"",1ZKID5P >QQ(I
MKG8_V6OV<<@-^SWX&Q_%_P 4I:?_ !N@#\4U_P"#SCQDY^;]B5.!_P _<W^-
M"_\ !YSXQW9/[$<?U^US?XU^V!_9:_9G!W']GKP/C';PK:?_ !NH_P#AE_\
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M[_@L'_P46\9?M-_'66YUGPEX3\1W=GH+P3$QA5821*<Y!&5Z4 =/^R!\&_\
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M^P5_P5Q^/Z6WCS]I3XU^$I-2L9X[:&'P6SVH2W9@79EC8<C&<]J /T ^-_\
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M6KQY1L@\21GAOQ% 'YY?\&U?Q)U7Q;XM^)MCIWAE1H<WC?6[BWU7?S(S7<I
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MXF:?\%OV,/\ @J_\0/BEXDN]3-E=:>UI'$(3R,[E3^\"/PK]9_\ @DM^QO\
M\%'?!C>'OCG^V-^W!XO\0_:-+9K[P%JL<1MUD<?WE0'Y<<<]ZZ#_ ()/_P#!
M%'X"?L!:,_CW6=&36_&VK6JIJ=_JK"[C7G?F,2@E&W%N0<U]WQ1PPQ".*%45
M1@*BX 'M0 @WQ=!N)_2GY('"\FD<87:I^HH5R2-G( Y% 'S!_P %F$GE_P""
M7_QMBCMB[?\ "%R[=HR2?-C[5\+?\&:[)'^Q/\0K>5]DO_"<C,;<-_JW[5^M
M7Q%\&>&_B5X1OO /B^P%SIVJP&"\@9059"<X(/':OP8_9D^-?CW_ ((I_P#!
M4+Q'X$^+>@W5A\'O%VJW=U!,D/EQQ32,$A8N> HW$]* /W@^+GQ5\$_!#X<:
MM\4OB)JZV>B:-;&?4;MAD11@XSC\:X[]F/\ :Z^ _P"V-X7N?'7P$\7)K>D6
M-T;:YNDCV[)A_#U]J^=/^"M'QY^%'Q8_X),?%GQ=\,/B-IVJV5[X0=K*YT^\
M#AR60X!'<9KYJ_X,[KRXN_V"?&S7=Q)*P\=R8:1RQ'RMZT ?KLI4 N5P>]?D
M3_P=J?$SP2G[)7A;X1QZOG7I?'FFW:Z>J<M%YJ?-7ZK^-_B%X/\ ACX4O/'7
MQ#\2VFDZ1IT?F7FH7LHCBA3U9CT%?S]?&WXG_%K_ (+4?\%0-'T7P5X?-]X
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M1W-I=0F.XA;E70CD'ZBO.OB#X0^-OC+]GN[\'PZ]86_B^XM0K:@L96 29Z@
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M6?$+P1XO_9A\6?";PR-:\3:?\49I=)THR[/M4WV4X3=V[U^L9Z&OR1_X.?\
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M?L9?L*V.I^$?B%\1[>3Q2VBO<Z/IELOG+<RE,QH60\9.!7Q__P &\N@?&?\
M:6^/7Q7_ ."A_P 7OA[_ ,(O;_$/4H-2T2SC=G69=J@_>&1C%>@_L]_\&O\
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MMR/G!^7GBGJ1V7&>: &&)7.=N"?O5\[?\%"_^"=?P*_;^^&$W@'XJ^'[8SL
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M,#R,&@"E\8/@[\.?CEX$U7X8?%CPW;Z[X>UB#R=1T>^4F*X3^ZV"#C\:X_\
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MKW)@TX'RYCG"JD><9P:]E^'6MZMXE\$:9KFKZ?);7EU9))<0R)@HQ&2".QH
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M[]UX1_P<%01VLWP[M(_E1/&FB!?;_38J]X_X+E_\H9OB[_V(*_\ M.@#V_\
MX)Y_\F/?"G_L1K#_ -%"O9:\:_X)Y_\ )CWPI_[$:P_]%"O9: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^;'_!8?\ Y27?L2_]E*N/_2::OTGK\V/^"P__
M "DN_8E_[*5<?^DTU %C_@Y<_P"31/AO_P!EP\,_^E\-?HCX8_Y%RQ_Z\XO_
M $ 5^=W_  <N?\FB?#?_ ++AX9_]+X:_1'PQ_P BY8_]><7_ * * +U%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1M@M@-\W]*
M5AG[K<>OI2LF>E*4!.?SH $SMY%+2*"!@FEH 1L8YJ*;=(A5B5]"*E8 CG/X
M4QPQ4KM^E 'EO[6'QA\3?L]_ 3Q1\7/"?A:/6KKP]I$U\ME(S#S]BYV_+SS[
M5^;O_!/W_@Z1^#WQVCU73_VR_ !^&&H+?Q0Z)#8V=Q*ERC 99VD(V88XK]9K
MO2(-0LI;+4;2&YBF4K+#/&'1U/8J>"*^;/VF/^"1G[%7[4'A/4O"WC_X8):#
M53YDD^AB.S>.0?=*LB949]* /H#PI\4OA[XOT>SUGPUXPTVZAO;:.>W6*^C+
M,KJ&4[0V<X(XK=%RC1F<+Q_.OYQ/V^_V1OVDO^"1GQF\'6_[)_Q>U:XU/7/$
MB6FBVFK:G<7T?(W1H4=\' (&*^L/@9_P7V_:C_9SUR#X>_\ !1O]G/Q)!<GB
M3Q'!IT=G9RXX+J#N.,G]* /V+1_M"9SM_P!D=Z186W\?+[BO!_V1O^"C_P"R
MA^V+I*2?"SXJZ3/J8&Z;1$O0]Q",X!8 #@G(_"O?P4;Y5(YH 1CL !<D_P Z
M4,<<<GTI#U&2#DT [2<#\* /GK_@JKXZ\;?#/_@GS\5_'GPRUN[T[Q#IOA62
M;2+^Q'[Z"42( R<'G!/;O7Y0_P#!K;^QE\$?VJ?"GCC]JO\ :5\&V7B?QG9^
M-&7[9K$1,QD*E_,)!'(90>E?N1X\\)>'O'OAN_\ !?BNR2YT_4H/)N[>101(
MI(..<^E?@=^SY^T+\6O^"(O_  4[\3?#WXV::;;X.^-M8N[ZV2&V$/DR2,$A
M<R'(VKN)( [4 ?K+^W1_P2=_8I_;5\$:]#\2?A9HEIK^J67DQ^,6@S<V1& '
M4LVW(''(K\5G_P""C/[8G_!OM\;KK]E[5XK;X@:-?&2;PY'J6KC8ML3LC/[G
M 4C(X-?8_P#P58_X+/7'QAM[;]CS_@GIK(\1:[XK!LYM7TAA<1Q%UW*>,,,$
M8X->>_LL_P#!L%+\>?A+>?$']N_QE?ZSX]OG:73+J/4IXEM(V4E496+'AL=#
MVH C_9:_9N_X*D?\%D?%>O?M/?%S]J?Q'\(_!6J*D_A#0_"FH07<* X#C$B%
MEZ]S6%^UU\$_VY?^"*OQ2\(?'6^_;)\8>// >HZ]8Z;JL^MM#&(_.E4.-L:#
M. 3WJIX(T?\ X*C?\$6?'6O?!KX2?"[Q!\0O"$I6'17T;36N%MU7DDM(QZX[
M 52_:-\1_P#!4_\ X+-^*/#'[-OCO]G_ %SP1X+L-4M-5U"[\0:$$WRQ.I8"
M16R,@' H _=;X#?%WP+\>/A;I7Q7^'.IM>:3J]L);6Y=-I<?2NQKS7]D;X#V
M/[-7P"\/_!G3YM\>BV@B5MQ/\Z]*H **** "BBB@ HHHH **** "BBB@ HHH
MH *_+']IO_E-1\-O^QK3_P!%O7ZG5^6/[3?_ "FH^&W_ &-:?^BWH _4S_XF
MOSD_X)H?\IG?VQ?^ORP_]EK]&_\ XFOSD_X)H?\ *9W]L7_K\L/_ &6@#]':
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MI&8*,F@!:9)*J<EL#VH$R,.N">@->;?M$?M >&O@?X1DU#4)Q)J-P&CTZR5Q
MOEEQD  ]<T 6_CC\?_ ?P7T%]5\2ZF%F\HM!#&-S.><# .>M?-GA#Q1^TO\
MMW6A@A>Z^'NAVMT[0:II$NZ6\4';M=9 <#&#^-:_[/G[/7CGXW>-!\>_CX[R
M+(QDT72B&06\3#E9$)*L<CKBOJK0-$T[181;V.FQ6X48"P1!%Q] * /'_A3^
MP=\$_A["UWX@\.VWB#5Y)%EGUB_AQ-)(/XCM(&>E>SV>G?8E1(FVHJA5C'0
M=!5HHS AB.O&*78,YH A>%WFVXPF.13T0C*X 4=*>0<8!^M((\<*>.] "$.R
MX!P!WH.2FXCGM3B@/':C:,;>U #8]@.%&#W%/IJI@Y/6G4 %%%% !1110 44
M44 %%%% !7/?%S_DE/B?_L7KW_T0]=#7/?%O_DE/B?\ [%Z]_P#1#T ?#_\
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M=_%GX??"_3M1\8HGFV,\S,CR2=LMGBNG\$ZQXFU?PY#)XST6'3[TH/-ACEW
M''/)ZULV+B\A2\B=60C@KTK@/B?XAUFZ\40^#M.TZ>QMK1%O[S6YA_HXC7ED
MR.0<9H O^!M<^)E[XZ\2:5XJ\,PVNBV4H&@WR3%FO%QR67^&N7TCX_ZQ\-?
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M,:UHNIZR/LMUI^K7)8*L3<,J=%SZB@"#]G:X\/0ZCXJL]'\>7^M.VMNTT=[
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MC7_!/(Y_8=^%1(QCP/8#_P A"O900>AH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#G5_V;1XD;Q8S^&WU1R"-0>SB,RD=#OV[OUK;_X6[\+PNV7QMI^0?EVR8.*
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M4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N>^+?_ "2GQ/\
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M:,EE_P"".GQH.?6.UX_\=H'_  76^+0.#_P1U^,Y!_Z9VO\ A0!P6B?MM_\
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MS&/KRE6_@1^V-_P7A^#WA&3PUJ?[#7A+7W>[DF^U7_B>8. QSM^5.@KU,_\
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M;_"@#F+[_@I#_P %W+ZQGLK7_@G%X%B::%E$J^*KC*$@C(^3J*X+X$_M0?\
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M?^"=OQ1\.01+I?AEO$.IR01VIN9&2%3T)P2<XK]:-*N(KJTBN800LL2N%)Y
M(S0!;HHHH **** "BBC(]: "BBB@ HHHH ***"0.IH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!&SM./2OR9_X.8_@CIG[2GB?]F/X$:]K4UA
M;^*OBC/8RWL"!G@5K8G<H/!/'>OUG/0U^4'_  <K:[X[\-^.?V7-;^&%FTWB
M"T^*LTFD0K%O+3?93@;>,]Z /A__ (*Q_P#!+?\ :]_8'T#P/IOAS]K#Q+XR
M^#R^,-'&HZ/K=U!$L%S]L00JD*+E@!NYSQ7]#WPF*GX9^']BX']BVO'_ &Q6
MOP8_X*Z_LN_\%2M:^%/A']K3]KS]HGPUJ7A:'QSHEO;>$--T:6UN;?S;M2BR
M'S"K,I7DX[U^\_PID,GPUT MC/\ 8MK_ .B5H Z&BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\V
M/^"P_P#RDN_8E_[*5<?^DTU?I/7YL?\ !8?_ )27?L2_]E*N/_2::@"Q_P '
M+G_)HGPW_P"RX>&?_2^&OT1\,?\ (N6/_7G%_P"@"OSN_P"#ES_DT3X;_P#9
M</#/_I?#7Z(^&/\ D7+'_KSB_P#0!0!>HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** $< CDU'/A4W D #CWJ1L@<
M&F/\RG?QZ4 <%\=?A9=?''X5ZM\/K3Q;>Z!)JEI);?VIIX!FM]PQO7=QD5\9
M?LC_ /!O5^R7^SMXMU'QK\7M4N/BQJNJW(G?4_%^GH95;: >4;OBOI/_ (*'
M_%[QY\ OV1O&/Q2^&^HQVFKZ/HMS<V4LT6]1(BY!QGGFOST_8D@_X.!_VV?V
M<O#/[1'A3]O3X=Z/9>)-,2\M[&]\&RO)"K$C:Q63!/% 'ZM_#'X1?#CX.>&8
MO!_PG\)V>A:1'*SIIUA'LB5CU./>NE,(W9<?2OS;'[(?_!Q6#M'_  4=^&&W
MK_R),W_QRG']D+_@XM8?\I'_ (8 >A\$3?\ QR@#]'R+B/\ U2 @>IIT<LSG
M+HH'?!K\W?\ AD#_ (.*R,'_ (*/?# CV\$S?_'*]4_8W_9S_P""Q7P]^-]E
MXB_:[_;+\#^,/!*6LJWNB:+X9EMIY)3C8PD9R !SVH ^TBOS99NO:EXS\O4=
MJ#(!@ $T*.Z'&>N: (9'<2GRU!QV-?FY\8/^" OC/XM?%+7_ (B6O_!2+XH:
M*FMZG)=KI=C!;^3:!CGRTSS@>]?I)- \K%E.TC[IHBMO*."V0>6^M 'Y<'_@
MV_\ &J8#_P#!4KXMC'<6UM7P+^V7^QG^T#^S7_P4D\(_L4Z!_P % /B-J&D^
M(M"2^GU>Z,2SQ,TBKM"CC'S5_2(ZL!N4Y';BOQ+_ ."M, 7_ (+]?"Y"<Y\&
MPD_]_HZ /:+?_@W \<3V\,O_  ]+^+9\R-6Q]GMN,C-:GP]_X-[O&?@KQ_I'
MC1_^"EOQ3U%-(U*&Z>QNK>W$=P(W#&-L=CC!^M?I?IBA+"W;!'[A<$GIP*F>
M%B<(0 ><XZT )8-'Y?E)SL4#)[U8ID,(C);UZT^@ HHHH **** "BBB@ HHH
MH **** "BBB@ K\L?VF_^4U'PV_[&M/_ $6]?J=7Y8_M-_\ *:CX;?\ 8UI_
MZ+>@#]3/_B:_.3_@FA_RF=_;%_Z_+#_V6OT;_P#B:_.3_@FA_P IG?VQ?^OR
MP_\ 9: /T=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** &RL%0FN*^/?BQO"/P=\0>(HM06VDM],E>.7S I4@=5SU-=I."4P*
M^6_^"ET]U<^#_"'@Y&E6#6_$Z6=WY;D>9&P *\4 5O\ @G%\*;33O#%[\<=:
MNY=0OO&4B7\=Y<I\Z_+M//\ P&OJNT011^6'+<YR:Y?X/_#O3?A?\,]&\!Z%
M;&&UTRS$,4;\D $GK^-=5 GEIM)YS0 ^BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "LWQCHK>)/"&J^'58J;_39[8,.V^-E_K6E0>1B@#\
MA?A-\#O^"U'_  3RT*__ &=_V1?V=?"?C'P4FN7FJVFM:[XH:VN'DN92[J8T
MC( '&.:_.?0?^"EO_!17]AS]K;QUKFK_ +,]A-XDU/7YI]5LTN;AX(I=H#!9
M%C^8=.:_J,,#]-X..HKRGQG^Q;^SWXYUJ?Q%X@\!6DU_<R%Y9FA3+$]<_+0!
M^%B_\'/_ /P4L2'Y?V0M))_Z^KO_ .-TB_\ !T'_ ,%,6Z_L@Z3_ .!5U_\
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M>K_L,_\ !QQ^VC\=_P!I+2/A!\5_V?-)T2UU":-6G2[GW ,X' =1ZU^M4O\
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M,#\D9-*MW'U*'/UH FP,XW'\Z-O^T?SJ,7*GGRS1]J3^Z: )-O\ M'\Z-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $89&*0A1A6.33JCEP%/E_>% 'S%_
MP5]8']@?XBQLW/\ PC%WC!_V*X;_ ((";%_X)<_"H,YY\*P_^AO7U%\9O@QX
M$^/?P_U+X:?$K3)+K2M7MGMKZ!)=I>-A@@'MQ5']GS]G7X7?LN?"K2/@O\(-
M&EL=!T*T%MIMO+-O,<8)(!.!GDF@#T*,\!B/PJ08(J-"PC ;DU(.E !1110
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M ^_;>X2YC$T?W6 *GVJ2H;%!# MNH^5% 'TJ:@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\L?VF_\ E-1\-O\ L:T_]%O7ZG5^6/[3?_*:CX;?]C6G_HMZ
M /U+)<$<<8ZU^<?_  35S'_P6?\ VQMO.+NPZ_\  :_1Q@>"6&,=*_./_@FJ
MP;_@L_\ MBD\;[NPVY[_ ': /T= SU8YQ2[?]H_G29P?N\TNX_W#0 ;?]H_G
M1M_VC^=&X_W#1N/]PT &W_:/YT;?]H_G1N/]PT;C_<- !M_VC^=&W_:/YT;C
M_<-&X_W#0 ;?]H_G1M_VC^=&X_W#1N/]PT &W_:/YT;?]H_G1N/]PT;C_<-
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M\.[[1IK93;7-YXOEA9U&!G'E&O8O^#M?PWJ7C'_@G#HWA;203=ZK\1])L[=
M,G?).J+^I%>&?L"^!_\ @K-^Q-^SUH?P1\#^#=0ELM.M0L+)I*G(.#U+Y- %
M[X8_\%+O^"[?QB^,=[\"_!W[*WP[?Q%IT4CW-M/XNE1 L9(8AC%STKE;_P#X
M+&_\%J;/]KNU_8CB_96\$S>.[F^-H+>+Q%.UK'(!G#S"+"CW(I_PE^!O_!7S
MX5_M4:A^TE8>&;[S;_3Y8'MET<;LN22?OX[U'\./@/\ \%8? O[6WBG]JQO
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M5!%G>58<5ZI\#/VY_P#@OY^T1\ ]*_:7^'7[+WPRD\*Z_IG]HZ?<W?C=XG$
MS]Y3%\I^4\9J3XA-_P %;O'?[.MU^SU=_#O5!IDWAE=&1/[*4;85A$0YW^@%
M>*_ _P#9Y_X+?_!7]DNX_93T.2\72HK5+70MFBG_ $2W&<HQWY.<F@#U#]D[
M_@H__P %Z?VU_!5]\0_@3^RK\/+O2K+6+K29YKOQ?+"1<VTACE 'DG(# X/>
ME^ G_!1__@N_^T9\1O&_PB^''[+GPZEUKX<:T-)\1PWGC"6+%P463]V3%^\&
MUAR*K_L+?#7_ (*N_L,?!-O@WX!\":D+675[G4YG_LI6WW$[[Y&R7SRV:XOX
M1_ ?_@L=\(/VL/$?[1GA/1KVU3Q1J4E[K%E_8XW3S%%56^_C@** +'Q0_P""
MS?\ P6I^%7[5MI^QAXD_93\&OXYNQ;E;33O$$\\,:S9\MGD6+Y!\IY(Q77_'
MW_@I=_P7:_9L\>:)\-OBE^RQ\/K?4]?A,FG+;>+99$8!PG+>4,<D5S_P]^"7
M_!6_PO\ ML^*?VT_$7@N?4-<\1Z!;:63)H2,8T@9RI4,V%/S=1S6E^UK\*?^
M"K7[4=UI7BK4/ >I0>(=$DC&F7TFE+MCB#AV4J'Y)(% '9_&C]LW_@X'^ OP
M>U#XW?$?]ESX9V^C6.G?;)A%XVD>9XL _NX_*!=L,/E%8D__  40_P""]6F?
MLY:9^U/J7[)_P_A\(:E9QW%M-)XLF$Y23.W=&8<J?E/%8/[4'PX_X+'?M+V/
M@O1?$WA[4ETSPM>I-<67]DA1<*(@A4X?!!QT-=MX^M/^"J'Q&^!TGP#U[X8:
MF="-IY5O;1Z4B"/"L%Z/VW4 ,^ _[<W_  7Y_:2^&5O\8_AM^RS\,7T*YED2
M*[NO&\D6"APV[,6 .?6L+]G+_@I9_P %SOVJG\80?!/]E_X=:B? ^M2:9X@D
MF\7R(J7**698R(CO& >:\W^ GP#_ ."VOP._9F\1?LMZ/'?+X>U&VF32D31L
M/;/)(&9B^_)X&.*Z[]A;X&_\%/OV#_ 6K^$?AI\/=667Q)J(O]<GDTX2?:+G
M:5+?,^1G/2@#9^"__!2;_@O#^T'\8?%'P-^''[+/P\D\0>#H(YM<M;OQ=+$L
M2.VU2"8N>?:N:^/_ .VS_P %\?&'QUM_V Y_@3X+\/>/->\/3:M8SZ1XND8+
M;(,,WF&+ (R#C%9O@;X%_P#!:7X4_MH>*/VK/AMIEU8CQLD$/B:Q?1 S3PQ$
MD*OSX4YQS6CIWP>_X++WO[<=G^VOXRT&\O-7TSP_<:-IR1Z*%,=M+C@_/@]!
MS0!Y-\,OCG_P7Z_X)D_%S0O@O\;]+TOQMKOQ2OOL'AB+7_%C/%%,N7.'6+Y>
M%/->]_M;_P#!2S_@N]^Q%\+[+XR_'+]E7X>VVB7VH0V%LUAXMEGD>>4A4&T1
M#J2*Y3]M[X$_\%C/VM?'WP_^)=GH%WIFM_#O49+W1KNXT4$+(RE<X#\\$T?M
M@_!;_@L]^V+\/_"7P[^(>C75QIWAK6K#4Y(O[$ \VYMI%<-]_H2O0T =G??\
M%*O^"ZNB?LK3_MBZ[^R?X%M?!T%E]KGDN/$TR7*1YQGRFA!S6W\&?VX_^"^G
MQZ^'G_"V?AY^S'\,;C0EC\QKE_'#J5 &XY'E'!Q[U9^,?_#TWX]_!R_^ WC_
M .%>HR>'M2LQ;WMC:Z1'$&3T&&X_*O$?V>OV<?\ @M)^S7\$?$7P ^'UMJ$6
M@:W/<O'%)I)=XEE!&-Q?/ /:@#T7X"_\%./^"X_[3WQ#\9?#'X._LS_#G4-2
M\#SK%X@+^,)%BC9@"-CB(AQ@U6^ ?_!3W_@N=^TKX_U3X7_"_P#9B^'%QK&C
M2RI?6]SXQDC*F-BK$?NB2,@\XK!_8)_9G_X*5?L'^'-8/@+X;ZU+KWB55/B?
M4'LA(+IU& 0&;*]*YWP!^RE_P5H^!O[5.H?M*_ 3PQJ6BRZO9F'4;6ZTSS?-
M9F+.0-^!DDT >C?$;_@IK_P7/^&'[2'A+]E/Q%^S/\,V\8^-!+_8UC:>-7E7
M]W]X2,(OW9]B*S_VC/\ @JS_ ,%R?V6OB-X=^%GQ=_92\"6FI^*-1AL=):W\
M3S20R32XVJ7\H =:XKPC^QU_P4XL_P!M&Z_;A\=^"M9U'Q?!?O<Z%,++Y+3>
M &&POCG':NM_;I^$_P#P5W_;.TSPA]N\&7EIJ/@[Q)'K&FW<FBKE9DQM)P^2
M..E '9_M3?MZ?\%_/V./@WJ'QV^-G[*'PXM/#NFS117,]IXQEED#2':N%\D9
MYJN__!07_@OI;_LYWG[4<G[)GP_3PGI^FMJ%S/-XLF680!0Q81F'GAA7"?MD
M_#K_ (+C_MD?!*R^!'Q$EFDTF4Q2:_'_ &"%^U2QR;E92'^4>U>I^(9?^"L7
MC']G^7]G;Q'\-]1ET"]\/QZ1>00Z0B;X5C5#SOX.%ZT 5/@=^W#_ ,%^_P!I
M7X+Z9\>_A9^S+\+;SP]JVG?;K:3_ (3MQ*D7)^=!$2A^4\&O ?'W[1W_  7Q
M_P""H=PGPE^ GAGP]X-U+P=?276IWGA_Q@R&Y7/EF-F:+! 9370?LL?LQ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;'_!
M8?\ Y27?L2_]E*N/_2::OTGK\V/^"P__ "DN_8E_[*5<?^DTU %C_@Y<_P"3
M1/AO_P!EP\,_^E\-?HCX8_Y%RQ_Z\XO_ $ 5^=W_  <N?\FB?#?_ ++AX9_]
M+X:_1'PQ_P BY8_]><7_ * * +U%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 C9QD4A4,,J.M..0,BH9Y1' TOF!
M?<]J '%8W'-*$CX4C.?:L+QMX_\ "_PW\+WOC;QQK<.G:5IMLUQ?7MP<)#&H
MR7;';%?E7JW_  7P^.'[2W[9#_#3]@[X!Z]XV\#^&-2-AKGB'0I89+>^+;66
M92S*RKM;N.U 'ZXYV@9]>U#.VW]VO/850\+WU[J/AO3]4O[5X+BXL8I+BWD^
M]%(R LI]P21^%8?QC^,7@3X#^![OXD?$KQ%;Z7HUE&3<WMTQ"*V#@9 /7% '
M6JQ(S07':ORL^(W_  =)_LU^$/%UMH?@?X;7GBG3CJ#0:EJVFZE&(K&($@S/
MNP=N1VKZS_8/_P""J_[,W[?)O+3X4^*[(WUK/Y9L$N=[O\N21@8XH ^G1/O_
M -6IXZY%/.'& :,XSQ],=Z1 O)4_44 *$ Z4BQHN<+U-.HH 3:,DCO2! !@G
M/-.HH 0HK?>&?:C8 >/RI:* $50@P*6BB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\L?VF_\ E-1\-O\ L:T_]%O7ZG5^6/[3?_*:CX;?]C6G_HMZ /U+
M8C('?%?A[%J/_!2G3O\ @LM^U"/^"?'PV\+>(7-]:?\ "0#Q+K1LQ".-NS"M
MN[5^X3,. .N*_%#PS^VQ\>/V0_\ @LO^U/+\$_V)O%_Q?;6+ZT6\7PM/ AT\
M+C!?S77.<=O6@#UT^)?^#E_=Q^S7\+,>O_":O_\ &J/^$D_X.7_^C;?A9_X6
MK_\ QJNF/_!;7]O;/'_!$CXP8Q_S_6/_ ,=H_P"'VW[>W_2$GXP?^!UC_P#'
M: .9_P"$D_X.7_\ HVWX6?\ A:O_ /&J/^$D_P"#E_\ Z-M^%G_A:O\ _&JZ
M;_A]M^WM_P!(2?C!_P"!UC_\=H_X?;?M[?\ 2$GXP?\ @=8__': .9_X23_@
MY?\ ^C;?A9_X6K__ !JC_A)/^#E__HVWX6?^%J__ ,:KIO\ A]M^WM_TA)^,
M'_@=8_\ QVC_ (?;?M[?](2?C!_X'6/_ ,=H YG_ (23_@Y?_P"C;?A9_P"%
MJ_\ \:H_X23_ (.7_P#HVWX6?^%J_P#\:KIO^'VW[>W_ $A)^,'_ ('6/_QV
MC_A]M^WM_P!(2?C!_P"!UC_\=H YG_A)/^#E_P#Z-M^%G_A:O_\ &J/^$D_X
M.7_^C;?A9_X6K_\ QJNF_P"'VW[>W_2$GXP?^!UC_P#':/\ A]M^WM_TA)^,
M'_@=8_\ QV@#F?\ A)/^#E__ *-M^%G_ (6K_P#QJC_A)/\ @Y?_ .C;?A9_
MX6K_ /QJNF_X?;?M[?\ 2$GXP?\ @=8__':/^'VW[>W_ $A)^,'_ ('6/_QV
M@#F?^$D_X.7_ /HVWX6?^%J__P :H_X23_@Y?_Z-M^%G_A:O_P#&JZ;_ (?;
M?M[?](2?C!_X'6/_ ,=H_P"'VW[>W_2$GXP?^!UC_P#': .9_P"$D_X.7_\
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M(O\ @Y=_Z-L^%G_A:O\ _&JZ?_A]M^WM_P!(2?C!_P"!UC_\=H_X?;?M[?\
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M8AH-D1&,BTCYQ_LBOSQ_X.7O^33/AI_V7#PU_P"E\-?HAX:_Y %E_P!>D?\
MZ"* +C1*PYH$,8(.T<=/:G44 ,\B(\% 1G.*<8U/7FEHH 14"G/?UI&B1NWX
MTZB@!HB7/S<_6D:"-GWE13Z* $,:'JM((D4D@<^M.HH 0JIZCZTGE)_=^E.H
MH :8D;&1TH,,;'+(#CI3J* &B-0Q;/7M0$ &*=10 FQ<8(S0$4 A1C/I2T4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?FQ_P6'_ .4EW[$O
M_92KC_TFFK])Z_-C_@L/_P I+OV)?^RE7'_I--0!8_X.7/\ DT3X;_\ 9</#
M/_I?#7Z(^&/^1<L?^O.+_P! %?G=_P '+G_)HGPW_P"RX>&?_2^&OT1\,?\
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M;!ZFEHH 38/4T;!ZFEHH 38/4T;!ZFEHH 38/4T;!ZFEHH 38/4T;!ZFEHH
M38/4T;!ZFEHH 38/4T;!ZFEHH 38/4T;!ZFEHH 38/4T;!ZFEHH 38/4T;!Z
MFEHH 38/4T;!ZFEHH 38/4T;!ZFEHH 9Y1Y7<<'OZ5^:W_!?I3%\1?V=U4##
M>.YP[]P/LTE?I97YJ_\ !?[_ )*)^SO_ -CW<?\ I-)0!D?\%\X]O_!+WX9$
M,2/^%I^$^3_U_1U^E7@,9\$:,?33+?\ ]%K7YK_\%\_^477PR_[*IX3_ /2Z
M.OTI\ _\B/H__8+M_P#T6M &M1110 4444 %%%% !1110 4444 %%%% ",ZK
MC/>C>,XIA=0"K(1GI[TTS+&NXN !QB@";('>DW#UJ$W40<;^-_ YI'D$89W/
MW>?H* )I)5CC,AY ZXJO<:E!! UW-*L<2*6=G. H'))ST'O7@?[67_!3W]C3
M]CC0[BZ^-'QIT;2M25#]DTJ[G99+EQSL7@C.,G\*^!]?_P""A_[?/_!5/7KC
MX8?L/_#O6? 7A&Y5[>]^(L\:7-E)$>'C 5MP+H6P<<4 >_?MF?\ !9OX8:%X
MX\0?L??LOPW?B3XP,@MM!BALGETO[4W*^;<Q[E1< \GO6Y_P3K_X)?67PIO)
M/VC?VC;E_$'Q"UMVNIY-099Q8>;\S0Q/U"*3P/:M?_@G+_P1^^"'[#V@Q^,]
M3M8?$/Q$OAO\0>)R6/VI@<@JKC*X-?9$2^5&-J9/91V% #(8%B8E205Z@=*L
M#I33GJJ8)ZGTIU !1110 4444 %%%% !1110 UT+@@G'/45\Y_\ !0__ ()M
M_#3_ (*+>'?"^@?$/QKJVA/X2U9]0TJ^T<+YJS,FS.21CBOHZB@#\ZS_ ,&\
MW@$XS^V?\3>/^GA?_BJ4_P#!O-X!(Q_PV=\3?_ A?_BJ_1.B@#\ZS_P;R^ L
M8_X;0^)O_@0O_P 52?\ $/)X"_Z/1^)W_@2O_P 57Z*T4 ?G5_Q#R> O^CT?
MB=_X$K_\50?^#>7P$3D_MH_$[_P)7_XJOT5HH _.O_B'F\!XQ_PVA\3?_ E?
M_BJ5_P#@WG\ 2!5;]LOXEC;W%PO/_CU?HG10!^=2_P#!O+X P5_X;+^)8'M<
M+_\ %4?\0\?@#I_PV?\ $W_P)7_XJOT5HH _.K_B'C\ ?]'G_$W_ ,"5_P#B
MJ#_P;Q> ",#]M#XFC_MY7_XJOT5HH _.G_B'B\ >86/[9OQ,Y7'_ !\+_P#%
M4^+_ (-ZO BC8W[9?Q+PO"G[0N3_ ./5^B=% 'YU_P#$/)X!&<?MG_$WG_IX
M7_XJC_B'E\!?]'G_ !-_\"%_^*K]%** /SJ/_!O)X"/_ #>C\3O_  )7_P"*
MH_XAY/ 7_1Z/Q._\"5_^*K]%:* /SJ_XAY/ 7_1Z/Q._\"5_^*H_XAY/ 7_1
MZ/Q._P# E?\ XJOT5HH _.K_ (AX_ )X/[:/Q._\"5_^*J!O^#<;X(:GKFEZ
MMXR_:9\>:]#I6IV]]#8:HZ/$TL,BR(2-WJHK]'** *>E:/#I%A;Z?;.?+MX4
MC0>R@ ?RJY110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y:
M?L\_\IY_C7_OV'\S7ZEU^6G[//\ RGG^-?\ OV'\S0!UO_!R]_R:9\-/^RX>
M&O\ TOAK]$/#7_( LO\ KTC_ /017YW_ /!R]_R:9\-/^RX>&O\ TOAK]$/#
M7_( LO\ KTC_ /010!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OS9_X+I?\ )T_[&?\ V6F3_P!)
M&K])J_-G_@NE_P G3_L9_P#9:9/_ $D:@#H/^#E?_E'EIO\ V5?PU_Z65]U?
M##_DFOA[_L!VG_HE:^%?^#E?_E'EIO\ V5?PU_Z65]U?##_DFOA[_L!VG_HE
M: -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K\V/^"P_P#RDN_8E_[*5<?^DTU?I/7YL?\ !8?_
M )27?L2_]E*N/_2::@"Q_P '+G_)HGPW_P"RX>&?_2^&OT1\,?\ (N6/_7G%
M_P"@"OSN_P"#ES_DT3X;_P#9</#/_I?#7Z(^&/\ D7+'_KSB_P#0!0!>HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[]A_,T =;_P<O?\ )IGPT_[+AX:_]+X:_1#PU_R ++_KTC_]!%?G?_P<O?\
M)IGPT_[+AX:_]+X:_1#PU_R ++_KTC_]!% %ZBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-G_ (+I
M?\G3_L9_]EID_P#21J_2:OS9_P""Z7_)T_[&?_9:9/\ TD:@#H/^#E?_ )1Y
M:;_V5?PU_P"EE?=7PP_Y)KX>_P"P':?^B5KX5_X.5_\ E'EIO_95_#7_ *65
M]U?##_DFOA[_ + =I_Z)6@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M H'04 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^6/[3?_ "FH^&W_ &-:?^BWK]3J_+']IO\ Y34?#;_L:T_]%O0!^IG_ ,37
MYR?\$T/^4SO[8O\ U^6'_LM?HW_\37YR?\$T/^4SO[8O_7Y8?^RT ?H[1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7YJ_\%_O^2B?L[_]CW<?^DTE?I57YJ_\%_O^2B?L[_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?FQ_P6'_Y27?L2_\
M92KC_P!)IJ_2>OS8_P""P_\ RDN_8E_[*5<?^DTU %C_ (.7/^31/AO_ -EP
M\,_^E\-?HCX8_P"1<L?^O.+_ - %?G=_P<N?\FB?#?\ [+AX9_\ 2^&OT1\,
M?\BY8_\ 7G%_Z * +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 ASZ4V1&8%2!MI]-+D<GH.HH R]>\):)XLTR?
M0_$^EP7ME<QE)[6YC#I(IZJ0>"*P/AO^S_\ !CX/F:+X5_"S0?#J7+AKD:1I
MT<'F,!@$[0,UV231S?=.1ZT,4YWM_P#6H 0?NP PX/ Q4@  P*8S!<8/!X I
MP( VB@!:*1G5?O'&:;Y\6<;J 'T4A;"YQSV%(K[NWUH =1110 4444 %%%%
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M )1=?#+_ +*IX3_]+HZ_2GP#_P B/H__ &"[?_T6M?FM_P %\_\ E%U\,O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "ORT_9Y_P"4\_QK_P!^P_F:_4NORT_9Y_Y3S_&O_?L/YF@#K?\ @Y>_
MY-,^&G_9</#7_I?#7Z(>&O\ D 67_7I'_P"@BOSO_P"#E[_DTSX:?]EP\-?^
ME\-?HAX:_P"0!9?]>D?_ *"* +U%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;/_!=+_DZ?]C/_LM,
MG_I(U?I-7YL_\%TO^3I_V,_^RTR?^DC4 =!_P<K_ /*/+3?^RK^&O_2RONKX
M8?\ )-?#W_8#M/\ T2M?"O\ P<K_ /*/+3?^RK^&O_2RONKX8?\ )-?#W_8#
MM/\ T2M &Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5^;'_  6'_P"4EW[$O_92KC_TFFK])Z_-
MC_@L/_RDN_8E_P"RE7'_ *334 6/^#ES_DT3X;_]EP\,_P#I?#7Z(^&/^1<L
M?^O.+_T 5^=W_!RY_P FB?#?_LN'AG_TOAK]$?#'_(N6/_7G%_Z * +U%%%
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M "N>^+G_ "2GQ/\ ]B]>_P#HAZZ&N>^+G_)*?$__ &+U[_Z(>@#XB_X-MO\
ME&V/^RE>(O\ TJKRW_@ES_RDJ^-'_8[77_HM:]2_X-MO^4;8_P"RE>(O_2JO
M+?\ @ES_ ,I*OC1_V.UU_P"BUH _4V'[M/ID/W:?0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?EI^SS_RGG^-?^_8?S-?J77Y:?L\_P#*>?XU_P"_8?S- '6_
M\'+W_)IGPT_[+AX:_P#2^&OT0\-?\@"R_P"O2/\ ]!%?G?\ \'+W_)IGPT_[
M+AX:_P#2^&OT0\-?\@"R_P"O2/\ ]!% %ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-G_@NE_P G
M3_L9_P#9:9/_ $D:OTFK\V?^"Z7_ "=/^QG_ -EID_\ 21J .@_X.5_^4>6F
M_P#95_#7_I97W5\,/^2:^'O^P':?^B5KX5_X.5_^4>6F_P#95_#7_I97W5\,
M/^2:^'O^P':?^B5H W**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OS8_X+#_ /*2[]B7_LI5Q_Z3
M35^D]?FQ_P %A_\ E)=^Q+_V4JX_])IJ +'_  <N?\FB?#?_ ++AX9_]+X:_
M1'PQ_P BY8_]><7_ * *_.[_ (.7/^31/AO_ -EP\,_^E\-?HCX8_P"1<L?^
MO.+_ - % %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *CGW;,_F*>W;ZU'-\D;NW2@#,\1^)?#O@K2)=>\2:K;
MV5E"A>>ZN9 D<2CJS$\ 5^4__!1#_@X5TN*'Q1^SS^P9X(UCQ7X]M-22P@UB
MQT\WFG;C@%@R C&&'.>U?HG^U[\!KK]I[X#:]\&(M:?3X_$.GRV4MZB!C"KK
MC=@]<5X5_P $Q_\ @C'^SM_P3@\!QZ)H-G:ZQKK*AN_$#6WERW$BC&\@=\8_
M*@#Y-_8C_P""&GQH^,/QCLOVI_\ @I#XP77[V2U@U'3-%MK]I;6*0_.JO"[%
M1@-@C':O,_\ @GG\8?AY^P[_ ,%G/BY\!OBGH<?A+3O'7C*XU#PU?3P+:V"6
M\4,:85B H!;. *_<6."*W 2-<J0 1Z"OBO\ X*K?\$:?@]_P4CT>UNWU6+PU
MXPT^+&D>)H;8230+N+,JYR.3C\J /J3Q#\>O@OX5\)VWC?Q7\4] T_2+N0QV
MVIW.HQI%*0 2%<G!."*_%'_@EE\&=>^/?_!?;Q_^V'\.]4M;[P9X8UO4M-N;
MV"3>)I)XXV1D8<%<*:Z'6?\ @W0_;C_:!TA?V:?C;^W?XC/P]\/9N=!CN+"-
MHC._R. NWCY56OTX_P"";_\ P3D^!W_!.+X(VOPE^$^B6RWKQQMK^KPP['U.
MX0$><X]<'% 'T8_R]!U'%.7G!/44C'.1NP#P*5000-V0!S0 ZBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\L?VF_P#E-1\-O^QK
M3_T6]?J=7Y8_M-_\IJ/AM_V-:?\ HMZ /U,_^)K\Y/\ @FA_RF=_;%_Z_+#_
M -EK]&__ (FOSD_X)H?\IG?VQ?\ K\L/_9: /T=HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD9B.!
M4;7&TXS0!+7YJ?\ !?TG_A8W[.XQ_P SU/\ ^DTE?I*+Q3P>U?FO_P %_9U;
MXB?L[X_Z'J?_ -)I* ,__@OAC_AUY\,B#_S53PG_ .ET=?I1X#.?!.CG'_,,
MM_\ T6M?FE_P7P=C_P $O_AB%Z?\+3\)Y_\  Z.OTG\!WL?_  A^CPGJ=,M_
M_1:T ;E%)SNR#QBEH **** "BBB@ HHHH **** "N>^+G_)*?$__ &+U[_Z(
M>NAKGOBY_P DI\3_ /8O7O\ Z(>@#XB_X-MO^4;8_P"RE>(O_2JO+?\ @ES_
M ,I*OC1_V.UU_P"BUKU+_@VV_P"4;8_[*5XB_P#2JO+?^"7/_*2KXT?]CM=?
M^BUH _4V'[M/ID/W:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?EI^SS_P I
MY_C7_OV'\S7ZEU^6G[//_*>?XU_[]A_,T =;_P '+W_)IGPT_P"RX>&O_2^&
MOT0\-?\ ( LO^O2/_P!!%?G?_P '+W_)IGPT_P"RX>&O_2^&OT0\-?\ ( LO
M^O2/_P!!% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *_-G_@NE_R=/\ L9_]EID_])&K])J_-G_@
MNE_R=/\ L9_]EID_])&H Z#_ (.5_P#E'EIO_95_#7_I97W5\,/^2:^'O^P'
M:?\ HE:^%?\ @Y7_ .4>6F_]E7\-?^EE?=7PP_Y)KX>_[ =I_P"B5H W****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OS8_X+#_\ *2[]B7_LI5Q_Z335^D]?FQ_P6'_Y27?L2_\
M92KC_P!)IJ +'_!RY_R:)\-_^RX>&?\ TOAK]$?#'_(N6/\ UYQ?^@"OSN_X
M.7/^31/AO_V7#PS_ .E\-?HCX8_Y%RQ_Z\XO_0!0!>HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ.?9=6"PO^['KE3SR#7E?@C_ (.I_P!F2^U^WLO'N@#1M+;_ %UZ\$V$_/\
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MJMXTU"]82R1:K"/W)QR 5QGGFO>O 7PL\#_"S1X_#G@/PM;V-G"24B@! 7-
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MZ_\ 1:T ?J;#]VGTR'[M/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORT_9Y_
MY3S_ !K_ -^P_F:_4NORT_9Y_P"4\_QK_P!^P_F: .M_X.7O^33/AI_V7#PU
M_P"E\-?HAX:_Y %E_P!>D?\ Z"*_._\ X.7O^33/AI_V7#PU_P"E\-?HAX:_
MY %E_P!>D?\ Z"* +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^;/_!=+_DZ?]C/_ ++3)_Z2-7Z3
M5^;/_!=+_DZ?]C/_ ++3)_Z2-0!T'_!RO_RCRTW_ +*OX:_]+*^ZOAA_R37P
M]_V [3_T2M?"O_!RO_RCRTW_ +*OX:_]+*^ZOAA_R37P]_V [3_T2M &Y111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8AD>5%W.P3&<#(K]%974IO097H!Z5^%OQJ^"%A_P3'_X.%O!OQ>\&:R^NO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(?VDOCS^S3XR^%/C;5]0L? 'Q-?5O$TYT*9?LUJ;=D#XQSR: /L3_@Y3*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% ",2.V>:CN%#1LI/6I:8VV0F,CZ4 ?FA_P<]?L9?$+]K;]@J%/
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M'\S7ZEU^6G[//_*>?XU_[]A_,T =;_P<O?\ )IGPT_[+AX:_]+X:_1#PU_R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB_\ 2JO+?^"7/_*2KXT?]CM=?^BUKU+_ (-MO^4;8_[*5XB_]*J\M_X)<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_M!_\%!#P? &K'_:^P<?^A5H#_@LK\?5Z?LIV/\ W[N?_B:7_A\O\?\ &/\
MAE2QQ_USN?\ XF@#-_X:"_X*!?\ 0A:M_P" '_V5'_#07_!0+_H0M6_\ /\
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M'BM[J/XK>%%E91SG[='FOTQ\"*/^$-T=L<_V9;\_]LUH V!C/"TM(ISGZTM
M!1110 4444 %%%% !1110 5SWQ<_Y)3XG_[%Z]_]$/70USWQ<_Y)3XG_ .Q>
MO?\ T0] 'Q%_P;;?\HVQ_P!E*\1?^E5>6_\ !+G_ )25?&C_ +':Z_\ 1:UZ
ME_P;;?\ *-L?]E*\1?\ I57EO_!+G_E)5\:/^QVNO_1:T ?J;#]VGTR'[M/H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P")K].O^$-\+?\ 0"M_^^*/^$-\+?\ 0"M_^^* /S%_X?M^*_\ I#%\3O\
MP%L?_B:/^'[?BO\ Z0Q?$[_P%L?_ (FOTZ_X0WPM_P! *W_[XH_X0WPM_P!
M*W_[XH _,7_A^WXK_P"D,7Q._P# 6Q_^)H_X?M^*_P#I#%\3O_ 6Q_\ B:_3
MK_A#?"W_ $ K?_OBC_A#?"W_ $ K?_OB@#\Q?^'[?BO_ *0Q?$[_ ,!;'_XF
MC_A^WXK_ .D,7Q._\!;'_P")K].O^$-\+?\ 0"M_^^*/^$-\+?\ 0"M_^^*
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MLL<1ZJ#?Q\<5^BO@/_D2=(Q_T"[?_P!%K7YI_P#!?!!_PZ]^&3CC'Q3\)_\
MI='7Z5^ SCP3H_OIEO\ ^BUH UP .E%%% !1110 4444 %%%% !1110 5SWQ
M<_Y)3XG_ .Q>O?\ T0]=#7/?%S_DE/B?_L7KW_T0] 'Q%_P;;?\ *-L?]E*\
M1?\ I57EO_!+G_E)5\:/^QVNO_1:UZE_P;;?\HVQ_P!E*\1?^E5>6_\ !+G_
M )25?&C_ +':Z_\ 1:T ?J;#]VGTR'[M/H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_'* /TFHK\V?^(K[_@CM_P!%5\3_ /A,G_XY73_![_@YB_X)1_''XG:)\)?
M_P 5=;_M;Q!?+:6!O]#\F'S""1OD:3"#CJ: /O\ HKE(_CK\&)W6.#XL>&G9
MF"JBZ[;DL3T &^NHBGCG59(7#(PRK*<@CUH ?1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;'_!
M8?\ Y27?L2_]E*N/_2::OTGK\V/^"P__ "DN_8E_[*5<?^DTU %C_@Y<_P"3
M1/AO_P!EP\,_^E\-?HCX8_Y%RQ_Z\XO_ $ 5^=W_  <N?\FB?#?_ ++AX9_]
M+X:_1'PQ_P BY8_]><7_ * * +U%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 A)'09ILC #WIS9QQ45R3Y/ Y]:
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M_P"V+Z_:[#_V6OT<_P#B:_.+_@F@#_P^@_;%/_3W8?\ LM 'Z/T444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#\37G _P"".G_!/,\_\(=X>_[\1?\ Q5'_  YT_P"">?\ T)WA[_OQ%_\
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M_#VC_@F[_P!'A^#?_ U__B:/^'M'_!-W_H\/P;_X&O\ _$UYQ_PYT_X)Y_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5^;'_  6'_P"4EW[$O_92KC_TFFK])Z_-
MC_@L/_RDN_8E_P"RE7'_ *334 6/^#ES_DT3X;_]EP\,_P#I?#7Z(^&/^1<L
M?^O.+_T 5^=W_!RY_P FB?#?_LN'AG_TOAK]$?#'_(N6/_7G%_Z * +U%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ7Y\M_P1<_X.>S_S<I<?^' '^%)_PY;_ .#GO_HY2X_\. /\* /T'_X=$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3)_\17GO_#!?_!(__H8OAG_X.+#_ ..T?\,%_P#!(_\ Z&+X9_\ @XL/_CM
M'H7_  ^A_P""7G_1YO@__P "9/\ XBC_ (?0_P#!+S_H\WP?_P"!,G_Q%>>_
M\,%_\$C_ /H8OAG_ .#BP_\ CM'_  P7_P $C_\ H8OAG_X.+#_X[0!Z%_P^
MA_X)>?\ 1YO@_P#\"9/_ (BC_A]#_P $O/\ H\WP?_X$R?\ Q%>>_P##!?\
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M+S_H\WP?_P"!,G_Q%>>_\,%_\$C_ /H8OAG_ .#BP_\ CM'_  P7_P $C_\
MH8OAG_X.+#_X[0!Z%_P^A_X)>?\ 1YO@_P#\"9/_ (BC_A]#_P $O/\ H\WP
M?_X$R?\ Q%>>_P##!?\ P2/_ .AB^&?_ (.+#_X[1_PP7_P2/_Z&+X9_^#BP
M_P#CM 'H7_#Z'_@EY_T>;X/_ / F3_XBC_A]#_P2\_Z/-\'_ /@3)_\ $5Y[
M_P ,%_\ !(__ *&+X9_^#BP_^.T?\,%_\$C_ /H8OAG_ .#BP_\ CM 'H7_#
MZ'_@EY_T>;X/_P# F3_XB@_\%HO^"78Z_MF^#_\ P)D_^(KSW_A@O_@D?_T,
M7PS_ /!Q8?\ QVE'[!/_  20/3Q%\,__  <6'_QV@#T'_A]%_P $NR,C]LWP
M?_X$R?\ Q%(?^"T?_!+S/_)YGA#_ ,"9/_B*\_/[!/\ P21'_,P_#/\ \'%A
M_P#':0?L%?\ !),GGQ!\,_\ P<6'_P =H ]!'_!:+_@EV>G[9G@__P "9/\
MXBE_X?0_\$O/^CS?!_\ X$R?_$5Y]_PP1_P21_Z&'X9_^#BP_P#CM+_PP;_P
M21 Q_P )%\,__!O8?_': /0/^'T/_!+S_H\WP?\ ^!,G_P 11_P^A_X)>?\
M1YO@_P#\"9/_ (BO/?\ A@O_ ()'G_F8_AG_ .#BP_\ CM'_  P7_P $C_\
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M3)_\17GO_#!?_!(__H8OAG_X.+#_ ..T?\,%_P#!(_\ Z&+X9_\ @XL/_CM
M'H7_  ^A_P""7G_1YO@__P "9/\ XBC_ (?0_P#!+S_H\WP?_P"!,G_Q%>>_
M\,%_\$C_ /H8OAG_ .#BP_\ CM'_  P7_P $C_\ H8OAG_X.+#_X[0!Z%_P^
MA_X)>?\ 1YO@_P#\"9/_ (BC_A]#_P $O/\ H\WP?_X$R?\ Q%>>_P##!?\
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M\-0,9/QP\-=?^OZ*OT6\-AAH%DK=K2/_ -!% %ZBBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGP[\*?L9_P#!>+X1^/?V>=,.BZOXP\,ZA=^()T?=]KF:XA1G(_W>*_93XO\
MQ2\%_!CP#?>._'.M06>GV,#2S23S*AVC&<;B,GFOQ!^"/Q=\4_\ !9K_ (+<
MZ-\0KK1&B\"?#"SU#2+'6-.A8>8"T4L>]L;<D@]Z /W:\/W4UYH=E>W;9DEL
MXG=CW8H":O#DYS4&GVB:;IT%@ARL$2QJ3U(4 #^53HVX9QB@!:*** "BBB@
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M_P"B%WO_ (/):/\ B')_X)2_]$+O?_!Y+7W110!\+_\ $.3_ ,$I?^B%WO\
MX/):/^(<G_@E+_T0N]_\'DM?=%% 'PO_ ,0Y/_!*7_HA=[_X/):/^(<G_@E+
M_P!$+O?_  >2U]T44 ?"_P#Q#D_\$I?^B%WO_@\EH_XAR?\ @E+_ -$+O?\
MP>2U]T44 ?"__$.3_P $I?\ HA=[_P"#R6C_ (AR?^"4O_1"[W_P>2U]T44
M?C3_ ,%;_P#@BM_P3_\ V:_@?HOBWX0_"^^TR^N]?2WGF&LRMNC.,C]:\N_;
MC_X),?L5?"3_ ((Q2?M3>!? %]9^-%LK60:J-7E)W/*58XSZ5^@'_!>?_DVK
MPY_V-,7]*\5_X*7@#_@W:F/_ %#;''_?XT ='^S#_P $ _\ @F5\0/@/X3\8
M>*?@U>W%_J7AZRN;R8ZW*-\DENC,?Q)->C?\0Y/_  2E(_Y(7>_^#R6OI#]B
MF//[+W@3/_0J:=_Z2Q5ZN".@[4 ?#'_$.3_P2E_Z(7>_^#R6C_B')_X)2_\
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M'\,-2A0SWVE3QV$[KD03,A"OCO@UZ@JJ?F+'+?I4.H6Z7$04NR@-QM[_ %H
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M'_!8?_E)=^Q+_P!E*N/_ $FFK])Z_-C_ (+#_P#*2[]B7_LI5Q_Z334 6/\
M@Y<_Y-$^&_\ V7#PS_Z7PU^B/AC_ )%RQ_Z\XO\ T 5^=W_!RY_R:)\-_P#L
MN'AG_P!+X:_1'PQ_R+EC_P!><7_H H O4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% ".2!P,TP@,!'C*]S3R<?G3
M)3Y:E@>.] $4MC972&&:-73^XPR*_'C_ (*)_P#!(/\ ;*^!'Q3\=_MZ_P#!
M/SXKS1^(]:\0)J%QX*TFP)FORVU3@G"C"H!U[U^P<FIV\%NUQ<RI#&@)9Y2%
M _$UER>.OA_.@63QAI+9ZJU]'C^= 'XH>/O^#K7XU?L7:I:? 7]JS]A77+'Q
MI8:;;O>K?:G&DDJL@ DQNX#$$_C72?%__@\.^"W@?P_X.O\ X??!1_%.H>(=
M),^M:9::HJOI%SO*B!\D9;&#QZU^I7Q"^!O[%OQ1U\^*?B'\/O >MZD\:H]_
MJ5M;RRE5Z#<W.!6*/V1_^">4(WI\%?AJ&#!MXTZUR#0!^0?QR^,/_!5?_@NK
MIF@^ _AU\ O$OP[^'&KWYCU+7I2L\"PLH#D[6)P.#^-?JG_P2X_X)H_"#_@F
MA\#5^%/@1;:YU2],4VOZM&A!OKE%*^9R,C(/2O;?".H?!?P'I*:!X)OO#^EV
M$?W+:RGBC5?H :W--\5^$-1NA;Z5XBL;J5N1'!<H[_D#0!KNN\<\'^&GJ6&%
M8\XYI J@9+<>]+'(L@)7MWH =1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5^6/[3?_*:CX;?]C6G_HMZ_4ZORQ_:;_Y34?#;_L:T
M_P#1;T ?J9_\37YR?\$T/^4SO[8O_7Y8?^RU^C?_ ,37YR?\$T/^4SO[8O\
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MOZUY5^Q7_P FN>!?^Q3T[_TECKU9>@^E !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^6G[//\ RGG^-?\
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MES_DT3X;_P#9</#/_I?#7Z(^&/\ D7+'_KSB_P#0!0!>HHHH **** "BBB@
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M?LE> ]8^(7Q;\<Z;:V^DV+7,FF/>1K<SA1G:D9.6)[ "OQ*\6?'O]O+_ (.
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MT5?TY>!/^1+TC_L%V_\ Z+6@#45,-D' /:G444 %%%% !1110 4444 %%%%
M!7/?%S_DE/B?_L7KW_T0]=#7/?%S_DE/B?\ [%Z]_P#1#T ?$7_!MM_RC;'_
M &4KQ%_Z55Y;_P $N?\ E)5\:/\ L=KK_P!%K7J7_!MM_P HVQ_V4KQ%_P"E
M5>6_\$N?^4E7QH_[':Z_]%K0!^IL/W:?3(?NT^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I'^Z:6D?[IH ^&O^
M"\__ ";1X<_[&J+^E>*_\%+O^5=F?_L'6/\ Z.->U?\ !>?_ )-H\.?]C5%_
M2O%?^"EW_*NS/_V#K'_T<: /OK]BO_DUSP+_ -BGIW_I+'7JR]!]*\I_8K_Y
M-<\"_P#8IZ=_Z2QUZLO0?2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *_+3]GG_E//\:_]^P_F:_4NORT_
M9Y_Y3S_&O_?L/YF@#K?^#E[_ )-,^&G_ &7#PU_Z7PU^B'AK_D 67_7I'_Z"
M*_.__@Y>_P"33/AI_P!EP\-?^E\-?HAX:_Y %E_UZ1_^@B@"]1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -:/+;EX]:0AF&
M>A[^]/HH Y'XJ_"/PE\9O"MUX#^(6D1:AI-\N)[:9>"/3]:_-K]IK_@AM\4_
M@)K^N_';_@F/\89?A_):6!NK?P?IEJ93?W()9E#$8!=CFOU3..]5;N,M()(S
MG/WE/0B@#\@OV?/^"\7[17[*?C3PO\!O^"JOP2O_  .NI:<\ESX[UZZ 61D.
M-VT'^(G'3M7Z"?LC?\%,/V+/VV_$VH>$/V;/C;I?B?4]*LUNK^ULG.Z*)B0&
M.>V0:]'^(/[/OP4^+LPG^)GPGT'6VBC9(7U32XYF0'TW XKY0^./_!!_]EWX
MMZP?$7@KQ9XF^'UT[_OI/ ]\=/:5>R,8BN5]J /N4WMN&P95'XT^.>*491P?
MI7Y?7?\ P0L^,VCS2:7X5_:E\<2Z;&^VUDO/%LQE*=MQW]:\E_:*UK_@IE_P
M27\=?#GX8_!#QMI'B5OBOXD.@Z1)XPU!KHQ3",REF+$[1QUH _9DWEL)Q;&4
M;R,A:D#*>,U^17[6'[9O_!>_]AKP%I/QL_: T?X2S>&IO%.G:1=C245Y_P#2
MIQ&" !Z9K]7_  -JMUX@\'Z5KMZH$UYIT$\H4<;GC5CC\30!KT444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?FQ_P6'_Y27?L2_\ 92KC_P!)IJ_2>OS8_P""P_\ RDN_8E_[*5<?
M^DTU %C_ (.7/^31/AO_ -EP\,_^E\-?HCX8_P"1<L?^O.+_ - %?G=_P<N?
M\FB?#?\ [+AX9_\ 2^&OT1\,?\BY8_\ 7G%_Z * +U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR4G]G?\ ['N?_P!)GK]*6)()7/6OS/\ ^#@.\M;#XA_L]7MU,(XQXYG,C.V
MH^S2<^U 'Y4_\%(/^2F>#_\ LI&C?^ET5?TY>!/^1+TC_L%V_P#Z+6OY@_\
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M*** "BBB@ HHHH *1_NFEI'^Z: /AK_@O/\ \FT>'/\ L:HOZ5XK_P %+O\
ME79G_P"P=8_^CC7M7_!>?_DVCPY_V-47]*\5_P""EW_*NS/_ -@ZQ_\ 1QH
M^^OV*_\ DUSP+_V*>G?^DL=>K+T'TKRG]BO_ )-<\"_]BGIW_I+'7JR]!]*
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M% $8#GKU[4K@;@>XZT^B@!BJNXE> ?UK\V_^"Z:@_M3_ +&I8YW?&B3 ]/\
M1&K])Z_-G_@NE_R=/^QG_P!EID_])&H W_\ @Y2)_P"'>6F1D8 ^*_AKYO\
MM\K[J^& Q\-O#_S9_P")):<_]L5KX6_X.5_^4>6F_P#95_#7_I97W3\,/^2:
M^'O^P):?^B5H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OS8_X+#_ /*2[]B7_LI5Q_Z335^D
M]?FQ_P %A_\ E)=^Q+_V4JX_])IJ +'_  <N?\FB?#?_ ++AX9_]+X:_1'PQ
M_P BY8_]><7_ * *_.[_ (.7/^31/AO_ -EP\,_^E\-?HCX8_P"1<L?^O.+_
M - % %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG^'PM:<_^0Z_";]@#P]H/A?_ (.B]4TGPYHMKI]E$-:6"TLK=8DC4"' "J
M* /Z'Y"JL/,;K]T>].C4*2,8S3 6?YMO;Y<BGH,<D'/>@!U%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y8_M-_\IJ/AM_V-:?\
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MDI\3_P#8O7O_ *(>NAKGOBY_R2GQ/_V+U[_Z(>@#XB_X-MO^4;8_[*5XB_\
M2JO+?^"7/_*2KXT?]CM=?^BUKU+_ (-MO^4;8_[*5XB_]*J\M_X)<_\ *2KX
MT?\ 8[77_HM: /U-A^[3Z9#]VGT %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_-G_@NE_R=/^QG_P!EID_])&K])J_-G_@NE_R=/^QG_P!EID_])&H
MZ#_@Y7_Y1Y:;_P!E7\-?^EE?=7PP_P"2:^'O^P':?^B5KX5_X.5_^4>6F_\
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M_8O7O_HAZ /B+_@VV_Y1MC_LI7B+_P!*J\M_X)<_\I*OC1_V.UU_Z+6O4O\
M@VV_Y1MC_LI7B+_TJKRW_@ES_P I*OC1_P!CM=?^BUH _4V'[M/ID/W:?0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4C_=-+2/]TT ?#7_!>?\ Y-H\.?\ 8U1?TKQ7_@I=_P J[,__ &#K'_T<
M:]J_X+S_ /)M'AS_ +&J+^E>*_\ !2[_ )5V9_\ L'6/_HXT ??7[%?_ ":Y
MX%_[%/3O_26.O5EZ#Z5Y3^Q7_P FN>!?^Q3T[_TECKU9>@^E !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^6G[//\ RGG^-?\ OV'\S7ZEU^6?[//_ "GG^-?^_8?SH Z[_@Y>_P"33/AI
M_P!EP\-?^E\-?HAX:_Y %E_UZ1_^@BOSN_X.7CC]DSX:'_JM_AK_ -+X:_1'
MPU_R +(_].D?_H(H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7YL_P#!=+_DZ?\ 8S_[+3)_Z2-7
MZ35^;/\ P72_Y.G_ &,_^RTR?^DC4 =!_P '*_\ RCRTW_LJ_AK_ -+*^ZOA
MA_R37P]_V [3_P!$K7PK_P '*_\ RCRTW_LJ_AK_ -+*^ZOAA_R37P]_V [3
M_P!$K0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?FQ_P6'_Y27?L2_P#92KC_ -)IJ_2<U^;'
M_!8CC_@I=^Q-[?$JXS_X#2T 6/\ @Y<_Y-$^&_\ V7#PS_Z7PU^B/AC_ )%R
MQ_Z\XO\ T 5^=W_!RY_R:)\-_P#LN'AG_P!+X:_1'PQ_R+EC_P!><7_H H O
M44 YHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH2,QD@8VXX %.5<9/J: % QP***0'/8T +1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YL_\
M!8C'_#R_]B?/_12KC_TFEK])7SCBOS6_X+&-C_@I=^Q._8?$FX_])I: +G_!
MRYM/[(WPW _Z+?X9_P#2^&OT/\-$#P_8*/\ GTC_ /0!7YU_\'*[.?V1_AL0
MIY^-_AG_ -+XJ_1#PU)G0K')X%I'G_OD4 :=%(#D\=,4M !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD:@#H/\ @Y7_ .4>6F_]E7\-?^EE?=7PP_Y)KX>_[ =I_P"B5KX5_P"#E?\
MY1Y:;_V5?PU_Z65]U?##_DFOA[_L!VG_ *)6@#<HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!% )+$<YK\Q_^"VGA+P[XZ_X*'_L8^$O%ND0W^FWOQ%N8[JSN!E)5^SR\
M&OTY) &37YL_\%B/^4F'[$__ &4JX_\ 2:6@#A_^#@[]EWX _"#]F7X<^*/A
MK\*]*T;4#\:_#<9N[.(A]K7\61R3Q7ZC^&$8:/8J/NFTBR/^ BOSW_X.6O\
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M-&T^W,UY?73;4A0=68^E?AW^S9K?Q!_X*\?\%K+OXR:[XAM=:^'GPMN;[1M
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MHZ_2GP#_ ,B/H_\ V"[?_P!%K0!JHBIT_&EHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5^;/\ P72_Y.G_ &,_^RTR?^DC5^DU?FS_ ,%TO^3I_P!C/_LM,G_I
M(U '0?\ !RO_ ,H\M-_[*OX:_P#2RONKX8?\DU\/?]@.T_\ 1*U\*_\ !RO_
M ,H\M-_[*OX:_P#2RONKX8?\DU\/?]@.T_\ 1*T ;E%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  0
M",&OS8_X+#G/_!2[]B8^OQ*N/_2:6OTGK\V/^"P__*2[]B7_ +*5<?\ I--0
M!8_X.7/^31/AO_V7#PS_ .E\-?HCX8_Y%RQ_Z\XO_0!7YW?\'+G_ ":)\-_^
MRX>&?_2^&OT1\,?\BY8_]><7_H H O4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-?G)_P $T/\ E,[^V+_U^6'_ ++7Z-__ !-?G)_P30_Y3._MB_\ 7Y8?^RT
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MXU[5_P %Y_\ DVCPY_V-47]*\5_X*7?\J[,__8.L?_1QH ^^OV*_^37/ O\
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M?]@.T_\ 1*U\*_\ !RO_ ,H\M-_[*OX:_P#2RONKX8?\DU\/?]@.T_\ 1*T
M;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7YL?\%A_^4EW[$O\ V4JX_P#2::OTGK\V/^"P_P#R
MDN_8E_[*5<?^DTU %C_@Y<_Y-$^&_P#V7#PS_P"E\-?HCX8_Y%RQ_P"O.+_T
M 5^=W_!RY_R:)\-_^RX>&?\ TOAK]$?#'_(N6/\ UYQ?^@"@"]1110 4444
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M/^"5CXD\-M9Y;Q)87\^I7CHK8W.L<6 QYXSVKU3_ (+JH?\ AN#]G=Y9@?\
MBY]GLQV/EU]:_P#!07_@I[^PQ^RAX,O;/XS^+_#^KZ['^ZC\+S%?M4X.0VW>
MA Q]>] &+^P;_P %QOV,/VZO$%Y\//"WB^XT?Q-H]C'<ZK9^([3^SXU1CM&Q
MIF&XY!XKZ^\->+O"_BM9;GPOXDT[4HHGVO)IUZDZJ?0E"0#7\OG[6WPCOO\
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M /8+M_\ T6M?FM_P7S_Y1=?#+_LJGA/_ -+HZ_2GP#_R(^C_ /8+M_\ T6M
M&M1110 4444 %%%% !1110 4444 %<]\7/\ DE/B?_L7KW_T0]=#7/?%S_DE
M/B?_ +%Z]_\ 1#T ?$7_  ;;?\HVQ_V4KQ%_Z55Y;_P2Y_Y25?&C_L=KK_T6
MM>I?\&VW_*-L?]E*\1?^E5>6_P#!+G_E)5\:/^QVNO\ T6M 'ZFP_=I],A^[
M3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH)
MQR::94Y#<#U]: '45& Q& >,YS3@68;AP/>@!U(_W:8Q*N'=P!T ]33)FDRS
M \CI0!\/_P#!>8@_LT>','_F:8OZ5XM_P4N(_P"(=F?G_F'6/_HXU['_ ,%W
M,/\ LT>''D0JW_"51\$]>E>-_P#!2\?\<[$S$<?V=8X'_;8T ??7[%9'_#+G
M@7G_ )E/3O\ TECKU8$;1SVKR']BR1A^RYX&)4@'PGIW/K_HL5>HJ[<9N0 .
MB'J* +V0>AHR#T-16[HT.4[G%.4;&"@=1S0 ^BFX;OW/-( <E>O/&.U #Z*1
M=P^5N?>EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "ORT_9Y_Y3S_&O_?L/YFOU+K\M/V>MJ_\%Z/C4V\?>L,_G0!UG_!R]_R:
M9\-/^RW^&O\ TOAK]$?#1!T"RP?^72/_ -!%?FW_ ,'17B&/PM^Q1X&\22P&
M9-/^,/A^Z:%3@R!+R-L#ZXK9T?\ X+U>#;'2[: _LZZ\0MNB_P#'[%V4#UH
M_1FBOSP_X?[^#/\ HW/7_P#P.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_
MX?[^#/\ HW/7_P#P.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\
MHW/7_P#P.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7_P#P
M.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7_P#P.B_QH_X?
M[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7_P#P.B_QH_X?[^#/^C<]
M?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7_P#P.B_QH_X?[^#/^C<]?_\  Z+_
M !H _0^BOSP_X?[^#/\ HW/7_P#P.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^B
MOSP_X?[^#/\ HW/7_P#P.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^
M#/\ HW/7_P#P.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7
M_P#P.B_QH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7_P#P.B_Q
MH_X?[^#/^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7_P#P.B_QH_X?[^#/
M^C<]?_\  Z+_ !H _0^BOSP_X?[^#/\ HW/7_P#P.B_QH_X?[^#/^C<]?_\
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M (.7/^31/AO_ -EP\,_^E\-?HCX8_P"1<L?^O.+_ - %?G=_P<N?\FB?#?\
M[+AX9_\ 2^&OT1\,?\BY8_\ 7G%_Z * +U%%% !1110 4444 %%%% !1110
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MNS*3WTVQP/\ ML:N_MZ1)!_P2W^#K1C&8=)S_P" T55/^"EP"_\ !NS.V/\
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MU\.OBQX$^+?A:W\<?#?Q+;:QH]U_Q[7]HQ,<G3.,@>HKHA(2 V>* 'T4U6+
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M*_\  "/_ .)H_P"%"?"#_HG^E?\ @!'_ /$T ?FQ_P /MO\ @C1_T;)X\_\
M#4WG_P 31_P^V_X(T?\ 1LGCS_PU-Y_\37Z3_P#"A/A!_P!$_P!*_P# "/\
M^)H_X4)\(/\ HG^E?^ $?_Q- 'YL?\/MO^"-'_1LGCS_ ,-3>?\ Q-'_  ^V
M_P""-'_1LGCS_P -3>?_ !-?I/\ \*$^$'_1/]*_\ (__B:/^%"?"#_HG^E?
M^ $?_P 30!^;'_#[;_@C1_T;)X\_\-3>?_$T?\/MO^"-'_1LGCS_ ,-3>?\
MQ-?I/_PH3X0?]$_TK_P C_\ B:/^%"?"#_HG^E?^ $?_ ,30!^;'_#[;_@C1
M_P!&R>//_#4WG_Q-'_#[;_@C1_T;)X\_\-3>?_$U^D__  H3X0?]$_TK_P
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M -$K0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?FQ_P %A_\ E)=^Q+_V4JX_])IJ_2>OS8_X
M+#_\I+OV)?\ LI5Q_P"DTU %C_@Y<_Y-$^&__9</#/\ Z7PU^B/AC_D7+'_K
MSB_] %?G=_P<N?\ )HGPW_[+AX9_]+X:_1'PQ_R+EC_UYQ?^@"@"]1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M +!=O_Z+6OS6_P""^?\ RBZ^&7_95/"?_I='7Z4^ ?\ D1]'_P"P7;_^BUH
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M_E%M\'/^N.D_^DL54_\ @I?Q_P &[$Y_ZAUC_P"CC5S]OK_E%M\'/^N.D_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]=#7/?%S_DE/B?\ [%Z]_P#1#T ?$7_!MM_RC;'_ &4KQ%_Z55Y;_P $N?\
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M44 %%%% !1110 4444 %%%% !7YL_P#!=+_DZ?\ 8S_[+3)_Z2-7Z35^;/\
MP72_Y.G_ &,_^RTR?^DC4 =!_P '*_\ RCRTW_LJ_AK_ -+*^ZOAA_R37P]_
MV [3_P!$K7PK_P '*_\ RCRTW_LJ_AK_ -+*^ZOAA_R37P]_V [3_P!$K0!N
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?FQ_P6'_Y27?L2_P#92KC_ -)IJ_2>OS8_X+#_ /*2
M[]B7_LI5Q_Z334 6/^#ES_DT3X;_ /9</#/_ *7PU^B/AC_D7+'_ *\XO_0!
M7YW?\'+G_)HGPW_[+AX9_P#2^&OT1\,?\BY8_P#7G%_Z * +U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_8,M_P#T6M &N"#THI%[_6EH **** "BBB@ HHHH **** "N>^+G_)*?$_\
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M,F7_ (=I_!U >?*TW_TCAKS7_@UE_=_$G]IYS_T/MK_Z2QT ?L712*=PS2T
M%%%% #7 . 2:C:.,MY1'7G-2L<#--*J%P!G- 'P/_P ' OPBU?Q%^QKJ?Q^\
M-6%C+J'POLY]8MY;HC=$Q C!3OGYNU?1_P#P3U\8ZAX]_8N^&?BK5R3=ZEX1
MM9[AC_?*\XJ3]O?X:Z!\4OV0_B!\/O$]DLNFZMH#P7D;]'0NIQ^E?/'_  0<
M^)WCSQI^S[XH\%>,O$#WUEX+\1#1_#T;+@6UHBMMC'MQ0!]U(I^X"=R\^QJ4
M9QS4+7!WA1T8X!]*F'3K0 445'+-L;% $E%1+< ]:>L@<X% #J*** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\V/\ @L/_ ,I+OV)?
M^RE7'_I--7Z3U^;'_!8?_E)=^Q+_ -E*N/\ TFFH L?\'+G_ ":)\-_^RX>&
M?_2^&OT1\,?\BY8_]><7_H K\[O^#ES_ )-$^&__ &7#PS_Z7PU^B/AC_D7+
M'_KSB_\ 0!0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORQ_:;_Y34?#;_L:T_\
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M_P */M?_  <R_P#0(^!__@0G^%5/^'\'Q/\ ^C1;G_P/_P#KT?\ #^#XG_\
M1HMS_P"!_P#]>@"W]K_X.9?^@1\#_P#P(3_"C[7_ ,',O_0(^!__ ($)_A53
M_A_!\3_^C1;G_P #_P#Z]'_#^#XG_P#1HMS_ .!__P!>@"W]K_X.9?\ H$?
M_P#\"$_PH^U_\',O_0(^!_\ X$)_A53_ (?P?$__ *-%N?\ P/\ _KT?\/X/
MB?\ ]&BW/_@?_P#7H M_:_\ @YE_Z!'P/_\  A/\*/M?_!S+_P! CX'_ /@0
MG^%5/^'\'Q/_ .C1;G_P/_\ KT?\/X/B?_T:+<_^!_\ ]>@"W]K_ .#F7_H$
M? __ ,"$_P */M?_  <R_P#0(^!__@0G^%5/^'\'Q/\ ^C1;G_P/_P#KT?\
M#^#XG_\ 1HMS_P"!_P#]>@"W]K_X.9?^@1\#_P#P(3_"C[7_ ,',O_0(^!__
M ($)_A53_A_!\3_^C1;G_P #_P#Z]'_#^#XG_P#1HMS_ .!__P!>@"W]K_X.
M9?\ H$? _P#\"$_PH^U_\',O_0(^!_\ X$)_A53_ (?P?$__ *-%N?\ P/\
M_KT?\/X/B?\ ]&BW/_@?_P#7H M_:_\ @YE_Z!'P/_\  A/\*/M?_!S+_P!
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MZ_X4\7G_  <R?] CX(?]_P!?\*J'_@N]\55X/[(5S_X'_P#UZ/\ A^_\5/\
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M_M?_  <R_P#0(^!__@0G^%'VO_@YE_Z!'P/_ / A/\*J?\/X/B?_ -&BW/\
MX'__ %Z/^'\'Q/\ ^C1;G_P/_P#KT 6_M?\ P<R_] CX'_\ @0G^%> _\$T'
M_:M_X>__ !9F_; A\/1^,C]B_M1?#C VP.>-N*]S_P"'\'Q/_P"C1;G_ ,#_
M /Z]>$?\$R/V@M6_:8_X*^?%CXG:UX+?0Y;_ .Q%]->3<4P?6@#WW_@Y1(E_
M9+^&KID8^-_AK[W_ %_15^BGAS!T*S?IFTCX_P" BOSK_P"#E3,G[)?PT"C
M'QP\-#'I_IT5?HKX<_Y 5GW_ -$CY_X"* +M%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;/\ P72_
MY.G_ &,_^RTR?^DC5^DU?FS_ ,%TO^3I_P!C/_LM,G_I(U '0?\ !RO_ ,H\
MM-_[*OX:_P#2RONKX8?\DU\/?]@.T_\ 1*U\*_\ !RO_ ,H\M-_[*OX:_P#2
MRONKX8?\DU\/?]@.T_\ 1*T ;E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YL?\%A_^4EW[$O\
MV4JX_P#2::OTGK\V/^"P_P#RDN_8E_[*5<?^DTU %C_@Y<_Y-$^&_P#V7#PS
M_P"E\-?HCX8_Y%RQ_P"O.+_T 5^=W_!RY_R:)\-_^RX>&?\ TOAK]$?#'_(N
M6/\ UYQ?^@"@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?EC^TW_ ,IJ/AM_V-:?
M^BWK]3J_+']IO_E-1\-O^QK3_P!%O0!^I; ,,'TK\TO^">7@[PGXN_X+.?M@
M#Q/X<LK\07EAY0N[99-OW>FX<5^EW_Q-?G)_P30_Y3._MB_]?EA_[+0!]\?\
M*;^$QZ_#?1/_  6Q_P"%'_"FOA-_T3;1/_!;'_A72T4 <U_PIKX3?]$VT3_P
M6Q_X4?\ "FOA-_T3;1/_  6Q_P"%=+10!S7_  IKX3?]$VT3_P %L?\ A1_P
MIKX3?]$VT3_P6Q_X5TM% '-?\*:^$W_1-M$_\%L?^%'_  IKX3?]$VT3_P %
ML?\ A72T4 <U_P *:^$W_1-M$_\ !;'_ (4?\*:^$W_1-M$_\%L?^%=+10!S
M7_"FOA-_T3;1/_!;'_A1_P *:^$W_1-M$_\ !;'_ (5TM% '-?\ "FOA-_T3
M;1/_  6Q_P"%'_"FOA-_T3;1/_!;'_A72T4 <U_PIKX3?]$VT3_P6Q_X4?\
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M]$/#7_( LO\ KTC_ /010!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ K\V/^"P_P#RDN_8E_[*5<?^DTU?I/7YL?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^@"@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?EC^TW_P IJ/AM_P!C6G_HMZ_4
MZORQ_:;_ .4U'PV_[&M/_1;T ?J9_P#$U^<G_!-#_E,[^V+_ -?EA_[+7Z-_
M_$U^<G_!-#_E,[^V+_U^6'_LM 'Z.T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7Y:?L\_\IY_C7_OV'\S7ZEU^6G[//_*>?XU_[]A_,T =;_P<
MO?\ )IGPT_[+AX:_]+X:_1#PU_R ++_KTC_]!%?G?_P<O?\ )IGPT_[+AX:_
M]+X:_1#PU_R ++_KTC_]!% %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-G_ (+I?\G3_L9_]EID
M_P#21J_2:OS9_P""Z7_)T_[&?_9:9/\ TD:@#H/^#E?_ )1Y:;_V5?PU_P"E
ME?=7PP_Y)KX>_P"P':?^B5KX5_X.5_\ E'EIO_95_#7_ *65]U?##_DFOA[_
M + =I_Z)6@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *_-C_@L/_RDN_8E_P"RE7'_ *335^D]
M?FQ_P6'_ .4EW[$O_92KC_TFFH L?\'+G_)HGPW_ .RX>&?_ $OAK]$?#'_(
MN6/_ %YQ?^@"OSN_X.7/^31/AO\ ]EP\,_\ I?#7Z(^&/^1<L?\ KSB_] %
M%ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!+X:_1'PQ_R+EC_P!><7_H H O4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y8_M
M-_\ *:CX;?\ 8UI_Z+>OU.K\L?VF_P#E-1\-O^QK3_T6] 'ZF?\ Q-?G)_P3
M0_Y3._MB_P#7Y8?^RU^C?_Q-?G)_P30_Y3._MB_]?EA_[+0!^CM%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5^6G[//_*>?XU_[]A_,U^I=?EI^
MSS_RGG^-?^_8?S- '6_\'+W_ ":9\-/^RX>&O_2^&OT0\-?\@"R_Z](__017
MYW_\'+W_ ":9\-/^RX>&O_2^&OT0\-?\@"R_Z](__010!>HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD+@,%/?I1DXZ4
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M!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "ORQ_:;_ .4U'PV_[&M/_1;U^IU?EC^T
MW_RFH^&W_8UI_P"BWH _4S_XFOSD_P"":'_*9W]L7_K\L/\ V6OT;_\ B:_.
M3_@FA_RF=_;%_P"ORP_]EH _1VBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_+']IO_ )34
M?#;_ +&M/_1;U^IU?EC^TW_RFH^&W_8UI_Z+>@#]3/\ XFOSD_X)H?\ *9W]
ML7_K\L/_ &6OT;_^)K\Y/^":'_*9W]L7_K\L/_9: /T=HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%'C*RBURZAQH>CM*%GNR25R@(P<&OE[_ ()J?\$W_%_Q1\=O^W;^VOJ,6O\
MBO67,NB0(C1Q6]B6,EM^Z<LNX1LH+#&<5XK\3O#?BC_@L9_P5_TOPW%\/M)U
M#X6?!#5YK#Q%=27!)G\S$D;&,\-][L:_8WP[X;LO#&BV7AO38%CM;"UCM[95
M'W8T4*JX]  * +L5E;I$B6\*QH!\J(H 'T Z5.B!!@4BD $=A2[E/>@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "ORQ_:;_ .4U'PV_[&M/_1;U^IU?EC^TW_RF
MH^&W_8UI_P"BWH _4S_XFOSD_P"":'_*9W]L7_K\L/\ V6OT;_\ B:_.3_@F
MA_RF=_;%_P"ORP_]EH _1VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>!=$@TS2["+R[*PM8]L<2>@':MO.3RHV@=: '#J?EQ2TB,S9)'':EH ****
M"BBDWKZT *2!U-%& >U% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5^;'_  6'_P"4EW[$O_92
MKC_TFFK])Z_-C_@L/_RDN_8E_P"RE7'_ *334 6/^#ES_DT3X;_]EP\,_P#I
M?#7Z(^&/^1<L?^O.+_T 5^=W_!RY_P FB?#?_LN'AG_TOAK]$?#'_(N6/_7G
M%_Z * +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5^6/[3?_*:CX;?]C6G_HMZ_4ZO
MRQ_:;_Y34?#;_L:T_P#1;T ?J9_\37YR?\$T/^4SO[8O_7Y8?^RU^C?_ ,37
MYR?\$T/^4SO[8O\ U^6'_LM 'Z.T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_OF@!U%-RO\ ?-&5_OF@!U%-RO\ ?-&5_OF@!U%-RO\ ?-&5_OF@!U%-RO\
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M_/VE?S??\.9?^#H'_HX&;_PO!_\ $4?\.9?^#H'_ *.!F_\ "\'_ ,10!_2
M=6L<<W:5 =8L#/Y<4ZONX4 ]Z_G&_P"',O\ P= =_P!H&;_PO!_\17(:_P#
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M[O\ @Y<_Y-$^&_\ V7#PS_Z7PU^B/AC_ )%RQ_Z\XO\ T 4 7J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (+W?])6?!G_ (2$]<M_P\>_X+"_]&Q^#_\ O_-_\;H_X>/?\%A?^C8_!_\
MW_F_^-T =3_PP?\ \%[O^DK/@S_PD)Z/^&#_ /@O=_TE9\&?^$A/7+?\/'O^
M"PO_ $;'X/\ ^_\ -_\ &Z/^'CW_  6%_P"C8_!__?\ F_\ C= '4_\ #!__
M  7N_P"DK/@S_P )">C_ (8/_P""]W_25GP9_P"$A/7+?\/'O^"PO_1L?@__
M +_S?_&Z/^'CW_!87_HV/P?_ -_YO_C= '4_\,'_ /!>[_I*SX,_\)">C_A@
M_P#X+W?])6?!G_A(3URW_#Q[_@L+_P!&Q^#_ /O_ #?_ !NC_AX]_P %A?\
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M9\&?^$A/7+?\/'O^"PO_ $;'X/\ ^_\ -_\ &Z/^'CW_  6%_P"C8_!__?\
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M)6?!O_A(3URG_#R#_@L/_P!&R>$/^_\ -_\ &Z/^'D'_  6'_P"C9/"'_?\
MF_\ C= '5_\ #"7_  7R_P"DK'@W_P )">N9OO\ @D'_ ,%-OB_^T'\+_BQ^
MUY^WYX8\7Z/\,?%(UNQTJT\.S0/))Y91@&/'(/>HC_P4@_X+#X_Y-D\(?]_Y
MO_C=96D_\%AOV_/A_P#M%_##X3?M(_ [PWI6E?$/Q2-(M[JS>1G#;&<]4 '
MH ]2_P"#DU%/_!/'2Y XRWQ5\-$^_P#I@K[O^%R;?AMX?Q_T!+3_ -$K7PE_
MP<H2H/\ @GII<6WD_%7PT1@?]/@K[N^%QS\-O#_.?^)):?\ HE* -VBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\V/^"P__ "DN_8E_[*5<?^DTU?I/7YL?\%A_^4EW[$O_ &4J
MX_\ 2::@"Q_P<N?\FB?#?_LN'AG_ -+X:_1'PQ_R+EC_ -><7_H K\[O^#ES
M_DT3X;_]EP\,_P#I?#7Z(^&/^1<L?^O.+_T 4 7J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K\L?VF_P#E-1\-O^QK3_T6]?J=7Y8_M-_\IJ/AM_V-:?\ HMZ /U,_
M^)K\Y/\ @FA_RF=_;%_Z_+#_ -EK]&__ (FOSD_X)H?\IG?VQ?\ K\L/_9:
M/T=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT0\-?\@"R_Z](_\ T$4 *-'L!UTZ#_OP/\*7^R-._P"@=!_WX7_"KE% %/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_-C_ (+#_P#*2[]B7_LI5Q_Z335^D]?FQ_P6'_Y2
M7?L2_P#92KC_ -)IJ +'_!RY_P FB?#?_LN'AG_TOAK]$?#'_(N6/_7G%_Z
M*_.[_@Y<_P"31/AO_P!EP\,_^E\-?HCX8_Y%RQ_Z\XO_ $ 4 7J*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K\L?VF_^4U'PV_[&M/_ $6]?J=7Y8_M-_\ *:CX;?\
M8UI_Z+>@#]3/_B:_.3_@FA_RF=_;%_Z_+#_V6OT;_P#B:_.3_@FA_P IG?VQ
M?^ORP_\ 9: /T=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %!Z444 ,!=1G.X5!JMC9:KI\MAJ, DAEC*O&PX8&K.P<\GFF21
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OS8_X+#_\ *2[]B7_LI5Q_Z335^D]?FQ_P6'_Y27?L2_\ 92KC_P!)
MIJ +'_!RY_R:)\-_^RX>&?\ TOAK]$?#'_(N6/\ UYQ?^@"OSN_X.7/^31/A
MO_V7#PS_ .E\-?HCX8_Y%RQ_Z\XO_0!0!>HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"ORQ_:;_ .4U'PV_[&M/_1;U^IU?EC^TW_RFH^&W_8UI_P"BWH _4S_XFOSD
M_P"":'_*9W]L7_K\L/\ V6OT;_\ B:_.3_@FA_RF=_;%_P"ORP_]EH _1VBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_+3]GG_ )3S_&O_ '[#
M^9K]2Z_+3]GG_E//\:_]^P_F: .M_P"#E[_DTSX:?]EP\-?^E\-?HAX:_P"0
M!9?]>D?_ *"*_.__ (.7O^33/AI_V7#PU_Z7PU^B'AK_ ) %E_UZ1_\ H(H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?FQ_P %A_\ E)=^Q+_V4JX_])IJ_2>OS8_X+#_\
MI+OV)?\ LI5Q_P"DTU %C_@Y<_Y-$^&__9</#/\ Z7PU^B/AC_D7+'_KSB_]
M %?G=_P<N?\ )HGPW_[+AX9_]+X:_1'PQ_R+EC_UYQ?^@"@"]1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?EC^TW_RFH^&W_8UI_Z+>OU.K\L?VF_^4U'PV_[&M/\
MT6] 'ZF?_$U^<G_!-#_E,[^V+_U^6'_LM?HW_P#$U^<G_!-#_E,[^V+_ -?E
MA_[+0!^CM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^6G[//\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?FQ_P6'_Y27?L2_P#92KC_ -)IJ_2>OS8_X+#_ /*2[]B7
M_LI5Q_Z334 6/^#ES_DT3X;_ /9</#/_ *7PU^B/AC_D7+'_ *\XO_0!7YW?
M\'+G_)HGPW_[+AX9_P#2^&OT1\,?\BY8_P#7G%_Z * +U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5^6/[3?\ RFH^&W_8UI_Z+>OU.K\L?VF_^4U'PV_[&M/_ $6]
M 'ZF?_$U^<G_  30_P"4SO[8O_7Y8?\ LM?HW_\ $U^<G_!-#_E,[^V+_P!?
MEA_[+0!^CM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_-C_@L/_P I+OV)?^RE7'_I--7Z3U^;'_!8?_E)=^Q+
M_P!E*N/_ $FFH L?\'+G_)HGPW_[+AX9_P#2^&OT1\,?\BY8_P#7G%_Z *_.
M[_@Y<_Y-$^&__9</#/\ Z7PU^B/AC_D7+'_KSB_] % %ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_+']IO\ Y34?#;_L:T_]%O7ZG5^6/[3?_*:CX;?]C6G_ *+>
M@#]3/_B:_.3_ ()H?\IG?VQ?^ORP_P#9:_1O_P")K\Y/^":'_*9W]L7_ *_+
M#_V6@#]':*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;'_!8?\
MY27?L2_]E*N/_2::OTGK\V/^"P__ "DN_8E_[*5<?^DTU %C_@Y<_P"31/AO
M_P!EP\,_^E\-?HCX8_Y%RQ_Z\XO_ $ 5^=W_  <N?\FB?#?_ ++AX9_]+X:_
M1'PQ_P BY8_]><7_ * * +U%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 (Q(X YH+$=OI22,J#)[\4P2J#M;JO7F@"6BD4[AD4M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7Y8_M-_P#*:CX;?]C6G_HMZ_4ZORQ_:;_Y34?#
M;_L:T_\ 1;T ?J9_\37YR?\ !-#_ )3._MB_]?EA_P"RU^C?_P 37YR?\$T/
M^4SO[8O_ %^6'_LM 'Z.T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-D
M<(,]^PIU-*DGGKV/:@#YZ_;U_P""B?P8_8*\ 1^-?B?J(1YKR&"& QLVXR-M
M'0^IK\C/A!_P5)\"^%/^"GWQ$_:GO_#-XNA>*C:_8I183$$)R>U?5O\ P<+6
M=K<2^ DO+>*9)/&FBH\4J!E93>1 Y!XK]#/#7P%^",?A;3T'P>\,%GL8LN=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;'_  6'_P"4EW[$
MO_92KC_TFFK])Z_-C_@L/_RDN_8E_P"RE7'_ *334 6/^#ES_DT3X;_]EP\,
M_P#I?#7Z(^&/^1<L?^O.+_T 5^=W_!RY_P FB?#?_LN'AG_TOAK]$?#'_(N6
M/_7G%_Z * +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4UI%3[QIU1W"Y6@"CK/BOPWH6/[<URTLU/1KJY6,?^/$5XUX6_;_\ V7O'
M_P <O$'P \+_ !/L9/$?AF=8M8MY)T6-&;IM<MAOPK\O/^#NWQSXR\%_!O2[
MGPCXMU33)6O[0-)INH20'!89&485^5?_  3'_9ZT_P#:2^&7Q7^+'C;Q[XG&
ML>&[:":SO;/Q%<12,S%<F1@V7Z]S0!_8!!XCT*2P_M&/6+9H%7+3K.I0?CG%
M26&M:3JEJE]IFH0W$,@RDL$H=6'L0<5_.]\//VI/VP+[XC:9^QPG[3GA_P !
M_"N70XKC6=?\7K(TEPI4"2&.YW[ED*YP>Q-?3/[''[2'QS_9^_;X^''['?[/
M?[3OACXE? S5[N2W@BTT/>W^E6RCY5N;IV)+$]\=Z /V025)/NFG56LD;>9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I/
MFV^]+10!^6__  <)<WWP]"K_ ,SKHF3_ -OL5?IOX60GPQIH+<"PA_'Y!7YD
M_P#!P?\ \?OP^_[';1/_ $MBK]./"O\ R+&F_P#7A#_Z * +,R$X 8KST%?S
MS_\ !7ML?$_]MH%>/[-M\-Z<K7]#4_:OYY?^"OW_ "4G]MO_ +!EO_-: /W$
M_86_>?L:_#%6&<>"-.(/_;NE>L1KA03U[UY/^PG_ ,F:_#'_ +$?3O\ TG2O
M64^Z* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_-G_@NE_P G3_L9_P#9:9/_ $D:OTFK\V?^"Z7_ "=/
M^QG_ -EID_\ 21J .@_X.5_^4>6F_P#95_#7_I97W5\,/^2:^'O^P':?^B5K
MX5_X.5_^4>6F_P#95_#7_I97W5\,/^2:^'O^P':?^B5H W**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OS8_X+#_ /*2[]B7_LI5Q_Z335^D]?FQ_P %A_\ E)=^Q+_V4JX_])IJ
M +'_  <N?\FB?#?_ ++AX9_]+X:_1'PQ_P BY8_]><7_ * *_.[_ (.7/^31
M/AO_ -EP\,_^E\-?HCX8_P"1<L?^O.+_ - % %ZBBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'Y<?\'!__'[\/O\ L=M$_P#2V*OTX\*_
M\BQIO_7A#_Z *_,?_@X/_P"/WX??]CMHG_I;%7Z<>%?^18TW_KPA_P#0!0!;
MG[5_/+_P5^_Y*3^VW_V#+?\ FM?T-3]J_GE_X*_?\E)_;;_[!EO_ #6@#]Q/
MV$_^3-?AC_V(^G?^DZ5ZRGW17DW["?\ R9K\,?\ L1]._P#2=*]93[HH 6BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\V?^"Z7_ "=/^QG_ -EID_\ 21J_2:OS9_X+I?\ )T_[&?\ V6F3
M_P!)&H Z#_@Y7_Y1Y:;_ -E7\-?^EE?=7PP_Y)KX>_[ =I_Z)6OA7_@Y7_Y1
MY:;_ -E7\-?^EE?=7PP_Y)KX>_[ =I_Z)6@#<HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-C_@
ML/\ \I+OV)?^RE7'_I--7Z3U^;'_  6'_P"4EW[$O_92KC_TFFH L?\ !RY_
MR:)\-_\ LN'AG_TOAK]$?#'_ "+EC_UYQ?\ H K\[O\ @Y<_Y-$^&_\ V7#P
MS_Z7PU^B/AC_ )%RQ_Z\XO\ T 4 7J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OS8_X+#_\I+OV)?\ LI5Q_P"DTU?I/7YL?\%A_P#E)=^Q+_V4JX_])IJ
M+'_!RY_R:)\-_P#LN'AG_P!+X:_1'PQ_R+EC_P!><7_H K\[O^#ES_DT3X;_
M /9</#/_ *7PU^B/AC_D7+'_ *\XO_0!0!>HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQQFEI%'J*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $2M &Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5^;'_!8?_E)=^Q+_ -E*N/\ TFFK])Z_-C_@
ML/\ \I+OV)?^RE7'_I--0!8_X.7/^31/AO\ ]EP\,_\ I?#7Z(^&/^1<L?\
MKSB_] %?G=_P<N?\FB?#?_LN'AG_ -+X:_1'PQ_R+EC_ -><7_H H O4444
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M** "BBB@ HHHH **** /RX_X.#_^/WX??]CMHG_I;%7Z<>%?^18TW_KPA_\
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MG ^'6K_^%%/0!]GG]HKX #_FN?@W_P *>T_^.4?\-%_ #_HN?@W_ ,*:T_\
MCE?&/_$-Q_P3+_Z)UJ__ (44]'_$-Q_P3+_Z)SJ__A1ST ?9W_#1?P _Z+GX
M-_\ "FM/_CE'_#1?P _Z+GX-_P#"FM/_ (Y7QC_Q#<?\$R_^B<ZO_P"%'/1_
MQ#<?\$R_^B<ZO_X4<] 'V:?VC/@ !G_A>?@[_P *:T_^.5^=O_!:GXI?#?QW
M^U;^QW;^"_B!HFL-!\97:6/2=5AN'0?96Y(C8D#W->B_\0W'_!,O_HG.K_\
MA13UO?"K_@@%_P $[/@W\5- ^+_@[X8WHUOPWJ"WFD75SK$DH@F (#!6]C0!
MRW_!R;OD_P"">6FRL<#_ (6QX:"_3[77WA\,1CX;>'QG_F"6G_HE*^$?^#DO
M(_X)XZ=$XR?^%L>&LG_M\%?=GPP<?\*X\/A3D?V):?\ HE* -ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\V/^"P__ "DN_8E_[*5<?^DTU?I/7YL?\%A_^4EW[$O_ &4JX_\
M2::@"Q_P<N?\FB?#?_LN'AG_ -+X:_1'PQ_R+EC_ -><7_H K\[O^#ES_DT3
MX;_]EP\,_P#I?#7Z(^&/^1<L?^O.+_T 4 7J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+C_@X/_P"/WX??]CMH
MG_I;%7Z<>%?^18TW_KPA_P#0!7YC_P#!P?\ \?OP^_[';1/_ $MBK]./"O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7YL?\%A_^4EW[$O\ V4JX_P#2::OTGK\V
M/^"P_P#RDN_8E_[*5<?^DTU %C_@Y<_Y-$^&_P#V7#PS_P"E\-?HCX8_Y%RQ
M_P"O.+_T 5^=W_!RY_R:)\-_^RX>&?\ TOAK]$?#'_(N6/\ UYQ?^@"@"]11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLA_*OR2_X*Q?\HN_V4/^QX\(?^AP5^M]C_R#X/\ KD/Y4 6%Z#Z44+T'THH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^XH^] #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_+']IO\ Y34?#;_L:T_]%O7ZG5^6/[3?
M_*:CX;?]C6G_ *+>@#]3EZ#Z44+T'THH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8=J_\$O?V4%'WSXW\(<_\#@K]<+*,_8H=YY6-?Y4 65Z#Z44+T'THH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-PXP<
MY]*7K4:A(UPIP">!0 \L <57NM1M+:)[FYE")&,NS'  ]ZE>0JNTO@^M?!'_
M  6M_P""@_C']FGX=:7^SW\!/#<NM?$?XH7<FB: EG,%FL[@IO20 GDG!&*
M/"? ^C^)/^"I'_!7UOCI900#P%\&HK[PQJQ8[9'O6:.6)E'\0^0\U^LVDVPL
M;&*S0?+&@1?H!@5\W?\ !+S]D?3OV6_V;;$ZWX(_LGQEXLCAU/X@-)_K+C4]
MI#._^U@U],Q D99<>E #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^5 %A>@^E%"]!]** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\,?\BY8_]><7_H K\[O^#ES_ )-$^&__ &7#PS_Z7PU^B/AC_D7+'_KSB_\
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M;<&@"O9Z=;V,0M;2-4C'1%& OL!5H+CN:-J@[L<TM !@9S0"2.:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K\V/^"P__*2[]B7_ +*5<?\ I--7Z3U^;'_!8?\ Y27?L2_]
ME*N/_2::@"Q_P<N?\FB?#?\ [+AX9_\ 2^&OT1\,?\BY8_\ 7G%_Z *_.[_@
MY<_Y-$^&_P#V7#PS_P"E\-?HCX8_Y%RQ_P"O.+_T 4 7J*** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/Y5^2'_!6+_E%W^RA_V/'A#_ -#@K];['_D'P?\ 7(?RH L+T'THH7H/I10
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ K\X?^#BG_D1/@'_ -EQTK_T;'7Z/5^</_!Q3_R(GP#_ .RXZ5_Z-CH
M[?\ X.,?^43WC[_KXLO_ $;7U=^S1_R;;\/?^Q(TG_TCBKY1_P"#C'_E$]X^
M_P"OBR_]&U]7?LT?\FV_#W_L2-)_](XJ .Y7H/I10O0?2B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;_L:T_\ 1;U^IU?EC^TW_P IJ/AM_P!C6G_HMZ /U.7H/I10O0?2B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "ORT_9Y_P"4\_QK_P!^P_F:
M_4NORT_9Y_Y3S_&O_?L/YF@#K?\ @Y>_Y-,^&G_9</#7_I?#7=_\%^_^4+'Q
M@_[$M?Y+7"?\'+W_ ":9\-/^RX>&O_2^&N[_ ."_?_*%CXP?]B6O\EH ^:_^
M"L7_ "B[_90_['CPA_Z'!7ZWV/\ R#X/^N0_E7Y(?\%8O^47?[*'_8\>$/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-C_@L/\
M\I+OV)?^RE7'_I--7Z3U^;'_  6'_P"4EW[$O_92KC_TFFH L?\ !RY_R:)\
M-_\ LN'AG_TOAK]$?#'_ "+EC_UYQ?\ H K\[O\ @Y<_Y-$^&_\ V7#PS_Z7
MPU^B/AC_ )%RQ_Z\XO\ T 4 7J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_XJ@#]$:*_.[_B*'_X).?\ 12?$_P#X2LO_ ,51_P 10_\ P2<_Z*3XG_\
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MI5_X.BO^"3)N)+5?B=XD,D1Q(@\+R$J?<;N* /T2!(^\PI<CUK\[C_P="_\
M!)P'YOB/XF_\)27_ .*H_P"(H;_@DR.GQ(\3_P#A*2__ !5 'Z(T5^=W_$4/
M_P $G/\ HI/B?_PE9?\ XJC_ (BA_P#@DY_T4GQ/_P"$K+_\50!^B-%?G=_Q
M%#_\$G/^BD^)_P#PE9?_ (JC_B*'_P""3G_12?$__A*R_P#Q5 'Z(T5^=W_$
M4/\ \$G/^BD^)_\ PE9?_BJ/^(H?_@DY_P!%)\3_ /A*R_\ Q5 'Z(.^P9_3
MUINYV3*]<]/2OSQ'_!T+_P $FG(W?$?Q.3V_XI67_P"*J&X_X.B_^"4-M"6;
MXC^(T9I J;_#$@!S_P "ZT ?HKE@W)'/2EP_J*_.Q_\ @Z#_ ."45O.;.Z^(
M_B=9T 9X6\+2AU!Z$C=D4X?\'0W_  2?[_$?Q/\ ^$K+_P#%4 ?HED>HHK\[
MO^(H;_@DSW^(_B?_ ,)27_XJC_B*'_X).=OB1XG_ /"5E_\ BJ /T1HK\[O^
M(H?_ ().?]%)\3_^$K+_ /%4?\10_P#P2<_Z*3XG_P#"5E_^*H _1&BOSN_X
MBA_^"3G_ $4GQ/\ ^$K+_P#%4?\ $4/_ ,$G/^BD^)__  E9?_BJ /T1HK\[
MO^(H?_@DY_T4GQ/_ .$K+_\ %4A_X.A_^"3F/^2D>)__  E9?_BJ /T.,CL"
M%&".Y'6G!^< @G%?G9+_ ,'17_!)N&!I;CXF>)(QD8+^&) /U:G3?\'/W_!*
M6UNOLMQ\0_$T4IB#B*3PM*'*GHV"V<'UH _1/ZT5^=J?\'0G_!)_8,_$CQ/G
M_L59?_BJ>/\ @Z$_X).8Y^)'B?\ \)67_P"*H _0\TT%^Y'7DU^=US_P=&?\
M$D[2 W-U\4/$<2*<%I?#$BC]6J]H?_!R_P#\$O?$EG]NT+Q;XRO8&X2:S\&S
MRQD_[RDB@#]!"?;/THW?[)_*O@0_\'(__!->%=CZKX\R/3P+<TG_ !$F_P#!
M-;_H*>//_"%N: /OS=_LG\J-W^R?RKX#_P"(DW_@FM_T%/'G_A"W-'_$2;_P
M36_Z"GCS_P (6YH ^_-W^R?RK\M/V>6)_P""]'QJ 0_?L,_G7I__ !$F_P#!
M-;_H*>//_"%N:^$_@Y_P5M_95\)?\%7OB;^U'K-GXTC\(>)6M/[,O5\'W)=]
MA^;*8X_.@#[*_P"#EQ@?V3?AH>H'QO\ #7 ]?M\-=W_P7YR?^"+/Q@!.#_PA
M8X].%KX9_P""V?\ P6#_ &/?VR?@#X*\!_ Q/&U]J.C_ !0T36;Z.?P;<1!;
M6WNHY)6!(.2%4G%>F?\ !4#_ (*U_L;?MM?\$D?CA\./@;XGUF?5])\()'J%
MMJNBO:M&QV@<,<T 3_\ !6'G_@EW^RB1T'C?PAG_ +[@K];K!@UA 5X'ECC\
M*_)#_@K"<?\ !+O]E!1R/^$W\(?^AP5^MUB ;2(XP/+&,?2@"TO0?2BA>@^E
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G#_P<4_\ (B?
M/_LN.E?^C8Z_1ZOSA_X.*?\ D1/@'_V7'2O_ $;'0!V__!QC_P HGO'W_7Q9
M?^C:^KOV:/\ DVWX>_\ 8D:3_P"D<5?*/_!QC_RB>\??]?%E_P"C:^KOV:/^
M3;?A[_V)&D_^D<5 '<KT'THH7H/I10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M88X-?C7^R/\ LT_"/]K7Q1!\-W_;Z\:_#CQ.M@)T\/:,D"6LL('$@>1@2Y]
M*]R_8/\ ^":W[+/[/_\ P4+U/Q%X6_;8\>:_X[\/ZL/[>T?Q!IT,$6JS%1CY
M]^9<#'*B@#]8DDWG 4_6G56M6E$OED?+MZU9H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "HK@$XST_E4M,E+%2JKDXH _-+_@O
M;^S_ ..O'>GZ)\5/"?P.U/Q[+H]BUN-)T6W1IWWR9R-W'&*_+$_##]H4<?\
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M+@26$!$BX^[Q7Z1_\&H%CKJ^%/VA5\2>$+GP]?CXCV_VG1;Q LEHWV;F-@.
M1[5^NA2;:',2JVXY&>,5^<W_  0UNDT_]I_]L"SU!Q#-<_&57MXICM:11:C)
M4'EA[B@#](($91\QZ5,"",YJ*!Q)D5)M&,4 +1110 4444 %%%% ",,@C%?C
MS_P="?ME_#?PCX;\!_L[?83K'B>U\:Z;JXT2VD4RW$ D0[ I'.>G-?L,Y<(2
M@R>P-?S;?\'+HM$_X+F_#%9,H&T_1P"HZ-YD= 'E4_PJ_:B\8_M)?$#X^P?\
M$S/'\^B>,M06ZTFP@T^ ?94  P>W;L*Z-OAG^T.>#_P2I^(_O_H-O_A7](7[
M/D4EM\(=#B,A<BU&7;J:[:@#^87_ (5C^T+_ -(JOB1_X V_^%'_  K#]H7_
M *15?$C_ , K?_"OZ>J* /YA?^%8?M"_](JOB1_X!6]'_"L/VA?^D57Q(_\
M *WK^GJB@#^87_A6'[0O_2*KXD?^ 5O1_P *P_:%_P"D57Q(_P# *WK^GJB@
M#^87_A6'[0O_ $BJ^)'_ (!6]'_"L/VA?^D57Q(_\ K>OZ>J* /Y4_C9^SI^
MUA\0/#^FZ=X0_P""8_Q$T^XLO$%E?R2RV,!#QPRAW3CU QZ5TWQ-^&/[5?Q
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M$^%7AGKU.A6__P 17X!_\%9-&T;0/'W[:NCZ+I-I90+IEN$AM+=8HUY7HJ@
M5_1)/VK^>3_@K[L_X6;^VUO'_,,M^?3E: /JC_@JTRQ_\$N?V4EC.#_PF_A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?D97K7X]_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U#YHP#S4U(RYZ=:
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MOS0_X*4:#9?LM?\ !4WX/_\ !0WQI90V?@#PYX:O-$UV]MOGG-[>3QB'$?\
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M^7^S;?</7E:_H;G[5_/)_P %>Y!'\4/VV"RY_P");;\?BM 'UO\ LN?LF?\
M!>_5OV=O ^I^ O\ @H=\/M.T.Y\+6;Z38W'@^9WMX#$I2-F#\D# S7?K^QM_
MP</+B-?^"E?PW^7_ *DJ;_XNO)OV9/BO_P '$>G_ +._@J'X=?LG?"Z]T%?#
M5FNCW-WXSD222W\I?+9E\HX)7&17>GXN_P#!RP -O['GPFW'K_Q7$G_QF@#=
M/[''_!Q ?^<EGPW_ /"*F_\ BZ/^&./^#B'_ *26?#?_ ,(J;_XNL+_A;?\
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M(/\ I);\-_\ PBIO_BZPO^%M_P#!R]_T9W\)?_"XD_\ C-'_  MS_@Y>'/\
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MP3_9N^&_C+X?>"HK"_\ ^%T>&X1,BJ"$:^BR.%%?JWX7:2/1+-50[3:1;?\
MOD5^>_\ P<M?\FC?#?\ [+AX9_\ 2^&OT.\,_P#(OV!_Z<X__0!0!?48'2EH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7U.,K!%>S2233%/X0>G.:_;.VU"VNEC>TE21)%W(Z-D$>N10!8HHHH ****
M"BBB@ K^;'_@YL_Y3H?"W_KRT;_T;'7])U?S8_\ !S9_RG0^%O\ UY:-_P"C
M8Z /Z'/V?_\ DD6B_P#7J*[*N-_9_P#^21:+_P!>HKLJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKXEM8;?4/$^A)>W4%LVZ-'9F&%)ZCBO7* "B@C-% !3&+&0#. /UI]! /44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YL?\%A
M_P#E)=^Q+_V4JX_])IJ_2>OS8_X+#_\ *2[]B7_LI5Q_Z334 6?^#EK_ )-&
M^&__ &7#PS_Z7PU^A_A@9\.V!_Z<X_\ T 5^=_\ P<N?\FB?#?\ [+?X9_\
M2^&OT1\,?\BY8_\ 7G%_Z * +U%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5%/"LGWQD5+0<8YH ^(?^"UW[#]S^TY\"]-^
M*7A*:&#Q+\-+J;6M'\N$^;<3; @12!R<$]34O_!&;_@H)I'[87P)NO"?B'1I
MM*\3^ +F+1M9ANY@SW$X0LSX&<=.E?9>LZ=;:KI[V-W:I-!("LT<@R&7TQ7X
M]_\ !6CX.?M2?\$ROVH?#G_!0_\ 8P\#6]S\/H8_LOCSP]9!BUQ<7$R W'V>
M(%G*1H_S8XS0!^QT<P8\FI*\5_8D_;+^$O[;'P-TCXP_"W6UE2\B"W=C<$)<
MP2J 'WQ9W*-Q(!(%>T!P%R>E #J*16##(I00>E !10"#R** "OYL?^#FS_E.
MA\+?^O+1O_1L=?TG5_-C_P '-G_*=#X6_P#7EHW_ *-CH _H<_9__P"21:+_
M ->HKLJXW]G_ /Y)%HO_ %ZBNRH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"#FS_E.A\+?^O+1O\ T;'7])H8$[:_FR_X.:\G_@N=\+6Q_P N>C?^C8Z
M/Z'/V?\ _DD6B_\ 7J*[*N,_9_8'X1Z*/^G4=:[.@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?FQ_P6'_Y27?L2_P#92KC_ -)IJ_2>OS8_X+#_
M /*2[]B7_LI5Q_Z334 6/^#ES_DT3X;_ /9</#/_ *7PU^B/AC_D7+'_ *\X
MO_0!7YW?\'+G_)HGPW_[+AX9_P#2^&OT1\,?\BY8_P#7G%_Z * +U%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_0!0!;G[5_/+_P5^_Y*3^VW_P!@RW_FM?T-3]J_GE_X*_?\E)_;;_[!EO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7YL?\%A_P#E)=^Q+_V4JX_])IJ_2>OS8_X+#_\ *2[]B7_LI5Q_Z334
M 6/^#ES_ )-$^&__ &7#PS_Z7PU^B/AC_D7+'_KSB_\ 0!7YW?\ !RY_R:)\
M-_\ LN'AG_TOAK]$?#'_ "+EC_UYQ?\ H H O4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 0W5U;V<+W5Q*%2-2SD]@!DU1\.
M^*M!\4Z<NK>'[]+FV+$>8AX!!YK\Z?\ @L_\1/'G[0GQM\(_\$O_ (1^*]4T
M'Q#XSLEUY]4TVY>W9+.VE43*)5(()5^F>:]'^-4FC?\ !'?_ ()6>*/^$#^)
M<FIZ[X7\.RWFAR^+]2\V:]NRT>Y,N27QEN!F@#[>2:*1B48'WS217"3-Y:OR
MOWQ7X8:I^P)^U2W[)VB?\%)=/_:1\6GQ=KNLZ?XBOM"7Q+-_9J:87$MRBQ;L
M!MBD*N.]?KI^Q'^U!X$_;)_9V\/?'GX<PW<>EZA#Y*B]CV2EXP%<L#[T >O1
M[@2I.?0^E/I 1G&/RI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^7+;N"K#V8 5^Q?[27B7]G/P=X+O?$G[1#>'!IMI;/*RZ^(BC[5)"@2<%CC
M'K7YZ>"?^"T7_!,K1-5_X2CX8?L2ZTTEM<LMMK/A_P $)AG0D;DD2/\ 4'O0
M!O\ _!1O]L/0/V0?AKX(_P""<'PZ^&HU37M?T2WL+/2X92K6EF["!YL=Q&)-
MV/:OK?\ X)L?LFS?L2_LG>'/@)/XG.L-9*\YO#%LW&4A]N/;.*^2O$'_  70
M_8H\7^(;?Q=XH_8P\<W^K6JB.TU&Z\&&2>)<YP':/(&0.E?>/[+?[0'A_P#:
M=^"VD?&3PSX<U'2K/4PWDV.K6QBGC"X'*D B@#T2/..1BG4U&8DAJ=0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'Y<?\ !P?_ ,?OP^_[';1/_2V*OTX\*_\ (L:;_P!>$/\ Z *_,?\ X.#_
M /C]^'W_ &.VB?\ I;%7Z<>%?^18TW_KPA_] % %N?M7\\O_  5^_P"2D_MM
M_P#8,M_YK7]#4_:OYY?^"OW_ "4G]MO_ +!EO_-: /W$_83_ .3-?AC_ -B/
MIW_I.E>LI]T5Y-^PG_R9K\,?^Q'T[_TG2O64^Z* %HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M IDPRN<\#J/6GTR<J(R6!( Z"@#X@_X+UZ?8:Q^Q&-)U&V#P7/B:SCFB/1T9
MP"/R-?ES_P % ?\ @EM^P=\.?^"1'_#1O@G0M,\,^,X=%FN(XXLM)J4H(^7V
MQFOT=_X.0?%Y\+?\$^&BAL[F2XU+Q3965JUNA)CDE<(K''0 D'-?FK\7/^"-
M/A3PI_P0Z\0_M9_%'XU>-M1\9:+X;EO5TL^(YI-,#[QA1$6*XP>F* /W _X)
MKDG]B7X<9_Z%&P_]$K7NI&>#7A?_  39Q_PQ-\.,?]"C8?\ HE:]S'WC0 M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7YL?\%A_^4EW[$O_ &4JX_\ 2::OTGK\V/\ @L/_ ,I+OV)?^RE7'_I--0!8
M_P"#ES_DT3X;_P#9</#/_I?#7Z(^&/\ D7+'_KSB_P#0!7YW?\'+G_)HGPW_
M .RX>&?_ $OAK]$?#'_(N6/_ %YQ?^@"@"]1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS]JKX(?\%)OA1_P21\6:QK'[1^N^-OAOJWAYQ>Z;.BI#IT 8'L.0>!7Z=?\
M!PMXKM?"G[ ]QK;74<4T/B"U:S68\/,&RB@=\L ,5^4_QB\9?\%?/BS_ ,$9
MM7\;>/G\'V/PG&@2M?:>NF^5J/V?< <GUZ4 ?NO_ ,$UMW_#$OPX##!'A*P_
M]$K7NN0&.37AO_!. H_[%/PY,8./^$3L.O\ UQ6O<B2#U'XT +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^;'_  6'
M_P"4EW[$O_92KC_TFFK])Z_-C_@L/_RDN_8E_P"RE7'_ *334 6/^#ES_DT3
MX;_]EP\,_P#I?#7Z(^&/^1<L?^O.+_T 5^=W_!RY_P FB?#?_LN'AG_TOAK]
M$?#'_(N6/_7G%_Z * +U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS#(*<\@5R7_!(S]H_P 5?M7?L1^&?C/XWTG2[+4M0N;E);;1;!+:W0(^!B-
M .* /J!%"< =>II:12"*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[O\ @Y<_Y-$^&_\ V7#PS_Z7PU^B/AC_ )%RQ_Z\XO\ T 4 7J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKC_TFFH L?\ !RY_R:)\-_\ LN'AG_TOAK]$?#'_ "+EC_UYQ?\ H K\[O\
M@Y<_Y-$^&_\ V7#PS_Z7PU^B/AC_ )%RQ_Z\XO\ T 4 7J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MES_DT3X;_P#9</#/_I?#7Z(^&/\ D7+'_KSB_P#0!0!>HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :S8^7'-(66,_+C'<>E>
M6_M2?M6_"/\ 93^']SXW^*'B.WM43 M[:2<(]Q(0=D:Y'WF(P/<U^3G[=?\
MP6[_ ."I_P 2=&T5O^"=G[$'COP_)!?RG6-0\0Z%'>PWEOM(3RL%<<X.?2@#
M]M#Y9&T'KS2IND7<S8)Z>U?FY^PS_P %RM7\;>)?#7P,_;:_9_\ $_PT\17>
MDC[9XG\4)';6-U=\ )&H!(+L0%&:_1C3;Z'4$62W?< H<,#]Y3R#0!<CS]TC
MI3J11SD'BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.0%SCB@#]JO^":__ "9-\.?^Q2L/_1*U[K7A7_!-DH/V*/ARJN#_ ,4E8_\
MHE:]UH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OS8_P""P_\ RDN_8E_[*5<?^DTU?I/7YL?\%A_^4EW[$O\ V4JX
M_P#2::@"Q_P<N?\ )HGPW_[+AX9_]+X:_1'PQ_R+EC_UYQ?^@"OSN_X.7/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "OS8_P""P_\ RDN_8E_[*5<?^DTU?I/7YL?\%A_^4EW[$O\
MV4JX_P#2::@"Q_P<N?\ )HGPW_[+AX9_]+X:_1'PQ_R+EC_UYQ?^@"OSN_X.
M7/\ DT3X;_\ 9</#/_I?#7Z(^&/^1<L?^O.+_P! % %ZBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HP!T%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RX
M_P"#@_\ X_?A]_V.VB?^EL5?IMX8<)X7TXGM80Y_[X%?F3_P<'_\?OP^_P"Q
MVT3_ -+8J_3;PLH/AK3=W.;"'_T 4 6;JX6,C=T(XK^<S_@M/XUO/"G[1/[4
MWPWG^'GBJ]OO'MO#;^'Y=,\.W%Q!(ZX)W2(I ''6OZ,[BV220.RY(Z"LS4?
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M#@DK0!^/'_$6?_P59[?L!6W_ ()K_P#^,4?\19__  5:_P"C K;_ ,$VH?\
MQBOZ%D^'/P^!/_%#:,<]_P"RXO\ XFG?\*Y^'_\ T(VC?^"N'_XF@#^>?_B+
M/_X*M?\ 1@5M_P"";4/_ (Q1_P 19_\ P5:_Z,"MO_!-J'_QBOZ&/^%<_#__
M *$;1O\ P5P__$T?\*Y^'_\ T(VC?^"N'_XF@#^>?_B+/_X*M?\ 1@5M_P""
M;4/_ (Q1_P 19_\ P5:_Z,"MO_!-J'_QBOZ&/^%<_#__ *$;1O\ P5P__$T?
M\*Y^'_\ T(VC?^"N'_XF@#^>?_B+/_X*M?\ 1@5M_P"";4/_ (Q2-_P=G_\
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M_M#^ O WPJ_;(\.?#K0_^%7VL^O^)=4N;B6"/4Q&OF6YV)N#%LC&,>]:R?\
M!(G]CF0L6_X+D_#12O3*ZA\W_D.@#^C7_A[7^Q$/^:L6G_?^+_XNC_A[9^Q%
M_P!%8M/^_P#%_P#%U_.4?^"0?[&IY/\ P7.^&?\ WSJ/_P :I/\ AT%^QI_T
MG/\ AE_WSJ/_ ,:H _HV7_@K5^Q(Y(7XKVG R<SQ?_%TD7_!6?\ 8MN'\NV^
M)]O(Q^ZJ2QDG\ ]?SF?\.@_V-@@(_P""Y_PS//0+J/\ \:J+X,?LI?L0?LM?
MMV?#W1OB;_P4)\+?$OP)K&GWLFOZCH]U=PPZ;(JD1I(9$!RQ&1@'K0!_1[;_
M /!5G]CNY4M!\0ED ."T>PC/IPU2_P##T_\ 9!_Z'P_]\K_\57XY_P#!(-O^
M"(=]^SCK[?MC?'C1K#Q*OQ"UE=/BO]<G1VTX73_9F "'Y3'@BOJW[%_P;'?]
M'*>&/_"BN/\ XU0!]O\ _#T_]D'_ *'P_P#?*_\ Q5'_  ]/_9!_Z'P_]\K_
M /%5\0?8O^#8[_HY3PQ_X45Q_P#&J/L7_!L=_P!'*>&/_"BN/_C5 'V__P /
M3_V0?^A\/_?*_P#Q5'_#T_\ 9!_Z'P_]\K_\57Q!]B_X-CO^CE/#'_A17'_Q
MJC[%_P &QW_1RGAC_P **X_^-4 ?;_\ P]/_ &0?^A\/_?*__%4?\/3_ -D'
M_H?#_P!\K_\ %5\0?8O^#8[_ *.4\,?^%%<?_&J5;'_@V,(Y_:5\,?\ A17'
M_P :H ^WO^'I_P"R#_T/A_[Y7_XJ@?\ !4_]D$G_ )'S_P =7_XJOB$6'_!L
M;W_:6\,?^%%<?_&J22Q_X-BPO'[2?AD^P\17'_QJ@#[9F_X*M?L>6\H$_P 0
MXT5CA=[("WT^:H_^'M/[%**3-\5+52&QCSXL_P#H=?B?_P %2V_X(]:?\=?@
M?%^RA\9],OO#\_B.8>.Y+'6IG6"U\I]I<E1@;L=,U\D?"?\ 8+_99_:.UCQ5
MXRUG_@J1X-^'-K#XBGATK2-;DO'DEM]QVR*8T(QC% ']-'_#VS]B+_HK%I_W
M_B_^+H_X>V?L1?\ 16+3_O\ Q?\ Q=?SE?\ #H/]C3_I.?\ #/\ [YU'_P"-
M4G_#H+]C3_I.?\,O^^=1_P#C5 ']&W_#VG]B9P3'\5[3CKFXB_\ BZA;_@KG
M^Q(MSY!^*EK]W.1-%U_[[K^=!/\ @D)^QL21_P /SOAGQT^74.?_ "%5'Q=_
MP2D_9%\/>%+_ %?2O^"UGPYU*YL[9YH+* 7X>X8#(1<Q]3TH _9;_@H[_P '
M%G@+]G[X;:CK7[)UA8^*]<TY,2V>H*1&[YX"E-V[MTKX1B_X.T/^"J<L*W$7
M[!5F\<B!HWCTF_(8'D$8AZ5\R?!WP[^QCIGP'TG3K+XH:=K?C^(0AXUNY&:X
MDWC/RLN.GJ:_J!^ 7P_^'UU\$/!]Q_PA6CESX7L-[-IL1)_T>/\ V: /P8_X
MBS_^"K7_ $8%;?\ @GO_ /XQ1_Q%G_\ !5K_ *,"MO\ P3:A_P#&*_H6'P[^
M'Y('_"#:-_X*XN?_ !VG?\*Y^'__ $(VC?\ @KA_^)H _GG_ .(L_P#X*M?]
M&!6W_@FU#_XQ1_Q%G_\ !5K_ *,"MO\ P3:A_P#&*_H8_P"%<_#_ /Z$;1O_
M  5P_P#Q-'_"N?A__P!"-HW_ (*X?_B: /YY_P#B+/\ ^"K7_1@5M_X)M0_^
M,4?\19__  5:_P"C K;_ ,$VH?\ QBOZ&/\ A7/P_P#^A&T;_P %</\ \31_
MPKGX?_\ 0C:-_P""N'_XF@#^>?\ XBS_ /@JU_T8%;?^";4/_C%*O_!V?_P5
M8W#=^P%;8[_\2;4/_C%?T+_\*Y^'_P#T(VC?^"N'_P")I&^'7P_ Q_P@VC<]
M_P"RX?\ XF@#^>EO^#LW_@JRIX_8#M<'I_Q)[_\ ^,5N?"[_ (.X/VYK;XI:
M%IG[0G['MMH/AB[O0FIWD.E7GGK%@DF)6B&]NG K]^#\._ "<-X%T9F[#^RX
MO_B:_,/_ (..'TKX5Z7\*_&'A?X86VISV6NW$B:5IUE%')=$0M\@X _.@#KO
M"_\ P=-?\$V]>L%ECM?B'<RQ )>"Q\#W$JQ2=U)7H?K6K_Q$\?\ !.11N;0O
MBA@],?#V[_PK\,/AGX>_X+0?"NXU_4?V?/V6M=T_1/$^LOJ:07&BV\Y&_.,,
M7Z8-=3_PL#_@X863R_\ AGG5 >P_X1BV_P#BZ /VF_XB>_\ @G!_T OBE_X;
MR[_PH_XB>_\ @G!_T OBE_X;R[_PK\6C\0?^#AT<']GK5/\ PF+;_P"+I/\
MA87_  <.?]&]:I_X3%M_\70!^TW_ !$]_P#!.#_H!?%+_P -Y=_X4?\ $3W_
M ,$X/^@%\4O_  WEW_A7XL_\+"_X.'/^C>M4_P#"8MO_ (NC_A87_!PY_P!&
M]:I_X3%M_P#%T ?M-_Q$]_\ !.#_ * 7Q2_\-Y=_X4?\1/?_  3@_P"@%\4O
M_#>7?^%?BS_PL+_@X<_Z-ZU3_P )BV_^+H_X6%_P<.?]&]:I_P"$Q;?_ !=
M'[3?\1/?_!.#_H!?%+_PWEW_ (4?\1/?_!.#_H!?%+_PWEW_ (5^+/\ PL+_
M (.'/^C>M4_\)BV_^+H_X6%_P<.?]&]:I_X3%M_\70!^TW_$3W_P3@_Z 7Q2
M_P##>7?^%'_$3W_P3@_Z 7Q2_P##>7?^%?BS_P +"_X.'/\ HWK5/_"8MO\
MXNC_ (6%_P '#G_1O6J?^$Q;?_%T ?M-_P 1/?\ P3@_Z 7Q2_\ #>7?^%'_
M !$]_P#!.#_H!?%+_P -Y=_X5^+/_"PO^#AS_HWK5/\ PF+;_P"+H_X6%_P<
M.?\ 1O6J?^$Q;?\ Q= '[3?\1/?_  3@_P"@%\4O_#>7?^%'_$3W_P $X/\
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M%A?\'#G_ $;UJG_A,6W_ ,70!^TW_$3W_P $X/\ H!?%+_PWEW_A1_Q$]_\
M!.#_ * 7Q2_\-Y=_X5^+/_"PO^#AS_HWK5/_  F+;_XNC_A87_!PY_T;UJG_
M (3%M_\ %T ?M-_Q$]_\$X/^@%\4O_#>7?\ A1_Q$]_\$X/^@%\4O_#>7?\
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MT ?M,?\ @YY_X)PXXT+XH_\ AO+O_"H[C_@Y\_X)S0QF;^Q/B<$499F^']T
M!ZGBOQ>'Q"_X.'%3Y?V>M4 /_4KVW_Q=17WC+_@X*U>RFTF;]GC53%<P-'.@
M\,VV65@0<'?QP30!^S2?\'4'_!,*6V%[%)\06A[RCP3<%1^/2M6W_P"#F7_@
MGU?VZ7.G^#_BO,D@!22+X;WC*R^H(&#7XT^$?%'[3GP:^ =E\)?CU^Q-XATF
MZU!Y8Y?$U]!;K$"QW%L!BV!C]:_H[_8O^'G@%_V6? 5Q+X)TEY)/#-L9'?38
MB2VSU*T ?+[?\'+?[ :MC_A!OBY_X;2]_P#B:3_B)<_8#_Z$7XN?^&TO?_B:
M^\5^'7@(* W@;1B>Y_LN+_XFE_X5WX!_Z$31O_!7%_\ $T ?!O\ Q$N?L!_]
M"+\7/_#:7O\ \31_Q$N?L!_]"+\7/_#:7O\ \37WE_PKOP#_ -")HW_@KB_^
M)H_X5WX!_P"A$T;_ ,%<7_Q- 'P;_P 1+G[ ?_0B_%S_ ,-I>_\ Q- _X.6_
MV B^/^$&^+F,?]$TO>O_ 'S7WE_PKOP#_P!")HW_ (*XO_B:C;X?> 0NUO .
MCDD]M+BX_P#': /B+PK_ ,'&O["GB_7+?0-,\%?%59[B0(AG^'-XBY)QR2O%
M?>'AW7+/Q-H%CXCT])%@O[.*YA6:,JX1T##<#R#@C([5GP_#[P- _F1^!M(4
MJ?E*Z;$#_P"@UM0A5C")$$51A5 P * '4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2;E!P32U')$&!YY(Z
MT ?EY_P<(\7GP^(.?^*VT3I_U^Q5^FOAC'_",Z:0>180_P#H K\X/^"_OP-_
M:5^(WA'PYXC_ &<O@EJ_C74-'\0:=>/IVDJI=UAN$D;[Q Z+7.Z/_P %;?\
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MX4_Z%^T_[]"C_A!O"G_0OVG_ 'Z%:U% &.?!'A('GP_:GV,=#^!_"07*Z#;
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M\T >&K_P3*_X)^,./V1O!'_@F2E_X=D_\$_?^C1O _\ X)DKW%20<E>3UI]
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M<:IN_P!;WVT ?J^DBMC"]*?O'H:_+1?^"O'_  53!+-_P1T^)I8=/]+M>/\
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M.)*_2GPQJ5[K'ARPU;4M+DLKBZLHI9[.4_- [(&9#CN"2/PH O4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML,5_,S_P09&?^"M6KJ>@UV/'_?;5_34 .#CG% "T444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H(##!%%% #&544
ML!VKSGX_?L__  X_:&\ W_P\\?:%#=P7T1VEX5;8X!VL,]""<YKTAE#*58<&
MHEME!.Q-A'0B@#\8O%_PR_;N_P""'?C*X^*OP^U/5/'W@'7KEH)-*GEEU*YL
MHPQD8JGS;!@@#@=,5^A?[%?_  4E^!7[6'@.POY/%MIHGB*:!3/H.K7"076\
MCG$3$-QQGCO7T3K/A_2M=LIM/U2Q6:*YC\N=&'#+Z&OBK]K/_@B'^SS\5FG^
M(_[-B6OPR^)GVI7M?'NG6^^X@4G,B '(^;"_E0!]NVDWVE1(#E<94CH14R[\
MG=CKQBOR7\3_ +47_!6/_@EEX@U+2/C/X&UOXT?#G0K-)KOXDWUP(52+^([!
MC[O _&OH;X)_\'!O_!-;XK>'M'EN_CU86.LZF88I=*:)R89Y"%$>?J0,T ?<
M3EL?**Y;XW%A\%?%^\?\ROJ'_I-)6M;>*-)U"SBOK'4X'CGB62)A,O*L,@]?
M0USWQHU2"?X,^+T\^-O^*7U#A9 3_P >TE '\Y/_  08_P"4MFK_ /8=B_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 & >HHHHH ,#KBBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ !S4<R>;"03CZ&GJ",Y]:9<%O))C]* ./\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "F2C(Q3Z0@$8H QO$G@'P=XVMOL7C7P
MAI.KP9RL6I:=%.H/8X=37/K^S7\ PGEGX(>#L#[O_%,VN?\ T77=#@8HH X9
MOV=/@(I&/@=X.R/3PS:__&ZZ;PYX7T'PK8+IGAG0K'3K=%Q';6%JD,:#T"H
M *T\ ]11@#H*  # HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image011.jpg
<TEXT>
begin 644 image011.jpg
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MCS0>:3S2>*3Q2..1QB.-1QJ/-!YI/-)XI/%(XY'&(XU'#LA9ZQ, C3+P
) $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image012.jpg
<TEXT>
begin 644 image012.jpg
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M#@/T!&-F"Q<L%&08V@I*V_BZIFF)]6"E"2,_LG5&_T$.^&J( [X?MA3_'NF
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M6!FV$R?.)J*T_(FYMMM;K_C!(YPXDX"U&_="O78OYB[?@XFJC1BZ,!C_G1R
MC^T]+1B.&?!^.4MTP6AD,-;/UAU?#76#U51O;#T4A[KZ%SV]&8F(B(B(B(B(
MB(CH'2=>[5/RX %N9]W%U9N9N'#EADDE^5HZBAZ6H?G5*]34U**@L! 9M^\B
MY7I&A^$NBI)R#?=R"_!,X>NHGDK#W<TMU/G9@DG!V/G4+,SQWHRO1WC@H\%Z
MP@9]-_[; H?6]WXI"">,"!4,GK<N6H-I&T:$8I\.<L9?4Y=A]>887+]3A(SL
M(MR]7XA'94_PX@5;^+02+>4>EI8C)Z\(F3G%2+M=@"-GDA"VY0!FJ</Q[9AE
MNK>U,2T!6P,Q0]Y1IVM;*PE.C0UE]0S[B9T[?AOOCNE+_7#XQ'EY'1(1$1$1
M$1$1$1$16=*C1Z4XGW 1&[;LP+*@""ST#C*IN*X,Q^F+5]#0V(C<O'R<.!F+
M\$W;X;%Z_3_#>:W!(J] +/9<A1T'8U#\L%31O!8_*L..PZ=T?K9@4C!V.NDV
M1CE%X5]6;E)1F2<8,R2LL&0PIBW<T/'Y_8?[X#^35L!F=B!&+PZ"R\JMB$^^
M9<JJ?>^(;A>+BHMQ^7(*(G?%8);/-@Q:$(8_9ZZ1UFT /I?6L7F",87CO0'!
M6!]K%?K9NN'K4;[X<U8PQKE$PL$O$L$16Y%TY9I\T" B(B(B(B(B(B(BLJ3"
MHB(<CCX*[^4K,761"G^,G==6?A=ES%S-S['S\9M4?I=+ZS#S.PPORK"9SM@5
M'8OG]2^0D7D;6[;M@(NW/T;/<9;'UQ3-=/\8/1L!ZS8C.Z]0[SR^:&A 9645
M+J?=A.>:J';3Z5@$DX*QV*3;&.FX00[%>EDRT-+7FDS79UGZ757MBO7L(+@%
M[D3D[I,X%)N$2VE9*'[TV)15^]X1[UA[^O0I'I66(N->/N*N9&'?J12LVQX#
MMU7;8#MG3=<AD[&!IR$!JL[6A09TSZBP?&SKBJ_LG3#.82U"=YU![*5T)*9F
MX$9ZEMS:KKGY54]O-B(B(B(B(B(B(B)ZQQ47E^!8S GXKPK"K*7NL!H[MZT,
M'#,' \?.P9]2$6'8;ZVAV.C9^+/E;^V'MY;*R)F.V!-]2NX537<PUA*PC9D+
M_W5;<"]7?S!66E:&E"NIV+IK/Q:X![2%=&8+QD3KGH:&!AQ/N(GA#E&&M[XQ
M-AA3&EQT0SC62W1M-\0'WXP)P,+EVW'T] 7<R\Y&=76U,:N4M*BNKL'MVUDX
M$G,62P.VX[MQ*_#%"%^YV\X/;#3;0.>^I*25HC'!F+'[IX+]290/;-3H/\P7
MWXX-P&^3_6 WPQL!8;N1>2^_IS<'$1$1$1$1$1$1$;V''CYZA+CX\U@?M1%N
M/BLQ<:Y+6QD[RQ$CIBV"W>0%&#A>$XK]*0*P<7,P=,I"C)OMU&%X4>8Z^>#H
MJ3BYE5?G8.SW<=)T)BR$U<1%^$OZ*<(LWY#-R+R7BZ:F)KQZI;W!2';.?>S>
M=T":OP",G^^F"<;&F#$8JZBHE#XD!QOWG8'MO) >"Z=TAV,*N\PSX3,^M//"
M!/>M"-E]'B<OWL3=G (\>2+>(\;W/IF+6)?EY8]Q)SL7L=(ZCCR8"*=5NS!D
M]G+\-%J-CP=WTWZE-$S3U]UB%Z6WE0I];5SPS4A/S/3:BO#]%[$U^@)V'SV/
MBU?24?:DJJ<W!Q$1$1$1$1$1$1&]AT1O;WEY^4A-NX9S"9=P..9L6]F\ZR!6
MAD1@J8<_1LUQP9_C%L!^RB*,F[4$GBO68L?^HQV&%R7F]'G<S<G#RY?-KP5C
M(A ;.]<%LQT],6JV,_X<OQ"JE6&(3[R,AP\?H:ZN3NL\WLB\@\#P+9BT4 7[
MJ4OP^YAY^&W,//,%8WGY^7(ZN"QD!WZ;NN+-",7:P@D#NUTT*GAS1_\1RQ"T
M,PY5M75XV=PLIY2B.T R+[%.Q;IMEDI34S/.G$^"J\\:V$_WP("A%@R]=+UC
MS)!@S(!P[ -K-WQJZX0_)GEARR&1E#?)!P6Q;S5SWR(B(B(B(B(B(B*B'M)Z
MG[ZUB%X%6TMA81'B$RX@;.,VS'3VE5M[C9OM@/D.KC@0?0SECY]T&+ZUO&JY
MY]TY&!LT90GFNWAC^<I S'+TD(.RQ5ZKL??@4=RZE8['TO2T24I+AX-?"/X8
MMT .Q7X?-5<3CIDK&+LL?4!@^$Y,<@S"=V-\WZQ@K"T<4Q)>&#[M :.68YS;
M%OAOBD7"U6R\:&PR<E<B8]S+R</QV'A$[8J!?]11S%ZV"[],[>+]8TK#,7W_
MU_4[O<&8[F%[6:G0V\H-_YL6B#G2,GB%'8%?1#3"=I[$E5O9<AA&1$1$1$1$
M1$1$1/0F*RDIP84+%Q&^:7M+,+8 8V<[8*&C&PX=/8Z*2OV]H74.Q@9/78(%
MKCY8&1B,N<Y><C V89$'/%:&8N_A&&3G=GSM4&MHEYAZ$TM\@V$S>3$F+'#'
M'&E>1LUVD8,RLP1CT:>3,&'Q*OPT2O5/=W;:PB9#W@UFD8"L\_QH"2X,_/S?
M9ZZ5N_0K+JM"S;/ZME23NL?S^A>HK*K!@]+'R"LJE=]S-]5SN\*PRK105.=^
MWGE_;[]OZ9B.",7Z6KMBFL=FG+AP$WG%Y2AZ^ 2/RJOPM*Z>+<2(B(B(B(B(
MB(B(Z(UGB6!LD<H7JX/68IZS-VPF+8;UI$48.MT!GJO7(^5Z>H?Q12CV\N5+
M7$BY+@=CPV<YP\UO#4+"-V*^FU_;>\I,#L9V'4N$U;3E^&20,SZP4>D)H=Z
M8$SKYRD/,%K+-V,",'1)!+S"CR/IQGUC5AN9T2NY:\4FY!26(NK@14Q6;\-O
MT]>@GZT;^EB+?;+3?FG.5HQZN^G4O5]];.^-/V>MQ12/K9CNM16S?;9AX\$$
MW"\JE9N.,@PC(B(B(B(B(B(BHK>)N8,QNVE+Y6 L,#@$#FH_C)OK#/NIBS%P
M_#PL]@Y$8NJ-#N-75%3B;G8.=A\^@9FN_ABWT /K-N[ J3/GX!VX'@,G+C9/
M,+;UZ"7\,F6E'(KU:@V:=+;*,B(8,R2XT#I^5^\8ZR(8TS+ND,41<@!SXTX1
MRBIJC5EM9$:MS2-%ZZKLPC*<O9P%Y\ ]&&#O@@]M7=!;A&.F!&"F!&DZNE+\
M;FP U.N.X/R5+%RZ=@\IMW)QOZ@,3Y]I6H@Q&",B(B(B(B(B(B*BMXDE@K'%
M*E\$K0V%E]]*+%7Y8,I"-]A.7H1%WD&X>*5C,)9Q.PN[]Q^$1T 01L]UQ31G
M/QPZ<0[W\PJP;NL^6$]>8IY@;/.1)/PT:;7V\,M<P9C2,$)7,-;E>#JZ4NST
M_[ZV[OC4SAUS?;<A^4:.YJ5P?/_3&Z?VV7/LB4G$!,>U^'/:<GPUP@,?#5:A
MCTT/!&,M^]<7(_SPR]1 #)P= NNYZS#-:P<.G[N&Y\^?RZW=&(01$1$1$1$1
M$1$1T=O,W,&8?;M@+#0L'.%1F^"V;+7<1>)<]2J<B$M$=74UZE^\D,>_D'09
M7@&!F+S &8.G+,(<]Q4X=^DJ:IX^P]8#)V S9:F9@K'HEF!,7Y"@[5UC2H(R
M7=-4$HCIFXZ1P<B7P]SQ^P1W> 5MQ\W;]^50C('&FZ>QZ27NY);@9,(U!$0<
MP.@%_OAYM$H.-4T.QHP9STJT,@S'BDTGL/-X,O;%7L7II-O(*2R3^SMEN$I$
M1$1$1$1$1$1$;SM+M1A;&QJ&@X>/X,K5-&S><QB3E_I(Q1L16W?C<LH5E#QX
M((]_,BX1\]S\8#]U$:S&S\,<E3_.)5ZQ4# VL9N#,7.W*E,XSB_C/3%UB2\B
MM^Y#=FZ!,:N+NEEBRC7XK ['J+D^^&&4!_K:JM';A(!+2>ECHY;?(?;Y"%]\
M,6(9!HST@TO005R]E8W:VEHT-C;V]&HA(B(B(B(B(B(B(C(K2[UC3+062[R4
MA*=/G^+<I53,<5^%D7-<Y-9CVW;NQLU;Z7(#E,.Q"1BWR M_CIL/VTD+L,1K
M%1*2+=5BK',P9DHQMKLZ8UN#&5 FND9@R[Z32+V>CB<5^C<@O1D*BAX@/C$%
M85L/88XZ% .G^N"K$9ZF[Y-Z6I%]-7HY)JDV87G4,01N.XW0/>=Q.BD3):5/
M\.+%"[D+3B(B(B(B(B(B(B*B=XDE@[%+2<FHJZM#7-)5.1@;-&4I)B]RAT?
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M1$1$1$3ODQ<O&I"=<Q]GSL7C8'0,-F[;BW4;=F+-^JT("-D,[\"-<%\1!56
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MZ[B<DHI+22EMVS#Y\A5D9MY&86&1W-T;>Q6BM]GC)T_D@"(V+A&1NV*P+.P
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M\784Q\9&Z?C;W,QC(G4/<;QXV=PL?P]M.\>WVS]OW\W!X6,GL6Q-%(;-]L$
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M9K66(GZODH.VGR:M0/#.<]+VKY);V+YL]VZMMFO*NN?R$_]B'SD0<QY+/-?
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M%%8@:5,.)@2FHL>04'4^&-49GO*W)[YQ"89KQ!ILSSJ,DHN7\>2I]FK4F])
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MVO.J=.T7(,M@9D0Z<L]=-FP3;*1,)%8XE',* 0N68=3L</SU3P2^<@E]<RH
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MQ74\>/A0'M/OSCZ$N6$IZ#' 5[XWNL7=X-3M5,"0TK]Y9<HJ)R-)*J6Z>&(
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MH3D[$TV]8XQ63XWJMUZ_1<A,M#_DX0OSMY5W<RGJD9Z=4K5E"KN_FWVW:[\
M?#L\'#^.62 ?L?VILR^Z.+TZ_<4,GVF&?'AUQDB]FG(Q:@M8Q@Z-SQ)YM>OM
MB1^'^6/4K##$)*Y%07&I "_[_A")%QX\>H)5VXZCS[_+\/6P^>CLY$?O^[7L
M@YKO%8DA+9^G]C<>/(GPI[P^AN8=$3['K)BAM]>K^5!/R;;ZRXE7LBMW=TYQ
M:ZO_>T-<B;$FVG.L&(/F)J+Q(G!//F$;28Q1@=QZRMI4NO?WQZ!_%\(G(@F)
M:;NP)Z<0ATY=0$[>>12<+\?UFEOR! A9'6PC&]D(J*UKP-F2<JS,R,($CT7X
M?J K/G%RYW=,UBXB!G!,=E/E-Y'MX UD:))BPGFEXT=X@E'-9Q1\BV*;WO[-
ME,28D<!.[3T6^;#Z8RHY"$Z,J<E'A.[KQC=ZSW#P7*_]/+K/^QZEC1KAN0*K
MI0'CV0M7<;OA@0"O\7X0&4R3Q68/'CY"8>D5;-U_&JY1Z?AF>)A8&\DJ<]$V
MVAKMMF;?S!Q8T^!+U/O-_9E=\W]_N(FQ_R1,7KEQ!SGYY0A+WHW?)D2SV7$:
M?6.)X?2>TXU7#.B1DEYHZ1?KL6TB$F,T_6?NM_+B)F:>4?.!IA\"$F,6=;P3
MB3&C?69YGN<WH_(07:^:'5?#L!JO:&1(LQ"2IM]M,=Z@:8]9>J'$K[?^9F"G
M,D=BK.G?Y#C%GUS<,3,@%OMR\N2%_[93L2 GQ,Y?OH&=1PHQ,R(=7?L':,N3
M%2=M+3'&:I^-VG1:VT03*^G:-*-\%-1'RM)K="0"XW?@L.2#R>+3%R]>MC8<
MWFDRE!@C&<I!<Q/PO[\]%,"EHQP\BL-J4 PK*4=B37JG$[E;8W @?AL3AC[3
M8N#BEH2QWDF8ZA>'\+@T',@YC9LW;^+APX>BY&@C&[W3E'NF!*&Q:1@Q)PH_
MCPA$5T</=+)G3+93#< H!O8\=H,W2.!]AB8 ,/(=,PMK4*\V&&.JCY(/O,]2
MMD5X8JPM#"1Y TN:P3:KS'EL F\?67X3;1M8Y<!C;XSRK0GGK_[]S= P])^Y
M#&%)N^3DF(T:Z>7+EWCTZ!&N5M<@)?,PAKDGX9=QD6]VBFG*E7-7+@M>K>DC
M:/TS#S\4,:&5'&?X#BT>5+]A<+>SB%A"[_NJMOI->5\28V1B8?OA0DP-3<-?
MDQ?CDP&!;_==U]8R+@+1^PZO#K+$-;2RY_)-.OS@]:&\OQGI?XM^:<E/1!V\
M/*?3!5..4M0J9NN:FER,RE_4.Z+\*:UM4<,>2T)+!(Y:?$^M70KUL.J$*-GK
M\E:'5S18YL$$+3]8%AW0V#:ID'F9;DZ>&#IG"3)VYZ"NKDZ.7S]D(HO;KM;4
M(S'C"%S<EN.GL9%R+*2KURQ8UL(B:W):!,XMXQ06'+!@FN9]O;8KXD9YARLS
MKWCE*+"0)"PYLO:?@#78M.\L'CU^UMJ0>*?)4&(L.[<(HSP2T+6/)SHY6()4
M1TE$!QN:1H.W+I6 5_,]9;!U<7!'C[YS,6!J"**3-^%@[EF<+BQ#:64M+EZ1
M2N4-5%V_A=OU=^6$F6TWF8W>=WKYWW^XTW ?%5=KD+1^#_I-"L'G3O/0V9YB
MIQAO\&QV8LP,6\;R&ZO]:R5';FBW2_-!%>LW]/C ^RQEOX4FQL(_H,0831#+
M:Q-X^\CRF]&!CU$Y\-H;0SRSM+6>^-]?'N@_(Q9KMQ_#52G>N7O_PUT<1 ;3
M)"EV]_X#7+Q\#7N.Y&-F>!HZ._DRR)7C*+*V[".4<$[35AI^J#VK.*CG.,F"
M%9]V%FVA:K/&[[QMY;'5*OUXUQ-CY'Z0VCOW472I&H$).]%C2(B^[%3UBI:W
M&BO!C23&U&(:7K]BQ(_2S@D8T#W=WUC;3/,=LQ)CM+99[YL4^M"F$V/<,A-\
MXH"H]T3TC:5MHA-C1MNLU386W=5MJX$);]:V:\E8K1^L^L"#*9;84$L_5-KT
MYX1H1*[8@=PSQ;AVXY8<SWZ(]/#Q4U35W)$WBDP,6JO/8Z/X,HIE43AO$:>H
MQ3 ,.DW35ZVVTGQ'K<U&>272MG,6DB#S7K(%^>>OR#'XTV>V/ (/&4J,'<LK
MAEM8$GX?X87/^UMAA0:-HNJ"@4+1:8%,"W:I=+#WP$<.;NCIXH\!,Q=C2M!J
MS Q?CWE1F^"Q* />,>F(6[L+^PZ?0%E9.>KK&T3)V$8V:I/T^,DS'#IQ#@L2
M-F*LQU+T'.(K8<1=ON15%]MMJ9B].HTZ$.;@DV6@0&M;M?XN2E9Z@P&6-NG5
M(:*M%,^9GACC[0MO4*<VL-7B+\^@E2: INF7R,!5Y$"'1Q8LDZ\\/!6E TWE
M[\8CMW\8$8I)OHF(2]V!,T7&L?"N$CE^AJRTO5!^%<LS#F%BP&K\.7&1%"OJ
M3&;HZH7.,ZSZ]=9[E+(VI$N<NTM8=5DS,<;)0Q[?0_-.<][S\%2W#92+A73*
MNYX8JVMX@,W[SV+NP@SYCI N9->FTN2'FJZPV%06/:;U;THRUXN;-/6<,>EN
M1E'CAZ@X6%0,959?1?%<Q8:8<I0B2[]HVLS<5\Z=QSSZ0BM/YF0Y[;-*I5G_
M%7]7**;KMIJ?I?!KM&UELFW-ZF>2HP%]T/JN4%Y;Z( )[>@Q.!C.LV+A%9.!
M_2?.XP/-B^%"10T2,XYB8N!:_#(^RGP\T6"&*:[4*+0X>_UW@PEI%IPQ]Y$W
M?N;@H4%L<;5#*IT<?>$P=3'F1*1AXYZ3N''+ED?@(4.)L7/%I5B2N 9C9@7C
MQV%^YAD"%D#1 %X5T)23?#3!*T/]'>W<\;'#/#A/G8_(9:G(VG<8I645N/_P
M28ORX-%3/'[R%$^?/</SYR_D%<?__?>?('6PD8W,I__^^W_R2H8;-^]@Z:IM
M^'6H.SYS<D5'>P]][+6FC=&R&]:P;68,FI4&4BS?UK*[9MEOEO;0\E64C'2>
MLTIBC)?WK/Q@\9E*[XEJHU']-(H=HWK%T\:W5@A:4>:J.D#?CH\</-##:2X&
M3@E!^LXC<H+H0XMAR.K:AP\?X7K-3>P^G(_Q?BH3BJS8II$GK<RU=FV*PI"J
M/FE\4YC]YTR,:>'&".YIV\O#3\U^4.S2HRP=[-_-Q-C+E__AT9-G*"J[#K=%
MF>I\H)$Y"TYI?V/R<5J[F#16=O/H#J-^<!6C/I]%#B)C0E%]%=5G%7E:)3'&
MJS-*.DOUG@8&C.HPCWZQQDE,SRH5G1T<HN(_(_*@^4VM_;1RT<,2K7Z)\OE:
MWQ7&:X9^&6V']'S/D>%8MN$0'CQ\+,_K?"@[Q\CN<K);;-?18@QU3WX;KV;B
M26NW(HL\>6V"YF^"=F&)CK.X_0AK'2IM-&HW*)]M)Y4.O3W0J;<K9H>OPYF2
M2CFN??'RPQI?&R5#B;$;M;>0>S(?L:NW8M"L)>89 B/ IG7^O,_I.EW]=]H3
M1;9WQP_# C%T=@QFAZY$4-P6+$K=WZ(LSSB(S7N.X,BQDR@Y7XJ:FAK<OW__
M@YM8LM&[2_5W[^-X7A%6I.W ))\X?.'L(1\UJKA3C-6)6"-1I81S:]LXL^L0
M87]9Y"?:CIO59Y;W%7XSY8XQHWP3P0>C\F#E-TL]1O3)[**%%5I,B=!=H_Q@
M^$X'R<Y_[.B./\<&8_'*K;AXZ1)NU=5],!=XD\5,SYX]0]&EJUBUY2AFA:?A
M]PE1UM%'9AMO<42+81LCZ-@F7EO B@-6?%+SE?,],_2@N5P,[@A\5Q-CY"BD
MK0<+X!^W'4XSXK1UR8BO99$-BUZ+T&5>_>'%L*BZ#.N^B;)DX8=>G7I_I_V^
MQ=^MNF/,B)Q$R-FH;K'J!Z]>L;2+]MM&=5R$+(SPD]:6\?++:+T\_!%MVVB^
M*=+62<]_-C 04P*2L29C#TX77,##1X\%>.2V3\1FKMR6BYD+TO'3V(7F^ U>
MG16A![QV360?>?#-^EW:]WF_;09?-.ILU]M#3HXY3HV![Y),9&;GH>+:K=:&
MRSM%AA)C9)4=V;ETNK@"T\+2Q!H"3471&,2]I3 &5MVP*BP+8"PF!]J]^HT<
MH=.YCP\^[NN';OT#T'U@T*L2_+K\/C84D]PC$;DX 5NV[4)A81%NW*CY8":5
M;/3N4T75=<2F;,3 "=[HY>*-C@[>KS% [9P4':?&.<M,N!:T@HVE;J5V:]DV
M4?V@L5<L\E"T=Q3?-1*D,?-:X1F6U=$LP9#%,\(38VIZP<)':P1UO.^SZ#Z-
M?O'BPXRBMUN%%P,L=2K%22:O[B6VOIWTC6^'!L,C(@5[]F;AXL5+>/KTJ0#O
MTO:)W!]+[I'=?C ?PSV6X^/^_NCHZ"->UD;Q02-S&CVUU"M1N#-JMQ3;KI$
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MS<I/+1[0+!#6X:%5$F-&Y:7TFQE\I]5!%I_-Y7,Y^&08![3O*/CN%GJFLIA
MC^=J]I-&9C3OZ?%<SP;HM9G57O#(CO995MG3?%NA7QWL/='=R1T]!\Q#5/(6
M5-?4R2=8O8]'*CY]]@)%EZYAR_X\S(G<@*^'AFGPF#/&I4V,T>J#INY9M%'+
M']+H$DT=U%@6K/N\F--K(ZW=86V;'E9U\AMDYUC[WNYPG+P02U9MQ^G\(OGH
M?AOIDY#$&#$4<Q:DH:.]&SK8>0A0#L:$UNMW#*P6,0H2&F-!"WZ- **CO1>Z
M]O5!CP%^Z#DT&#^-CL"OXQ;BSXDQ^&ORXK?*WY-CT&?J0CA/"\<4KV@$1<8A
M(3D5F[?N0$Y.+DHO7D1=79U\ ?S[Z,1LU+;H<N459&[=!=_P./2='(8NCIZR
M/O-AF7,WE CG989MT9J44G6*G+O!>/FH^#VE%?8T$_X& PF]X-$,>6OUN84<
ME7XS,S'&X#.Y T-!P1^WKEGPGZ4_-'Z9E2\\&%2J4^V[6A@RRD>C_6)>6=CR
M>;)#_K,! ?AIU'PL6W\ =^X^%.!EVCYMVI>/8>[)Z#DB'!_W"]"T%[KQ(H_,
MM;[#K5\&5H4:Z2-M72Q\TK432O9'R0^RU,^!=\,QAV7Y\!)C>X^58%) *GX<
MM0"?] _4YZV:[^&)/6CU3006>>P^K[TQBEVC=:C*SH"L7K]OTLIPK3;2]%W+
M)FF];V="8HQ7/F;K"0T_6SRC$(N9@5DC[POW Q3]8_55+?328+MI,6PD1J?I
MLU);K"$SRV^)^ X/[^P:3X#HZ-!X=W#@LBVHO'937FS_/E[OTG#_$59N.0+G
M&8OP_8@0^80O+EFWIE^EL7NTF-.S?[PVA3OV8>@'2Q]IWA>-:=JB4G\[^;^>
M^,[%'V/F1" Z;B5.Y!6T-H3>"1*2&".K[N(W[,?0><OPT^AP><+#F$*\(XDQ
M6H5F,4@"C2C9O=?9W@W='.?BEV&>&#3)'Y/=%\ G/!'12>E8E9&%;?M/(>M8
M(8Z<N21/V"J5G+/E.%%0AKS"2RBZ4(ZRRU=PK?HZZF[?QH,'#^3[,FQD(S4B
M^D'TY-BI H3&K,3@J<'H.<3/&):;GF/!A0B'9:9]85J9;R Q9F=1I[428[TI
MGZ&JGV*P*EKF6GWNK?*;Q?MC_&R),7Y=:\Y?E<E)+@QPZ@RK_:'UZUKX-CI@
MH-(/!OO+\CV5^LDQ).0H[AV'"U%:68/[#Y\(\#IMB\A*T\O7ZF3L>R_9BB]=
M0I5YHR5K9OW4T7>M]YAUBV(7& T&1,?HU.,'E:+XC-HDM,[[NORCY)DH7BGV
MV9B-?Q<28^0B\JLWZG"JL SSDW9*8]8%\B1".QK=4>(1;^Q!JW/,<C60&%-J
MHQEX,ZJSO.W@E55SV1M>U,701MJ^J]DDK?=?_=N6&-/[F\Y8P_)]H^VVYGM*
M_3%BDZAD3QDWLK99\3F#,3K+;ZQ]$AGG&/V.&N\8YU0G^*_&QKTG472Q"G?O
M/Q+@K=L&/7[\!%>K:W#TU#FX1:Y%USX>Z&#GKG\%B)J,6/5$I(Q9?8N:GE/;
M3X[W>/I,BT&C\0&KWS8B(Q[;;/&W3_IZX=?A7ICHM@"9NP[)Q_B3.5G;9AAU
M$I(8(T?@%)==P^9]IS$U9.V;,]JU#*N2\F@%'[P.2Z2!87F?MOVBVJ;P'3+0
M(\=;=I0,>'<)'%\/],&/PP/QQ[@P.$Y9B $SEV*H6R)&>"9CM.]*>3>#4AGK
MMPK3@U; -30)$;%KD+(V SMW9^-T7CXJ*Z^@H:%!A!K9Z#TEHA]$3S9L.XBQ
M'K'X>I ONCHIK+0QZ@Q?%\;!:_/WC.)/))9I^BRJC48# +6_\;2?-K!2\R$T
M23?:@):Z_]J3_TWO"4^,Z<F NJ\Z25DS]9CI'9W$F&; *&"EJIE%L=U*DUL"
M[)31V(I%7CK/M)>>^7EL)(:Y)R$^_1 JKM4)\#IMBVXW/,2Z7:?D>.J/"8O0
MI:^_!L\M)^($3,8:T1VM 9BESS436WKX5N0C0Y* RK<(QH=EO:*_K<0;2[T2
M*"^2Y&[KB;''3YYAQ\$SF!VV$DY3H_&I<\";I)B:/$3K3@L]%2<#31VCT0LC
M^DL3=RG9#E']H8D1>?J@Y)=Y=EBJM9FWST:>>55,.4I1+9;16P2BIA\"=K,:
M]E4TV-=\7V"=(HJHN$)'OQ3]&FN?6#&M%]<JR86E_8KU6>@I39MI[1^+W:2.
MCQ3XP,)#A=]^'!6.8:YQ6+HV"Q<K;PCPUFV#;MRLP[8]!^$7F0CG:1'HY. I
M;SQHIVG3K.#7:;%#*U<1[QEM*Q5F5'@MVI\::;N9O*+ED50Z.7K)\__V$\,1
MOW87JJJNHKZ^'B]?OFQM6+59$I(8(YG'%R]>H+:N ?.3=^,C)YW$&*W#X06)
MVF]&E94WJ!$5T(IJHQ:O%9\E9PB[X?L!<]'_'Q],=9^/D*A$I*S;@MW[C^%4
M0:F\&MJRD FNRNI;J+I^"S=JZU!W^P[NW7^ IT^?ROIBRUB_WT3D2\KE*]7(
M/GP"P;'I^'U\I'@,J VDF-\5.0$I ,MFUL%B?[5X)NI]FN]0^0-!.X>9VT@Q
MV+8S.3&F)5?=_NKL6#!#G[GQ3ID8LU-XQQI!JTA^M.BK8!M%H^>\O&*8>)<'
MF7^[8X)_"@X<+Y+OHWSZ'NQ$?_;L.>KJ[^)T43GF+=S(J=^B9,[Y'2J;W 82
M8XIX9]QA:M3G&>D;33M$R$ZT7C4K;3DQ]N+%2WG\45%U'1&)F_'U $]\9.\J
M+QZDEJLIOYDT0:V)#\'Z11UG6!8S;1)#'S5C!Z6Z.)(U+#$RJP[Q//.JV!)C
M OA/Q?,V,'FK) ]3ONVEW%?>_K#@FM4.ZXTGJ+^MDQC3>H^Y_SJ;#G3ME^4S
M&G$2 X^)+^UDYX;) 2DX?O:2//G^+A^I2-I/=M>47+R,!7&IL!_EAF\&>KS9
M*::;&#/9K[-@AP6#1GV5T;:RZ![OV-Z,_O#$'J+DJM..KX>&PF-A&K(.G<#%
M\BH\??KNCZ_-(F&),6+\;M7?1T3*'G3IZPN23'DM("V!F:E(:M^TIO** *>H
MX(VS$"?PD4/C!9O?#O+&'Z,#T6]*.$;,6XK)_BLP.SQ-/A[(>VFS(OW;9^EF
M!,9N0GA"!I:OVX;-V_?@Y.DSN'JM&O?NW9//(;;1^TO$)I $:/:Q0GA$K4>_
M?Q>CQZ @<W66!=<L3I@WF+>J+6$(L(WP3VO@RMI&D3*@"?YH T2]@1&337Z3
M'##ECC$J&=&VE>([>KIA39W7DTV3?AJ1'VO=S/I!\9X1&\2CQV]AF[8N'6QK
MV@L2+WJ@W_0H1"=NP,$CN;AV_=U?<5I=<PO;LX\A</%:J6^+6@\G9B>M]'1-
M3U=HODM;'Q/>+":R='57H4Y+&],:,K;$*ZO-%V07VW)B[.[=>\@[6XC4]&V8
M[!LGKZ(E=V*WX_63FOH@0)ZMI4M:V-+T%PR3P:+:9Y2O+')M\2SC[A">.LS@
MF\7?K':4(G7,T>P9EG>4Y&,MOM+J*Y>O$MP/HSIG3;[2^&%JO)K=1I5QL)DX
M5[/1S+9(0.*Y=^,"-^)3Q_DD8U_N.=R_?_^=OFKET:-'J*VMQ8&</,P)6X&O
M!GB@FY/GVSO,C>H,S;-FZPQ-?2SQ@.@VJ;YCQ<6NHF.ZMWXS,#Y3]'TM>=*U
MGS_LIRS"M*!5R,P^_5X==2J:A"3&FHA<GAZ=FHW/!@6@8Q]OM+.W$)JB(S-Q
MI:EJP*106@W8>H!A_+:U VV-^CM*#K*;XSQ\XSP'@R?[PM4W#"FIZ3AY.A]5
MUZI1+PU4GSQ[_J8\?8ZGTG_)*NOG+U[(JS5LN\K>32)),;(BX=Z#AUBV_B"^
M'QDA1K]%88 &_UIV@JH.AE5=AOO,L%/*J+U1M-\T]>L,&E@",KUG:&2F.:A6
M^#N/S[#@S3N1&-/UV3H\:RW_HRASAMTBW+K'N$)43U:\[6#1 2J[Q[HBGF8G
MGX:]D'[_8:@O1L\(P**X%)PM+!'@B5J'FA:+%9POA^_"%?AQT&Q\ZN1J3)[<
MN+#";BZM?JEADE4?M?2;"Q>4N\KT[!_K:FM1\E1L*X>L>>V60FG+=XQ5WZA%
M6L8V3',+0N\Q?NCDX*W<?Z,\,RI[&@RQX(2W?M9V\"2)1/*(I5^BL,#C^P7B
M303/K)X88VFC%H]H;+(U]<NH[FGIEQ7T@*D]5O-U+$5KO&W.[AVRJ**=G2?:
MVY-%(=Z-Q=X;[>U>G8)@Y_7VP@LS^:/&,VK^BN/1</<D9.[-Q;7JZ[C_X($
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M"9![]'/'KT/F8?!D/\SP7HC R 1$QZ<B<74F5J?OQ(:MV=B6E8/LHV=P(+=
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M_D+;4S0"V*#8\^=L;PGWL&1VT9;(2%%-U<7PIAQ[BD9.2)YW,WPPWQ2?+K3
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M1-8'G+V!'S>XLHMQ'^K)7)0291=(Q">?SJ.RF_^E0X-]_@@\<P5%=TM16=.
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MI&TBE]^X9+,:AK9**5;6ML S/!D+=GJPFR6FZ*K !<VW*\UG2L\O,TBY:LN
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MS/IWA"OA2]/:JH/Y63)]C:' F*KWI\&G5#E'^0Z?+;'&CVOL8.9U#G?*'BM
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M9DOHJ[LW=^>C!I3%WT!A4!SN!%U \:!Q^: [0G5V(FCN>H1^OQXGOUN/",K
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M O<FU<)(W]7O5MGC^+D;Z)T,C(UN**VJ1\"IR]AE<P);K,*PQC0<OV[V9'=
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M;A4;,/Q[4@>..FA^T@/[X&3&T31]M[-T6,EJ*8LI(WZCS!13@,?5$1BKJ&Z
M/R.7UAQTPT]K[;C?4<RBE 9+NW^@0_H9F6"C>1@R"R<7;\<BD%*>3Y\^17U#
M(]S"+N'+%0[_\JHJ7YF31BCH31WVF*KW>'??<1T8XS@V?X</0F/345=?CYZ>
MG@F_(>M)1Q?B+E[# 0MWZ&VUQ_0%JGPF#0?&*,[Y;KD%EFZW@OOQ*#RHJ-8V
M&D<-W"ZOQQZG<]Q\+V4^:/2JH,S13&",!+J)O9M>4(YUYB?ET9_8=0*QM@G?
M_3B.3=.WQ.K#OO */H/K.;?0V2U_ STIG5A_ZSYN1R3AX@Y'A'VW'B='01!+
MG2/LAXTX]L=6^!CN0:+G"93D%Z&9T?&O7[V2C<_RQRT(.I^!S58G\<LF#TGR
M3:TV@%SZ9(:1-PF,36:,C2L@BP6]O;V,4="#ZH8G#"&WHKRF!44/:A!T*A';
MCSIBWD9KS-"72&!RB)KV&J[%%RZ#76@1BG=H8;<)[_4\_3EH<$]SOM3WYW+$
M5;W_H-](UM@,?0M\OM@2]H$)J'K<Q"[T:6I1BSRKM;4-1<7W8>X=PUTR1"[M
M2J%/$7,W;X<O3L1EHKZI#3W/GD]XQV>L0O[M$K@%1&#- 1=\NT)%D%8*'?+)
M!IK?9,@TM0?&Y,A4)0PQD=<M/AB$Q.O%&I5QDS 27K]^@YZG3Y&:<P_KS</%
MS[F:Z(/F^IF,CMIN<1RGSUW [3MWV=)K<J'@WD-8>$5AWA9[S%ZJ(B#/QSN<
MYRBP$,\EBSB>O=/A#(I*:]F%@DD=./J -$MW"+Z(J3I&^&"^R;M^KA+X1,R"
MEQ -">H/;CK^4%?Y'F-%I8]QR/4L9AM:XV,#2W'?P7D.Q68U&IQ3R#82%)NA
M:X2MEB>0552A&%XF07,PT.>N]\5+!)Q)9TM ]^\"%]%[6:I.4.H<#CF@>&!,
M:?M9*?MBT#&#?<<1=ZT(?7U];-GDB0Y/&1\YKZ ((2?/8+.)'V-364F;*Z%Y
MD;N>,NR</S?:X:"%.V/[):#Z<;VVT3AJ@#LP)I*?5.%^L/[D/6<XWVLN,$9D
M]:M7KW U]P'6F(9)E,T2<*4.VE=QSB>+;6%S/!&EE;5L4.R- C*LZ6X%KKN&
M(7JE,:+^W(4($CP:A]EBPS/'PN9NQ(G?MB!BES6B_4.0EY&%KHY.V?A\_J(/
M-0UMN)A1C*TV43SZ4,MMAF2,R<#8!((7+_N07UC,&@E67I'89!F&E2:A6&42
MAF6'@Z&WRQN_K'?$G*76F*IKRCBTIB,=6KF+C+37\#EX-(N^0D)\N#)4DD'E
M+.(.^7:A]Q;YK4J\/Z=1,.PWGF_?;!6)<RD%*'E8C^YGFLFFZ'GZ'+?N/$#$
MN61L-@_&='V*14$Y\TKK,%'.W11V=ZXI%NT/8!3278W@;!+4!X^J'^-2RC78
M>)W$'UM<Q=,A+>WPT:!2,F'^* ^,J<*-%-ZG.(\T/R?] 58;!2+UYGT%*&42
ME("\>S78:JNB!(L<6<\G\Q70+3/T+;%BGRM<O([C6GHF.CN[9.,A/?\^-IH&
M8.:"(_A(UT2Y;Y/C  U_!H_],FNQ->:NMH>57QP>5$WV,QJMT/FT%]')>5AK
M$H3?-KMCAH&U>+X22U=<.H]:=W 'X=01&",R:8O-*6%=0V/_#_9EA'J5B<4#
MQW7?K7: X7YON(<F,;9\G6)XF03-PU]__8V8E'PL/^B'[U;9,?QJ)5.?:3$P
M]HYF-1(8X]-C0KPG2@X*W/?=L44'@G QLT0!BA@?0 *$58\>(?U&)HQ<(_&9
MH9VP+)3CKXN]'\?U*P[ZX'AX#')NYJ.M[8FVT3AJ@ V,.2L4&%.%?ZDM-53(
M*'4$QD@/U[NE50@\>PT&^P(DRF8)UZB#]@>=0ZJ7S5ILB=\W.N%$[ WTOI2?
MV?2LNP=--;4H.)N,F,U6"/IA'<*^UW[02J/C^XTXL60?CN^VP-6H\PP^ZM@-
M$W)*[))K28"VK+H)1EYQF#)?146( 9X8HX&Q@VXQ*"Y[S.H/\JWC!28#8RJ
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M3P<CQ@SDTD:)L4;</G(.!T9':)-$+4U4M10YIK./&<38DR=/<.O6;6Q)2<-
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MM74F2Y2 HT BQI9M.8&O!\PV3V;59-! D&(78HPT8-<ZQD PKYB4N IBK#7
M[L38VT(W!_UT-4Z,)>X^A=^&ST9'%U^TYT6,T4QU2J)+*L<+8LPY0$V,:>B#
MS39:O:+Q'ZX-Q-AJ=F+LGW_^D3_H*K DUXO7[<5OHQ2F-57[HMO J!E>31!C
M;1>"&#-(C)'&V#3VRN;W +03Q)@JWA)C@V;;*?;3D0L=F1'$F#*HB3%6'31:
MN'?E2XS-3SB"3WJ%RC/(M&N\)@TQ9E0^2<Y-<7S TEVX>NN>7,>4ZIFLN'7D
M'%)&AR/^^^%8W](DE*,UB10C)<:ZCL9*U[]P>'8<[N??9'X?EW/RL7QM$L;Z
MS$&7(3/5_:%1_6+QPPSG_N_(.0B9OP8I^P[B^@WV?G$4"&),P&DA32,H.9."
MFZ7P6;23W;';'!.DOK_6.4C.3Y/8*YSOF_[AF!J^$ENV[T3VE1P\?_Z"J*_J
MB;&U9(&17C&F:9&":(HWA6=6.I_5/I_W#L5HWT58N7H=,LZ>1W5-C<D2)> H
ML"'&S&C-9%E?'DD:=V*,)I"A27RT@GF6@H6K(,9: YBF4F0M1FOY$4:=-4J,
M)>TYA=]'SL(';CYH[^*O+]=4STM9N"=9$[5)/PIBS#F@2HP1QZ<&]$C)YU$<
MRX,8JZJJPIT[=[!BTV'\=\P">ATDO6\*W=+5SX;?!#'6=J$YE:)2_,3!WU'G
MH K[VI48H\T/C?2/PG'2],CM_@Q SZF"&%.")C%&\IYH[+%B7J6B*XKG%%,I
MJN'*U2+X1BL18_QR66(?J[,//V*L&HL2#N*KW@%XSTUGQ@<MNTSS/#0ZH4@\
M:/?]E-E)2,O(DO.RVMI:YKZY>>P<DL>&RZ.=UG8>WO)D5"MMZ_M,P[J_PY&Z
M(1D/BHJ9W\?)<Y?ET6(>HT(L\AK4S*81Y\6L'Y2RUG(TVI]CYV'.LHU(/9&.
M.W?9^\51((@Q :?'];L/$1BS&^]W"Y&3EG:N0>P&PCJ@5RL>DP:'2N>F-6Y-
M?O^R=RA&>L_'TN5Q.)5Q#C6$SO0=,<8P%[)2H$4Z][W2/HH!LNUY/ND1C'X3
M9V%FU$(<.IJ&)T^?F2Q) HX"TXDQ17E6ET72QI48F]N"Q!AMD=9%$&.M =3$
M&.OZ)B1^A$&__!8;(\8V[#T)E]&1^,C-"QU=32+&B'V\2IRA<A^-Q)CT01#I
MVJ("C@=%8LR W:76226?1W@.H\28)+<U-34H+R]'_,X3^&/<(G(?1=-75 58
M'5UNLH\@QMHN=-<84\RG2$83$XQXT+R&MGS;C1ACR@\-VC*KWV5BS$408VI0
M)<9(;"1M3&>35VDT%9T(BMTKB#$%O"7&NBD18QQR6:)Z%IG>\EIC[/&3:L0F
M[<</_7SQB8</VFO%[R3R2?(\1O-MG?X?&; 2&W;LQ^7L'#QZ_)BY;ZX=/X=M
M$R.P[)<16/-CRQ-,K;)U]L2&<2'8O'P-3I](1X4E1F7%@;0+\/1>@&]ZSL!'
M'OY6NJDQ4(!"=C1ET&">;=W<)RQ"S+I=R+R8A;*R^\S]XB@0Q)B T^.!)4G?
M<>@\ID4E611XL4R0,3E&K6#.^EQJ1HI#(*%UK<]Z!J/_Q%D(F[T01XZ?Q+-J
MLE%45"/&]((+F^2'I$^USJ5\+Q]V"\(?PT,P:MI,;-YU"(^JGIHL20*. OL2
M8RKRS7!>?L18"3TQ9FV#2 J+6GI)VH\-_Q?$F..#GAAK8K]I@FRM IZ!8-TH
M,;8IY20\QD;B4P]O='3U(Y9M\N>F'!%.HL\-VW\:'HWE6X[CZ=.G\GJ;TN@;
M@=:'0QEYZ.^SFEX6C,JF$3O?T'@08]+TWQ(YMB'E#/X<OT3?1^GY+B//J5GT
MLAW1*8BQM@LJ8LR$XI3N-52N8Q=B3"L_-.H#*9H@QK3!O,:8G@W5V\8@MV+$
MF#H4B3'>MD>WKD-V?EXCQIY6UV#SGF,8.C42OPT-P8?=*.26Y%ZU<A9>]MNJ
M_3%Z+B:%KD#"CL.X>:>4N6_N9!?@8&P"$O\*0:+'E)8GF5ICZ^R)_0&+<>%8
M.HINW48-86U5"7M3L]!_VF)\[.&+]]R:C&Q4JY>JR1ZMCIH4=_2>MAP;]YQ
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M3(Q-4B#&>,H7;;U6D?2RLA<J=F-(0#R.GR\TW"^.@E9'C#6=@U[ZNE)\D2=
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M]V!TM+3V6E\LV 0[VLE'TR:-EI&<P \#@K!\$U\V7:#UPX88TY(G+0/&N^#
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MQR7;;(*0G'D']8V/,?!$_LXQ,K?_Y,D3M%.Q8&E")JY;^B%QO37._[8#YS0
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MS-D=1,VKZ0SK,JHMW.D&1Z] )*5FT."87")S921+S_.GS]#7U(:V!Y7(][V
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M H[,>1-X1H+>5,(NBO1//EUF#^<SEU'7\)C^9@((OFW$"HR1E $#@\_0W3N
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M(JTI1(_;NG$L* '?4_[+YTLL\(&N#!X3RDNJM"VCVJ0"8PKYU<*;%ACC(D'
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MNP)WJM'@X%.TM7<@,2,7F\S\Z#D#DDI(TL2H6NRAA@)CO#I-AKR)]>?I<[3
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M_\WG7XAZGA88XZ()P)B8&$$H3PI)]RNP:8$Q9GH#C(U+I2BWWK80&15YCCJ
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MIW8%G^;22.H+LD7Z9D$5O,]?@Z'5.?R/;46(&/Y6!\\SO8.$^W^[V@Z;#GO
MTR\4=PJ*%>WC\IHF1"??A)E'!'[?XJ&LK#,>$^E0BS0$'^I9X']+S+!XAS-\
MS\7B83$I)M^NE7,U4UEU V)2LBF^.D\Y"6Z8]M=0S1M%Y6JRVQ@;I,D[QD3(
MF\0^T )CFD\3@#$Y^ERL+Z? A*(Z@+&2ZL<(2\S!0?<H_+*980$.US>(VC$F
M0]=(D%.2*OGCA>;X9H4YMAXY!9_09%R_6X*NW@&5]N=4)%)[E>Q<*GCP$!<N
M7X>C7RS6FI[&YRM$9"A0>OSYGL/V;![^_6Z]"ZR/1R S^S9JZNKQZM7D^DG_
M_/L?PA-N8.$V9\Q9:D[[<YS]*J??5"EWHZ[[8[L7#E'Z).SR+935-M,QS51=
M(3U5Z<7+?W#K03450V9@L_4Y?&DP+IT<6VUDA?2O++D68G]8SE<[,"9'1OG.
M%W)/[8XQ5GH#C+DH,^<F51;8;-:X\RQ]M< 8$Q65:RHP-G$\:6 L13W &%F,
MFWVO FZ!2=A@<9;2\0SSA*/U^QB]S_"M8G67R&/Z>T[BB$\<+J;?H_A\:(Y*
MNUEC:A(9M_:.#AH<BXJ_"E/7("S9Y8ZO5K'4NQ/",Q,:AW\BL>G_[06OL[&X
M>3L?3<VMD]V-:J'W D,C<=0GF"X*)TKIB=K5(>(<MD%6PD@S_3[J_.EZ5G0N
M5Y):T>%D-&[?N8OZA@8:I=>29M+(RMWVKCYXA67@:\JAFT6-X0=ZUA"]BI.+
MSWEX1Y$F59:HO__<<A2.)T*1EGX-M;6/%.UC,A$R^.PYTFZ58+U%$'._*"&+
MJMZU,OP\LL*8I(^:M\8>AQQ.(>;2$#BFE7/U4GSZ+6PZ[(;O5UM@]NB=B*J>
M6!##IW+Y<MSUAM8AR@%C1R\H&X3R3?9(F=08U8?3="WQ@X&%%AC38&*M,2;&
M1G'Q%:=/*>'>XWY7!S!&@FNR$.<*90_7F@<J+X.LLJAL?8[Q;=JP;?Q UP*?
M+[7 #ZLMX>)_"=7U+2KMSZE(O7U]R+]7@-#(B]AEXX\O5CEBYB*;H=6?<G8/
M<?$WZVX5CDP%C#L4!<15H\[]8_MQA%W.I7>*$5]PL@&;?RA_/R[E.HSV.^#G
MU:;X>)$%OT\I2K>(G%R08A?'74NO#*?BEHU'@I&:4ZR= )L$>O+T!4Y%W\!W
M&]PP:[$MI0>M6&1)YDX8N;I:B&_*Q?OC^%1]P)@E>^/3<:+[ANT^VAIC7#0$
MC-T8!L9DI'*6.I?!I8L9YCVTP!@ST<"8VRA@3%+L)B #D@+Q@#J!,6)3.[MZ
M4%GS"+[AJ?A]ZS'QND2BC9<B X<]8W"OI Y]_8-X^5*;VGRJTT@]XK***L0F
M),/*[0SF;W&5J!NYF@1\AL5F&EJ%("NO',_ING;OQF[%]^[<S<.EI&O88A4@
M3)&-49H"E8/8\\8,E @%).K]V:^;O<06JP^?A+-?-$Y'IB(ZY3;N%%:CHUN[
M<E93B*2_>_+D"5TH_D9^.0)C<V@!GJYO/98_I?('%^^J8%)*M)R,NV;17F\$
M7DA%>7D%.CN[5-+G9$*?3.Q/&RV?4F1Q]'<RR;O2_<K2QZ1V %FQ8>SDCXBX
M-#H=$LD%3 R7EE1#)'5BS:-&7+^5#WN?\_A]HPT^7FB"&;H6$\9G4AJ;DR'K
M?F^N5Q08<YU*P-A(C3$M,*;)Q F,2>$U,;93+/\RG&]V0O7 V AE%U1BLU40
M79_K_046TN5/:-^.]XE5I">)G,[0-<-L/1.L,SD%WXAKE(]5B9:./K7TJR93
M>V</\AZ4(R;Y!CP#8K#'Q@\ZVX[2B^J&QDB$W\DG$Q/.X4JYP@:,,? ,TZY%
MAF=_O,0*/ZRSQU9+?Z3<T)S: B2UY_V'%0B.3,0>V].8M\Z)N3_ER(M<WU;4
ML]Z<_\N68[#R34!B5B$J'[5-.@CY+E#?DV>X5]J \*2[V&Y_G@:XV<=8IOY5
M2F>/>1^VU%TL[SJ.3R<=&&.3)5G]PB;#6F",B][4&..ID2E4#\J5!:XYP 5:
M8(R-7@-C"T?M&!,S/FPRQ#9_(\'6C?Q["!C+4TN_$'M*=ON33&"A"3>AL_.$
M,'[F^@XQWRQ !F8NMH7>'E_L<XU"=%H^Y7?WT MEE/0%R/VZ.CM16U6-VNH:
M/*JM0WM;&YX_TZ9Q[FGO1-7]AZ@N*D5O1Y=*=N^3>4:R&/]"?!I,7(.AM]T-
M7QO8B[.!G/,R8A>#393WC_3,\=DB,^QW.H>\AS6*?K^FTWL]E((H**G!88_H
MB9W(U?%2#*94(RM$H3"=*W'UT0=4D#MGI0-^W.B*^5O=L7B7)YS]X_&PLG&R
MQTM+PT1 L<>/FY&94P!+[XOTJE92,'::$+Y@XV\I1HWM>K95)F+EA-,POUD5
M8&!R!DG7[]/]HBI@)[N@"D8V)/ QG]C/4N1:2I\+,@K"GC%=WY(N@/GC!B<8
MNP3B4D(R;:SZ^[4 N*JHMV\ E]-OP,3>"\O^=L+G2RWIB>4)=4*4LB-<O**
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M\,LF9SI%^W0],7ZD1'D>=0U9!#E=E]07LX"#?R(:6M[-U)HT,/;L^7/4/FK
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M%P:[G3!GN;4PIW]D<D147G6%SA'2I 8S?-<-_TWR@,Y<:$5/B,Q9Z8COUKM
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M'>7VPW@Y&_-<;8TQ-N*M,28VKE(J=F/Y6PN,,9,@8(S#UDB:-Q%CZT:=.]G
M&,D4T-S6B>R\$APX&J4Z732J$?MSV.,";M\O1TM[%_T.2F^<(+Y;57D%DN,3
M<<'1&^&K#B/DIRT(^<Y(V ZIX5UC050+^WD;HO[:@TB]O0C3I_YO:(FKIR-0
M]* 0+<W-BM=$4X)Z>WJ0?^<N+IT[CXMF[HA>>  7%NQ%E,X>1/R^<RAMXMRA
M%))"^R.<ZH<+5#_D.)Q%:U&E2GQD<D\RGUM67H7H2Y=AZ>H/G6VNXN24U<\8
M'\>/E4N2+?!XV%5T]?11,=)SZMO>S<T\8X Q,K%97EF-RRE7<<3]''[8X").
M(8K9+2+4@5-200DQUF*<699W),7K_K?8##\9F&&?0R""X[)QZ>H]Q&<^0$IV
M(;)R"W&OL 2-C]^L$GA7=I.129+&QB84E58A,[<8B5D/J%:(V(S[<#MS"=M,
M/:"SV1Z?++42:9PEU )BVY4EQ/&3PZM" RJ69Y )YNFZYK3#<^1$#*KJV]0Z
MAB, R..65G@$IV#.*D=F^5?",18+C,D:%Z;S+6B0C*26-;(.0>CE7*3?>HC<
M@F*45]70Z5G>=>KN[:?DN1KIV?<0FY:+H$O7L<TV!)\L8UCE(D4^I-H!,0&<
ME/LSZ8SQO#_NW"FY8TQN&Z6WM,"89I.BP!B3[(K9S2MA@F4R@+$1>OGJ'US)
M*8:)9PP]\4;O2I @)Y)E>+3-%/H,,?<5>.Y'BZSPUQ9G[+ X!I=3T8A,R44"
MY>.1EI)=A.R[#W&_J 0-38_IW7;$!U8% $/NV4T%QW5U]2@H*D?&K4(D7;^/
MR]<+$9.6A].1:7 Z&06#0][X>+$5;><EZS<NGTUHW*%J/<S1/EID@P5_G\!N
MIS!<N')WRBT :FCIQ/G$;.QU",9?VSWI]#.2]0P?[XN]+^MQ:=DE/M*WP-P5
MYEBTQ0;6QR.HV+( ]TH>H;VSAZZCI:X%<II(Y-N)/FEHZ<*->U6T+VKN%D0#
MB=^OL:'X0L1X<LJKC$PE(N82%--#'/KFW0#&1NL#+3#&1F-VC/'9,S%\+Y>/
M6>1%"XPQDVQ@3.PX\?DV3'-MP_^>;&",V QB-ROKFN#@=PD?+S3#A[KF;](R
M*Z6+J#9KB2UT=I[ WX[AB$S.Q>/6#L5M-DG'2&J*D?2).0FIB';R0>CF(PCY
M<Z=@ (@5*/MV(\[.VXB@OW;BTCX77#MU'OD12:A.R4%->BXJK]Y&Y8T\5#\H
MIIY?1X-3JB#BVY/O?#+P!,T-32A[4(2*6_=0??4.:E)OHRXM%\67KB+UQ#F$
M&;L@S,!8%"#(URYOLD6!_T4TY#Q 7U.;XCO'"'5T=N)!81$NQ%V!B6L0#8Z1
MG6.OTWWRRAS+<090C&SJ^<W(%=NL A"?D4^707F7:0PP1@9V@ I46]O:$11[
M'7_M."Y)^*4J#5G7*#7!R7F.L-7.1*'.T+7 [(46F+?6B5*$WM#?<Q(+]_IA
MC;$?]MN=A,?)8&3EW*6+/Q)'_ET!QNKK&W MZP;\@F.PQ_XLEN[UQA+*25VX
MSP^_;7;'-P:V^'2I-;T+C]=@*^5@:\I]!/'@$'_-UC?%ETL.P]XGBMZ&K4XB
MO$I6-?13NL(GXAJ^,!BW0I[+81+BB(V_3DA J<1D!<N[#CE(%OAJC0L6[/+!
M%DM_V'J<141, @V.O>M47ET/OY X;#?W@L&!X[3C]\U:5SJ'MFR94J7>YN4K
M@3O7QMR#>]>DXL"8$K*@I%WE.%<+C&D^24NE*("/A%S'9BN$VA&=R07&2%W%
MIM8NY#VLAEO0%?RZY9@H^9 M>ZK2HT)JIX[2?^]3OMNG2VWPK8$=?C%R@]X>
M7RS:=XINJXU/X;#3:9PX%8RKF=EH;FFA?6!5K#@E@7-Y124N)Z?BF'\$=ECZ
M8>7^$UBZSY?VQ^=O]\+/AD?QQ2J'(7]3;M\)Y6%5^(EB[ ##L<]7.,+*-QYW
M']:@L;4;+UYJW@I@+GKZ[ 7J'[<CZTX)#KA=>.-[R/4-I8Z5I&N$+3H@B[1F
MZE-CMM0*/VYTI7G9(_@*[A=7H;N[F\Y.\JX2^7:B3Z[>*L8ACQCH_'T"/VQP
MQISE5IBYB-0Y9>E;J79(BDY][2<*O%Z(O,O@5[4!8V+>5:Y/RKHRW@+_WU_F
M6+Q7"XPQ$7LJ18FU^$2-&1.?<\^Y6?IH@3$FXJ\Q)C*[#YM=Y+I.H.\SV<#8
M2!VJII8.'#L;BWG+#^&S1:9TQB!^_A2@IT:=\\T:%UCYQ-*[TZH?-5-^RW/%
M096G@T]15ER"U,0DQ#J=Q'D""A%0[(?-\D&AN4.[R,[]8(3S.KL1O=($<6N/
M(&F3+>(WVR%FJPTN&+OBDO=9I"8DH;J\4B5SVR1>&!P<1,OC9N2D9R+4VQ]1
MEIZ(W6Z/!$-;)!G:(6&#%2ZL,$:HWAZ$_K:=?G>E@+'(/W8A=J49LFU/H_[F
M?3K64'I!$O%E>GO[4%9138-C5FZGL?AOMZ'%/6RZ46P9F>$V;YT3]MB=QKFH
M1#PHKGAG=XJ-T'ML!S)R2['+,8QR*EUY:B8(,'A"%*TJ'2FY]Q9HI(6TCQ<=
MP2]K+;!NKP,\ V*0=;<$M^Y7(:_X$>Z5UB._Y!'NESU":54]:NH:T-+:CKZ^
M?GI5@::F-2'O190"V0U&0-7:^B:44>]?6%Y'?0OYIC?M8LI->)PZCVUF7OAQ
MK2T^T#$=6JDK9!):J:!5:=Z1R]<BWX.D5/G=R!E;S$X@]-)5/&Z;G *)9(5\
M;,8#;+8)I2<!9R^UXW>8N)QIOK$7&R1*T2$">/"K%598LLT6Q@Z4TY&0A0**
MQZLH)Z>5DM5^%4WR:0H1.>_NZ4/MHT9*1S70\GT^\2:V67AC[G)C>K65(G*D
MI+Q) <:84I()<H)9 LCA?ZL4&),Z<2,DN%%@/+3 F.:3:&",3S>+X3V^B18!
M?#F9P!@ALLB)!&R7TNY@U4$??+*8LM=Z,N5377J45;>) \:X?+G9BRSQYT9K
M&!UPQ%&_\TC,N$.#&7>*:L?XB4JTVX75"(^]"GO/LUA_P WS5A[!1[HF0S6H
M1G^;DOTGQ'>1,ZY"?2"!L=*'"ZWPU2I[+-YS'&&).71*'TV-,[AHI,A\:T<O
MW .3\2DM=Q9#BYKDR)N<<1)]C<0:O51;:WH&9Z,SD)[S@(HG*U%2_1CM7?TJ
M6<FL*42^BS22VKVQM0L%I76X_: 2F7>*X7HV";]M/<8N?W+D5ZY.?:TG1<BZ
M4#]/ N],.C F-!X3>MT869JX6TP+C+&3+&!,*L]RWD\+C$DAR<"84'D3HA,%
M^CV3#8R-$,E\<S'E!O98>T-WFRMF+;+FUTD"OY]DS_EULR>VVH0@)O4.>GM[
MZ73>2OI:)/;HZ^U#0TT=LA-2<=[%!V&;CR#TYZV* 4)<+7#>)OA_OQ%^NMMQ
M>KL%PIU.(#<F&>V%58JWYGMEJ+OU $4IUQ%_+ !>VTUP<NDN!/Q@A*!O-HI*
MCRBG$7#LGE\,FA]4H+^Y __^HWSVM]Z^/A06/41,7!),7 /QZR9G?+'2#M/)
MXJ\),BP.&)NF,U0VYL^M[O ,N(C\_'MXW-S\UOJ,0HD5&"NK;D#8I:LXZ!R,
MWXS<V)6=" =,ML/$JX04"'(%!I12&TFS^-F2(YAG8(U%N[VPV>8<MMF'88?#
M>>QT"*>WV!YP#8.33SC.A%Q :L9UE):5H[6U52-7 A(!(F@Y >Y(D>/4JYD(
M/!\+9]]PF+J=HPMB[W2,>-W6FYW!PK\]\>-Z1WRRQ KOT^EK)*:P4>58<YVC
M5+ L\3YD._8^E_-(RLRCY?3)X.042"<KY&L:.Y!QIPQVIR[C)R-/;OGEDW5&
MYTO:"@AQXR(N[<ZL19;X:J45_C!RQFIC?^P_&@7?T,M(3<^D5Z@_?:K9!>OE
M$*EGD5?P$&?#8N#D&X']KN>I/CB-GS8Z8?9",\S0-1>GMSEYPI*;/[C&4PK?
ML3U705Y322I%)=^9S[Y*&8_AI@7&-)\D 6-LLB7FF%3>'7?-9 -C)- E"R,R
M;M[#/EM?_+INR-_CU3E<]DB,WA.M:Q70&R+TP72](_C?4DLZK9D^Y0=NL#B+
MS=;GL-T^'#N=(L:V47XCYS&F1IU#_.K5QGY8L.THOEMC1R]*^V"!F?B4B2)\
M U']R!7C" $CI8S5N/M]N<H.:P]YP<D[#%FW[]-UIJ=J4$S>NZ.[C_;%?EIE
M2J>S?[WJ6TD_7FD98?1[A=SSS<3_O/5'L>+@*6RV"L)VNQ#8^27@>EZY2E8R
M:PJ-Z-J6]F[$I.;B@$L(=CF$8"L54^OO]IV8RI:K_WG'3D8<PE3GBDN.^<9_
MO*\J1*=PW$MEP!BK;A/0!^/[7NCW\XTCK?O-M:D466@","99UW'P.]^X,QUG
MX6MM*D5F*BI_!%,W!F!,BJT1HO^DC/-PTQ1@[ 7%^S7US;B>6PASKVA\8> H
M70;&]2U9I&'M&XN$:_DHJVZDYW*)[5+2UR)@&]DIEI5X!0E.?@A=;8Q0W=V*
MIA#D2[,8.)=J/V]&D-XNA%'/3]CAB"PS'UPW]V5I)SF.L;=,4V]</>R%Y#U'
M$;G>'&?T_L;9W[8B:-Y0S3!U 6-DYQA)JYAM?P:U&7?QXMESQ4LC$5XA:15)
MF:NH^#18N)[&\CT>^&2IC3@99)!#4E?X?1TS+-I]'.$)-]#>T4&7R7G7B148
MZ^SLPL/B8@1?2*97OI))K6DB%9XL92+4.+X^)G\W%_\S5/#-8^Y)ZAF9X9.%
MIOAS@P4,]]G"Y40@8I.NXG9^$9TRK[FCE[.U4*VUHP=MG;UTSOF.+G&-7-/6
M.71]"W4?ON<];N_!H\?MJ*8,2D)J%ER.G\$V8V?\M=$<7RPY+&RURF0UP4Z!
M GR@P'UH&:1XY'\K[.D"B7T#@Y.^(G1DI6[<M?MTL/'^:#TA5>;'\XDJ)S#$
M\B+#N\Y>;(W5^SW@2O%^?$HFRFL:T=K91\E3+WK[!N@5K5.-1M(+D!7DW;T#
MM$YIZ>A#36,;91.2L.6 '?Y<;XG9BUCZ1<I$SX3[L$PHR!U/3N>!J5BW<DUE
M-<9DK#87I).DCL<X_:4%QC2;)@T8$ZLG6*Z9;&!LA H*2W#</P2;#CKC^S6V
M_'J'2X>)T7NB;:^*]8:Z>(?M7+DQB]CKY)X[W@YQ?9.,?B8K1=]?8(&?-SG#
MYE@PKJ2FH[*J>LJ#*#V4OQ45GX%-^QWQ^P8;S%S(4H]!E3&L$'[DX@-1\CXV
M5=S0"F!S_&+H!I_S&:AK:D-C2Q>:VWO1T=V/OOXG=%'UJ9;5@/BC+R@_^LG@
M(+VRG_C736W=J&_NP*V""IAZ1&"6GC%FZ)I1?@8'\"VGKR6//0\P)L579M,3
M8N^Y0$7 &-=[B/+GN;Y19'Q(7Z,%QKA($6!,*,^+L?4L>E,+C#'3$# 6JA P
M-K$F$:]]$V%?-048&Z'_*%L3GG0'>KN]\>GRX9TYDF3@"&8MML67!D[T8HVD
MK'MTJF.R4TQ)(K;\.77/^II:9%Y.0<11'X1O-%<+,"2KS34<:I/]'@JTJ/F[
M<?=$!#IK&C'8W8=_7RGO7Y'-)P^+2Q ;EP SUP#\:NA"SSV^3@,O0=>2Z^>N
M=L!.NW.X=J=4\7>>JL0*C#U]^A1M;>U(SKR+S4?.8,8",RJ0,F=W>I1J4H,_
MMH!#[+.Y%#W?-3(;"6K(-O\/]<SQY3(+_++.BD:&=]@$X)!;!*Q/)L#A3 IK
M<SJ3A*-G$^$9F #OX'CXA<3C3'@\@B,3!+6 \ 2Z5I /=>TQZAYN 8EPIN[)
M]4S[T\FP/769KD^PTS80*_:XX[>-E#%8;H%9^F:8SK2#A,\("^$-I?E.5?PK
MAY_'_48F,F;HFN+KE5;P/9^._B?/-&)U+WF'R]?O8^4!;WRD9SHV59%2?<EY
M7(&)/:'CR'",I+;\89T#S?M$!JQ\XN 1E(0S$4E(3+V.ZKK&R1XBT416J?21
M+=REU8B\?)W6*20]C8U?(C:9^^.W]3;X8AE+FC"YO,]T/Z9C F2&_QD,*5?$
M!-TBGZDR8$R(O CI;Z'?.&%\^650"XQI/KT&QHX/ V-</*6$# KA/1$\K2G
M6$M;!W+S"W$R-!%+]WDKJQNE]K/H9W#(M-SWE\,3@J\?I;]9;8F*OE%*[*)&
MOW:ZK@4]8;9HIQL"(E-055V#KNYNC? GY=#SYR]17%&+^-1L''0-HR>E&/EI
MO.V7RF.JYF.1;20USO]6.&"-20#MK]F=2H2]_V4$1&<@+>LV2DK+T-W3,]E#
M)8H(8-O0V(1;N7F(IOS18R&IKV//0^X7H+?K! V*D=ACFBIMD- QYY)O)>T
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M(Z6\L@:9-^\B-C4'88E#OBAI9RYFP_I$%#:;>&'^9B=\O-B:>URDR*R@6$/
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ME#O&NJHPC[T.C$E1)V",11<(\B=#Y@JIN1.1;1T8$R;9.\:4^CXL^HS2YO#
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MCW<TOISH)B_?4GV6ZH/DWX723LCW3W-@C*6O6O.05'T"O^O 6/>G#\#8MO?
M& O_2('WQEQ$::=;=&!,F!J;7^#^HW*<S;B/,QDYG,W,@4O08?PRVP,#S6WX
M-&!"XRFMTQGG4*G_R\@#'>IBU7>L/B&-[A,;*R6RH*5\F;7JY/[F=A@ZW@%6
M-ML1&+87Z5>NZRG &>EI71-NWB]&?,H5N ?$8M8:+_PZVQ7]+"3FQL#7T50G
M=N()@Y/X<C(MI=/E>,T8.EZPK2I.5M'*OV&_1A,PV9;7F3,VAF#WH73L3KC
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MEB-FK7!$Q+[#*"E[S"_4Z$$Z&SVMJ<6I,VGP#0C%(OM _+9P"[Z=YH4!_+4
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M3$9F^IK;\_?P_##9 <X[$G EJX"/%>[GEZ#T<16:6Z07M5Z\?(6*JAI<O?T
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MQ>"[:1["I\:Z"AAKQQ=]1]OQI]A&SG*#W>9H'#]]$0_R"GD@6J?N3>3.$;)
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MFN,0B?/7'^KK<5U O.]-QIG$2EQI:6K&]2L9B-X5AHC5K@C[:S'"A\U%9#<
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M)W]8+O;"Y^.<Y668(@6]6"Q,TH_.6>L)[\ 8'#U[#?<?/4'M,_V$D5)Z6M>
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MTW(DQU]'I'<  FR=X6MZ#H$'K1"ZW0+1AB>1H'<*UU54XO5/(7+;203M.HD
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MKUHP'/1 2R=:'U5H?+_P9M_XI!K#W:I]Z$G<]W8\K9&Y?G&?_6I /:,1B/O
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M'\Y?Z"-XCR6>I-]1PE8JW[/KV4C8?!)!"PW&]5X1;Q 77(K$0%N7W/HJ2,R
M^PY3."[?"J_%!F^"Z="O=B/3/@ 5)65H:VN3ZEU;:"08^_57E(8G(WKM,:FN
M@\;6]9<[<=74 4DQ\2AY7"S-P:-*[P1C0KMU^5(?YW4,<.[[7; V4/Y^\]RN
M8[ [9@%W&WO<R;B-EVH.B+4S&#,8?XQ@,*8VF@[&GI24(B[Z&L)/.B+XV[</
M)(3K'L MIT"4E92@M:5%97.<:8O__/8?H?R&TJ@T7%E_'+[_UGNWU]CKWG32
M/E,H00L-7Q?AO\5CKG"<]=AX$!>/6B A/ I-=0V:WBRMPV",B(B(B$B&P>&7
M2+M3BM/N,?C!R!-_VW!&></>316.33< F6$P-EH^6F&.+_2LL>6H/<SL@^ 6
MEHJX] <H*GF&EI96Z88IC1"'37SRK ;7TW)QY48.@A/R<-(M#LMW.>(C76/,
MEWH7CJE_F=^WG!YC;_[_--N:(J^=13#V.UTS_&&E"?1-+R/]KGIOZJO;AQ",
M>7VY#2ZK=L)I]2ZU%=<5.^']^5:M#L9\%QO"36>':NI@C5AVX]HI9U05%*ME
M6T?)"\9"O]F+1$M7Y"2GXTY:)N[?RL;]S)PI2_XMX<_T+-R_F8G\Z^EX$)N*
M1U=3478E%:41-U$2GBP]O1ZU^00N+]23YHD:#1K$GF+!/QU'PJE+N'_E!EK*
MJ]5:'_*(0<WH/J#T:AIB?SHQ[@E]GX5Z\/K<$'?=(S'8T2UW676E%<B.3$"\
MN3,BQO1\"%ZR'0F[SDJ]T2INW</ %,M1)W4$8^+0@<]*RO @(QN/$FZA+#(%
M&<8N"%^V=]P-7[]_ZR'HZSU(M?.3>CN(0ZRINE?AQ&#,?^%(>[WTA3Z<EV^#
MLPKV#<[K]L#UQX/PW6V!_-@4O!Q2;T\8!F/*Q6!LYL1@K/1Q,6(BHQ!ZP@Y!
MJ_:_67_$BH.X?2D$SRHJT-[>_L',I=7\L!Q%?G'(L/9"_'$'1&P[B9"5!V2V
MKW%E@3AL\19XZ>R$VT9A_VULA[N>5Z3]K52$8_7CZ%047DO!\_N/I)[LXO7>
MAU*OHQB,$1$1$1')\*MPX=W>U8MGU8VX&)R")8;V$P(L!7OV3'R]LGO]R O:
M% Q'Q-Y-GWQK@?_^[A3^=^,9?+K9%@9F7O"+3,+#1X^E<(Q&B/.P7;N1B5TF
M%_#=7EM\M?4"_N^G<_CCVI&YZ.;)_>XF&3IQ&B'FI,N<SFL4"6,GO.>3E2;X
MQQHC[+;PP.W[)9K^&E3J0PC&Q)N]?I\9PE>-Q6^1@30GAC8'8^+G$S^GRNI@
ML2&2CSB@+N^16K9UE+Q@S/_S;?#:8@37$V?A:F$#MY/GX';*=LKB:FX#5],S
M<#UR"NZ[S."E9X2@C4:(6G<,5]<92;U_(E<<1,@7.][,*2;]AC[3@^-7>E(O
MH/+;]]'?T8U7P]HSA*(8C(F_?_'&:V%8(JYM-'U35WX+]."Q: M<OM)'MF?$
ME('6BZ%A]+9WXDG";21NMWZS'/%I_M O=R%BY4'<=PE'3TV3FK9N:NH(QAIK
MZI 4<16>9F<1O,-":B\17^]#\*=O@W,QA/06ZCM =R_N^UZ3AJM4]AQXLDP,
MQJ3?B/!9_,1]IJKV#<)^P6_)5H2N.H"B@'B\'!A2Z39.Q&!,N1B,S9SX_98\
M?(RKX9$(,;N P)7C@[$<]W#4UM1(Z_]0 IQ7@\,8:.U$S>.GR+V1AC@7/T0:
M6DP=C+WN31:PR% ZSH=\LP=7OCTL[6_%(AZK0WXX!I^?CB+Y4B">%#Z2>C#/
MU6'2)\-@C(B(B(A(!O'FBWC1)3Z='!2?AV4[G60$"E,$8Q-?JXI>/TH(QMYY
M[7)3?+;9!ONM?. :%(^PA!S<S"M%=GX9"AZ6H:JV'@.#ZKUQHV[B]R[.>5-=
MWXR[#\N1FE>"E-P2Q*07PM0^!%_^;(I_K#/!QRO-IMFS:Y)V,)M@3*'P3$Y;
MD1OBC2S_"WU;[#3WQ.6P&RBMJ-7TUZ-2'T(PIFU%6X(Q=934 W:HSWFHEFT=
M)2\8$V_V>ZS8!<<?]\/AIP-PW'10H>(@OOZ'?7!<MQL7=;?!^<N1GC5BH/$F
MW'@=*@0LV8;HC2:X<>"\],1[S$DGW+V2B,XZ[0F$1OTJU%7STTH\2KR%]#.7
M$?GMX;>!UA<[$+'%##'F%U&<E(7A/L6&]:O)+D3B?ENIMYG_F#EBQ))SQ@=M
M3ZNE\PU5ASZ*D!6,N7^]#?;?[T'0B0O(B[Z!\KP'4Y?< CS/+D#5[0)49Q:@
M-O.!4$;^?!!Q Y'F#G#>>$#JS3!VZ$2IS0@EY.L]B#&TE'I)5&7F2]^+.L@*
MQE1=1K<Y=-D>%'K'X&6_>N=Y93"F7 S&9FXT&(L.BT"PZ?EW@K%<#^'<J[86
MW=W='TPP-JJWIT?J+5>0GHU<STC<,K[TIMP\[("XW6<1N<D,?BOVXO*2\?-:
MRMSOB'.4+=+#I25ZN++W#+(N1Z(H)A7E*7EH*"A%7W.[IC=9+1B,$1$1$1%-
M0KQ))0[K$9IX#\MV.$T=+"AA#B>5!V.*+&>Y&?ZTYA06;3D'W=T7L>: *S8>
M]\8!*V]8.WHC/BD=C<USNQ>9>-%=75V#A-1<F%\,PZ;C[OC1R!/?'?'$%X87
M\)<U)_#[56:8ISO-8$S1[U!9[66ZRY0YW.,)&%CX(_KF7917-:"[=VX/K<E@
MC,&8*HNV!6.!"PVD'BM>2[>/E&4*%O&U7PGEBY'YLWP6C?2J"1P3C(DAD/>"
M+0A8L1<I9SQ1DIJ#9[D/4%M4AH[:1KP84&\ H(A70R]0&G<+L?MM$/'=401_
M_G9>O,B5AY!E%X!G]QZB7?C\BH8UU3F%B#UX#NZ+MDCAV+@;Y9:7T?"X'$-#
M0UIQHU=6,.:UQ  NRPSAON$@_/:>1/#Q<U.6,*-SN'+P+&+V6"-A]UDD[;)!
M\NYS4HG5/X7@-8?@_=4VJ1?EV'6) 9&OT(:B-IH@W^LJ6DJ>H[^U4YIO1QTT
M%8R)VQRX;#<>^# 88S"F60S&M)-8WWV]O>AL:45;12U:BIZ^*>69]W$OYB:N
M._G!9^<)."XWA,?GLGOHORD+1D8/$(])(;K[</5G,\1NM43<SC/(M/96>\]V
M36$P1D1$1$0TA>2<$NPZ$X(E!O;XRW=64P=A[U,PIN!G$X<(7/C#":S==@*G
M+_HCZ?8#%#]K?%T:\*2R <^KZ]'2VH&!P<'WXN;%X- 0VMH[4%O?C(KJ1I0(
MVU%<T2!M3];]$L3=S,:92Q'0V7X.O]<]CH]TQ\X?IL PFN]U,';BS3";\U>8
MP<@A2JH?;>C1H&H?0C 6J7, \3^;X[J^I=I*[ ^FB/AZK\P;--H2C(5]N0O7
MUANKM![NV@5)X8,ZR0W&5'2C7^PI%OCE#H1\=P2QA\_CP=6;TC!-_?W]6GUL
M$$.) I]K"%BV2YH7+>#?>F^&@8Q>=PR/0F]((9:XGU!T?UA?] 2I=CX(_LD(
M0<O'_Q:3#]FC)"X#S4^K,-33I^*MFYJL8,Q'J ?/UST+')?JP^Z;J8O#,GU<
M^EQXW\+-TOM'ZS!0[!VVX-T;MD%?[D3PROT(7W\,49O-D6%Y&75W'JM]^R<&
M8^+PJOY?;(>_\+V)06G\EI-*WR<DB/M'_5.(WW,.93&WI*'3U(G!F'(Q&)NY
MMW.,12/47)QC[.U<6F(PEN4:BN?/GG]0<XPI0@P*JRJK<%<XSE]S]D' 82M<
MV75ZW'XFYN<3B/S>""$K]B/H<]GG /ZO]_=7-AS' ^]KZ"ROQ5!'-_ZCY;^Y
MV6 P1D1$1$0TA<JZ-B1E/\89SP1\L\MYZN!!D6$6%0VG)@Z5-YWP:QH!R.3%
M_$U \N?5)_"O[T]@Y2X[;#\5@,-V45(YYG %EBX1</ (16)J-BJK:Z5A"%5Q
MT:Q,M74-2+N5#=_0&-BX7X&173B.VD5*V[3[3# ,3GACU9Z+^.?WEE(H-D_'
M3+'O;\(PA.^\1]EAUG26.U7[&E/$[_PC71-\LN(XC!TB4/J<P=A<",;$8<M2
M#SF@+"(%E4EY:BN/?&-Q8\P\2]H8C,7]= +YPKY,E?70E%^*P;8NM6SKJ'>#
ML9TC/;M&BY*#,3]Q?JB%>@C[P0B9=OXHO9F-QB>5TN]J.H&2NHDWW(=[^U'H
M$X/@I;NDFX2!"T:'NMN"J.^.H3@B>=HWYWM;VJ6><GG>48C?<69<75U9>Q2)
M!VQ1X'M-&E)1TV0%8V+//]^%PG>Z2-@'+M:'AP)%?)WX>C%<]!\3+DY60G\\
MCG#C"[CI$HC"*S>EW@I]C6UJW_Z)P9@8BGE_?PA>>RUP\Z(_RN-O*W^_D)R'
MYT*I3+N'#F'_]-LOOZIUFQF,*1>#L9D3@[%R8=TWXA-PY;030E8??/O@BLY^
MI#GXXV%A$1H;&J0Y!VF$./Q[3T\/FH3KFF>%Q2BY=0?E:7?&[6>*(I*0XAJ,
M:R8.T@,(DS[4(NROQ6%=$[>?P1W; &GXVU^&YVY=,Q@C(B(B(IJ">"$N3D:<
MDEN,S6:^"@1C;X>@4VS^L<E>(R-<46LPIMAV_&ZE&?ZUWA@ZFX[!RM$7:5GW
M\/19-1I;.M#9,R"C]$O#\77W]J.G;P"]0ND?&)3F+1-[<0T/OY N>,6+;K'N
M)Q;QW\6+P*&A8:EWVH#PWK[^ ?2\7M[(L@?0U2MKW6]+UMU"V%WRA<%!*WS^
MTPE\K&,D!4$SJD=9H=C$[V\F89>J@C1Y;6Q,,/;?:RWPZ8\G_W][]^$6U97_
M#_Q?^7W3D\UF-YOL9F-/HC%V38PUTA1[%Z5)MV #!.F]@_0J7;J@(+U)[[UW
MQ7W_[KE*&1Q@9I@"^GD]SWD289A[SYUS[\!]S^<<7+<-QHNZ5D6?BG+QO@=C
MK%KCF84OAKCS4YXZ2ZKYFZQ+.1B+.WU;[M,<RH/P8$SU32BV0A7>/QV#W\;3
M?//_[8Q(C3W6]]=3\/[E.#S6'!%8.XN%(?8KE1&@;HB"X'AT-[>AOZL'(T-#
M&!\;7Y+!V,2K"8QR[R5LW;.G5G[P67]B>FRL4H/[S^H(5KZ*LK#'8C\W>]]B
M569-!15XK&\K4(7&AT[_54+T&5/4I^=)OV-B$A:,2:VMY,;<FL/\6FW>&TY,
MC[E-9Q%TY2["O1XB)_LINKNZ%=;_V<&8"W>NV*AKP<;T'IX\3L78J'RKN>2!
M@C'IHF!,<BP8JZZLPN.$1(2:VL+G]XO3X?EOIQ!A8H.4I&14O:CD_RXCHNMH
M[T!N3@[BO((0=OZ6P/LY^QW 8X7:.^.5O0\^LWF(OM8.C'-_F[V>6-KGGB0H
M&".$$$(((60![(]P]L=X8E8IE'1=Q @J9@1+XH9;TIY.3X;M8VY?_[Y#&__Y
M0Q-_G+F+BZ9>,+0.P4VG:-QQB\,=][?--99O%NZ/8.,5#4??*+CZ1\$G. 8A
M40F(34A&6D86<G+S4,K]45Y?WX"6EM9W6E5U#0H*B_$D^QD2D],1&9N$@/ X
M> 1&P\4O"@X^4;#VC,)]CVB8N3W"7;?8M_L1/Z/%0>.V#_:=NX>?#QG@V]_?
M5$=]O%E']-=(E,!Q,<\E[G;F>XP$V_A\NSX.:CIPKU<T'F<7H[-'\=-\R0,%
M8[)!P9CB" W&9MSXBCUWAY\V*<\Y%(5N$2(U]OAT2V_$&EC#[Z 6'%8J\X'8
M9-C#UBWQV7$><9?-\<3:#QF^X4A]%(_JLHHE&2X,=O>A//4IDFR\$7;J.CS7
M3J\MYK?]/"(OW4&&4P :GI>*_=SL=PAV76DKK<9C([LW550_"GY"/^;T+=2G
M/><?J\C@4);!F.O&$W Z< D^YZXA[H8]GMH%\-5YA>Z1*(E)0WE^$5\),C*L
MN+7G*!BC8&RQ*!B3''MM6UM:4)"7CT3N6LRF])O<OL?ZX_"Y> /^KE[(R\[!
M\-#[O=ZMM+%IC)N;FE&57X+2J-2I]_("UW D:ECP'U*8/5[9^V#(>5/$>P2@
M[&D>AOKZ%=T-J:-@C!!"""&$$!&EY+Z BIZ;&%4\PJJ&9E5AS1=H2"L\D4,X
M]A$_W:(./MVFQP<J7VPWP)<[#/'ESLG&_FV K[BO?[=+%ZOW:F+C7U>P4TT+
M!T_JXO05$^B9W('Y WNX>_DB*CH&6=E/45A8]$Y+>IR"P*!0V#FYX<8=2VCH
MW<21"X;8K:Z-K<J:V'!0$ZOV:.*[W[7PS4Y=_&VG_HS],)KZ?[:?GVZ]R@=[
M'V]AQTIG_@HZ<0.K=[XV=W768M8!D[@B<8']^-LN(Y@ZQZ"EHQ?CXR_Q^O72
MJ_*0!0K&9(.",<69;XVQ@.T7\-PE%/W=/1@9&,2KT3%,C(TOV 9Z>OES(#<A
M%<$Z9GBPYDV5F-O;RC&WMV/-<_41N&\X#EN5RS#7-49*5!P&EN#-M<ZZ)L1:
MN,%L\Q'8_*3&KRTU>;Z$J!H@TRL,514OT-TE^7G355F/Q]<<8/^CTMOURZ;'
M7NSI6ZA+R57XC7]9!F/.N\_#CGNO?^CL@;RLI^AJ:^=OM/)CBANCK&I/T<$@
M!6,4C"T6!6.28^<^FQ*PL;$13[TC$'Q0=SI87W>$?Q^Q,+R)Y$?Q2_)]9"EC
MQY:=.^PZ.\']3L^NN^S]_N7(*(I]'B'H]\OOC%>WE:IXL/483 ^=0:2S-]H;
MFQ7=#:FC8(P00@@AA! 1O:AOAUMX)LZ8^F'#,0L10P9AP=@"886T*XOD$(R)
M&L!\])LN/M^LA6^V7\'WNZ[@Q]U7L&Z_-C:KZF'W"6.H7+J#4WI6T#1U@8F5
M'TSM@]]I^N9>N&!BAZ-:YCAX[B9VJ!M@PR%=/@S[X8\K^-?.R_C[MBOX?(LF
M7P4VM3;80E-#+C84F^^8SPS'I/$ZR2H8V\2FQM3%/W?I8+VR$>S]XOCI*9?B
MU&>R0L&8;% PICCS!V,7D><>CB$VS>&XZ-,<LL?V]O:BX44U\L(2D737%<G<
M=3OEFB.BCE^'[\93TS<T5ZO!GAN##PY=1)2-!\KRB]#1T;&DIL+JJFE$PBTG
M/%BG\C;@FQX7$4>OH3#B,3H[._EK@Z3Z6SN1%Q"+L,MWX;]?$QZK#D]M(WB?
M%E+NN*$T+AV=U0U2[)EXA 5C3NL.P^:WH_!6TD:\CA6R;KE+U#(<'B(U)!HY
M3[+06-\PM>;<4D+!F.*"L8;B"@1=M\:M36JP_DDP&$O2M$1+;IG"@U-14# F
M.?;:LO<%]MY2&!2/T$-Z N\C#CM.XX'J9:1Q^S;0U2OU[7]HV/%FK84;LWD.
MP?SZLP';+DP'8RM48??+85AL44?<?3=TUC8I>I>ECH(Q0@@AA!!"1#0\.LY7
MSR0]+<?IF[X+APW"UNL2)?R:K[)HL:'*7.N'B;+_PKXG2E]GMM]T^ JM3S;K
MX+,MVOA\JPZ^W*:#O^W0Q3]^U\.WNPWP_1XC_+#_&E8<NHE5RJ98I238?CQX
M __9;X)__6F(?_ZAC[_OO(JOMNOB"^ZY/MNJS34=?++ES7;>5++-<>P7$QJ*
M^QHM]'HLYF?G#,:N"G^-%GA>=BQ_.J"#0Z<-X1L:QZ__]B&A8$PV*!A3'%D$
M8Y-3#(\.CV"PLP<]]2WHJ*I'<TDE<IR"$;Q72V#,L9N:+K^H(U#K+A)"(E%<
M6(2^WCX9]UQT/56-2+ON#)<5*OPTAS.#L4<G;Z+F\3/^VL#6P)'4R. 0ZLI>
MX-FCQWBD:RDP7:/[ST?AMNL<@B[>0EE\IA1[)AYAP9CMYF.X<^ ,'II:HRPE
M&_WUK1*UON9V]'9T8:"_GP^8V+%<:B$'!6.*"\8:BRH0:F2%N^NY,;=&<#]8
M,-:65['DQHLP%(PMSN1[2V5T.B)4#*=#&NZZ[,P^9/'S$61:^V&P77%K$;YO
MQMA:S\V=J A.0O01DQGOW2K\>Z+S:E6DWG1!3W6CHG=5ZB@8(X000@@A1 SL
MC_*ZY@[<=8G$ZK^,\,_=!F^FX1,EB!(UT)(D&!-[&KX%JJ?$#<;>>>Y%!D8+
M]6N^YW^GCT*.YZ)",3GU<3$_/U>?1=C6]WN,<5C+$I8.7DC/?H[1L7%%GW9R
M1<&8;% PICBR",:$8>?.R,@(ZM+SD''+#9%J1O#;=$;@)INOD@Z"KEDA.R(>
M74VM4NRE9(8'!M%<6X^"F%3$: @/!\(/Z2'?,01-&06+:K7).2B*3$:&1P@B
MS]^&YYHCTP$,=VSL5BK!:]]E% 8G*.QX" O&V%1:-U7.(<#6!?4OJA6V;_)
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MQ=@!E1&IZ"JMY</R]Q4%8X000@@AA,C X. 0LK*?P=G5$\=U+/G*,58U]I%
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M'4NJ%".$$$(((820I8R",4(((8000HA0K.II:'@8)645B(Y-A(M?!&[:!<#
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G0@@AA!!"""&$$$(((800\D'X_SIV_<5WI@K2     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
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M56Y>@,/']K#0GNR$3#87;9$R;B\//.A$#Q"E@J<'(262G(T VH&/>,*<(#=
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>=%4(3Q6M3 +_#Y-*L5NP*T^!     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image11.jpg
<TEXT>
begin 644 image11.jpg
MB5!.1PT*&@H    -24A$4@  ! T   %3" (   #=HV*:    "7!(67,  )]Z
M   T(@'=C#6Z   @64E$051XG.W:6W(D26X%T%Z*]J#]+ZA7D?K@&%7#(I/Y
M"/<+P,\Q_,A,Z@I<((*$4?_< ( %_OV?_]U3Z4:!F?Y)/P  S.1. %IS)P#
M$NX$H#5W @ LX4X 6G,G , 2[@2@-7<" "SA3@!:<R< P!+N!* U=P( +.%.
M %IS)P# $NX$H#5W @ LX4X 6G,G , 2[@2@-7<" "SA3@!:<R< P!+N!* U
M=P( +.%. %IS)P# $NX$H#5W @ LX4X 6G,G , 2[@2@-7<" "SA3@!:<R<
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M  #HQ)VPASL! (!.' E[N!,  &C#'Q.V<2<  -"&(V$;=P(  #WX8\).[@0
M 'IP).SD3@  H %_3-C,G0  0 ..A,W<"0  5.>/"?NY$P  J,Z1L)\[ 0"
MTOPQ(<*=  ! :>Z$"'<"  "E.1(BW D  -3ECPDI[@0  .IR)*2X$P  *,H?
M$X+<"0  %.5("'(G  !0D3\F9+D3  "HR)&0Y4X  * <?TR(<R<  %"..R'.
MG0  0"V.A K<"0  U.).J,"=  ! (8Z$(MP)   4XDXHPIT  $ ACH0BW D
M %3ACPEUN!,  *C"D5"'.P$ @!+\,:$4=P(  "4X$DIQ)P  D.>/"=6X$P
MR',G5.-.   @S)%0D#L! ( P=T)![@0  )(<"36Y$P  2'(GU.1.   @QI%0
MECL! ( 8=T)9[@0  &(<"66Y$P  R/#'A,K<"0  9#@2*G,G   0X(\)Q;D3
M   (<"<4YTX  & W1T)][@0  '9S)]3G3@  8"M'0@ON!   MG(GM.!.  !@
M'T="%^X$  #V<2=TX4X  & 31T(C[@0  #9Q)S3B3@  8!-'0B/N!   =O#'
MA%[<"0  [.!.Z,6=  # <HZ$=MP)   LYTYHQYT  ,!:CH2.W D  *SE3NC(
MG0  P$*.A*;<"0  +.1.:,J=  # *HZ$OMP)  "LXD[HRYT  , JCH2^W D
B "SACPFMN1,  ("O_@]O*TDX#ST\.     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image111.jpg
<TEXT>
begin 644 image111.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_XP 8 !0
M /_; $, !00$! 0#!00$! 8%!08(#0@(!P<($ L,"0T3$!03$A 2$A07'1D4
M%AP6$A(:(QH<'A\A(2$4&20G)" F'2 A(/_; $,!!08&" <(#P@(#R 5$A4@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(/_  !$(!" #, ,!$0 "$0$#$0'_Q  ?   !!0$! 0$! 0
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M]O?X^?K_V@ , P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MD;.3LW;<J!@N><$+U- 'HE !0 4 % !0 4 % !0 4 % !0!R'Q2_Y(QXX_[
M-]_Z3O0 ?"V)X/@QX'@E&)(]!L489S@BW0&@#KZ /*?'FI>+X/B#;Z?X9M[[
M4A+I(E-G974$1C9;N(M(PEECX9 T8922-QZ4 =IX+CUR/PTY\0Q7$-]+?WTP
MBN9EE>.%[N9X$+*S+Q$T8P"0  .U '14 % !0 4 % !0 4 % !0 4 % !0!X
M-JDMW8_&K59X=!T6YAGU:TW7]P]LUQ$Q_LJ(8#MYBX22? 4?>DBQR02 =?KW
MASQ+JGBV.X>SMYOLNKVM[I^HR&$I:VJJ%FA*LI?>W[W!7J70[ALQ0!Z50 4
M% !0!Y/X&MBO[0WQ=O-@Q(=(CW9.3MM"<8QC^+USS],@'K% !0!\[>,;[3Y_
MCY86]AJNO3>(?MT-C!;WTEE'I]GF%I2T22P23?,B./,1?F8[?,7B@#Z)H *
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M-P0ALT ?0WP]^)7AOXDZ-->Z')+#=V;B*_TZZ3R[BRDY&R1>WW3@C@X/<$
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M692,O/$YRL<09VWJH ;RV#'=B@#VN@ H * "@#S7P3_R6GXJ?]?6F_\ I$E
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M0!Y_\#/^2 >"/^P5#_*@#T6@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:_BM>VNI>"O".HV,ZSVEUXET2>&5#PZ-=Q%6'L00: /4J "@ H * "@ H *
M"@ H * "@ H * "@#D/BB2/@SXW(."-"OL$?]>[T :OA'_D1= _[!UO_ .BU
MH VJ ,C5/#.@ZS?VNH:EID-Q>6F?(G.0\7?*L.00<$>A (P1F@"QH^D:;H&C
M6VCZ1:K:V5LNV.)23CG)))Y)))))R22222: +] !0 4 % !0 4 % !0 4 %
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M 'G_ ,#/^2 >"/\ L%0_RH ]%H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#R_P"+X)N/AV1NP/%]CG&<=).O']10!ZA0!XM\<M,\0SZ/J6HZ=:$Z
M7#HERE]-&EN[&/<"ZGSC\NT 2#;@GRV^92$R =MX@\*R^,/#FE(NOSZ>T40<
MK:2;[6ZW(!B15V^:@/( *@_0XH TO!FCW?A[PK::)=6]C#]A5;>)K%2J2HJ@
M!RI VL<'(Y^IH Z&@#S7X[?\D0U__>M?_2J*@#TJ@ H * "@ H * /)/VD9&
MC_9Z\2%(VD):U7"Y& ;J($_AUH \_P#C-="]^+NJ%W"CPYX1=X@[I& ]Y/\
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M'CC_ + -]_Z3O0!J^$?^1%T#_L'6_P#Z+6@#:H * "@ H * "@ H * "@ H
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MX&?\D \$?]@J'^5 'HM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MCVW@W5KCQ!;M<:5';.US&HR2@'.#D8(Z[LC&,Y&,T ><>!];\,7OQ'L[32=
M.FW;:-+<QS/=/,T]NUY+R1NP2SKYK2$-N,O#MU8 I:!X\T^S\7ZW/>68GM=3
MEN-8@OQ'O">7#Y<.#_MVMN9!M&2I/HQH X/PA;7]M^RY\.[B^B"RZCXOT^^(
M4$!5EU(.IP?7C'7@B@#ZKH * "@ H * "@ H * "@ H * "@ H * .0^*7_)
M&/''_8!OO_2=Z -7PC_R(N@?]@ZW_P#1:T ;5 !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 >1WNFZD?BA]NM/#\UIK":O&RWEG:O%;WFFM%&LPN)U.QW!4L
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M\%/&[!=W_$CO1CGO X[ T ;/A'_D1= _[!UO_P"BUH VJ "@ H * "@ H *
M"@ H * "@ H * "@ H \NG\3WR_%%]'?4-1^R&_BB2T62WCD7]V"7$93S'MR
M2H+ @@[CR.@!ZC0 4 % !0 4 >9^!V+?&CXJG:5Q=Z<.2.?]"3GB@#TR@ H
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M=I>ZEEM4T&_!%EJ!*D%U*X:&7!/S*0<DG(R<@&)H?Q9T?P%INHZ5\2_ &O\
MA>[O)6NIY9;,7EB_"1HD<D8VE$C6) ,<!!DYY(!P_P -OBSX+\*>./%>J:WX
MJM=:MKF\E_LVTTS3G26-BYW,D.PC$G8B1L#L-QP 7_#>A>-?$1A@^'O@AM&L
M&G\R/Q%XDMQ"+=%#QQ216N29I1$Y(F<MOW#)^5=H!] ?#CX:Z3\.]*N5AN9=
M5UK49#/J>L77,][*3G+'G"C)PN<#W))(!D?&15:T\"A@2?\ A+]-*G!X.YO3
MVR/QH H7%Q$_[3%K D4;O' H=A("Z9MYB/5@N/X>%RP;!/- 'K] !0 4 % !
M0 4 % !0 4 % !0 4 % ' ?&HD? ?QN5)!_LBXZ+G^ T =+X1_Y$70/^P=;_
M /HM: -J@ H * "@ H * "@ H * "@ H * "@ H * .)_P"%<:;_ ,)NWBO^
MT[YKDW"W*1.4982 P98SMW(KY7< >0N.AH [:@ H * "@ H \D^%<(7XG_%V
MXSR^NPIW[6L9_P#9J /6Z "@#Y[U;2M6G^/EKJD6BWT%M!J</G:C/X<BF29=
MP55B=8RPP&P;AW!49(&.0 ?0E !0 4 % !0 4 % 'E7[.[%_@'H,C#'F7%^X
MP  0;Z<@C'&,'M0!ZK0 4 % !0 4 % 'DWPBU>RT#]GWPS=ZFTL:,LJ(L<+R
MN[&:0@*B LV1SP.G/2@#U*SN4O;"WO(QA)XUE7/HPR/YT 3T % !0 4 97B3
M(\):P1G/V*;HNX_ZL]N_TH R/AE_R1[P7_V [+_TG2@#K* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H \U^)'_(\?"W_L8G_](;F@#TJ@#YP\>>(;
M;7/B/JN@S7NC:8TD5QI#37>KO;1/#&D$C"[0,/,0_:I J+M8_,-P!)4 ^CQT
MH * "@#S/X\2)'\$-=WL%W/:J,]S]JBXH A\:11)\7?">HW%Q;1);M'$B-,B
MRRM+(R?*BKYK@';QNV#=N93C( /4J "@ H * "@#S7XX?\DJD_["VE?^G"WH
M [6]\1:'IVLV>C7NI0P:A>D""!B=SYW8^@.T@$]3QU(% &K0 A (P1D>] #%
M@A1RZPHK-U8* 30!)0 4 >3?&YBD?PY(P?\ BM=-')QVEH 9/->2_M+VUK]D
M5HXK3>M[(^TI'Y+;H47;\WSE6+$G(8@8V&@#UR@"$75LUZ]B+B,W21B5H0PW
MJA) 8CK@E6&?8^E $U !0 4 % !0 4 % !0 4 % !0!Y_P#&O_D@WC?_ +!-
MQ_%M_@/?_.>E &M+XAT_PK%H&A:DMPTUS:[4E1,J#'Y:'<2QP29% Y.3WH Z
MJ@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /&_">JP>&K_
M .,'B.6UN;P6_B+YH+==SN!:6V H]?G/?\J /6-*OX]6T6QU2*-HX[R".X5&
M96*AU# $J2IZ]02/0F@"Y0!\[:'I^F6_Q%U"XUVU\ KJ,WBV=;1[VTC_ +2(
M$R2)LEC_ (]KH5W<Y=0>2!0!]$T % !0 4 % !0 4 >/_LS%C^S7X4+C!_TL
M=,<?:YL?IW[T >P4 % !0 4 % #78(C.03M&<"@#PWP_H6B:[^R_X8\/:Q?-
MIMOJ<0"2A&=E<EY?EP>#@,<]NW8T >L:AJD7AWP1+JPC-W#868E^3<-RJH^;
MG<0,<GJ0 >IH ;X1UFZ\0>%X-8O+86[W$LYC0*R@Q"9UB8;N<-&$;)"DYR57
M[H -Z@ H * ,;Q6XB\%:[*20$L)V)&<C$;>A'\Q]: ,OX9?\D>\%_P#8#LO_
M $G2@#K: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \U^)'_(\?"W
M_L8G_P#2&YH ]*H K/I]A([226-N[L<EFB4D_I0!9H * "@#R?\ :#1I?A!+
M;I&LAGU33HMI.,[KN(=<@?F0* '^,YY?^%S^$;!(8)/M.QU7R$>4B-W9V#??
M15&"6^[DA>KT >JT % !0 4 % 'FOQP_Y)5)_P!A;2O_ $X6] &?XDCFM_VE
MO!UT/LTD-YI\UL4E3+)L$DFY<D<D[1D E0&!&&R #UJ@ H * "@ H \R^+D4
M<UU\.DD7<O\ PE]DV.G(BG(_44 6KCQ!<1_&FS\/);V\8D4R/.+B4-+%Y#$(
M8@-A8.,[F( 4X')- 'H= %)=,MDUV;607^TRVZ6S#/R[%9F&!ZY<_I0!=H *
M "@ H * "@ H * "@ H * .!^-()^ _C<!58_P!D7'!./X#[&@#%^+*6YO\
MPL+I8GBGD>UV^:!(#(\(W!,CS$XPP/R@$$CI0!ZQ0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (  20 ,\F@!: "@ H * "@
M H * "@ H * &QQQQ1K%$BQHHPJJ, #T H =0 4 % !0 4 % $4=O;PVZ6\,
M$<<,8"I&J@*H'0 =!0!*0",$9%    , 8% !0 4 % #9(TEC:*5%='!5E89#
M ]010 D444$$<$$2111J$1$4*JJ!@  = !0 ^@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * .&\;ZWJFD^+?A_:6%T88-4UI[6[0*")8_LD[[3D<?,
MBGCTH [F@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * ,[7M570_#6J:T\/GK86LMT8PX3?L0MC)X&<=: &^'M6&
MO^%M)UT6SVHU&SAN_(<Y:+S$#[3[C./PH TZ "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H \\\=AY/B%\,XD8\:Q<2%0<<"RGY_7]: /0Z "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
MYKQ^Q7X8^*6! (TFZ/+;1_J6[]J )?!  ^'7AH!8T TNUPL8PH_=+P!@<?@*
M .@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#SGQHHD^+7PQB.SB
M\OY.3S\MF_0?CU[<>M 'HU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 <WX^'_ !;+Q3QG_B577'_;%O8_R- %
MGP?'Y7@/P_%AALTZW7#'GB)>O _D* -N@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /-O&+L/C7\+T#':9-3)7/!(M>#^I_.@#TF@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .8^(D
MGE_"SQ9)C.W2+L\_]<6H T_#G_(IZ/\ ]>4/_H H U* "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H \P\;R^5\;OA5P#OFU->3CK:T >GT % !0 4
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M\BR;MAST.=C?E0!<H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@".6:*$(9I%CWL$7<<98] />@"2@ H * "@ H * "@
MH * "@ H * "@ H * .5^(ZQO\*O%<<R1-$^E7*N)G*)M,3 EF'(7&<D<XZ<
MT 87PM:()K44FGKIVH><LDUM_9T=DPB8OY+LJJ&9BH^9C\I8,%  (H ]'H *
M "@ H XGXN?\D.\=_P#8!OO_ $G>@#HO#G_(IZ/_ ->4/_H H U* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H \U\9?\ );OA=_OZI_Z2T >E4 %
M!0!R/PRD\WX2>$I<$;M*MCSC_GFOH!_*@#KJ "@ H * "@ H * "@ H * "@
M H \,^-T]G_;.F_VM=:786T-I.;>:^O/LAEF)C(56,B!U&W) RP.W^\: /8M
M"6)?#>F+;LC0BUB",BX4KL&"!DX&/<_4T :- !0 4 % !0 4 % !0 4 % !0
M 4 % '':-_R5OQ=_UX:;_.YH [&@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * ,7Q$BO#IH=0P_M"W.",\AP0?SH VJ "
M@ H * "@ H * "@ H * "@ H * "@ H RO$FG/J_A?4]+2))C=V[P&.1E57#
M#!4ED<8()!RK?2@#F/AIX:U[PUI=_#XAG2YNKB82+*LYGVIMP(_,90[[?[S=
M<G 4<4 =Y0 4 % !0!Q/Q<_Y(=X[_P"P#??^D[T =%X<_P"13T?_ *\H?_0!
M0!J4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YKXR_Y+=\+O]_5/
M_26@#TJ@ H * ..^%?\ R1WP?_V";;_T6M '8T % !0 4 % !0 4 % !0 4
M% !0!XS\3_%^IVVL7^@6[36D$-EYLC&54AE@:.9Y9')C8@+Y*Q#:1EIQ[4 >
MLZ3C^P[#%J]H/L\?[B1BS1?*/E)/)(Z9/I0!=H * "@ H * "@ H * "@ H
M* "@ H X[1O^2M^+O^O#3?YW- '8T % !0 4 % !0 4 % !0 4 % !0 4 ,=
MRCQJ(W?>VTE<83@G)]N,<=R* 'T % !0 4 % !0 4 % !0 4 % !0 4 8OB%
ME6'32S #^T+<<GN7P* -J@ H * "@ H * "@ H * "@ H * "@ H R_$.N6G
MAOP]>:U>K(\5LF1'$NYY6)PJ*.[,Q"@>I% '/0>%KG6;!M3\=,M]=R0D_P!E
MHY-C:9'*!.!*W3+R \YVA02* .,^$7@;P^?AHB6=NNG3)=7"0WFEO]GF"AP
M2R_>^Z.'W CKD4 =]X8U;6%U.]\+>)GAFU6R19X;R%=BW]LQ(679_"X(VNHR
M <$8#@  ZJ@ H * .)^+G_)#O'?_ & ;[_TG>@#H?#2+'X0T9$4*BV4("@8
M'ECB@#5H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#SGQ:SCXU?#0
M(I93_:8<C/RC[.O)Q[X'/'/KB@#T:@ H * ,?PM9Z;IW@[1['1KIKK3;>SBC
MMIVQF2,* K': .1@\ ?2@#8H * "@ H * "@ H * "@ H * "@!"J-D,H.?4
M4 <E=:MXCE^(%UH.F3Z;%:PZ<ETHN+:1W:0NRD%UD "D!?X21R><X !;?Q)<
MZ6V/$^E'3H#@_;K:4W-JOL[[5:/'.69 G^UVH Z)65E#*P*D9!!ZT +0 4 %
M !0 4 % !0 4 % !0 4 8ECH\=KXQUG7%O5D:_@MH&MPN##Y7F$$G/.[S/08
MQWS0!MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!F:SI\^HPV:6\R1-!>0W#%QG*HX9@/<@$?C0!IT % !0 4 % !0
M4 % !0 4 % !0 4 % '"_$C[<R>%([%K==^OVV]KD,T0PLA0LH(S^\"8&1\V
MWOB@"^8?B#(CQR77AU0RXRL$Y]?]L=L?K^(!QOP\3XAQ>"88+"3PZ\,%W=V^
M^X$X=FCN98V. < %D) ';% %YE\6?\+@\)R:\NC,?L=^H-AYH=8L0EBV[.1O
M$0QP.<YR " >GT % !0!Q/Q<_P"2'>._^P#??^D[T =%X<_Y%/1_^O*'_P!
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M3@#+$#)) % '.^$-7T*#P+H$,>JV2*FGVX"_:%X_=K[T ;G]N:+_ -!>R_\
M A/\: #^W-%_Z"]E_P"!"?XT ']N:+_T%[+_ ,"$_P : #^W-%_Z"]E_X$)_
MC0 ?VYHO_07LO_ A/\: #^W-%_Z"]E_X$)_C0 ?VYHO_ $%[+_P(3_&@ _MS
M1?\ H+V7_@0G^- %:_\ $^B6&FW5\=2M9A;Q/+Y<<Z%GV@G &>2<<4 <];_$
M&6YLH+J/P\VR9 X5M3LPP! (S^]]Z !?B!=_+N\*3C) .-4L#M&,D_Z_MTH
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MM'T[X9^+-9DTB\DLY9=-MEN(]R2,N25/&0,@'UQVS0!A>&/VBK%?B=<Z7?\
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M\ 7-PA26;Q/;RNJ*?E8V5B2,$],_E0!]@#I0 4 % !0 4 % !0 4 % !0 4
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MY#;@N2!D ^BJ "@ H * "@ H * "@#BOBV,_!'QP/70[S_T2U 'SW\3=,O\
M3/CE\,+RXMBD%]XCMWMF4K^\5;:RC8@ \ ,K#!]..U 'UR.E !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <SXJM)KK4?
M"K16TDZP:NLLA1<B-1!,-S>@R0,^XH Z:@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S?PII=_K7P#T_2]+UF?1;VXL2D-_ NY[=]Q(8#OTZ4 >=>!?!O
MQSUS2;\>)?BWKN@:G8WTUJ\3:3;R13J#E9HG8#<C \>F"/2@#W3POI6I:)X7
MLM*U?7)M=OK=6634)T"//EB02 2 <$#\* -F@ H \[^.)<? ;QCLW9^P/]U-
MQQD9X],=^W7M0!Z)0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
MYKKO_)QO@G_L":K_ .C+2@#TJ@ H ^??VOLC]GNXP6P=1MLX&1U;K[?_ %J
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M * "@ H * "@#*U>74XKO1UTY&:*6]"79"[ML/E2')]/F"#/O[T :M !0 4
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M-)/!:>)[=((\\1JUM8L0OH-S%OQ- 'UT,8H 7B@ XH .* #B@ XH .* #B@
MXH .* #B@ XH .* .>N/&WA6UU!;";6(A<-,UOA59@'5XD8%@"  \\2DDX#.
M 3GB@#H>* #B@ XH .* #B@ XH .* #B@ XH .* #B@ XH .* .>\1W]Y9:I
MX9ALYEC6\U/R)P>=\?V>9BH'U53^% '0\4 '% !Q0 <4 '% !Q0 <4 '% !Q
M0 <4 '% !Q0 <4 '% !Q0 <4 <'\/-2T[3/A)X=GU*^M[*)X0BO<2K&I8EB!
MDGKP?RH Z4>)_#C:7>ZK'KEA+8V+^7<W$<ZND#85MK,"0#AU.#V8>M &OQ0
M<4 '% 'FGQZ /P \8#UL_P#V=: /2(T$<21@Y"*%R<<X^E #^* #B@ XH .*
M #B@ XH .* #B@ XH * "@ H * "@ H * "@ H \UUW_ ).-\$_]@35?_1EI
M0!Z50 4 ?/O[7Y/_  SY/C/_ "$;;HN>[?E]?P[T =EI/@K1?&OPUT(ZU&QO
MK.X>\L[^%]L]M*)G961UP<>HZ$>O6@"_X6\5:KI+1^%?B)*(M<CF6VMM2$>R
MWU<-G8Z8&%D(4AX_X2/1A0!Z#0 4 % !0 4 % !0 4 % '.>)?"6G^(K6Z+
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MR \K^)XI')'EEMMOIY!)XY&.GX4 ?68Z4 % !0 4 % !0 4 % !0 4 % !0
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MVDJ!@#C% &]0 4 >:_'G_D@/B_\ Z\__ &=: /2J "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /-==_Y.-\$_\ 8$U7_P!&6E 'I5 !0!X+^U>L
M<OP6M;:09%QK5G& 6(!RS=>.> >M 'J?@%U?P)II4L=OF(2QR<B1@><#N#0!
MK:SHNG:]IDEAJ4"RQL#M; W1,5*[T)^ZV&(S[D=": /-K/Q+JGPTUQ= \:S3
M7'A^^O([?2-7.62'> JP2LQ+9R,[F)^]P<?*@!ZU0 4 % !0 4 % !0 4 %
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MGQ/'>7'QWM)]6LK.""2YMK52'*-<0&Y4!9HS<;6RT2%2$.1MR#]V@#Z&H *
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M_%439P]LJG'7F1?0'^1H ]%H * "@ H * "@ H * "@ H * "@ H * "@ H
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M'A?^P=1U6QM)M(NKC3TADN4#+#%,RPD@G()B$9YYYH Z;_A)?#G_ $,&F_\
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M\2@P.G0'O0 0OK1M9C<6MDMP!^Z6.=V5O]XE 1^ - %;S?%'_/AI7_@7)_\
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MC Y( )'4 %O2M2N+Q7AU*P&G7HDE"P>:)!)&DA42*<#((VG& 1N /4$@&I0
M4 <=\5/^2->,_P#L#7?_ *):@!_@% NEZU@8SKNHG[P/_+R_IT^E '74 % !
M0 $ @@@$&@#QWQ)X>M=,^)_A^VMKJZ:TN;*Y9+>5PZ6W_$QTG(CR"0"<G!)
MS@8&!0!5^#L;CQOXB:0_<TO3(U5@V5'DD\=5QR>^?:@#VR@!DD4<J[9$5AZ$
M9H YJ!6\/G[/JLEL-'BVA+N6( LSN%1&(/!'=BN&WKRN"" =&+:V'(MXO^^!
M0 &VMB<FWB)]=@H B;3M/<DO86[9.3F)3S^5 #?[*TO_ *!MK_WY7_"@ _LK
M2_\ H&VO_?E?\* #^RM+_P"@;:_]^5_PH /[*TO_ *!MK_WY7_"@ _LK2_\
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M54* =H /3KCO0!I4 % !0!YE\?&2/X">*)'QL6*(ME0P($\>1@D Y]* /3:
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MN.HH ZN@#COBI_R1KQG_ -@:[_\ 1+4 ;'AO_D$S_P#80O?_ $JEH V: "@
MH * /./&B _$[PI)N *V5PNW/)SJ6E<_I^M $GP\56N(YAY)<:%IT<IC))#[
MIS@]NF* /0Z "@!&570HZAE88((R"* .8AMK_P +WLS)+/?Z%.6E*RN7DL6V
MDX4D_P"IPJJ%QE2<Y(/R@'31R1S1)+$ZR1N RNIR&!Z$'N* '4 % !0 4 %
M!0 4 % '+ZGX:N(=:C\0>&)TT_4'N(Y-0AV_NM3B"E"L@[.%/RN.<JH;*\4
M:.@:];:[8EPGV6_@PE[82.K2V<N,E'VDCW!Z,,$9!H UZ "@ H * "@ H *
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M?RH 6@#Y]_:CC\W0_AY$03O\76:X7J<K)['^1H ^@J "@ H * "@ H * "@
MH * "@ H * "@ H BN/^/6;_ '#_ "H Y?X9?\D?\%_]@.Q_]$)0!UM !0 4
M % 'EG[044EQ\#=6@B ,DE[IJ*">I-_;@4 >IT % !0 4 % !0 4 % !0 4
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M= !0 4 % 'FOQR_Y)#=_]A+2_P#TXV] 'I5 !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % 'FK?\ )T$'_8HR?^EB4 >E4 % 'S]^U21_P@_A!<_,
MWB>S"@$@GA^F.?RH ];\ ?\ )-O#O_7A#_Z"* +6J>&=/U+5K35ANMKV"2)G
MFAX,Z1DLL;_WE!8D=P2<=3D Q? WBF[OM+M=$\4L+;Q7:QF._@;:OS@D!EZ!
MPZ@,&48QV4_* #MJ "@ H * "@ H * $=0Z,C9PPP<''ZT <#<:IXA\(:W(E
MY9I?:%J>L[;5X6=I+2%[8N^_CDFY5@HS_P M0H_A4 ';V-]9ZE8Q7VGW45U:
MS#<DL3!E8>Q% %B@ H * "@ H * .1^(\5[+X#N5L;47;+=6;RP%D420+=1-
M,I+D 9B#_P!.<4 9/_"SF_Z%V3_P/M__ (J@"EJ?Q&L;FQ\K4_",UW:>;&SH
MEW;R,N'4APN\9*D!L#GY>,G H V+3Q7I#)+K&C7EO-#/,\=Q97-X(9(GB?RG
MV(Y(!&Q_E&T,0#GDM0!T<7B;P]-!',FN6.R10PW3JIP1GD$Y'T- #_\ A(=
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M50 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!YJW_)T$'_8HR?\
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MPR&!Z@B@#EKF]N?"VKSR7/GS^'[E3,)2?,:UN7G1!$/XBCF4L,YV;6&0NU0
M=/!/!<PB:VF2:,D@/&P8$@X(R/0@C\* )* "@ H * "@ H * / ?VEX(6C^&
M-P8D,R>,;)%D(^95.XD ^A*KGZ#TH ]^H * "@ H * "@ H * "@ H * "@
MH * "@#*\2,4\):PX8*5LIB"06 ^0]AUH 7P[_R*FD?]>4/_ * * -2@ H *
M "@#S7XY?\DAN_\ L):7_P"G&WH ]*H * "@ H * "@ H * "@ H * "@ H
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M0!C7&L:AI7B6SL+ZV-QI^H&?RKJW@?%J41&6.3&X?,!,=Y(&5"XR: .@5E=
MZG*L,@T +0 4 % !0 4 % !0 4 <Y:Z9<>&AJ<VF6XOK2ZN?M?V.)%259)''
MFL'+!6&,L 0#P1DY& #H8Y%EB210P# , RE3SZ@\CZ&@!U !0 4 % !0 4 ?
M+?QMU6[O;OPO;7=T+A8/B/;16Y P$C2&/Y5X[,[ \_>!_  ^I* "@ H * "@
M H * "@ H * "@ H * "@ H R/%+%?!FN,K["+"<AN./W;<\D#]1]: '^'?^
M14TC_KRA_P#0!0!J4 % !0 4 >:_'+_DD-W_ -A+2_\ TXV] 'I5 !0 4 %
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MN?\ T4U %GP[_P BII'_ %Y0_P#H H U* "@ H * /-?CE_R2&[_ .PEI?\
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M "@ H * /DGXZ )XT\$B-QLE\>!V5<A=P2U7\3U_$G'&* /K:@ H * "@ H
M* "@ H * "@ H * "@ H * ,7Q:-W@;7U"J^=/N!M8X!_=MP3QQ0!-X=_P"1
M4TC_ *\H?_0!0!J4 % !0 4 >:_'+_DD-W_V$M+_ /3C;T >E4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H RO$O_(HZSU_X\INB[O\ EF>W?Z4
M+X=_Y%32/^O*'_T 4 :E !0 4 % 'FOQR_Y)#=_]A+2__3C;T >E4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:Z;_P G,>(_^Q8T_P#]*;J@
M#TJ@ H \#_:64/%\,4;.&\96(."0?XNXZ4 =AX>U'6O#FCZ3-/;2W7AV?3[0
M6J6\)>6!R$0HY+\?>!# 8(4@[6P7 /1;.\MM0L+>_LIEGM;F)9H95Z.C#*L/
M8@@T 3T % !0 4 % !0!D7MK>VLMUJ&G2P#99^5%;/$VTNNXKDJ>G.,!<CGK
MP  7-,OHM3TJTOXI(G6XA27,,F]/F4-PV!D<\' S0!;H * "@ H * "@ H S
M]4TBUU18I) (KRV+-:W:J#);.5*ED)![$@CH1P<B@#-L=2DL?$?_  C=\UU<
MSW7VJ]MKB3:085DC+*< 8"&XCC7J2%)/0F@#>G@@NK=[>YACGAD&UXY%#*P]
M"#UH QY/"'AB0ATT*SMI5!"SVL8@E3/7;)'AESCL10!E-?ZEX0U&&#6;Q[_P
MY<%8HM1G(\VQD/"I.1@-&QP%DQD-@-G.X '8T % !0 4 % $-W_QXW'_ %S;
M^5 'G?PT9QJ-Y;RG#1Z-I6U#R53RY=O( '8\>N?44 >E4 (Z*Z%'4,K#!!&0
M: .7BBF\'M=NJI_PBL,#W"QQ1L\UK)N!*(B@EXSEF'=3D?=P% .FBECGB66)
MPZ-T(H ?0 4 % !0 4 % !0 4 % &5J^CQW\4MQ:.MEJHB\N&_C1?-C 8.$S
MU*%E7<N<$4 )9:OB73=+U<):ZU=6AN&MTRR$IL$NUNA 9U]\,.* -:@ H *
M"@ H * "@ H IZAIMIJ=MY-TC<$,KQN4="&# JPP1RH^N.<B@#+BU34=.U*V
MT[6+4M;20(J:C&2ZO,!(9/, 4"(;40ACP2Y7L,@'0 @@$'(/>@ H ^1_C IN
M?%/P\A&7(\?7*[=RC'[Z(XSSC\>?PQ0!]<4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!E>)?^11UG&?^/*;HVW_ )9GOV^M "^'?^14TC_KRA_] % &I0 4
M % !0!Y7\>YF3X96ULK[3=ZYI<('][_3(FQT/]W/;I^! /5* "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * /-=-_Y.8\1_\ 8L:?_P"E-U0!Z50
M4 >"?M)_=^%__8YV/_LU 'K7@J8WOPZ\/336SP&73;<M#*.5S&O!% &#/8'X
M>LE]I"21>$XOM5[J<(>,K9QI;@KY:D!MF8^BL=I( 4J<H =Q:W<%Y"986SAB
MK*>J,.H/O_\ K'!H GH * "@ H * "@"G+80L[2VY^R3.T1DEA50TBHV0C$@
MY4C*^N&.".M $=EK.GWTRVT=S&MX8?/-HTB^:B;BN2H)P-RE?J"* -"@ H *
M "@ H * "@"M>6-O>Q;9=R2 $)-&VR2//4JPY'0?7O0!4N[R\TZ5/]&EOXKB
MX2-2C1HT08@'@D;@OWCWQG )'(!=:\M%8JUU"K X(+C(H J:DFCZMI-WI=_/
M!+:W<302H9!\RL,$=?0T 4/!=_=:AX-L);^226[@\RTFEE #3/#(T32<?WBA
M;Z-VH Z&@ H * "@""[_ ./&X_ZYM_*@#S;X57%Q>W-_>7F/M#Z=8H2NT@HI
MG"?,HP3MQG^0S0!ZA0 4 % &3?6E]%>1ZEIMTX2"*02:> /+NF)# YQE6!W<
MCKNYS@8 +&D:DFL:+9:FMK<V?VJ%)OL]VGES0[AG:ZY.&'0CU!H O4 % !0
M4 % !0 4 % !0!5N+&WN+FWNVC4W5KO\B0Y^0LN#P",C':@#._MB+2I=/T[5
MF:.6Y+11W#'*.5*J"[=%9RPPO.2<=: -N@ H * "@ H * "@ H AN[:&]L9[
M.?)BGC:)]K;3M88.".G!H Y])9?"TJ0WE]+-H45F\IN;D9-F(4B4*S@?,&'F
M.6<YR#R1@  Z8$$9!!H ^3?B( ?B)\/P651_PL.ZY8@#[\/<@_RH ^LJ "@
MH * "@ H * "@ H * "@ H * "@ H PO&1QX \1$'!&FW//_ &R:@"SX=_Y%
M32/^O*'_ - % &I0 4 % !0!Y-\>D$O@OP]$55P_B?2QM;.#_I"]=I!_(@T
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MKZ#18XO#4-ZVFJ[[/LBV#QAMQWX(G(SNSGWS0!J^?XK_ .??6/\ OS8__'J
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M_()\'_\ 8W:1_P"E2T >E4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M 6Z ,'QH0OP^\1L5#@:9<G:<X/[IN.* ."^$87^V]?P3N^RVV1VQ]HO,?UH
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M_P"QNTC_ -*EH ]*H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M*D\GQY\(9L$[-:E; .,X5#UH ]H\$MO^'GAI\8W:7:G_ ,A+0!OT % !0 4
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M[^Q'K[]P: /5* "@ H I:MI=EK>CW6DZC$9;2ZC,<BABIP>X(Y4CJ".00"*
M,^YO-6TWQ!IT#1&\TJ\#0R3!1NM90-R,QX^1L%<\G<5Z9H V8)X+JVBN;:9)
MX)D#QR1L&5U(R""."".] $E !0!\I?%9<?'#X)'<3N\3:D>>W^G1]* /JV@
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MM9A8: M^393 %C!#(D?EQHJJ=RB3S\]"BA>"IR #OE8,H92"",@@]: %H *
M"@ H * &2Q1SPO#-&LD4BE71QD,#P00>HH X?7[+6O#EU::IX4LVNC(!#>++
M(\GGG<HB\SDE5PS@RJ"R83(**0 "KXYUG3=8\&V;6<_F&/7-%\Z(-MDMV>]M
MI%61"00VUERIY&[..* +_AC54T;PMI^E7EA>BYM80DH2 L%8=1GOB@#=_P"$
M@C_Z!.J_^ ;T '_"01_] G5?_ -Z #_A((_^@3JO_@&] !_PD$?_ $"=5_\
M -Z #_A((_\ H$ZK_P" ;T ,?Q)"F=VD:N<*6^6QD/ ^@Z^W6@#G?&'B.R?P
M;KTIT35A.FG742ROIDGR IS\VW[I(4GL=N>W !9\#W$-QJ6OF"6*5$E@4M$Y
M8%O)4OV ^\6^[\N,$=: .UH Q_$GAS2_%>A3:-JT<A@D9)%DAD,<L,B,&21'
M'*LK $$>GI0!R=AXFUGP7<KH_P 1[Y)[.:X$.G^)"J11W&[E8[A5PL,N<J"
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M,;$:9X+ 95W>,-(&",Y_T@' ]/7\* /3: "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /-?"7_)>?B9_U[Z1_P"BIJ /2J "@#YU_:1_Y'3X3?\
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MBG19IYX;>)K(QB2>58UW?VGIS8RQ SM1C]%- 'I/_"5>%_\ H9=+_P# R/\
MQH ;)XO\)PQ/++XHTF.- 69VO8@% ZDG=P* -L<C(.10 4 % !0 4 <OK?AF
MY-Q=:YX3GM]*\0S(%>62+=#=[<86<#D\ J&'*Y[@8H ^9-:DEN_BA\$)[NSD
MM)I?%7B&22W=E9H7_M1B5)!*D@\$@GIQVH ^PZ "@ H * "@ H * "@ H *
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M_P"$?NPBHGBK6554V?>@8GIDDF(G/'7/&3C% $G]CZC_ -#7JO\ W[M?_C-
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MI3/X4\6QI8>+K"-/M$6-B708R!98L_WO)=BHSC'!9<,0#OJ "@ H * "@ H
M* "@".X@@N[66UNH$GMYD,<D4BAE=2,%2#P01QB@#C=3T74O#<NL>(/"%I#+
M/>30W,VG .!=/N"SOR^T.T83:0HY3YBP.  =%H.O:=XCT:#5--D8QRHK-%(-
MLD)*AMDB]4< C*GD4 :E !0 4 <CX\D*6GA\!0=^NV*\YX_>@_TH ;\+6W_!
M?P.V ,Z#8G & /\ 1TH ["@#FO$_A<:Y;RS65V;'46CC03;0RL$D$B!@?1@2
M&&"I)(- $ND:Q>RSSQZQ +19;J6*R,B^7)(JL1AD)/<'# D.N&XR,@'04 %
M!0!S_C=UC^'?B5V8*%TRY)). /W34 <I\++5K*]\4V[.SL+BT8E\YRUE Q'/
M/&<<^E 'I= !0 4 % !0 4 <)\3]"L;WP%XAU3S)K.[MM.FE:>VP&F1(9?W4
M@Z2)B20;6Z;B1@X( ,_X9:K;1OK>FWTL5KJ-SJ\[Q0%\B95BAR4) W84J2,
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M<[][/^Z9E&T%=H 9L%@Z Y8\@'2T % '.>/&V_#;Q.V=N-+N><GC]TWIS^5
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M_P"QNM__ $ENJ /2J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MB@#4H * "@ H * "@#Y3U#_DM_P>_P"QE\6?^E\U 'U90 4 % !0 4 % !0
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MKD9&#N(P230!J:%XDM=7GFTV4K;:S:11R75BS?/&'&5< X.PX."0#P00""*
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M 4 % !0 4 % !0 4 % !0!YK\5/^0O\ #3_L;K?_ -);J@#TJ@ H * "@ H
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MN W"@#-^)8)\'6V'*XUK2"<8Y_XF-OQ0!H^!XGA\ Z*D@P3;*_7/#?,/T(H
MZ*@ H \]^(&D:Y=ZKIVH:5H=IK4,4)AF@NU$J)FYMW\P1ETW.JQN5.<AL>IH
M QIK;40@1O!,1$AV?)HHR,]\BZX^M %:XN;FTMYKBY\%)%# ADDD;00%50,D
MY^U4 =:_@7S"Q9="&<YVZ9*OIZ7''0?KZF@!9? QFM7M9!H7DNXD95TR5<L#
MD=+CL>0.QQZ4 8%YX7UG0$1C?/?67G ;X$O7FC5Y44+A;D$HA8$ D[40X^Z
M0#7/@*Y:)?*U> 8.Y"?MQ /'/_'Y["@"1/ ^J1.IBUV% K97 OL@;2,?\?O7
M)//H<8[T "^#O$"($C\30*JKA0%O^/EQ_P _WKS]./>@#PW7Y0?VE/@M;$P!
MH#J*,(58 D22KORSN3N*D_>;G/)R* /JR@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /-/BJQ_MKX9KM)!\6P'=Q@?Z+<\?Y]* /2Z "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /./ ;[OBE\4QC&W5;,=3S
M_H$!_KVH ]'H * /F3]HE2_QF^%P !_T?5CRI/2!3V_R* /?O%?A71_&7AZ?
M1=9@+Q2#=',AVRV\@Y66-NJNI ((]* .2\,^*]5\.:_!X!^(5TKZA+QI&M,
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M5 '">&?%WB'PGXK7P#\29C<&YD(T3Q&4"1:BI)*P2D *EP!QC@/CCGJ >KT
M% !0 4 % !0 4 07=G:WUNT%Y;I/$01M=<]05/TX)'XF@#S[3KS4_AU-HGAO
M5HUNO#9A2R@U1"Q>*?< OFJ?N([.$4+\J80#AL( >CJRLH92&4C((.010 M
M!0 4 % !0 4 <QXPA%Q_PC\94-C6+=\$_P!W<V?TH O>%/\ D2="_P"O"#_T
M6M $.N>%=.UJZLM0VFVU"QNH[R*>+"F22-)%C64CEXQYK_+D=3ZF@"AX=UM]
M-TS1]$\4ZBYUN<O:K+<0^5]KEC^\4[$, 67N5&?6@#KJ "@ H * .7^(H#?"
MSQ4I0.#I=R-I&0?W;<=#_(T 1^"O-+>('GCD25]15F$HPY/V6WR3VS]"1Z4
M=90 4 % !0!Q?BSPMJ$DTWBCP;.MAXIBAVKO.(+\ J1%.O0Y"!0^-R@G!H T
M_"WBW3/%=@TEJ)+6_MU7[;IUP-MQ9.<_)(IZ'Y3@]&&",@@T =#0 4 % !0
M4 % !0 4 <[XPB6;1K-2\B$:G8D;'9,_Z3&""5]B?Q H Y[P#?W>A?#WP[:Z
MPZ-I-KH5FRZL<*I.T@B3+'&$$9+=,D\T >A@@@$<@]Z "@#!U[Q9I?ARZL[;
M4$NGEO&5(A! T@W-(D:@D< EY$ SZGL#0!:>[U2[@'V#3S:L63,E[@#9D;B%
M4DE@,X!VC(]* #1M%@TB*=_-DN[VZ?S+J\FQYD[=LXX"@<*HX _$D U* "@
MH * ..O='O-"UO0+OP[;3_V5;O):W=A;RG8L,F2K+$S! $?8?EY500H(.  ;
M^F:YIVKW&H6UE,S3Z=<&UN8G0HT;@ C@@94@@AAP1T- 'R=(Q?\ :)^"#D %
MH+XG  '^NN.PX% 'V'0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % 'E'Q/C,_Q0^$D!(V?VW/(59L E+25@?KZ?_7H ]7H * "@ H * "@
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M * "@#S7P!_R5/XK?]A:S_\ 3?;T >E4 % 'S9\?O^2V_##_ *\]:_\ 244
M?2= !0 4 4=7T?3-?T:ZT;6;&*^T^[0QS03+E74_YZ]0>: /-M U;7?AI?6_
MA7QW?_;] NKE;71-?8_,"Q_=VMSW#X&%D^ZV "0<9 /5Z "@ H * "@ H *
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M 4 % !0 4 % !0 4 ?(=K_R<1\%>6'^@ZA]W/_/6X]* /KR@ H * "@ H *
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M#T'2-;BU0S02VTNGWT#LLEG<%?,"ABHD&"0R-CAAQU'4$  UJ "@ H * "@
MH * /D:Q0O\ M$?!?!88T_42<?\ 72XH ^N: "@ H * "@ H * "@ H * "@
M#Q'2= M_$GQ/^*/A3^V=<T:VM=5T_56_LF[-F9&FLE5E,B_-@M&6."N2%]#0
M!+-X:TWP;^T1X(N+==1N[75].U'3XGO=2N+PP7($<^_]^[%=T<4@^7J>O:@#
MVF@ H * "@ H * "@ H \U\=?\E@^$__ &$=0_\ 3=/0!Z50 4 % !0 4 %
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M2?\ R10!\\Z+&8OV@O@M'QE-*U%3L.P</<= <\>U 'UO0 4 % !0 4 % !0
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MGGMZ\ "?\-J^#P2?^$:U!P#@#<JY]^^/IS]: &C]M?PCN;/A6_V]L3#/_H-
M#O\ AM?P?_T*FH?]_E_^)H Q+']K;P;;>-]:\3GP_?%M0LK2U$/FXVB%YCUP
M02?//I]V@#H8OVT?!<F-_AZ[AZ_?E)]/1#Z_H?;(!C:W^TY\)O%$]E=:[X8G
MN);56\I6NIE\LMC/W$P3QC//4^M &1+\<_@// ]O+X)=HI,AE-[<X.>O\- '
M<VW[8'P_C@BA6S,2*H4!Y)SM R.3Y)ST'KU'O@ JZO\ M4_#'7-.:RU#3;2X
M5MX3[3'+*L3;64/@VY[$].<'!QS0!C^"?VI_"_AC0+#PMJ,T.HV^FV<,$.H+
M]H3S D:H593"3NRK-G@88#D@T =7_P -?_#[_IE_WU<__(] '.>*/VE_ /B-
M])G@UJ?2+O2[EKF&>U\UB2T3Q$$/:D8VR-^(% %%_P!I313&JI\1M15E;=N%
MNN3TX.;(C''IW- %C2OVB+75/$VBV-O\2+I1<7D,,D3V E#(Q"E<"U4L2<8.
MX=>_2@#ZB\)WNHZEX(T+4=86)=2NK"":Z6$802M&I<+UXW$XYH V: "@ H *
M ..\864OB*_TKP[:--$8KF+4KFY3[L2PNLD<;>N^54^7NJ/R,"@"9_$=[H6L
M/;>*E@@TZX DM]2CRL$))BC\B5FZ.9)#L/\ $O4 J20#JZ "@ H * "@#Y*T
MPC_AHGX-9*C_ (ENI?>&?^6EQ0!]:T % !0 4 % !0 4 % !0 4 % %"ZUC3
M+'5=/TN[O$BO=2:1;2%L[IBB[WQ]%&: +] !0 4 % !0 4 % !0 4 >:^.O^
M2P?"?_L(ZA_Z;IZ /2J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /,OAP"OQ$^*BA'5/[=A(Y.TDV4&< ]_7GTX'2@#TV@ H ^6OC:S+^U%X(V
MYY\/Z@#@CIY,_L: /;_&OA'4-2EB\3>$+U-)\6Z?&XMYR@\J]0C_ (][CC+1
MD@$'JA&1WR 7?!WC.W\5V]W!+I]SI&M:<RQZCI=V )+9V7(P1PZ'G:XX('U%
M '4T % !0 4 % $-U:6M]:2V=[;175M,I22&9 Z.IZ@J>"* /'S?W/P.O[>Q
MU&:6[^&]W*4MKI]SR: Q/RPMU+P$D!#U3D=,8 /8;>X@N[6*ZM9DG@F021RQ
ML&5U(R"".H([T 2T % !0 4 % !0 =1B@#S.ZL-=\"^)+N_\,Z-+J'AZ6T%Q
M<6,3Y99%DP_E+V?RW#  '>(F!(.TD [_ $G5M.US2+;5M)NX[NRN4WQ2QGAA
M_0@\$'D$$&@#S7XZ;V\*Z+&D33;[^<&-%8LX_LZ\.T;2",XQG. "<Y7((!WO
MA+_D1]!_[!]O_P"BUH VJ "@ H * "@#B/'89M>\!JJ*W_$_4G(R0!:W'(H
M[*>WM[F-8[F".9%=9 LBA@&5@RMSW# $'L0#0!\Q?!8V,G[3?BI].B,=DWAV
MU,"-U6/='M!SGMCO0!]0[5_NC\J #:O]T?E0 ;5_NC\J #:O]T?E0 ;5_NC\
MJ #:O]T?E0!SGCN5;;X=^(9\[-MA-\P7./D(Z4 6M)5?[<\0?*/^/J/M_P!.
M\5 &SM7^Z/RH -J_W1^5 !M7^Z/RH -J_P!T?E0 ;5_NC\J &^3%N9_*3<P"
MD[1D@9P/U/YT ?/7[2=O;V\_PM\B"*(?\);:#Y(@>,D]._))Q[GUH ]O\*?\
MB3H7_7A!_P"BUH V: "@#F]9\9Z5HNOVVA30W=QJ%TB/%%;Q;MVYBJC<2 "=
MK'D]%- %B:X\0WRB&QL%TI71P]Q>NLDD38.TI'&65^>N77'OTH T[6R@M/,:
M-<S3$--,0 \S!0NYL 9.% _#B@!FJ:78:UI-SI6J6L=U972&.6&10RN/<&@#
M(EU'6=)UQDOK2.;0##&?MT95&MG"R&0R)VC C4[@<YE Q@$@ Z($, RD$'D$
M=Z %H * "@#Y,TK=_P -%?!K;N_Y!FI9VG''F7'7VH ^LZ "@ H * "@ H *
M "@ H * "@#R_P =M&WQE^&T4B2NJ+JLSA$8Y06FT@$=&^<8&1[4 >?_  7\
M4Z_K?B;P6]Q;^*#IG_",7%G+/>PS+:33I/$T;_,Q1F$>]/,/S'D'B@#Z0H *
M "@ H * "@ H * /-?'7_)8/A/\ ]A'4/_3=/0!Z50 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0!YQ\.X&3Q[\4)RRXDUV)0 !D8L;?KP#W]/Q/
M6@#T>@ H ^5/CQ,;;]I?P9.L#SE/#]_\B%0>8IQGGMS]: /JN@#S_P =?#Z?
M7-3M/%WA345T3QGID96UO""8;M.3]GN5'WHB>_WER2O/! +?@7X@V7B];C2[
MVTDT7Q3IP U+1KD$2P'.-Z9 \R)NJN."".AXH [6@ H * "@ H @O;*UU&PG
ML+ZW2XM;A#'+%(,JZD8((^E 'CK-?? W5!A7O/AA>2@8#/+<:!*PY/))>V)!
M8XY0L3C Y /9;>X@N[6*ZM9HYX)D$D<L;!E=2,@@C@@CO0!)0 4 % !0 4 %
M !0!YA>:9J/P^\5:UXE\/:&MWH=_:I)<:=9MY;RWGG,6=(U3;N,;GYB5W%5#
M-T( ,'XOZWHWB+X9>&->TV]CN-+O+N6>.X C.U3IMX=V)2%#+_M<J1T)&* /
M6_#\9B\+Z3$T(@*6<*F(!@$P@^7YOFXZ<\^M &E0 4 % !0 4 <5X[M#>ZIX
M,@2XFMG_ +;#K-"JED(M;@_Q @>G(- &R^B:HQ)7QAJR9QP(K3C!Y_Y8=^E
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MA77_ !;K&JW<6L> I?#6DQ1*;6:XOH999FW$%3%$6" * >6[X^@!U] !0 4
M% !0 4 % !0!YKXZ_P"2P?"?_L(ZA_Z;IZ /2J "@ H * "@ H * "@ H *
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M6UZ\B@9_<3)-C)Z [,9[9S0!3\*?$/1O&>J7EKHMCJK6<""6#4YK&2.SO4R
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M5B=Q&[.X!@ :G@O69]+\'HGB#3+^#4I;N[NIH;73;N5$,UU)* #Y0SPX^G-
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M<Y., 'MU !0 4 % !0 4 % !0!YKXZ_Y+!\)_P#L(ZA_Z;IZ /2J "@ H *
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M DMI< F-P"0& 8="0<@@D$$@&I0 4 % ''^+9)(O%O@1TB,BG5I4;&<J#97
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MY^_:1M8)];^$;O&ID_X2^TB$FT$JK,-P&0>#M7CIP* /:/"G_(DZ%_UX0?\
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M$YQQC<.,\Y/IP >H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M->/&D&GN\P\F>X>>5V1HP#-)(61%5B %YX4;L @@'IJ(L<:QKG:H &3G]30
MZ@ H ;)(D4;2RNJ(@+,S' 4#J2: .:NO'&C0:==ZA:17VI6MI%)-+/:6S-%L
M098K(V$?_@+'OZ&@#R;]H&XBN[[X.7<!)BF\7V$B$C&02"/YT >S^%/^1)T+
M_KP@_P#1:T ;- !0!YAX[N],M/&%G->ZQ%I]U!)8S6:21"3SY!]L7;MWIQM8
MDG< ,#UH YOQ)'!KVN:?XDMM>L](\1Z>0(=4L[.(2-%GYH) ;LB2)LG*D<'D
M8(S0!9\+_%#Q9JCG1]:M+:R\0QJ\OV:UT\W4=Q L@7SHF2YY!S]W&0<\8&:
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M]K87'V/'S#OSC\: /5* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MPL\%223.VGWN9M^_&J78'SK&K$ 2\$B*,9&/N_6@!)/AKX0MH'FAL[U6BS,
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MV8<A;ZXC<I))+@X:-64HL9X)#,P.$P ;?BEEM_ ^MLA$2QZ?.01P% C;V/\
M(_0T >&?&K_CP^!O_8SZ9_): /=/"G_(DZ%_UX0?^BUH V: "@"GJ&E:9JT"
MP:IIUM?1*P<)<1+( PZ$ CK0!G_\(=X3_P"A8TK_ ,!(_P#"@#DO'7@7PIJ5
MCI.E6VA6=GJ-QJ5L]M=6=JJ36PBE6:5U=0&C_=QLN\$8+J.] %K3?%][X?\
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M@T%CA=;T]C@G N4Z#D]Z /GO]H^ZAD^(OP1DBGC> ^)%)=2".)K<'GVYS_\
M6H ]Z\*30_\ "$^'OWJ?O;"#R_F'S_N@>/7@$T ;321I]^15X+<G' ZG]10
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M<L<#H.V,"@#D_$^/^%W_  \^[G[/JO\ #S_JX>_8>W?CTH ]"H * "@ H *
M"@ H * "@!LB"6)XR<!U*G@'K]>* '4 % !0 4 % !0 4 % !0!YK\*?^/\
M^(__ &-UU_Z(MZ /2J "@#Y6^(C[/VW_  ZNW._PV%^G[R<_TH ^J: "@ H
MP?%OA;3O&/AN?1=2,D:O\T4\3;9+>3!"R(?[RYR* .2O?%'C+2HG\-:O;6D>
MOZBT5MH^I6^#;W,CJ3(?+/S PA9)"IX**HW$G% '=:-HUAH6FK8Z?&53<TLD
MCG<\TC'+R.W5F8\DF@#1H * "@ H XWQEX&MO$4UMKFF3'2O%&G!FL-3BX93
MM("2<?O(LG)C/!]1U  >"?&DGB*)]+UO3VT?Q+9PQR7E@YXPRA@\?<K\P![J
MQVGGD@'94 % !0 4 % %+5-3L=(TR6^U&7RX$P,!2S.Q.%15'+,Q( 4 DD@"
M@#Y[U?2O$"^(]>^(&BZ:Z;I8)-5M+:1G^RJH$4RP;<J]WY)R\J+^[\LQKN9V
M8 'NOA+4_#FJ^%+"\\*2PR:0T2^0(1M"KC(!!Y!YR<\\Y[T ;E '%_$K3[2\
M\*V]Y?VXN;+2[^WO[F)@2&A5\2DX!/RHS/COMQQG- %[_A ?!?\ T+EE_P!\
M4 *O@'P6LB/_ ,(U8,48.NZ(, P.0<'C@@&@#HHXXH8EBAC6.-> J+@#\* '
MT % ')Z[X1M[S7+3Q':W36=W90RQD)&,.CY+#C!R2<GDJ>"02 0 >"?LV(%^
M+/B\G:I/A[0B "06_P!#3G!'/U!Q^? !]3T % !0!P9\":RWBS6_$$?CC4-/
MDU*>)T@L8(A''''&$56$BOO8X.6X'(P%QD@''^)M8\26NLQ^%=8O++5]065;
MN%&T@7"36S+(B,B#)CE$@$98[E4.&P0QV@%G5-9\5>$];TCP[H.G69FO;F(W
MB)"JP0)(^Q&W1QJ=S".7D(X7RP6P#F@"EKWQ CU72[_PV=9AL=5F-JJS6IBO
M8)%EFPKQ/'EM^T'!D0*#&"1@X( ^^\9_\(OXJ\6V,FLVUYJ=UJ\*+82VJ")0
MUK;+&2[R1C)&"Q#-T)"\4 5M<^)&IV>J6VA&^\)WBWDD=M*T$9N8H6D;A' <
M;"8S-)ELKB)@<;AD LW\WB#0_%VD:/INC>$GUG4!,@>WTEF%K]UE61D<,L94
M.Q;'5%7^(&@#=UCX<>)-9O=/N;_Q79W(M-4M=0CC&F>2ML(G#?N]KG<QP<&3
M>!GVQ0!ZA0 4 % 'S1^TU#'<_$;X*6TP)CE\0A' )4D&6V!Y'(_"@#TS0]>O
M_!OAK2Y/$#O=>%Y;>$V^JD#S-/1E79%<A0 47.//  QC>HP7(!Z4K*ZAE(92
M,@CD&@!: /(M=;'QY@^;&3I ZXS\NK>X_K]#0!Z[0 4 % !0 4 % ')>(_"D
M]S/)K_A>Y72_$J*I28\0W6W.(K@ '>A!89P2N[<.0* +/AGQ7;Z\U[8W$!T_
M6-.G:VN[*5ANW* ?,C[M$V<J^!D=@010!\S^"/\ DY7X.?\ 9.;3^'/_ "QF
M[]OK^'>@#Z\H * "@ H * "@ H * "@ H * "@#S_P"-.G>(-7^"'BW3/"]K
M]JU2YL'BC@^;=*A(\Q5"\EC'O"CN< \$T ;7@75HM:^'FB7ML5CF^Q1)-"3N
M-M,(U#Q.."&5N"#@\=J .F[<T % !0 4 % !0 4 >=^*' ^.7PZ3S<$VVK'R
M\?>Q'!SGVS^M 'HE !0 4 % !0 4 % !0 4 17+[+29QU5&/WMO;U[?6@"6@
M H * "@ H * "@ H * /-OA4K+??$4E2 WBVZ()'4>1;C^E 'I- !0!\J_$>
M4P_MLZ$^"W_%,_<&=SXDG. !P3QWX_'% 'TE_;K_ /0"U7_ORO\ \50 Q_$)
M1@K:#JY)_NVP/<#LWO\ S]#0 P>)@V,:!K/..MH1UQ[_ .T/U]#@ 3_A)ADC
M^P-:X)7_ (\SZ@>OOU^I[&@#A/B':7GB_P#LD6/AVZ>2QDD<?;[290IDC,89
M&C((8;CSD8&: ,'3/'WQ#T.[TKPEKMM:+J%S&4L;C4+6XWW^TG^)3MWA0I()
M#'/3)Y .OB\3?$B._M4D\/:?>12&3>D<-U 0!$[ ^8RE5RRA>1G)'3(- '3V
M?C#3;B73;:YMM0L+K46$<45U8S1#S/+:0IN9 N0J-W[4 =%0!0U?5['0M)GU
M74I6BM8,;V5&<\L% "J"222!P.] $%OXCTJXU&#3PUS!<W 8Q)<V<T'F;1E@
MID4 D#G YQD]C0!C^-O""^([*._TZYDTWQ!8*QL=2@'[V')!90,@,&V@%6X/
M0\$T 9'ACXFVMU:C3/%EK/H_B6VBM3<V7V:0F5ID!5H5 +,N[<I&,JRD'L2
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M0TOP-ISVUW97WDQS0CY0T9V,2&:1AR00%'7<=H!V?_#+-E_T-OB'_P '+_\
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MFT9 R,@'HW_"*>%_^A;TO_P#C_PH B;P;X0?=O\ "VD-NSNS91\Y&#_#Z<4
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M!UM !0!Y!XL\+:_X.\;#XB?#ZWC>*Y5(]<T@#$=W&BD+(H'W9 -HW <!02&
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M8V]M#$L444:HD:# 0 8  '0"@#SOQ5_R7_X;?]>6L?\ H%M0!Z50 4 % !0
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M - MJ /2J "@ H * "@ H * "@ H IZLS)HE^Z)YC+;R$+G&X[3QF@"Y0 4
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M1\"6DMO''C758-/>_GTW2O#URD*,P;;]B"2E0OWV$3R;5YR<#KB@#Z^'(S0
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M8YHCD'!P0>X((((/(((."* +] !0 4 % !0 4 <EXI\)S:A)-KOAR[.E>)A
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M;A>K*J@(7&3PK'.YMH!Z#!/!=6T=S;3)-!*H>.2-@RNI&001U!% $E !0 4
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MQ*1T^M 'U#0!YEXI8_\ #0WPW7/RBPU<XVG^[;]^A^G^- 'IM !0 4 % !0
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M @ \F_9W\00RPZGH-[;QVNI^3:3IY&'BN(A:09<,O1LN"P;#$N3@$D* >^T
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MF_NOLJ-<W2V\:GRI)<EF]HB, $\^F30!B3^/XX$=R-$=$&2PUR$#'?J!_D4
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MMO!X@XS_ )ZT >HT % !0 4 % !0 4 % !0!G:Z?^*:U3_KTE[@?P'N>/SH
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MV% 'RI^TJH?XW?"U3G&R\/!(_N>E 'U-:[Q9PB3._8N[=C.<=\<?E0!+0 4
M>=ZO*3\7M$3?'Q=1K@')_P"/*^.#Z'G/TQ0!Z)0 4 % !0!P-WX7U3PI<ZKK
M7@"U@DEU&ZBN;C1W*0P2OQ')(&QE6*X8\]4S@DD$ Z/PYXHTOQ-:W#V#O'<6
MDIM[NTF0I+;2 X*LI^AP1P>Q- &W0!E>)&*>$M888RME,1D9'^K/8T <EX.C
MLQJ^@RQRL;QO#%N)4[*@*;"..Y+_ )4 >A4 % !0 4 % &#XGT!]<LK=[2Z-
MIJ-C-]JM)NPD"D /CDH21N (SC!R,@@!I?B%KOQ!J.A:A8OI][;/NMU<Y6\A
M"1EIHS@;E5I I_NG&<9% &]0 4 % !0 4 % #98TFA>*1=R.I5AZ@]: .7CM
M;_PCI[BTGCN= LH=RPW#L9H%#98"0D[D5,XW<C: 20<J =+:W,-Y:175N6,4
MJAU+*5)!]B 1^- $M !0 $@ DG '>@#YE^#(DOOVFO&VHB1I5@T'3XYI' !>
M69(YB>.,9W=A0!]-4 >8>)E!_:-^'K%&;&F:M@@ !>+?DGJ?3''4<]J /3Z
M"@ H * "@ H * "@ H S?$"+)X7U:-G"*UG,"QZ ;#S0!I4 % !0 4 % !0
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MX(TOQGH,]E<Q1P7QV-!?H@$T#H249'QE2-[@$<KO)&#S0!SG@WQ;K>D:Q:>
M/B1<6ZZ_) LFGZ@K@+JRA<N,  +*AX(_BP648R  =-XWCGAT*'7+2!KBZT.Y
M344C15+.B@K,J[B!N,+R@<CDCZ4 =%;W$%W:Q75M*LT$R"2.1#D.I&00?0B@
M#D_B'_R!M%_[#^F?^E<= !\,/^29:0 Z/M$JEHW+J2)7!P30!V- !0!R7BO2
M=.L/!?C2_L[98;C4=/GENG4G]ZZVY0,1TSM51D=0!GI0!X1\ ]-L;KXY_%5+
MRSM[D1IIX02PJ=@,;< $<< ?E0!]1JJHH1 %4#  & !0 M !0 4 % ''>)O^
M2@^!?^OJ[_\ 262@#G_BA=6>HV?@R:QN(KN(^)K$">!_,"D2<XV@_0]/>@!?
M UU;67CCXBW-Y<Q6T*ZA%NDE<(HSO R3QU(% '76+ _$375W,=MA8\'H/GN>
ME '14 % !0 4 1S00W$+P7$231.,,CJ&5A[@]: /E/\ :%TS2=*^+_PO@TO3
M;*QW_;"RVUNL9("J!DJ!D>V: /I_4='TS7=(.FZQ8Q7MG)M+0S+E2001^HH
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M'R'@T =KX;\1Z3XL\.VNO:+<&:SN <;E*/&P)#(ZGE65@00>A!H UZ "@ H
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M<CI*>&7AN1UX (O"][?W7QD\=Z-:KJ%O;V]W%/<367EEI3)YBHI+GY$78['
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MQD,&:3!SSYC9ZY !)HWBG3M9G6S59+74!$SRVDX"R1E6VR*1ZJ2O/0AT()#
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ML^'<O_&=P()SQP.  * .Z_X6!X,_Z&.S_P"^_P#ZU !_PL#P9_T,=G_WW_\
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M0 4 % !0!@Z[X8M-9N[745=K74[2*:&&ZB)5A'*FUT)4AMI(5OE92&12#QR
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M'&.AH ]2_P"$MT;_ *B'_@LN?_C= '!^-M4L?$>OV6EZ5)*]_'I&IR"":W>
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MSMH SM)\8/:W,>B^+5AT[4P2BL]Q'B8;TC1P/E+;VD7!1-H.0=APM ':4 %
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MS"I$-[&#@E<_=D7C<F3@$$$C. #HZ "@#%\2^%]$\6Z'=:/KMDES;W$+PEL
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M.@ H * "@ H * "@ H * /,/@7C_ (5G/MVX_MK4\;%VC_C]EZ#L/:@#T^@
MH ^5=6@23]N;4)I'=$M].L)&=7"A0)H3\V>WX?B.H /IW^UM*_Z"=I_W^7_&
M@ _M;2O^@G:?]_E_QH /[6TK_H)VG_?Y?\: #^UM*_Z"=I_W^7_&@ _M;2O^
M@G:?]_E_QH /[6TK_H)VG_?Y?\: &3:AHMQ!)!/?V<D4BE'1IE(8$8((STH
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MY^<72;>#@\Y]>* -"":"YMHKFVF2:"50\<D;!E=2,@@C@@CO0!)0 4 % !0
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MWVG1^06.R.SG59-R[?F N><=1Z'F@!__  @LI_Y>-,_\!+CW_P"GGW/Z>@H
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M*H'U /IZ@ H \TO75?VH-##, 6\*7P4'N?M=L?Y T >ET % !0 4 % !0 4
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MS)Y^HPG[=/'C%G:$X<L>SR#<B#UW-T0T =9&B11K%$BHB *JJ,!0.@ H =0
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M9R1U[9H W: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MB52,WR%Y'\]>26&)47.3_"<D,I(![+0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % ",H92K ,I&"".#0!XQJ]E9VWQZTYK>"",_;=.XCC"E<V>J9[=\#\J /:
M* "@ H * /-;S_DY_1?^Q3OO_2NUH ]*H * "@ H * "@ H * "@#+\1HLGA
M/6$=796LI@1&,L1L/3WH U* "@ H * "@ H * "@ H \U^!G_)&]._Z_=1_]
M+YZ /0;XWXMO^):MNT^X<7#,%V]^@)S0!G,?%>5VQZ21GG+R# _+F@#YL^(,
MWQ@/QD6WTV'45#&3[.(6G^S%#;1;S"Z$,-CKC[F"TIW8 & #Z%LO#URUPPU#
M[1'#M^5H-;O78G/<%@,8SWH 33O#]T[R#5EG@0*NPVNNWLI9N=V0Q7 ^[CKW
MH S?[#\4^2O_ !+[82[?F_XJC4"H..WR=,_I0 W^P/%>3^YM<=O^*@U"@#BO
MB5#X[T#PQ;ZII\GV<07D<EP;76+^=WA4,[IMP3AMH4D#(!R* .N^'^JZSJ-Q
MJYCB$NF"^A(-W?R2RVZO86TI1 RL6&^0GYG'WFXZ9 .QN)_$"W#K::9I\L /
MR/+?.C$>ZB%@/S- $7VCQ1_T!]*_\&4G_P 8H Y7X@:QXMTSP3<7<5C9VI^T
MVD326VH2M)M>YC1@H$ .2K$9'(SD<XH X"/QG#>:8)[>_>SN3-+%):WNLZHC
MP['*?>6-LGY,XP,;C^ !9N_%,431MIWB&&;)#N)]7U.,*PZ ?NGR.3G..W%
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M@ H * "@ H * "@ H S/$*&3PQJ<8&6>VD55P#N)4@+@D Y/&,C.: -.@ H
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MQS:WXV:9%D*ZZ5!<9P/LEMQ0!UWV:V_Y]XO^^!0 HM[=6#+!&".00HXH EH
M* "@ H * "@ H * $95="C#*L,$>HH Y/P+*UEI,OA.X1H[GP^PLT# #S+8#
M_1Y!@#(,8 ) ^\CCM0!UM 'E'P;\->';GX+^&9[K0-/FFDMR[R36D99B78Y)
MQS]>OKS0!WW_  BGA8=/#>E?^ <?^% !_P (KX6_Z%O2O_ ./_"@ _X17PM_
MT+>E?^ <?^% !_PBOA;_ *%O2O\ P#C_ ,* #_A%?"W_ $+>E?\ @''_ (4
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MH ]*H * ,._N-(3QGH=M=6CR:I+!=-:3 ?+&B^7YH//?*8X/3MW -R@ H *
M"@#'\5?\B7KG_7A/_P"BVH Y3X4@C2=9R&&;JT(SC_H&673']>?TH ]#H *
M.,^)SI'X!D=V"HNH:>2Q. !]M@YH SO!'BK0X?!L,<-X=0G^TWC>180M<28^
MU28)2,$J.1RV!R.: -;^S-5\4WEO<^(K,:=I%M*EQ!I3,'FEE1LH\[HQ3"D
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M!B4$^@0@?WCUH R/A+IE_HWPB\.Z9JEF]E>6]N5E@D!#(=['D'OS0!V] !0
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MD:\N]'EDE:-=JEO+;) [4 5?A0A72=:;C#W5J1@C_H&60YX'I[_6@#T2@ H
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M^0SXX_[#S?\ I);4 =C0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M % 'G9S_ ,-)@[6Q_P (KUP<#_2_7./T]>G.0#T2@ H * "@ H * "@ H *
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M\JE@S;1@ L<"@#Z@\$_\AGQQ_P!AYO\ TDMJ .QH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@#E/"CA_$WCM0V=FMQJ1
MDG'_ !+K,^G'7W_H #JZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H \Z1 ?VE9W*Y(\*QA25Z9NWS@X]AQGL.!W /1: "@ H * "@ H *
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M: /2: "@ H * "@ H * "@ H HZL95TTF%$=_,BXD.!CS%SW';/XT 7J "@
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M % !0 4 % !0 4 % !0 4 >:P_\ )T-]_P!BC;_^EDU 'I5 !0 4 % !0 4
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M^('@WP'H/A-OV>_%MT^F6<=KYHBG3S=@ +!3 <?3)ZT ;I_:;\<!0Q_9X\5
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M/^+3^+=Q^\/)&!QVXYYQZ4 )'^UI;G;YOPG\6+P=VV$-@YXQP,\?E[T 2?\
M#65C_P!$K\7_ /@,* /*O'WQB?5]?'BKP)X"\6>'?$%S%]DU&583&M];Y!&X
MIG$BD *^T\$CTP =1X1_:0N-#OM5GU#X=^,YK>\*-!:M))="V(:0D!Y3DY#)
MZ?=Z<4 =;_PUE8_]$K\7_P#@,* /'9-:C\8_%WQAXKTGP;J7AO2G\'7\/DW5
ML8U600-DC'RC.<X'4Y/4F@#[$\$_\AGQQ_V'F_\ 22VH [&@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .:\-%CK_C+)
M8@:NF,G.!]AM>GI0!TM !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 >8QR,/VJKJ,*2K>#X6+8X!%[+@9_$_E0!Z=0 4 % !0 4 % !0 4
M% &1XDV_V&V_.//@Z?\ 79* ->@ H * "@ H * "@ H * /)/V;)_M/[-WA&
M7)),4X.5"\BYE!P!QCCCVH ]'NK36I+YYK/68H(&15$$EH) I&<L&# \Y'7C
M@8[Y (5L?$BK@Z_:N?4V'/Z24 <IJ]CKY^*7A5FUJW9Q9:AM(L\*O,&<C?D_
MF,>] '6_8_$?_0<M/_  _P#QR@ ^Q^(_^@Y:?^ !_P#CE !]C\1_]!RT_P#
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MUS^SH6CM['[<6_>HTS^6%YY4[,D_=X('4\\<@$'F>*,C_1=*(R,_Z1(.._\
M!0!(C^(=B[[?3@V\9VS/C;W_ (>M $EE)K3-<_VA9V4*K_J/(N7D,G7[^8UV
M_P /3=U/IR 1V<WB%[>Z.H:?IT$RH#;K!>/*KM@Y#DQ*5&<<@-QV[4 1_:/%
M'_0'TK_P92?_ !B@!K7/BO*[=&TG&><ZE)T_\!Z )(I_$K74*SZ7ID5N6_>N
ME_([*N#RJF$ G..I'>@"2.773JACEL+!=/WG$RW;F79MX/E^5C.[C&_ISGM0
M!'+<>)!,XATG37C#'8SZA(I([$CR#@^V3]: &_:/%'_0'TK_ ,&4G_QB@ ^T
M>*/^@/I7_@RD_P#C% %B[EUI&06.GV4ZE<N9KQXBK>@Q$V1[\?2@#F-$FU=?
M$WC1=.L[2Z0:PF[[1=M"4/V"TX 6)LCOU[T ;C7?BL-@:%I;#CG^TY.YY_Y8
M=NM "I=>*F12VBZ6K$9*_P!IR''M_J* +*W&LG3$E?2[<7QEVM +LF-4WXWA
M]F3\GS8VCT]Z &27FM1Z9!,-%BEO&DVRV\=V-L:\_,'*C=T'&!U]J ($U/7S
MGS/#++Z;;R,Y_E0 @U/Q!M&?#!!VY(%Y'PWI]/?]* +5G>:M.9S=Z,+14C4Q
M_P"DJYD?G*\#  PO.><G@8Y %MKO4Y;*>6?2#;W")F.$SJPD;'3<.G/&2.]
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M 4 % !0 4 9/B8:P?"6KCP\3_;'V27[']W_7;3L^]\OWL=>* -:@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#)T>Y
MU2XOM;CU&#RHK>^\JS.S;YD/DQ-NZG/SM(,^W08Q0!K4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!YK#_ ,G0WW_8HV__ *634 >E4 %
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MQVVYF)\0OG<.F+2V QZC % ':T % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!YK#_R=#??]BC;_ /I9-0!Z50 4 % !0 4 % !0 4 % &7K
MY T<DL5Q/ <C_KLGL: -2@ H * "@ H * "@ H * /-?@+_R;YX*_P"P<G\S
M0!Z50 4 <=>?\EKT7_L 7_\ Z46= '8T % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!B>+X_-\$ZU$69-]G*NY>HRIY%
M&V.E !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % '&^!=IO_ !F1(')U^;)'8^3",?A@?_KS0!V5 !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 ><0+G]IK4'\MCCPG;#>/NC-Y/P>.
MIQZ]C^ !Z/0 4 % !0 4 % !0 4 % &;K8+:7M4D9G@&0I; \U,]/\B@#2H
M* "@ H * "@ H * "@#S7X"_\F^>"O\ L')_,T >E4 % %"32;.3Q#;ZZRM]
MMM[:6T1MWR^7(\;L,>N8DY^M %^@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * *FI62:EI=U82.42XC:,LO4 C% %N@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@#(T71FTFXUB4W)F&HWS7@!&/+S&B[1_WQG\: ->@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * /.8&7_AI?45.-Y\*6I''./MD^>WT[_GV
M /1J "@ H * "@ H * "@ H H:NN[3PN<9GA[L/^6J^G/]/7C- %^@ H * "
M@ H * "@ H * /-?@+_R;YX*_P"P<G\S0!Z50 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'FL/_)T-]_V*-O\
M^EDU 'I5 !0 4 % !0 4 % !0 4 4-617L$5Y-@^T0<A=W_+9,#&#UZ9[=<C
MJ "_0 4 % !0 4 % !0 4 % 'FOP%_Y-\\%?]@Y/YF@#TJ@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /-;(A_
MVF]98Y)B\+V: GG -U.>W3IT.3Z8% 'I5 !0 4 % !0 4 % !0 4 4-6<1V,
M;';@W-NOS=.9D'Y\T 7Z "@ H * "@ H * "@ H \U^ O_)OG@K_ +!R?S-
M'I5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 >9:8SM^TYXC#)POANQ"LIXQ]HGSGWSTZ\#MTH ]-H * "@ H
M* "@ H * "@#.UIVCT^)E&2;NV7IG@SH#W'K_P#KZ4 :- !0 4 % !0 4 %
M!0 4 >:_ 7_DWSP5_P!@Y/YF@#TJ@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /,-'_P"3F_%9_P"I>T_^ C_E
MM<=^] 'I] !0 4 % !0 4 % !0 4 9FN;CIT6T9/VRU['I]HCST__5Z\4 :=
M !0 4 % !0 4 % !0 C,J*7<A549))P * /-O@+_ ,F^>"O^P<G\S0!Z50 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'F.C #]IKQ:0#D^'].S\N/^6MQW[T >G4 % !0 4 % !0 4 % !0!D>
M(MITJ'>2!]NL^@SS]IBQ^M &O0 4 % !0 4 % !0 4 4M8N#::%J%TH#&&WD
MD )(!PI/5>?RYH X+X"_\F]^"O\ L')_,T >E4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 >4:"&_P"&IO&A ?9_8&G9(7Y<^9-C)QP>N!GG
MGTX /5Z "@ H * "@ H * "@ H Q_$98:3"5)!^WV0X_Z^HJ -B@ H * "@
MH ;N^<KM;@ Y['K_ (4 .H * ,?Q5_R)6N?]>$__ *+:@#D/@3$T7[/W@E7Z
MG3(F_ \C^= 'H] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 >7>'[?=^TQXYNN/W>B:7'U.?F>X/T_A_P[T >H
MT % !0 4 % !0 4 % !0!D^(/,.FP+#OWF]M/NYZ"XC+9]L T :U !0 4 %
M!0 4 % !0!C^*O\ D2M<_P"O"?\ ]%M0!S?P9VCX$^!]JLH_L:UX;KGRUSV'
M^?7K0!WE !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 >:>'50_M&>/G*C<-(T@!L<@%KK(_0?E0!Z70 4 % !0
M4 % !0 4 % &7KVTZ9%NB\T?;;3Y0<8_TB/G\.OX4 :E !0 4 % !0 4 % !
M0!C^*O\ D2M<_P"O"?\ ]%M0!B?"=43X)>!510H_L&Q. ,<FW0G]: .SH *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#S7PY_R<1X__ .P3I'_H5W0!Z50 4 % !0 4 % !0 4 % &5KK#[%;)O
M*%[RV (8@\3*V.AZXQCTS0!JT % !0 4 % !0 4 % &/XJ_Y$K7/^O"?_P!%
MM0!C?"G_ )(GX%_[ %A_Z3I0!V- !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >:^'/^3B?'_\ V"=(_P#0KN@#
MTJ@ H * "@ H * "@ H * ,S6#A+$;L9NXAP<$_-GCD?_JSP1D$ TZ "@ H
M* "@ H * "@"MJ%E%J6EW>G3LRQ74+PN4X8!E(.,]^: *OA_1;7PWX6TGP[8
MR2R6NEV<-E"\Q!=DC0(I8@ $X49P!]* -.@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ..TCPWJ-E\6?%7BB8P
M_8-4L;"V@"ME]T)G+Y&.!^]7'/K0!V- !0 4 % !0 4 % !0 4 9^I%Q+I^P
M9S=*#QGC:WO0!H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ,B,K1@
MS(J/D_*K;AC/'.!VH ?0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % &?J5M<7$VGM!C$-TLDF?[H5A_,B@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image21.jpg
<TEXT>
begin 644 image21.jpg
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,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>sgmo-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20200630"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20200630.xsd" xlink:type="simple"/>
    <context id="icc60e28018564ffd939811f6b225a28b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ica30b2d4cf0e4ea79bfc15962f3df122_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i74a14aa270784e14b78266b6b869c0f0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8f3eeebf2a8e4f38866132567e9f313d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i715b0ac6795a432590fdb6520e45e891_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifc447274e11c46e99da86c204d9a409c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib6090981ce294ff29297fc34c8c6e128_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if5a97ca934e54652924592147ff418b4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i965e1b6625f34d2e8a6e6973f636c12c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i210399ea6286402c8dcca9da42a400de_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4ba413aed2bb4cb89498cb2272ebe365_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6e7d0c3d3b6440a1ab0e041e0722d6e3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i11f2c0ec83df46a188ead01f731d71b8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i87f58c14ac1f4042b5cec8f4b7109999_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0ecc067020854944955a76da1ab1237b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7be5df5dcc8640e9a57dc51049938bb2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib42b494f9fd740a38702396e27d699c3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idfcdc625f9d448fa81dac8d80c9ab4f4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3fee24599ecb470992405d7a99ed9663_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebb11f265f924c26864eda12977fa01a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa736117878e411eb5f7b20e853a01b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia07e3195343d45368e897c17d04de6a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i278c4f07da5c496fac619001ae98ef64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic12e6135fb424ea38f6945f7ac5f2eab_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ife139e9caa184ca68f4d842bbb1a6e58_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i14a3d5f5eac24d569f20aac4bfb416fc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9461724558f4674a9d41050e9ebaae9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2490d9038aa647379f0431522bd71baa_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id966f8a5fab94bbcbd2b71c5797f8185_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4ee7332332064c54a42898aae0aafedb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6bdcd18b9c3d4780a78d371c7e732f38_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia9cad5c531bc43ee9ebfdead3cc3a5da_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i38d659779f044072ae939f9bb6c17be9_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i553271530d1747ccaa14899dff3e1650_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i316b6d05c95040e2b1eff737183a7185_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i539ed8df47a24071adb12e36bb3089ea_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ice6e0c73ca7c4fb19915320974638f19_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia6d04447fa724128824a433975c7334b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5bb20f98f6494310aba335324fea603a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i009a92cb8ae04cd0bfbb29c780c42950_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4d016582d2524cb58d1a7cb653294394_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5fb00e01938c41218801d630e5eed895_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id113f3f8a5e9489f8ba5ce4e97f34e4e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0726daec490b495ab4b81b5cc062f239_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if268975f048242d19e806873ecf0328f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i015db7a76e3c48e099a7af789a5fad56_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i086101d733d94f44b607cc9a00cdd045_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie7cdf45d785d456babc436bb1d8a2750_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3613e176873c4760beea58bab9dd7524_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i293b616727bb4417b41b877fe73be3a6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0015c60565ea4383b437165b9285c82d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie92671d3c141420f88e50a9fe64c3bf1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i94be9ec349764546bf3b7c36db8f8ca3_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i63ba29b6972848c1bc27ede3e93b882d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerAndSanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibf55388c1bfb4f1cb45c0812eebe6af4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic5c61a6784f940f8bd95841c65cc3de2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idc7d9b485d384d6f8ad54269d553b696_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7e52d1ac0635451a9b507adfd21181b1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i21370c70454d46adbd1945146055d853_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia4d8ff36c0ce4c9a8a25a0dd9e3431fa_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i48bb61da0bcf4909ad5eeb72eb273bc7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1c97ee7ce62e4dd8ab9222f36c803f8b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i56021bdaf9354623bd7e8749bb327b83_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8ec51d23f3a45679c02cba5fcfadea5_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5840d5f60f4d44dd9851bb922ea77df3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i946c25911d16465c94ce83c9e4b06fdb_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0fa847036ee74f318716774b63f7a97a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9afe62008bfd4661a107bdae92e16531_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i653ce1faadc3465a97bc8136db41ce20_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icfe937211c1b4e088c934d0abe849d2a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie4a578789cb147eebdc1bb90088efe97_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8d45598ab29c4e2db9f9dbb7cec8d9e7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id08dc51273904752aaf728a6e1df8383_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iab71f71232254a6f82150b71c8f007fb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3461528899214d58b2a932f24904ee6e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icd13016ac46c48bc84616522d16a595d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i65c6ac9671754abdb804515a0bc88a5b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4db5a3fc61af496597d6be764fbf968a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1ae3532bd280450d9b3d2aaf3fd3183f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i45cab4a727634aa0ad89eeb42596a594_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i97ba6efdd77a4d1fbdd0f8dac7ce03e2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic095f3bf93224fd7830f1bf15820b81b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9c8eb3ee87c64e9aacf30737f5a51adb_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7fd6b25106a84026b8dd26c57d4b4125_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9bad4096995042179cc11bc904b183d9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i452e2107611247cfb0d8f189bfc13b86_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7c8bf564147c432e8c52d88f72ff45c0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i62b06a1912424ff4a4459beb539c32da_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6936e5949976449dbccf475a22595e86_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib4a4a0a8362b4d67a4a3abae87fd40b9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaa5e29888c3a4d52998814f37ae4dba1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i911ca0f0d74e4372b382c1e5cbdefc37_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8298c84318b24ddfbc0a9b713fac9edf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia404f432f5f04e0c86cf5127ad1ee352_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie762e1bf5be24949acbc40644a441c6e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ceaaffd9f074529ba2189860ced6058_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d2acfe069e546dca06761088abb331a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i676d2b24c5dc42c3b6ff774ebc9c3059_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb8cbc3d9d7b430fa2d784ba2a45bd2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7fe4c003fa7745d7a49e88abcde0d99c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e5eda06ebd043a18f2310ccfa139d5c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i762ba37e09d5444aa3f6af77efa79d0a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia92733266bea4a4a995ec95b550ebc2d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7e24edd72a4402e947ad3a231a68484_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i365bc9823489411ba4d7b9edcded0fbf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8b0f5f2adab4805b0479111e623e2ee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3157fcf32f8c4a93b027d26e140b1f9e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5d4d876ac904a2a86c3d4eb8f225dcf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cfa387702344d33a007d4a3e6c45c05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74627613ca30495088c9bc6d70c91441_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieaab7f3f0f42483f8054df0951921a69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6149f30571a74f36b05d423ef49c6d84_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icef63d53d6da4bbfb421afc3382da2ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b2aa92c23ee4bfeb3ee17ccff6a2fbf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10649c65a0334bc2a8640fb0be3a04f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ff8aa476e974c09bfed85e41fcd2fab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide0bd3414e1646898d32c7957fea55c8_I20180720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-20</instant>
        </period>
    </context>
    <context id="i7ba32d30d24546eca925d1e03e695212_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0521a31195cf4bf6ba85a5da0f003cad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b51e6431f1d4e99b4e005735f3156ba_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i80ae933af9fe439582f72421ca16b2d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ebf882acb394d3abcff4f7fbb84922d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:TxCellSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic2a5014580264671a94f115ba17d478c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7a6f009aa07a4c399d8a95a107332098_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8dfb37df32ca419f81e76d4115394730_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i550ea41dd94f4cde8ebccae40c9ea1ec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2cd51b31128c404a88c55c12be0f8933_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3c895422f38a4eb1a177bc4ea8d56a62_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i88202f1ce8de4ff58b28e17316576426_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i244af883f9fa4b53b32c33db2e3117c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i308ef5827e2d49879e8d190e7c992de4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i26b1c09f8aad47379da7b97362291428_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c70a615e27849df839c9cf2964b75f7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3065b36e03d44c578c215e8d30a54eea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide9f1db38f654cd1aac9ab696795190d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie8f47ed72c944d6aa88add3d596b953e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id33600c2c7f34d30a00314cf2c69f6c1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i255ad07213a74331b5ed4902d8ecc090_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i46e4e2653abb4a21bb55a0af1318ca23_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib3210ae261f447489700bf8bcecaa49c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if36f128cd73641d78e18a584b4115086_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i27597a1795c6422786f8357584decb2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc450a3922854b8c925f767597c09e9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb25efc099444173a12e09cc80696876_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-08</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i426f14e574704e28836ba330c9dbd8f1_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i37a3af3ab08043c79aea248e4b3d6b16_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ia146054470dd4f3f970c2b2d6eeea2c7_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i33efcc2cf083437d856a10fb09d87586_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i8c8c2d2b28bb459ea77a5e1aca05aab8_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i354359e0d25047c4ad89c7354597c2fe_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i301f2d2ad4b84c369aa116bdd117c17a_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="i28405f7b815347269a780c9b058a7e44_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i379eea47507e40cf90ab3746c20d3ff7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i76b3b95cd14d487b848403cb66fe002a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iae8d5183fb0e4f4ab6e439efc56e5af8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4cb17ceebd9543aba79ec3e8fbd2f4e8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id2532bc5c847458ea5c245c9d0539d8a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1ea81ce0c28543c297d2984b8efc8ccd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i38d05a55da884263b1ec48182e49e978_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab06d3a3d932466caba07743e70c8ce3_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7495828dd6da4b6dab035cf784124b17_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic6f7cee7975f4b6f99d9a6ff2291d024_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if597a7e574f64566b96eae1440d9452d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic346d49a489e488999ebd8bf7e2e449b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifa40a47c29de44d5a91538a3a9a70128_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="ida7d1959f6e6453b984185527fca88b9_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="ibcd815dd54d643efa93f63fde2181db7_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i610fb576d4dd469d840dbfd922ba836c_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="idadecadd2c3540d29b8bfd732262ee0a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i534bf494758d4e65a8c5a9cd993bd211_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3be7ebfec658496c9a397474592935f4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie4f3b66fa9254360addb420ddb70e7f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c1ae59129e94570aabd4555fc76fe34_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6ed1d741701d4d8896d2e39462a3d431_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i100c20eec6fc4407969c367a22a5aefa_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7f9f41236129499cad0f6ecbb3d8b103_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i83e4ca4b8d794be49441483d40aedae6_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifdd22789c61a44f18dd2221f8e41eb4f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i30c126a939724395a8b70904f39a6201_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie3874265bf7a4b8885aa894e0fca3eaf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c63d999a16941d1a68fc47f694643a4_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i10b9a9ad5cd14b529d554f21d154e6d7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia075c77e790a4ac991c3cd8ee89ad36b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i25f1c9d94c66418ba25576f42bb0c41c_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib291aca8325c43a6a2835d40a832c89d_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i97cf3acb2d224d289dbcc3817e983d58_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="if87eed0b34b64bfd8323247a51d95e6b_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ide9b91c91f3c407cbef414beccd16d53_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ie25d43c8653a40efb6068acc53cc63a5_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ic8b47130e76b4541a0d85cafca758698_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="icf5586bb63c84bd9bc5dba5e7ee29b1e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i68bf878067e24fd7b9f9e0feeab74893_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id835cc5e8ed34090b3843efa34d914a2_D20170601-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if5ad04bab0bd4c97b5268f8c70c60007_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9a76ad6dd6db47e8bdb42c22f63955fb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie42151476a064738ac709c94dbe11690_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibbed171f600d4452b7074be69d363203_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3e6673b29e749caa0cfd406195b12b2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib203359cf79c4a78b76345ab5cdd5ada_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2c1215983e16448081567393da2a173e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i874cc070d9494a23bb75d5fe3a959fe7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id1c975adb10c4c80a444e6e169fef905_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0e71b2952fdc443c82251bc33b95a5ca_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie8f1db50a2ee45a69dd2f7dd10845478_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic6a077c7a6e84585bf477e2bde29c32d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icd717c13dbff4c08b4ac853e8fba45b5_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0621e82b115e42d3be6403068e7b2f9a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i265e9d79e9a3440ba73a2f8dd054a88d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9d56781fdc104f368a6db7f99c183153_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0042ba179bcf4a8d838c6c062581603d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia5be0c8a3eaf44cfbdff12b3693acb7b_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib6c53a13e3ed4b41a51ff5afc0e24f34_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i61c86f3985aa4e6aaf7123281f53e1c9_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iece818eb67d544e1b9ce5641695dda6a_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if5106f4851d54887b1c366031ae40b6b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9a27653fa2ae413986a3b7ac8ab2240d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74bd1c64097a48dab6c41893d097e234_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2b663765efe486ba3be90af8e53ab8d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i3679ea31262c4a9a8be73e04e54ce1da_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic37ca88da7bc49fbaa868d8671da3f88_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie5657715ba8e402b814e812ea70780d8_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i497ca7fec0544874896474aa8c59e3c8_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="id6b492f3a18749d2a59bd07e6e047e96_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ie2bd3d15a17e4dfeb83bce33be451571_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i41bcbb1429a64230b1a3f20305b3b458_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib17dbd8e9112456da64bc13b7c66591e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if322408f9ba44ac3a3050f9173bd5dbf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i8fdbfad3304d46fdbce872a95bb8f3d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibb38c2c18aaf4cf6a67227cc3d5e88e2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia4e426bbd60b445f8f58775980820ade_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2993707ab04450c93d7c0cde818957f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia6ebcf7335d143a7b2165fc287c91a99_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8e132461b3d342eab6814cba414941b1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7718ad78b270467e8ae7dd73f6379efe_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if4652dd95590400a98b5f80879a90ffd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0a527321d23c4aed94f50804dacc5d03_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if2f14044865d4879afb8479d9c63829d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4da0f61970a045f19353779959c20d90_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i56befc014b3d45ed9d4357b46df3211e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib38f03f2a7b44058af0b32589f5cb20e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i136a0633a1d642fe8d52aea0bb57ae3e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3250dbc4b25847b3b6cf42f0917717c0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8ed406253dd0408fa025ccc1e539acff_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if997601e608240a49794adff9baae92f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib5ba64af70834af7acab6ecdc62729b3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibbab28971c8f4c168f2a753a668b5dd3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8f81298b72494b5d8bfca23ef7846819_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i936718d885f345a0962a1f03189aeecb_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i7921fa4bd7c7486b81fa47d950ada799_D20180601-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia8b8e663d405457c8f481e73b7494220_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3be268974b9a4fdc9861bb34708345c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ad8f21a630e48d2a8a38df95bced575_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3c124d01f92f4f20abe3ffd4deee75f4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8278bf8bca164e85b22804fbba447080_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4037038f39cc4dbd9f695b7bbd7e376a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4787cbcb6bbc401c9aed2cc60462afc9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie78f712514d644f0aeb72decbb03a5df_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2fe52cb8512a433bacfe3d8fc79e20c9_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i3439f2f47737467aace116123f9168f1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i780b21af471142fda76665c4670e1f9e_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:ManufacturingObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i35a93dc1df704160a8e800276312cdd3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i001922d1aa724eb9ba89ce4a309abafb_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:NonCancelableContractualCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i85c2dfc465984dfca02266cbfed874c2_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="iafe38837c16248a78d0de8b944f254fb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaa400bd785134038a5e827fe16db92fd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i56a3424384d1467db3554580d425e34a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ae7ba47695144fd9e5a674b88fd5103_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i11ee1f4e6dd5429489a79d5f03928607_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0ae307928d74e0dbeabc531a4d6b23b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i60b6a65590a94cb39bd8e14b7ac7d841_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b2ede07af0343f389b427458e393a41_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id89248aaa3ba492aa4b8f488c3be6df5_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i95ccc4fdb8ea4e4c9cf7485785db1170_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i77dd9fd15a104e948837f14e23f36760_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i7739ea8df1214054a989dcff454b94a4_D20181001-20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="i6dbedaa261e3453a99f6f409adcb45d5_D20181001-20181123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-11-23</endDate>
        </period>
    </context>
    <context id="i90c49293724e4810919a1e33caec7e6a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i277faef5976144519b807ff6099f0c2a_D20180101-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i885f1a5affb04c469c5e9e4b478422c3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6874113b1491428eacb8504f0de4cfe8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8989c058d5ad4d3083e46b8de83336a3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic6b4b4f1e90f4a7183a57a1c0fce157c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic55a7e77392b4473b8950e77235bfa85_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i40cf24533b514984a2ae3200f4197e14_I20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="ic0dfb29e9e7045fb83ff2c12782a719e_I20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="iab09691164b34490b35b944f2f9fd50f_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="ib91cbc7a1cd2485baa09f334bf5ffbe1_D20200727-20200827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-08-27</endDate>
        </period>
    </context>
    <context id="i5e110ed49cfa4b80989b60ab5d0101ae_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i81e7c06ca04f44e2b3804131674178f4_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product_target">
        <measure>sgmo:product_target</measure>
    </unit>
    <unit id="option">
        <measure>sgmo:option</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV8yLTEtMS0xLTA_5d06f7f8-edb5-4b6d-954e-0c2de7d99ddc">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV8zLTEtMS0xLTA_addf82d7-22db-4acd-80e7-6e040a32c484">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV80LTEtMS0xLTA_1efe7424-8428-4a9d-b12b-6b27712c6f5c">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV81LTEtMS0xLTA_307773bc-a8cf-4dab-b7d9-2ee2c1c611b8">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80L2ZyYWc6OTlkMWUzZWVjY2ZlNDdkZWJhNmFlYjFkNjk0MzlkN2EvdGFibGU6MmVmZDdhYmU2OTZhNDRhNjljZTEwOTYwMzJlOTBlMGUvdGFibGVyYW5nZToyZWZkN2FiZTY5NmE0NGE2OWNlMTA5NjAzMmU5MGUwZV82LTEtMS0xLTA_5e752201-1d8a-497f-8539-9ed912b80a7f">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ie7cdf45d785d456babc436bb1d8a2750_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0wLTEtMS0yMzU0L3RleHRyZWdpb246ZmQ5ZWViNjc3NjI0NDcyMDllNmE0ZjBiZWM4OTMwOTJfMzI5ODUzNDg4MzQwOQ_0c145ee5-f11e-4897-8b01-2b110be132b5">us-gaap:AccountingStandardsUpdate201801Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ie7cdf45d785d456babc436bb1d8a2750_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xMjkzL2ZyYWc6NTAyMDQ3NzdmMDNiNGVlY2FhNGIwZGY1OWY1ZjU1YmYvdGFibGU6NzhkZGE2YjExZjI1NGVkNjkxYmQ1OWM3NTE2YjVmNjAvdGFibGVyYW5nZTo3OGRkYTZiMTFmMjU0ZWQ2OTFiZDU5Yzc1MTZiNWY2MF8xLTEtMS0xLTIzNTM_0c145ee5-f11e-4897-8b01-2b110be132b5">us-gaap:AccountingStandardsUpdate201801Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <sgmo:CollaborativeArrangementStandstillRestrictionPeriod
      contextRef="i354359e0d25047c4ad89c7354597c2fe_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk2MA_8a0774d0-1ee7-45ae-b865-08409446f2a7">P3Y</sgmo:CollaborativeArrangementStandstillRestrictionPeriod>
    <sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod
      contextRef="i354359e0d25047c4ad89c7354597c2fe_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNjE3OQ_91e689ec-675c-4164-b538-3b9389226c79">P2Y</sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod>
    <sgmo:ExtendedResearchTermOfAgreement
      contextRef="idadecadd2c3540d29b8bfd732262ee0a_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAyNzM_91569598-dc9b-4299-8c21-58e8ed1c15e0">P1Y</sgmo:ExtendedResearchTermOfAgreement>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i4037038f39cc4dbd9f695b7bbd7e376a_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNjY2_e5a325f2-0b18-490c-80b9-c74fd88bf207">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sgmo:CollaborativeArrangementPeriodOfCollaboration
      contextRef="iab09691164b34490b35b944f2f9fd50f_D20200727-20200727"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk1NA_938ff3c2-f0c1-40b0-bd71-520363c2dffa">P3Y</sgmo:CollaborativeArrangementPeriodOfCollaboration>
    <sgmo:CollaborativeArrangementExtendedPeriodOfCollaboration
      contextRef="iab09691164b34490b35b944f2f9fd50f_D20200727-20200727"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk2Ng_dc93b536-40db-442b-b669-b33786af281b">P2Y</sgmo:CollaborativeArrangementExtendedPeriodOfCollaboration>
    <dei:DocumentType
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjY5_99993108-a328-4cee-ac1d-10dd14553bb8">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZjQ1ZWFmMWMxZGFjNGRlOTlmMmMwNzM4MGU3MWIyNTAvdGFibGVyYW5nZTpmNDVlYWYxYzFkYWM0ZGU5OWYyYzA3MzgwZTcxYjI1MF8wLTAtMS0xLTA_24c25f50-55de-44c3-8195-beadfead1b77">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8zMjk4NTM0ODg1NjY2_9e58ca9c-ba3d-414b-b545-ce7cf242e9c7">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NWQ5OGJhNDAwYjI4NDQzMTg1NjVjNDAwMzUwNjI1NzQvdGFibGVyYW5nZTo1ZDk4YmE0MDBiMjg0NDMxODU2NWM0MDAzNTA2MjU3NF8wLTAtMS0xLTA_e4dc1558-ae4e-4f12-a2b6-7990cfb22483">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjcy_76078133-5563-4d32-aae9-43f530217cb1">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjcw_304d03d2-2f43-402b-b0c0-e7b8589d4df3">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8wLTAtMS0xLTA_0be6b811-8918-46e6-8935-f9f807e9b35c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8wLTQtMS0xLTA_62b39e20-d61a-4859-ae79-533d05f43fef">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV80_53a481ef-3656-4ec3-900d-91cee3c49b3f">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV84_a28b6cff-3d85-440b-ab86-c86ea821eefe">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV8xMg_a609a4c0-8b95-44aa-a1a1-63d879d248ad">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6ZTlhNTc3MGVmOTM2NGM1OWExYWQ5Y2QyNTU0YWEwZDAvdGFibGVyYW5nZTplOWE1NzcwZWY5MzY0YzU5YTFhZDljZDI1NTRhYTBkMF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjozNzExOTNiODBkZmE0NDFjODY3MmUxZDRlZWM3MDZkMV8xNg_cc3dd169-8a3d-4178-ba78-915c69fd9ad4">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc0_385dbe26-6a18-48db-8deb-e202db19bcf2">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc1_eba439a3-ca60-4943-9231-5f43530fcacf">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NjNlMTc0YTU1ODRjNDg3ODgzY2IxZTQzNmQ3ODRmMWQvdGFibGVyYW5nZTo2M2UxNzRhNTU4NGM0ODc4ODNjYjFlNDM2ZDc4NGYxZF8xLTAtMS0xLTA_2a2880ee-0030-4dea-976d-d794695df2fa">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NjNlMTc0YTU1ODRjNDg3ODgzY2IxZTQzNmQ3ODRmMWQvdGFibGVyYW5nZTo2M2UxNzRhNTU4NGM0ODc4ODNjYjFlNDM2ZDc4NGYxZF8xLTItMS0xLTA_d01649b7-0897-4ffd-b3d3-017f33bc8702">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6NjNlMTc0YTU1ODRjNDg3ODgzY2IxZTQzNmQ3ODRmMWQvdGFibGVyYW5nZTo2M2UxNzRhNTU4NGM0ODc4ODNjYjFlNDM2ZDc4NGYxZF8xLTQtMS0xLTA_c5b03fff-dd14-4e3a-9164-e3a726f595db">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjcx_fd50d477-a340-4666-b1f3-7d03834eb5cb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc2_0ee79546-e3b2-4c17-b493-142afcff33ae">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6OTFmZGNiNWRkNTRmNDhkNDliNWNiNzdjYmFiY2E0NGIvdGFibGVyYW5nZTo5MWZkY2I1ZGQ1NGY0OGQ0OWI1Y2I3N2NiYWJjYTQ0Yl8wLTAtMS0xLTA_bd5f5863-d806-441a-9e31-4dd6db666a66">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6OTFmZGNiNWRkNTRmNDhkNDliNWNiNzdjYmFiY2E0NGIvdGFibGVyYW5nZTo5MWZkY2I1ZGQ1NGY0OGQ0OWI1Y2I3N2NiYWJjYTQ0Yl8xLTQtMS0xLTA_98c174ca-aa6e-4cce-9ee3-e138ee0485cc">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGFibGU6OTFmZGNiNWRkNTRmNDhkNDliNWNiNzdjYmFiY2E0NGIvdGFibGVyYW5nZTo5MWZkY2I1ZGQ1NGY0OGQ0OWI1Y2I3N2NiYWJjYTQ0Yl8yLTQtMS0xLTA_51f41cac-2485-44b2-a377-4b4c6946fff1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMjc3_38c6721d-0d7f-445f-904b-fed8bc7d7cd1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ica30b2d4cf0e4ea79bfc15962f3df122_I20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xL2ZyYWc6MzBjZWE5MjgwODc5NDVlNTllYzRkNTY1YmRlNWM3NDgvdGV4dHJlZ2lvbjozMGNlYTkyODA4Nzk0NWU1OWVjNGQ1NjViZGU1Yzc0OF8yMTgz_a254ad88-2135-4573-9599-6580176169ae"
      unitRef="shares">140988008</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMy0xLTEtMS0w_9dbb5902-0a29-444c-972a-9e5cd80db207"
      unitRef="usd">467443000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMy0zLTEtMS0w_48a49aba-3964-4558-b76c-4b127c333265"
      unitRef="usd">80428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNC0xLTEtMS0w_dd5cdb30-7749-416e-a53f-152aecae4d8f"
      unitRef="usd">197410000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNC0zLTEtMS0w_4ff15843-6027-45b1-b387-51342fc05193"
      unitRef="usd">282046000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNS0xLTEtMS0w_5963201f-faa9-44e9-8e8b-8fd16594df78"
      unitRef="usd">534000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNS0zLTEtMS0w_4abbb02f-3d71-43a9-8d05-7d19fc4a4976"
      unitRef="usd">682000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNi0xLTEtMS0w_d0ec3916-b0ed-4d8e-bf2b-21e03d5e9af8"
      unitRef="usd">5618000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNi0zLTEtMS0w_034f938b-de7f-4721-baa5-446e90d5163d"
      unitRef="usd">36909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNy0xLTEtMS0w_774c3f43-4106-4ce6-ac75-b5dbb6b1d45f"
      unitRef="usd">8395000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfNy0zLTEtMS0w_3e54227f-4f12-45fd-97bb-c8a67f7b4f55"
      unitRef="usd">5408000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOC0xLTEtMS0w_1dda80ad-bbac-40cb-b6e2-867e08b6a65d"
      unitRef="usd">679400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOC0zLTEtMS0w_4956c5a7-140b-4c9c-a54e-e8dc16046d5c"
      unitRef="usd">405473000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOS0xLTEtMS0w_1a7bf4a8-b2c3-4cec-aec1-89a0460eff35"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfOS0zLTEtMS0w_379858dd-3d0f-41b5-80b6-396383de40ad"
      unitRef="usd">21832000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTAtMS0xLTEtMA_012fbe81-fe04-418e-9b72-682f0a59c9a8"
      unitRef="usd">33907000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTAtMy0xLTEtMA_116c5a89-04d5-4f5d-ae0a-968a13558497"
      unitRef="usd">29926000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTEtMS0xLTEtMA_9dca6cd4-bd31-41ff-8b48-acef22cc4bc5"
      unitRef="usd">53219000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTEtMy0xLTEtMA_2fdaff2d-0cf2-4d38-a090-4842411ef188"
      unitRef="usd">53156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTItMS0xLTEtMA_9c1fccfb-3b6f-4cce-ae33-2a07223e5cb9"
      unitRef="usd">39318000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTItMy0xLTEtMA_9cabff06-aa0e-49b2-ad3c-6b5801012c9a"
      unitRef="usd">39273000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTMtMS0xLTEtMA_a8ca7175-dbb5-4ac1-b4c8-98115fa88b6c"
      unitRef="usd">73501000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTMtMy0xLTEtMA_ab0b4a36-53fa-4e71-8cca-20c986808f0b"
      unitRef="usd">77289000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTQtMS0xLTEtMA_cfcee5b0-efc9-4d3c-88b8-872ec19b756e"
      unitRef="usd">13814000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTQtMy0xLTEtMA_f167c368-c4cf-496d-bd06-08ae71db5e78"
      unitRef="usd">9067000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTUtMS0xLTEtMA_899ba789-e7dc-4c75-9cc3-91631df619cb"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTUtMy0xLTEtMA_7b8755bf-b57f-4b8e-b63e-1e71abe19e51"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTYtMS0xLTEtMA_f44abfe9-0d01-4054-9bd3-1db9d6e344b6"
      unitRef="usd">894659000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTYtMy0xLTEtMA_eb9d5b97-b058-4f19-96ea-2a3e249c0fc4"
      unitRef="usd">637516000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTktMS0xLTEtMA_972e1b27-a03f-48d1-a1d8-071efe7618c2"
      unitRef="usd">19221000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMTktMy0xLTEtMA_b33d6abf-a16b-44d6-b8f7-4c2746a5e78f"
      unitRef="usd">17556000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjAtMS0xLTEtMA_b30b0d16-d772-422f-b757-9dfdf7386097"
      unitRef="usd">13332000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjAtMy0xLTEtMA_51f11a26-58cd-4018-9b43-9c94985534cd"
      unitRef="usd">13605000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjEtMS0xLTEtMA_e5ac432a-6526-4ac4-ad6a-acd9f8e17fd1"
      unitRef="usd">61389000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjEtMy0xLTEtMA_21cce942-a4f8-45a1-9b16-1fc0a5a7090c"
      unitRef="usd">38711000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjItMS0xLTEtMA_5691d7ca-f630-45e9-95be-fcb8e0fbf2d5"
      unitRef="usd">93942000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjItMy0xLTEtMA_2a4a1221-1946-4cf1-9336-7cb49a5c2a86"
      unitRef="usd">69872000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjMtMS0xLTEtMA_a0519c5b-9f40-402f-83e5-e6e990aef5de"
      unitRef="usd">237644000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjMtMy0xLTEtMA_7ffe1c2c-9274-4053-b889-73deaaeb1aa4"
      unitRef="usd">81432000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjQtMS0xLTEtMA_d482ab9a-ecf9-49f6-b1b6-0397c6eb4550"
      unitRef="usd">39234000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjQtMy0xLTEtMA_97af7251-11d1-4cb1-9636-d9204d8d3f4b"
      unitRef="usd">41192000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjUtMS0xLTEtMA_d90443e5-ef68-462b-9105-bb4ea531f149"
      unitRef="usd">6578000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjUtMy0xLTEtMA_6593e49b-02c5-429b-a1bf-2192e6ee83ad"
      unitRef="usd">6570000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjYtMS0xLTEtMA_6901fe40-6206-41cc-bee9-43214c2d561b"
      unitRef="usd">6055000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjYtMy0xLTEtMA_1ec8e369-6d61-4010-b82f-4f427184deab"
      unitRef="usd">5711000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjctMS0xLTEtMA_5e04bdca-f18a-41b1-93bb-affe93a43ff0"
      unitRef="usd">383453000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjctMy0xLTEtMA_a2dfdb61-d652-434a-9025-bb7337c7ce11"
      unitRef="usd">204777000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjgtMS0xLTEtMA_f4633b6f-9c8f-46c3-bc9e-ff99b8d27b55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMjgtMy0xLTEtMA_463f1ee2-c17a-4c27-8167-8e7d14125359"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzAtMS0xLTEtMA_f707fc91-877b-451f-956c-33f059fc0088"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzAtMy0xLTEtMA_c115078a-b3d0-4889-a5d2-3736c9249297"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzEtMS0xLTEtMA_8d6baf85-e074-44b5-81b5-1953419401a4"
      unitRef="usd">1410000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzEtMy0xLTEtMA_8f8fc9fc-7891-45f9-a2a0-e9d97a263c09"
      unitRef="usd">1160000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzItMS0xLTEtMA_192f592a-7e66-46da-a582-219fe174d761"
      unitRef="usd">1247527000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzItMy0xLTEtMA_ceae34df-3ac7-4e89-8f53-2b72de307de8"
      unitRef="usd">1090828000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzMtMS0xLTEtMA_a767ccc7-f612-4ba7-836a-67a33039bbf4"
      unitRef="usd">-735827000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzMtMy0xLTEtMA_00acb9fe-3943-4fcb-9248-343208d1983f"
      unitRef="usd">-656985000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzQtMS0xLTEtMA_ee9b7804-3f88-480e-a0c3-80da3148a77c"
      unitRef="usd">-1653000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzQtMy0xLTEtMA_7ccce311-f5b2-4507-973c-ee8ee0d1b3a0"
      unitRef="usd">-2449000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzUtMS0xLTEtMA_d7816de3-ee21-4a5e-982e-cb3e42b8b7e5"
      unitRef="usd">511457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzUtMy0xLTEtMA_be670f56-1bf8-4562-b7a7-eba9c01a3ccf"
      unitRef="usd">432554000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzYtMS0xLTEtMA_fb232da5-c292-4a4e-84ad-87b0988eef81"
      unitRef="usd">-251000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzYtMy0xLTEtMA_c7c3f2ef-32bd-45bd-a6c8-f3d2aa275f58"
      unitRef="usd">185000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzctMS0xLTEtMA_3c43485d-1304-4e33-b4fc-4906f4fd0ca9"
      unitRef="usd">511206000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzctMy0xLTEtMA_e8333227-bdf7-455b-a114-ad516e7cb026"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzgtMS0xLTEtMA_f6e7af6b-871e-4810-807c-00f88e66667c"
      unitRef="usd">894659000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8xOS9mcmFnOmZiYWZiZTA0NDczODQwZjY5Y2M5YTU0MjUwY2VmNzc3L3RhYmxlOjNlYThjZTM5MzkwMjQ4Yjk5Nzg5ODk4ZmU4MmE2NmRlL3RhYmxlcmFuZ2U6M2VhOGNlMzkzOTAyNDhiOTk3ODk4OThmZTgyYTY2ZGVfMzgtMy0xLTEtMA_0b0bf097-6fdf-421a-b1a0-a658fac5a428"
      unitRef="usd">637516000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0xLTEtMS0yODA_2371016b-d31e-4e53-bef2-02c3cf8cdf36"
      unitRef="usd">21553000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0zLTEtMS0yODA_e144a0cf-12fe-414f-818d-9238e17cba99"
      unitRef="usd">17548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0xLTEtMS0w_5b523547-1f0e-42ef-9f15-adcee1bb3f85"
      unitRef="usd">34629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMi0zLTEtMS0w_57afc49b-531b-4662-91bb-eb08a15d5a09"
      unitRef="usd">25619000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0xLTEtMS0yODA_204719df-c357-4413-8529-b180dceedf07"
      unitRef="usd">41523000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0zLTEtMS0yODA_dd4cf10f-3824-4718-b888-f02349eabe94"
      unitRef="usd">36455000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0xLTEtMS0w_eab31bd3-7fdf-42ee-a246-6354abed36e0"
      unitRef="usd">83002000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNC0zLTEtMS0w_f1a86c6d-2f42-4d2a-9811-e17065d1903d"
      unitRef="usd">71305000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0xLTEtMS0yODA_f886a2fa-3639-416c-bd25-a09b21fe2a2b"
      unitRef="usd">17927000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0zLTEtMS0yODA_1473e746-9639-4662-844e-ab891059d14e"
      unitRef="usd">14597000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0xLTEtMS0w_29877009-9b7f-41cf-9a82-33cff630e6c9"
      unitRef="usd">34046000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNS0zLTEtMS0w_a2a6f4be-7a2d-41ad-bd27-e40eda528c2a"
      unitRef="usd">31715000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0xLTEtMS0yODA_b30abb9f-39c6-4a57-8720-52bc51100d09"
      unitRef="usd">59450000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0zLTEtMS0yODA_20535205-aef9-40ad-bbc5-1f532d19b589"
      unitRef="usd">51052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0xLTEtMS0w_faa54b2e-5e38-435b-b746-077d11be6d2c"
      unitRef="usd">117048000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNi0zLTEtMS0w_bf30ae9b-5ddf-4a05-bd7a-f2215358af36"
      unitRef="usd">103020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0xLTEtMS0yODA_730a3f21-fa0e-48e8-9025-7e83a243d56d"
      unitRef="usd">-37897000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0zLTEtMS0yODA_0f67bb1e-45cb-4407-acc0-ab34acb4e278"
      unitRef="usd">-33504000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0xLTEtMS0w_727e8e0f-18b4-411a-86b6-6a85acc263c3"
      unitRef="usd">-82419000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfNy0zLTEtMS0w_5a3dedaf-f601-4e03-8ef3-cfd672e068f4"
      unitRef="usd">-77401000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0xLTEtMS0yODA_66617bc5-11b4-47eb-8810-ee7ef7de4148"
      unitRef="usd">1932000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0zLTEtMS0yODA_196ade00-d3de-4b4c-8c8e-a0b78c40f855"
      unitRef="usd">3148000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0xLTEtMS0w_edac0a43-e7a3-4c35-bf19-eb3e21eb84fa"
      unitRef="usd">3480000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOC0zLTEtMS0w_09a14a2a-b71c-4fb8-93f9-904ce0960c25"
      unitRef="usd">4842000</us-gaap:InterestAndOtherIncome>
    <us-gaap:ProfitLoss
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0xLTEtMS0yODA_c383af34-1c91-4c0d-aa79-b93461c980a9"
      unitRef="usd">-35965000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0zLTEtMS0yODA_c4f0e21b-fee8-4e2e-a1a2-33243783a015"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0xLTEtMS0w_a60f55c5-67aa-4903-96ff-06bb67546c26"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfOS0zLTEtMS0w_6d095648-1d9d-43f3-8106-4cd28b75a884"
      unitRef="usd">-72559000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMS0xLTEtMjgw_09dd6bda-33ea-433b-86c7-2b5f75660c1e"
      unitRef="usd">-36000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMy0xLTEtMjgw_48580c84-bd2a-4986-aa0b-c4c1af3cc882"
      unitRef="usd">-72000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMS0xLTEtMA_44cc1de5-1605-4bd0-86a7-b6d840091b94"
      unitRef="usd">-97000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTAtMy0xLTEtMA_ddf7dc9c-58ee-4abf-8a80-b37e1e8227e8"
      unitRef="usd">-125000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMS0xLTEtMjgw_e7fa1b0e-8fa6-4cd1-bf24-6b176b44ca22"
      unitRef="usd">-35929000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMy0xLTEtMjgw_eb28338f-472c-4630-9280-24e6c76f4a33"
      unitRef="usd">-30284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMS0xLTEtMA_9b4c91c5-b0a0-47e9-95bf-41e24b389cf9"
      unitRef="usd">-78842000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTEtMy0xLTEtMA_640cd587-432a-45d7-b2a6-02702f51d5ec"
      unitRef="usd">-72434000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMS0xLTEtMjg1_9e450e16-ed1e-497d-97ec-5a9fc8eaab36"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMy0xLTEtMjgw_d08a4b62-cd80-40ae-b8ef-934fa7ef7f6f"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMS0xLTEtMA_72c96407-0fb2-4cb8-8739-ef6e29291d23"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTItMy0xLTEtMA_3302f247-7b6e-4ca2-8277-8f3873e94ba8"
      unitRef="usdPerShare">-0.67</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMS0xLTEtMjg1_e7342e0a-b4fb-40ea-96b4-26d2e66d4d7d"
      unitRef="shares">138977000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMy0xLTEtMjgw_e3d9f365-8b28-434e-9ec8-44eccf8eca96"
      unitRef="shares">114382000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMS0xLTEtMA_6771bf7b-9c3f-4448-9f98-fe0ab70b5011"
      unitRef="shares">127519000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yMi9mcmFnOjRiZmYxZTk4ZDNjZTQ5MmE4ODEzNmQ0MGQwMDEwNTM3L3RhYmxlOmZkZWQ3MzliM2RiMzRlMzJiZTY5MzIzNGEzOGI4NWI0L3RhYmxlcmFuZ2U6ZmRlZDczOWIzZGIzNGUzMmJlNjkzMjM0YTM4Yjg1YjRfMTMtMy0xLTEtMA_3d9b3da6-1952-4adc-8150-a6d98ac22317"
      unitRef="shares">108360000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0xLTEtMS0yMDc_e7e8c3dc-f0f1-457a-9291-94904761f61c"
      unitRef="usd">-35965000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0zLTEtMS0yMDc_8090c041-40c2-4429-bc85-549574d03b56"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0xLTEtMS0w_a60f55c5-67aa-4903-96ff-06bb67546c26"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMi0zLTEtMS0w_623dbad7-a000-4720-a655-82873760695d"
      unitRef="usd">-72559000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0xLTEtMS0yMDc_1761f49c-e9ce-4522-a3f9-3bfa2d26128b"
      unitRef="usd">1783000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0zLTEtMS0yMDc_f20a264d-2ad9-4398-b576-831089e75eee"
      unitRef="usd">1442000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0xLTEtMS0w_5769ad03-e4c4-4d85-8913-ae7ef9a1a2c6"
      unitRef="usd">150000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfMy0zLTEtMS0w_715ef121-241f-4c3f-836f-b9ef14e3cd93"
      unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0xLTEtMS0yMDc_fc738945-295f-4c02-8666-f49b4e066ac0"
      unitRef="usd">392000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0zLTEtMS0yMDc_8f3f9c03-6022-4390-8173-5424fe3eb812"
      unitRef="usd">484000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0xLTEtMS0w_eba966f3-9fd7-40d9-b773-098c3ad3df35"
      unitRef="usd">646000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNS0zLTEtMS0w_96462689-5bb6-4592-9573-316d00e6d42b"
      unitRef="usd">737000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0xLTEtMS0yMDc_08e108c3-6f9b-4ef7-afe7-c8bfa5afc94a"
      unitRef="usd">-33790000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0zLTEtMS0yMDc_bcb5cf53-bd67-4df6-a248-cbfa1c8c3ff7"
      unitRef="usd">-28430000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0xLTEtMS0w_08b5298a-e3ea-41ad-84f5-7987b16fd4ff"
      unitRef="usd">-78143000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNi0zLTEtMS0w_82c3dbf4-f313-4e60-b6c2-38ec61c3c962"
      unitRef="usd">-71884000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0xLTEtMS0yMDc_f7bfd6ff-c6c6-4e21-a139-31f276704677"
      unitRef="usd">-36000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0zLTEtMS0yMDc_87db20f0-d5bc-4669-949e-fcc3af247fd1"
      unitRef="usd">-72000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0xLTEtMS0w_6cfbc906-1e4f-42f5-9e01-a333347a8eb5"
      unitRef="usd">-97000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfNy0zLTEtMS0w_82b940b1-5a9f-47c4-8139-e202aed29b60"
      unitRef="usd">-125000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0xLTEtMS0yMDc_a6e00dd2-dacd-49c1-a996-11c0fe7e39f8"
      unitRef="usd">-33754000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0zLTEtMS0yMDc_8e05480e-52b0-44c4-be9c-a4f595ed6c9a"
      unitRef="usd">-28358000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0xLTEtMS0w_5a34705c-b66a-4b84-852c-f3a036b82140"
      unitRef="usd">-78046000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yNS9mcmFnOmMwMDdjMmVjYWFiNTQwMzY4YWI5YmRlMjZiNTg1YWQwL3RhYmxlOmMzZGRjZDg3M2QwZDRkMzliYmQ1YzMxMGU2OWRlM2UzL3RhYmxlcmFuZ2U6YzNkZGNkODczZDBkNGQzOWJiZDVjMzEwZTY5ZGUzZTNfOC0zLTEtMS0w_a50053ed-6e91-41a2-926b-fe4ec847d55b"
      unitRef="usd">-71759000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i715b0ac6795a432590fdb6520e45e891_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0xLTEtMS0w_cba0cf0f-417b-4c51-bf24-c3f8635fa8b1"
      unitRef="shares">116278553</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i715b0ac6795a432590fdb6520e45e891_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0zLTEtMS0w_c09caef1-fdd0-4a56-b870-9489fa074f6f"
      unitRef="usd">1163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc447274e11c46e99da86c204d9a409c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy01LTEtMS0w_eba41734-05b8-473d-9a18-da89b72746d6"
      unitRef="usd">1096854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6090981ce294ff29297fc34c8c6e128_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy03LTEtMS0w_dc8f3473-1f7f-4161-95f6-79fd5c47b849"
      unitRef="usd">-699898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5a97ca934e54652924592147ff418b4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy05LTEtMS0w_349f2137-e6f9-4dab-bd13-2e1c91b3bcc4"
      unitRef="usd">-3828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i965e1b6625f34d2e8a6e6973f636c12c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0xMS0xLTEtMA_270af5d2-74e1-4e87-ae52-27daf42ff70c"
      unitRef="usd">124000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i210399ea6286402c8dcca9da42a400de_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMy0xMy0xLTEtMA_036444b4-34a1-41ce-8b31-664ec9d2563d"
      unitRef="usd">394415000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC0xLTEtMS0w_d7cf6a96-23b2-4270-b873-97fcbe594e5d"
      unitRef="shares">103262</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC0zLTEtMS0w_529db1d1-d2a0-4447-a5c2-c62c2cb3671e"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC01LTEtMS0w_877a9d82-920f-4eec-aa24-7988b4ae45d5"
      unitRef="usd">442000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNC0xMy0xLTEtMA_db107711-20f8-42c6-bde6-d0ec0c9e42d7"
      unitRef="usd">443000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0xLTEtMS0xMDIw_76e22287-d416-41b0-9f6a-788bdfbcae6f"
      unitRef="shares">171305</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0zLTEtMS0xMDIw_7377e689-6f5c-46c8-9ff8-d5c94095222a"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS01LTEtMS0xMDIw_34af9138-023e-4b75-bd0f-e7f350984f3e"
      unitRef="usd">1185000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0xMy0xLTEtMTAyMA_86810d3c-4eec-410e-a4d6-096cd72c50dc"
      unitRef="usd">1187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xLTEtMS0xMDIw_dbd34f7b-9f1d-482b-8714-a7657e92723d"
      unitRef="shares">24420157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7ccfedb13c79471bb919f748e2dcbee7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0zLTEtMS0xMDIw_281619bd-26e9-4894-9a41-7cdab4568b2f"
      unitRef="usd">244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi01LTEtMS0xMDIw_7984e53d-d9a8-4c24-bf11-65f68076165b"
      unitRef="usd">142282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xMy0xLTEtMTAyMA_960975b8-b97c-43bd-81be-3e2cc98e6d47"
      unitRef="usd">142526000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7895da45f86e46b593d7fd58999fd6a0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS01LTEtMS0w_364299a0-3a2a-40f4-8c6d-38e1612994a0"
      unitRef="usd">6764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNS0xMy0xLTEtMA_ea464391-ba37-4d8a-b01b-36d60e85f73d"
      unitRef="usd">6764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i4ba413aed2bb4cb89498cb2272ebe365_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xMS0xLTEtMA_fb985bf5-5c41-4900-9824-ab7913ac4b4a"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfNi0xMy0xLTEtMA_52ff2bfa-e8e1-449e-8952-213158ecfd7b"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6e7d0c3d3b6440a1ab0e041e0722d6e3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOC05LTEtMS0w_b1b37ef9-eb3b-48d6-acac-a5fc442b3158"
      unitRef="usd">-1783000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOC0xMy0xLTEtMA_f395ff01-c23c-4231-93e2-6d7ad4659b50"
      unitRef="usd">-1783000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6e7d0c3d3b6440a1ab0e041e0722d6e3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOS05LTEtMS0w_243d0404-4f92-4a2d-acea-cdfec9abc935"
      unitRef="usd">392000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfOS0xMy0xLTEtMA_8598f4cf-91c9-42cc-bacb-3c2e830748b1"
      unitRef="usd">392000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i11f2c0ec83df46a188ead01f731d71b8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTAtNy0xLTEtMA_b5c0bc60-27d3-47df-bb3a-ce5f51d8c05e"
      unitRef="usd">-35929000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4ba413aed2bb4cb89498cb2272ebe365_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTAtMTEtMS0xLTA_ff2c1d2b-17a8-4977-ab20-94f279840e35"
      unitRef="usd">-36000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTAtMTMtMS0xLTA_9db28557-04bb-43de-946e-ef8882694dfe"
      unitRef="usd">-35965000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMS0xLTEtMA_907b1268-34f3-4a02-a6dc-7462d249b649"
      unitRef="shares">140973277</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMy0xLTEtMA_68b40b96-d480-4e99-93c9-8cbf51789bbc"
      unitRef="usd">1410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ecc067020854944955a76da1ab1237b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtNS0xLTEtMA_d2587f3e-9220-44c5-9404-410f7cf85962"
      unitRef="usd">1247527000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7be5df5dcc8640e9a57dc51049938bb2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtNy0xLTEtMA_3e4cd5e7-c6b6-4c26-9680-aaa7c4827876"
      unitRef="usd">-735827000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib42b494f9fd740a38702396e27d699c3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtOS0xLTEtMA_11941aec-df33-4627-b845-0e80afea20de"
      unitRef="usd">-1653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfcdc625f9d448fa81dac8d80c9ab4f4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMTEtMS0xLTA_2f1563e2-080a-4c5d-bb5b-63dc78a84730"
      unitRef="usd">-251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0ODZmN2M5YzgzNzQ1NTU5ZTk4ODMxMTIyZjM2ZWIwL3RhYmxlcmFuZ2U6OTQ4NmY3YzljODM3NDU1NTllOTg4MzExMjJmMzZlYjBfMTEtMTMtMS0xLTA_5a8b5b56-6e11-4e56-8e8b-3496e07c25c6"
      unitRef="usd">511206000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3fee24599ecb470992405d7a99ed9663_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0xLTEtMS0w_e4edb9ba-2c64-4e2f-b0f4-e5f3125bfa4d"
      unitRef="shares">115972708</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3fee24599ecb470992405d7a99ed9663_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0zLTEtMS0w_e5cf20c1-8710-4739-855a-dd5e3c5845fd"
      unitRef="usd">1160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebb11f265f924c26864eda12977fa01a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy01LTEtMS0w_77695df5-58ba-4ed5-b76b-e18e0119a2e8"
      unitRef="usd">1090828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa736117878e411eb5f7b20e853a01b0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy03LTEtMS0w_20e9e6f4-ab40-47c3-bf52-0f7ec88b40a0"
      unitRef="usd">-656985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia07e3195343d45368e897c17d04de6a7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy05LTEtMS0w_60a2ce71-17d7-469b-aacc-7b0af1669015"
      unitRef="usd">-2449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i278c4f07da5c496fac619001ae98ef64_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0xMS0xLTEtMA_802ff2b0-6f4f-4755-8548-1dce2b6e5381"
      unitRef="usd">185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMy0xMy0xLTEtMA_29b797d5-c6dc-40d1-9d1f-315cc575dc09"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS0xLTEtMS0w_e3027868-bac3-4acb-9f7c-5217836a53e0"
      unitRef="shares">409107</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS0zLTEtMS0w_eb0fdfc1-94fd-4758-9102-f2c56b1b6c36"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS01LTEtMS0w_388706bf-1225-4ae0-8129-8460c9eb19cf"
      unitRef="usd">848000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNS0xMy0xLTEtMA_6d679fe4-d557-4a08-b2e2-e5bdfde2da21"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi0xLTEtMS0w_ea750d36-26ea-4d34-8df1-e4c8e4ce8fd3"
      unitRef="shares">171305</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi0zLTEtMS0w_e5818675-7697-4615-9b86-55c934125451"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi01LTEtMS0w_a5e5ef67-d720-4b06-9c9b-48a5e5f17f17"
      unitRef="usd">1185000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNi0xMy0xLTEtMA_9f472637-4c40-42a1-8991-7105e51f0ddb"
      unitRef="usd">1187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xLTEtMS02Ng_c22ed0b3-1e2a-4bae-9166-1ad521ee5ce6"
      unitRef="shares">24420157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i67634cd616724446afb7c5d432a6c6bb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0zLTEtMS03Mg_02d8557d-8ae9-40aa-ab07-ebbad2bd1f73"
      unitRef="usd">244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy01LTEtMS03Mg_bb472d0d-e6c8-4d92-8fcd-90bf81ab7f44"
      unitRef="usd">142282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xMy0xLTEtNzI_be9efc2f-7cdd-48de-8079-0c2b36eec734"
      unitRef="usd">142526000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xMS0xLTEtMA_4a2a1304-33ee-4da4-9cfe-abf7dd53039e"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfNy0xMy0xLTEtMA_c0435f71-9754-4a69-8c1d-9bccc2026a15"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2b0d40d697a4d37b4fa8d70a39c8f08_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOC01LTEtMS0w_2f1f3420-204d-4ba6-be08-52b92b87dc20"
      unitRef="usd">12384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOC0xMy0xLTEtMA_2154b611-c4e0-4cc6-88d1-4a57364ad18f"
      unitRef="usd">12384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ic12e6135fb424ea38f6945f7ac5f2eab_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOS05LTEtMS0w_48211eff-53bc-4a2e-819c-1699ee0a48e4"
      unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfOS0xMy0xLTEtMA_b6ee8c33-21c2-4db8-8be4-a84f843c467e"
      unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic12e6135fb424ea38f6945f7ac5f2eab_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTAtOS0xLTEtMA_c8b36cec-a8aa-48ff-bb53-43926832bf96"
      unitRef="usd">646000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTAtMTMtMS0xLTA_0f65c0db-6f48-4f5e-afa4-e4d38e01f292"
      unitRef="usd">646000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ife139e9caa184ca68f4d842bbb1a6e58_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTEtNy0xLTEtMA_ff10b567-5ca0-439e-a2f4-0e098ee3ff13"
      unitRef="usd">-78842000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i14a3d5f5eac24d569f20aac4bfb416fc_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTEtMTEtMS0xLTA_6f005e0d-e8d3-411b-8b6f-00436977de16"
      unitRef="usd">-97000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTEtMTMtMS0xLTA_5ed118b8-314a-4646-bf6c-f980b7604c4f"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMS0xLTEtMA_31a80e4e-1a79-4465-a0f1-8ec020d6cd5a"
      unitRef="shares">140973277</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87f58c14ac1f4042b5cec8f4b7109999_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMy0xLTEtMA_6d827725-0bf4-4f84-9008-296c249a2185"
      unitRef="usd">1410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ecc067020854944955a76da1ab1237b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItNS0xLTEtMA_84161c74-9484-4ec9-aa96-9f26be64b335"
      unitRef="usd">1247527000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7be5df5dcc8640e9a57dc51049938bb2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItNy0xLTEtMA_4fef9e57-b932-4023-a7a5-5cdebc0b50f5"
      unitRef="usd">-735827000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib42b494f9fd740a38702396e27d699c3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItOS0xLTEtMA_844fd9b1-3107-4e8c-8349-6d2c52c40e9c"
      unitRef="usd">-1653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfcdc625f9d448fa81dac8d80c9ab4f4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMTEtMS0xLTA_6f284035-e070-4b65-83dd-11cc5b7d1caa"
      unitRef="usd">-251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjE0ZWYxYTQ0MTZhZTQxZWI4YzQ3MmViNGViNTg4MzMyL3RhYmxlcmFuZ2U6MTRlZjFhNDQxNmFlNDFlYjhjNDcyZWI0ZWI1ODgzMzJfMTItMTMtMS0xLTA_6d287422-4e37-4365-a826-148a40b5df4d"
      unitRef="usd">511206000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic9461724558f4674a9d41050e9ebaae9_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0xLTEtMS03Ng_d4892ea9-bc67-4697-a1a0-c9d9f3d1ffdc"
      unitRef="shares">102328752</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9461724558f4674a9d41050e9ebaae9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0zLTEtMS03Ng_95776056-cd83-4967-a699-7f423ec7db81"
      unitRef="usd">1023000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2490d9038aa647379f0431522bd71baa_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy01LTEtMS03Ng_8068246e-511c-4e8e-ad9c-4fd15e428bf0"
      unitRef="usd">934112000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id966f8a5fab94bbcbd2b71c5797f8185_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy03LTEtMS03Ng_142ecc07-1d15-40d6-979f-7bae6dca0567"
      unitRef="usd">-603949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ee7332332064c54a42898aae0aafedb_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy05LTEtMS03Ng_635e07a4-336d-4c82-a281-25e13440b2fe"
      unitRef="usd">-2691000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bdcd18b9c3d4780a78d371c7e732f38_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0xMS0xLTEtNzY_475ae51d-b87b-43de-ab90-8c8eebc250a3"
      unitRef="usd">686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9cad5c531bc43ee9ebfdead3cc3a5da_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMy0xMy0xLTEtNzY_9df2b074-841b-4840-8c5c-2beddfedaab1"
      unitRef="usd">329181000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS0xLTEtMS03Ng_c6581f77-a2af-4f4b-8d28-c999baf84dc1"
      unitRef="shares">492635</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS0zLTEtMS03Ng_f51b7bdf-b999-423f-8cd6-94ae6884e5bf"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS01LTEtMS03Ng_e65165e4-66e9-4204-9ae4-39efc022649f"
      unitRef="usd">2439000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNS0xMy0xLTEtNzY_782f9509-1a00-46bc-aa37-e2cec97b5fd0"
      unitRef="usd">2444000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi0xLTEtMS03Ng_4fe45a3c-aa91-4c56-af7d-bbe0dc0260af"
      unitRef="shares">131709</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi0zLTEtMS03Ng_b8f72204-732a-4e29-97d8-813e1cd63b04"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi01LTEtMS03Ng_686f1202-0aac-4a50-9600-749d90875532"
      unitRef="usd">1137000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNi0xMy0xLTEtNzY_f7161770-60a3-42da-8061-51bc8f20b2ce"
      unitRef="usd">1138000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy0xLTEtMS03Ng_a314fcf9-39d8-4746-a469-6f03bc686f07"
      unitRef="shares">12650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i12831ff019884f19860abdd2f7ad15c7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy0zLTEtMS03Ng_6d2bfddb-6741-46de-9f36-6a9033119ff3"
      unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy01LTEtMS03Ng_4f4f6405-a265-4fb5-8c6d-1799a1e96e66"
      unitRef="usd">136439000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfNy0xMy0xLTEtNzY_2d5f075d-4fdb-435c-819e-e02c60dbd91d"
      unitRef="usd">136566000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOC01LTEtMS03Ng_2887db48-558c-4c57-a2d7-e20e767d3f89"
      unitRef="usd">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOC0xMy0xLTEtNzY_a8ab887e-f0fd-4ec1-9281-f2a82cf20529"
      unitRef="usd">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i66101d929a1c45ef936d6c32e561b76b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOS01LTEtMS03Ng_a652f996-0dd3-4542-82c2-c285b8408f61"
      unitRef="usd">4867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfOS0xMy0xLTEtNzY_f2fa508a-d2a7-496b-8c8c-c17c978e245e"
      unitRef="usd">4867000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i38d659779f044072ae939f9bb6c17be9_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTAtOS0xLTEtNzY_7b91292d-4252-4eed-b376-3a277664e05a"
      unitRef="usd">-1442000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTAtMTMtMS0xLTc2_ebb118a1-c6c5-43a5-935a-908ea120a086"
      unitRef="usd">-1442000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i38d659779f044072ae939f9bb6c17be9_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTEtOS0xLTEtNzY_625f6fd9-1de2-4ffc-9b04-eb5764d7301b"
      unitRef="usd">484000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTEtMTMtMS0xLTc2_87403bd1-c96a-4d9d-9b05-c185da87e524"
      unitRef="usd">484000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i553271530d1747ccaa14899dff3e1650_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTItNy0xLTEtNzY_bf30a9cb-883e-4e8d-9aea-8db2ac853abe"
      unitRef="usd">-30284000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i316b6d05c95040e2b1eff737183a7185_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTItMTEtMS0xLTc2_c03de015-87d2-4b49-b065-baf64a4bc618"
      unitRef="usd">-72000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTItMTMtMS0xLTc2_f1bdfc68-58fa-4c1b-8cf2-ca564a2b9b10"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMS0xLTEtNzY_0d5f66d4-a06f-4ca8-bb01-145408d27a2e"
      unitRef="shares">115603096</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMy0xLTEtNzY_7ddc0e81-342f-4215-b075-be95798f023c"
      unitRef="usd">1156000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice6e0c73ca7c4fb19915320974638f19_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtNS0xLTEtNzY_d8f04c9b-434a-42f7-a8a0-1cc15a1507ef"
      unitRef="usd">1078976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6d04447fa724128824a433975c7334b_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtNy0xLTEtNzY_e22b6436-e723-457f-9c87-126d133c4a03"
      unitRef="usd">-634233000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bb20f98f6494310aba335324fea603a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtOS0xLTEtNzY_2cd5ed39-8a3e-4915-8097-8cccadc90cbb"
      unitRef="usd">-765000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i009a92cb8ae04cd0bfbb29c780c42950_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMTEtMS0xLTc2_8f89b7a2-27ab-454a-b3ec-6214bd852c40"
      unitRef="usd">614000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjRhNWFlYjk5MzE1NTQwZmNiYmFlNzA4NDEwMGFkNjRjL3RhYmxlcmFuZ2U6NGE1YWViOTkzMTU1NDBmY2JiYWU3MDg0MTAwYWQ2NGNfMTMtMTMtMS0xLTc2_75a758ce-882a-4a72-b82a-9c70f818c94a"
      unitRef="usd">445748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5fb00e01938c41218801d630e5eed895_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0xLTEtMS0xMTQ_7db937bd-7103-489f-9605-aef09fe35496"
      unitRef="shares">102187471</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fb00e01938c41218801d630e5eed895_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0zLTEtMS0xMTQ_dac62ebf-26de-4327-8d53-ba1bb283ca34"
      unitRef="usd">1022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id113f3f8a5e9489f8ba5ce4e97f34e4e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy01LTEtMS0xMTQ_672e55df-8f96-4c61-bce2-557b7d3e9e75"
      unitRef="usd">929632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0726daec490b495ab4b81b5cc062f239_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy03LTEtMS0xMTQ_69266f1e-3361-45f9-94d2-33338842c717"
      unitRef="usd">-562696000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if268975f048242d19e806873ecf0328f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy05LTEtMS0xMTQ_c8daac30-d70c-4db8-8659-fe4840c66c92"
      unitRef="usd">-1440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i015db7a76e3c48e099a7af789a5fad56_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0xMS0xLTEtMTE0_1035178f-5cf7-4f46-bebc-425d89edcfc5"
      unitRef="usd">739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMy0xMy0xLTEtMTE0_7a458e7a-8bc9-4e14-9a27-2cdc8b6b4c29"
      unitRef="usd">367257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3613e176873c4760beea58bab9dd7524_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC03LTEtMS0xMzg_7ca14b8c-7a38-4f96-8e37-2ad6d8bd52df"
      unitRef="usd">897000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i293b616727bb4417b41b877fe73be3a6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0xMy0xLTEtMTM4_1fd4e989-041d-47ed-990b-c5e2e0d26e6e"
      unitRef="usd">897000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0xLTEtMS0xMTQ_ddb88777-a9e1-4cd7-9f6e-d630285f381d"
      unitRef="shares">633916</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0zLTEtMS0xMTQ_374ec395-ca9e-421c-87e0-77cb989c4f6d"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC01LTEtMS0xMTQ_b318af45-360f-45a5-83c3-1004eaf138d3"
      unitRef="usd">2654000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNC0xMy0xLTEtMTE0_47616388-1581-4bd9-829d-d818d83595a7"
      unitRef="usd">2660000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS0xLTEtMS0xMTQ_b5514366-177c-4bda-956d-fa6c9ae6c3b9"
      unitRef="shares">131709</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS0zLTEtMS0xMTQ_c84d50f6-c36a-4e84-b62e-8bf6ac25e73f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS01LTEtMS0xMTQ_c898ae58-22d9-4beb-a480-7223c48f487a"
      unitRef="usd">1137000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNS0xMy0xLTEtMTE0_d2acb0ec-c184-41ae-beda-972f7c503fc9"
      unitRef="usd">1138000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi0xLTEtMS0xMTQ_252a4632-8a5e-436d-85bc-9575b2f54975"
      unitRef="shares">12650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0015c60565ea4383b437165b9285c82d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi0zLTEtMS0xMTQ_820398cf-a243-4c7c-9a67-dcef6e587517"
      unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi01LTEtMS0xMTQ_0be9a5f7-b5e6-45e1-8652-f1133b6eaf3c"
      unitRef="usd">136439000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNi0xMy0xLTEtMTE0_387d9819-1e14-4852-8a20-bfc068487253"
      unitRef="usd">136566000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNy01LTEtMS0xMTQ_0eb1cbe1-389e-4873-842a-1ffaa674bbdc"
      unitRef="usd">276000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfNy0xMy0xLTEtMTE0_b510416e-6bbf-448d-b10c-d08c9a4e1195"
      unitRef="usd">276000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idd1f463ffb7e45b2a2c4e7f47c79a264_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOC01LTEtMS0xMTQ_bb637322-8368-4a3c-b37a-d274917af001"
      unitRef="usd">9390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOC0xMy0xLTEtMTE0_8e6a7b51-18d9-4dd3-8c9c-fdfdd448e3df"
      unitRef="usd">9390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOS05LTEtMS0xMTQ_0dcb68fc-362d-4e92-a19b-51386cf63c72"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfOS0xMy0xLTEtMTE0_a4d1575b-b90f-4a6e-8efd-9f0c6f6c1238"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie92671d3c141420f88e50a9fe64c3bf1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTAtOS0xLTEtMTE0_8669e25c-e965-49ee-a4c3-e88b6952e996"
      unitRef="usd">737000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTAtMTMtMS0xLTExNA_f4610209-cdf4-41ba-b5fc-5056ac6bc558"
      unitRef="usd">737000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i94be9ec349764546bf3b7c36db8f8ca3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTEtNy0xLTEtMTE0_cb611608-d651-48f6-b686-d4ac3758e268"
      unitRef="usd">-72434000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i63ba29b6972848c1bc27ede3e93b882d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTEtMTEtMS0xLTExNA_baa10d58-98d8-4b3a-9c73-4f13e7e51dd3"
      unitRef="usd">-125000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTEtMTMtMS0xLTExNA_fe180899-5c02-48c1-af4f-8de4e13e16b9"
      unitRef="usd">-72559000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMS0xLTEtMTE0_d55740e0-6c2f-4daa-8acb-df84dbcaaf16"
      unitRef="shares">115603096</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i539ed8df47a24071adb12e36bb3089ea_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMy0xLTEtMTE0_8062af12-bc38-40d3-bad6-0982b1c2e306"
      unitRef="usd">1156000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice6e0c73ca7c4fb19915320974638f19_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItNS0xLTEtMTE0_2e9cab1f-cedc-45f9-9ba2-525b3e0b844b"
      unitRef="usd">1078976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6d04447fa724128824a433975c7334b_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItNy0xLTEtMTE0_9dd67715-364e-424c-8710-5da067ab286d"
      unitRef="usd">-634233000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bb20f98f6494310aba335324fea603a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItOS0xLTEtMTE0_f4b50bf4-10c2-4f6d-b1cf-1b1c91b9e552"
      unitRef="usd">-765000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i009a92cb8ae04cd0bfbb29c780c42950_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMTEtMS0xLTExNA_b0428e8d-6092-4fbc-a880-ad8515f2e219"
      unitRef="usd">614000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8yOC9mcmFnOmMyM2MzMTJkOGM1NjRjMjliMjBmMDMyMWRjYjc5MzVlL3RhYmxlOjk0MTAyNGU5NmJiYjRjMmE4ZDM4Njk5M2ZjMjVhZjNiL3RhYmxlcmFuZ2U6OTQxMDI0ZTk2YmJiNGMyYThkMzg2OTkzZmMyNWFmM2JfMTItMTMtMS0xLTExNA_ea3eec42-20e6-4bd2-b363-a904849e9865"
      unitRef="usd">445748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMy0xLTEtMS0w_53d122a7-1b54-41b5-977c-7fa59dba473c"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMy0zLTEtMS0w_62f2dd48-9279-42b9-becd-33fef6fdd3e5"
      unitRef="usd">-72559000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNS0xLTEtMS0w_7db5448c-801b-4321-aeec-05374d5a68e1"
      unitRef="usd">2639000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNS0zLTEtMS0w_f0985d6e-9b44-49ff-83cd-67b7b6af3346"
      unitRef="usd">1583000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNi0xLTEtMS0w_8cfec018-c1e9-4851-b051-9456d0e0f258"
      unitRef="usd">1146000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNi0zLTEtMS0w_8856fd94-6574-4612-ad8c-48a68e46e4d4"
      unitRef="usd">2455000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNy0xLTEtMS0w_e5a9d9d2-8cee-4153-8d33-9da343594aed"
      unitRef="usd">-3788000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNy0zLTEtMS0w_0284cbf8-ef82-40a4-a9f6-9bc75088d793"
      unitRef="usd">-1923000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:GainLossOnFreeShares
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOC0xLTEtMS0w_57214808-d7b0-4d82-a797-d60f938076de"
      unitRef="usd">48000</sgmo:GainLossOnFreeShares>
    <sgmo:GainLossOnFreeShares
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOC0zLTEtMS0w_e668d866-f042-4c65-98c4-bdcfc8835e6b"
      unitRef="usd">551000</sgmo:GainLossOnFreeShares>
    <us-gaap:ShareBasedCompensation
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOS0xLTEtMS0w_bebd9898-0a2c-4949-ab4c-bd663633dbbc"
      unitRef="usd">12384000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfOS0zLTEtMS0w_0da5cf29-2058-4991-8078-de8639aca8bb"
      unitRef="usd">9390000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTEtMS0xLTEtMA_b3ff4fdf-7130-4d8e-a866-af392ccce077"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTEtMy0xLTEtMA_5a48b1c6-8c9c-40a8-8631-7c78e1f069e9"
      unitRef="usd">-218000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTItMS0xLTEtMA_4b56ffac-cf47-401d-9de0-3754944282e4"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTItMy0xLTEtMA_3e803602-33d4-4aec-a56d-23a8e5eeff77"
      unitRef="usd">-11000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTQtMS0xLTEtMA_add9e20f-d45b-446e-82f1-bd49dcf6f47b"
      unitRef="usd">-148000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTQtMy0xLTEtMA_14a644d8-574f-461e-9052-1b4ed6239eea"
      unitRef="usd">391000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTUtMS0xLTEtMA_63b58b2d-fd10-4d73-ab67-add41d6effc6"
      unitRef="usd">-31291000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTUtMy0xLTEtMA_eec2bc89-2b5d-454d-b9c2-73fa9490dd7c"
      unitRef="usd">7422000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTYtMS0xLTEtMA_0c680d9b-4871-4990-98a0-c9b493b25ea2"
      unitRef="usd">7763000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTYtMy0xLTEtMA_b47b6dde-1510-4337-adda-5ca911401b75"
      unitRef="usd">5449000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTgtMS0xLTEtMA_e891744f-e39d-4379-abbc-803d19a7f350"
      unitRef="usd">1559000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTgtMy0xLTEtMA_5c866f4c-ded6-4cd2-a541-52724608e091"
      unitRef="usd">1811000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTktMS0xLTEtMA_6df9f464-91e0-4dd2-b294-049d774d0432"
      unitRef="usd">-248000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMTktMy0xLTEtMA_bd227247-00af-4393-9f3b-c617283fe8ff"
      unitRef="usd">-764000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjAtMS0xLTEtMA_ba832069-bc6b-407b-9366-b800c8026337"
      unitRef="usd">178890000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjAtMy0xLTEtMA_736c5283-2600-4053-9a40-0a7dbb22fcad"
      unitRef="usd">-10821000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjEtMS0xLTEtMA_3cc6bcc0-a159-492f-bdba-77e26502e9d0"
      unitRef="usd">-1797000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjEtMy0xLTEtMA_8491bf05-bd33-458f-9a5a-a9442d60f3d6"
      unitRef="usd">-563000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjItMS0xLTEtMA_1adb3da6-de01-4db1-bb74-336c539489d7"
      unitRef="usd">345000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjItMy0xLTEtMA_a4e4b35d-c3ad-4052-b963-6d9cfd2e8e4b"
      unitRef="usd">1327000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjMtMS0xLTEtMA_79328853-a2e7-4acf-b9d6-476ffd4a7221"
      unitRef="usd">141103000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjMtMy0xLTEtMA_82ae0e7f-5973-4138-8be4-92866f0f03e0"
      unitRef="usd">-84712000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjUtMS0xLTEtMA_4ade0665-6406-4e85-8367-48c0b2c34154"
      unitRef="usd">43580000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjUtMy0xLTEtMA_9bfbbb72-a4ba-47e3-b49a-1a6d47174221"
      unitRef="usd">244306000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjYtMS0xLTEtMA_f4822c36-5e4b-4336-9fd8-9ba93d166aa8"
      unitRef="usd">151839000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjYtMy0xLTEtMA_6e9840c0-4982-40d8-a462-f40d374c1868"
      unitRef="usd">226884000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjctMS0xLTEtMA_0ed3f2f1-c39a-4137-86b2-93bc0c15f39c"
      unitRef="usd">6694000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjctMy0xLTEtMA_f1aa826f-968f-4a5b-859d-7fb595587816"
      unitRef="usd">9760000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjgtMS0xLTEtMTEzMg_832ff1b0-9474-497a-a04e-78c6e700e9b6"
      unitRef="usd">237000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMjgtMy0xLTEtMTEzNg_704e22ca-7b83-40d0-b338-9142612a521a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzAtMS0xLTEtMA_0d22b2af-99a8-41eb-b4ab-67bc43ea3265"
      unitRef="usd">101328000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzAtMy0xLTEtMA_d67fb42e-18dc-4e37-9dad-bc1b1169307e"
      unitRef="usd">-27182000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzItMS0xLTEtNzg4_9a167646-3cbd-4362-a854-3f9947aedbcb"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzItMy0xLTEtNzg0_4ac901b9-643b-4408-bba8-76948321d21d"
      unitRef="usd">136308000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMS0xLTEtMTA5Nw_cd300532-4c9e-4bbc-a869-f8272b493610"
      unitRef="usd">142526000</sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMy0xLTEtMTA5Mw_ed99b979-adb1-4f89-8715-a2f48ab872e6"
      unitRef="usd">0</sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMS0xLTEtMA_db693978-5473-463e-9616-84526a2a131b"
      unitRef="usd">455000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzMtMy0xLTEtMA_37c866c4-1638-4c74-81d6-918e1cfeda8e"
      unitRef="usd">296000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzQtMS0xLTEtMA_826d3d6c-3c6c-404a-9df9-dceea3ffd27f"
      unitRef="usd">1307000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzQtMy0xLTEtMA_e40f2b61-f5b8-49e4-9bab-4404434e9b2f"
      unitRef="usd">4094000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMS0xLTEtMTEyNQ_bd737755-1e8c-4756-920f-b9f89889129f"
      unitRef="usd">1187000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMy0xLTEtMTEyMQ_d5918238-aaa8-47be-a33a-a67d699777df"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzUtMS0xLTEtMA_27654f5d-b11f-48ec-bcd7-c23ad68f8a91"
      unitRef="usd">144565000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzUtMy0xLTEtMA_4750027b-f31c-4de4-99b8-d7b53de7067e"
      unitRef="usd">140106000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMS0xLTEtMA_8f12ce7f-e35e-49d8-a26d-fa4fabc9e575"
      unitRef="usd">19000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzYtMy0xLTEtMA_0fa0c883-a888-4223-8804-2d02115ce3be"
      unitRef="usd">592000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzctMS0xLTEtMA_2fa1361c-4073-4ed7-b6ad-e5eb1b6e79ff"
      unitRef="usd">387015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzctMy0xLTEtMA_6e20cf07-2650-4656-920c-474720166061"
      unitRef="usd">28804000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzgtMS0xLTEtMA_6237b600-ed63-44da-8ea7-c8290c8525c4"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzgtMy0xLTEtMA_f5c1918c-f890-4ce6-ab72-d41502973333"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzktMS0xLTEtMA_e638a7ff-fa06-4394-b195-c15248b940fb"
      unitRef="usd">468943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfMzktMy0xLTEtMA_d21bdfe9-fa1c-4717-9da2-e4d80aaf1f62"
      unitRef="usd">172722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDEtMS0xLTEtMA_8babb1be-127d-4de0-865e-fb35b1a9724f"
      unitRef="usd">1977000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDEtMy0xLTEtMA_9467b78a-6cf5-4fb1-9610-c0f8757cc789"
      unitRef="usd">1679000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDItMS0xLTEtMA_8c997fb4-c8fe-4967-8cd8-cafb65111327"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zMS9mcmFnOjI4ZTBlZTYxNzE2ODQxYzU5YWI5MjBmODkyZGIxMDQ5L3RhYmxlOjE1YTZmYTUxYWE0OTQ3ZmZiMGM0ZGJjNjg4ZjJlOTQxL3RhYmxlcmFuZ2U6MTVhNmZhNTFhYTQ5NDdmZmIwYzRkYmM2ODhmMmU5NDFfNDItMy0xLTEtMA_cef9c0e3-ad33-4046-8f88-2ad5dbaab921"
      unitRef="usd">29671000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODg_ef4beb94-c301-4fa7-918a-8d0d87ff9439">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995. Sangamo is a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#x2019; lives using the Company's platform technologies in gene therapy, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene-edited cell therapy, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome editing and &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome regulation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. The Condensed Consolidated Balance Sheet data at December&#160;31, 2019 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 (the &#x201c;2019 Annual Report&#x201d;) as filed with the SEC on February&#160;28, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company's Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2019, included in the 2019 Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaboration funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2020, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12 months from the date the financial statements are issued. Sangamo may require additional financial resources to complete the development and commercialization of its products including zinc finger protein (&#x201c;ZFP&#x201d;) therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#x2019;s business and ability to advance its product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#x2019;s stockholders, and any debt financing may include covenants that restrict the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi Genzyme (&#x201c;Sanofi&#x201d;) as a result of a decision made by the joint steering committee of Sanofi and Sangamo to increase the project scope and related project cost, which resulted in a decrease in the measure of proportional cumulative performance. In March 2020, the Company also recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;). This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs after the successful investigational new drug (&#x201c;IND&#x201d;) transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;research collaboration and license agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Pfizer-related adjustment in June 2020 increased revenue by $3.0&#160;million, decreased net loss by $3.0&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.02 for the three months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Pfizer and Sanofi-related adjustments in March and June 2020 increased revenue by $3.1&#160;million, decreased net loss by $3.1&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.503%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pfizer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2020, the Company had not incurred any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#x2019;s development programs. Contract funds are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of June&#160;30, 2020, no impairment of goodwill or indefinite-lived intangible assets has been identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of June&#160;30, 2020, no impairment of any long-lived assets has been identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;estimated fair values. The free shares asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.191%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.046%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.615%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;467,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;468,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;172,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in Accumulated Other Comprehensive Income (Loss) (&#x201c;AOCI&#x201d;) within stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in other income (expense) within the accompanying Condensed Consolidated Statements of Operations. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the estimated fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an IND application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 808&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2017-04&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-04 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes &#x2013; Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&#x201c;ASU 2019-12&#x201d;). The guidance removes exceptions to the general principles in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(Topic 740)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODk_618d2e06-c93f-4bb7-a16e-11dc6eab075e">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. The Condensed Consolidated Balance Sheet data at December&#160;31, 2019 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 (the &#x201c;2019 Annual Report&#x201d;) as filed with the SEC on February&#160;28, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company's Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2019, included in the 2019 Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMzI5ODUzNDkxMDQ3OA_a38450fb-7a2c-450b-b18e-e1d04bb14f9c">Use of EstimatesThe preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTA5OTUxMTY1NDIzMA_e8f7c87d-a8c9-4e5d-aded-3a9a9879f5c8"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTA5OTUxMTY1NDI0NA_90f23e1a-0a71-4a6f-8a8e-bee4bad19675"
      unitRef="usd">-3000000.0</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief175a090cde47e2b775efc1f37f1786_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTA5OTUxMTY1NDI1MQ_65828224-44cf-4592-ae7d-f4c730ea1e5d"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfNTY4Nw_5fb816a0-e912-4e10-b1cd-fda396ca6dac"
      unitRef="usd">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfNTcxMw_5a797531-5c0c-4c28-b9e8-ba2186b2e5b0"
      unitRef="usd">-3100000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9fd1be21f61a498b82b4f70c6d119350_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTY0OTI2NzQ2NzQyNw_ff69dba6-6848-414b-829a-b7fc54f52020"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMzI5ODUzNDkxMDQ3OQ_c0d56397-72d5-4687-a223-308cbd7b855d">&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.503%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pfizer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2020, the Company had not incurred any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#x2019;s development programs. Contract funds are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODM_557be307-523d-4863-81a1-e8612955b045">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.982%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.503%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Pfizer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sanofi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibf55388c1bfb4f1cb45c0812eebe6af4_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0xLTEtMS0xOTc3_52ab2767-7e56-427c-a964-e84b772d17e1"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic5c61a6784f940f8bd95841c65cc3de2_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0zLTEtMS0xOTc3_7386a59f-59d3-40d2-87c3-470838ac1c69"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idc7d9b485d384d6f8ad54269d553b696_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi01LTEtMS0xOTc3_99d88413-f1bb-4b71-b5a6-e4d4a8e18215"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7e52d1ac0635451a9b507adfd21181b1_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi03LTEtMS0xOTc3_0c8dc802-a1da-4ae6-af27-de763fbc5e94"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i21370c70454d46adbd1945146055d853_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0xLTEtMS01MDQ_b4876f69-ed27-447a-9fd3-d6346025e1b0"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia4d8ff36c0ce4c9a8a25a0dd9e3431fa_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0zLTEtMS01MDQ_1007c23b-0324-4c44-8fe9-1a2427b0519b"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i48bb61da0bcf4909ad5eeb72eb273bc7_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0xLTEtMS0w_de187a30-5d45-4981-89e1-67294bbaa90f"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1c97ee7ce62e4dd8ab9222f36c803f8b_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMi0zLTEtMS0w_c175db52-f608-4d79-8416-c3e388702ac2"
      unitRef="number">0.61</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i56021bdaf9354623bd7e8749bb327b83_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0xLTEtMS01MDQ_6dec59cf-a324-4b83-87f3-189d2ba25e9a"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib8ec51d23f3a45679c02cba5fcfadea5_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0zLTEtMS01MDQ_9ec05935-09bb-4327-b557-2b50067c494c"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5840d5f60f4d44dd9851bb922ea77df3_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0xLTEtMS0w_c5c25a0e-885d-4e0d-a4d5-5789a1e38b13"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i946c25911d16465c94ce83c9e4b06fdb_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfMy0zLTEtMS0w_60dbddf3-8908-4896-bc40-9b10aadbc989"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0fa847036ee74f318716774b63f7a97a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0xLTEtMS01MDQ_1158db97-3f37-4e52-8a11-9fec9b274f37"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9afe62008bfd4661a107bdae92e16531_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0zLTEtMS01MDQ_868ace2b-2861-43a2-9cf2-4e6948d5103a"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i653ce1faadc3465a97bc8136db41ce20_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0xLTEtMS0w_57751843-bb47-41ce-ace5-b8e6a060f9ee"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icfe937211c1b4e088c934d0abe849d2a_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjVmMWM5ODRjYjgxZTQ0ZDZiYjQzNWRjOGQ1YjE1OWJlL3RhYmxlcmFuZ2U6NWYxYzk4NGNiODFlNDRkNmJiNDM1ZGM4ZDViMTU5YmVfNC0zLTEtMS0w_ccf85b21-a157-485b-888a-f2e1af599b21"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2NzY_f0611061-99c9-4509-be6c-e942497902ad">&lt;div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODI_b82576a6-a6dc-4d4a-996a-b810fa66c532">Goodwill and Intangible AssetsGoodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2Nzg_779134e5-845b-4084-ac54-2d91b8326ffb">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2NzM_b0f1ea65-0366-4f99-8140-c86ded19ded5">&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their &lt;/span&gt;&lt;/div&gt;estimated fair values. The free shares asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTA_840545c5-e5e0-4e7a-9a4a-6d314ee9862e">Cash, Cash Equivalents and Restricted CashSangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMTU1MTE_a24bfd25-3172-44e8-a089-79af488bbb24"
      unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTc_4ee2308a-dad3-4ed2-90a6-bc3c205078f3">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.191%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.046%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.615%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;467,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;468,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;172,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTc_a28d6e0b-a24d-44cb-9959-76fc60aa70b8">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:52.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.191%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.046%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.615%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;467,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;468,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;172,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS0xLTEtMS0w_d9efcba9-1260-4427-be60-0d718da428da"
      unitRef="usd">467443000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS0zLTEtMS0w_06434fab-8958-49ed-8107-82ce91af9c44"
      unitRef="usd">80428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS01LTEtMS0w_781f6ec2-0a96-4bb0-aa9f-fd37fa2f06e9"
      unitRef="usd">169222000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMS03LTEtMS0w_c03f3e54-ddfb-4f76-87a8-5e61be1a542e"
      unitRef="usd">140418000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi0xLTEtMS0w_cef8d5cb-ae7d-45fa-8b31-1e1f9fb8eb35"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi0zLTEtMS0w_106fc9b0-e239-46ad-ac51-28c71c42f5c4"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi01LTEtMS0w_f0a7871c-3a9b-429a-b536-0d1339076576"
      unitRef="usd">2000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMi03LTEtMS0w_d25103ad-f53f-4e18-8a42-0fce653e2be5"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy0xLTEtMS0w_a4f6cbf4-1c24-4916-a6f1-d2128b04904a"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy0zLTEtMS0w_db96e2df-0d8d-41fc-9258-0138991a0c4a"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy01LTEtMS0w_40207275-f6aa-4c9b-8c9c-5f04544da77e"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfMy03LTEtMS0w_48c2ffbb-5aba-4337-9b2e-e24d6c263dda"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC0xLTEtMS0w_d68ada5b-f0eb-424c-9e8d-9b05c400edc3"
      unitRef="usd">468943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC0zLTEtMS0w_f9a3ed5b-9215-47a7-be95-9eab563c110c"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d016582d2524cb58d1a7cb653294394_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC01LTEtMS0w_1ced0599-3b80-40cf-b195-c0bd4ac9a0dd"
      unitRef="usd">172722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i086101d733d94f44b607cc9a00cdd045_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RhYmxlOjIwY2NlODE0MTBjYzQ1OGZhMGE3ZGI0MTRhMTE3ZGQ1L3RhYmxlcmFuZ2U6MjBjY2U4MTQxMGNjNDU4ZmEwYTdkYjQxNGExMTdkZDVfNC03LTEtMS0w_d6115296-d3f0-4d2e-84c1-df3a795c05fa"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODE_6493df70-e960-4e0a-919d-1c7ba3e68995">&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in Accumulated Other Comprehensive Income (Loss) (&#x201c;AOCI&#x201d;) within stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in other income (expense) within the accompanying Condensed Consolidated Statements of Operations. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the estimated fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2ODc_9d4617ce-eb9b-417b-bef4-075d287bbbe7">&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an IND application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTg_b03a2b8f-612a-4009-a03a-f663557a626a">&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2NzQ_45332edd-96e8-4182-84cf-7b1152c14a71">&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl8zNy9mcmFnOjRkOTQ3NzIwYTg5YTQ1ODNiMGU3YjcxYjExOWU4OWQ2L3RleHRyZWdpb246NGQ5NDc3MjBhODlhNDU4M2IwZTdiNzFiMTE5ZTg5ZDZfMjU2OTE_274fb8ec-d6f5-40bc-9642-8929084e014f">&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASC Topic 808&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2017-04&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-04 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes &#x2013; Simplifying the Accounting for Income Taxes &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(&#x201c;ASU 2019-12&#x201d;). The guidance removes exceptions to the general principles in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(Topic 740)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on Company's Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk2Nw_6e0f2aa7-ce58-46ec-b0ed-b63158fb3338">FAIR VALUE MEASUREMENTS&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:0.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;313,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:23.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Commercial paper securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company generally classifies its marketable securities and some cash equivalents as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Free Shares Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of the July&#160;20, 2018 Share Purchase Agreement (&#x201c;Sangamo France SPA&#x201d;) to acquire Sangamo France (see Note 10 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Acquisition of Sangamo Therapeutics France S.A.S.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;), the Company entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $0.2&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#x201c;Monte Carlo simulation model&#x201d;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company purchased approximately 111,000 shares during 2019 and 117,000 shares during the three months ended June&#160;30, 2020, of the 477,000 total free shares for a cash payment of approximately $0.3&#160;million and $0.2&#160;million respectively, upon exercise of the put options. As of June&#160;30, 2020, approximately 249,000 free shares remain outstanding and subject to purchase by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the free shares asset was approximately $0.2&#160;million at December 31, 2019. The Company recognized an increase in the fair value of the free shares of approximately $0.1&#160;million for the six months ended June&#160;30, 2020, offset by approximately $0.1&#160;million for the shares purchased during the six months ended June&#160;30, 2020, resulting in an asset balance of approximately $0.2&#160;million at June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.100%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.230%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.232%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD / EUR Exchange Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Correlation Sangamo and Sangamo France Stock Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD / EUR Exchange Rate Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk Free Rate and Cost of Debt by Expected Exercise Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk2OQ_37bb7eeb-15e0-4bca-812c-04b63dcb5271">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:0.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;313,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:23.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;Commercial paper securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;306,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie4a578789cb147eebdc1bb90088efe97_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS0xLTEtMS0w_d72bd940-18e8-4b06-8ad0-507fcb5af713"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d45598ab29c4e2db9f9dbb7cec8d9e7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS0zLTEtMS0w_9e35bcff-1ed8-4853-9da1-1a5576e1563f"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id08dc51273904752aaf728a6e1df8383_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS01LTEtMS0w_6e296aee-32eb-48b8-bb80-7915c0c00bde"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iab71f71232254a6f82150b71c8f007fb_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNS03LTEtMS0w_5e7c83e2-608c-47a5-b6ab-58d0a920c499"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3461528899214d58b2a932f24904ee6e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy0xLTEtMS0w_5877c237-9c13-4703-ab16-28ed77d0246e"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy0zLTEtMS0w_1bedf63a-c58c-47c7-aaec-fed692b8dea5"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icd13016ac46c48bc84616522d16a595d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy01LTEtMS0w_319a7f32-9ff2-465d-8abb-2c59833b4784"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65c6ac9671754abdb804515a0bc88a5b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfNy03LTEtMS0w_652c2717-eab8-42fc-b320-67373fa35ae3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4db5a3fc61af496597d6be764fbf968a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS0xLTEtMS0w_15aa4d45-43ea-4ff3-be6d-cc553e358cd5"
      unitRef="usd">90179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ae3532bd280450d9b3d2aaf3fd3183f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS0zLTEtMS0w_62c3f126-020e-4ad4-8641-3c0367f3d090"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45cab4a727634aa0ad89eeb42596a594_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS01LTEtMS0w_31b3a1b2-26bc-40fd-a598-792596683a82"
      unitRef="usd">90179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97ba6efdd77a4d1fbdd0f8dac7ce03e2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfOS03LTEtMS0w_4a48ffed-12f3-41aa-befa-cbe76c655621"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic095f3bf93224fd7830f1bf15820b81b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtMS0xLTEtMA_29a4678a-ec0a-43c5-abcf-c7041448ff28"
      unitRef="usd">81844000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c8eb3ee87c64e9aacf30737f5a51adb_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtMy0xLTEtMA_7504058c-9619-441f-81db-0c8f23fe501e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7fd6b25106a84026b8dd26c57d4b4125_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtNS0xLTEtMA_da324e8a-1314-467a-8966-f46aef756008"
      unitRef="usd">81844000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bad4096995042179cc11bc904b183d9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTAtNy0xLTEtMA_208ef13d-dff4-4a26-8ca3-7af7697e93ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i452e2107611247cfb0d8f189bfc13b86_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtMS0xLTEtMA_e23c6dac-5354-424e-a053-f4400eced9ad"
      unitRef="usd">25387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c8bf564147c432e8c52d88f72ff45c0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtMy0xLTEtMA_7f5ab89c-6478-48de-89e4-e186d532e4c8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62b06a1912424ff4a4459beb539c32da_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtNS0xLTEtMA_c8f369ea-24cb-4da3-99f2-8989bf9e3370"
      unitRef="usd">25387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6936e5949976449dbccf475a22595e86_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTEtNy0xLTEtMA_37381a5f-2dac-4696-83ca-e5d9f8b1bf9f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3461528899214d58b2a932f24904ee6e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItMS0xLTEtMA_65cef788-95ff-4165-9718-a6bfc7b8370f"
      unitRef="usd">197410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItMy0xLTEtMA_7cf3e884-74c6-485e-b773-0b092bf9ce07"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd13016ac46c48bc84616522d16a595d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItNS0xLTEtMA_575bae1c-f93f-47f1-ab71-003e2e731503"
      unitRef="usd">197410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65c6ac9671754abdb804515a0bc88a5b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTItNy0xLTEtMA_a8c7a2e0-e5f1-4768-937a-a8fdef4a7e29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3461528899214d58b2a932f24904ee6e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtMS0xLTEtMA_6f11eee6-5896-4785-8fba-a55b71b27954"
      unitRef="usd">313803000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iccb3e5ad4e0d428987a5a65af1d282f2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtMy0xLTEtMA_ec3a1d39-cc6e-41c2-b31f-318f6167a324"
      unitRef="usd">116393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd13016ac46c48bc84616522d16a595d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtNS0xLTEtMA_da6eea41-836b-405d-9707-8e188654457a"
      unitRef="usd">197410000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i65c6ac9671754abdb804515a0bc88a5b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTMtNy0xLTEtMA_9bc3d46d-3bc4-4faf-a979-1c36dcaf9c64"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib4a4a0a8362b4d67a4a3abae87fd40b9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtMS0xLTEtMA_0caf299f-5844-4371-aee3-35bf3cd4aaa2"
      unitRef="usd">167000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa5e29888c3a4d52998814f37ae4dba1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtMy0xLTEtMA_1ed46a06-402b-4258-918a-46a837b8016e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i911ca0f0d74e4372b382c1e5cbdefc37_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtNS0xLTEtMA_2c190811-e57f-4b05-ac06-c66cb0111a90"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8298c84318b24ddfbc0a9b713fac9edf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOmEzZWRlNGUzMjZiZjQwN2Y5NzU2ZDg1N2EwYmVkN2UxL3RhYmxlcmFuZ2U6YTNlZGU0ZTMyNmJmNDA3Zjk3NTZkODU3YTBiZWQ3ZTFfMTUtNy0xLTEtMA_c07426eb-d7cc-433e-bd36-eee4ab65ae7f"
      unitRef="usd">167000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia404f432f5f04e0c86cf5127ad1ee352_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS0xLTEtMS0w_6a06c86f-4bc2-4765-9abc-0fdd1c071d0b"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie762e1bf5be24949acbc40644a441c6e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS0zLTEtMS0w_41c8c74b-3bfc-4276-862e-c653b5a8a96f"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8ceaaffd9f074529ba2189860ced6058_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS01LTEtMS0w_61f46880-5bee-40fd-85e8-69abe289e94d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3d2acfe069e546dca06761088abb331a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNS03LTEtMS0w_175fd836-b815-4e6b-9dcc-9e8f96d3877f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i676d2b24c5dc42c3b6ff774ebc9c3059_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi0xLTEtMS0w_ef7110c0-b1b6-45a0-83c4-c8ee2bce151d"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibb8cbc3d9d7b430fa2d784ba2a45bd2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi0zLTEtMS0w_5bf28c68-bb52-4f0d-80a6-52c42640ed24"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7fe4c003fa7745d7a49e88abcde0d99c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi01LTEtMS0w_5adaa163-e239-4a1c-80ab-f4fce05bb75a"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7e5eda06ebd043a18f2310ccfa139d5c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNi03LTEtMS0w_db7be0c6-4270-44ac-9c9e-c050c24d2a81"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i762ba37e09d5444aa3f6af77efa79d0a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy0xLTEtMS0w_34b01cf3-fadb-4eb7-9cf3-3361f6f5f289"
      unitRef="usd">33495000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia92733266bea4a4a995ec95b550ebc2d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy0zLTEtMS0w_26817a0d-d1ef-4747-bb32-f15fc2120c7c"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy01LTEtMS0w_981688fd-bc86-47c7-b74a-edbfc744d7d1"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic7e24edd72a4402e947ad3a231a68484_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfNy03LTEtMS0w_d91b7f69-be94-4911-affe-683be11d2dbf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i676d2b24c5dc42c3b6ff774ebc9c3059_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS0xLTEtMS0w_29368c78-dec8-4179-9a22-c4ab21eb106d"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb8cbc3d9d7b430fa2d784ba2a45bd2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS0zLTEtMS0w_73c70a99-88fe-4be2-93b5-f9e68e4fed45"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7fe4c003fa7745d7a49e88abcde0d99c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS01LTEtMS0w_1172ca86-c1ea-4168-b698-1f87e698cd7b"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e5eda06ebd043a18f2310ccfa139d5c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfOS03LTEtMS0w_4c687f5a-f45f-41db-a045-01481e2f950f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i365bc9823489411ba4d7b9edcded0fbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtMS0xLTEtMA_52c03b00-311d-46e4-9736-f1e927f7f729"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8b0f5f2adab4805b0479111e623e2ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtMy0xLTEtMA_fd211efe-b1d8-484e-acdf-73cd6753787e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3157fcf32f8c4a93b027d26e140b1f9e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtNS0xLTEtMA_7d2e2ed3-83a1-46f9-ae76-43f9d936069a"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5d4d876ac904a2a86c3d4eb8f225dcf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTAtNy0xLTEtMA_2dd50d78-c082-411a-8f91-b2d95206923b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cfa387702344d33a007d4a3e6c45c05_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtMS0xLTEtMA_7397b7cc-2781-4f81-8099-ffd7108e5324"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74627613ca30495088c9bc6d70c91441_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtMy0xLTEtMA_a3353d9f-82e0-4a48-819c-1fe7a44616cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieaab7f3f0f42483f8054df0951921a69_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtNS0xLTEtMA_d91e7e6a-d869-4212-8bc2-4fb69f1445a3"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6149f30571a74f36b05d423ef49c6d84_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTEtNy0xLTEtMA_5a0e1a9f-1bab-4710-9bfc-24905f7476c3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i762ba37e09d5444aa3f6af77efa79d0a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItMS0xLTEtMA_814c4f0c-df76-4007-8a51-70eece0ce40f"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia92733266bea4a4a995ec95b550ebc2d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItMy0xLTEtMA_fcaf3132-45d3-4ae6-8482-483a4e0b1b6c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItNS0xLTEtMA_530beb31-3165-4827-acbf-45dc20686dad"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7e24edd72a4402e947ad3a231a68484_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTItNy0xLTEtMA_2a66c48d-712e-41ba-9eba-82112a0e561b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i762ba37e09d5444aa3f6af77efa79d0a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtMS0xLTEtMA_96b08416-f5dd-4c28-8f81-83836e7c87ba"
      unitRef="usd">337373000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia92733266bea4a4a995ec95b550ebc2d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtMy0xLTEtMA_94bb3a65-1099-4d40-b4c8-f690f2df91ee"
      unitRef="usd">30496000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie0a83ad6b85f45a9bb1995fa1bb34707_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtNS0xLTEtMA_fd91b96d-6e3d-48e5-bff5-36409e56279d"
      unitRef="usd">306877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic7e24edd72a4402e947ad3a231a68484_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTMtNy0xLTEtMA_2deacdc3-1679-4967-a651-e5b55aeab8dd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icef63d53d6da4bbfb421afc3382da2ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtMS0xLTEtMA_202fb99b-772b-4dba-a4f7-18193b587d52"
      unitRef="usd">236000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b2aa92c23ee4bfeb3ee17ccff6a2fbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtMy0xLTEtMA_4017a6c5-1d3f-45cb-a62e-096d3e269387"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i10649c65a0334bc2a8640fb0be3a04f7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtNS0xLTEtMA_1bf6ec75-a528-4e78-a1d7-d7276c572f31"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6ff8aa476e974c09bfed85e41fcd2fab_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjY1NTg2YmNjYjczOTQ0Yjg4YmFhYjgzM2ZlNDljNjJmL3RhYmxlcmFuZ2U6NjU1ODZiY2NiNzM5NDRiODhiYWFiODMzZmU0OWM2MmZfMTUtNy0xLTEtMA_526f3715-2c84-4fa7-9cd7-8bfe7c742823"
      unitRef="usd">236000</us-gaap:AssetsFairValueDisclosure>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMjYxNg_2dca1d96-23d7-4d9c-8528-755b12236cfe"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMjkxNg_034ca22b-4675-4b01-9686-136ecc44d815"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i7ba32d30d24546eca925d1e03e695212_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjE1Ng_91a1504a-ae02-42b2-8cd9-1087e4f723b7"
      unitRef="shares">111000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjE1OQ_f2dd38a6-aaf3-451d-a163-b8726cfbb6e3"
      unitRef="shares">117000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjExOA_944d9909-5303-40a4-92dd-b0a31ea0af1a"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i0521a31195cf4bf6ba85a5da0f003cad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzU4OA_50271a76-2e19-435c-8b43-3a87405abb83"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i1b51e6431f1d4e99b4e005735f3156ba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjIyNA_5ac36520-2091-4a96-94ba-1eb5cddd3a3e"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase
      contextRef="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjEyMQ_c92f1da9-9fef-46b2-a2c4-e7c73828414d"
      unitRef="shares">249000</sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="i80ae933af9fe439582f72421ca16b2d4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTA5OTUxMTYzMjQ4Mg_89389c5a-398a-4de4-86b6-5807f50f3d80"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability
      contextRef="i4ebf882acb394d3abcff4f7fbb84922d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjA1MQ_1c5000c1-d1b6-4ae5-9726-974acccc409d"
      unitRef="usd">100000</sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability>
    <sgmo:BusinessAcquisitionSharesAcquiredValue
      contextRef="i1b51e6431f1d4e99b4e005735f3156ba_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMTY0OTI2NzQ0NjA4NQ_6b1ad341-cfda-44ae-8751-3f463722fbfa"
      unitRef="usd">100000</sgmo:BusinessAcquisitionSharesAcquiredValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib4a4a0a8362b4d67a4a3abae87fd40b9_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk1Mw_a9bf8440-d54a-48a9-8931-d46d28d7cc55"
      unitRef="usd">200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RleHRyZWdpb246MDBmNjEwNjNiMGE1NDcwYzk5NTlkMDY0MWU5NDg5YTBfMzk2NQ_5bbcebaa-ab94-48ee-bdfc-969f6ea235dc">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.100%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.230%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.232%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD / EUR Exchange Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Correlation Sangamo and Sangamo France Stock Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo Stock Price (USD) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Sangamo France Stock Price (EUR) Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;USD / EUR Exchange Rate Volatility Estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk Free Rate and Cost of Debt by Expected Exercise Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="ic2a5014580264671a94f115ba17d478c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMS0yLTEtMS0w_a06e15cd-a86c-4ec3-af49-329bda0de258"
      unitRef="usdPerShare">8.77</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i7a6f009aa07a4c399d8a95a107332098_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMS00LTEtMS0w_ffabfcc6-cb8a-4df5-ae3b-d17c256473a4"
      unitRef="usdPerShare">8.68</us-gaap:SharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i8dfb37df32ca419f81e76d4115394730_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMi0yLTEtMS0w_fea35e27-e581-4c81-bd16-d376be94ebfb"
      unitRef="eurPerShare">2.16</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i550ea41dd94f4cde8ebccae40c9ea1ec_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMi00LTEtMS0w_8bd9138d-d2e0-4359-85f9-32bbef396bf7"
      unitRef="eurPerShare">2.14</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i2cd51b31128c404a88c55c12be0f8933_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMy0yLTEtMS0w_21e9964f-34ff-4161-9a9a-0041b1b9fe83"
      unitRef="number">0.89</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i3c895422f38a4eb1a177bc4ea8d56a62_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfMy00LTEtMS0w_dcc0a02c-a737-490c-a946-2e156b9d0de5"
      unitRef="number">0.91</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i88202f1ce8de4ff58b28e17316576426_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNC0yLTEtMS0w_ca874d96-ee44-43d4-8a5f-c2534cce747c"
      unitRef="number">100.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i244af883f9fa4b53b32c33db2e3117c5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNC00LTEtMS0w_244e4a97-0a3e-47dd-a36b-c624c53f5ecc"
      unitRef="number">100.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i308ef5827e2d49879e8d190e7c992de4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNS0yLTEtMS0w_14ba9573-b081-4ba5-917f-ecd4c21fd387"
      unitRef="number">73.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i26b1c09f8aad47379da7b97362291428_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNS00LTEtMS0w_b4c0f966-7364-46b7-b562-7f41b4281753"
      unitRef="number">72.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i2c70a615e27849df839c9cf2964b75f7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNi0yLTEtMS0w_77b207fc-c056-46de-a52d-3deefb6c03d0"
      unitRef="number">73.8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i3065b36e03d44c578c215e8d30a54eea_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNi00LTEtMS0w_98b1162b-50d8-437d-9410-17e0bf03a562"
      unitRef="number">72.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ide9f1db38f654cd1aac9ab696795190d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNy0yLTEtMS0w_ca725931-b6b1-46f4-b03e-e430746ae461"
      unitRef="number">6.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ie8f47ed72c944d6aa88add3d596b953e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80MC9mcmFnOjAwZjYxMDYzYjBhNTQ3MGM5OTU5ZDA2NDFlOTQ4OWEwL3RhYmxlOjkxNTM2MTcyZTc0MDQ5MjQ5NzdjNGEwNjNlNjE3M2NjL3RhYmxlcmFuZ2U6OTE1MzYxNzJlNzQwNDkyNDk3N2M0YTA2M2U2MTczY2NfNy00LTEtMS0w_b7dc14ed-ca38-49c3-9df4-cb0f3ef43283"
      unitRef="number">6.6</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzI5ODUzNDg4NTA5NA_54171648-733e-48b5-b9e8-962a96fa6248">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.710%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:59.191%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.156%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.720%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.866%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.163%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;312,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;313,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.165%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.046%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company had no realized losses of its available-for-sale securities for the three and six months ended June&#160;30, 2020 or 2019. The Company periodically reviews the available-for-sale investments for other-than-temporary impairment losses. No investments were other-than-temporarily impaired at either June&#160;30, 2020 or December&#160;31, 2019. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For available-for-sale securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company's review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company's ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these securities at June&#160;30, 2020. All available-for-sale securities with unrealized losses have been in a loss position for less than 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMTY5NQ_4dee42ae-64fe-40b7-8cb3-cf7fbe91c611">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.710%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:59.191%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.156%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.720%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:6.866%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.163%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;81,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;196,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;312,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;313,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC0yLTEtMS0w_022dd440-7408-4078-bb6e-be0c96499d89"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC00LTEtMS0w_74e070e8-61d8-4386-a049-fdcdcce0a921"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC02LTEtMS0w_e5efc00c-c9f1-4436-bfdc-dfd49274a272"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNC04LTEtMS0w_b769ab0c-9c33-4477-a8ea-969747b76975"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi0yLTEtMS0w_88267bdc-3393-4c50-a703-e779c4190abc"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi00LTEtMS0w_9484b87c-191d-4570-864a-ef9c92784a81"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi02LTEtMS0w_c110234e-5c2e-4970-9703-861530de616a"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id33600c2c7f34d30a00314cf2c69f6c1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfNi04LTEtMS0w_7e7eae58-bafa-4a20-98db-39c6c2c16a19"
      unitRef="usd">116393000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC0yLTEtMS0w_0e5b9775-2370-471e-9d73-f8235e836d2c"
      unitRef="usd">89796000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC00LTEtMS0w_d1026516-1398-451c-ba2e-a36b5d86f069"
      unitRef="usd">383000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC02LTEtMS0w_bda6663f-bc28-44ab-91bb-8d3ea8973170"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i255ad07213a74331b5ed4902d8ecc090_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOC04LTEtMS0w_c8cee4a3-e4d0-4cd7-ace0-c11920e8513b"
      unitRef="usd">90179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS0yLTEtMS0w_2d5424f6-e958-4ae0-8211-d98e362a2f7a"
      unitRef="usd">81424000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS00LTEtMS0w_2fd17cfa-ae03-4086-bd09-3eb1f1b81c59"
      unitRef="usd">420000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS02LTEtMS0w_c6bbfe9e-a7c8-4dac-a7e4-f4bbc13e7671"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46e4e2653abb4a21bb55a0af1318ca23_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfOS04LTEtMS0w_1489dcac-cc85-4055-ae41-968f128412c2"
      unitRef="usd">81844000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtMi0xLTEtMA_a170b7e3-8b9e-4a50-a3f2-7347d545474b"
      unitRef="usd">25211000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtNC0xLTEtMA_d59e45d2-58fc-4433-ac6f-ebc3ace41db0"
      unitRef="usd">176000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtNi0xLTEtMA_b0d2104e-0228-48c9-8cc2-5157cecde25d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3210ae261f447489700bf8bcecaa49c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTAtOC0xLTEtMA_1e00e9ee-08a7-4f5d-9188-9b194680381e"
      unitRef="usd">25387000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtMi0xLTEtMA_3b2d9222-180a-40b9-93b4-09b827e46210"
      unitRef="usd">196431000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtNC0xLTEtMA_cf309f0c-f19f-431f-ae7f-0f680e1a0493"
      unitRef="usd">979000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtNi0xLTEtMA_e5568c70-235d-422e-8521-e5e62315c7e8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTEtOC0xLTEtMA_f3d0bf02-11d4-4c77-9f55-a03490433068"
      unitRef="usd">197410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItMi0xLTEtMA_f925084b-bc04-482d-b080-937c4ab525e6"
      unitRef="usd">312824000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItNC0xLTEtMA_37fd33a0-7fe2-4318-a256-18c95ca13d97"
      unitRef="usd">979000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItNi0xLTEtMA_28731c45-6a1a-40a8-905c-a4eb4a9861cc"
      unitRef="usd">0</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTItOC0xLTEtMA_7cf0f395-9ec7-4cd6-b50f-8dacc89a5607"
      unitRef="usd">313803000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if36f128cd73641d78e18a584b4115086_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctMi0xLTEtMA_713ec372-f65b-4f99-8011-55a76c21fe73"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="if36f128cd73641d78e18a584b4115086_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctNC0xLTEtMA_5c341ea8-d781-467a-a9c6-31f59db05e1e"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="if36f128cd73641d78e18a584b4115086_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctNi0xLTEtMA_43eec33d-2d7c-4e78-b3b7-9c2df2b5a5ff"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if36f128cd73641d78e18a584b4115086_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTctOC0xLTEtMA_bfb3c226-998e-4dad-9dff-09bd377cdf10"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtMi0xLTEtMA_f7dbf84e-1b8b-48d1-876d-41c96556067c"
      unitRef="usd">2998000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtNC0xLTEtMA_561aac24-7203-4e17-adc4-7256dee80b04"
      unitRef="usd">1000</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtNi0xLTEtMA_33edda64-7d62-4b47-aea5-11a4cd7c2342"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTgtOC0xLTEtMA_bb2c243a-c804-46c7-ab28-0b9220af6a43"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktMi0xLTEtMA_db28eea4-ae63-4c0e-a56c-fb5fc3b6f4d8"
      unitRef="usd">33494000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktNC0xLTEtMA_4367c0aa-03e2-4e4e-bd9c-925db132712e"
      unitRef="usd">1000</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktNi0xLTEtMA_33b6d2c1-0c80-47c5-9469-7aa5cda12504"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2e12e3c2aa524bc5bf6bfca5e85a11ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMTktOC0xLTEtMA_d2dac307-e0ff-42d6-9273-d4cff8765a70"
      unitRef="usd">33495000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtMi0xLTEtMA_5cf42443-9f67-4347-a2a7-c2dab47f4934"
      unitRef="usd">155230000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtNC0xLTEtMA_d7563643-32d3-4fe7-8f5a-b2a58ba89130"
      unitRef="usd">145000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtNi0xLTEtMA_b1b03990-0a54-4126-9ee0-208eb1434957"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27597a1795c6422786f8357584decb2c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjEtOC0xLTEtMA_22985304-346f-4960-b199-48c03785834d"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItMi0xLTEtMA_6692226d-4021-4557-a010-2ed29ff46d5b"
      unitRef="usd">94905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItNC0xLTEtMA_70c3868c-9aac-47be-9acd-b35327792a7a"
      unitRef="usd">115000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItNi0xLTEtMA_1763b100-341b-474b-85e0-cd32d5cc579d"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc450a3922854b8c925f767597c09e9f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjItOC0xLTEtMA_c667e05e-9631-4fae-a799-bb67920ac7b5"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtMi0xLTEtMA_936cab1e-d91c-41f1-b885-1a7ecdc9a8b9"
      unitRef="usd">53411000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtNC0xLTEtMA_00b3f7c8-3e1f-4711-a337-85cb6c959edd"
      unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtNi0xLTEtMA_1e210207-39d4-469b-a669-e08262fb3d66"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0504f2fdaa94f409b56ef1a164bbbc4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjMtOC0xLTEtMA_1c5f9a10-0c31-4bc5-accb-ab76bfbb4b6f"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtMi0xLTEtMA_abee4700-7281-48f7-9a74-7b683365c704"
      unitRef="usd">303546000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtNC0xLTEtMA_1aa33fed-b3ca-4863-8f68-b45673d07b83"
      unitRef="usd">351000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtNi0xLTEtMA_686e8402-3c90-4f24-aec6-86711a689eb5"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjQtOC0xLTEtMA_bd826152-57ba-4fe2-a6dc-a2ae293eb426"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtMi0xLTEtMA_97bf8790-e329-4d8b-ac48-67824d1015ea"
      unitRef="usd">337040000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtNC0xLTEtMA_f99f07dc-0a92-44d4-8236-ff6182b426ef"
      unitRef="usd">352000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtNi0xLTEtMA_faffc5fb-4dae-4dde-a128-6178075fa36a"
      unitRef="usd">19000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOmZhZTliMzc5MDc5ZjQyMWM5ZThiOTJlZjI3ZWEwYzMxL3RhYmxlcmFuZ2U6ZmFlOWIzNzkwNzlmNDIxYzllOGI5MmVmMjdlYTBjMzFfMjUtOC0xLTEtMA_8adba5ed-f44d-4465-b3c4-31e49165ff7a"
      unitRef="usd">337373000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMTY5Nw_9fae9ce2-ae10-4dcd-8ec6-97c8b05a4329">&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:72.165%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.046%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.339%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;282,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMS0yLTEtMS0w_26f96a53-8efc-437b-9090-f9a8b1b51138"
      unitRef="usd">197410000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMS00LTEtMS0w_17bb00a6-efa3-48ac-9f43-299ad2b277fb"
      unitRef="usd">282046000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMi0yLTEtMS0w_fa199b12-39b4-458d-84d1-ff41037ed695"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMi00LTEtMS0w_9a5ea12b-e6ff-47ad-ada8-67d8918c99a4"
      unitRef="usd">21832000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMy0yLTEtMS0w_0fd612d3-9aab-4fd5-8ae5-e4f4f3476fe3"
      unitRef="usd">197410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RhYmxlOjAxMDNjODFhNTc0ZDRhZjRhNWM2ZTFkNGIxZDdhNDkyL3RhYmxlcmFuZ2U6MDEwM2M4MWE1NzRkNGFmNGE1YzZlMWQ0YjFkN2E0OTJfMy00LTEtMS0w_7ecf70a8-2259-4f75-af49-45fb231b776b"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_05ec4f66-92a1-40de-a119-bfb261ca8fb8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_1169cb41-d5f6-43f1-9ccd-60c33ac789f4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_54d3c4ec-654e-413c-a7a1-c999e9c385d7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfMzQw_8c0376bb-98a1-49e0-abbf-95853f1ae16d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="icb25efc099444173a12e09cc80696876_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfNTQ5_429e142c-4a77-4b6c-8173-5613f3d0198f"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80My9mcmFnOjBhYWVjM2UyYjk1ODRlY2FiNTM2NjZhZDc5MDBjMThmL3RleHRyZWdpb246MGFhZWMzZTJiOTU4NGVjYWI1MzY2NmFkNzkwMGMxOGZfNTQ5_aac934bf-7ceb-425e-9386-3d04758de03e"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80Ni9mcmFnOjEzNzVhYjI5MjkwYzQ4MjFhMDM3MGZjMmMyN2FiMWQ1L3RleHRyZWdpb246MTM3NWFiMjkyOTBjNDgyMWEwMzcwZmMyYzI3YWIxZDVfMTA3Mw_e9a9bcc9-3c79-4271-9284-0616c9dd6989">BASIC AND DILUTED NET LOSS PER SHARE&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total number of shares subject to stock options and restricted stock units (&#x201c;RSUs&#x201d;) outstanding and the employee stock purchase plan (&#x201c;ESPP&#x201d;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of June&#160;30, 2020 and 2019 totaled 14,964,567 and 10,155,033, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80Ni9mcmFnOjEzNzVhYjI5MjkwYzQ4MjFhMDM3MGZjMmMyN2FiMWQ1L3RleHRyZWdpb246MTM3NWFiMjkyOTBjNDgyMWEwMzcwZmMyYzI3YWIxZDVfMTA1MA_1492eb33-0646-4618-b745-7bb2f5b9d2d6"
      unitRef="shares">14964567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb25efc099444173a12e09cc80696876_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80Ni9mcmFnOjEzNzVhYjI5MjkwYzQ4MjFhMDM3MGZjMmMyN2FiMWQ1L3RleHRyZWdpb246MTM3NWFiMjkyOTBjNDgyMWEwMzcwZmMyYzI3YWIxZDVfMTA1Nw_0886fc53-6706-4d35-a136-57751f674e74"
      unitRef="shares">10155033</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDkyODYwOQ_69286f0f-66a5-4586-8840-fc9d4e938675">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (together with BIMA, &#x201c;Biogen&#x201d;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#x2019;s proprietary ZFP technology delivered via adeno-associated virus (&#x201c;AAV&#x201d;) to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company's common stock (the &#x201c;Biogen Shares&#x201d;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#x2019;s disease, ST-502 for synucleinopathies including Parkinson&#x2019;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP transcription factors (&#x201c;ZFP-TFs&#x201d;) (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#x2019;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e. through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#x2019;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#x2019;s outstanding &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk2MA_8a0774d0-1ee7-45ae-b865-08409446f2a7"&gt;three&lt;/span&gt;-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The stock purchase agreement also provides that until the first anniversary of the effectiveness of the collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#x2019;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNjE3OQ_91e689ec-675c-4164-b538-3b9389226c79"&gt;two&lt;/span&gt;-year anniversary of the effectiveness of the collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock and (iii) the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic 606 and concluded that Biogen is a customer. As of June&#160;30, 2020, the transaction price includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#x2019;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of June&#160;30, 2020, the Company had deferred revenue of $197.8&#160;million related to this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company paid $7.0&#160;million for financial advisory fees during the quarter ended June&#160;30, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the upfront license fee of $125.0&#160;million and 2% of the excess consideration from the stock purchase of $79.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other Assets and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Deferred Costs&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#x201c;Kite&#x201d;), which became effective in April 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#x201c;ZFNs&#x201d;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors (&#x201c;CARs&#x201d;), T-cell receptors (&#x201c;TCRs&#x201d;), and NK-cell receptors (&#x201c;NKRs&#x201d;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex vivo&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. Kite reimburses the Company&#x2019;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial research term in the agreement is six years. Kite has an option to extend the research term of the agreement for up to two additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAyNzM_91569598-dc9b-4299-8c21-58e8ed1c15e0"&gt;one&lt;/span&gt;-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4 million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0 million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand-ready obligation to perform research services, and (2) the on-going research services. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $94.0&#160;million and $106.5&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;SB-525 Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for SB-525 and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, a $25.0&#160;million milestone has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of June&#160;30, 2020, the total transaction price under this agreement is $104.0&#160;million, which represents the upfront and research services fees of $79.0&#160;million and one unconstrained milestone in the amount of $25.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has identified the performance obligations within the agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going research services through 2020, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $0.7&#160;million and $4.0&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the Company entered into an amendment to the agreement, pursuant to which the Company transferred the IND for SB-525 to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The Company recognized $1.1&#160;million during the six months ended June&#160;30, 2020 and approximately $24.8&#160;million on a cumulative basis attributed to this milestone as revenue. The balance of this milestone payment of $0.2&#160;million will be recognized as revenue commensurate with the provision of research services over the remaining term of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.694%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.520%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.520%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.520%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Pfizer SB-525 agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee and research services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019, the Company received new data results, and expanded enrollment of patients in the ongoing trial. As a result, the estimated project cost increased and the proportional performance was updated based on the actual services delivered to Pfizer as a percentage of the updated project cost as of March 31, 2019. The increase in project cost resulted in a decrease in the measure of the proportional cumulative performance. During the six months ended June 30, 2019, the Company recorded a revenue reduction of approximately $3.0&#160;million, or 38% of total revenues, due to a decrease in the measure of the proportional cumulative performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $2.4&#160;million, decreased net loss by $2.4&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP-TFs&#160;that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;fifteen years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company concluded the total transaction price under this agreement is $12.0 million, which represents the upfront fee. None of the clinical or regulatory milestones have been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has identified the performance obligations within this agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services, over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $4.2&#160;million and $8.0&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Recognition of upfront fee related to Pfizer &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;C9ORF72 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $3.0&#160;million, decreased net loss by $3.0&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#x2019;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#x2019; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company is also eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $2.3&#160;million and $1.7&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019, the Company achieved a $6.0&#160;million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The Company recognized on a cumulative basis approximately $5.6&#160;million as of June&#160;30, 2020 attributed to this milestone as revenue and a revenue reversal of $0.1&#160;million related to a change in scope was recognized during the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the Company achieved a $7.5&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The Company recognized on a cumulative basis approximately $7.0&#160;million as of June&#160;30, 2020 attributed to this milestone as revenue and a revenue reversal of $0.1&#160;million related to a change in scope was recognized during the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. This adjustment decreased revenue by $2.2&#160;million, increased net loss by $2.2&#160;million and increased the Company&#x2019;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;California Institute for Regenerative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2018, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#x2019;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of June&#160;30, 2020, the Company had received $5.2&#160;million under the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of June&#160;30, 2020 and December&#160;31, 2019, $6.1&#160;million and $5.7&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNzM2_e7298b63-5d34-4d4f-b522-430b054704a4"
      unitRef="shares">24420157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i426f14e574704e28836ba330c9dbd8f1_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODIz_6dba2835-091d-4237-8a8e-07f32e3ba4e3"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODc2_f554df6b-0121-488c-baa3-e1ff9823e149"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTEzMA_bc1d1daf-c32b-4532-8b4b-8298061e0330"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTI1Nw_bf0dd2a4-23d8-4f57-a522-db958ff27e01"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTQxOA_cfd79e83-ca97-4bef-b09c-1055614e9dbe"
      unitRef="usd">2370000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ia146054470dd4f3f970c2b2d6eeea2c7_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTU4MQ_dd1ae014-ad0e-4e51-9b44-b1e9f78eb8e2"
      unitRef="usd">925000000.0</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i33efcc2cf083437d856a10fb09d87586_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTYyOQ_a3891216-7052-41d9-9b65-576061b2ee53"
      unitRef="usd">1450000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementNumberOfProductTargets
      contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjM0MA_314c79f3-2fe0-45da-b44f-b879728a3c5b"
      unitRef="product_target">12</sgmo:CollaborativeArrangementNumberOfProductTargets>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjQyNQ_b5e249da-0c8f-4df5-b232-c4ff8b425e78"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationAgreementNumberOfAdditionalProductTargets
      contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjY1Mg_c04f1cec-873b-4a6f-ad96-2a3b91b272d9"
      unitRef="product_target">9</sgmo:CollaborationAgreementNumberOfAdditionalProductTargets>
    <sgmo:CollaborationAgreementTargetSelectionPeriod
      contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjcwOA_f8594b93-c3e3-420a-97dc-4a00f63cbab9">P5Y</sgmo:CollaborationAgreementTargetSelectionPeriod>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM0Mg_7dff881b-0b77-40f1-aefa-7be86d07e2a7"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="i37a3af3ab08043c79aea248e4b3d6b16_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzYwNQ_e6903220-821c-49f5-b462-e053a809036e"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationArrangementResearchPeriod
      contextRef="i8c8c2d2b28bb459ea77a5e1aca05aab8_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDkzOTI0Ng_410d6ca1-8460-43c1-89e1-504b408df505">P7Y</sgmo:CollaborationArrangementResearchPeriod>
    <sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDk0MjM4OA_c801d43a-b4ac-430d-af60-4ad6a5e47fd8"
      unitRef="product_target">10</sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace>
    <sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage
      contextRef="i301f2d2ad4b84c369aa116bdd117c17a_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNTA4NQ_1dabd71d-1848-42cc-b4ae-42e24ba4bbae"
      unitRef="number">0.05</sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage>
    <sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld
      contextRef="i301f2d2ad4b84c369aa116bdd117c17a_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNTQwNQ_3c5a662c-e7d0-414e-b97f-bb9d326791d9"
      unitRef="number">0.50</sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld>
    <sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage
      contextRef="i301f2d2ad4b84c369aa116bdd117c17a_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNjMwNg_2df46a43-e3da-4e75-b6a3-6dcdad668366"
      unitRef="number">0.05</sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY2NjY0MQ_8d6dd2ea-e8fb-42f7-9b8e-de63171b8879"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="i28405f7b815347269a780c9b058a7e44_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY2NjgwOA_1215d77b-86db-4d63-9ac9-01016633b6cc"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY3MjcwMA_f9d4fabc-1319-44aa-8a30-4bfc19e2828e"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY3MjczNg_1c00814f-c538-4d91-8538-ce18d033517e"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <us-gaap:DeferredRevenue
      contextRef="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY2NjA2NA_aaa2e82d-6455-45bf-a79e-a3d75867823a"
      unitRef="usd">197800000</us-gaap:DeferredRevenue>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzI5ODUzNDkyODYwOA_20623e55-e92b-489e-a8e8-1ac727673822">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company paid $7.0&#160;million for financial advisory fees during the quarter ended June&#160;30, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the upfront license fee of $125.0&#160;million and 2% of the excess consideration from the stock purchase of $79.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other Assets and &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Deferred Costs&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds.&lt;/span&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i379eea47507e40cf90ab3746c20d3ff7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy0xLTEtMS00NjI_1562b56f-3c80-4620-9601-bb0ecac5e063"
      unitRef="usd">6744000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76b3b95cd14d487b848403cb66fe002a_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy0zLTEtMS00NjI_58ba1bdd-ea67-4586-b764-76db25d11fae"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae8d5183fb0e4f4ab6e439efc56e5af8_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy01LTEtMS00NjI_8c9e62de-25f5-4312-9894-9892d42b9530"
      unitRef="usd">6744000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cb17ceebd9543aba79ec3e8fbd2f4e8_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfMy03LTEtMS00NjI_161b068d-374e-4a47-81f4-69699e1c3970"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2532bc5c847458ea5c245c9d0539d8a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC0xLTEtMS00NjI_cb5cc0e6-7ebf-4480-a99d-9c8315b0f849"
      unitRef="usd">1434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ea81ce0c28543c297d2984b8efc8ccd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC0zLTEtMS00NjI_c14be5a0-2bc4-431f-803e-dd7297562667"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38d05a55da884263b1ec48182e49e978_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC01LTEtMS00NjI_d8b93eaa-57e4-48da-85fa-4801d6f84ed0"
      unitRef="usd">1434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab06d3a3d932466caba07743e70c8ce3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNC03LTEtMS00NjI_e3e1847b-9f18-4519-bed2-9fec636138d3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7495828dd6da4b6dab035cf784124b17_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS0xLTEtMS00NjI_317b3dee-2c70-41bb-a245-ca00e6435538"
      unitRef="usd">8178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6f7cee7975f4b6f99d9a6ff2291d024_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS0zLTEtMS00NjI_3a5755c4-bdb3-4aec-b7cd-4dd1befe70c0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS01LTEtMS00NjI_95f0f172-6b7c-4c71-8170-46dd55c377e5"
      unitRef="usd">8178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if597a7e574f64566b96eae1440d9452d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY1OWFkYjMwNjZjYjQ5Y2JiMDM3YTYwNzhkZmM3Y2NjL3RhYmxlcmFuZ2U6NjU5YWRiMzA2NmNiNDljYmIwMzdhNjA3OGRmYzdjY2NfNS03LTEtMS00NjI_413a64bf-4cfb-47f5-9ae0-11506a283515"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="ic346d49a489e488999ebd8bf7e2e449b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTQ5NQ_c7f24363-955d-43cb-a6f0-b066e16adea1"
      unitRef="usd">7000000.0</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTU2NA_55fdf547-a4be-4e7e-94ca-34ce87fca52c"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTU3MA_f9d4fabc-1319-44aa-8a30-4bfc19e2828e"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTYwOQ_0f86c205-e6bf-493a-bd89-4d1b6effcee5"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTYxNQ_8d6dd2ea-e8fb-42f7-9b8e-de63171b8879"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ic346d49a489e488999ebd8bf7e2e449b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTkyNw_d537e667-d6b0-4379-9221-d2a971050a74"
      unitRef="usd">4100000</us-gaap:ContractWithCustomerAssetNet>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTk0OA_4ed35f6b-9258-4894-86fd-80b5f646a6a0"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ieb8f0b0e3f3541ea8e1a6aa393944a06_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTk4MQ_8d6dd2ea-e8fb-42f7-9b8e-de63171b8879"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MTk4OA_3e4b25c6-043d-4851-a702-31c41b9929cc"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="i28405f7b815347269a780c9b058a7e44_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjA0Ng_1215d77b-86db-4d63-9ac9-01016633b6cc"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ifa40a47c29de44d5a91538a3a9a70128_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjMxOA_eeebb2bb-5ab8-48aa-b5e2-cd19d3f73516"
      unitRef="usd">2900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="icb38ff1148634d56beb5a189268d6b0b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjMzOQ_d4c4c5a1-a316-4f52-8136-ff585ca39bb7"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="ifb2b990377bf46ffbeaf5eed10b83ad4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk0NzgwMjM5MjM0OQ_1c00814f-c538-4d91-8538-ce18d033517e"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <sgmo:MilestonePaymentsReceived
      contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODc0NQ_f9a98664-5538-42f5-a425-bbdf38171a3c"
      unitRef="usd">150000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ida7d1959f6e6453b984185527fca88b9_D20180405-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfODk3NQ_a5086d73-e566-4c30-86b2-385217ebb74d"
      unitRef="usd">3010000000.00</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="ibcd815dd54d643efa93f63fde2181db7_D20180405-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfOTA4NQ_eb659c43-4768-4e97-98b0-f52b14d00b0c"
      unitRef="usd">1260000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i610fb576d4dd469d840dbfd922ba836c_D20180405-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfOTIyNw_7b452eb3-a910-49ea-a651-19803cd32ab9"
      unitRef="usd">1750000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAxODE_fafafa38-b50b-462f-8e82-efed97d7241b">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:NumberOfOptionsToExtendInitialResearchTerm
      contextRef="idadecadd2c3540d29b8bfd732262ee0a_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAyNTk_1891db50-dd00-447f-910c-bc73d0f2c8e4"
      unitRef="option">2</sgmo:NumberOfOptionsToExtendInitialResearchTerm>
    <sgmo:SeparateUpfrontFee
      contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAzMTk_6e248f9d-292e-4507-b550-116305557461"
      unitRef="usd">10000000.0</sgmo:SeparateUpfrontFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
      contextRef="i534bf494758d4e65a8c5a9cd993bd211_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA2MzI_38b97354-37ae-455b-acd5-008df8529f36"
      unitRef="usd">3400000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA3Nzk_07fb44c5-786c-40ff-81bf-afd8bf520c8b"
      unitRef="usd">189300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA4MjI_97dcd97a-2651-4591-96af-c1f335acba80"
      unitRef="usd">150000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="ibbd09136e5714a6796cdd61339269e94_D20180405-20180405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA4Mjk_ba2bf59e-15e7-48d6-b870-8c3effa0277a"
      unitRef="usd">39300000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3be7ebfec658496c9a397474592935f4_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTMzMjk_1fe6ab89-b606-4f43-a02a-9af09df78e27"
      unitRef="usd">94000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie4f3b66fa9254360addb420ddb70e7f0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTMzMzY_238a13d5-d045-473d-af41-079216125f2f"
      unitRef="usd">106500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i0c1ae59129e94570aabd4555fc76fe34_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NTQ_47948c61-b18a-4949-8fa1-f58eab11becb">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.844%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.502%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ed1d741701d4d8896d2e39462a3d431_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0xLTEtMS0zNjI_8ff954b9-e4aa-4da8-8a0c-6cca6ddd27ac"
      unitRef="usd">6227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i100c20eec6fc4407969c367a22a5aefa_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0zLTEtMS0zNjI_36444052-fac1-4266-8305-3eb80fcb10a3"
      unitRef="usd">6227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f9f41236129499cad0f6ecbb3d8b103_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0xLTEtMS0w_8ee72da7-dabf-4c50-a444-5b3dd33cc87f"
      unitRef="usd">12454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83e4ca4b8d794be49441483d40aedae6_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfMy0zLTEtMS0w_db1810d2-c594-4e78-954e-b01d4fa28fa5"
      unitRef="usd">12386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdd22789c61a44f18dd2221f8e41eb4f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0xLTEtMS0zNjI_0c8921c5-7944-43ef-8b1d-17bc57554247"
      unitRef="usd">1195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30c126a939724395a8b70904f39a6201_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0zLTEtMS0zNjI_1256d323-6181-4f98-8751-c53fcb42478c"
      unitRef="usd">2833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3874265bf7a4b8885aa894e0fca3eaf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0xLTEtMS0w_718f719e-59b5-4d60-83f7-407637a4ebcd"
      unitRef="usd">2187000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c63d999a16941d1a68fc47f694643a4_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNC0zLTEtMS0w_ebb6db00-cb3e-4d57-af2f-0f232d21619d"
      unitRef="usd">4986000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10b9a9ad5cd14b529d554f21d154e6d7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0xLTEtMS0zNjI_dbbac219-2b04-4d48-bb9b-4b5c5623a96f"
      unitRef="usd">7422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia075c77e790a4ac991c3cd8ee89ad36b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0zLTEtMS0zNjI_bd1f1e5b-b1f5-468d-9207-08765752b3e3"
      unitRef="usd">9060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c1ae59129e94570aabd4555fc76fe34_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0xLTEtMS0w_aa5a0b70-f83f-4fd9-abec-79f2ce2edffc"
      unitRef="usd">14641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25f1c9d94c66418ba25576f42bb0c41c_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmYyNGI0ZjNiNGIwNDQ1MjE5NjNmN2UyNDc0N2ViZmE1L3RhYmxlcmFuZ2U6ZjI0YjRmM2I0YjA0NDUyMTk2M2Y3ZTI0NzQ3ZWJmYTVfNS0zLTEtMS0w_339c7f1a-5bae-4ef8-8eef-ab5d28dc1427"
      unitRef="usd">17372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTUzMjY_5dc69705-3e2e-493b-b3ae-a5c12131ba6d">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ib291aca8325c43a6a2835d40a832c89d_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTYyMDU_ab8e8ba2-67c4-462d-a4ac-aaa9c2c9ccd7"
      unitRef="usd">70000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i97cf3acb2d224d289dbcc3817e983d58_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTU_f624011e-4e84-43b1-9adb-ecde64cdfdd9"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="if87eed0b34b64bfd8323247a51d95e6b_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY2MjQ_1245ad43-91bc-423a-b3d5-40461fabd824"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ide9b91c91f3c407cbef414beccd16d53_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY5MzI_078fb1f3-ed28-4bdf-9fc6-776baa06bddb"
      unitRef="usd">475000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ie25d43c8653a40efb6068acc53cc63a5_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY5NTc_493d2083-be8d-488e-a69d-cb38c820a45f"
      unitRef="usd">300000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ic8b47130e76b4541a0d85cafca758698_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY5ODE_04008889-881d-489b-b0e5-b7f3891ca1ad"
      unitRef="usd">175000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="icf5586bb63c84bd9bc5dba5e7ee29b1e_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc1NjI_8b8a8dfd-2594-461d-a0de-bb36b04d1f0c"
      unitRef="usd">25000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i68bf878067e24fd7b9f9e0feeab74893_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc2MTE_a32593b1-c41b-41f4-8083-18b9fb59018b"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i68bf878067e24fd7b9f9e0feeab74893_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc2NTY_cf359d91-366d-4505-af0f-95651e195d08"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc5MDU_3de2cdb6-efc3-4693-b1b2-244de83becae"
      unitRef="usd">104000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementResearchServiceFees
      contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTc5Njg_d91f52a7-98e7-4120-92bb-af6b06dcb71a"
      unitRef="usd">79000000.0</sgmo:CollaborativeArrangementResearchServiceFees>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="id835cc5e8ed34090b3843efa34d914a2_D20170601-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTgwMjA_729a60f0-a350-4ba5-9cf2-3c83df168a2f"
      unitRef="usd">25000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if5ad04bab0bd4c97b5268f8c70c60007_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTk3MzA_9b79fccd-64e6-483d-99c0-8f8970520330"
      unitRef="usd">700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9a76ad6dd6db47e8bdb42c22f63955fb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTk3Mzc_3af92766-c21f-40d9-abf6-d0cb7feac943"
      unitRef="usd">4000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ie42151476a064738ac709c94dbe11690_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTk5NzA_4203c2ac-5bcc-47b6-9a29-f30c62dd4418"
      unitRef="usd">25000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ibbed171f600d4452b7074be69d363203_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTA5OTUxMTY3MjgwMw_ae3d45a8-9615-49ad-9edd-38ebf9c601cf"
      unitRef="usd">1100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned
      contextRef="if5ad04bab0bd4c97b5268f8c70c60007_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjAwOTg_3f6ac41b-c2f9-45ff-a977-9246213f6ad4"
      unitRef="usd">24800000</sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic3e6673b29e749caa0cfd406195b12b2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjAyNDY_a1c7eac1-7501-4686-999c-66bb5e441b79"
      unitRef="usd">200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NTg_a451203c-9183-4a22-81db-74e68d2ee744">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.694%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.520%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.520%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.536%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.520%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.538%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Pfizer SB-525 agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee and research services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib203359cf79c4a78b76345ab5cdd5ada_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0xLTEtMS0zODc_c929023f-fddd-43c3-8df8-6ea87b7ec3e3"
      unitRef="usd">326000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c1215983e16448081567393da2a173e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0zLTEtMS0zODc_f8d6208a-f03d-4b21-bd28-f1ad165e30bc"
      unitRef="usd">4635000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i874cc070d9494a23bb75d5fe3a959fe7_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0xLTEtMS0w_f3d30f21-1d39-4fd4-8e83-3aae91587383"
      unitRef="usd">2516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1c975adb10c4c80a444e6e169fef905_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfMy0zLTEtMS0w_eb676c73-8f4e-45a2-9cdd-47ce2c73c1d5"
      unitRef="usd">1595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e71b2952fdc443c82251bc33b95a5ca_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0xLTEtMS0zODc_e08bfa82-457b-42a1-bfe2-ab4fceb2cf32"
      unitRef="usd">103000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8f1db50a2ee45a69dd2f7dd10845478_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0zLTEtMS0zODc_f957fbe3-6edf-4d2d-b67f-a1f35550278b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6a077c7a6e84585bf477e2bde29c32d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0xLTEtMS0w_a8b7ddf6-57ed-452f-9449-0dc07d1608e2"
      unitRef="usd">1096000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd717c13dbff4c08b4ac853e8fba45b5_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNC0zLTEtMS0w_1757f95c-b5ee-4c49-8f15-10f8fd66ea10"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0621e82b115e42d3be6403068e7b2f9a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0xLTEtMS0zODc_53a7cbc0-0648-4088-805e-59f581869e38"
      unitRef="usd">429000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i265e9d79e9a3440ba73a2f8dd054a88d_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0zLTEtMS0zODc_7e04aa79-7d08-4023-9e47-24dbd2ce16a8"
      unitRef="usd">4635000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0xLTEtMS0w_92e7475f-7022-4d57-84fd-c4f0d243dd6a"
      unitRef="usd">3612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d56781fdc104f368a6db7f99c183153_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmEyMGNhNWU1M2MwMTQyNjE4OTQxMTEzMGU0MzRkNDkwL3RhYmxlcmFuZ2U6YTIwY2E1ZTUzYzAxNDI2MTg5NDExMTMwZTQzNGQ0OTBfNS0zLTEtMS0w_91ff639d-5a19-4333-9701-0101668ea04d"
      unitRef="usd">1595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i0042ba179bcf4a8d838c6c062581603d_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjEwMjE_c093571a-45ba-4464-b420-654586a5af52"
      unitRef="usd">-3000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <sgmo:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjEwMjc_96da5092-5046-42de-bd1c-7e35392b08f9"
      unitRef="number">0.38</sgmo:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjE2MDk_5fb0b870-9bb9-4e74-a72b-f52c1247e5ee"
      unitRef="usd">2400000</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjE2MzU_136c2c5f-a5ff-4bd1-90df-68cfa11a82b5"
      unitRef="usd">-2400000</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="i6d2cccdddcc24a888e8dab92242c5df7_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjE2OTU_abcb5d66-45a2-4fcb-9534-ebf163985b21"
      unitRef="usdPerShare">-0.02</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:AgreementTerminationTerm
      contextRef="ie95f69374c3c45c3bf9593436fff15c9_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjMxNzY_83a780a4-6d5b-47d7-8a3b-3030e125a0e2">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived
      contextRef="ia5be0c8a3eaf44cfbdff12b3693acb7b_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjQ5OTM_531ebec3-a07f-496f-a013-ef5314645923"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ib6c53a13e3ed4b41a51ff5afc0e24f34_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjUwNTc_264283ab-0090-401b-903f-bcd24e0e703e"
      unitRef="usd">60000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i61c86f3985aa4e6aaf7123281f53e1c9_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjUyNDM_b0d54dbe-44b2-47cf-a436-741709eb1ee3"
      unitRef="usd">90000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ia5be0c8a3eaf44cfbdff12b3693acb7b_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjYwNDA_5d5c0ab2-00cc-4a91-b528-cdff36ab5b5d"
      unitRef="usd">12000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="iece818eb67d544e1b9ce5641695dda6a_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjYwNzg_8ecfbaf8-1811-4b51-8ed3-60961b57c5ae"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if5106f4851d54887b1c366031ae40b6b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjc1NjM_a654ef6f-fc2c-40b7-92ad-b3c1c7ce98f3"
      unitRef="usd">4200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9a27653fa2ae413986a3b7ac8ab2240d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjc1NzA_b0a8ed40-7e7c-4e8c-bfb0-12c6a783bbf0"
      unitRef="usd">8000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ibbed171f600d4452b7074be69d363203_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NjE_bd617d20-b44c-401c-bb1a-e972b7b95bc7">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Recognition of upfront fee related to Pfizer &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;"&gt;C9ORF72&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;&#160;&#160;&#160;agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74bd1c64097a48dab6c41893d097e234_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0xLTEtMS00MTM_8e309dd6-53e9-4611-bab8-de3a868330d2"
      unitRef="usd">3425000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2b663765efe486ba3be90af8e53ab8d_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0zLTEtMS00MTM_94f02189-e70f-4ecd-8b3e-1eab05a23c8a"
      unitRef="usd">455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3679ea31262c4a9a8be73e04e54ce1da_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0xLTEtMS0w_381d50fd-1d48-4ccc-993a-f0f30171e770"
      unitRef="usd">3785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic37ca88da7bc49fbaa868d8671da3f88_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOmQ2Y2M3OTMwMmU0NTQzNWE5ZTE3NDllMWNlZTNhYmMzL3RhYmxlcmFuZ2U6ZDZjYzc5MzAyZTQ1NDM1YTllMTc0OWUxY2VlM2FiYzNfMi0zLTEtMS0w_111394de-9315-4002-9175-726262de2b34"
      unitRef="usd">1070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTI2NzQ4MzE1MQ_79d34ed2-904a-4d68-a4b0-9c0c2778b02e"
      unitRef="usd">3000000.0</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTI2NzQ4MzE2NQ_e9b6811a-3a45-48ff-b8ad-257d359bde5c"
      unitRef="usd">3000000.0</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="i6e9482021f7547c3b19f0aadbbb31828_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTY0OTI2NzQ4MzE3Mg_a6ea243c-bc99-45c3-b1e6-1efc65b4ab14"
      unitRef="usdPerShare">0.02</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:NumberOfResearchProgram
      contextRef="ie5657715ba8e402b814e812ea70780d8_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMjgxMzU_ae649733-8a5e-456e-8f54-daad6e9a26a8"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <sgmo:AgreementTerminationTerm
      contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzAxNTk_42b41c73-60e0-419d-8f75-52efc11d6b38">P180D</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ie5657715ba8e402b814e812ea70780d8_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzA0NzY_4ab7ed34-0573-4786-9ae7-db541ff36d19"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i497ca7fec0544874896474aa8c59e3c8_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzA2OTU_9f62a244-7626-40b8-ae95-ae393a77e325"
      unitRef="usd">115800000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="id6b492f3a18749d2a59bd07e6e047e96_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzA4MDk_4e173737-d2d8-44e9-bfc2-bd3d4ca62ea4"
      unitRef="usd">160500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ie2bd3d15a17e4dfeb83bce33be451571_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzEwNDk_030be77d-44e1-4ff7-b6ce-81a6abd0a8ac"
      unitRef="usd">276300000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestonePaymentsReceived
      contextRef="i41bcbb1429a64230b1a3f20305b3b458_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzEzNTg_9b36200b-9bb2-4429-8cd9-24ff2427cbeb"
      unitRef="usd">6000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ib17dbd8e9112456da64bc13b7c66591e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE0NDA_bf50981d-19d6-4f54-8604-4ec495295f85"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE0OTU_8f038a64-1e93-4853-bc7a-2f1ae7b2f393"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="if322408f9ba44ac3a3050f9173bd5dbf_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE1NDA_d1f5609e-f58e-4d2f-be0a-200dac1fba36"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE3Mjc_273afd6c-0f02-40e6-8c59-57bf3b811640"
      unitRef="usd">93300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE3NjY_06acd00e-e0e9-4085-bb87-58c73f4df5f5"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i8fdbfad3304d46fdbce872a95bb8f3d2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE4MTY_ca3e4587-4108-4c18-bf90-63b5c5e0c8de"
      unitRef="usd">13500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="if96e6feb015749d6ae1e0bc10f87f928_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzE4NTE_022d1fa6-73be-4323-a513-861bdbab1644"
      unitRef="usd">59800000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibb38c2c18aaf4cf6a67227cc3d5e88e2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM2NjM_10390095-7f4b-4e2c-a45e-a85af6b8e6fa"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia4e426bbd60b445f8f58775980820ade_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM2NzA_5df6447e-2048-4ca1-bbd6-73402af6bd03"
      unitRef="usd">1700000</us-gaap:ContractWithCustomerLiability>
    <sgmo:MilestonePaymentsReceived
      contextRef="i41bcbb1429a64230b1a3f20305b3b458_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM3NTQ_9b36200b-9bb2-4429-8cd9-24ff2427cbeb"
      unitRef="usd">6000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="ic2993707ab04450c93d7c0cde818957f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzM5MjY_dc72e8fc-e27d-4354-895f-e3bec1a4f62d"
      unitRef="usd">5600000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementMilestoneRevenueReversal
      contextRef="ic2993707ab04450c93d7c0cde818957f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQwMTY_32fcd565-1703-47ca-a70d-1d3799cb822c"
      unitRef="usd">100000</sgmo:CollaborativeArrangementMilestoneRevenueReversal>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ib17dbd8e9112456da64bc13b7c66591e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQxMjE_bf50981d-19d6-4f54-8604-4ec495295f85"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="ibb38c2c18aaf4cf6a67227cc3d5e88e2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQyNzM_4a476040-120b-48b3-ba33-b9f14ce661f8"
      unitRef="usd">7000000.0</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementMilestoneRevenueReversal
      contextRef="ia6ebcf7335d143a7b2165fc287c91a99_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQzNjM_abafa7f4-1421-4617-8c93-3426997c4c4b"
      unitRef="usd">100000</sgmo:CollaborativeArrangementMilestoneRevenueReversal>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzY1NjI_03f54f23-bfd5-47fa-be7a-fce623833529">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:45.391%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.608%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.524%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e132461b3d342eab6814cba414941b1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0xLTEtMS00MzA_91f5454f-fc42-4de3-878d-b51dc0491103"
      unitRef="usd">380000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7718ad78b270467e8ae7dd73f6379efe_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0zLTEtMS00MzA_cd524ab3-7198-4e98-881a-7755afb069b2"
      unitRef="usd">901000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4652dd95590400a98b5f80879a90ffd_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0xLTEtMS0w_6f2131ad-ba0c-40dc-b0be-fb857836ee05"
      unitRef="usd">-349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a527321d23c4aed94f50804dacc5d03_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfMy0zLTEtMS0w_65431d6d-0985-48ce-bb2b-781bd6e78e9a"
      unitRef="usd">1654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2f14044865d4879afb8479d9c63829d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0xLTEtMS00MzA_d71e9637-c713-4915-9523-fd31677736ee"
      unitRef="usd">1155000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4da0f61970a045f19353779959c20d90_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0zLTEtMS00MzA_fd2ffd12-0b57-4cf1-b4f7-2092fd07f2e3"
      unitRef="usd">2158000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56befc014b3d45ed9d4357b46df3211e_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0xLTEtMS0w_5421a276-44de-44da-8219-299853db8287"
      unitRef="usd">2875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib38f03f2a7b44058af0b32589f5cb20e_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNC0zLTEtMS0w_6a6f77bb-a321-4a7d-af5d-456c05bca5dd"
      unitRef="usd">3355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i136a0633a1d642fe8d52aea0bb57ae3e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0xLTEtMS00MzA_5a2f570d-6542-43fd-ad33-af0d95657593"
      unitRef="usd">257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3250dbc4b25847b3b6cf42f0917717c0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0zLTEtMS00MzA_391f9ead-587d-49c5-a044-29035e45ca3b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ed406253dd0408fa025ccc1e539acff_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0xLTEtMS0w_a04936fd-35b4-4a8c-be88-43996135b1a2"
      unitRef="usd">-235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if997601e608240a49794adff9baae92f_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNS0zLTEtMS0w_11eda0cd-2674-452d-a77b-8394990cddb6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5ba64af70834af7acab6ecdc62729b3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0xLTEtMS00MzA_270e71b7-95a0-405c-adaa-188769203718"
      unitRef="usd">1792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbab28971c8f4c168f2a753a668b5dd3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0zLTEtMS00MzA_b58cb3ac-05ed-42cf-8305-138fdf2054d3"
      unitRef="usd">3059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7c84c08b7c14d3ca4ca1005a470e83b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0xLTEtMS0w_612437d5-e757-4ace-b1a0-fa20cb6c989b"
      unitRef="usd">2291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f81298b72494b5d8bfca23ef7846819_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RhYmxlOjY5ZjU3NTAwZjM2NjRkODVhMmY4NjU0NDczZjI3ZmQ0L3RhYmxlcmFuZ2U6NjlmNTc1MDBmMzY2NGQ4NWEyZjg2NTQ0NzNmMjdmZDRfNi0zLTEtMS0w_398ac3f7-93ba-4c9d-854b-2a16ed630ff9"
      unitRef="usd">5009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQ5NDI_81ac3027-5693-44b4-90d4-df8db6582126"
      unitRef="usd">-2200000</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzQ5Njg_2309cec9-114c-463e-81fc-eef7ea6b29b2"
      unitRef="usd">-2200000</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="i0fa6fc1a292c4fb1a048d38a91ef17d7_D20200301-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzUwMjg_fed1924d-1aa1-405e-81ca-3dc8e7735521"
      unitRef="usdPerShare">-0.02</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:GrantFundingAmount
      contextRef="i936718d885f345a0962a1f03189aeecb_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzUyMzY_1c41b37e-993c-47c2-81ae-c18d34af330f"
      unitRef="usd">8000000.0</sgmo:GrantFundingAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7921fa4bd7c7486b81fa47d950ada799_D20180601-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzU2NDg_463633cb-10b6-4f4a-b0c5-807369ec5cb1"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia8b8e663d405457c8f481e73b7494220_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzYyOTU_4c22d008-9166-4c00-8c4b-96c1b597084f"
      unitRef="usd">6100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3be268974b9a4fdc9861bb34708345c1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMzYzMDI_40463839-b363-4bd4-b4e3-dc240d6d3513"
      unitRef="usd">5700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81Mi9mcmFnOmExZGMyNjIzYTFlNjQ1M2E4YTcyM2UwNTc3YWI0NmUzL3RleHRyZWdpb246YTFkYzI2MjNhMWU2NDUzYThhNzIzZTA1NzdhYjQ2ZTNfMTYwMg_9ef32d67-783b-44df-98fc-a62c026914e2">INCOME TAXES&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#x2019;s history of losses. Accordingly, the Company&#x2019;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 27, 2020, the President signed the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) into law. The CARES Act is a relief package that includes changes to the US tax code including but not limited to, (1) modifications to the calculation of interest deductibility in 2019 and 2020; (2) changes to rules related to the uses and limitations of net operating loss carryforwards created in 2018-2020 and (3) technical corrections for qualified improvement property. The CARES Act did not have a material impact on the Company's Condensed Consolidated Statements of Operations for the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjQwOQ_7e676806-8b7c-41e1-ab78-7d9a2e292a1f">COMMITMENTS AND CONTINGENCIES&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 45,600 square feet of research and office space in Richmond, California pursuant to leases that expire in August 2026. In addition, the Company leases approximately 20,800 square feet of research and office space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNjY2_e5a325f2-0b18-490c-80b9-c74fd88bf207"&gt;five&lt;/span&gt; to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the three and six months ended June&#160;30, 2020, the Company incurred $2.6&#160;million and $5.1&#160;million of lease costs in relation to these operating leases. These lease costs were included in operating expenses in the Condensed Consolidated Statements of Operations. Variable lease expense was $0.5&#160;million and $1.0&#160;million for the three and six months ended June&#160;30, 2020 and was not included in the measurement of the Company&#x2019;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#x2019;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#x2019;s election to not separate lease and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June&#160;30, 2020 was $3.1&#160;million and was included in net cash used in operating activities in the Company&#x2019;s Condensed Consolidated Statements of Cash Flow.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.495%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ending December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reported as of June 30, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the weighted-average remaining lease term is 8.3 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company does not have any financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contractual Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020, the Company has manufacturing obligations that include a fee of $3.2&#160;million for dedicated capacity pursuant to the Development and Manufacturing Services Agreement with Brammer Bio MA, now a Thermo Fisher Scientific Inc. subsidiary ("Brammer"). The Company also has an Option Agreement ("Option") with Brammer, entered in April 2019, whereby Brammer granted the Company an option to secure dedicated capacity for manufacturing in Brammer&#x2019;s facilities. The Company paid $3.0&#160;million for the Option, which expires on December 31, 2021. In addition, the Company agreed to pay Brammer $2.0&#160;million, $1.0&#160;million of which has been paid, to assist it in establishing its manufacturing capabilities in Brisbane, California, which may increase Sangamo's contractual commitments in the future. Furthermore, the Company has non-cancelable contractual commitments under manufacturing-related supplier arrangements with Brammer, which requires minimum purchase commitments totaling approximately $2.5&#160;million through December 2021, $0.5&#160;million of which was paid upon execution of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May 2020, the Company entered into an amendment to an existing lease to acquire approximately 8,500 square feet of research and office space in Richmond, California that expire in August 2026. Total lease payment over the life of this lease under this amendment are approximately $1.6&#160;million. Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The commencement date of this lease was determined to be in the third quarter of 2020, therefore the lease is not included in the Company&#x2019;s operating lease right-of-use asset or operating lease liabilities as of June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company also has $1.2&#160;million of license obligations related to its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sangamo is not party to any material pending legal proceedings or contingencies. From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i0ad8f21a630e48d2a8a38df95bced575_I20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfODA_07e2a433-e78a-4001-9d34-b18e2e7078c9"
      unitRef="sqft">87700</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i3c124d01f92f4f20abe3ffd4deee75f4_I20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjU3_5f8f10be-2875-485e-94af-26be8c5c36fe"
      unitRef="sqft">45600</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i8278bf8bca164e85b22804fbba447080_I20200630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNDE4_d2152f5a-106a-4a88-a99f-8ef30184d1f4"
      unitRef="sqft">20800</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i4787cbcb6bbc401c9aed2cc60462afc9_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNjcy_8ff0cca7-712e-4a74-ad97-12a0bac4a2be">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA3MA_430c74e6-a754-409a-899b-dd0dbcdb8be6"
      unitRef="usd">2600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMDI0OQ_7f3d351a-b42e-4db9-9889-b92c06e2ac61"
      unitRef="usd">5100000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTI0MA_fae5426f-159f-408e-b82a-90e76d349d5a"
      unitRef="usd">500000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMDI3Nw_45e3fb78-e3ef-42f4-8ce0-b9e6e16246fe"
      unitRef="usd">1000000.0</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTcyNQ_be8bbd8b-4003-4235-b7e6-4b9485d59642"
      unitRef="usd">3100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjQxMQ_bd738d01-67e2-4345-90bb-943706bb955f">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.495%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ending December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;54,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(12,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reported as of June 30, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6.75pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMS0xLTEtMS0w_37e069b2-cf25-41b4-938d-1963395da6b8"
      unitRef="usd">2717000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMi0xLTEtMS0w_ed1f925e-bf46-4d69-87a7-278af15b077b"
      unitRef="usd">6390000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMy0xLTEtMS0w_a81a4c0b-f4f3-4052-a0fb-1c21f5899f3a"
      unitRef="usd">6468000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNC0xLTEtMS0w_6370e1df-a260-4649-ab69-affdab78d468"
      unitRef="usd">6556000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNS0xLTEtMS0w_cdafc47f-4512-4fb4-9746-8a4012ef6c46"
      unitRef="usd">6694000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNi0xLTEtMS0w_03f74107-1463-48b9-ad77-97f23ae17e3c"
      unitRef="usd">26141000</sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfNy0xLTEtMS0w_5262491d-8b1f-409e-98e0-aaa4c966ef49"
      unitRef="usd">54966000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfOS0xLTEtMS0w_e8b2c3f7-50b4-407e-a2bb-de7c11f9ad4a"
      unitRef="usd">12356000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTEtMS0xLTEtMA_6f58298d-a91c-43f0-8def-80b7ee98e7ea"
      unitRef="usd">42610000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTQtMS0xLTEtMA_7c246695-a0c4-4e2a-b1e0-bd4d1e1bb7ab"
      unitRef="usd">3376000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTUtMS0xLTEtMA_587f66b6-424b-40cf-b4c4-11b8db7b1dbc"
      unitRef="usd">39234000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RhYmxlOjM2NWI0ODU4ZjgwZjRlZDk5ZGNjMjlkZmRmODQzOTg1L3RhYmxlcmFuZ2U6MzY1YjQ4NThmODBmNGVkOTlkY2MyOWRmZGY4NDM5ODVfMTYtMS0xLTEtMA_2d98ce12-2516-46d4-8811-5cff63b8cd18"
      unitRef="usd">42610000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjAxMA_e870a063-3f82-4a58-8797-2021c8e9361d">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMjExNw_cac6d7fb-7201-4d97-909b-4664ac4a405d"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OtherCommitment
      contextRef="ie78f712514d644f0aeb72decbb03a5df_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMzEwOA_0a2969f9-9450-4e4a-a748-1cc2d6936bd6"
      unitRef="usd">3200000</us-gaap:OtherCommitment>
    <sgmo:PaymentsForOtherCommitment
      contextRef="i2fe52cb8512a433bacfe3d8fc79e20c9_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDIzNA_3cf08685-7e61-4632-8526-bd0939d7ef4f"
      unitRef="usd">3000000.0</sgmo:PaymentsForOtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="i3439f2f47737467aace116123f9168f1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDI3Mg_55e12dce-99cb-4dfe-9377-5a50f69fbee7"
      unitRef="usd">2000000.0</us-gaap:OtherCommitment>
    <sgmo:PaymentsForOtherCommitment
      contextRef="i780b21af471142fda76665c4670e1f9e_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDMxMA_839ccb92-7f35-4f50-944e-5a4beb201f60"
      unitRef="usd">1000000.0</sgmo:PaymentsForOtherCommitment>
    <us-gaap:ContractualObligation
      contextRef="i35a93dc1df704160a8e800276312cdd3_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDM0OA_5383547d-8380-428c-9739-57414aa3975e"
      unitRef="usd">2500000</us-gaap:ContractualObligation>
    <sgmo:ContractualObligationPaidUponExecution
      contextRef="i001922d1aa724eb9ba89ce4a309abafb_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNDM4OA_44600414-5854-4e84-8305-6fc20458b637"
      unitRef="usd">500000</sgmo:ContractualObligationPaidUponExecution>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate
      contextRef="i85c2dfc465984dfca02266cbfed874c2_I20200531"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMzI5ODUzNDg5MDkyMg_63a4eebf-1405-44f6-ac09-5274d7fc3def"
      unitRef="sqft">8500</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i85c2dfc465984dfca02266cbfed874c2_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzMTIzNg_4123e2b3-6cb9-4d64-84c3-3e3e6547b5a5"
      unitRef="usd">1600000</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <sgmo:LicenseObligations
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfMTA5OTUxMTYzNTM1MQ_06c7a55a-9d4f-4922-91ff-735500a2fa68"
      unitRef="usd">1200000</sgmo:LicenseObligations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RleHRyZWdpb246YWU0ZmFiM2MzODQzNDMwNzk2YjIyN2Q5NjNmNDc1NmJfMjE4_219b1857-68e3-4daf-a415-59ac5261a2f4">STOCK-BASED COMPENSATIONThe following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.534%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.362%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.362%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.362%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.365%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RleHRyZWdpb246YWU0ZmFiM2MzODQzNDMwNzk2YjIyN2Q5NjNmNDc1NmJfMjIw_fdb59735-abf7-4fc4-a8bc-cdf4dd6857a4">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.534%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.362%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.362%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.362%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.805%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.365%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iafe38837c16248a78d0de8b944f254fb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0xLTEtMS0zMjY_4f6434ed-0163-4528-bc94-d20611d0a180"
      unitRef="usd">3578000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa400bd785134038a5e827fe16db92fd_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0zLTEtMS0zMjY_0c9230f9-bb3a-4767-bfb2-ae50e8b56705"
      unitRef="usd">2763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56a3424384d1467db3554580d425e34a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0xLTEtMS0w_b145dcc7-f94a-43ed-ae6d-237886cced65"
      unitRef="usd">6417000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ae7ba47695144fd9e5a674b88fd5103_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMi0zLTEtMS0w_3b0a3af1-2709-4725-bd3c-ef934d98061f"
      unitRef="usd">5061000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11ee1f4e6dd5429489a79d5f03928607_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0xLTEtMS0zMjY_8f856716-a4a4-4a38-91ca-1a9c7dd8b307"
      unitRef="usd">3186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0ae307928d74e0dbeabc531a4d6b23b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0zLTEtMS0zMjY_2bcfe353-50d3-4c37-9106-7647312ea4ac"
      unitRef="usd">2104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i60b6a65590a94cb39bd8e14b7ac7d841_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0xLTEtMS0w_e8777539-5c3d-47fd-8913-786e077217d0"
      unitRef="usd">5967000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b2ede07af0343f389b427458e393a41_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfMy0zLTEtMS0w_c802296a-5720-46eb-a15b-93612ed09f11"
      unitRef="usd">4329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0xLTEtMS0zMjY_b251e8a8-ee22-404b-903d-8116d682ef10"
      unitRef="usd">6764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0zLTEtMS0zMjY_12e8ca5d-2ee2-4541-9f04-a707b002dbf3"
      unitRef="usd">4867000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0xLTEtMS0w_cfefbef7-adeb-40e4-a822-7b9f6471f8ae"
      unitRef="usd">12384000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81OC9mcmFnOmFlNGZhYjNjMzg0MzQzMDc5NmIyMjdkOTYzZjQ3NTZiL3RhYmxlOjMyYTkzMzA2OTcxODRiZTE5MTY5ZThkMmI5NDMyZTcyL3RhYmxlcmFuZ2U6MzJhOTMzMDY5NzE4NGJlMTkxNjllOGQyYjk0MzJlNzJfNC0zLTEtMS0w_c17b1d63-5043-4dc8-86ee-2fb9df173c32"
      unitRef="usd">9390000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfNDI1_63574589-153c-49d9-a6eb-4e79a39e6d3c">STOCKHOLDERS&#x2019; EQUITY&lt;div style="text-indent:27pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the collaboration agreement with BIMA described in Note 5 of these Condensed Consolidated Financial Statements, the Company also entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase the Biogen Shares at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million. The Company closed the sale of the Biogen Shares on April 8, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 12.7&#160;million shares of its common stock at a public offering price of $11.50 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $136.3&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i426f14e574704e28836ba330c9dbd8f1_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMTY0OTI2NzQ0NTA3NQ_2adfd67c-9f87-469b-9dc1-3294270623f8"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i57b1fd4355ed4fbaa8e978fc19c46805_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMTY0OTI2NzQ0NTAyMw_f9d4fabc-1319-44aa-8a30-4bfc19e2828e"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id89248aaa3ba492aa4b8f488c3be6df5_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMTY2_a0e51a1b-2bbf-47da-a590-e3ad7c0d01a4"
      unitRef="shares">12700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i95ccc4fdb8ea4e4c9cf7485785db1170_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfMjI2_28d77f32-091c-4d20-a61e-7864ac42fb0d"
      unitRef="usdPerShare">11.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i77dd9fd15a104e948837f14e23f36760_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82MS9mcmFnOjFjZGY0NmE2ZDFkMjQzNWI4YTlhNmQzNGFlODY3Mjg2L3RleHRyZWdpb246MWNkZjQ2YTZkMWQyNDM1YjhhOWE2ZDM0YWU4NjcyODZfNDIz_1f370683-925a-42d5-ae04-290ae2f4cfc1"
      unitRef="usd">136300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzM1MA_31a69d0b-260f-4026-831b-1c6f6ed3770e">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On July 20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#x2019;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired 13,519,036 ordinary shares of Sangamo France (&#x201c;Ordinary Shares&#x201d;) as part of a block transaction that closed on October 1, 2018 (the &#x201c;Acquisition Date&#x201d;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire 11,528,635 Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November 23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned 98.2% of the Ordinary Shares as of December 31, 2018 (or 25,047,671 Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#x201c;Free Shares Options&#x201d;). In June 2019, Sangamo France became a soci&#xe9;t&#xe9; par actions simplifi&#xe9;e (&#x201c;S.A.S.&#x201d;) and was renamed from &#x201c;TxCell&#x201d; to &#x201c;Sangamo Therapeutics France.&#x201d; During 2019, the Company acquired approximately 111,000 vested free shares, increasing its ownership of the Ordinary Shares from 98.2% to 98.7%. During the three months ended June&#160;30, 2020, the Company acquired approximately 117,000 vested free shares, including 80,000 from a former executive of Sangamo France who is now an executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $0.2&#160;million of cash, increasing its ownership of the Ordinary Shares to 99.1% as June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $0.2 million. See &#x201c;Note 2 &#x2014; Fair Value Measurements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;-Free Shares Asset&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d; for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#x2019;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $0.2&#160;million as of June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Business Combinations, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;in exchange for total consideration of approximately $45.9&#160;million at the Acquisition Date. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#x2019;s Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There were no goodwill impairments during the six months ended June&#160;30, 2020 or during 2019 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Non-Controlling Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the remaining non-controlling was determined based on the number of outstanding shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the Acquisition Date. The non-controlling interest is presented as a component of stockholders' equity on the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Non-controlling interest as of June&#160;30, 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.495%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTYy_c970d7b3-b12b-4885-9759-60799f3c15c7"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i7739ea8df1214054a989dcff454b94a4_D20181001-20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzIz_cbfa02a1-7e26-4984-b9e9-51a8243270ba"
      unitRef="shares">13519036</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i6dbedaa261e3453a99f6f409adcb45d5_D20181001-20181123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfNTk1_5656699e-0968-467f-b13d-472cb65229ae"
      unitRef="shares">11528635</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i90c49293724e4810919a1e33caec7e6a_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfODQw_007e2875-6b12-40ad-8526-02370deeed57"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i277faef5976144519b807ff6099f0c2a_D20180101-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfODk0_221c7749-7936-43fd-816c-5d49ac7efcc8"
      unitRef="shares">25047671</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ide0bd3414e1646898d32c7957fea55c8_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA2Mg_16328202-9289-4800-8320-df5b6e99fc94"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i885f1a5affb04c469c5e9e4b478422c3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTU0OQ_b64fb94a-a2dd-4c51-8915-4b92d36e16a3"
      unitRef="shares">111000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i90c49293724e4810919a1e33caec7e6a_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTYyNQ_007e2875-6b12-40ad-8526-02370deeed57"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i6874113b1491428eacb8504f0de4cfe8_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTYzMQ_b5eb91c7-9efe-4ef6-8bd5-363aba8b0ab8"
      unitRef="number">0.987</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i85712feac5eb4f42afbf2e3e67d9c585_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTY0OTI2NzQ0NTQ4OQ_6ab827ab-b7e3-482a-82cc-389c49589beb"
      unitRef="shares">117000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i8989c058d5ad4d3083e46b8de83336a3_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA5OTUxMTYzMjExNg_d0beb2b4-06db-466d-9983-09d7d311f1ce"
      unitRef="shares">80000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="ic6b4b4f1e90f4a7183a57a1c0fce157c_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTY0OTI2NzQ0NTUwMw_3a5447fa-df3f-4b1a-aedb-cf0a3643a8dd"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ic55a7e77392b4473b8950e77235bfa85_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA5OTUxMTYzMTg4Mw_56b03e1b-b304-4cbe-b1ef-bab5f8740de8"
      unitRef="number">0.991</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="i40cf24533b514984a2ae3200f4197e14_I20181001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTgyMg_e7a6781c-558c-4f4d-81b5-fe4b0fbe6721"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="ic6b4b4f1e90f4a7183a57a1c0fce157c_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMjEzNg_8eb06063-8ac9-4d4c-861f-f5796e70af53"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7739ea8df1214054a989dcff454b94a4_D20181001-20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMTA5OTUxMTYzMjM4OQ_18511579-df9d-480b-b230-2d3b03a6c81e"
      unitRef="usd">45900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMjQ0OA_3acbf9dd-8ac7-4bd1-9922-a2233bd7027e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8296012a1d2e45588145cfe4b6c306e3_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMjQ0OA_82ddf848-711c-4a7b-86d2-e77a6c6220cf"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ic0dfb29e9e7045fb83ff2c12782a719e_I20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzA4OA_5003d793-2234-4a54-997e-3df10b28a86c"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RleHRyZWdpb246ZjA2ZDVmOWRkODRjNGVhNmEwMjg4MGE4YmIyYWY4ZGFfMzM1NA_49c49237-6e68-4bfe-a097-ef06d7bbc8b8">&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Non-controlling interest as of June&#160;30, 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:86.505%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.495%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="i8f3eeebf2a8e4f38866132567e9f313d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfMS0xLTEtMS0w_e387ec78-4b79-49db-9d9a-c1c62a45c358"
      unitRef="usd">185000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfMi0xLTEtMS0zMzM_9a0e3d20-42c3-4192-8c99-4715a75f6be7"
      unitRef="usd">339000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfMy0xLTEtMS0w_a365ba41-371a-4cf6-8bd6-4de00882e293"
      unitRef="usd">-97000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="i74a14aa270784e14b78266b6b869c0f0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82NC9mcmFnOmYwNmQ1ZjlkZDg0YzRlYTZhMDI4ODBhOGJiMmFmOGRhL3RhYmxlOjc3Mzg1ZGM0YTQwMjQyNDQ4MGYxOGVlOTIyMmNkN2NlL3RhYmxlcmFuZ2U6NzczODVkYzRhNDAyNDI0NDgwZjE4ZWU5MjIyY2Q3Y2VfNC0xLTEtMS0w_e395dcff-5679-41ff-884c-1ba889763af9"
      unitRef="usd">-251000</us-gaap:MinorityInterest>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="icc60e28018564ffd939811f6b225a28b_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfNDYw_c52d5c2f-c2e6-4b0c-b43a-dd2ccb8683d5">SUBSEQUENT EVENTSOn July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. The collaboration became immediately effective upon execution of the agreement. Under the agreement, the Company granted to Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its ZFP-TFs targeted to three undisclosed genes that are associated with neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. Over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk1NA_938ff3c2-f0c1-40b0-bd71-520363c2dffa"&gt;three&lt;/span&gt;-year collaboration period, which may be extended by Novartis for up to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk2Ng_dc93b536-40db-442b-b669-b33786af281b"&gt;two&lt;/span&gt; additional years, the Company will perform early research activities for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, investigational new drug-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company's proprietary AAVs for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. Under the agreement, Novartis will pay the Company a $75.0&#160;million upfront license fee payment no later than August 27, 2020. In addition, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate the agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ib91cbc7a1cd2485baa09f334bf5ffbe1_D20200727-20200827"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk3Mg_c1c897d4-30e3-4ff9-914d-d86aead348f8"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i5e110ed49cfa4b80989b60ab5d0101ae_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk4Nw_daff17be-efde-45ee-94c8-005d76471fc7"
      unitRef="usd">420000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i81e7c06ca04f44e2b3804131674178f4_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5MzAwMw_e7e0cc18-1f61-4360-867b-943d701eddad"
      unitRef="usd">300000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i85c2dfc465984dfca02266cbfed874c2_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl84NS9mcmFnOmQ0ZmRmMGJhNWJkYzQxMGRiZTAwZmUyNmY3MzYxM2VhL3RleHRyZWdpb246ZDRmZGYwYmE1YmRjNDEwZGJlMDBmZTI2ZjczNjEzZWFfMTA5OTUxMTYzMDIyMw_4123e2b3-6cb9-4d64-84c3-3e3e6547b5a5"
      unitRef="usd">1600000</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988844501032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,988,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988847721176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 467,443<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">197,410<span></span>
</td>
<td class="nump">282,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">534<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,618<span></span>
</td>
<td class="nump">36,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,395<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">679,400<span></span>
</td>
<td class="nump">405,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,907<span></span>
</td>
<td class="nump">29,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">53,219<span></span>
</td>
<td class="nump">53,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">39,318<span></span>
</td>
<td class="nump">39,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">73,501<span></span>
</td>
<td class="nump">77,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">13,814<span></span>
</td>
<td class="nump">9,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">894,659<span></span>
</td>
<td class="nump">637,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">19,221<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">13,332<span></span>
</td>
<td class="nump">13,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">61,389<span></span>
</td>
<td class="nump">38,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">93,942<span></span>
</td>
<td class="nump">69,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">237,644<span></span>
</td>
<td class="nump">81,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">39,234<span></span>
</td>
<td class="nump">41,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">6,578<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">6,055<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">383,453<span></span>
</td>
<td class="nump">204,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,247,527<span></span>
</td>
<td class="nump">1,090,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(735,827)<span></span>
</td>
<td class="num">(656,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(2,449)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Sangamo Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">511,457<span></span>
</td>
<td class="nump">432,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(251)<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">511,206<span></span>
</td>
<td class="nump">432,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 894,659<span></span>
</td>
<td class="nump">$ 637,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988847593976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 34,629<span></span>
</td>
<td class="nump">$ 25,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">41,523<span></span>
</td>
<td class="nump">36,455<span></span>
</td>
<td class="nump">83,002<span></span>
</td>
<td class="nump">71,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,927<span></span>
</td>
<td class="nump">14,597<span></span>
</td>
<td class="nump">34,046<span></span>
</td>
<td class="nump">31,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">59,450<span></span>
</td>
<td class="nump">51,052<span></span>
</td>
<td class="nump">117,048<span></span>
</td>
<td class="nump">103,020<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(37,897)<span></span>
</td>
<td class="num">(33,504)<span></span>
</td>
<td class="num">(82,419)<span></span>
</td>
<td class="num">(77,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">1,932<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
<td class="nump">3,480<span></span>
</td>
<td class="nump">4,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(35,965)<span></span>
</td>
<td class="num">(30,356)<span></span>
</td>
<td class="num">(78,939)<span></span>
</td>
<td class="num">(72,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</a></td>
<td class="num">$ (35,929)<span></span>
</td>
<td class="num">$ (30,284)<span></span>
</td>
<td class="num">$ (78,842)<span></span>
</td>
<td class="num">$ (72,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">138,977<span></span>
</td>
<td class="nump">114,382<span></span>
</td>
<td class="nump">127,519<span></span>
</td>
<td class="nump">108,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988940550904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (35,965)<span></span>
</td>
<td class="num">$ (30,356)<span></span>
</td>
<td class="num">$ (78,939)<span></span>
</td>
<td class="num">$ (72,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on available-for-sale securities</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">737<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(33,790)<span></span>
</td>
<td class="num">(28,430)<span></span>
</td>
<td class="num">(78,143)<span></span>
</td>
<td class="num">(71,884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (33,754)<span></span>
</td>
<td class="num">$ (28,358)<span></span>
</td>
<td class="num">$ (78,046)<span></span>
</td>
<td class="num">$ (71,759)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988843224200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Revision of Prior Period, Accounting Standards Update, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,187,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2018</a></td>
<td class="nump">$ 367,257<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">$ 929,632<span></span>
</td>
<td class="num">$ (562,696)<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="num">$ (1,440)<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">2,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">2,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">136,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">136,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to public offering</a></td>
<td class="num">(276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(72,559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,603,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2019</a></td>
<td class="nump">445,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">1,078,976<span></span>
</td>
<td class="num">(634,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(765)<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,328,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Mar. 31, 2019</a></td>
<td class="nump">329,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="nump">934,112<span></span>
</td>
<td class="num">(603,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,691)<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 1,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="nump">12,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">$ 136,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">136,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to public offering</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(30,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,603,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2019</a></td>
<td class="nump">445,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">1,078,976<span></span>
</td>
<td class="num">(634,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(765)<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2019</a></td>
<td class="nump">432,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">1,090,828<span></span>
</td>
<td class="num">(656,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,449)<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">142,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">142,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(78,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,973,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2020</a></td>
<td class="nump">511,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
<td class="nump">1,247,527<span></span>
</td>
<td class="num">(735,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,278,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Mar. 31, 2020</a></td>
<td class="nump">394,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
<td class="nump">1,096,854<span></span>
</td>
<td class="num">(699,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,828)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">142,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">142,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities</a></td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(35,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,973,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2020</a></td>
<td class="nump">$ 511,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
<td class="nump">$ 1,247,527<span></span>
</td>
<td class="num">$ (735,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,653)<span></span>
</td>
<td class="num">$ (251)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988845182344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (78,939)<span></span>
</td>
<td class="num">$ (72,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,639<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on marketable securities</a></td>
<td class="num">(1,146)<span></span>
</td>
<td class="num">(2,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets', window );">Amortization and other changes in right-of-use assets</a></td>
<td class="nump">3,788<span></span>
</td>
<td class="nump">1,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GainLossOnFreeShares', window );">Gain on free shares</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,384<span></span>
</td>
<td class="nump">9,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net loss on lease termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="nump">148<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">31,291<span></span>
</td>
<td class="num">(7,422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(7,763)<span></span>
</td>
<td class="num">(5,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">178,890<span></span>
</td>
<td class="num">(10,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities', window );">Long-term portion of lease liabilities</a></td>
<td class="num">(1,797)<span></span>
</td>
<td class="num">(563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">141,103<span></span>
</td>
<td class="num">(84,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(43,580)<span></span>
</td>
<td class="num">(244,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">151,839<span></span>
</td>
<td class="nump">226,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,694)<span></span>
</td>
<td class="num">(9,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional shares of Sangamo France</a></td>
<td class="num">(237)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">101,328<span></span>
</td>
<td class="num">(27,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</a></td>
<td class="nump">142,526<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(455)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">4,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">144,565<span></span>
</td>
<td class="nump">140,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effects of changes in foreign exchange rates</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">387,015<span></span>
</td>
<td class="nump">28,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">81,928<span></span>
</td>
<td class="nump">143,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">468,943<span></span>
</td>
<td class="nump">172,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in unpaid liabilities</a></td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 29,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization And Other Changes In Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AmortizationAndOtherChangesInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GainLossOnFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GainLossOnFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long-term portion of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840772952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Business Overview</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995. Sangamo is a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients&#8217; lives using the Company's platform technologies in gene therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene-edited cell therapy, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">in vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome regulation. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. The Condensed Consolidated Balance Sheet data at December&#160;31, 2019 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 (the &#8220;2019 Annual Report&#8221;) as filed with the SEC on February&#160;28, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company's Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2019, included in the 2019 Annual Report.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaboration funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2020, and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12 months from the date the financial statements are issued. Sangamo may require additional financial resources to complete the development and commercialization of its products including zinc finger protein (&#8220;ZFP&#8221;) therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to advance its product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Summary of Significant Accounting Policies</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi Genzyme (&#8220;Sanofi&#8221;) as a result of a decision made by the joint steering committee of Sanofi and Sangamo to increase the project scope and related project cost, which resulted in a decrease in the measure of proportional cumulative performance. In March 2020, the Company also recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs after the successful investigational new drug (&#8220;IND&#8221;) transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">research collaboration and license agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pfizer-related adjustment in June 2020 increased revenue by $3.0&#160;million, decreased net loss by $3.0&#160;million and decreased the Company&#8217;s basic net loss per share by $0.02 for the three months ended June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Pfizer and Sanofi-related adjustments in March and June 2020 increased revenue by $3.1&#160;million, decreased net loss by $3.1&#160;million and decreased the Company&#8217;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.982%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.503%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2020, the Company had not incurred any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div><div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill and Intangible Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of June&#160;30, 2020, no impairment of goodwill or indefinite-lived intangible assets has been identified.</span></div><div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Valuation of Long-Lived Assets</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of June&#160;30, 2020, no impairment of any long-lived assets has been identified.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">estimated fair values. The free shares asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%;"><tr><td style="width:1.0%;"/><td style="width:52.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.191%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.465%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.046%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.615%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">468,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">172,722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in Accumulated Other Comprehensive Income (Loss) (&#8220;AOCI&#8221;) within stockholders' equity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in other income (expense) within the accompanying Condensed Consolidated Statements of Operations. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the estimated fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Risk</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an IND application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Goodwill Impairment Testing</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2017-04&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-04 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Credit Losses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes &#8211; Simplifying the Accounting for Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 740)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988844679128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:0.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:23.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Commercial paper securities </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company generally classifies its marketable securities and some cash equivalents as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Free Shares Asset</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 10 &#8212; </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Acquisition of Sangamo Therapeutics France S.A.S.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">), the Company entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $0.2&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company purchased approximately 111,000 shares during 2019 and 117,000 shares during the three months ended June&#160;30, 2020, of the 477,000 total free shares for a cash payment of approximately $0.3&#160;million and $0.2&#160;million respectively, upon exercise of the put options. As of June&#160;30, 2020, approximately 249,000 free shares remain outstanding and subject to purchase by the Company. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the free shares asset was approximately $0.2&#160;million at December 31, 2019. The Company recognized an increase in the fair value of the free shares of approximately $0.1&#160;million for the six months ended June&#160;30, 2020, offset by approximately $0.1&#160;million for the shares purchased during the six months ended June&#160;30, 2020, resulting in an asset balance of approximately $0.2&#160;million at June&#160;30, 2020.</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%;"><tr><td style="width:1.0%;"/><td style="width:72.100%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.230%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.232%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free Shares valuation assumptions:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD / EUR Exchange Rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Correlation Sangamo and Sangamo France Stock Prices</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD) Volatility Estimate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.8%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR) Volatility Estimate</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.8%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD / EUR Exchange Rate Volatility Estimate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839196696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Equivalents and Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.710%;"><tr><td style="width:1.0%;"/><td style="width:59.191%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.156%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.720%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.866%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.163%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,424&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">420&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">312,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,905&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%;"><tr><td style="width:1.0%;"/><td style="width:72.165%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.046%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.339%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span><br/></span></div><div style="text-indent:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company had no realized losses of its available-for-sale securities for the three and six months ended June&#160;30, 2020 or 2019. The Company periodically reviews the available-for-sale investments for other-than-temporary impairment losses. No investments were other-than-temporarily impaired at either June&#160;30, 2020 or December&#160;31, 2019. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For available-for-sale securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company's review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company's ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these securities at June&#160;30, 2020. All available-for-sale securities with unrealized losses have been in a loss position for less than 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840760344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
<td class="text">BASIC AND DILUTED NET LOSS PER SHARE<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of June&#160;30, 2020 and 2019 totaled 14,964,567 and 10,155,033, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839253400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Biogen MA, Inc.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via adeno-associated virus (&#8220;AAV&#8221;) to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company's common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP transcription factors (&#8220;ZFP-TFs&#8221;) (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e. through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNDk2MA_8a0774d0-1ee7-45ae-b865-08409446f2a7">three</span>-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfNjE3OQ_91e689ec-675c-4164-b538-3b9389226c79">two</span>-year anniversary of the effectiveness of the collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock and (iii) the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic 606 and concluded that Biogen is a customer. As of June&#160;30, 2020, the transaction price includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of June&#160;30, 2020, the Company had deferred revenue of $197.8&#160;million related to this agreement. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"/><td style="width:45.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company paid $7.0&#160;million for financial advisory fees during the quarter ended June&#160;30, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the upfront license fee of $125.0&#160;million and 2% of the excess consideration from the stock purchase of $79.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Assets and </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred Costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Kite Pharma, Inc.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective in April 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex vivo</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial research term in the agreement is six years. Kite has an option to extend the research term of the agreement for up to two additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl80OS9mcmFnOjgyYWUwOTVmNGVjMTRhY2FiNWUzY2FiYjgzYjUxYWI4L3RleHRyZWdpb246ODJhZTA5NWY0ZWMxNGFjYWI1ZTNjYWJiODNiNTFhYjhfMTAyNzM_91569598-dc9b-4299-8c21-58e8ed1c15e0">one</span>-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4 million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0 million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand-ready obligation to perform research services, and (2) the on-going research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $94.0&#160;million and $106.5&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pfizer Inc.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">SB-525 Global Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of SB-525, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. In addition, Sangamo is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for SB-525 and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, a $25.0&#160;million milestone has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of June&#160;30, 2020, the total transaction price under this agreement is $104.0&#160;million, which represents the upfront and research services fees of $79.0&#160;million and one unconstrained milestone in the amount of $25.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the performance obligations within the agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going research services through 2020, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $0.7&#160;million and $4.0&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company entered into an amendment to the agreement, pursuant to which the Company transferred the IND for SB-525 to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The Company recognized $1.1&#160;million during the six months ended June&#160;30, 2020 and approximately $24.8&#160;million on a cumulative basis attributed to this milestone as revenue. The balance of this milestone payment of $0.2&#160;million will be recognized as revenue commensurate with the provision of research services over the remaining term of the agreement. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%;"><tr><td style="width:1.0%;"/><td style="width:45.694%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.520%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.520%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.520%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.538%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Pfizer SB-525 agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee and research services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, the Company received new data results, and expanded enrollment of patients in the ongoing trial. As a result, the estimated project cost increased and the proportional performance was updated based on the actual services delivered to Pfizer as a percentage of the updated project cost as of March 31, 2019. The increase in project cost resulted in a decrease in the measure of the proportional cumulative performance. During the six months ended June 30, 2019, the Company recorded a revenue reduction of approximately $3.0&#160;million, or 38% of total revenues, due to a decrease in the measure of the proportional cumulative performance.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $2.4&#160;million, decreased net loss by $2.4&#160;million and decreased the Company&#8217;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.&#160;</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">C9ORF72 Research Collaboration and License Agreement</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP-TFs&#160;that bind to and specifically reduce expression of the mutant form of the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;fifteen years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> gene for a period of time.</span></div><div style="text-indent:36pt;margin-top:6pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company concluded the total transaction price under this agreement is $12.0 million, which represents the upfront fee. None of the clinical or regulatory milestones have been included in the transaction price, as all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has identified the performance obligations within this agreement as a license to the technology and on-going research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the on-going services, over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $4.2&#160;million and $8.0&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"/><td style="width:45.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Recognition of upfront fee related to Pfizer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;agreement</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,785&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">C9ORF72 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $3.0&#160;million, decreased net loss by $3.0&#160;million and decreased the Company&#8217;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.&#160;</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sanofi Genzyme</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. In addition, the Company is also eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">period and as uncertain events are resolved or other changes in circumstances occur. None of the clinical or regulatory milestones have been included in the transaction price.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of June&#160;30, 2020 and December&#160;31, 2019, the Company had deferred revenue of $2.3&#160;million and $1.7&#160;million, respectively, related to this agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019, the Company achieved a $6.0&#160;million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The Company recognized on a cumulative basis approximately $5.6&#160;million as of June&#160;30, 2020 attributed to this milestone as revenue and a revenue reversal of $0.1&#160;million related to a change in scope was recognized during the six months ended June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the Company achieved a $7.5&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The Company recognized on a cumulative basis approximately $7.0&#160;million as of June&#160;30, 2020 attributed to this milestone as revenue and a revenue reversal of $0.1&#160;million related to a change in scope was recognized during the six months ended June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"/><td style="width:45.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(349)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,654&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,158&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(235)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. This adjustment decreased revenue by $2.2&#160;million, increased net loss by $2.2&#160;million and increased the Company&#8217;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">California Institute for Regenerative Medicine</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of June&#160;30, 2020, the Company had received $5.2&#160;million under the award.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of June&#160;30, 2020 and December&#160;31, 2019, $6.1&#160;million and $5.7&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839167400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo&#8217;s history of losses. Accordingly, the Company&#8217;s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 27, 2020, the President signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package that includes changes to the US tax code including but not limited to, (1) modifications to the calculation of interest deductibility in 2019 and 2020; (2) changes to rules related to the uses and limitations of net operating loss carryforwards created in 2018-2020 and (3) technical corrections for qualified improvement property. The CARES Act did not have a material impact on the Company's Condensed Consolidated Statements of Operations for the six months ended June&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839330488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 45,600 square feet of research and office space in Richmond, California pursuant to leases that expire in August 2026. In addition, the Company leases approximately 20,800 square feet of research and office space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl81NS9mcmFnOmUwN2JhYzdhNDMzZDRkOGM4ODY1M2FkNTQ0YmE2OWU1L3RleHRyZWdpb246ZTA3YmFjN2E0MzNkNGQ4Yzg4NjUzYWQ1NDRiYTY5ZTVfNjY2_e5a325f2-0b18-490c-80b9-c74fd88bf207">five</span> to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the three and six months ended June&#160;30, 2020, the Company incurred $2.6&#160;million and $5.1&#160;million of lease costs in relation to these operating leases. These lease costs were included in operating expenses in the Condensed Consolidated Statements of Operations. Variable lease expense was $0.5&#160;million and $1.0&#160;million for the three and six months ended June&#160;30, 2020 and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June&#160;30, 2020 was $3.1&#160;million and was included in net cash used in operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flow.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ending December 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,717&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,356)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reported as of June 30, 2020:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,376&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities - long-term</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the weighted-average remaining lease term is 8.3 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#8217;s operating leases.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not have any financing leases.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contractual Commitments</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, the Company has manufacturing obligations that include a fee of $3.2&#160;million for dedicated capacity pursuant to the Development and Manufacturing Services Agreement with Brammer Bio MA, now a Thermo Fisher Scientific Inc. subsidiary ("Brammer"). The Company also has an Option Agreement ("Option") with Brammer, entered in April 2019, whereby Brammer granted the Company an option to secure dedicated capacity for manufacturing in Brammer&#8217;s facilities. The Company paid $3.0&#160;million for the Option, which expires on December 31, 2021. In addition, the Company agreed to pay Brammer $2.0&#160;million, $1.0&#160;million of which has been paid, to assist it in establishing its manufacturing capabilities in Brisbane, California, which may increase Sangamo's contractual commitments in the future. Furthermore, the Company has non-cancelable contractual commitments under manufacturing-related supplier arrangements with Brammer, which requires minimum purchase commitments totaling approximately $2.5&#160;million through December 2021, $0.5&#160;million of which was paid upon execution of the agreement.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, the Company entered into an amendment to an existing lease to acquire approximately 8,500 square feet of research and office space in Richmond, California that expire in August 2026. Total lease payment over the life of this lease under this amendment are approximately $1.6&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The commencement date of this lease was determined to be in the third quarter of 2020, therefore the lease is not included in the Company&#8217;s operating lease right-of-use asset or operating lease liabilities as of June 30, 2020. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company also has $1.2&#160;million of license obligations related to its intellectual property.</span></div><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingencies</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo is not party to any material pending legal proceedings or contingencies. From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839006424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATIONThe following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.534%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.362%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.362%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.362%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.365%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,578&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,763&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,967&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,867&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839354568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Common Stock</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the collaboration agreement with BIMA described in Note 5 of these Condensed Consolidated Financial Statements, the Company also entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase the Biogen Shares at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million. The Company closed the sale of the Biogen Shares on April 8, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 12.7&#160;million shares of its common stock at a public offering price of $11.50 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $136.3&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988843867624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</a></td>
<td class="text">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On July 20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#8217;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired 13,519,036 ordinary shares of Sangamo France (&#8220;Ordinary Shares&#8221;) as part of a block transaction that closed on October 1, 2018 (the &#8220;Acquisition Date&#8221;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire 11,528,635 Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November 23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned 98.2% of the Ordinary Shares as of December 31, 2018 (or 25,047,671 Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;). In June 2019, Sangamo France became a soci&#233;t&#233; par actions simplifi&#233;e (&#8220;S.A.S.&#8221;) and was renamed from &#8220;TxCell&#8221; to &#8220;Sangamo Therapeutics France.&#8221; During 2019, the Company acquired approximately 111,000 vested free shares, increasing its ownership of the Ordinary Shares from 98.2% to 98.7%. During the three months ended June&#160;30, 2020, the Company acquired approximately 117,000 vested free shares, including 80,000 from a former executive of Sangamo France who is now an executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $0.2&#160;million of cash, increasing its ownership of the Ordinary Shares to 99.1% as June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $0.2 million. See &#8220;Note 2 &#8212; Fair Value Measurements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">-Free Shares Asset</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221; for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $0.2&#160;million as of June&#160;30, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Combinations, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in exchange for total consideration of approximately $45.9&#160;million at the Acquisition Date. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no goodwill impairments during the six months ended June&#160;30, 2020 or during 2019 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Non-Controlling Interest</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the remaining non-controlling was determined based on the number of outstanding shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the Acquisition Date. The non-controlling interest is presented as a component of stockholders' equity on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-controlling interest as of June&#160;30, 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of additional shares acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(339)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(251)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839344360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTSOn July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. The collaboration became immediately effective upon execution of the agreement. Under the agreement, the Company granted to Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its ZFP-TFs targeted to three undisclosed genes that are associated with neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. Over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk1NA_938ff3c2-f0c1-40b0-bd71-520363c2dffa">three</span>-year collaboration period, which may be extended by Novartis for up to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1OWU1Mjk0NDVhMTRhMTBhYjE4ZjdkN2ZkOTViZDBmL3NlYzphNTllNTI5NDQ1YTE0YTEwYWIxOGY3ZDdmZDk1YmQwZl82Ny9mcmFnOmY0MTE0ZjIzOWM4NTRkNzQ5NTY5ZmY1NjczYzQ1NjIxL3RleHRyZWdpb246ZjQxMTRmMjM5Yzg1NGQ3NDk1NjlmZjU2NzNjNDU2MjFfMzI5ODUzNDg5Mjk2Ng_dc93b536-40db-442b-b669-b33786af281b">two</span> additional years, the Company will perform early research activities for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, investigational new drug-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company's proprietary AAVs for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. Under the agreement, Novartis will pay the Company a $75.0&#160;million upfront license fee payment no later than August 27, 2020. In addition, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988847692408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020. The Condensed Consolidated Balance Sheet data at December&#160;31, 2019 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 (the &#8220;2019 Annual Report&#8221;) as filed with the SEC on February&#160;28, 2020.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company's Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2019, included in the 2019 Annual Report.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.982%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.503%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2020, the Company had not incurred any losses related to these receivables.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company&#8217;s development programs. Contract funds are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-indent:9pt;padding-left:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Combinations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible AssetsGoodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their </span></div>estimated fair values. The free shares asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashSangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Marketable Securities</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in Accumulated Other Comprehensive Income (Loss) (&#8220;AOCI&#8221;) within stockholders' equity.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in other income (expense) within the accompanying Condensed Consolidated Statements of Operations. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the estimated fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentrations of Risk</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an IND application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Translation</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-indent:27pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Adopted Accounting Pronouncements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Collaborative Arrangements</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASC Topic 808&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASC Topic 808 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Goodwill Impairment Testing</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2017-04&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December&#160;15, 2019. ASU 2017-04 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Credit Losses</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Income Taxes</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes &#8211; Simplifying the Accounting for Income Taxes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Topic 740)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on Company's Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840720136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.982%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.503%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kite Pharma, Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pfizer</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sanofi</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%;"><tr><td style="width:1.0%;"/><td style="width:52.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.191%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.465%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.046%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.615%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">468,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">172,722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%;"><tr><td style="width:1.0%;"/><td style="width:52.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.191%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.465%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.046%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.615%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">467,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,418&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Non-current restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">468,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">172,722&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">143,918&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840545032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:0.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:23.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Commercial paper securities </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">306,877&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free shares asset</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%;"><tr><td style="width:1.0%;"/><td style="width:72.100%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.230%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.232%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Free Shares valuation assumptions:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.77&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.68&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8364;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD / EUR Exchange Rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Correlation Sangamo and Sangamo France Stock Prices</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo Stock Price (USD) Volatility Estimate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.8%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sangamo France Stock Price (EUR) Volatility Estimate</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.8%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.5%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD / EUR Exchange Rate Volatility Estimate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.5%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Free Rate and Cost of Debt by Expected Exercise Date</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840732584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.710%;"><tr><td style="width:1.0%;"/><td style="width:59.191%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.156%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.720%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.866%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.163%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,796&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,424&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">420&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">176&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">196,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">312,824&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">979&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">313,803&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,496&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,998&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,494&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">155,368&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94,905&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,411&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,493&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,373&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair value of investments available-for-sale</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%;"><tr><td style="width:1.0%;"/><td style="width:72.165%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.046%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.339%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturing after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,832&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197,410&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">303,878&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988844145528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"/><td style="width:45.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,434&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company paid $7.0&#160;million for financial advisory fees during the quarter ended June&#160;30, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the upfront license fee of $125.0&#160;million and 2% of the excess consideration from the stock purchase of $79.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Assets and </span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Deferred Costs</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds.</span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:45.844%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.502%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of license and stand-ready fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,833&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,187&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,422&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,372&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.712%;"><tr><td style="width:1.0%;"/><td style="width:45.694%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.520%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.520%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.536%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.520%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.538%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Pfizer SB-525 agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee and research services</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">326&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,516&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">429&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,595&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"/><td style="width:45.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Recognition of upfront fee related to Pfizer </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">C9ORF72</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;agreement</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,425&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">455&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,785&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues recognized under the agreement for the three and six months ended June&#160;30, 2020 and 2019 were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.137%;"><tr><td style="width:1.0%;"/><td style="width:45.391%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.608%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.524%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of upfront fee</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">380&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">901&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(349)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,654&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,155&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,158&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,355&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Milestone achievement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(235)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,059&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,009&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839175608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ending December 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,717&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,556&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,694&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Thereafter</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total lease payments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Imputed interest</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12,356)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reported as of June 30, 2020:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed    Consolidated Balance Sheet)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,376&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities - long-term</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,234&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,610&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840744136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2020 and 2019 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.534%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.362%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.362%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.362%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.805%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.365%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,578&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,763&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,417&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,061&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,186&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,967&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,329&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:top;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,867&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840772392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock', window );">Summary of Non-controlling Interest</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-controlling interest as of June&#160;30, 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of additional shares acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(339)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to non-controlling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at June 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(251)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988841558408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 34,629<span></span>
</td>
<td class="nump">$ 25,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Decrease in net loss</a></td>
<td class="nump">35,965<span></span>
</td>
<td class="nump">30,356<span></span>
</td>
<td class="nump">78,939<span></span>
</td>
<td class="nump">72,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">467,443<span></span>
</td>
<td class="nump">169,222<span></span>
</td>
<td class="nump">467,443<span></span>
</td>
<td class="nump">169,222<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">468,943<span></span>
</td>
<td class="nump">172,722<span></span>
</td>
<td class="nump">468,943<span></span>
</td>
<td class="nump">172,722<span></span>
</td>
<td class="nump">$ 81,928<span></span>
</td>
<td class="nump">$ 143,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="nump">$ 8,178<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,178<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Customer Concentration Risk | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="nump">$ 7,422<span></span>
</td>
<td class="nump">$ 9,060<span></span>
</td>
<td class="nump">$ 14,641<span></span>
</td>
<td class="nump">$ 17,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Customer Concentration Risk | Revenue from Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Customer Concentration Risk | Revenue from Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 3,059<span></span>
</td>
<td class="nump">$ 2,291<span></span>
</td>
<td class="nump">$ 5,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Customer Concentration Risk | Revenue from Contract with Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember', window );">Change in Collaboration Agreement Scope | Collaboration Agreement | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Decrease in net loss</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember', window );">Change in Collaboration Agreement Scope | Collaboration Agreement | Pfizer and Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Decrease in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerAndSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerAndSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988842174184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 197,410<span></span>
</td>
<td class="nump">$ 303,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">90,179<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">81,844<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">25,387<span></span>
</td>
<td class="nump">53,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">33,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">197,410<span></span>
</td>
<td class="nump">303,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">313,803<span></span>
</td>
<td class="nump">337,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">90,179<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">81,844<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">25,387<span></span>
</td>
<td class="nump">53,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">197,410<span></span>
</td>
<td class="nump">303,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">197,410<span></span>
</td>
<td class="nump">306,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">90,179<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">81,844<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">25,387<span></span>
</td>
<td class="nump">53,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840849160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Narrative (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Estimated fair value liability of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase', window );">Number of free shares outstanding subject to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionSharesAcquiredValue', window );">Value of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share Purchase Agreement and Tender Offer Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember', window );">Tx Cell S A [Member] | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability', window );">Increase in fair value of the free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition estimated fair value liabilities of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionSharesAcquiredValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Shares Acquired, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionSharesAcquiredValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in fair value of free shares asset and liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_TxCellSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988843210856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sangamo Stock Price (USD) (in dollars per share)</a></td>
<td class="nump">$ 8.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember', window );">Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">USD / EUR Exchange Rate</a></td>
<td class="nump">0.89<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">73.8<span></span>
</td>
<td class="nump">73.8<span></span>
</td>
<td class="nump">72.5<span></span>
</td>
<td class="nump">72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France Stock Price (EUR) (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France Stock Price (EUR) (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock Price Correlation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimated Correlation Sangamo and Sangamo France Stock Prices</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">73.8<span></span>
</td>
<td class="nump">73.8<span></span>
</td>
<td class="nump">72.5<span></span>
</td>
<td class="nump">72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988844101432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporarily impaired investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988841744184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 467,443<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
<td class="nump">$ 169,222<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">196,431<span></span>
</td>
<td class="nump">303,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">197,410<span></span>
</td>
<td class="nump">303,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, Amortized Cost</a></td>
<td class="nump">312,824<span></span>
</td>
<td class="nump">337,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">313,803<span></span>
</td>
<td class="nump">337,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">116,393<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">89,796<span></span>
</td>
<td class="nump">155,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">90,179<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">81,424<span></span>
</td>
<td class="nump">94,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">81,844<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">25,211<span></span>
</td>
<td class="nump">53,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">$ 25,387<span></span>
</td>
<td class="nump">$ 53,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988843815048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing in one year or less</a></td>
<td class="nump">$ 197,410<span></span>
</td>
<td class="nump">$ 282,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Maturing after one year through five years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,832<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 197,410<span></span>
</td>
<td class="nump">$ 303,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839319032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options and RSUs outstanding (in shares)</a></td>
<td class="nump">14,964,567<span></span>
</td>
<td class="nump">10,155,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988822007752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">16 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>product_target</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>product_target</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product </div>
<div>option</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace', window );">Maximum number of product targets replaced | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Recognized portion of equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage', window );">Revenue reduction due to decrease in measure of proportional cumulative performance, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,553,000<span></span>
</td>
<td class="nump">$ 17,548,000<span></span>
</td>
<td class="nump">$ 34,629,000<span></span>
</td>
<td class="nump">25,619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California Institute For Regenerative Medicine Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California Institute For Regenerative Medicine Agreement | Research Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,178,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,178,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,744,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,744,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargets', window );">Number of product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected', window );">Number of product targets selected | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets', window );">Number of additional product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementTargetSelectionPeriod', window );">Target selection period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Portion of contract asset recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementResearchPeriod', window );">Research period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and License Agreement | Pre-approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and License Agreement | Sales-based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod', window );">Standstill restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage', window );">Standstill restriction, ownership threshold percentage ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld', window );">Agreement restriction, percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod', window );">Voting provisions expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage', window );">Voting provisions, ownership threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction', window );">Excess consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Recognized portion of equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementEquityIssued', window );">Collaboration agreement, equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,422,000<span></span>
</td>
<td class="nump">9,060,000<span></span>
</td>
<td class="nump">14,641,000<span></span>
</td>
<td class="nump">17,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,227,000<span></span>
</td>
<td class="nump">6,227,000<span></span>
</td>
<td class="nump">$ 12,454,000<span></span>
</td>
<td class="nump">12,386,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm', window );">Number of options to extend initial research term | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExtendedResearchTermOfAgreement', window );">Extended research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate upfront fee</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan', window );">Collaborative arrangement estimated reimbursable service costs for new research plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">39,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">3,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">1,260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration and License Agreement | Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned', window );">Contract to perform for others, cumulative compensation earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Revenue reduction due to decrease in measure of proportional cumulative performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue', window );">Increase (decrease) in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss', window );">Increase (decrease) in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare', window );">Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,425,000<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="nump">3,785,000<span></span>
</td>
<td class="nump">1,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | SB-525 and Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Maximum | SB-525 and Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Maximum | SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Maximum | Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones | Maximum | SB-525 and Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of First Commercial Sale Milestones | Maximum | SB-525 and Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Achievement of Commercial Milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementResearchServiceFees', window );">Research Service Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,000<span></span>
</td>
<td class="nump">4,635,000<span></span>
</td>
<td class="nump">$ 3,612,000<span></span>
</td>
<td class="nump">1,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,000<span></span>
</td>
<td class="nump">4,635,000<span></span>
</td>
<td class="nump">$ 2,516,000<span></span>
</td>
<td class="nump">1,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | SB-525 and Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,096,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Amended Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Amended Collaboration And License Agreement | SB-525 and Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue', window );">Increase (decrease) in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss', window );">Increase (decrease) in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare', window );">Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792,000<span></span>
</td>
<td class="nump">3,059,000<span></span>
</td>
<td class="nump">$ 2,291,000<span></span>
</td>
<td class="nump">5,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="nump">901,000<span></span>
</td>
<td class="num">(349,000)<span></span>
</td>
<td class="nump">1,654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(235,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and License Agreement | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMilestoneRevenueReversal', window );">Milestone revenue reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and License Agreement | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and License Agreement | ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMilestoneRevenueReversal', window );">Milestone revenue reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and License Agreement | Achievement Of Specified Clinical Development And Regulatory Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and License Agreement | Achievement of Specified Sales Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Additional Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfAdditionalProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementTargetSelectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Target Selection Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementTargetSelectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cumulative Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementCumulativeMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Increase (Decrease) In Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Number Of Product Targets To Replace</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMilestoneRevenueReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Revenue Reversal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMilestoneRevenueReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Net Income (Loss) Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNetIncomeLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets Selected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementResearchServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Service Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementResearchServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExtendedResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended Research Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExtendedResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GrantFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfOptionsToExtendInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Excess Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_AmendedCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_AmendedCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988840853592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 34,629<span></span>
</td>
<td class="nump">$ 25,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8,178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,744<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,744<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,422<span></span>
</td>
<td class="nump">9,060<span></span>
</td>
<td class="nump">14,641<span></span>
</td>
<td class="nump">17,372<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,227<span></span>
</td>
<td class="nump">6,227<span></span>
</td>
<td class="nump">12,454<span></span>
</td>
<td class="nump">12,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma Inc | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">4,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">4,635<span></span>
</td>
<td class="nump">3,612<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">4,635<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">3,785<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">5,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (235)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988844843976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities included net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,610<span></span>
</td>
<td class="nump">$ 42,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LicenseObligations', window );">License obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapacityMember', window );">Manufacturing Capacity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PaymentsForOtherCommitment', window );">Payments for other commitment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingObligationsMember', window );">Manufacturing Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PaymentsForOtherCommitment', window );">Payments for other commitment</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=sgmo_NonCancelableContractualCommitmentMember', window );">Non-cancelable Contractual Commitment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContractualObligationPaidUponExecution', window );">Contractual obligation paid upon execution</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember', window );">Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lease not yet commenced, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate', window );">Lease not yet commenced, area of real estate | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember', window );">Office and Laboratory | Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,700<span></span>
</td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember', window );">Operating Lease One | Office and Laboratory | Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember', window );">Operating Lease One | Research and Office Space | Valbonne, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,800<span></span>
</td>
<td class="nump">20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractualObligationPaidUponExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation Paid Upon Execution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContractualObligationPaidUponExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Real Estate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LicenseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LicenseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PaymentsForOtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Other Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PaymentsForOtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_ManufacturingObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_NonCancelableContractualCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_NonCancelableContractualCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988848099208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Summary of Maturities of Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Six months ending December 31, 2020</a></td>
<td class="nump">$ 2,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">6,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">6,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">6,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">6,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">26,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">54,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(12,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">42,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheet)</a></td>
<td class="nump">3,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">39,234<span></span>
</td>
<td class="nump">$ 41,192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 42,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988847867272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,764<span></span>
</td>
<td class="nump">$ 4,867<span></span>
</td>
<td class="nump">$ 12,384<span></span>
</td>
<td class="nump">$ 9,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,578<span></span>
</td>
<td class="nump">2,763<span></span>
</td>
<td class="nump">6,417<span></span>
</td>
<td class="nump">5,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="nump">$ 2,104<span></span>
</td>
<td class="nump">$ 5,967<span></span>
</td>
<td class="nump">$ 4,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988845037784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock issued (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988842145528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire', window );">Percentage of equity interests agreed to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Estimated fair value liability of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares', window );">Estimated fair value asset of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share Purchase Agreement and Tender Offer Agreement | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share Purchase Agreement and Tender Offer Agreement | Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Estimated fair value liability of free shares</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition estimated fair value assets of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition estimated fair value liabilities of free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, percentage of equity interests agreed to acquire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988843770120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Fair value of additional shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to non-controlling interest</a></td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">$ (125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at June 30, 2020</a></td>
<td class="num">$ (251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988843834872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Additional Information (Detail) - Subsequent Event - Novartis - Collaboration And License Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2020</div></th>
<th class="th"><div>Aug. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementPeriodOfCollaboration', window );">Period of collaboration</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration', window );">Extended period of collaboration</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum | Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 420.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum | Achievement of Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Extended Period Of Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementPeriodOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Period Of Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementPeriodOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139988839252568">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">us-gaap:AccountingStandardsUpdate201801Member<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "+@P51V+'[TS\%  !C%0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)68;V_J-A3&7]]]"@OMQ2:5QG& TBN*%"B]E^VVI:5WT]VT%R8Q$#6QF>-
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MOX!O3>]W]/8G1FWR3;&%,D8E^>%:\%!H^P#<7RIECB?V!<6^ZO _4$L#!!0
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M0[P'U7=4<13LYBA'J"<,G!I0JO&*RWVH_C&V(@+$?:YPK,@BIN*GH999+O>
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MKVYNZF+5_K+Q0U'7Q;*]7(A8)J(&(+^_+XKZZTWS8\GM3XC/_@]02P,$%
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ME&5%]Z(FJ>+$F*G.O31VD.AE[^)+BH);Q>&< AY\;$-R(5N._+%R<+Z=-.0
MDPIW2"?3'I+T7*K?Q\9CU$"'(@LAS2>F1[TZ22CG>? ;<V/C))XJJB[UN"5B
MX(:JM)(/!=ZQ&0CE?X'.MWMY>NW1')D#;?CQ('M"+49)N>-X;(0P-=>TDCM<
M.TC[)!+_(OG91YDQU4"#8B%+VUS$5=3N@4I"JC0O5+='&O4?1F8H@[Y[_Z=R
MLWT>BZ&^Q7&6=26P2?3ZI-W=TG#KV;'R46'9K4ROU;=TK_,4O4RDNDL:4'P?
MX!A%7(C-NWH#AQ[N4H?BX."1T0(/;2"TH ZH+H3W$/,.&-271I@65HML@302
MV$I\B;T48S)?0L#((;Y1*77\#S8ML?;S+1#[>EG RJIT&GVD:$U:3_R6QCTH
MGMK0W'F=5(1?_-R[Y C3_'"$.(L?6_Q'Y+J7=H&DI5R[7!(@F"3!8N+9J\B/
M38D7NRH5.^TOEU8M24#M1FGUGW01WN\E.1#MJH:Z.!=TA,>C''MD&I]QC;&/
M3RQV:93Q3V*;LY93FSM.@=79&!-DKU'6@-=!VAY]#W(.2U17,'6>UVG37MQC
M)[/7SDK@1!:3UO2O$\L1ANMO!YJ[/#>(3B5SL3=#LJNIO>0U+I^?\>L=-:SC
M8[Y!<Q@LJJ2?YP2U;=/\>\)Z!U6I)+><-*ZV:MO2 9P0D&2)U^71%>"(W<'Z
MAW<3;SVD<5E-<.-;&<J-.-<VE^,%LS&T'N&^*U5]B0P/O" /X'AY;B+J8Z9_
MCQ5BN)M3KQ>[M.7N*R@-BFSR^*IG^[#*661$FWV>X:H[35!W0ABQ(W(\0+*E
MF&AN^AL<;-$'LM3(I9(D%8WG<Y803%B$:SGS4?DC7PA-8O8MZP24'0K*]-"5
MF1)XI851CISC3/D^(D-+H':>'G!M6YMM?QD1R&?^OH@_)'CE'%H(@X^+OW&"
M1TW4SS@B\3._KIJ0?U$FX5]2]P+%0=/UDH2 28N]Y[>#,LIFC @+UD?"JUAZ
MMS3'O:8>?7ZVX0,)/B&KYR?<L%H9UT>O+V^[%)H+-&FK.NRF9CF.N0V$OT@'
M>&A75G02OP5-.==3MQ3ZQ,K"B*PA.2&K>GLLG02HX$LLCT <)R26B%FS]+YV
M3@7C.CB3\5@X%L:<#.:G.2DXJ]5RI$,U-9FK1R9!4"$!: Y"(GG2?6MY1UI,
MN5/7B]\$SGU6/W>LN+"B*PMP7\O^$LV-^'.:RU]CR;_QDK]$]T4\]+'T,3NF
MYZ,H#AYD>'Y&E,G$!RU&)UIFT=N/467RX[;<Q7 ('==FY ;$5$J*+&UT$_7A
MUJBCT)!P N>7Z2,TG9$C)XDYCXH[45>BH9?(D'#[E!.$WO> [3+"2]!"3DJ-
M,V]E<T1FJH?[#">:CQK8A28SV4M626?^'V>=#^4PN:MO$A44:_)1(OQ;O!H=
M)7JO)QEH G[NVWL]OSL^^[NN5^MF1ZQ#;R^T252(''TD=E)L5Z_JED^T>%P+
MVR8-=.BSX ,CHFM"1.%;1>=FCT=D"Y/LX]G,\QCRA"S&;(<69L,I8G*V=\$3
M\)R5'_LA1MNB'S/!"*^E\XM+2I#WO72\:OX&_/^'T^-'L4\ON,%"= 4G=.4T
MW$89O&*]V:!8FW*AB6J&_ 5I1W*L#.A&(;[MVKI$'1]*EV2-&,W;H5L.BG6C
MO81#&DF$\C6'E5U>CG&3$WW-4<O\N"@3]36K;NYZ#=G'XB[/:0='NW#WOHO:
M+3L(.?WK85;Y0_'P\9/9PX</Z-/3D]G#LZ?TX?3QL]G9V1D^/:3?3I\6%YKM
M'V//IRM##G-V<G(2OJ'OK#KPYNGL$8U,_WW _UY\/>G*WP'IP,?3V3/!Q^GL
MF>#CR=GLB>+CP>P9X2/1E<GM!D%3-*3Z:FY!J?F$YX&SB>$4VA$Q\Q%Z_G2?
M<D99!#8JEK*?U+S1P_['8/%(A5KZ:+@[8(Z^"09 GW$G@LAOLT'/HQ@[SO*K
MAQ4"[:'M#(X TLPX'\97@%"HH.=-)!N:%N[.*ZUST=>W[&G!;>[,&AV:Y*U>
MMESAO?LSO7HO-IV^O;B,=YP(-=,S:7_6$V[3#3(9FF"QACE7R;AU7:Q$7:7F
M7RQ*'E6$K*+C]NXXF)1QMS)<7/2%\IGOK%B8BMLME/ERWV1,P>"_2Z.I!!WT
M/Y2J@AO%9W*.<*#]B'@4NA!I=/6^)AF U;"R%IM968>SWYD+E2=Z8G'6]YM)
M)1D'#<F?^(2SQ'RN'LZM'L>5O*?3ZU3BHG.# I4TY[624)90EUU@E+$\ZT5?
MSJ]JT,4C-\C(]1.<SO1^MW4AAHZH]*DS];4]PY1IZG;4LF('<BS):+NXGN_3
MXKQSE[.6')/91Q&)$Y<$>HX?D/&E60(^(H2!8KGGN^<T3U%[EN,6;3P=#AZ1
M\;8WK2]L3+$"=V'Z4Z$YM:/[XK>BYEI%V'R&R\#9Y7:7'<T^3T?*N! 1JUV/
MC'@@]IC+L2WY3AN*ES:H#=5L02(72G2/AF-1)B-4>?ESZ<F43#C8[&4[U51>
M4%A6PT%12YKYN_>OF91X[4/.59$*_BPB@E3;J6L6VV=#"ZB->NF06LKZ.,E>
MKN1 $;.];S:2.GAL@IK$58A]<O+L=_U[(@F+Q6"G0CHV'/-I3=G)C0GDA#MI
MMLI$V<2@;E^C]SX7D!RAAC$8JP*Y-V<D[6Y8+G&<5;:-AM6;P-N'%!0GIQ,E
M!<=7#=^>P<,.]ZWW*&Y*F2S<XQ%/F0K'S5 :\-D\.3VA30*+I+03JIJC!F;?
M/G(1JK+^T,A[5%&GO:G9+5<F)+'#= RKN3D](=_LHJW-:Q%E4BGV;GE2WU7=
MJZRI7)&5.+0P\BT^^;B7ZYJ3=[Q]L5].*XJ:/Y?$$>XJXU)0N%0)\:-+6N7K
M5N.](L1[(X3,4;;@(R'H(* -[A_>(%@(V;5;@Y]H$NG6T 9/D%DPPO7+?H?F
M##1M!5)[HJ5!9$(W>MNTVO\UJ@FAUU*<@8C_$:;<H3*\8I\S0OZD+-\ Z<_(
MYDQ2]X->$*2>8JWX/^#29WX;Q_IN@'*$[Y0\RIDEL(;])M:XT"Y*[\+)BNC2
M@7*G<#@0,\4@[:=AE[!N]V[R0.Y7T^:%O\T#$@N)&K;;IJ:MH/%5RL?)C]C?
M:&$EKD+&'4YD,]O2EW/:XO+-2Z0S&B_ZH^ND^!:#UU;3(2]Q0O5\ 8YT7@)5
M44K.?Y;5"8D9RYUTA'+^VIMW+:;'9O^2S[_ZC:1-N^SP:)?73FY+TY[2D'#<
MNW,BX(-;;5A%=L/67RTF/CG\N<G&D:'U]W_P/#L>G]]0$@_<2E8NOZV :/,S
M,@]YH3VH7RVEI.T07"B1K@TQ")JZ*+E'Q&RE&LTM*V1 1R<YLHGB%&U^),KG
M81.7?.V;X-'<+=W*7"X70SAZF8P6]X#;Y1'RNSZ\>O_V8W+X70M@WGF;HDU8
M#+,0D-SPT4B>DX',DS=LY=D^\M<T&WG[.DEWG2]@RQ3)^;':A1LBPHI*NSSO
MF;>&J"3+=)S5\N=[.:^6%J;V_5A_0B^')11FXZX)X6\_9D6:=-Z)DS@YAK0#
M$\%&N-80>>E\7;Z5@.R198=0&OXG]B7.GIX)T;/),,%25V-]6_.]-GJ6.C]K
MP*E3U3!<P#AW/H+!U2#2)1CM<4['1B2)!"16)(?V4TL!2RZ]W!LI@7$EB$'Y
MS7:=G-7J]DB37>T8K@+Z G'K_<-H>R2.+;PYML4VW@)>4M4OV[W&XGACFR_J
M^:W[>A\4K%X#-8(=D1*OQ8I'*BC9M7%C?I3C20VR+9WZJAH]>4YER=1$;>E/
M-+EZ0WCLXIUSIKVN.ZE8'PI81A[$+,P<X)II!^58@$-Z/E[DAC!&PX$(ON;N
M0_LVIUA(75>#NDBWLXT2+HJFRSIH;>S#94>"CQOX'AN38%?/+F2=8+MP"",C
M*)(AYC.RY4[DEONQK>^Q><]5?0DHP];W-&!P.Z,,I1WGAX[V3.JB/:>S"2$X
M/%\GMR?Y=SA(L^U1X$3OC<0#ZG+@J-1;YBJ[A=E70+GC/KE*93;J4@MZ[. Z
M<F1(7*;1PXG3SYR1R3=4LN5GZYB<"5&?Q(M4 ,1?;Q=8-UZY%DHPZ,FPQN47
MS;9*T[0'1I.C([.XYT >X"(;^(8OP33DC&F6O=I)YU(3+QA>#FT5;I/0,0=:
M*Y<Z5WJUIQP/\<$,WGHU=/;8U^C'740+OL,YW.GI9]25O:'U5T(++=C[7$"2
MN[0CT?B[?K7!7%"C]XH6SM_ZFN @[*]/<)#VH8V;*<O(,GQ7PMN+RZG\L;]>
MVF>10R-YUJ]^T%6=1.L(#7';S%/P2)&?7.VA :DJ.6>UD!,:;)XD@4'/8I(F
MNW-53^1,(TK;W/;R%!FVOB(-<;@=\MMR7N@RQ[UN"\ON?'J_&YD9^ESI>Q>Q
M/?O:%.=IZ_%E6[PA)<=5K+.3TZ?B1[P^OWJAMQY.7XSQ<<L>0+S-(GJ^F.4(
M$]VRZMUX'O?IR=-[WQ47Q-/U<N?I= D,*KI]LT(8SF@-AWDG;M2@,1X:G_.I
M>/YP85?0$"GM_4))M[;S9Y/3G:0A1KR,5;6RAE72NIV=.HY=U#*PPSH[O2I>
M3S&/4LO9EN!;Z;DY.$1R'I1E*:G[YNV.<M];QKQ?V$_2X:[G%K)[3*IPCTF]
MG-P*FXMX*%O,,312!(%4XM5'SR6<%6$QY;Y%&#1_07*]T?;E5JY+R_L10*Y5
MW;)G*5=*A6+LZ2.YJY8O\?M+V?+%SZ=39P]*+SD1(#T]N%!3!&670$MQ+F]Q
M?*)3/"T(]A=O+IZ^HCET8E[&U/,'(UTLEW$7!,>3"0DE"-^0J<'3HY.'LZ01
MTTF=^/1YWNLI)<.[PEL/'IV0!%YQ!!)%$*MC^U.0)6+O%\VOL$'^ NDWL4 R
M<ZVMU,G1QE'@%EKE*+KW5UZ+VC';XBS:C3 NR=.CA3!P%@"*_=N3P[E:,FZ1
MTF" EM=,<<)VN%0@)N='76/H.39:38[YU9D4]:P^/M1O5O=I6_KD%GQJG\4U
M24]IZ\Y(@D1BOD%.TC6UI5J.]XW3S1NCW6N2$I<_9;'DJX9C'(C!4SB/@) 2
MDLN<OE%  >!! 67H?S<!O9"@[&>Q^/'&M]/'M\KCXZ/3![-DRLLDI^TE,Y_:
M"^79XWMC.<-DR5]NB#]R]B"<QTMQSAU>LX)3!)[+?;=(*!VFE4=I"?.)_'B#
MB!_K3V:5FG&3.]KD?(\\.RX^AG-+J1Z8)69+F2R4W!AL+B"%RWO3B'\*4BZ:
MIBCX_0R)Y(TU6^Q9TC?7;?B*,*YR];F4=K:LUMKCX1T.: (?N+XJ^6RPY^2:
M#QCSY9>+;Y8,1L%\][50'10BGN=W$R+M2OE0?A89"IB6J^5OD:-G1Z=GL_Q]
M+SYCPW6>GW/.WAD)%&;-#5<P6F25[#57[#W!?'9(4V^COP23+R,R_.3AR3W/
MBM;W7)2?0[+".YP3]XXG\?LL/;DM68G8RHL[I<UF$R_W;9,_:Q"OD_21U5XI
M2.4CQ$6\"< X.BV^XRJS/6*O7W4 *PDU;7JF(U$"&39]+_^DH?IFB<0?5MD#
MWL5> ER?NZQ=%2[Y9Q$TN;A]@ZPE;T:) ^\<%",\_-W$:.HO@]U/_E@;.=XK
M_I-T3MQS^;MMX=?"_]6[<_EC;W&X_,F\7\INA0"W,4MZ]>3XR:,[4JCP7WJ[
MY3_]-K<]>?G\$5VDIL, >HZ_*.&_8('PMP!__#]02P,$%     @ BX,%4::B
M>KA "@  Z1L  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6R]65MSV[@5
M_BL8-^G8,S(E2K(NMN,9QU:FV=EL72O./G3Z (F0A#5), !H6_WU_0X 4M3%
M3C>=Z8LDD@?G^IT;=?FL]*-9"6'92Y;FYL/1RMKBO-TV\Y7(N(E4(7(\62B=
M<8M+O6R;0@N>N$-9VNYV.H-VQF5^='7I[MWIJTM5VE3FXDXS4V89U^N/(E7/
M'X[BH^K&O5RN+-UH7UT6?"FFPCX4=QI7[9I+(C.1&ZERIL7BP]%U?/ZQ3_2.
MX)L4SZ;QFY$E,Z4>Z>)S\N&H0PJ)5,PM<>#X>A(W(DV)$=3X'G@>U2+I8/-W
MQ?V3LQVVS+@1-RK]729V]>%H=,02L>!E:N_5\]]$L.>,^,U5:MPG>_:TO?X1
MFY?&JBP<A@:9S/TW?PE^:!P8=5XYT T'NDYO+\AI><LMO[K4ZIEIH@8W^N%,
M=:>AG,PI*%.K\53BG+WZ=/WYGGV[_O5APKY,KJ</]Y,OD]^^3B_;%LR)I#T/
MC#YZ1MU7& W8%Y7;E6&3/!')]ODVE*HUZU::?>R^R?"7,H]8K]-BW4ZW\P:_
M7FUIS_'KO68IEYI]XVDIV*TT\U294@O#_GD],U8#'/]Z0T:_EM%W,OK_NS=_
MBA'[NA+L1F4%S]<L$]R;,!?:(OW80N8\GTN>,FZ,L(;Q/&&IY#.92BM!R"U;
MD!>>G!<H)Y!7\U)KF2\)V]*TF,SG:9G0C3DW*R:^EQ+D(K=XQI^X3/DL%:>H
M!J<&MP%%_2@LW6.&6 5!$&RAZD(+W%]QTM+I%+%/&P6D0?Y8H0%KD;C<2KQ2
M=H5SI^"DV0H?7,]7:U8"5]IQY:5=*4CBE-!L6<H$9D.8TDWS@GLR4MTIE#2B
M;E?P1:$EL9'_=C>@3UZ4H"U)#[C3,R!/-+AR SDI2IDY9[^*)Y&R^)P]Y#SY
M [F*<]]+15]@/0=7696=X*<@&/[ ?1 828[#'1+?4)@EW'J#9()+.>=I"PZ
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M$)56]$P<?[TZ&Y6) R:;"LD1^YRC69=A_$#5KEDG#3(T7)$W>FT%[-"WMR:
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M1PARU8+5=Q[X^5>CY-I;6VL%<">2J0%G:2]#IR@<7((L(!,3E(9(@/JT0PG
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M:G4I;A&;Q&&&=XR![+%#:E4BZ4BQ0H>0TW^+%B-NI#6\I$I$"G 9N@0((OG
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MKR+5 D/V^UD4B5IZG'#P0@WRJN-7I4TS,>IZ;_!D@"9?=4;V12D5S3FAFA#
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M7KBS<[_?W?D^&.ZD>M %HH%]Q84>>84Q]2 (=%9@Q?2YK%'0E[54%3-T5)M
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M9I*J*:PY:5KR,F>&#@M#PKZ:!KF&NQJ5H]'D7#F<*10B,)&#+O=0-9V!MC.
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MW+%.V!O5?\*AGIG#*Y0P_A?ZL#>GC$5GK&J&8+(;+L,_NQ]T. @X2U\)R(>
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M7Q!;PC>Z"&#&Y)(5"KBT7/,4A+0*5DP+51E@2\TY)JDU2%R;@<TX+!7+02V
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M#;O#0<>/P<V-5:7[)C17UJK"76:<86!I ;Y?*"P)]0TIV'PDO/D_4$L#!!0
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M&S\;ON#0!@?>KXRAPR(D&*_,Q5]02P,$%     @ BX,%4:X;2(2='@  /6,
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M K4@JJJ20P%9&T!P''XI4FL0%=9?T%A31A,[R(*APC:QY$E^+H0XDL&(@G@
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M9NAGO]'%>=JK?=D6[\ =T(>6SDX7SQEQO3F_?LGA?#7])9%/6\)*\?,?,4;
M44YPH".SWH\'F)^?/G_P?7$!JF96.R\^E[BQ(@6^%2$\3KL=3C]/?(($GO'4
M^#QA2>.';\L$6YJ*I)\H:6]W_C!WNI(T&(L?Q!+_)=$O][IGQ[1CVSD_V.$\
M.SXZ[H]]C\H1V9(0A<I!0X2.?("65%P@)9_;2KL@^=-$F4Y]93W)D0 YZ)%]
M^*4,'WXQJ\FED&.-I]@9N*"AC"2 I;[^Y*6$DE=D/:B5$5V__TB=::3-NN4O
M^^3'!G&[UJ8E#*Y6\'C\7MCB"7\OC+XW]0_5TL?W%E.'-937G$B0'+>LQ&FC
M#4ZHK0R?[A@?@65,BO;FJU^/F_Y,7FC.O(SEBH^:.THNXRJ CF<3&@H4O@,/
MB'=/3A_/DMY,QZ>#%B_R]D\N,]]GV7KTY!0T\)IBM:B".#LN?XJR1.W]I/DW
M?S#-A%E2=HP\LI&6[^0LZ"C$#0V'RUWX["";';TMSJ(["\\EM1WL(PR2A03%
M/O/)QZG"-FZ DK )II?J0B)V^!6&6- 9]81A*[*6#H28!I]Q(=C*[4/=9*9/
MV^<GE^#+0:2N2191OA(QTB#6F#OH23JG=%KS><AQ5:#1TIO&911;VS5_US2-
MF/'A*9Y'0L (\8<P[ZB@2.!!!27J_S0%O>#P]2T#$51)/ ,&TSX]JH]/3Q:/
M9LF0ETGIP6MF/K17RK.G#\9ZAH,E7\^-%RG/$@XPICQO;*4A.*9DBI=R?PPW
ME)O3:C6]$.HM\9,K_EE_E$U);E*U\4 4WYL7G\)!K]0.S!*W)4(6RK1$-A4=
MR6*,SUY/44J%]I0%?YXCX?2^)/6]2#(^5L@P?W2LS[6TLZK<2%^0!QQH"7R(
M_UK186HOR89.9#?8MU#=63.(!<O=MU)U4(EHG#]-B:23Z:/ZPCH4.,V?]SRB
M1]^=+,YF^?M>?<:.ZSP_&)Z],U(H'#5W7,%I@5>R-]3EX3?,Y]$D23GZ&G<^
M#>OPL\>G#[PH6M^GH[Z$M(X'G!.?ITXR';/TJ#OG;V*CKL,/535-_ YEFWQ:
M5L*T).K=J]B)?H1PC1:!-(Z.U^^H,\&>$.H7&T!&0ER;'/%(C$#&3=_0/^FH
M[JR1^''K/>)=[#_!+SVNC,-2$=(MV%7GZG8'74O>C!J'LG-0C?#FGZ9&4^'H
MP^0O&@#P7M/?;7 ,S_F/&X2KA?_;$.?\%Q'BX_R')7Y1W1KC[EJOX-73^;,G
M][BDXW_I[9;^/L+2]H#RZ<>-5F#R\0&XCU_U];_@!.$O9OST?U!+ P04
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M+[641EMOCSI!&%0-?]#?N]!Z<4BH,_!]?'J#B 1.C"/7BVSD!)3B.W;<OFN
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M3&Q4ECQ):=I_/TI.W!1HBUU"BN9[)$61&>ZD>M %HH&GB@L]\@ICZD$0Z*S
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MW;KJ.Z"JX:\,(_?EP(72T/B6RX3N2U0V@/:W4IJC80GJ&WC\%U!+ P04
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MSEA\SPHAP#]_R//J^4:\1=[^VX#C_P!02P,$%     @ BX,%4?D]SGY7!
M_1$  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULO5A;;]I(%/XK1Z@/
MB=3&'AMSJ0@2#; A:=(H)-F'J@^#/>#9VAXZ'D,B[8_?,\;8L!C'JV[R KZ<
M[YSO7&8^AMY:R)^QSYB"YS"(XO.&K]3RLV'$KL]"&I^))8OPS5S(D"J\E0LC
M7DI&O104!H9EFBTCI#QJ]'OILSO9[XE$!3QB=Q+B) RI?/G" K$^;Y#&]L$]
M7_A*/S#ZO25=L"E3C\L[B7=&[L7C(8MB+B*0;'[>&)#/UY:I :G%$V?K>.<:
M="HS(7[JFXEWWC U(Q8P5VD7%+]6[((%@?:$/'YE3AMY3 W<O=YZ'Z?)8S(S
M&K,+$?S)/>6?-SH-\-B<)H&Z%^M+EB7D:'^N".+T$]:9K=D -XF5"#,P,@AY
MM/FFSUDA=@"D>01@90"K+L#. '9=0#,#-.L"G S@U 6T,D"K+J"= =IU 9T,
MT*D+Z&: ;ET ,;>=,VM#\F9OAFXS)>F(#:FB_9X4:Y#:'OWIBW1.4SQ.%H_T
MDIHJB6\YXE1_/)C<P]/@Z^,(;D:#Z>/]Z&9T^S"%3W!+I:1ZWN%DR!3EP2D^
M?)P.X>3#*7P 'L&#+Y*81E[<,Q12T0X--PO[91/6.A+VFZO.P"0?P3))IP1^
M40V_%:LSL.RC\&$U_"J)SL V-=PR2^"C:O@-E0@G1^'CWXO^1VTXZ9; +^O#
MRTHWJ88/F5N9^U5M>"GYZ]?(!]CW4O(&#GX^_58^_5;JSSY*9Z9@RMQ$<L59
M_!$&*QQT.@O8)U2K3S$-&'S_BB"8*!;&/RI"VGE(.PW9/!+R+I&NCQH 8@[4
M\[@6%AK E$8+&@H82QJY#&*?2E:VKL8;[ZW4N];+5=^RVSUCM3M AS9F;K%'
MNIF3;E:2WF=7404G=^B\5^%;><A690ZW23AC4I=]4UQ4\U\)E\R#$]S+-L].
MRW:RC5MGIYK$=DC7M%O[9;\H,22.U6G93GGUVSGS]G^H/OP-4TT6\DD:+"1C
M^#-' 6[&\, B#_/\-I_C9_ZJHH"=G$;GO7K6S4-V:_9LCGEL&^>SP(/9"RB?
M@2\"S#9^I8?7W8/6--MMTSRR+(A9J*=927 4*XZ_ZW"(YI1+6-$@81!P.N,!
M5R__(EZZ79J'ZWF'5K8I5AOM<]]1?O(F"V*8^=T?]+UJ9BI:9D<.["Y+["S'
M;+9;;;)O>?6ZQ_U:%#I K#?=E3/W3JT.%5)!JK6B?/SQ8!0K7.D\6N!):/87
M'DY "5AN4WBM>_8AU6;W> T+C2#5(O&4#G\Q3I)M*7FE)6L>]O(HB4)7B//F
M>R6B\+C&7!I7;9ND$![2>J^-DQ2:0:I%XS<G>I*YW]US[*/M*22$="I9/3R#
M/C[#% ;P_8;I\?[QOPL:*>2%=-^K,U:A&5:U9DPB5S*=)J[3'=7 /FE!J]:+
ML74H!8>KQM@Y#^H_1O# LN!1# &;(\H\:^,:DIO_&C8W2BS3(^),*#QRII<^
MHUAU;8#OYT*H[8T^=>;_^/3_ 5!+ P04    " "+@P51_(Z9E24$  !0$P
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ME?87;0M;ST'SM50\*\#:@XRP_(N?BCSL 33/84!0 (*W@,810+T U-^KT"@
MC?<J- M \RV@=030*@ MF_L\63;3$5:XUQ%\BX2QUFQF89_+HG6""3.%-5%"
MWQ*-4[U!.+E"\<_IZ"&\CF_O)RB\C=!-./X>WX?]ZQA-XL%T/+H?Q1-40V&2
M$%,/F*(1RXO:5,=9! H3>JXMII,(G7TZ[[A*^V84W'GA1S_W(SCB1QW=<*92
MB6*60'( 'U7C6Z?PPVJ\'U00N#JI96:#76;[027CMS6[1'7O @5>X!UP:/!N
MN/_U4#X^IAY_3'U8#8]@KN'^(?BK7-;+*JU;OOH1OA';@%2ZGREY@2*8*819
M@N*_:Z*>T03F:Z'K$B3Z'<ZD$KI;_:D0;92B#2O:."(Z!DS)/T@0Y5)J<KY
M>*/K',\HU'3UUR2F@&2I?JCH<X6653 ]?M/3C['9KX*3%M%)B[C*XE7HS3+T
M9F7H/U0*HJ92S&H*LA476!#ZC$BVPD3HC)"7]SA4FLU3'@^K+'*/W;V>EH%8
MVNDCT9ROF<H+ISPM!UQH^_J;\[[?'O@'SB._'>?SZX4^GZ8W6"P)DXC"0DMY
MEY^UMR*?4/E&\97MJ#.N='^VRU0/=1#&0-\O.%>[C1$H_R;T_@-02P,$%
M  @ BX,%4?KLEM#0!0  ,R   !D   !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&ULO5IM<YLX$/XK&D\_M#-U0"^\=1S/N+;;YJ[M]$+2^TQL.68*R!5RTMZO
M/X$ILI$@M"29S"1@=M?[2+O/(XE,[AG_EF\I%>!'FF3Y^6@KQ.Z-9>6K+4VC
M_(SM:":?;!A/(R%O^:V5[SB-UJ53FEC(METKC>)L-)V4GWWATPG;BR3.Z!<.
M\GV:1OSG6YJP^_,1'/WZX#*^W8KB VLZV46W-*3B>O>%RSNKCK*.4YKE,<L
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M7:-DNWX@&4H?4;T,T&ZEYO0<O5E%<[) ?R'E(I[L7N94+RM/]\\?,)VY9XF
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MF,+Y?Z-/&H]>2P:N%A,N_.$3_F8THV&ZV !!+AB+%1*S7;$2AFD:)NMB55R
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M>[B6,@&#YEP'>B%%R%>Y/@<U-J @(J[VX)I@N.>9N492>)!=>'2NWU.9D50
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M<VAE971S+W-H965T,S8N>&ULO5EM4]LX$/XKFESOIIVAQ);R1B\P X'><4.
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MX?[:_OYS:F 'W67-A<7OZ2W\,F/0#VW'=3X9IM*Z#/CU#-"*4:4106F...$
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M?PM5V4"'S*$? I^?_L$SNGWH$#3T0^BY%.\C*B*69'.)38NRU0"XZE+VE%+
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M27PP_3<8^[D,?*61+GY)/^1>7%%2=@Z-&L&^ B7TL/+=.(=#P/P$(!T!Z7O
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MT_5E49<KB?K#88,Q..]7_9M]78>Z+FV7HJB.__Z._RT__ -02P,$%     @
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MJT0A:X)"U@2%K D*69/_).N[UJN__JG1KG&MRN;HS[H_1_-/4$L! A0#%
M  @ BX,%40=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "+@P51XUXOF>\    K @  $0
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M=#(N>&UL4$L! A0#%     @ BX,%40B$-I+6!   H!$  !@
M ("!-10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (N#
M!5%7UL+5P0,  -0+   8              " @4$9  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " "+@P515YC>TD4*  !./   &
M        @($X'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ BX,%43)=3:?:!P  IA\  !@              ("!LR<  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (N#!5$[SJS6'",  !=P   8
M              " @<,O  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " "+@P51IJ)ZN$ *  #I&P  &               @($54P  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ BX,%48OA#?<W!@
MK0\  !@              ("!BUT  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( (N#!5%K#9QS= ,  ,$(   9              " @?AC
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ BX,%46G6
M$ZUK(   "88  !D              ("!HV<  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " "+@P51CU]"/]\$  "%"@  &0
M    @(%%B   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M (N#!5%1V"Y UP@   X7   9              " @5N-  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ BX,%4:D?I2CK @  /P8  !D
M             ("!:98  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " "+@P51]4YYPX8#  "H!P  &0              @(&+F0  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (N#!5'0CMGGMP<
M # 4   9              " @4B=  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ BX,%4>.$Z>EG P  /@<  !D              ("!
M-J4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "+@P51
MKAM(A)T>   ]8P  &0              @('4J   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( (N#!5%3;?B** 0  (\,   9
M      " @:C'  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ BX,%430^G6/)!   *PT  !D              ("!!\P  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "+@P51"TS:'4P$  "'"@
M&0              @($'T0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( (N#!5'Z0]*>6@8  /,6   9              " @8K5  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ BX,%49>)3:%'
M P  Q 8  !D              ("!&]P  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " "+@P51DXTVK_T"   Z!@  &0
M@(&9WP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (N#
M!5%B9@WQLP(  (T%   9              " @<WB  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ BX,%4:Q5@VKV!@  <2,  !D
M         ("!M^4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " "+@P510J$"?-D'  !"0   &0              @('D[   >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (N#!5'Y/<Y^5P0  /T1
M   9              " @?3T  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ BX,%4?R.F94E!   4!,  !D              ("!@OD
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "+@P51)D&W
M3N("   R"   &0              @('>_0  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( (N#!5'Z[);0T 4  #,@   9
M  " @?<  0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MBX,%4=4W!GFE @  + 8  !D              ("!_@8! 'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " "+@P51\1&!%6@"  !L!0  &0
M            @(':"0$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( (N#!5%#*858.A,  !B%   9              " @7D, 0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ BX,%4>IT'!W/!0
MX2   !D              ("!ZA\! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " "+@P51@Z.L0/0%  "!&P  &0              @('P
M)0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (N#!5%.
MI^?-@ ,  %$*   9              " @1LL 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ BX,%40_]F8%" P  "0L  !D
M     ("!TB\! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (N#!5&<IWS$X $  %0$   9              "
M@6-# 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ BX,%
M4=)$B.!? @  9 P   T              ( !>D4! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "+@P51EXJ[',     3 @  "P              @ $$2 $
M7W)E;',O+G)E;'-02P$"% ,4    " "+@P51=YZPL_<#   ['0  #P
M        @ 'M2 $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ BX,%4>Y)
MW?^> 0  "!H  !H              ( !$4T! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ BX,%4:C*A]FK 0  01H  !,
M     ( !YTX! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #, ,P#<#0
&PU !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>318</ContextCount>
  <ElementCount>341</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2105102 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2306302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - COMMITMENTS AND CONTINGENCIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Summary of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail</Role>
      <ShortName>SUBSEQUENT EVENTS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - sgmo-20200630.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - sgmo-20200630.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sgmo-20200630.htm">sgmo-20200630.htm</File>
    <File>sgmo-20200630.xsd</File>
    <File>sgmo-20200630_cal.xml</File>
    <File>sgmo-20200630_def.xml</File>
    <File>sgmo-20200630_lab.xml</File>
    <File>sgmo-20200630_pre.xml</File>
    <File>sgmo-20200630xex101.htm</File>
    <File>sgmo-20200630xex102.htm</File>
    <File>sgmo-20200630xex104.htm</File>
    <File>sgmo-20200630xex105.htm</File>
    <File>sgmo-20200630xex11.htm</File>
    <File>sgmo-20200630xex311.htm</File>
    <File>sgmo-20200630xex312.htm</File>
    <File>sgmo-20200630xex321.htm</File>
    <File>sgmo-20200630xex51.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20200630.htm": {
   "axisCustom": 1,
   "axisStandard": 25,
   "contextCount": 318,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 460,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://www.sangamo.com/20200630": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 13
   },
   "keyCustom": 70,
   "keyStandard": 271,
   "memberCustom": 46,
   "memberStandard": 32,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - INCOME TAXES",
     "role": "http://www.sangamo.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.sangamo.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "ifc2f16d8a1de4251b480b9bd9d3df945_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - COMMITMENTS AND CONTINGENCIES - (Tables)",
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i8f3eeebf2a8e4f38866132567e9f313d_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i3461528899214d58b2a932f24904ee6e_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i1b51e6431f1d4e99b4e005735f3156ba_D20200101-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "ic2a5014580264671a94f115ba17d478c_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "ic2a5014580264671a94f115ba17d478c_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product_target",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product_target",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id2532bc5c847458ea5c245c9d0539d8a_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i74a14aa270784e14b78266b6b869c0f0_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i79bc9a529289406ba4208392ca4fe2c3_D20190401-20190630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i77dd9fd15a104e948837f14e23f36760_D20190401-20190430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "id8bc0fc55f0d4c998a106a95dcdc31af_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i8f3eeebf2a8e4f38866132567e9f313d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDecreaseFromRedemptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "ib91cbc7a1cd2485baa09f334bf5ffbe1_D20200727-20200827",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail",
     "shortName": "SUBSEQUENT EVENTS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "ib91cbc7a1cd2485baa09f334bf5ffbe1_D20200727-20200827",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i5fb00e01938c41218801d630e5eed895_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "i5fb00e01938c41218801d630e5eed895_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105102 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20200630.htm",
      "contextRef": "icc60e28018564ffd939811f6b225a28b_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - sgmo-20200630.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - sgmo-20200630.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 79,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "verboseLabel": "Achievement of Commercial Milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Specified Clinical Development and Regulatory Milestones.",
        "label": "Achievement Of Specified Clinical Development And Regulatory Milestones [Member]",
        "terseLabel": "Achievement Of Specified Clinical Development And Regulatory Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of Specified Clinical Development Intellectual Property and Regulatory Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "verboseLabel": "Achievement of Specified Preclinical Development Clinical Development and First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achievement of Specified Sales Milestones.",
        "label": "Achievement Of Specified Sales Milestones [Member]",
        "terseLabel": "Achievement of Specified Sales Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesMilestonesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "label": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "terseLabel": "Acquisition of additional shares of Sangamo France"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement Termination, Term",
        "label": "Agreement Termination, Term",
        "terseLabel": "Agreement termination, term"
       }
      }
     },
     "localname": "AgreementTerminationTerm",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_AmendedCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended Collaboration And License Agreement",
        "label": "Amended Collaboration And License Agreement [Member]",
        "terseLabel": "Amended Collaboration And License Agreement"
       }
      }
     },
     "localname": "AmendedCollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AmortizationAndOtherChangesInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization And Other Changes In Right-of-Use Assets",
        "label": "Amortization And Other Changes In Right-of-Use Assets",
        "negatedLabel": "Amortization and other changes in right-of-use assets"
       }
      }
     },
     "localname": "AmortizationAndOtherChangesInRightOfUseAssets",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen MA, Inc.",
        "label": "Biogen MA, Inc. [Member]",
        "terseLabel": "Biogen MA, Inc."
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrisbaneCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Brisbane, California",
        "label": "Brisbane, California [Member]",
        "terseLabel": "Brisbane, California"
       }
      }
     },
     "localname": "BrisbaneCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition estimated fair value assets of free shares.",
        "label": "Business Acquisition Estimated Fair Value Assets Of Free Shares",
        "terseLabel": "Estimated fair value asset of free shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition estimated fair value liabilities of free shares.",
        "label": "Business Acquisition Estimated Fair Value Liabilities Of Free Shares",
        "terseLabel": "Estimated fair value liability of free shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, number of free shares held by the holders.",
        "label": "Business Acquisition Number Of Free Shares Held By Holders",
        "terseLabel": "Number of free shares held by the holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesHeldByHolders",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "label": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "terseLabel": "Number of free shares outstanding subject to purchase (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, number of shares acquired.",
        "label": "Business Acquisition Number Of Shares Acquired",
        "terseLabel": "Number of ordinary shares acquired (in shares)",
        "verboseLabel": "Number of shares acquired (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesAcquired",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business acquisition, percentage of equity interests agreed to acquire.",
        "label": "Business Acquisition Percentage Of Equity Interests Agreed To Acquire",
        "terseLabel": "Percentage of equity interests agreed to acquire"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_BusinessAcquisitionSharesAcquiredValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Shares Acquired, Value",
        "label": "Business Acquisition, Shares Acquired, Value",
        "terseLabel": "Value of shares repurchased"
       }
      }
     },
     "localname": "BusinessAcquisitionSharesAcquiredValue",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "verboseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "California institute for regenerative medicine agreement.",
        "label": "California Institute For Regenerative Medicine Agreement [Member]",
        "terseLabel": "California Institute For Regenerative Medicine Agreement"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAgreementMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedTotalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "label": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "label": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Cash equivalents, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ChangeInCollaborationAgreementScopeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Collaboration Agreement Scope [Member]",
        "label": "Change In Collaboration Agreement Scope [Member]",
        "terseLabel": "Change in Collaboration Agreement Scope"
       }
      }
     },
     "localname": "ChangeInCollaborationAgreementScopeMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAgreementEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Equity Issued",
        "label": "Collaboration Agreement, Equity Issued",
        "terseLabel": "Collaboration agreement, equity issued"
       }
      }
     },
     "localname": "CollaborationAgreementEquityIssued",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementNumberOfAdditionalProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Additional Product Targets",
        "label": "Collaboration Agreement, Number Of Additional Product Targets",
        "terseLabel": "Number of additional product targets"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAdditionalProductTargets",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAgreementTargetSelectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Target Selection Period",
        "label": "Collaboration Agreement, Target Selection Period",
        "terseLabel": "Target selection period"
       }
      }
     },
     "localname": "CollaborationAgreementTargetSelectionPeriod",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration And License Agreement",
        "verboseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "label": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "terseLabel": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value"
       }
      }
     },
     "localname": "CollaborationArrangementCommissionFeePortionOfGrossProceedsValue",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationArrangementResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Arrangement, Research Period",
        "label": "Collaboration Arrangement, Research Period",
        "terseLabel": "Research period"
       }
      }
     },
     "localname": "CollaborationArrangementResearchPeriod",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Axis]",
        "terseLabel": "Collaborative Agreement Milestone [Axis]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneAxis",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Domain]",
        "terseLabel": "Collaborative Agreement Milestone [Domain]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneDomain",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborativeAgreementPercentOfInitialRecognition": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Percent Of Initial Recognition",
        "label": "Collaborative Agreement, Percent Of Initial Recognition",
        "terseLabel": "Percent of initial recognition"
       }
      }
     },
     "localname": "CollaborativeAgreementPercentOfInitialRecognition",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "label": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "terseLabel": "Agreement restriction, percentage of shares held"
       }
      }
     },
     "localname": "CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementCumulativeMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Cumulative Milestone Achieved",
        "label": "Collaborative Arrangement, Cumulative Milestone Achieved",
        "terseLabel": "Cumulative milestone achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementCumulativeMilestoneAchieved",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs for new research plan"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementExtendedPeriodOfCollaboration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Extended Period Of Collaboration",
        "label": "Collaborative Arrangement, Extended Period Of Collaboration",
        "terseLabel": "Extended period of collaboration"
       }
      }
     },
     "localname": "CollaborativeArrangementExtendedPeriodOfCollaboration",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)",
        "label": "Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)",
        "terseLabel": "Increase (decrease) in net loss"
       }
      }
     },
     "localname": "CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Increase (Decrease) In Revenue",
        "label": "Collaborative Arrangement, Increase (Decrease) In Revenue",
        "terseLabel": "Increase (decrease) in revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementIncreaseDecreaseInRevenue",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "terseLabel": "Maximum milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePaymentReceivable",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "label": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "terseLabel": "Maximum number of product targets replaced"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementMilestoneRevenueReversal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Revenue Reversal",
        "label": "Collaborative Arrangement, Milestone Revenue Reversal",
        "terseLabel": "Milestone revenue reversal"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestoneRevenueReversal",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementNetIncomeLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Net Income (Loss) Per Share",
        "label": "Collaborative Arrangement, Net Income (Loss) Per Share",
        "terseLabel": "Increase (decrease) in basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeArrangementNetIncomeLossPerShare",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets",
        "label": "Collaborative Arrangement, Number Of Product Targets",
        "terseLabel": "Number of product targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargets",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets Selected",
        "label": "Collaborative Arrangement, Number Of Product Targets Selected",
        "terseLabel": "Number of product targets selected"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargetsSelected",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementPeriodOfCollaboration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Period Of Collaboration",
        "label": "Collaborative Arrangement, Period Of Collaboration",
        "terseLabel": "Period of collaboration"
       }
      }
     },
     "localname": "CollaborativeArrangementPeriodOfCollaboration",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementResearchServiceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Service Fees",
        "label": "Collaborative Arrangement, Research Service Fees",
        "terseLabel": "Research Service Fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchServiceFees",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "label": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "terseLabel": "Standstill restriction, ownership threshold percentage ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction Period",
        "label": "Collaborative Arrangement, Standstill Restriction Period",
        "terseLabel": "Standstill restriction period"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionPeriod",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "label": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "terseLabel": "Voting provisions expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsExpirationPeriod",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "label": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "terseLabel": "Voting provisions, ownership threshold percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development - and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress, Percentage",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress, Percentage",
        "terseLabel": "Revenue reduction due to decrease in measure of proportional cumulative performance, percentage"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressPercentage",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_ContractualObligationPaidUponExecution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual Obligation Paid Upon Execution",
        "label": "Contractual Obligation Paid Upon Execution",
        "terseLabel": "Contractual obligation paid upon execution"
       }
      }
     },
     "localname": "ContractualObligationPaidUponExecution",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ExtendedResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extended Research Term Of Agreement",
        "label": "Extended Research Term Of Agreement",
        "terseLabel": "Extended research term of agreement"
       }
      }
     },
     "localname": "ExtendedResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_FreeSharesAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Free shares asset.",
        "label": "Free Shares Asset [Member]",
        "terseLabel": "Free shares asset"
       }
      }
     },
     "localname": "FreeSharesAssetMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_GainLossOnFreeShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (loss) on free shares.",
        "label": "Gain (Loss) On Free Shares",
        "negatedLabel": "Gain on free shares"
       }
      }
     },
     "localname": "GainLossOnFreeShares",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_GrantFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant funding amount.",
        "label": "Grant Funding Amount",
        "terseLabel": "Funds due under the agreement"
       }
      }
     },
     "localname": "GrantFundingAmount",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) in long-term portion of lease liabilities.",
        "label": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermPortionOfLeaseLiabilities",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase in fair value of free shares asset and liability.",
        "label": "Increase In Fair Value Of Free Shares Asset And Liability",
        "terseLabel": "Increase in fair value of the free shares"
       }
      }
     },
     "localname": "IncreaseInFairValueOfFreeSharesAssetAndLiability",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma Inc"
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "terseLabel": "Lease not yet commenced, amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Real Estate",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Area Of Real Estate",
        "terseLabel": "Lease not yet commenced, area of real estate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LicenseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Obligations",
        "label": "License Obligations",
        "terseLabel": "License obligations"
       }
      }
     },
     "localname": "LicenseObligations",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ManufacturingCapacityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Capacity",
        "label": "Manufacturing Capacity [Member]",
        "terseLabel": "Manufacturing Capacity [Member]"
       }
      }
     },
     "localname": "ManufacturingCapacityMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ManufacturingObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Obligations",
        "label": "Manufacturing Obligations [Member]",
        "terseLabel": "Manufacturing Obligations [Member]"
       }
      }
     },
     "localname": "ManufacturingObligationsMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputExchangeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Exchange Rate [Member]",
        "label": "Measurement Input, Exchange Rate [Member]",
        "terseLabel": "Exchange Rate"
       }
      }
     },
     "localname": "MeasurementInputExchangeRateMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputStockPriceCorrelationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Stock Price Correlation [Member]",
        "label": "Measurement Input, Stock Price Correlation [Member]",
        "terseLabel": "Stock Price Correlation"
       }
      }
     },
     "localname": "MeasurementInputStockPriceCorrelationMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone Achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NonCancelableContractualCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cancelable Contractual Commitment",
        "label": "Non-cancelable Contractual Commitment [Member]",
        "terseLabel": "Non-cancelable Contractual Commitment [Member]"
       }
      }
     },
     "localname": "NonCancelableContractualCommitmentMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Novartis Institutes For BioMedical Research Inc.",
        "label": "Novartis Institutes For BioMedical Research Inc. [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfOptionsToExtendInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Options To Extend Initial Research Term",
        "label": "Number Of Options To Extend Initial Research Term",
        "terseLabel": "Number of options to extend initial research term"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendInitialResearchTerm",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office and laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other Products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PaymentsForOtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Other Commitment",
        "label": "Payments For Other Commitment",
        "terseLabel": "Payments for other commitment"
       }
      }
     },
     "localname": "PaymentsForOtherCommitment",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PfizerAndSanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer and Sanofi",
        "label": "Pfizer and Sanofi [Member]",
        "terseLabel": "Pfizer and Sanofi"
       }
      }
     },
     "localname": "PfizerAndSanofiMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer SB-525 [Member]",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PreApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-approval Milestone",
        "label": "Pre-approval Milestone [Member]",
        "terseLabel": "Pre-approval Milestone"
       }
      }
     },
     "localname": "PreApprovalMilestoneMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock, Net Of Issuance Costs",
        "label": "Proceeds From Issuance Of Common Stock, Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PropertySubjectToOperatingLeaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Property subject to operating lease one.",
        "label": "Property Subject To Operating Lease One [Member]",
        "terseLabel": "Operating Lease One"
       }
      }
     },
     "localname": "PropertySubjectToOperatingLeaseOneMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned",
        "terseLabel": "Contract to perform for others, cumulative compensation earned"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ResearchAndOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and office space",
        "label": "Research And Office Space [Member]",
        "terseLabel": "Research and Office Space"
       }
      }
     },
     "localname": "ResearchAndOfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RichmondCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Richmond, California",
        "label": "Richmond, California [Member]",
        "terseLabel": "Richmond, California"
       }
      }
     },
     "localname": "RichmondCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveAndOtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "S B Five Two Five And Other Products",
        "label": "S B Five Two Five And Other Products [Member]",
        "terseLabel": "SB-525 and Other Products"
       }
      }
     },
     "localname": "SBFiveTwoFiveAndOtherProductsMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SB five two five.",
        "label": "S B Five Two Five [Member]",
        "terseLabel": "SB-525"
       }
      }
     },
     "localname": "SBFiveTwoFiveMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone",
        "label": "ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone [Member]",
        "terseLabel": "ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone"
       }
      }
     },
     "localname": "ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Stock, Excess Consideration Received on Transaction",
        "label": "Sale of Stock, Excess Consideration Received on Transaction",
        "terseLabel": "Excess consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockExcessConsiderationReceivedOnTransaction",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales-based Milestone",
        "label": "Sales-based Milestone [Member]",
        "terseLabel": "Sales-based Milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SangamoFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sangamo France",
        "label": "Sangamo France [Member]",
        "terseLabel": "Sangamo France"
       }
      }
     },
     "localname": "SangamoFranceMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi.",
        "label": "Sanofi [Member]",
        "verboseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest.",
        "label": "Schedule Of Noncontrolling Interest Table [Table Text Block]",
        "terseLabel": "Summary of Non-controlling Interest"
       }
      }
     },
     "localname": "ScheduleOfNoncontrollingInterestTableTableTextBlock",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate upfront fee"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement and tender offer agreement.",
        "label": "Share Purchase Agreement And Tender Offer Agreement [Member]",
        "terseLabel": "Share Purchase Agreement and Tender Offer Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementAndTenderOfferAgreementMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_TxCellSAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TxCell S.A.",
        "label": "Tx Cell S A [Member]",
        "terseLabel": "Tx Cell S A [Member]"
       }
      }
     },
     "localname": "TxCellSAMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ValbonneFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valbonne, France",
        "label": "Valbonne, France [Member]",
        "terseLabel": "Valbonne, France"
       }
      }
     },
     "localname": "ValbonneFranceMember",
     "nsuri": "http://www.sangamo.com/20200630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r240",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r386",
      "r434",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r237",
      "r240",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r386",
      "r434",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r139",
      "r221",
      "r223",
      "r387",
      "r433",
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r139",
      "r221",
      "r223",
      "r387",
      "r433",
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r226",
      "r237",
      "r240",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r386",
      "r434",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r226",
      "r237",
      "r240",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r386",
      "r434",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r91",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r108",
      "r172",
      "r173",
      "r257",
      "r272",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r91",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r108",
      "r172",
      "r173",
      "r257",
      "r272",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r92",
      "r172",
      "r173",
      "r257",
      "r272",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r140",
      "r141",
      "r221",
      "r224",
      "r436",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r221",
      "r224",
      "r436",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r202",
      "r238",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r271",
      "r272",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r15",
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r30"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r42",
      "r44",
      "r45",
      "r422",
      "r445",
      "r449"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r45",
      "r46",
      "r82",
      "r83",
      "r85",
      "r302",
      "r440",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r241",
      "r242",
      "r259",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r205",
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance costs related to public offering",
        "terseLabel": "Recognized portion of equity issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r242",
      "r247",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r128",
      "r131",
      "r137",
      "r167",
      "r297",
      "r303",
      "r321",
      "r403",
      "r420"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r37",
      "r79",
      "r167",
      "r297",
      "r303",
      "r321"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value disclosure",
        "totalLabel": "Total cash equivalents and marketable securities and free shares asset"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r179"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r147",
      "r152",
      "r179",
      "r406"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r149",
      "r179"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r149",
      "r179"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r236",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r236",
      "r239",
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition, percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Sangamo France Stock Price (EUR) (in euros per share)",
        "verboseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S."
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r76",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in unpaid liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r70"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r71",
      "r76"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r70",
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r323"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r93",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r93",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r286",
      "r287",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper securities",
        "verboseLabel": "Commercial paper securities"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r201",
      "r407",
      "r427"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r55",
      "r411",
      "r431"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Sangamo Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r54",
      "r293",
      "r294",
      "r307",
      "r410",
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r50",
      "r53",
      "r292",
      "r307",
      "r409",
      "r429"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r142",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r142",
      "r319",
      "r320",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r119",
      "r120",
      "r142",
      "r319",
      "r320",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r115",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r119",
      "r120",
      "r142",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r142",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r208",
      "r210",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Portion of contract asset recognized"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r208",
      "r209",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "negatedTerseLabel": "Revenue reduction due to decrease in measure of proportional cumulative performance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r208",
      "r209",
      "r222"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r208",
      "r209",
      "r222"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r227",
      "r235",
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r118",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized losses of available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r68",
      "r127"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Volatility Estimate"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r56",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r99",
      "r100",
      "r102",
      "r103",
      "r104",
      "r108",
      "r109",
      "r412",
      "r432"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "negatedTerseLabel": "Earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effects of changes in foreign exchange rates"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r87",
      "r95",
      "r98",
      "r112",
      "r171",
      "r205",
      "r206",
      "r254",
      "r255",
      "r256",
      "r271",
      "r272",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r316",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Free Shares Valuation Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r310",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r309",
      "r310",
      "r313",
      "r314",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r233",
      "r235",
      "r310",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r233",
      "r235",
      "r310",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r310",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "USD / EUR Exchange Rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Net loss on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r184",
      "r186",
      "r402"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r188",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r68",
      "r185",
      "r187",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Research Grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r193",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r190",
      "r192"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair value of investments available-for-sale"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r400",
      "r418",
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Area of space leased (in sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Six months ending December 31, 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease agreement, extendable lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit established as a deposit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r79",
      "r132",
      "r167",
      "r298",
      "r303",
      "r304",
      "r321"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r79",
      "r167",
      "r321",
      "r405",
      "r425"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r79",
      "r167",
      "r298",
      "r303",
      "r304",
      "r321"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Stock Price Volatility Estimate"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Stock Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r35",
      "r79",
      "r167",
      "r321",
      "r404",
      "r424"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at June 30, 2020",
        "periodStartLabel": "Balance at December 31, 2019",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r206",
      "r295",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Fair value of additional shares acquired"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r49",
      "r52",
      "r69",
      "r79",
      "r86",
      "r90",
      "r91",
      "r92",
      "r93",
      "r97",
      "r98",
      "r101",
      "r128",
      "r130",
      "r133",
      "r136",
      "r138",
      "r167",
      "r321",
      "r408",
      "r428"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Sangamo Therapeutics, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r49",
      "r97",
      "r98",
      "r300",
      "r306"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r206",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r128",
      "r130",
      "r133",
      "r136",
      "r138"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r341",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total",
        "verboseLabel": "Total lease payment"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current (included in Accounts payable and accrued liabilities on the Condensed Consolidated Balance Sheet)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - long-term",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r338",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities included net cash used in operating activities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r346",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r81",
      "r124",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r39",
      "r43",
      "r322",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized gain on available-for-sale securities",
        "verboseLabel": "Net unrealized gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporarily impaired investments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Purchase of additional shares of Sangamo France",
        "terseLabel": "Purchase of additional Sangamo France shares"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r61",
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r49",
      "r63",
      "r79",
      "r86",
      "r97",
      "r98",
      "r128",
      "r130",
      "r133",
      "r136",
      "r138",
      "r167",
      "r292",
      "r299",
      "r301",
      "r306",
      "r307",
      "r321",
      "r413"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Decrease in net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r195",
      "r426"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r234",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r234",
      "r349",
      "r351",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r263",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r262",
      "r464"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r9",
      "r70",
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r70",
      "r75",
      "r454"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r75",
      "r454"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r206",
      "r257",
      "r423",
      "r444",
      "r449"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r87",
      "r95",
      "r98",
      "r171",
      "r254",
      "r255",
      "r256",
      "r271",
      "r272",
      "r440",
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r125",
      "r126",
      "r129",
      "r134",
      "r135",
      "r139",
      "r140",
      "r142",
      "r220",
      "r221",
      "r387"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Increase in revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r119",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r344",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r119",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r155",
      "r158",
      "r161",
      "r162",
      "r163",
      "r165",
      "r415",
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r280",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Revenues Recognized under Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r242",
      "r246",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r242",
      "r246",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r9",
      "r75",
      "r401",
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r244",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Sangamo Stock Price (USD) (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price of common stock issued (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r82",
      "r83",
      "r85",
      "r87",
      "r95",
      "r98",
      "r112",
      "r171",
      "r205",
      "r206",
      "r254",
      "r255",
      "r256",
      "r271",
      "r272",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r85",
      "r112",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r206",
      "r243",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r19",
      "r20",
      "r79",
      "r146",
      "r167",
      "r321"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Sangamo Therapeutics, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r85",
      "r87",
      "r95",
      "r167",
      "r171",
      "r206",
      "r254",
      "r255",
      "r256",
      "r271",
      "r272",
      "r290",
      "r291",
      "r305",
      "r321",
      "r324",
      "r325",
      "r330",
      "r441",
      "r442"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r206",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r331",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r331",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r331",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r331",
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r352",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r227",
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r117",
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Pricing Method"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r342",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Estimated Correlation Sangamo and Sangamo France Stock Prices"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121578510&loc=d3e41551-112718"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121604053&loc=SL77918607-209975"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r465": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r466": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r467": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r468": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r469": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001628280-20-011806-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-011806-xbrl.zip
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M.ZUMAM3!:['[]A7#C W.^FNS<Y9DBX^UW^ZHUC-_\M' O#AK;[=FC0]M0)M
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MHD<2D+*(A648DO,B@6(2LC0BF\THU)2D!%DPI_<J*Z,@1>.S9$\5+>L6*UJ
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MLU!B"=;C"D!_!T#?X_"U;A\-ZADO\>@FADIO!"L2J>X $IG<L)41.42=Z]B
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MS!9%P+-)X@Y(+B(X&XQDLYP#&;0.HO<E&[D0B^471< S6C(FB0-$()NS 17
M!W0AFR)T4-X*MVP^^/EX%K_+\EW+AYU>9S@ZG]-?9B\LD+1P+,_L@$2.A#$Q
MUT7(-JKS_:.6R0O/5,2S\<-61(NV%L#! "GJ4$O'2ZC[4[OL02Z;'YZY%L_
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M@W_^7D>,V<><8_[9QF:K\1O30;9F[6..:SJI<<$:-ZG469]D!2DOI#<6"K-
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MW6&]2HA8'QX.R\'HB<FH:_%%Z:AW53I11*5AMQA)>'4&)MJB5Z5>$VBPHS9
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M=C_]'7\%'W9W_R_]O;>_OK^UL]7:WWL0^!&^>#R[U^OX.+:+'F>)577\F+O
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M1G@/'&% C19 $JX!%YH02)0Q@:ZL"<(BPM_4=/^1O1C9;_NZH?#Q6FZ&PCI
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M0W"**(E0X 9CIK$T8\L/9<MO(9CFW/([.6"&8<*H "C 2#.I&HX*B 'MXAY
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M1Y!Q!(A1)33O@<:4 TX8C>CG"/=P94V2)H0X V &P R +Q=VS@#X[$K@R4%
M6G++'<"!8D =UB"1&/!(0,Y<7#3B5M8$:A*8-< EBR$OB"/XO>_ZOFY7?F#M
M.D6W* ?]JF[C"_>577)TGZ<K>+S&$=S7KZQPQO='X/O>56=PD))K'#0@G"A
M$;? .,R ALI@%#S6V%0G(A06]2GVNZ 0__A88W8&+Z S.#/%O)W!F2F>E2FN
MN(,1%<0+RH&JF")EFTI*/=!&*@29<HCZR!2TR51FBI=CBMIY0S(*SML=G%%P
M)OKRR0%64@@(%5!&A*@LVP"4EA@08D.(*^:Y5=6Y+DAKU!DC0V"&P#I X#P=
MPAD"9Z((GAQHK'F@Q@.AL8L0J%WR%PC@*?0N:OG28ATA$#4%FH=+>+DAL%ZY
MP9BNBD5P"8^:Q_9N'#"J0<[7:^TZ/D]O\<7)LC'6EQGLIP'[:Q7L#(':&!4
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M!"Y:!H ::H&TT@,-C9"6PB!9:C;:1'5+#:P[$.;LO^7'OGDF1&?L>T[=^.3
M.VVAI@1XH0F@EC!@ E+ &^(Q\D;2D(ZB-ZFL68Y?!KX,?"\-?//,;,[ ]YQ*
MW\D!5!I1C34P EE @Y% D:! U-&MAW%=+8X:'VU*FCT"=73U+G]5YI8?--J]
M,N<MO[:\Y8_]7B@&.<0W+;Q?J\ILB20Z$ J052BJMM !K84"1A'*XVL2ZE1H
MCC45OUEE*4?Y7CHW(CN#%] 9G#FEING*F5,>RRE7_,26!N@Q,B!X+P'UV .-
M="I>BBD1D6\@2GYBV"3L9O'2S"DOS2FU\Z-DO*QIEG+&RZ?JX"<'FL/ F&6
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M-?;"$Q7DZ/  6\1H\52[LGZP-\-4GQQ*6)C^R%D?R/I C?6!NIW:R/K =/K
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M :_3TDUAGCEI+ R6L0 =M4I)C2#7T62SSA*D0S;/:F>>34:3G4%0")06)TA
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M/:XE? $^%RL5'S^'_^MA.BY[6#;GMV0!SP*>!;P&2Y<%/ MX%O LX%G %U/
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MX3+#/8+A#,4F6FY!!2<HU$1&8XXH[K%P7"E+,L,M/,/M7IIR""F*M+? !4(
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M2AAONW5\^,96 56]^O&F/:Y&^?5;C!/,",QH8D;>CX_&73N*H;:=K9@J7XW
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MGPTS@#P621[G53E61!&35"@HBA%W6"+CC4-<ER.)J/S_6HJ\@3O%&XZ30"!
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MUX@'0Y%./B"#7=+$.I4X7ULGG+:IAFUW0!I &D :H,\ *  H "@ *  H "@
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M!(:XX!1EAYXB3[5PFF.=)%E;YVTM8>LV .ES 5+P%,# P<#!P,' P<#!P,'
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M+T&B>;Y$<_Z-44DVGV]]D])$*CR*1@K$38S(Y@E&46LGC:#1&+FVKIB"C6]
M)4 E0"7@4 (*  H "CR%W (XE(UT*'</=NMZU^Q4?NML?$Q<$DRQ03XDCCAQ
M%CF1/!)82.NE\WGRP:5L;@7#PV@I-+XLH9L1 M0/FN</KGH1$E2M/B]_$%
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M.:$=#2@%4HIK%$/6286RU7(29+9\+S/,DS:]!NEAH1EJ:U85&)LJT > ^!"
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M^?<5 >7'S+\#*#<;E,_C QDI]@DK1*7 B,M)_6"I).0JFX&46)*U=:K;.6@
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M=6^W5CV^G BTW$$TBQ4_'"UAZM@U?*NVXUNC,EE?9^XKF+_J@:D&2[U"B N
M=MK^9S5:C!(G0(D<U3#9_CF;^.7QS"$.UE_"2WL 6B. I;F']P"D$K0 TGA$
M)1O_Z/80F\8KU!OXB0!*6I3WA9CV$X(KIX^>_?.O_Z,G)X^>Q-_9HY\18-][
MP.>];#S29C1. ([ -FDH"W0,\(5$* <JD.I< AHB3C96H6Y8MH3!\]%8P)#U
M^VKZ*!>Q<@163<,_'_1X%>ML#$+_,P>PG<VF6PT%F(1X?F=$]E_T.,+IRV/O
M(S>!9ON/42Q0[,D*Q*(7T;;!2[,/M7WJ&H!O3?TY22?$[]#Y:#9SB.[[&0Z\
M\R"'2:WB6$*OO-X =AH"1G:B__;9 E@_<BPTK"!'<!>7/ET&'T5_$K4F$BR-
MH[H:+\]3O]0LL"/O@2@F>YQHU)I84;DVNH35;!MM)(?U>$[ R %I33889@9H
MZ4^K$RQ_-O79&6A90UO.#]?/B64F\P^6;'$RFT9-G84 #<%">E($^[FH7?':
M\FZRU09-; ]-HM4$XNNGBS0N4-O9FM'>8C8WG),?!Y!OF"+\7H_FP=0]FRZ!
M'8Z '!U$I4M,X174]LMX9O_^ 2G#BR?/WAG)BZK4)=&ELP0/WP?R4&IB)*-!
MEZ4M<IX"3\#JO#O @ZVYT+1P7BO'F+ YET*'DEL7"JZ$E'*38C2#$&=W-PQ9
M&H=S^G]/K?'_;+#CI&]7RK*3WMR?H!6-8'KL>Q:D]F86(W!M4M%+A*Z:JV\Q
M*)\%O6@OMR+=?G\LZ](B+.(8A=$4CR\&#RRLQE#N![^HW8G6JVX,'^A$8_M;
MF]]Z3#7:]PPSHK9'A\Y?TT;O9VL*./K\1J,WIR<S<#@_H<-TOMN]7FWKR[P;
MG]:;[>HCX^AW(<<:UV,Y.1G[9+>!K!EH]6P:[5W3P\X.7<BK? "FAVSC68C/
MHK_9?V&T:"KR#;'KW/.9!5.U0(^\_7;NCU;0R]D<C-D)] WDGCC#_&_D)MA=
MM[*QW)E9:E 7M[?9VD;@L]78H1"2?Y\B-'UAI+_$JN.K2VP O-\.0F:BXB3V
MM:X4#6=Q&^.X3'3U9#:J(P8PNQ-5:AE0I(U'Z\JR,4KGM0<)]0@*&,W3$"5Z
M.859/L96CI(N&[\\];Y]D*K:"'@88$V(./H4-0:G*!+%#W'&QP&91ZHRSV#:
M3(]\9+AV-+>KR6*)!+,FY$EDT'+@<$N_;>K7H^)KW32@$Z?G!6GU?'Z&-8+4
MT778/^_@7Q)FF\[6I!(ZN:*\KA8K( ,TS"-,0@$Q,'*]J-O D[Z )SUKA^K%
M_,D(:/%"CU^$/V;3HS]P? ;&U 19CMY5E6*Y\ 61HC!$4"F(MH4@W"EF9,[+
M$,PYQN2U$]Q2JDPI7$5U155PLJ)&,RH<WV1,_X*IVCIN. HD#L/ F*XCR\=1
M8 E7$ICT8Q)@IL!K7)Y%5$8_.%E#_.UR1-JK^<N'D3_%,/<Z[*.)],BT0A-2
M7D=F/\(H;8I.3).)G0.%:W]#KWFQ.@)47W81VQ:!VS  FA9L37P?:4D=NX":
M,>R[G_W5_((T[JP&^T6+JF"-6D9ESM+BRGRT2(JV5F4"??RSUT@O%K5_G"+)
M2R@!8^FC10P.06E6+XZS (9D$9U?6].A%"'H/'(,R?<M4+*RT+)HY] TN@@_
MHYIA]E^-C&631L4A:*E&V^BX@- -3[_?R26'>@(P9(^!F<8X;Y%Y'5_?B,;@
M7YJ:4^.^TCBF=:<-M;V&#;Q9J_ ;M!"AR#_O8B[)" RFX/#3\W>&!N9U61":
MER4102DBF:#$RM)YQQ3\4VR:@D!MGGN%-Q4&X54)X\MI7G')E#*J"M>-S_-J
M!_'\<UD-*E@6-2SKJ=B]#LAOLNIH2,#R@)D8Q;7U!8Q["IE&L%LL4WPR 2S"
M4?P!+1? $;ZWUP7WNR7JWA]/]%FW"&DM:-6&HX_>W,?H,_5ASL'_$M[#GQ;'
MX'B!T0'<CQ_M9\^CWQ<+CED$=5E@%L#D+?L.^^71SO.+AKWQ;@S!P^A@ S0^
M.AVYY3$('.19RU84:>"W?:;-8C9>+?VC.B^&]K_?,K=2R@NF0/CYKBL3XQN"
M[?U[/.\2A8X\,7.O_R8Z0*\>ZO&I/EL\^,=:YR<PA_KB/">EW1;%JZB&,$=P
M)?X\@+2F\CR9!,;.I*"&:D%%Y9W4H:2Y+HT%7!9%M8G>3)2!,2.$UJ7(<ZJ5
MSJN\R(/S5'*FUW7J;J'3=@E=::\>=P&77I@A15;"W ,>'.MYBB?ZY3\:X#E;
MHV1I#5)G9C2=30 &"<SV):Z&X9H8/IK,G*\C,HN.@T=F.O<G&!1":I]6@R+.
MQ94GI(5 H:;>NT08MT/=%NYV+0MT+TSP#5/(7\%8'4P=_N=I9[(&^OCBU<$[
M )Y"%+8@OO"4"(_7EFFA2>ER)KQ7LN1^$X"$U=Y3ZDW% )]<T+F"G[BGII#&
MR'.1!!3\7H;_9CWYQSGR%TQ<&'*<N/C\QXXJ7"E7/''A"#A;ZX*"$,?C[!B*
M'I^!VP;"Q:#!!]\L>'?+&W%]838?@9" X74D*GF2")$3:,]QC!J,<9&E=O_;
MS("8:9#\W4WRMY_&=ALO;/AC0Q[W,N<C,XJ!8^<G^!'4[,_:('Y#&6-QLPDH
M0B2E)Z!0\VT>;D^%8NUUC6E]"?JR!,81JT_)GTAU_^O"+/?5PFU>QBLT TO+
M*UI)X9DPE>1E:4HC2V5IH.^>;=L'18KU2WBGJXF;+>OGF_CT1VSCXD7X-3;Q
MQ6J)$1N,%!U$?MYFOI<_&DB]@KZ\>OI.<V&"XP7)6<6)$%X23:4BE=)!2)@;
M4#"0T?WB@@1VF,)C^&VO6[Y,IK[6Q:@3J.QCK[O0D)W-3S"KUV?'7KO_K/0<
M!PG5]I?Y:&'TU".FC4?P\72D;S4F\M(>>[<:^Q>A4_[M1N['-F_V'9@PGE.I
MB=,N!_/F.%%4XUE*N>6T@#D=\G/1CML:O N&#!V)'WW<0):N!,-'8.H[F/'6
M$*4*F/%E@!'0NJ+F7(K'/>('!S&@/K7@I;1+,,E\GC.P:";G&R8PN2/K*6O@
MEKJ4#G9)7F 37&_B0ML*0@,=UXH10R\H]26&7Q(%08\8V_1;#,N?ZI@E$6;C
M^.M/L<S9"H3E%C\_O)SNK05&-L:S_K4.L=0C7$>&ZB%.-YO'W1HG"_^P^>$1
MQOK'^NSA:!H'(GZT;0-2BD<HN2^+Q.'JD\/J\NMPQ7YZMK%5*CTL^'Y!BXN?
M7_KQI0_5/E/L"[^E^Y=\2?<+7G[AMY?6*O=%^:6B^#XM5OM47%+P#K98[I?L
MNC*^XBR\[[#1^9)MUS>R\[ &EF^_-UMN8'YU"[L1<<$OR^E>W%J(3&0W-[,/
M8_P58_S$6X][LK.<->/,U##.]VZ<-^;R,,;W<(RWS65Y\S?,A4"#O4H+SA]C
MP?9Y<0?.)TG!GPMCD]_TC.1K2[+V0[!TD%@6?::LZ=HYM=TM@?[7S8KLPK,?
MKB6SNW:@RC<+->>?$6K>'G(Z6/Y:9X3$/)@VWIS?S>A3?= *O,L/QR^>/*70
MIO=O/L$WO[\]?O[[T_SM[\]H:BO^_"?;/&CE^7MXG[\6SU_]^?'Y[X?O,6+U
M=@+M?.7^?O/^SX^'OS_]^!Q^?OOD7^'YR_X]W<H':[0BC)>4"(&W-WGXB;J*
M2:<%AW\>/!9EM2=$?AM'M]_('-L]8-HNN>OPHFLB]Q<QH<&@# ;ENQH4&7+O
MO0E<2R]"+F59LIP79>55R%GNT* PQ7C.!H.R2P:E.[F+EB(701LB52&)4-X1
MR6A%)+=>,1V4%>+!8TGWP+0,]F2P)X,]V75EO\OV1#C*RD)RQPLNK"FD8[JR
MIBQRKD2N1+(G@X.R:_:$M?:DDBR4WG)"M2J),(82K54@P>55T#S0TL=KI=0>
MYWPP*(-!&0S*KBO[738H5):,,E?EN5,B"&%*6EFK-*76.2J*:%#DX*#LFD')
MNZ.%:0Y.9B&(<\$0$:J2R$I+4OB2&<]T(;@'@R+ 0[F-\X5_9(-R$RM$(?Z_
M^[Y"A">B39>;:70W=17M>9G>_]/C;VJQXY.?SQR,U2;J7Y47/>#_5^#_J']9
MN0_2%=80[2M'1!$TD29GA'D65##2F[S >28YXX]N ?^_8'+M-CA]D<]P/=C^
MNO2. 05W)D(_H.!W0<$N3,]H&:PRE'B>*R)*[? \)D:XM!6S@H?"B@$%!Q0<
M4/![Q94'*+Q1*.PBS('J2@+HD5PK0P17FI@B+PEU+,\5K<JB*A\\YGN@2P,0
M#D X .&WCX<.=/"[8& 7% 4[AK<U.Q**/!#AF212"TYHL!Z,FN?&#T[Q3L<]
M?XC,^$.\MN1V8Y^?$9Z_QS!_"XG>5V$]C'T]] /,?P[,G_5BGUJ$TIH@"+-<
M$*$8WF 1&'$ Z])0H:C0#QZSO>)6J.X73*W=AJ==RY88,'#W(I\#!GX7#.PB
MG\ZHTG,7P+^7C@@6+%&\D(2R7"K%-+4#!@X8.&#@KL8]!PS\4@SL0IX"R'K%
MJX*$4FLBK#)$6F5)$:@HA'"ZJOR @0,&#ACX?5) !PR\*0SL0IY"6AZ",:30
M!C PSRNB#/?$<^%*R\O<X<[G?,# '0UX?FFB)]^O[D+ \]?K'YZHO_VQAS<;
MR[_$L%V:XEP_K&O+X;F;K?#$Q!]Q;\8UETB^J5SOOO&^I1-+-NSU.7N^_H?>
MFX,]_PQ[?OAK_R234FJG"T,"]9C&(2Q17CHPZK2PH(7>V1Q/,I%[ZE9.,OE^
M\W/W@&\W,T$&HS88M7MAU&[IU)3!J-V24>L6*X+2N7=@U!1G!1&5QN.Y5 &6
M39NBS"UCU#YX+-F>NI735 :;-MBTP:;=F4ESEVW:+9W<,MBT6[)IW>(3L][1
M0BF2&TF)H#80P\"F66J<T!A(=^[!8U;QO>I63G09C-I@U :C=F<FS5TV:K=T
M>LQ@U&[)J/4V4)2,%5R5Q.4!C)KCGDAA&7$AUY4J+"T"9I6)?$_=RJDR@U&[
M>D'R'_'FK,NN6.__?K-W['47P[]L[X5/]_W>S9GX=??I/7GZKA0J=Z&BQ"L\
MF-Q33113CC!;&9W[4BI57/<^O<TKIQD_KZ.[?^=TIR)9IR/W];[A]M[@L5XL
M1@'O_<4K>">=#!:M#' !7'_0HS'^G8"E) LP8O52N07T2M_VKQG6RVS;!>R9
MB5</@Q'_SVJ&C^HK?O%"=1]O&IX9Z-&'V(#ZV6AZLJKO[AU/9@OX \H<,39=
MWK[82U<9XY+\:CKW,-R?H.3CV1A!,SO2HVE:UA_/X'5LIAVO\.;UT30[L'8U
M68UC*U]  ?/LU]GD9.Z/_70Q^N"S9U,[F_CLIS_@TY^SGW!_'J>/#E[\^BS^
MR![]W"0$+)8S^S?6Z>>+_XX9!<NS_?NJ/*_B[9$Q]R%N6:P>;8S^'-1G9=Y[
MNXSWVV<G4-', :R/X*/1?)+VEWT8^=/]K%=85*>C*30%1ZS_LCT& ?F];!3P
MIFHH38]AV&&8XIV]%MN8U6D9/6T#G=E43./'L]/Z-E_0)=#'$;RPR-ZOW!$H
M0;K.>H:J0);'&D;$3_#.W_G9?O8LW0*\5:_CS=+UC#G#\E(]6+NM=]"F-_?J
MJS=3?SW^#<I:8%^B_HV6^/5D!A(<C_[VX[,,FY%-9WCY-LPJ>'XZ&H^A+O@'
MBVHK-3[@5Z.8Q +S8W02&XDB!5)RAN*I9U1J,DZ)IE88"M!%BS*$4=+Q,N18
M72NH^@KD3I38S+KL.%OK>:#ACWHQF\:_I6&/WX+^9;/5,NK5HJNOOET4K7T2
M<E\;@)S/MH@(4 +%@9("CC!U\8[25AY="]L1Z^G1:-'>E'[I:.^MRQ8^.X4?
MH#;@9J=3_!#EO$T5H%:0 A"V9;Q?NC_:W1WM35?J&\AK9/(?\5YTO'H:W^[P
M=S\[Z+^9WEO@7(CWL:?[JSM%C#E+(=ZFZC^>^)C'5%_3/AN/T^_0H7BG>U2N
M^GY7(*X(G+UY40]Z(X;]A)$;HFKF7[P(>^ODB%<MK?44 :*/P[.D^S7:8JNG
M"__SUR5;O0#MBU?E+M:UJAN%#QK4<[6 IMKE;%[?/P_@,AE-L99FD$!V+2Y=
M!$NQ+VG6X*7ATR,P2(W:8_<![_%]*.KT>&2/+P:28XW8 7JV/CR;:-L-4E*Q
M,)KJJ054Q.XEW8OU3KV&\8(N@9K,%J@,B_6I[%/[MM419]<R/M9F-,9Y .U'
M&[<)!5%E-V?[8A4"H%#=;8W7^[:Z?1% 8;E]D-K/_FKL^3D[CCT\3TKZK&5#
MR; _F-H7"^EKW!Z(:;E7CPQ^U6@!?+=:-*.*T@.B9&O^$2).0B,FH"4SMV'K
M;]>Y@5F =]\E=?]KM/C[USC;\*<?TKNQ[Y03):NL)][@F3.L,@3LHR"T*AR7
ME3'&5U_JW>P$0?M<YV9-12(&H';<5X*Z/;EW+\[\[2Y.M J)YW18"H@#JI$L
M2J1#)S.$1'@$O*PEN#W;$LFN[8LZ&N1D^^8@\(;PU/:@AN(>_B>'*@'6M2]I
M7S=P"9@7J?N)-"XB8YJC+)#W( R/)A-H%126S9*A!)B;>@]L"IPQD!&,"K;A
M&,0*/XU'\*D[+Q #]B5#>SD!<6$'UYN"U@S: L(>+8X1Q*$0G\C"W(]KGIDD
M\I^51A.SEX$6@G%N\;49M&4S4B"SWKC!USZ1S8UQ "721XD.]^2_(:G(D&:+
M1)#ZPU1+WW^H1PF]C*!78^CQV8;!19F,EJLTKQJO<U3+_X(,\S5G"7]?+%;(
M2-!AZ3U:5Y96-6:?HQKW=HK[^5)'GR:Y@TF0?WLD>,!,IYV.]A4#AFD<W4OD
M \B%6I(8#?_,8)FH#L?0U:/C#*T_ L7JY&0\@A':SUZ.HM]RW/LC#MM&Q;7.
MUBV;K)"M^6BUX\P&L3X[?))I+*"F$6$TKK<7Q,)?[[_<SWZ; 9_"HI[,5T?9
M@<.)MFB I29=\YE;66 OBQ$05)PTH"DPQ_09*B# CX6ITK@*<8ZUQ"6J]12&
MH^E(<ND21D3G">=JI&:SSNW.PGPVV<H7.WF<^DB]X(/YZF19 T[R[]$W7/>*
M)AI]UVQ5S^)9*N<LOE\[\'4GL4,N:ODBEHAN1XP#+:.8KZ!@^#L2K]%T%?N_
M-AD !")I?IA@Z8-_=#IRRV/01E"V6O%$D6;%ML^T@0FX6OI'=12?]K_?0BW6
M+BS>\9G&\@W!]OX]GG>K*$>>&!C@OXD.T*N'>GP*2OC@'VN=!PTF?7&>D])N
MB^)5U%'<R3.+SM%BFV0V]"P1<";*P)@10NM2Y#G52N=57N3!>0KS1Z>%3/C&
MNP-<AJ2*"RZE5J+DPE-K:,D+#[_:*I0\L <W[5/\ ?ZG]W_ A&T62EY!\;^,
M9_:']"E>';TS--?<R$!*QC4!#5%$PY](*,N\*"I=\E+_4#Y%4H[[2C#Z1+$-
M",2H&[19S^=Z>N2;F"(:(R@QA2BR,<H%ET"0*IQ$# #6B(L5B\5:8 GC6KV"
MNB*F;9 !C&=<Y5@+UP)+16:-W\<UX<A>,80ZJV.@&Q_O@[,'KY%9("MH6;..
M\=>+U^TR1EI*P7V.=3AQFX5O*\-2-&9B.#\?QY!<:B1:Y10!0PG$N%.,V,1?
MQZ,41AKYJ^J9@;]PE, S,OF_FQ)/]%FSPC"*HFS)2'R^G_UQKB:D=6WXSF4U
M'TS% 6&;8!@Z2A]Y1;<^M36R&E;@A9QK"T:O-GH- G_QNI$IMF"MW F\!^5,
M>A[@NH3.4M -P]]U "NRH8UZ)]IA&T>S&*+$M;/IMGZE\&,J)3T>1?\42$[C
MC(S0I07':X[^+(86XRH9;H!W>W'Q+_%4L'WWUITX6#1+!=!3] )1&T;;@Z]1
MBG'5Z,A/P7_ :,!J^O=T=KI!;5<+WRR-VC3>(&8SF\]GIZB\\W,:-YJF/*11
M/[AYE<YNA*VW:B[4KM/C=25*_O ES6LG:D2E)F3=Q9#KD&I\M]_UT]EJ[)(6
M8?NWM!V7)&)=$4\GH I+]).1SL]Z_>VFV33&5L:X6CNO@\+U,D4S 2/@1+>F
M471<E1N!ONAY!A@PG4V *?GIA]%\-DU+1-M7!C:B!GMMR6V[X$\S%-<F+N&\
M=>]7.(4:,,3U@CKNWC4_SJNIMV 2XG)37,L$7\:NZK#(Y6I3#UR'.(OH1S5H
M,3M)/BU&1S!XX! >DHHT Y4^C=6.ZL6\>MT.!%'[UFL#BJN._J.?V]$BP=%B
M98^;FC!0C^.75F[:KI\#]C;4U,VA'CC'(48'-UJKN*B[,<(]B+VO2'0N?C9N
ME_ PB+?P)SK.MIIEX"+/;$K:"=9$(&*,+UIT4!Z,P2WKA;C9";KZM?SA+PGA
M\="#U7BY%Q?:5DT!G=6YL)[X<1TFV7AX/A:85G37.Z2CMQ^Y3-*$B'YU'*)!
MBK8ABQ0BT>V,9#R;@%"/(PF+BV;85#?S*>;9V<]:5;&TD]7<'D=%BCDC&R3F
M7-#H@LDQ:Z?#=UW\^6TV!_V9IBO+P$L#/KE(:8^+@ZF+OXY3B&MPXPX__?E.
M%'G.O7-$E5X2P23'3-) *H,9II8)7;$?RHVK%2AK-"CKZ<Q]!MFPFL9I@HOF
M3==K$[]IMT(MHL7* $,8@?>1;%>W5()?/5W-9_O90<WZT>_I^2$@J5DROS$"
MW)18U]QX*LM:] D>8Q#8(6< 3M*M1 .;/T:G,3&!AAZ:.NZ_P+A_9(880%ZK
MY:PM/Q+,R%.ZC*UV?2%">HOB*!/,>-N6Z58+J,EW Q+PP4]7M5]1DX'%Q1'C
MK6+=$$/7[0CS&!C&E*.C<V+ [),0T(-QJWE+A%-. CSK\BZ6/81,\?&+!%5O
M.#B7>K FK6MD%LRV^Q&?F\;R/:T,3+R#Q Q M/\$^@P_)B)?FY7!N+QX]?0=
MKP1><6B)*T-!!#46S(P "Z.XHE)XRD38#/4R$+<IA*HXD_ UOL:+JJ)%Y7.
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M2=!%AOZ"#43GN<QG$I=TFF7O7(=DUA(72!MJ 3,6_2-3^Z>*MBSFI^00KT
M;O'SQ1QB8T3J7^L5N'J,ZM;7@Y1N,8@9I2<+_[#YX1'0GI.Q/GLXFD91QH^V
MW2+>+E?MTWK)JK[0O*Z@?KZ?GFW<X9 >BF)?"G'Q\TL_OOPAW2_HEWY,]]EE
M#PLFO_#;H<F[T61^S8_CK1BU5E_GSJ?M.'<3-T"UK>'LP2:+^IQ[4:YL<;TL
M?^DU*74%ZS>E7+-#VZ]%D5OB1-<V$%]X*TI,@<IIBA]>X\:O!B>!+_FM0W./
M7KUB(K3F%H9MQR;%US7M.MI__I*@.Z?Z,<82B7GVO$>.ADGP.9-@%Q0___[&
M8/N=67=M1KS"PX*^Y-K'KQGT;R#!02-N2B-BC"=C@TX,.K&A$WS0B4$G-G0B
M7].)*YC#%UUH::WW5]_CBX&:KY'@=[F?,D6''W[)M+JF6&YE(GUEX[YW_8-P
M!N%\7^'<!&Q>[_KS\[#)]GEQ!Z#SUXUUBR\#T1N\NGZH?ZC_AZU_AW@@%_O5
M70"TY[.I/VNR%@*\?RXJ^9U(]&Z)Z;]N5BI1.RX32U*?M'2V0V*I\UE^:X[-
MPF,M8C;+:N$>K*>W>*&+2E926<,$)E<XRXQ1E$KI@U?5NV==5HOS%B]06_S?
M!P1F;SH"'HKXN'PX74W<;%D_/W?M(QCG@ZG#_SSM3/26!&1 !!"SC]AP%_-;
MCM],/HZA;9_>_ONO\>'OKS\]?_]V]/;]GZ>'_$UQ^.DU?_ODB!URJ'?R+VCC
MZX_--U#7ZBU_7;YY=3A^^_MK^O;5\[/#R?].#I\<Y&_?_YT?OH+^/'F=OWGU
MR^CMO__,W[[Z+1R^I!__>/5T^?PE/7WG*FZ<$I0PB8<%&UH2J1TE!:V"-84.
M%<L?/&:LW,M5WB0;-^KQ.*5P[<14VCV(V2Z<[^V]#.@_H/\W0'_I1%$HJ0U7
M5GCNC K*&5-9;Z53?D#_'4;_3RWZ*Y\7QH9 F'> _K+(B7*:$::+HBH]*\H\
M#.@_H/^ _@/Z]]'?4>ELP7B5*RJJ@FO@B5QJ0 P79"[SZZ'_)S^?.4#W ?AO
M"?A9"_REYZK4WI.<>P/ ;R0Q1E)2*598:BDUSB.&I0VE _ /P#\ _P#\#T;:
M5"Q4C.><%T*7 ?"AH/ W*P.E53 #\.\D\.<M\!>^LC+WG)146B(J71!3:D,*
MZ:A6G%JAU #\WPKXKUB_V,VTW;OTZK#B_8TS=?FWEMV%T_EKDA[NL@G-1<D*
M+J52G E72,.URGG@ EPI[TL_1,YVU8Z>]=9-"EE5EN<549;E8$=I3K1A)>'2
MNZIRE(O2WV;D[%M/O%U%KZ_PKFXC26* SYN&3VM-[@OMA*=.<*DD4%A=%CHP
MQR7 Z "?NPN?W<(#,]Z%,M?$%M$-L171VEL2O"L5-])Y70SP.<#G )_?&CX=
MRRDKM16E%=)8"6RT+#AW\+="%6X(X.PD<G:1^YPI786<$Q4")Z(L')':&,)M
MH62>&U%)<9L!G $Y!^3\(9"S+"S IBHK5A5"&V<D%04K- 40E;H80M^[B9Q=
MZ!O,G.4P>L1K(XG@P1*3<TK**J_RH/-"^WQ SEV(B]_J*N4="=L^WW:<VK#E
M\WYLW!N$,PCGSF_YO"L[I'Z=329^'H_Q/M$G?M[#TQU8%KO'#%HX4^@\V)+I
M(%19J,J5QE>E"":H4NIO$+H]: Y0_VTV?PDT^64[M$^\67:_#2SZ,UCTB_Z&
M(?!XM'"B("+WFH@0<F)\"5IBBR+W>2&M*QX\5G2/56JW2/2NX](08;C_$,C
MQRQR;AS'Z %URN0.LZ?SX'(F\_!U080!_6X&_;IUJY+;/#!>$A@E3X1V@LA2
M,));FI=5R!U5=$=C" /\#?#WO>%/%%8;H2M>E;G0FFHGE?=&\$+A\I,8&.#.
M8F!_!<KDFAE.>&DL$30X F,G2:5P&$N9:\D'!CA X "!VR!054:7/CA75>!'
ML6"<HT$Z;2OK:>ZOF;\T,,#;1;]N%4EH(4/PCC .KJ]@6H/_&S2Q&,FP95&4
MG T,\!XN%-V=\.;\!"]<]P ?9GD+P<TOV,)S#W'=4E6$W 25<RZ"JV1. S.!
M%9)3(]DUTP,&:GO;X/[\U0$">PIP'KSC2HNRDIIX2S41N2V(-C806U'!!$(_
MEP\>2[8GA1BVQ]W]?=$#"'Y3<FNE-[GWLK*E\$IK&W):Y54H=,&T^\H<J0'_
M;@K_SEK\JPHJ*.;DJY(I(@0+1#)G"+4R\#SX@K+A8(@!  < W Z 57"EX06C
MI9:"\M)(YWAIB\H)@W>G#RQP=U'PL&.!3N=<>&"!+&>" "'41*JR)$&4VH>J
M*"D=6.  @@,(;F>!1CM!5:D4D G.*F4M8\8J*@R3N5,#"]Q-_.M8(*?2!Y8[
MXD( _-.\)-+JG%0Z5*6JO,I#&%C@+@<Y[WD.Y^O]E_O9T0RZ,\6;-\GB9#9=
MS.;>97B!^/+LMF*?PYI66M;GGC-:E8QQ4=E@J).!266"9;F1Y<!Z=Q7UG_9C
MGY[GMG3:DB(O /6! 1--BQQ8+^B;M]XI[1X\YL5>+JMA96M8V!] <,WUM]*$
MHA0,$%#DW$M;<"=EJ#APJ,+2@?7N)O[U8I^AT$8J2TI1X6GHSH/7[P7Q3):N
M@"$55@Y+^P, #@"X?8,\-[343 $'Y (P3PM1*.--D2N;<S=L[]EA%.S%/JT,
M>:F\)EQ80X0#MU^IP $*D= KG^<5'5C@ ((#"&X%0967OE!"J:H40CEC;1!5
MH3DO5.&OZPH/+/"V\:]C@7F52Z:+0#BZPJ)4)9&YU<073@5I&&#@K<8^[S<
M[E""YUTY">1&#W#^C$C[CWH0U"T<X#S@_(W@_+-^M+,LK ^5E$05(1#!RH*H
MBDFB2Q-L92307+S[3%5[@M'=6N.Z;\=!_9@9 #\J?GZ;$YP'BGS;T-D+E-J0
M>RD%J80M\=I(3TQ5Y80:JCCP8^MIM:/I 0-T#M"Y8Z-ZZZ<W#]3S>^!G+\1:
M5(71GED25 [4LPJ,X,5JA.(&8%_EK*#Y0#T'_!SP\TZ=X3Q YTU!9T<]M;25
MYIX27P!JBJH$_SVO--$R.!^$KCS?U?L+[QMT[E#:*KT;6:LQ<IM9@([,=X>\
M9WKJLLFVXYUO=AGA(LE^GG'8+0E_TQM^;^: ]KML/V\C]+U8^.'B@Z^WFL_7
M8MV!,0\#1 JI2K":LB R&+":10%^A^&5*L2#QSG+]R0=KMO:"8?C!C,^!C,R
MF)%[L (PF)';,2.=\^5MKIG+%;&V]$0PRXG)62 YDZ%D986[IH=;&P<S,IB1
MP8S<D]60P8Q\(S.R=KI&Z;T6C,B\-$30PA%5T8I(SZ0L"R&*2M_F\L=@1@8S
M,IB1']:,W/"BT&!!OI4%Z1P196SN1.E(;JP@(NA M*H4838OG=5!V7*X!'DG
M5H&.4^.8@-9^[RO[OF%;>J.8PRBZV0I7;K[9Y8:#U :I#5+;#:GMT#+W7=FA
M]-O<^VQQK.=0L$;^\UT7LNO2KJ,%NR7&[\S[KY;;W>?^1FBAJ99YR8UP906_
MY=IH+ZO@!#67'%4XL/R;8/FO^ZO6%)@\5RJ00@I@^7G%B/8^)WEA0FZ=T%KS
M!X]9N6/'$'SF]-D]W!GB1(/-&&S&A39#Z\)S):6TN1:N (22DHF05]H+9S0;
MXD4[8DFZ>!'S3I2:ED10;HC@A22*24W@CS*OC*2LO-5;#09K,EB3P9H,U@0/
M2V?,:AJHJX0'BLM-+KEEOK#&^6#S:K FNV%->NO7,#Z*2L:(+ZI A*$%T1:,
MBRU+:RAC3._L)>"#-1FLR6!-[J\UD>"86"ER)@T7S@5CJ5:F8GG05GD7AGC6
MK=N-S@NQM!*\](:XREHB\MP3X_*2>.^%-F6A?16&>-;MK5K_(^ZW@_^ZT8?'
MC<P/5Q.HRZ;?<6Z-IBL=!^%_X+6F1Q,]/QI-H\C+KK^/_\?,__&XK2@6V_OH
M9+8884D/YWX,17[PCTY';GD,0@'(J9>^1)&*V_:9-HO9>+7TC^JAH/WOU[_I
MC:OU@ _SS2&YIO#6)7[M@;IBP,>CJ2?-6A^/C6?%NMCZ_Q[/.U4_@CDS]_IO
MH@/TZJ$>G^JSQ8-_K \.C$Q?G.>DM-NB>!5W@<Y"]BLB^W2YV":9#>5,6%QJ
M6P8F2F=]A;?-*5DR8TN? R&UP81D+. ;[P[0<1!>YZ6N*!=5+FPHM:Q*YZBR
MK'!YR.V#RW2^_K76Q7H6;&V6R750WK+<@E&R5:4DY4IIJRLO;)DS^*[>^5H/
M2 (<$/A8GRS\P^:'1VZT.!GKLX>C:11;_&@;8K4#OD_K0:_7;^L*ZN?[Z=D&
MG*:'HMB70ES\_-*/+W](]POZI1_3?7;9PX+)+_QV:/)N-)E?\^,KLA*NB6DW
M>YP)^ZHDB2M;7!NV2],_Z@K6,^VNV:'M#$9N@'AU"P3FB;=^8OP\R]E>QBE3
MU_!_&ZP$2N.OR+JY\Z]>,P>1;\LJ^KX3X^N:=IT9<#[1],ZI/[JA6?1#L^=>
MHQ<Z6:-%.Z&#W_W5.V 1OBYK[@NGP]>>=[5ST^'R\[]O:,2_@00'=;@1=?C#
M?_#CC T*,2A$7R'XH!"#0O05(M_9>S?N0$9[6@]Y>/-'A][L+/K>^SL&X0S"
MN=/"&38#?39T_KIQW.67@>@-)F\,]0_U_[#U[Q /Y.)NG.+[?#;U9_6!O5F
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M""3@8  F0@:UOT;=6.N9TH#,9F0-A(T=\#)$Z?MVKET#=H#!!@F&092PY<B
M="&'+2/18IN(O<8F&):E&V<U8^D#JQS4Q_:T]"]<,"1O0XHQ*"1H"C'")^Z2
M=%8+*X+%"6/F;:B1B-1(=$%7W80=C_=WWU<-'NSV:M19F_@8-TN[>3#<[&;*
MT YMVV^_9E9\]HF#] A,\W%N8%%&8A!G BQ*QQEB5BN.A75.L\R*KRJ>-V;%
M64'=1BB($R1*SD@B@4=C'(\8"\5$8D2 B)P3B@OJJ1&*AX>7S=.M?&2<9U)0
M#--@".+62&2XLXA$)WP +699O(G9!*-\',N-I<[I<C$ZAJ_B]]CW[<&$GL\8
M3RO%6LFB+]-A/\.;%X$5377:]FA8[FJ $@?Q.X3AV>V-O;N-BJM4W&GKPYXW
M%&#"&F123&"_ Y^VU'.4HTN8IAJH25A:I=Q<KN)FE5L_'F7;MC<=^=H)50[_
MG"?+G<[:WRO%2]U[V/VQK9RW7HH3L+KOS@(TMM$P9A/,(6=&: IV$*?$ ^]U
M-%Q5C:1QC3WL6EO+S_P.:^ZL=?B!M_;WM&$:H- B9K1%/$2.M'02"2#X2>#$
M@L8WP7L[+-:CC^7N-R/E!I:9]X1D[\M^MW)I=?.&<C_:Z2[I]1+Y4X241Y>T
MIM8[9C@H,.=3 JL<K"[-#:7G">F=N$<IDYMUGS:[$PF<%;MR1W.M&\92>?J*
MY7 6\]<(8#[Q G#/$Q0(2!^W42 #MC'\PZV'_W&<BZGA%?(#.<S63!D^T/Y^
M$_,X9:0#Y+^[=#T&L[T*\>8=+J7 -3)5R13?^K G';'9D8%\"H!M(%1(*T$0
M2UPR17.2H[V53%5@-'7ISCAD;B1OU8Y_OB7' '5K1>MLI]R"^RF0<[G^<"XD
M*:GC02KX!$AGHU8I<.Q,UK<_:5?].)CZU<G<V5?2.MFS!A0,YQ@%P4'.-#!7
M4*L 95P&JH/R7MQHJPETZ$6I.1?^<S$&M7HD6!O !_VYLA!>XD@U)EI(GE(P
MH.0)24# J+!4NTNQ:7[2)]-=S?Z,^@)2U0)M!_,?MKL?<R!37@QPP5:OVQ]_
M_"/OYOP]CFW:C?Z@V_[O* YV<Z34+C3TCT[/?WU]8D,!GH1S/CIKD76&Y_JA
M$;F0/#+2)!DM92+X:I7#9,>PEM>HX<D1"4:05(R#<&7',?>,84YP LJU5$18
MB\?92NF#,E@=2UPM'G-VS'&OTB)O^K%3[GS]?M(.PP,P),!.J&T&+BJ#YK+;
MK!OT.J-A_+T.J<>S]R]=-)FJ4'Q?!K0LNI%$Y+EE-_/O07^:LK /<P:<[RNR
M"7KUQG9.[.E@Z;>YSA^!;3@[G!=&:;&'HERJ63F]S=#2'0XN&YG9[LY;P_7'
M6D9J^_@<B%7+GT?+I%68<I!MGZ352H: C2<BL,3\5??]<$VL_JL.S*X'N$H$
M@0'LV.-!?#/^X_=Q!D"[6PY#>=-EF235!!JS K!:SF&=@5$_OY[?E6I^SV6Y
M5#\JNC*>_TM_O_9F("S7_2B(N>.]U[Z5@/YBS[#)](8W/T!]M,L7[D4L_)G4
MS1OF)ZG'*I=61^].PYEGHD+>W"7?]8>#^)"%_)[7K.LGF/1,6 O@JO]R_=]6
M,XELYOC%S?$%Q]X"G9UXBX+H9(4^AZJ3X\#<G2%81L7[G"15_/)I9_W7UU<M
MX&(-U*;H_0VRG6\S;,^P5L#[V"]9QOD:F-0*3+C0F$HN%;%@%Q BG"4J<*7]
MY1ZPS:UWYUT>Y</+=??<-V7K*@%?OV_MMFAKUY]^V?6XM?Y!M X_B*VS<+CU
M9^FQZ&P=;K 6W3H\7R5@>W>#M,X^?]\Z^ZNS=?;A9&O]ZRG\GVW1%K1WC;;H
MI_S<L\]T*[5V\&E9(6 'G^Q9+",1/B"KI4<\>@86,C>(4>."Q2%2H9=6]<HB
M'8QR^V6S>'#S6NO*-)JBT10WUA3*RH2QL18KRSTS)FAKA"4X'^:(C;X\-J'1
M%/>H*?!$4Z1D7?)>(N_* (0DD(W,H4"4IT)RQ2S/FD+JYZPI+HD+6CQ-\1"6
MW,T..[AX1, S,];&6<:S-MO&IX]WL]D>\+"*AY_*JYJU6//V__P?S22_5^RX
M.#S78<=SU:IQU+]"J^J0'%,A,>HM)R9I$I4,'$PP9@#%\8WMKZL"71I%>VM%
MVYXQR5*T3$2J4!2:(.[A'Q>(1($IZ:+)47)N:96ND,>HV_8SBV41T>3.5E>#
M]0W6/S^LSP?< \B'8'CB/D0=G?<V<NQ-M"3Z&UM0#=;?(]9/C2KM@B%,!Q1H
MQ#G-RR M4G:_.1<3,](E56(]7W"L?[5VTUV/5GLF=M.GG?7BMP(LI&+C>U7'
MH?AHAW'1')>3]]/[GLV;+($KVOA\%$A5#?'\N3,^".(8(51[CKG5V@OA"741
M)VT8N[&=\*[7ASYVWX[ZN5#AZ5B0LASM@CD^J$J.D$:+W$:+G,Y8#)1$8R1/
MB/&4$">2(&.-11ASXH@S*5;)PMHLG&MNT?%O,?=I&KB[?[AC7AO!*4U,6["Q
MB25*.<^CU4%(*^F-J7(#=P\"=U/2'+S'%E./K&(*<8/A+\/+4@E".A-PB&4:
MA[DJ7VA1X.[5DN87OMDP27 NWO;Z5=(&P,]X"R+GM5^]'3%8-._4P\WY3^B:
MQ9OSVRD;K?-AL\1''2)P-J$=U9$H1J10DE-Y8V[]3UEIMLSW^IC[.EN[HL[Z
MRC56-G,9[$;CW$+C;+V=(=@^5]W)]5UCY!QQ%CC25B3DJ6 <-(#BRB^M$@RR
M<$'E_&^SH%_!@J:<VZ0U2R99[@1SC'K&@J,1#&CEQ8W98[.@'VY!3RDD3%?D
MUBB$+8N(JQ"09=(A+RGW@B41_0T7=.-3O+_ ^>+O7N9*987G,8=:6-/[WN?X
M%:,GPSH"":(JTL"-5@9X$3$X*F\,!89T8SJT#FW^5N9(3XJW-*#Y,Z Y&RM.
MN+-&*(8<SH$)S@IDB$HH^L ])2F4IUHKMG(Q O!N)*A9QL]K&5/IB,<F'PD9
MN&+*!*N<44Q2:@BG-X_7;9;QO2_C*?=QW.-DI$0P,3Q7[5/("4F12IPXF"6B
M!(-E3%?$$U"?%^X9^E$8ZKTQH,9^?.JIONUFJ\)6DASWI[D)23/CC4_42.Z4
MJ(YE;QC04T#G;&BF4HYBE3SR6$B SA#SF>P!L0 LP$F/6<#WRH":9?R\EC'#
M4C@F(P@"YUXH#;Q8@#'#L!4\1MLPH*=;QE,&9+0C1%*'! X:<:8",IQ@1%3$
M+F%F@0X]&0-ZX<Z?*P+*&M?/*T7,$$TBP3&=I. ^$&N]L4X:J8P@!H>&^#P5
M8I[.;8 I*G*I3 <F/A"?Q)'#+*+(&59<VL@E65J5/P3,9A6_S%4<=>(J!D5]
M/O9&6JLU](\%8:0S@L6&]SS=*I[Q_*C@"8\P]98![S&>(3 U.?(.)Q839S3'
MB<J5BXEEC>/G)Y?3Q_;@:U$6WBO93HX!>ML;E"<XK4=7EC;?^)X/8HD!_JC/
M7UEOO#_/%3[_+@\L:B;OI4Q>"7F_E95F+ZOM?<DW/RBW6_=XM:S'>.41-DWI
MYVM*/ZNK2S_G?I7<P H3!052(BSAEF#KB$XJJ!2,< &G/<Z6[J->-%U1KZMD
M-*$7E^V3=4]=WKTM8$H%R\<I$_K[ ]??W^Q^BX-A>9[=9C>K]+5N:)4G-><Q
MWOCO")CL3JZV7Q;DAQ_?5L<Y[_9MQL*J:O_TJ(:%*;E_.N:X\,Q__CX$;GGZ
M^? KV5[_V/E,W[4SA]TZ_'+P9=V+UOH?AZW=@Z,+)??_?'?PY9_6V9?=O]K
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MB(!\$Q2,CDQ22Y.R2ZN:+,-530[HRZX<T(#F(H)FX]A]<KB<.G9I"D3Y9!$
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MC>MWT97.YJSK5TJ829K+^V!*$!="(8L),/,8J$F)RR#<TJKARP8_@B_CA>=
M-F#8@&'CSUT8&)SQYRKLF9;:(V.M1URY"'_Y@!P3C"IEJ%46N#=I,+#!P->
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MC<:7Z&Q\F;BFVMWNSOJ5??5S^7,QFUR,JQCT=.)UVM]*>.P.R@LPN *0?4?
M7+6[7W'(N6XH8Q[>7A$9J0H@7ATE1$=P;8?O?%__WW\!8?5YO!V#OWFH Z!
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MJDAJ1&-(D0M%D,IT0)8$QH2V1N=X4SIRT"6I;2.7KU.)SYPN/IT834&L*(_
MFY 1R3U#)I<8/ WF0]"82JE! =XN;NZBYI)34L1@UV*B) ;*8B"O'(P_US;H
M_'$7%7.G8RB5<[,W^&TVB8R^:!(NJLW.@1??QNEB79(O9^?PK?\2LRUE>PAF
M,5J1PAAEJJ:NZ_Y2#@;LWWELM<H@5I'(,(OUW?'P/8BD8A03C0<QCCU)1F6,
M@_IXY*8MT*X*\>NKIROS2%T;8)"C&&T9SV#X.E5^[B[5P<>OZTK=Q2!_"F7.
M0_HI! VV00Q)1QMA-FH"F57U5>L-S"[FD=H4.RYK\R9.LG-7YWF+MDOR$28>
MU=/U\P8$"\;+XC3F>_593XI$-XN=.%8LJY4'-MO3V8)V@V)%FZZ.0\9N"[$B
M/M%1=5-W->HIQ\D"/8R',2 /A#-.!RWL610KZ7&VF-C9.7@OH]A&86SM#!RK
MHT@4]=HO'PZYI2#B3'_VX%GY.\STX;'D^L^Z^T *\3Z!\')#6+INS;[D)LY/
MO]S8PB+#64/JK8P (FX.8.B!K<L\.G'-)!7B<%)N *1",:H(>M'B'E7L#2PT
M\=.K1"ZC*B^RFJ,:I_C,2IU;W;LCA6Q2S5=L;3=(+1)B#*=-JXW&TZ(C!5-V
MK4H[W'V\XVJ99G,Y45%W>DY;-&3TZ%,\S6/3A")O E\.=R.KS*)@,BGC]U/G
M-1K"BTO;T5F5$@%Q-;E:4$UC,RQ.=:4K(O'5_%L=+YG7HI0O!K^0O\&N-E9X
M>V;%GHU@>J= Z<,QB*@V9A*EC$.PWNZJ\Y*4XJI>/U==36.7.D%)_U;M[PB=
MCJ/46[EN;U #(\S/@JQS$CKY9""=F)FL!]V>U!NYE;*SQ:%V)]$9><I6ML-:
M[<W2]V)Y2"\6TO=B^>I>++?V5EGJQ6)4"!)G&,QEQAVWBM)8'&:Q8$Y+FF_L
MQ?($I&';+RHF^^;)FOJP4)6);TXLF:NZ-/5@L?P^::$[BJ\JZISB%P%^_<\,
MS*4D>6%-3L_&LZJ>PLTFR^9T"@=4QG246XW-WQ53-TC4)KS=Z;=2N2/1:*ZZ
M;47+$A8&Q46JE78]JM3T/_;ZY[NK_DNT-9OJQ;7O7B.(%[RHRGOJ-/6M#L%.
M_>DD?=-X6<X/019.TCWI7&D[D\8^6%GKN'OU3D2OY<_Z'=4;XXKY+Q=5J4.;
M((A+.?>Q:^L5]A<\E%CL%@^ZSJ/H32XX3:\[I,IO6+=.7;6:"C$J[["*T:=I
M?2[\)=Q2PRX,K^HN:;$)3=W!8.2]BQ]3:4@8^KK@>5E+I7;)22^#5UA[>E4%
M3N.;P/#BQ]J+ZRQPF6@<OE^%>TC#>>5M2E[4/Y'=-5F,,^W@D75[HGJ-[AN3
M8\9+;X*WF<BYRJS23$DNN5!4,1&^IF/'39V+VSKH9QQ".;R.(102?*9-KI !
M+P/QP!G2F&JD=,#*!9E[*G?V%;]3$])[]:/E@9DL"UI1P5F&038;3C'\*[&7
M <>=)XI01OJ=?_R=O_YP0EFN"7,".<P%XI(YL*4X05@J2C)"1: A9F>SO4TE
MFVT2*;8 J X!#:]V%R5]UWU;\KAN**C"EF@O8/=CH%5(K+5Q7 @1K,R"9^N[
MCBY!@]@S[V:QI^BF^&IY,')'X%+?GMTIDREV#,/[QW!L/STW@KG^0(Z._SCA
M4O'<9@09DFO$%5<H#YJ@('*O#2'&6[.3JB\OHN<QF?DUOLC3=:O_7+4"UI4=
MM(8;V%:^,@%B'=HYO."LW(BQE*Z+ F]PZ6.=:8RGQ%-VY>"7Y(N/9S!V5_[M
MQ<:@Q8WQLGIYIU54NU[?"@ ND?]%Z5\T'WYU17DQU%<OBE%:A733.GBYUIW:
MP[5+%>'7YF!W]>][U6]+2'C5CUSLY9QO_OW&FV_^$>\)_-";\1ZYZ4=!\@?>
MVP]Y.X9,[WAS A2LJ?I1\(G7H=96/'I' .(5M&35CN:;@$O64:.O&?)ZS,A\
M2>K*[P 9>9Q$\F$EBE]'4?S?9O+W_>3]@B2^ R)U(QO!</%KM^-!E_9T]+3H
MZ!TH]!])14] ++$?2$XWXMX^-5J+UN$=2.I1]_R;+>"/0?3>IK$T.WGKAO9L
M\Y5L0]3W9IM>5/[H/7^2HK(GB.\F!&XQG!ZRW/_'6N]#N(U<8L#DR6G.)J_7
MB>@NEH2\> B[W6/%>D/DQQLBSXKBMVHLWV6+>A9[NOOW6';G5[[_V]I _>)\
M,],EI/^YOR G>U0\ 6'0P>3IM&>I4G*=2J;@_3*/_HA%W;KE^Z]ONRJ):FY:
MEHJLJFS,%BW+?9J7>4><Y$1BXKC+<Y4YZIGB&=7,<49N0S%C]SIQF&SU"G)Y
MM>[E]9?ZS,I!?13A6']I2V#8TZQH./MP_F7X]OS#U=$_W^"_/AX5\-_+^+[#
MCZ_%T<>C\R/Z_NHH=C2E,#:80W,/O&OV%WV?_?7Q#?[P\<_S0QK_>P!S>W]U
M>/R)'E(8X_$;?'3]!_OKW_]S_N'X_X7#*_SE7\>OIX?O\/71QS<G>0A*<*.0
MYUHC[G2.<HTMRJS5F7..2FUW]K-=2N6&\IFM8*_M$SOK%^=.BOD!J]!;MH]G
MV?9:L]>:CZ U"<:68N]M%BSG6*I,699)3:D6V@==]R+A32^27FMNM=:\[FI-
MEG'84D&!U"Q!G&89RAD6B'F3XV -P9KU6O-':\U'<Z=[C=!KA$?0"#*HP EE
M&:&**V6UPR'SUACF<A 9[):NB;U&V"Z-T/A1ER>Y]Y(Z+9'3)B!N!48:% 02
ML+..,6MS&<\@T%TN-F'$;@5S;9_0Z?5!KP]^6GV0,\^MYB9W4G'CN>*<\)PY
MCK5WVF>UAT!Z#^%)Z(/K5A\X0W*"'456*(ZXESE2@GMD8@ U:)H'+9(^8/DF
MO(NM8*[M$SIK%F>;BF&>3$9IZ03Z1@5+'WL='QK)?,IR/CA'J<R5S0B8A8'D
M\6]*0NXY\8:'/G_R=.3\T<O%_ FVN:(D]@H%[8TB!!4"7\XA(HT54@A.N011
MOTO4IN/'CRGI'\!OVRJCOL+R?SRILWW+LE5CN:4RJ%<>CZ \&+:$9EHQ)2EG
M2NC<2*PP#TSI#-R"/HWPI)3'0AJ!4)$Y1AG*P%] /*@<Y5(0<!M8L":JCMSN
M[-/=G&WJ_-HKCV^O/!Z_*J\7C(\@&#W+):>9,$'&&$J>"ZUSQ3T.5C.O0Q]-
M?U*"<1Y-ER0/DBB/A#("<9=AE+,@$<<R8[#7WE@7I2+)OT=RM9>*O53\T1MW
M#ZG(;<:<4DJ33''BB,[R8+D,\%?&F>9]3/E)2<5Y3-D;DSF#,;*&>9"*0B(=
M:$ X4$9=;'6F0"KR7?5=0LH_MU3<ID,*3R F<1S1D7Y,%>7&8RG-+_5[&/SH
MQK/8-^S_K#VQLETK^J-RJU^[G$]??Q)LE%;:">L(C[VFG1 \4-"D@OO,R3Y6
M_X3TY[O%6+TS0#&4*$0-YJ!">8Z,B;">1EB14:95%G;VY2ZG=+NRLH_#EMLG
MYOHS$D\UQO^#M?NMI-_K^/L+DWLMZM/7]!I+8:7T4F'-M56*6&9=[GT.ZI]E
MID^L/"E-OY!8,8X$XH5!A@2!>)8[I"B6".<R$U)0<*'9SK[:Q=FF?O _ 7-N
MG\A[SM6\O:>ZA2;Q4]9?#P(7Z/77MNJO>?Y+:Z&QD1B%G 7$@U-(&V^15(%:
M3[T+P>[L$[Z;<?)$M%?OI_Y\>JOWP;;#S'O*.HR*0*QRBML,A%EN-#P'M!>G
MQF#+B>VSE4]*A\VSE8PI*P/12!CM$?<A1^!9!U!DPM'<6<(C'A>1NTP^E5CK
MS^J!I63GWQ,\3A?V=8YIM1']B,J+!?0C0E?G^_WAC]*+7Q13V%*[TJIW#2#2
M[P'NGPS>C.P3AE+>..FU*%!I.B FQQ5ZYXL* "I>%E$A_H$$%8-_#L=&#P<O
MY[!B-3K>O^K^<P=-]]RGNVHW(V6]&0T.]56$LY*+B)&I\72"AX]HS*.!CZJC
M+#[[P6FU:'9ET=JF?8N@Z17M[0XN9I-RID<)-?SRK+!G@V(:83F!*8OR+$*'
M+CVS0>=JL$1W5]#N[?@<N-<60!'7+49KM;>["4;SU(\BNI>?Z(NK%AQ]CHH>
MWW#FS\<79\6PT(.#"L_:#L>E'UZUK93K^\HGS#HW$\'[&AJM"P"X2 T)#+6\
M&(_*(FJ"N&Y@X\15*6KXTM_/-&P]^3N%Y2M&4=\,IA'*/:UHNA[4D"Y& QCN
M+( 2G$WBK5$;?BZFA:]0Z9N] _J U]12:\W+RYDI(UYOI+'Q9.@N"^>[U+&[
M^)KXY^233X.]A6[V!N_TZ%2?C^&6")%>CCM4&;%P%^%MX].Z5 G/B=JQ1BX^
M./A_R,"ZN+6$6*[0WT]+8>]F)B'KMB#TD_.R02K>0'*G$Y 5L'(U$2R(H/F>
M3\97>CB]0@:V(^YN+8-VY[#VR4J)+TX/C)137U,FT-X94&U#FE-OST:P)*=7
M%<@S['N%--T=5R.50)Q=@)R(LZ@)H":T!?)>(K;X7:U[XD\K$J:9;3/Y[HOU
M ,P5U"["[GP5=IME& 18RMU!F$5LY M=N*];C\6Y=%:GGO &5,5JTMWUJV<U
M'7<>Z=?B)+>L,3W3T\%L"GQQ75T)O-2@(E\-RJMRZL_W!J_J91Y$4-,B%"V\
M\^Y@Y(O(;PM+.(*]FPL5N/*\F-;-\ANI-6QG-TA";KYWL(CCV;2,5-<B@7?4
MU6Z[;#W7MWIE"%[F %AS6,2=B.L]T@DY>Y%BSB+@>_J]VO<&\KZLX-!AHUKE
MG7"Z?=R9&5#850V.#I^+887!#L^?Q WZI?A;Y0@DE/0O%\4<Q?T"KH&WVJ$N
MSLOFC9]K6FE>5(R209+>L@M/V_RXB3^=P6O',)J&.XMI)2CTAL?%6< CFV?>
MA*_KE0B98I);9KFPS 0E%.,L V>/"*O6AL [ 0/8/?O"S28@+5SI1TW$H#P]
M'[]HS=OC>FM@1O'CTXP$? 7,\OOKPX\?3H2SF9*IQ1T%AUXQ@PP#UUX+2RAA
MQ.C,[>R'(DR]'PVN@*[+93=RH,.T)J103,II1X(,2CU,HF,]4;2R/S+#@J!N
M^6:):Z)(!XD$]FP4VO"L:/'"#\7$ _D!]:TP#WRWPCM[@^.%I[9FC_$=CHU2
MO!:H%WHR3??"M\GR!^ZSL^@KG$?>BS,U$Z_!.*HUY[AS6ZT\C1Y]FLPNIO:J
MD:6=B_8&[\'8:U_>N )1@,-SRRAJ$Z?7[D:C*Y?T-"S<7.W4(GUW0?\L*V=_
MDVJ&U1Z",3N;@ER<UHJB79XU(UYC-53[!!_F&C$2P.BJW9!QLS=%U,;U-6M>
M7*GN!>.@8Q[M;K**:FU]J[GST'6KC>,.U:R;V,^K[B(-^"_>SAK-<(-Y._'6
MPUZYQ#\783*.<-0^R8?_ND=PV5!%M-4YH\)RIC--<R9B<R7XQN;*I> RB+0J
MN P?&%D(+HM[!9<KI^=@Y%[-79X.#'L3<CX>_^XG\;&_C2=O(U^7<=9 @8DU
M7NO)R+LV[)P].V7SX>KPU?L3;7(?DP$HDY8CGE&'8HD6TEHK2ZVRULF=?0DD
MO"%V#"0\;$(O8 *!:7R:_&-@VYJX%CQ3N-R7TS$8I!?Z*GY3UF;6:?);*]8%
MJ5W /8TK.[>J6Z=^P<DN@!)!:(!8@%] 4H)RF8)UTS&(DO>_5A&VX^EZ_I5Y
M-X[F69$D7:T66O_HS:CUKW=;3WW#[&<7\:_[<).2-C!M#764<D>!?XRU+"?2
MJYPYD3\&-R7#JTG(-!SSKT(;< :F5X?-JOQ>;=+K>E['XS^K63UGOL%OC]^?
MA(QR3$A,N.2Q&8TA2&EGD+?.9]RZX)R*<'+YWJ9F- WC@+IJ66%V\8@<4!L0
M+1-T2#W^<G^Z#+GTWF'#N,FX"0Z$.Z-<:D&<$KXNXWP,NCPX!6UU"JK[H UB
MU2G%#D!+2Z.''@Q05U_04VJ'4NGAQS].".5".\Z0(L8B3ID&=\()Q#'/2-#&
MY90#I6;9_2GU,45J-/^G\73; &3IK"+[]OIO*?C;.8$_7):S\R:4O,2",.@.
M&W;F6)N;'0,K1@+NS5S.*Z.(522 @XVE-3YPPHT'!4PR)U@O]'\H*XG#ZS<G
M6.;!P 8A#UH9<>,"4L%F2,K,:(TSXYS9V>=2W&8M[3:IIU&LA/ /H1=/P<!F
M-L\$TQS[8#*<Y=I:P:S-F!8G;]:1R9NCW^Y*)RTYS$4O$$',73]K.C@ZMB=<
M,0>JG8%GFSO$\]PCG2D7SXOG-J=8<Q%V]AF^W6I>$I#W)P.;&RX)PQY(D M.
M-':YL#I8+46>J;PG@V]#!F]?O3[!X('G>:Y0GI-(!LH@@[U 1@:6@RS71+M8
M>7.K.$ADL*@0JWAPC((9?W.B8S<F3YJTUL2G;&CT^\%%L;;5I(W>/M=N.0#3
M)%[JG%(Q<:B*DJU5KTO.3Y,7BZ-)&0QXTV*$(06!FLQJ"LC-U7K]ZC:^=4M*
M)ZV)3K&?@8_$IZO$;Q%K!';K B'D0&U-8X0QPE;KTS9/HD>C.)&1GR8+(&7^
MRED<3R>H'Y^^=CW=S%?32T'[>>A]-\8ZP=)8#"?%[:[3!^FJA0#3Q;A,J_<B
M1?= L?YZ6;CIV0N"\?_]M0[F<%%%FM;=IDTY'LZF_M>Z. IW[]]9C64M@'AO
M>?0JG@=>6,C.OV>3>67:J4<QO/L)I4CW"SV\U%?ESM\7)@^F'.HNY\HJ;?=2
M'$<A&XDT6FJ1>=>MS!*=58+8J! DSK"4FG''K:(T)\)94 -.2YKOM*DM=Q 5
M@,3$ATP)1Y3DSF"%L=9.@##3@<IX4GMA69]4.!36SQ3 .?!LW16O50E 59!1
M.2>5B'P,"7D\'L3"'G H[J?+@P"=;4P&9AT8E\I8X8P6'KQNJ@SQ49>O.5UR
M9\N_5^5K5+DE"9O1Y#IWP2&:VLAGH,_!D@(98UAF,'<DX-@>\G9-/G<K8P+-
MQ Q=[4BZFLH*T%1GXTL?,[T;B:.FTV5TT-R$7.8XDY[RX"3PN?(X>*^-!//C
M-E2;9:LOY62!7-;E9!>*$0]&KBY%;%.UY='LW/C)V_![S5$'%S!FF&6JXFHO
M:PD+/S_"HH?'KT\T XJ*T4'+B4&<!([RZ#F0'#;/"(7AP\[^:+Q"5G-1=:8_
M^YJ2ZC5.E!3-10^[Z3=344N,/XZ.&C)Y60=PWD[^;*,SK3PJWU1^L'LS.IZ
ML*_F\?L$:.Y9$]#1\8<3&YA03A'$L@R<#($%F#PX("4R03P!I8WS]0345F-Y
MWR4BGQ)?Z^SKAZ=$ZS]K>S2IYBTW"XZ[6>OZ&,J:PH9NAAR\J8G3(^NK7P[>
MO01%?U'808:SIMJL(N/*49F7>.F!K8-N>X.#Y'?\SVSD*\7!\.X@,EF5EZTB
MH-,Y$X 8 "YH=ZM;&QN??*^(T4-*>!X489SKCL^^DYC=R-O/T.H0,?G*G*?6
MF0SY8!E8'8HA0PQ%E'/G<V:\U7YGGV!^UWCBQ%_$FN#1M*K=:3+Z52)H"8BD
MD@OW3/3_<!IJLO_OJEG\!G-XUF1T]/'T!+1#$%1+I'(OP<:@&"EJ#.@)L%TS
M9XTD>F=?JCOE\*/I.AO!II<@A8I1-]?1ICK:!,V]$APY$]8*GWO'.+B8AN41
MPR-ZJ(IP3>L$1]:0#GM(R+(O$GE< CN]//QX<"*ITAD.&&DF,.+@DR)E T7@
MIS(72)9K&N[B'>UU:R66#U-$7WHRJH]J -54?[1BRXY+D&K@4T7/NPGI=4N6
MXFU-T6*=T:HB>/^9 ?EVST-,?'%N9I.RTJ+PA/-65X?6YX\'2](-98H)GOOI
MWN H,D%3==UD)&'HZY/L<Y.K:.R"IC1M6;_'U&.588SQR#G#59Q6C: JI^\P
M9K(EFM5(19>?]7#6U@-7I>'UU4ME7_'[PJ635:-8,CJ>@3J  8TGY6X]VB8-
M&K^N Z^+"=$4/NF4%$PK\V0*9EK*@(Z:E6P*\>L:GRIS/$LU?%65? G:RU<K
MT]XUG1]\JD,UG_6D2!&Q9O!UP"M1TGCX.2Y(UZI+!8L3C^I5\9M6?C[=M(8E
M3""]=M/[;MO+*HP\'':WJMW(8E2%P$%1CR<I>%TM0753=]5BB*;>^69^@S9+
M8,^B'$N/L\7$SL[+:31,09U;.YO\M*6-W>V-K%[$B50)^50S7TGR9**/S; X
MU17_1G-].4N?&*ZM2&T/!+6EJ)4J1*?CN$<KMM,BI2W9_=VJ8*#.T7@Z<$5I
M)QYH, XZGF3VU?=)1,2]<T@/(\-'6O6=HF&=^#N)J(4#7ZT1-TT5TO7,5\N/
MNZ<=%WV]*#QT?.!LN%H3&FMLKGWDK!0HG ^@$;A-L+2MOX[!STC12< N;$1=
M6+UQ+>%G(+'3LXX7-&?"FCNFRWQ=OV'3SM0/: Y:3,8P[3(NUJ6>N$I%1 5?
MAIIQ:P&ZGH"JN-UDG')"40U5,N=SX2]AA/^9P0[YR; B&>T^@J<7DU&PTR/O
M73IE$K50&*:4TIK#1L"QDXHBR]GY146RL?QITLI@F$S\6(^R/GX495.YV9],
MPWGEK8_QE_HG$G\B:G&[SW0\.QC\)&J#9L/O:=L%H1T&N\!@$],-T@B:Y2&W
M$ML,9(+\BLAU8]&M:R31EJX\8POM$SN\/CA11JI@K4,9]QF*R+9(*8L1;$(\
M2D+!FL8[^WAO$XQ'UP.X5ZFJEIEVF8/_,USZW,!_J*4T9$P)$4PJ/U"$?D6]
M=[_QFS?>GC =%)59ABPE 7&<.EB%##D,;E\ 6T-QMK-_AP!"-,=]/ ;MAZF$
MKF-[=8-./ZUM\6;42LLU0G*Y#P%0Z,A5-0E+BG5=AX&% T'17JRE;?S^S=&K
M;A50J_J;PSS)IJ[O63QKTZ:5[A?!X90(PH%M<<8ERS4(:054XHPG)%.XZ@,$
MBU+U ?HJUNV]\$=B=7$$,IZ#%+=46R2,M8A+DR&EJ4*!@9:ESG%.\GOF*&MW
MN>/KIB-NB;(:XV-^]:5O'.'C=>;B_32',=X120+8!S!R08W$DAN?*<<R!C.]
M9PZJ)\3O08@'XNWQ^R^'QS#+CZ>7AY<GVC/'A<Z1RHA 7&FP.[QSB.7>! 7&
M'[%A9Y_L;>J>V)"DJP_W1\.\^#(XA^TXBZ=(HU.UP;9-R= OR4\ XWM+K-44
MN_X::IN=SZJ:L)[NYG3W\0#><7K"0J93&MW2H! 7(2"MI$0*GD=)_-7%DPQ\
M+[^%VM*)9-LN=7UZ7T^GD\+,NF;/@J2L?:-*^AD]G+NW"U<VKO$]72C+?)9)
M9JCRDBNK-;;!<9P1)0RAAO8NU+>CKJNC5Q].-+$2[&6"9#QCP;,<U"OX4"C+
MC!$>E"NX6-&%VM1$KR&N%)\POJL7Y\13'4,9E;/4QJ?MAA++.HJR;>2P'"%I
MNT),_+DN1E4;E,GYRMG>O:4JU,?NY[!(3N_LF7>SH7\;-B7K2I" 1^.1O3T?
M7*9BQV,8WC^&8_OIN9'@]0=R! ).<T&BD8<4R1GBFE*4$V>0!*<^=]2#9. [
MJ?+Y(CI<DYE?4^W[=%VPNBRQ[++.NC+PIO?1]&Q2YWWN:C-$CZ8R8W4T=8?#
M\64Y^"7%AL<S&+LK__9BHX-[8\U+O;RIMV.[OE4+RT3^%Z5_T7SXU17EQ5!?
MO2A&:1723>L:9%8%RTKM24)3S7(-E%<_OZYGWJOJF9>:=U8_<K&7*;[Y]QMO
MOOE'O"=8]L";\1ZYZ4=!'WIO/^3M&')^QYMO@7^\HX3ZIEBYZJO *&\=<'TL
MXVN&O+[I;;XD=.7W@*=,$OFPDL2OHR3^;S/Y^WZ4Q@,0Q'=HZ]Z(1K!;_-KM
M>-"E/1T]+3IZ!_K\1U+1$Q!+7X>1^W7D=&/C[J=&:]$X? C>Q-?L^3=;P!Y$
M<3V(8L\VC\\V1'UOMNE%Y8_>\R<I*GN"^&Y"X!;#Z4&((M9Z?S< I2>G.>N(
M5[?<HB[\:YJ"-$&O%P^"Q%I=NH>!L3RYA=VJL=S9)/FJ#>SW:/OWJ&>RI[&!
MW](&_<KW?UM[J%^<;V;&W!T'<G&@] E(@DY;SIB47CZ6M9+1_K: <W<V#[=K
M$7\40N;/@W%I8IV[4#9(9;F6N9$9XT(;89T3VNFZJ('?@-/< UE60):OKP[_
M>71V%,='#R\/C_^X.H)QO3W^X\OA\>OKPW^^QX?7?WXZ>O7I<AG(\L/QF\L/
M]#7YZQB>?WWPY>C5&WIX? IC?@WW'E[^=?S']=$__\!OC_\1#J]:,.;KMZ_L
MB5548<H""LXYQ)EE*'<A1YG7N3326^;9SCZCV78!66Z[>'Y44.7> ?F.]FNO
M&'O%^!C@SQ$Y2*B<>9)QGN.<B$PRQ9RFFDCF:_!GWH,_/PF=>=W5F2%W&<6Y
M1@$ST)F&$F1B>^I M".9\ P;N[//=S.VJ;_[5K#7]HF=1]6:C^8T]QJAUPB/
MH!%RR:W%$CO%%=>4&2.%$\$SK80*7M[6R*G7"%NE$1HOZO(D,,=P "5 '%.(
M!\=1[G.&F-9>$9%+EH,+17<%Z9VH7AWTZJ!7!ZDY&[%*"NT,P9;;'&O.N<_
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M7V*RW0',?!9BIF[B5PPV?YM]5@7G8B"PM=3B3R5([S+$&SRJ186=%)'A=9M
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MB>=FG*4R$A&+PS3&OR*9! Z7/$H2PZ-A[>Y*%MQ==^'1QW!W_8!\[/7WSL\
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M:7UW.72TMWOF1,KCS/=M%<4<3_)=.Y$^LT$#*D]%3A2+Y,7+..H!A2_':%4
M#@#79DJ1U0+&0BYT6/-:.\I$SZ&]DG%1FXJ 27XO\RKE(]7K!//TT/S#T[")
M.54S@=1\HA&XOE.' GG)3FT9@7U2/0I9^L+UF'3<+/$REGD #)0/"I%)I504
M9&Q+EM]$/7[PSX(LSEPG5;871]CQ.U!VPGAF>V&J8A$(/\Q O;&@%]Z!+N>(
MT1 I"%9!\?/OP=(&)"F[=#='=D1T59?J\+;=Z?D4$#WL?[@#YJ>%2283.OWH
M'BF8>Q].@;$7Q6D6IX*[(5-Q !@L=EB6IISAJ=BZ<] M!7X-!?;W]MF9]-S
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M]BE(K.VFKQ%8?O_JC 7*S_ <1OD*",#+F!T+Y8# 4J%R0W@!>I[<6Y/&LH<
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M95BR/$X!U<LH GV0>3Y7;J1\@06E>R[['@W9M]C^[XY&6J<+7'?'>PK* $/
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M\#,O0>>?FP9Z\Z!!SZ-4_YV2^!WFHWPX'2(^$A>F=V;SK@F>%N$2\?&X++X
MN4_48'8_:1OPQ)?"E5GD,-@\'JO8<;PH]%U/2.D_@K3MV$E'C4&PY3?-;PY
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M)>RCG IL-]Z*,_Q#@O$+TAAH#LMV(-WE544M4/'O EY0@@TW(9 A6_(S\<Z
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M(%!0+RG+F,>S-/.4K\)(@LJ)@\>H#K75,W<EJ4X<X3L&.B<$\O$BGMIII'Q
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MI#LL;'I-N/3^( !F ?*[-KR-#*\::%NUN*[4+;-A'')*$]0V-S:_SO73>M8
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MB(L1C.-\IOD+44 !]&W*_6+GB('N7F F1-"2=*[(%0(#.O, <5$,<V%A1+'
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M*K+<>J-&UV <Z^(E]-5*,V5U'&'CX;LJ"('A>7<^JAUQ/60%&)^^A* PP1*
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MJ^??D6\#]^J7R<-[]V8-7# U9?HHPQA!:RHT"T":-RF!TF;G^6(%E@8X/$_
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MFFEE^\95&X'<S;=1SA?T0VT2@;X12>^,(0Z.3Y<55M@]SE((H';6(3V -IE
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MB,(.=T9W8\=4)ECPJC"U_JMHCQCLPV.AY3R>/;NTI>Q;CV,U![:JM<! QJ-
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M/M0V.?-B*?A)\MIHAY*N ;-%N$HSI/J<%,.!#'6'&1HX?R)U;[JGXCYC]XU
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MN8C2PC"J6H,-6S U%<]W3P75L-IL5*3)990JO$3'BBHEJ].K4LO.1LNWN.!
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MP%,6*&<FWDW5-+DH$Z^U5.\,C60FF.9(JGBFF5AHH7G&2$,#N;(-"M5SD-(
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M 3DWNZ$L5MJ2GBB&O7ETF%(Z);Z19R540XS'#'8;\EBV[+0%\WM 6\+87\6
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MWA3;L/%, ZY<(_1]"G7VP 12'U5C&M)I/3,<[#N?]W]^7<8[K4W0"BPL3QO
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M$/.MI&('T&$L+4+!8T*;7OEM.(XI@<^'\ZT,(<BZREQA4W^@2]BKI XM56D
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M8'E-D,24UW3 ?;DGF,[UU,Y+%IFD^D-4LHV-R4MO)^Q*CU)#C(+-!%=S[Z8
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MZPDEQ@89D/199B+>X;:X1 K"U^DE&0I,(X/-4P@RBH :8:M,$;.6* L"L<"
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M$NV*L%EA?:X$280X)*Q=+SC=CR ,NOOB!O/266&,&W KUZ@48VEE%%ZI"'&
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MB\<;:V(\)58YAMENX. M@\#(_/[A/3_A$NMXG&4*8IIFIS*_/=*)*]< E,<
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M?DZ(7C]2:4 .U&@',A&'BQ1UB"/&_[4[<S/0%6&.FK;8SO KCP#G3P$X'XT
MY[M%Y%:4RSGH7/5I0 W+<*#1#,H^POT0I9U,NIZ3SB88R\GA%]Y)_EQ#G&L4
M 1"5I32/A:=HZAYM!0G92X: 2$"WY5CUCKM5)%'=+ZJPH3US>(([/])K\<L]
M>#-,-^B,H<_<3=6THZ#V+=P7/>EMC4Y>)"Q&+!Q^)V:PFTQHII%_-VH#[S3'
MT _[U+%O6'K3TIJ8HZ4I"WJ<P74M41%)FZ0ZWM@^3C1UYX$;0#X*DJTR+4_5
MP#L6I82"VN46Q81W?YM]"B.=.;;0#96[GO 0IG6QJ/R?..%:IQ^YYP_ \N*P
MF/9A[)2Z-UF=:[IXE\RFI8P^5#*5'#8G.+LS[X]]66Z\XTI@+/ROA/\3FAK=
M O1;P2[_$:J32,(5EB EGDD?,IX[LQY_FK0$ /I'@TYLR-X0$=6U0^1[ZCS+
MN:B; <V%<'*"E_D/""3Q$^BY^@\>'1P]Q)_S_^,QTONM2:T-A"K?7=S@5\U+
MXT]2Q$AF@L:0-#GI9N9SSJ5I6-_9V[RG_1:/.T>B>(U8N\X<F[;C1T?X[.-'
MQT+P\"+GZ.4M)6V]6T/,#(>/'WV/ 5\*O'@P'91**\O 782P@DJ"+)K\97I%
MZ3Q-+<!;XD#."S2JPO)17''"G7N!)\+<01G K)(8AQIR4)4"&\BE:PE3QR<'
M=@.MBPS0GDH[!15E-O_AYUBC$G$+D(1P;@]R-0E:Y_F$"5%T\(%3*;9!\.QU
MZ?;XUZY=_]"':[X%ZR?4KY$)PZ?[ '=/7V;&V4K_%:>M57ABW#P4>\)%"OLH
M:4^R!$9KR+=P:4GET<PE;"L,K4=H<,4[L=74;V1 _)<6@6:75!GT:1-.ORX,
MOF3J+#F(B:"Q$M'W.JAKT>O=B1C$M>N255;<E"<4=>-:26A^W_ PX?B<;H)X
MXU);R:6^%BXCRQG0SJRPU@B=(7!,)]Q-SO-"FQ.R#IB("@J@S&E_D]?D>H8+
MK(97X,'I*UO*"_#0EU1E*?!H^!N&,GF:]J3!TG8LKF 3GH:M,.'*C3]8.0XN
MOHPGO2@5Y*I<8NTE#;J,D!0SR;5;'+3X=,4OJ!F*I:5:"+PO9MD,.@C&.(SH
MX.^$A/07\RIVQ'>X%>C#_S<QI_FU>X<,+F^(P>7NNUJW=7%?+% 7UW\:D]EP
M*J>NOH+"?1.LF]"/8$(WRM=CM;*3L1?14R'.04,_J]E^9]@7N]A#^@T?M$R,
M(>YEZ0F$3&3.Z>><.7!H3M1>1K%W4$&]^ZM_C0S/IZRU5&G ,LY2T22_V0X0
MKP.I:\T> !?CR^R _>2,[W+\0O\ B2VD6U5"U3$4S,3J!&2CU@:2&,%'5)T:
M2;R0D]1_/V71("+2$S^;/=P8 X+PUX;U4FXP@1;6K *1Z9*S!Z3=B+WG$RL@
MH[U%J+1E".M%&0 *F,H[9^4#0MX\AENFI>MYN:KU>B!(0[] WKE(#M"P@\3.
M=-.:FN'WIW1%<#=N\AWBP<.D1YO*"!X1=]?QMR [@IQCHQ#JH.6PA^PFZV#
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M?3<%I_DF^#G&YHHUT$!CFZL8QR;7UPCO4YSR2=) -S$/+"""0APIZ]JP81,
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M43 ]<<'XK%\;D&Q&<.:K@E@_*QZ2G_6-Z4C"L-[/_!RR""I0@:5<ZGWIWX]
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M+)M2<8I0M*EJ,!;]&S9J3!"I2GVQ()QXPQ%/6H%E3_BHU.#$0PE'FMT_Z3"
M@W(/MN^G09"$FQ$9N3<!+F"Y'=F^F7N"+Q#!2<N>O*T'*&XD5I50(#K#,KLM
M/W,F19UX*VEMX W*#644/Z"HU3E>8H S4%NL#3VV5G;N_E:Y+;6O=8/[UWB(
M]'?K3+?46TU5U<27/4^.\K_$Q^L^9H39[/LXQ#1.X1/R@S \#D9[OH2QHGQ3
M2(99,1"(J54#9\)2,A;@;P^/MU!-A_YWVVE3)M5H0!/6W&@1MP*W2?X!#LML
M8]F#^=:AOK\+WOWHX4=J\<I#KUT/E 35GK-6 I%R@0'UV:+-YL>-)XCS=XXS
MP70/;LODM.3^K.-.%_2M!"=YIY/^HM^CWHGD'P7'%'9!!JVS/$S9E-(Z:17M
M=<Q#.A=%OCU,?\%%)=Q7UJVV(LIP)%$6-=0!<*3,',T1J$UG&;?)K9?IC'J@
M0ZBPU9WN\^W-DV-)Y[Z6YD$]=(0E128N4I"4YM+K("%]<@]<KT%#QZDR/--3
M)Q6!N19%"\-0WJ_Z$#A8F0TEA%9^"[BL)N4)_Q]_;_*9L/U?9-.LEG !1;G
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M5]+MQNBOX8WSUZ&_W+-<[G\_^_4>UE&8XI%NJMUXE]NN!.XM6HQJ-][@VM5
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MV0TSLUK7EC,JH.NR.D"-^*#+9;0A1A5MA9S%VF"B=-#^EG< '#DHQ$P&$/!
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M:7NMVD/(W(O)7MOZT]LT(8176M+&[HV@C"5ZS91B9G@J9H^9;@OW"R+"X99
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MJ#Q.!1P\$)A[RZG@H^H+E/0+3\ZHZ\$[A*6P$'#IG9SD8D%A4>\TA.PB0N*
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M'M1C-65A 6B,LYD8#0SE7[Q67"*8@3MCPK?OO)^+H//K#$H])7OL\GD#VJ/
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MDAA Q%-65O 3.8KHI8%\7YL(J,.4:7(0+P7N!AX7@1\36P#<4/9)W*\0:=;
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M'',8406_.FV]\_*^!*]Z.2=QLE,W9_)5>^^R9-_%X6QZ_<Y<U@B3*T+_R[+
M+F5>I.-]+K%PDEGD(U6(T\B0B=R#><):1D628;IR'^]WYPZ)6A/_9CR!?H/=
M?OOF6\Q6]LJ$7P*R$_^(7?<-R-4WWDTOSL_GST2#63R__OMLSRMR8C8N(_=+
MO4)7-E7\WOC\?##+LUONW=YX-(-9$&;##(@)200E'F&G)$Q 3B"' TQ%,1*3
MDE#*DAI$> ;3,L2@/P,Q2NFE&%$>]^]PY(<7V6DZ'4_F*IC-)@-W,;-N&'OC
MDS&X5*,92!2>^.EP-(N3.)WU:6):*,X0R, @CFE"3B:'E/&$)V\L354X50;^
M,O1C/P/]=J#MBDSM6T8"3A&L*G'9STX>:9HDV%?CG<C65=#ML&[3SIT"NCB9
MQ$N%_VZ'%[$?C'%6,X= O@)QJQ*R@<JYMB.GQLH@:O1N 98F3=P;\N#AD-A4
M\D6G[/'H#@H(&S5+,:# <Q1)(T: A (*H5-RP5$2:\W3=X$T:7(NK/R-9%Y,
M\ZT0!KGO=GAJ!^%PM&>_#&9V> =<GS/,>% ,W *%$1=.(RV90<(EEL#<"BJK
M!"@O0VO2W%F8'87U4HPO9W%F!Z,8VG8R@FEYVO+^XCQ+/8;]F 9^,.L[<!J5
M- D93QWB,G+DC(I(,:P-=X89[&OPY65HR_"%OTZ^%-9+.?MRBZ,S^QPG0. O
MD_@YCJ:#KQ$<P/%Y/!I/IR=QUDD]^[U/B%5*QIC3EQ2,H(#N,QF1I8+:I&)@
MS%4Q-JOA7(9)XG4RJ:;&BM'J3J2R=P$>U&C6!_^(8)DB2MR".90R@.-D!#*.
M6R&-P!)7"0,?0RDP9L87$*6?VA\Y%()0#-Z97,2PH-<I$"H)HTAKGQ"'4 @Y
M9PFRWO!HA2"I3ABR L8F.? ;\F;!6*FBJ9+F-\-IGW\9CG_$^#Z.8#*8W6#B
MD25*8>PJHRST/0$<IPW"'BN=@HSP627V/ .K24Y_><*4TD?!X&\TFU@_^_M@
M]GGO8CH# S^Y[O:/:V2$<!%S,"HY V2$8&244T@3A;GU%$+62HG;E\$U*0PH
MS)?BNFE:\E8Y(Y76 A&=5R@, 3^":.@%^*@,2"^YMZ\E>5LDKQB)U83J@%ST
MX+IAKY&1H%'I1$R1.)-(E6C[I;QBTQ)OU=GV<OYZ)5T5&WC'@]%X,A? =4:<
M2NB)P8AYQL"^:(CKB./(0F^ME0[>J.("/@32I&F[ 7S92$_E',#I--[Z%T0K
M[[D!PE)P+3CE$D'+,!]A1IFTCOA491W^'HJ-_14[_9P7,.&?K-JO=CA?TISM
MV<GD!VCO,ILJB-08&X:PX* P<+61-CPO:W(M*03!7M=Q6)9!UR33NCY#'CDK
MQ153;AA\M8-A'NH'XTD7<'6COYC,O;3]Z&:WKVX<<4P2BU(A C8><1LD<B)8
MI)(1- B#DZ^3AEH-9Y-,;CD>U516,49=F_4SF/J!ZH#V&@ZX^YQ$+,$33QQ^
M* CBL \H!.MU\H$$5\6#>Q)1D^*C<BPIHX"2F99Y*N@6SDF<72,*PAJ,A4%,
M<8HX5PYL'@E(AB@=QHF95&4Y_3E035H,*6@[2JFA&#%.)_&+'83V]R]Q-,TI
MPGE6_7Z/J>'&4 R^($R!B ?)$;B$%C'N(G=4,>9Q#7XL@:U)*QWE:%):*87]
M]3Z#,)*ZJ,$K8GFC?H)N2>N1("Q1"#IUPG76W.?-EPTZ># P+T>)C )+S"/U
MR(&BD#2!,VP3!S]PRT%'$SSNE73\R,RM+>&MN]0YM+["J95(PG*'" 35$ &#
MC^9P\$@3;B*E4>(ZN\I6A]H\QWHSNM355<&Y<OPE3F8_3H=V- .KG,/(+WG'
M,DSB?2&B!U0,:04>/L?1(<>=1"&2*, @,Z]XG4GR:5#-<ZTWXDDQ^9<,L^SH
MTR OKLZ[!T#:WZ\R>;^-Q^';8#CL!X]-3-XB;("FW(B(##4,*>FMCAIS4F>'
MVC+@FN=F;\20XOHHQI2;UJER M,HD!3<0.LN(BNL1H%XXY0/V*E4@PVK:'R[
M'O-&&E]+KL6TV@%[9/-!E:-HI_$LBZR3/DXOV==7QCAI* >?G >(]*F&^0DZ
M!WABY! <*&YJJ/I95,OH7[X>_9?30#E2W 9K=SP699/$C$C$C >/)3J,#'<)
MP;0DI LI.%ME%EB(9AD2J%=$@HTE7G '\G0V&?A9G"\TW$$#S6N3_52!68+^
M!0UHO$/*<\ZTB(:F4&??\6) RU! OQX*%)%[C0V@_9"PE<1+%(W B'NCD;4^
M'^+7@@2KX"-6>>=GA?VL1HID;23(T=RKD)?(G "QQF ,MA0'6R4G^&HV<*ZD
M]V=.2:\C\.ULOKLSR)+V*H+/A215(B<C'3(:JVQJH9_6:QNJ;/)8$E^3\B6E
M*%)#-97\XD6P5,2>T)00%02Z3K%%SFB 97T(A$4?Z@3%+R)K4LZD%%?*JJ,8
M2_:OSI=>'MOHV>]W^IM3.DHJB-,)N.N<<<0UEA#2929'@H5B6 E;Q:J\@*M)
M.9-2#"FIBK*!U%T@MWSEV@N<,$4ZY8H01"2DK98H&*HCD^#PDRI.U=.0FI17
M*68WRBC@ 2'^_.ZAB([@=<F:3]T>_#QNG_2ZG8/.:?NLU3N$3^_#V:#XTQ./
MKU4%:IG>%"H'=3H9I\$L'Z#K8^TP6'\"0]P0Q%4BH&I"D(^:1BNYYG625[<0
MBCDAM\<"^\E8XPTE2#GJ$;?@11L189X#0^:$9R9@5=7MN,72I+AE3;T_Z6>L
M*?'BV]^NMTY<XND;GW/\T+CE'GQA%Q(R43L4N;(X@C%THDK0NAA.DZ*20@0H
M(/=B' "WY0X-&4X0!&&&#(LP7YG$D?-,(&JCSSMT),R1-51_#T6!!>AK+5$K
MJ-7X:I&#&Y"KD58@IQD,+R^QD%66D9XRS[NU7^OK>L$:\SHBKL/:I4Z!6$JH
M@B@-:1? P-)<C<?!#R*)HD2%1$R5;2LK(UW1WJ%7PIBZ&BN?DKG3[<@B%9XJ
M%#3$<MR#DAV0&A''1(P D_DJ!VY>](;667?Y&D<7\0 4O2@S=K,+("\UP/]#
MK@V!J; L@&LB, V(8Z41."L:,6Y"_I_E=4;.&EB;9&PW9=+CI9NZJBL_A*XV
MYD)P+9@D5D4P&7/G-B=7+59(A* (1,?8LKHK_-=(&F5;2Q-D,[E75#]S/%%M
M\^%:<!.X4@&!XRQ1<,HX*S5UNHH!>4']:ZU:1Y!0/A^W#Z-Q.)YOJ[MZ>E]Y
MXIWD&!F=\F9+:9"VPB!L8&*,SJ; :BU=/XVJD19Q+68L6,HNI(QRN]?B"'HX
MS!5DPOE@-)C.<G^_QFM0R=)@*&<(W!@+'@V,3'"7(W*60.S'@C6N2EKE!5Q-
MBK#+<J2D0G::GMWK')^>M3_ =PY_;Q]UNG6RM(];V4:R]H6^%<K9+JB =E/]
M++H0M0(/24FG\[(-Q#6<B[P3CAIG"!.NRN&69S 5* ;[U*/7*J+@F0],6868
M2>!*)"\1C!V+3 R*)^(%KU/1I' _FC0=EF+D@IJT.U-]R6+&3W5B*= .8TX"
M<0BS &++)\D-T011HI0TV&/G*VVUV0AWHP*4'1"TN&ZW0<CU2N#;J*U*"2EM
M*41Z^>"KP1IIZ%B4).J@JBS-5S6H&^7JG6<N4A^0IN"W<V7 &6,T@=^7B F!
M@S]6)<W6S%S]+OGV3+9_%265W>'R1 G;@_$$U#&ZW/_I?_0F=C2U?BZ649B_
MNE)A^/\7T]G5,;A+&^8I4YKDL^%2V,NS<-KD'SYZ0H4F.E2I#U.G.TV*XII$
MW@:0I_I ^#B:1#L<_'<,'\;#^2D^.QCE#G9&M^>"6Y/!%#[:AY<@_3@9C,--
M;W(P+6QP*.4C?ER17-+62I08%5(K&["HMU&L0H>:M#WU-0R&K1)HIYF4;J^S
M][</G:/]]EFW_1\?#WO_K))*6=#,-G(I+_6NSN61][(YK>Z'@Z/.WRMEJ&Z>
MOI7,U.*^%,I(Y9I&=OH9G*NO WC:^Q\?IWEG\>'H*XSRO) '$]'7R]VI6EA!
M4[ZRRV:O*V(,HQTBGB23B-*"&X:K5$U8'N+&<8#],;_4KC=N^?^Z&$SBL9W\
M$>>&\-8 ]2WGTF,)<L"Y*!B5&#D=/3*!!&F\P5;5*;&T#+H5HX?J&S=JD.M1
M9%!<;27+D/@8PS0OF.=R*>#1'=M9AO2CDQ;#]#1RYPR*@6B86*-!QC*)HLCU
M=XS14=>J3;(:TB:Y^MLB6E5MEB/=P_'P9#&6OB:4.&\Q"M$IQ+GPR%&N *ZP
MS!)-DJL2?2X/<44G^N<T:&446(]@MW>,70<(AZ/NA9L.PL!.LC2$$1 L*(-L
MS&>2<(S(*9V0E-IPZR17:3MSYDM(5SPP]G/2K:@Z2VZW722-F\7Z.]*0@?!H
MG45&9WR!)V0)IHA:&TB.3C6NLM=K>8@%4]8R61T-=-:1^:T@)"+-;$)8:\>(
M=S'H*ALZFIFRKL229[+1J\B_X'G<+Y/H!W.)P._#>)4O;)WG),Y_S]_O:\E=
MLM0C'$*^P<T;&*:4((*#]II3RTB5@P?+@'L%[F-ISA376='+O2[1W('22?N#
MZ64-9 !Y.HGG@XOSZ>7D,Y\O^I8%P[PU2' C\DGT!)-.Q,B;?!.D<]2$*K'*
M>G!?@R=9FG);4.S&),P9N/Y=?-<GTO8^V]&G", >E J;]C%1PF$)-M:"M>7,
M:O!Z\SUG0EMM'4_$/E@I>)SF6[W9U^ ;EB)09:64(<WM^L#!),;N9SO)^\VE
M9]%(CO*1^5Q$!6 (DU#,%=LYP5PKL10W%CU]Q<H!KY\"&XNXW#5QN>WW%KJ8
MEX[B:'HY7Q(=/-@J@4+>:,WSP3#M),0CG'".60(&5CDLNAA.DRHV;FF**:"7
M<GO?;]C:BY/SP>AJNIN7TH%.:AQ]A*F,"(FX<A[9?)]QD)$'!EIFKDXUUV=
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M3R!FLGE!L_"<_/"YM>;+9_%7=I7:T]G@/.]]N*$63-LWA?GR&Y>,GP)1+Y>
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M"4I)OOA9HER,'NE\X8V2QD)T58 I]QIM4EBY4Z*LKXJBU2*62Z4D(SVW+J!
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MI*A! 0&75:G%98CGT9"4((LHF(NQ2I3E&E@WZ.%MF%./[X?J*K+"??*#,&M
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MI2"\D3$K8B!;(FDIA,,!_PA,9NN=I:9.[Z.M<>B9%-^70:%5U-)E<'!9GF<
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MC,O$1A_Q58A4)LZHCKH%FQ8.^H-"W>BC\\*XW^"\%\Y,>K<0)1BDL,^$E;+
MTB1#K#*2N.2<8,#,HQ(RC2BS;+S=9DLG6GA,%%?3:UN\YYX/3].G2PBI)P.3
MIC1HTJY =XH2ET4F(7HA#5/.^H:%(5OAV&%BU=;:@@/-=H$_R["?E;S6\:1_
M>8FRG8SZ#Y=2:2+"XI$H2<L;XCWQ7I5*-\Y(X5EBO)T%_L3@/[C5K7X6$*IE
MY>Y5 !__,4 Q?>Q_.D>>C#\.+R-.(>!OPT6Z^]G]1SUOK1/HH!(#P&_*G93K
M8:)8"&"#L#"?K=$%\U9$^8.B6]+X BZWK :^9&9WIN:W[]YL&K<7GK^ER]@3
M(BB6#"-<E:+2T5KB5$F@HEGCC +WK%E$;'LL/WA957L+V%?G"/]OPTE_<('6
MQ.=^B4H?'WSYU+\Q:F>N#E4B6Z D0PF]<J5CC!! LJ<J:)NYUNTX]QR"'TRK
MH*D%_*IS@#^/^JDENQ=Y,LYR?"^\,^4&PA"@E!/+-?X5@P;>L,]!!VA^\*ZR
M!A=PL,L[@-G"?(ON.!\6_0':#V%X<:/*'J*E(1M/P%A>SO\B&@0L$>K13\KX
MQO#,UR!<@Z%WFUU=ZV8!E5HWS)N)X^_]R<?]Z_%D>)5&TR9<1VG28S$FI:PC
MUI80?J80IC6:6)E2T#$+4Z= \U.@=HA2G>MH 8':G>X_B DZ^!+2>-P@,BA*
M'YU.I3ZU$Z7=FB,N)'O#>)48.-ZL\_@:@^\0>3:BGP6$6OO8_ZYO7_R?Z]OB
M;^?#!W=:T(^'@WWXU)_ Y71&M]&Q^"<,0BK]U\8]2#I#B8Z5QN/.[+)$27%%
M4((R9A8@S&=3=M11L07H'2+EQG6\@*"=73<\N#\K588G7V_ ]JCE.>F SJ\N
MYR_H[Q*(*A</A8DHI(VJV0+W_%@[1)T:TE\0>-HZ0/YMRFDT2O$4I3.X3CWT
M4ID.*A%O&:ZI,0 NIQI(4M& SXR%4"6<>0['#C&E"TTL8$:[,_[YB,3Q;//M
MX8+%C$#CWWD1<=.-DH",GC!KJ?!:,R>:I3@N'6*'=-^AK!=0H.71^*WI/IO[
M^S[X_B6N7/-X#R[[%_U21&QX"[P75(Q6@D$OD:(H<.K$)^])M%S;D'B$#,VV
ME+4Q[!J)-J2M!2QK>P0^*"=9".RAT :QN +C-S!.\='K<3Y\D^Y?$2DELYR3
M['3IG6XC\2P"H3(JR"E9.U^:9JGUT@K(SO%M@WI;0+IVY^)W!ULW$CQ/HZOC
M?&>?]806 AS@5ANG+T2BN ?33"+3D8F4@+)F039/C[-KE.E0Z@L8T>Z4>A;!
M<_SIIC;<\&":HKX <L_$X H>$G5&?\ZF2*QSF5!MC'?,.*9"(W8T'W/7F%))
M&PM8TRX,_>"VCL%22F?TWK3(!'AI!,HU)_@$618Y#RXYXV.S8)9G!MHU?G0I
M]P6D:'G(G#Y!:<'S^R<4VV#R+J6>5XJB(>](:0Q+I*&NG/XHXKB'X(U423>[
M0GW\[%U3?4OI+M!V9X'?WUS0'LP:AIRF_I6_'HU+-M]-BYZ;<T$4RE'ZXRXR
M^1(&/1VCR(",U5/:LHQK64ZE%BD/U!F;N&D7^[8&J%WCU[;TN8"8=0+-']R=
M3*LN]**01F8F"?,*+7%C)($0*-$&@#F3I&M8T;'IB#\HU8$F%F23MSX+;B&F
M_>'5IX2S*9,Y@-$ /3RA!%<J<X0O!)'!XK(L#"/4JZAEPHFZ*A56.IW%#G%U
M^RQ8P.DZD>K/+N:]Y+U56C-B8RGL*9DE/BM!?,PI.:IH].URV9^%L$/,VZ"N
M%E"L@Q:IC^-=[HY?>\J*$DLLB7-Q6M\0B+7X*E@E-.-9^C1_O5HO*.D.U0Z1
MJWLM+>!0NS/P-BON]=7UY?256;#V9H@L)JX(SL$0Z66Q/R&0:)V/-LN4YW?@
M)8M8)8 [Q,(7H^<%Y&UWEKYW<3%*%[A W\?%W-Y@/X@;O;L+^) F'X>S*^['
M5U$V6E_$2%BDLD0' O'6>I) @3.00LC-"I)WB6K7:+HUC2[@9KM3_3N0]_AG
M=9584"HE'4F TK<AHL,UC8E/1BM+&=*IH=>[?(Q=XTU'TE[ @BZ+Q0SB>[0<
M!P_*6X_GTK?'>Y\^C8:?4_Q]@,/?GRH;0Z/+(A &Q<[TI2L:"XSPG&EF-N"/
MUZD>LS:@7>/7-O2X@(SM;@=F&/?QI_T E\>CTW11MO;AZ#Y48WPX")?7<:Z6
M[LTAD4G,:XGVJ8LYH[>C \'M/Q-FI,HY@M7S!2&?N7Y<%\FNT6^CFEO NSKW
M%#.9WGK4[U(:]Y@+(7B@)%&#SI!5DECC2V,%KSUU 718)P'KR4%WC4VU]+&
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MZ3^^A_V,$H++GLI6^:@E44:C 9>4)E:A=V A6ZH4X/NP<L."1B/_H%*'FEG
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MNJB[FSQD.WM;/477JRO\DI9XV6J6="..<^W"P4'@>CZ'+))4A[!((/$# J.
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MU)AS;GN-$KDI9]:.(MB*;<9[.JCK\9QE+$?FM:/0C7!I:H"*3:K2F792:C+
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MM#@A_=%.%:<^:S&XM*X;=R-:OY?/)/%<F@CB0C? DA6=D$/"_1!B+Z(QB:)
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MDX&';?7KR19F6"K@. OTKEF!+X:OT(C)@>;HFN8)&LSPKBF#YDB<RQ[L,>+
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M$::&B!Q$F9I^W]!!D9>+>WD8J<S(O_#L,<<O3RG%R\I X*Z/?8<AZ,:>Y*R
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MDJ[X=<F?BP7B$444R5,2<@1$6*@24H$' R<,0QSQB.CUH+4@R]P(H:T-D.J
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MLC) 7\]T&@?3D?EC)S10XM9QD^HO+<$OP$YT>]:1.5PVS1^#V2>U;\Q1>6O
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M9=V660=;:5TZ4;<!:[$\^()KZ.WJ!:2ZE%)HA<REC;<GZ,9JZ.WZLCGV]+9
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M,T4BDW<<6QZ0V@\Y-1H[VE!M#9NMV."/2G 7$\<.?&?O@0=(Q_46C(EF9V>
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M*RB5!;5F9;#L_4+S?&6];34!.U7J@T_'1BF#O@26!O=$IG9HFWR8674WQ$>
MVZNM/J2\XYKS(R!_8O&/,6:_TB8S'D:12%4,LYACB)"(((D$A@+1),K"F"/L
M5CZX?O#4>+V1JUO)$L<B)1-BOJMZ=ZY",@3?;)_])I5&+GW')[_O&^!WN:S:
MIVT3Z"1&6' <PI"1!.K==@8ITN:<E!GF:9I@+)V:GSB-/K6OU^)THT<S;K>)
ML:."P>!^^W.D@;IW=T)LF/ ^&P'>*+K/ 9O+P7TN#YG>_G9WJ!!&"5,((YA&
M5$ 4$P$9BX79Z.(LXB&)0Z<8Z%&DGAJW/FU>7DQJZ%*!#\4Z?RE/A_<V3/K?
M/ZZD;%QBNXV2!FGS\EIZK*>S[W4^<9K:E$]Y)SS0Z=284_"OLCM^JU.O,>=B
MS/VRK].TO7[7134^W?W+_IE>G7H:2!'$H20P$U$,D>(1Q#A6D*<95E$62,F=
M2G@YCC^UQ69?_))M3,S[G@8'A^6.T6..,V.W/@R(]\!,?]"F'>SI4>*^__>J
MT86I% $.;_KC_?*%Y@N/7-\13J]!7XXBC!O>U0V?DT"NCH_IQHE-\\8GN?J1
M<UD:BIJ,30'X7>O2NL& _NE!:09??EN8R+%'N<J79:'XO1TVES$.$%*0AL3T
M:)0(XI0P*'D8HBA0 45.H0>>Y9L:IY;Z0&84 OL:'7SC["?8OZXNI01N_Z0K
M<7-XF]&VAS?%]]M@Q]-O.,<#\_C9:=O-[$U3I5[4*9FO^;J*RBS;?9BVW,/X
M:P9"W"?5^Q9QU*5@('R/EXJAAO&1$WJ:@'J[OM,KV4]M[9<;A9E"*L1A$D'"
M10912BDD62H@3U@@$<9,)G'W5-&KXT]M*;CSGSUZ?0[L"'I 9 <FX*-<T[.9
M[P-4[.X(V'!)J==%>,-<56M\VE-8[1_3TR]>.=P^F<8E4;TA91F-HU0E,!-Z
M*A SN:UI',,@3A,:X"CFW.DHOF6LJ?%6*1N(.KJ1SV#IZ/SMA]!H+MN;VD][
M VK !NA,9(')(#[4,\.]C>?SLMX7_94MMW3<46O^6?^\99J:]$9]QH-4$8X(
M)"HC$(785)[E&(J RBP,4\JXDY5S^/BID4$E'?BCD<]U_WF(G>7VL3,B W_\
M]F"X;^#.ZNQU_W4XPKC;I[/:G>Q^SE_5,:A.+N2*SK4-<2M>\D5N'FK\J(<=
M]'BJ/^ L2J#B@80H"Q0D"&&]94F$9#'+L(R<(NYL1IW:-UX+7=K2]$!LQP ]
M*\CM., [D -3PSZ&AQ(/V+C0"22OH8%6 X\;-^B"Q4E0H=/-'0\KRW/4K9GR
M/B_X?&E.46=1&& 29AG,PC2%*"$(8A4KF 4IRP))B0@3E^X;%T=R(I[1VFT8
MIPB0>X7KS#?T0E?_D%5NWJZX1?D;9>)?J@0\0(VFCB>3%Z>!H$AP$2.H$E,F
M5K$(8JI_PE%&A*121LSII,//-(R59O.C#$,16R%]H6IYLNL#JX$IOI+Q9C\<
MZ_UUN-Q/9:]!X?7\]>)@XYZT7M/YY$SUZ@T=25K\WTW=#N-Y>2M$;MSL=&XZ
MU=POZN.<)Y,-7)6<-7^:GH&EVWT61PPGB10:9*0@BE(!B4PES' JB8S2-(BY
M8P6C'N)8?3FC%BYJQ /<R =6LBI^LUZ"U\-"U8[<TV?.$A)C0DR)$AQA_4>6
M0!(B#J7"6&813P.!G$A_Z!D;M9%Y<[@$7DT7^>7"Q)_*:A-<50T?<:8L%Y*1
M\!]ZK=FI8;Z/G2)ETRQ3[:#6Y0:4VFS+D6^_L5(CCZN2!UR]+EQ]Y!EW;?.
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M,6-1%*72+H2[CQ!3VRSL%@2UJ[E0%K$P)N=>90L'!NLZ/Q8+Q@BH#[QV-!J
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M$/@2S#BA7)!,P#@U]<T2DN@M>QIK YHSRJ.8B8"ZGH-Y WGXXS ]PK#XVEK
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M(D9@J =Z :^5R,:#,2_3?O?RIQTL@2Z38F$^#0SUP-RS3:5NQ-<T!(P"P&@
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M.D;*8* 701!EF&O?2"E4H8RUW^0Q39RR*.R&'9NS/%*D]+IBDYSK/RII5+H
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MBJIB8=W#)9112A/(0T-IFF %"0I#B'@<J#3B29 P)_KY_>.,;8]LI^5%W07
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M!2R_Z<*1MP<9%W:\TQ :BA?O$U &GZ4&RGSCRQFW:-_.AK?GO@%Y\ Y+O<V
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MQ#!,X@C%&4,XCJW:+!T=:6S^Y=/EP\T5N/S^&7R^^?KC\?HS^'[]"+[>/CR
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M;6SDO=ER6TF2)GS?3Y%_S>T?E;$O;=T]1E%4%J>4(EMD5DW/#<QCHS % AH
M5(KU].,!<"=(83F!$\PQJV*2('6.+U]XN'MXN/_;?_]^.?KI6YK.AI/QO_^)
M_9G^Z:<T#I,X'%_\^Y]^._] [)_^^W_\R[_\V_]'R/]\]_GC3^\GX>HRC><_
M'4X3S%/\Z??A_,M/?X]I]H^?\G1R^=/?)]-_#+\!(?^Q^$>'DZ_7T^'%E_E/
MG'+Z]+?3?Z5<>>J\)3Q )#("(RZZ1&30CBIG1&3\_[_XURA3LM8GDBC'7V;A
MB-,A$,,\)*N]M-8M'CH:CO_QK^6+AUGZ"9D;SQ8__ON?OLSG7__UYY]___WW
M/W_WT]&?)].+GSFEXN?;O_[3S9]_?_;WOXO%7S/GW,^+W][]Z6RXZ@_QL>SG
M__GKQ[/P)5T"&8YG<QB'\H+9\%]GBP\_3@+,%S+_(5T_O?@7Y2=R^V>D?$08
M)X+]^?LL_ND__N6GGY;BF$Y&Z7/*/Y7__O;Y^-$K9S"^@,O)G\/D\N?R^Y\/
M)X@&I'3Q+^?77].__VDVO/PZ2K>??9FFC)]=7$Y(42G5@I;W_;?E/_SY_K5?
MIVF&2%FP^1$_N/GWY2T;DY"^S],XIB57MR\83<*C/QH5F4[N_N4(?!HM/AW$
M-!PLGGK@9_,IA/E \I"M")K8X!61.AD"0E@2F*):>B,4CX\Y+A3/D.2%"F8I
M_/EB\NUG?#"J@KGR#2G?$,IN%/#?GKUT*9SMJ+]==^?XMP,=.&=,9@+!9UP-
M5A"@&C7OH[# >69,=$#\PW<^IOVA:@^FX:?)-*8IFH_;E\(T/%/S8^C>_,7/
M7V&*#R+ARW!T)^]B1[K0VWS2@?R6RD%R__03<IW3=)KBQZ5N7F1NP1E2[2>S
MM/C;+C3_GU<PG:?IZ/IS^CJ9S@=4,)Z$8"B)((BT.1&(TA"?))7.4!.BZQ $
M3UZ_%AYX^WC81:I;0P-?V"$P3M-T.(E'X_@>-^2!H\%ICSNEU]D1)!D(V%BV
M2^LEN*1<"AW"XM'+UP*%:!\4VTNT$4B<3V$\&Q;!W\ :Y1!TR)G@%X.P9H98
M&H HSI15T>;,ND3%T_>O!0S9/C!VDFO/V#@:SX?SZP_#4?IT=>G3= #). :0
M2?1*$@E1$\B(<.\B#S3PR',7+M#3]ZZ%!=4N%G:28Q,8^)PNAD4(X_DGN$P#
MSB%$ Y(P91B&8"H6D5 20H@YN9AQ%^P,!X_?O186=.M8V$&>3>#A& /^*9JS
MA>#/4/[I<'(UGD^O#R<Q#3PHEC2S)!FT<Y(Y("YK2Z@$1H'3(*+M#!ZODK(6
M6DSK:.E.VDV YQR^'T<4WS /EQF-&ZOHM>9"TD# Q8@Q%GX!Z1U1R87LK+9:
MF,Y@\P(1:P'&M@Z8+B3<!%0.8D05S&[^\W$X3FQ@T% Z+32)*E!TH#@C'EP@
MB3NG3+9>6>@,)BL(6 LBKG6(["K9EN!QB-^>3,\GOX\'02C%0$3BJ<!@/"$+
M8)4A05*@FBJ?5>?@N'_]>BDO^D:PL:586T+&8K,\F9Y.)]^&XX".EA3>@63$
M<>V)% J(]2$2IR ZM(2,>=TU/)[0L!Y&&LZ+=B;@EH!R.IG-8?2_AE\7+I4P
MDJ/CS8FFO,1G4F!HYC(Q%)CEX+(*J6N8/*)@/9 TG"SM2+@]0Z18P(-I@@7=
M)HA0V"92V8!?LB%6(KZ5#Q"T= (L[0 4#]^Y'@P:3H]N+<">%5_.6D>G7R;C
MVXR-MDB\$D!T<)9(#AXWP(Q<Z()B*:(7L@/E/WWO>@!H. VZDR![!L%9"E=3
M!##C_GPX'V&D'4SR,4K"3$+:@Z$H!.I(A""EM-19V\4AZM/WK@>"AO.?.PFR
M9Q"<3Z%4MIQ=7_K):,"]--9"(E0%1Z2/F7BAT;T)TD.6G''+.D# HY>NI_Z&
M4Y[;B[ 1 W#T/7R!\45:Y&H]4\8:C'V$5)K(C/N98T$53JC0GC&9NCA$7_7N
M]9#0<#IS9X$V$3(<7DV+N);G>078J(.KV2 %ZC R%L2@AXM^K7'$0:!$:Q:-
MD2'8V(6+\!H-ZP&D^?1E!P)N BC'8WP:BF/X+;V'.=RP-3 QV.0D)5XEY(-F
M3YP+AO#(-?X09<Y=!!*OT; >4)I/8G8@X": 4HZ&IX<P3Q>3Z?5 *^-59IH8
M*R-Z1T")35D2"$I%:AE7L=M3]KM7KU>BU7S^<GMQ-H&&LTL8C=Y=S8;C-)L-
MC&/:,@R8J:.92-PD$<PV$<Y9!FF"SJJ[7-2C5Z^'AN8SE=N+LPDT'%VFZ05N
M@K],)[_/OQQ.+K_"^!I_'[+@B9*HG2?2FE2*X"EJU'EJC!"E\KDK5*PD83UT
M-)^BW%V\3:#D[$L:C6ZI3VCCE#1 LN*,2.,D<9PQ8I0/W(3$0N[N$.SAF]?#
M1,/YRAV%V004D/#+4B8R"?\X^X)RFYU<S<MMDA*##T**/GDT?U'%5))NFC@;
M)!$(ZYQX2+S#P_/7*%D/*@UG-CL6=N^7!@XNTSB6BM4/([@8>)D9B\$1<!J=
M)NLR\<YP(I61/ND,7O .</+HI>M!HN$\Y_8B[%W[M^7*'X:S */_2C#]@)_,
M!M)&9BA*041KBR@8<4&A*#0PKID0*719!?[D]>LAHN'49Q=B;>2"P)*%Y3V'
M)1,FN1C042**231O%"(!18%H+BGG262,N3O'Q@,"UD-'P^G0;D3;AM.!;$QA
M=#R.Z?M?T_6 4Z.$]9X$[M%KXBD1P "+6-SX&#5,H[BZ\S,>OWP]7+2?!=U!
MI'W732P3<?=6[_9BE*;2!6DH44*7.H"2PA44PRRK41SX):<N3E!?>O]ZR&@X
M[=F)8#L#Q[_]_$R.'_&#;:^1GWQZ?_3I[.@]?G-V\O'X_<'YT?MW!Q\//AT>
MG?WEZ.C\[#$#:]XQ__%3.[F OB'Q.]Y.OYJ1"X"O@T7Y7=E"3O*'X1C&88C[
MR&1YW^P.;%$HQPHV(N>E[B;Z<MO($!V]]PH!8_,*6WR[YC+,_ ('-^_\N8CW
MYS2:SVX_60C\P0K<A+AMK<SM.PYFLS2?W;,J14I6"F(R0[]*I$@<-89D(R1P
MYXQ:5:.U.ZN/R>CGYGLU3-P:H YDWN.^])CZ&T-ZQP1EEB84">&I'$(G10EX
M#<1K;@R/C'.H")PGU/2+GUW4NQ(IN\BZ < <PNS+P3B6_QS]GZOA-Q@A,[.#
M^2%,I]?#\<7?8'25!CPK;GG2N.,R7%!<">)-L"1K*6423MBD:@!H+>I: -1.
M*)C45DD#.#OX!D/\>)0^3*9GR-%-L<PPS=XG/[__Z?:4&UV<R"6"PG"* N3H
M\GG-@ 0('A<LTXSZ*B9K,SK[:?M1#WLUU=0 "A<E%6DV_YQ"PH6%?-XRPF.Q
M^Z)(R6#,@C$*AIZ:$\;Q ^_1HUAU$+T[WEZDJ)_>(?60U8WH&\#000CE?O+L
MGI%/:7[+2S#"V RQE&,8(JE ?\)33H R)JTU2= 5E\,[,%NO$-5/LY&*-JHK
M!30 IM-I^@K#>/3]:QK/$N[Z)_,O:?I(9@.ND2/&#(FELD,&7!J ;!)(DG(
M:CU;47JY.Z;6H*V?WB7UH-6U.AI V&/BA1 T,J"$"^Z0^(2V-J9$@I?9*RZ\
M=56PM#EJ.C_WJFB0MA;Q]OB8S&&T5\?\TV0<;E> <5*"M20QR8C,((F5U).8
MG,Q,:D-774/?GV]^3VH+[GDWN8:Z6FK 3IU.)U_3='Y].@)<EN-80M^O)=&'
MF_M @D!YX9K"I46)E-2BS:61!(Q]5;E0E4R5_,-K1+7@H'>"K<XDWP"*,,J
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M]K$QU@-=M]KIM8W$+4OO;UY<IA9=IG/X_D"0I5XB."ZB]AR=RK(?:&YQT]=
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MTVGZ"L/X_H:B&Q_D-N5TDU_RDD+2D1(=(KK%D>,6P]$C8<I0EQ1Z/VNULNX
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MK@YU@*:<@S<$(YMR1=PX N5L2T5T;A.EP<<J#<[6IK#G^4IU,%A'/PT [Z:
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MA#5FV':"P0\QMH-.&L#8#[IXWMCLS)V(R2J2TV)5EKQK!DN"84KQ[,J@\!I
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MF/LZ0[ V)+3?+$>'X*NJH1Y]KC7Y"^'J\FI4;.RKKH+27* 4$]$9(R,91:G
M=&CQ!41CP'G(5<XE.J&^WRF4^\-J!5TV$)5NR_1C;\4%X9D3&,L;R4JD1 E
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M)XAX:GJZD7ZCG:->7[8=]XW<_F7U+=2^^T2^"-7$G8$RR2DHORC9S02"",1
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MY*H,D^R>E3^"[=X$W2]W(^@%''U>[)S.<>>Z6O0$@>G\^A-<ID7;1)27"T$
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M<NT;'L\\6JU?;;T2: PYA<Q84"HKH% E0,F<%\\E#YMM2[86^6Q9HJ=ZSR.
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M5VY;*H8K2TQ87Z<=Z_I&(JRG+[UG7G+M<Y,9UKM ZRD5_=F:PQ7[%"4'2GD
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M;= H2V55X0IXU+R.XU804F)@; C<6U1^\UUL1\1NKM@,CJ__=:$]M0S@C>$
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MEA)2'C;]12';\!4G\R6]G_"Z!C2U1GU^^85,2R3UY/4]P+V!0"9**3D 3Z6
M4BF!MSE"9L8$;VQ2L9/"[\/(/O2H:;SZF\>K/PR05SIR,H&L)K!%J'?'Y,F5
M#-9*5T(.)H=.GJH.I+O?Y)4C(G7S*#NFO@>:<_B\25JV$9NW9SU7G]>=#7V.
MX&%84EN,0)<3B,0K1I:#T@*"%"6:K)G7J9,.!_U:TLOT!?/M-:U]2JB9?D>\
MQ-FW.N/M?CL])NKD>OF1]*^:VIVFGR?C_R*B<#:>WE'ZL.>\DC%X;<!I4>NA
M:.-Y0_ZKCT$&H5VAC=^%/#OCZ$5;WUW0O6E]AX&1%V67+Q?$WA/)G/Y5_XG[
M9WWOOUAW%GUG5H=A[I5AC#G"FI.J/N=R"SXK#=8+Z8T1R:E.>DJ^,G._;&.J
M$V<L1%:-"[EVEM,.%B: UI8I*Y''TDG-:"?<O&@SOPNJ.S?S.V-C )>89Q,R
M=W@_V/+]BL7E,(&,243%/?#"%:A<- 0;*8S1T6?I!=.-IGWN#/.?T-0O6 >
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MSDIM6#=-EYZEIF?,M:?MS3N.@T4_ /S40HGI9.F)KB_ O8KDNGH@]F4=\>;
ML>!!^R2%D@ZMZ.2N^ DE0S@@#]+NDY[XAXBZSSX;LP417TN.9R0[BE+"#2YW
M#S->QV3J[7BJ5C@H"$(C<++%=0"-B*E)J2Y]_B.8T%>;$-E&P%!N7?LXS5I1
M2L^@^H1?;V?I"PGEY/,,EY+:9&FU[RB0CD600UH0#>T[;\%9$<!PS5Q140K3
MY%*B$=(:4]73?.)6%#_M6@M]]P5Z,YY^QLF'D[-)6EG;7+P6=71$3"A 4<0#
M43D%9,]%CCD)+S<PM*7GSY./[@\('>ENVIH@!^#B7-'O791'UGBY6Q3/!AVW
MD#(+=1:- .]#AIRD9-:6E'4G;LZSU/3;S7$88=GA:AH UAZ+ZF22SZ>3\/"=
M*_K7/*1E@_;55O+(-*OU6;X.YU.J,(@Z2ZA3(J+2/MO<R27!CG3VZXJW@(S-
M![T.U=3WP;<,,#YNG@HK1KA 8B4P\A$,4KQ;YW<K3N+SQ).F'TAL=@;^;)5^
MT=*I;J=="'H =NN7AG^;W7]__\">-6<Q&P%H5 1E4$,DENE+R1E7A6/NYMWP
M8-+[[50[C-/WR  8 N3#4N;+33P;ISHY=\GAR*$P05H+R(RC#:N)CRPS<":M
M))\9L^FD9FD;03W?GQX9&)NX;$-+PT+;6SI[QGG9#Z16'"4<?\-\,7ET-(TX
MHR"-!P-<I>640ULKZ26@MLG9RK;I)#=\)RI[OGT;#"Y;UN<0P%K9.IO/;S'_
M=CL;3S[?9=0MY3D_QS^7/YJ/R,M&'3V"RR*!XIY!4$Y T0R#%UZ'C@QE(_)Z
MCJE[AF?[&AP"+I?DW['UXVF0HO-.<H**\!)45!Z\L0Y82%$[%Q"[22/?2E'/
M/F7/Z&M%3P, W,?9-"'F^3N2<&4G3-)=Q?#Z(6_D2T*M!$+@1H$2.8//$<$F
MX8M1FF7?27;H+RGK=[A!SP!L5V\#S:@\>?NO?YQ=GM7N$!?O+D_.?S_Y<''U
MM]-/)Q]/_[@Z>WOY[M/)^=O3RY/+?3(KFW]X&QF6>[+24J;EF]LYH6X^)WS$
M\61)_4.M/X^1LT PM*+6M!IT$))4A);"4_#(A.XDE>9G1!UJUI[Y[.>RCI5U
M1B?%P!IK0 7M(4IR%@HF56O4$HGE2*P/+@V\-<QLFJX.=//2[=?^[==V7>*H
MMJS#)FT_16=17J,K!KROUX1>U %^4D(6/@F3B@^FDP;[75BTNXOX^QO4VM9Y
M.EF0'N@7/Y_5=W"<+Y:"OOOC?O\@\RDR4;,C.#FB3$D(4=3L/YY#PF@9-AM=
MOL?B [9<NV#CQ\>0CG7PTFU8"\4N>Z]U5*MVC-*8GQ^^R:$4]='-(!V^Z")$
MS100?K-- 74.G21V=.FP/>RN]2HGZ1^WX_EXN<J;[X^^NGL*"CHQ7Z($D04%
M3[(6J"W;P-(6UC'0UTEW(81="1VP*=P%1]M+8CK0UP#N19[A:IF3(43M,IPU
ML*AKRP!GR"OE!E ;]))Q3M:^R[VW0<]0JEVZ ,&6L.$0C0P46/6?,USG,3+&
M PO2 7),Y*'X!%$%"<7E7!NI2"R=6+9?4C8,4W:0_AM@:G]E])X7=>?2O)O5
MR\!UEHYCMA3#("'+H)P-X.K0-&]30F>L524VBP*>?OCP\'" [J8M"K+GHH.+
M/R?T.5_&7Y?[PY2@+1,.?%&,COKLP"7)H10N:\M\LKNM%1;\L/)0:E<Z/)L.
MD_908++:+B)QR46TX'F=$:1"(4,J)/B(Q5BN"P]-7AAW TK?=28':.\Y#.PA
MRB&>&BFX& IWH"6O$\,B&;M< I 0N&$E(O?Y99T:!VOI5^?#+B(;@!OZ?,8Y
M9B<8&@W9UK;/GBL(I2 4:>K;(5=%=1+=#+IDY BQS>':& "D=DY+#Z:([$-M
MP4$>5=$(7M2[4A*6#EI&83M)KGH%E2$[(>/0RI =U-3[658S+IX4+!"75_52
M=G9!,IIMUC$85Y2W=,A'+D1MF\<AL$@[V!=#0J4@TIAF9]WNB[^P.I)=D# ]
MHEH&8/S^'JYOEXJ[PO1E,O['[5W%<K .(W>)? J1:PB*$&TP(#&+.HTU*]=)
MUM[SY RE#.0()VH+^A@DJE:N:R#?M:9W@;2UKX9+'#RK6:Y*9FG(,"G>R0OW
M-H+Z-61M*/N7^-E#\H-$T,77^F5-6AU//G^89KQ>65R55*$(QD(LSM27<3+T
M)GI06=:7:N8I(#H.IK:1.#24[0.)7^*L%?T, 'FK24,?:Y>&Q\[$F^^/?[+<
MJ%)IKM!RT)C8ZB'2*1)@E#HFKUEQG0S$:4YBS[G&QSPY.]+;P!"YVKJ:C@9O
MK *6D3A07 *=&05DB3YF8[R/G>2^/B6E7]O6E=)_@JT]--#SA?GI7YAN:^(/
M!2SCA+.57<9@*.PNU<.(M<2((G*'1H#C4NM K)G2I&]MHWOSYTD8#G;V4>JT
M50D/P,X\8Z3?WQ=]<.?)^30>8E(UKN6U>WZ(RWY%/&)P3G6:F_H<48WP8U[%
MZ=::;OJ^ZGJ&D8\X2U5QG^N8E&5SQW5NZGQYNY*OIJL7\I'W65AA"UEMCJ"B
MKD8\!=!,*>T<L]YMI!!NZQ1V"!F#2R#8$PK37O0R0 2>WU9[O>KS,5\QE4=9
M94&A4 %>ZGAF7W,GC.?@-/$E@\TE-DM%;[QDO[D'1T-6"_(>YGGY>,O\?;IX
ME&;_P*5-PK$4)%@>:B8_"3(N>QO9DK0KJ@KA2"=I W+[?<UL'9%'U-V [=P[
MLMYW>^]O>)W??/_;W:B3FGGF)$\6@I7DL#J5P0?)0,HBA/68A/]E,<2>:_=[
MQW]TR]>&!@9@ C^,)]/9(\?@/E7E83.]^?YQJ8*1R%I+0SX"9_6Z4=;";FT]
M"%N[#9"=%Z*3.2D[T-CO=5EGQJXK+0W0PIW.%^.;&M:_"^-9O:3&]^,0Q]?T
M0YP_WG8CGPJSA399H6 ?5/$.8HB64%2O@QS)@37+,#Z$BGXCV*-9O6ZT\B+@
M=S*?X^)''@4*%XJ@Z-_GVFK%.@@L:_#6VN L2=V+]I#WE(!&H+.O$'0'ZF(
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MXG-*BWKF**(;_42]C(YS9)CMH(&VW,^.]+G&?R&7%2)I$2)+R3J+>IPFY<P
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M5/TY6 VS@WA6D>XR>3:9MY'0/#%E$_5'743TJ\M$%\785$%RI\':TD<V_)'
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MS_W&UD,07#2P5[:&>A-V0@UO;NK>]ZQ?K\VC_EH5O'[QM8RCM>\E:%FC 52
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MFYW[LN9)>\4<( 96=^8@75O5M<T4J%NE&'GJ5FC#]\ZK)ND]!(JJ=&;@5*$
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MH+).47PQ[,3QMB)_T4E8!9=,YJQ4AP<GP_!X9J!DLLY88FOMF-Y83;R?-QX
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M='/I./@>2MQJ@@">1;C):D6*VB@^X"I4"EX:E;F]^]TB/;;[]NZA2UR+Y <
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MO*S@>'\4_K,-F=A!\_[!8,8FMOS7L]SL+(LA/0/MK_#ZA6?<&0XQPW:/ ?8
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M,#8S,'AE>#$P-2YH=&WM6VMSXCH2_;Z_HB^IG9NI,@^;1PAD4L4 F7 W(:G
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MG:#92IO-Z$5RK^G;$9@L285BR%.RZI?"R,Q#<WWC)VJC^0UWL/S>VURC1<A
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MCTK")I1&MC5L'9UB-="FY[U&F"#%<LE,^S>W?*W$KT'][*%1K%W!UKXX32M
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MII?T6 92,C4+X^>D#D<996R3-Q=!1O8SCMS&X^@/"T<3]0U-S:T)S=O#*^I
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M11Y$_]F%#]&OF]6._;W&0XQ9_;;.7]T;5WB0_?TRRO=E/1D[_#@ 8TN962#
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M(OA:#2.Z#Z270XDFH7)-E8J7L*5A!B/!8>#CI7:CB!<L)83ASSB+8*9 QK/
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M@PE)BC2BL;#B<\Z3Z:DA!J;B):6GU'_YMOH1*1-2?!OO8@$H%LMV4_!;QRB
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MG)\YFS.2Y\UYHXH=A0GE'3N.XO1^Q_8$==(),TT>(*]9JMR<'F;00&5;_G9
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MPA(RC[EK9Z6("6 XS8(R+&.DGA2YKCTA^SEJUEAQ6#GW]T?3%@K6'>.#VMQ
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M%45,%W[PR4?Y#I1>4FD7D>T!I!>H?6_^SP$0W?*W?W079\M7=G>[M=;#V8J
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M?.DT@\Y%(B4!MI*@+ O2N>17Q#@"\_6<PW-V?_9>G2C^+0B7M6,X2UH3?+E
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M92'>KP4PQ0.(N=T>-"C _KD7<!;E (B=":731!?N1EYYG Y6E)MAV$N7('3
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M,#(P,#8S,"YH=&U02P$"% ,4    " ",@P51$%G?(;X4  !FUP  $0
M        @ '-* , <V=M;RTR,#(P,#8S,"YX<V102P$"% ,4    " ",@P51
M4:U-GH(@  !<4 $ %0              @ &Z/0, <V=M;RTR,#(P,#8S,%]C
M86PN>&UL4$L! A0#%     @ C(,%49,!9NA(70  G]D# !4
M ( !;UX# '-G;6\M,C R,# V,S!?9&5F+GAM;%!+ 0(4 Q0    ( (R#!5'A
M^L,SIN$  .8Z"0 5              "  >J[ P!S9VUO+3(P,C P-C,P7VQA
M8BYX;6Q02P$"% ,4    " ",@P516^()"7^#  "=O 4 %0
M@ '#G00 <V=M;RTR,#(P,#8S,%]P<F4N>&UL4$L! A0#%     @ C(,%4=,U
M,<T(1@  D.\! !<              ( !=2$% '-G;6\M,C R,# V,S!X97@Q
M,#$N:'1M4$L! A0#%     @ C(,%47M)'&&'!   .Q$  !<
M ( !LF<% '-G;6\M,C R,# V,S!X97@Q,#(N:'1M4$L! A0#%     @ C(,%
M40%@K4!D(P  C@4! !<              ( !;FP% '-G;6\M,C R,# V,S!X
M97@Q,#0N:'1M4$L! A0#%     @ C(,%49UXM,CY"0  +SD  !<
M     ( !!Y % '-G;6\M,C R,# V,S!X97@Q,#4N:'1M4$L! A0#%     @
MC(,%441V$4UDK   RQ0& !8              ( !-9H% '-G;6\M,C R,# V
M,S!X97@Q,2YH=&U02P$"% ,4    " ",@P51,W12K$((   E,   %P
M        @ '-1@8 <V=M;RTR,#(P,#8S,'AE>#,Q,2YH=&U02P$"% ,4
M" ",@P51ZNTDM$T(  !J,   %P              @ %$3P8 <V=M;RTR,#(P
M,#8S,'AE>#,Q,BYH=&U02P$"% ,4    " ",@P51QD10Q)0&  "H)P  %P
M            @ '&5P8 <V=M;RTR,#(P,#8S,'AE>#,R,2YH=&U02P$"% ,4
M    " ",@P51LO0$-GL*   &.   %@              @ &/7@8 <V=M;RTR
F,#(P,#8S,'AE>#4Q+FAT;5!+!08     #P / /4#   ^:08    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
